Metabolite;metabolite name;metabolite (paper);(metabolite name);adduct;PUBCHEM ID;HMDB ID;Average Molecular Weight;Monisotopic Molecular Weight;KEGG;Pathway;sub-pathway;M/Z;Specimen;function;participantsn(cancer type);stage;number;gender (M TEXT, F);age mean(range) (M / F);smoking status;participantsn(control);number.1;gender (M / F);age mean(range) (M / F).;smoking status.1;Chromatography;Ion source;Positive/Negative mode;Mass analyzer;Identification level;Data processing software;Database search;statistical software;statistical difference method;mean concentration (case);mean  concentration (control);fold change n(case/ control);RAW p-value;FDR;VIP;Classification method;Cutoff value;AUROC (95%CI);Sensitivity (%);Specificity (%);Accuracy (%);Survival analysis method;time cut-offs (<=/>);HR (95%CI);p-value;FDR.1;Country;author-emphasized biomarkers;other information;Pubmed ID;Authors;id;;
C14-carnitine;C14-carnitine;C14-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,03;0,02;1,5;0,805;–;–;ROC analysis;–;0,52;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;1;;
C14-carnitine;C14-carnitine;C14-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,04;0,02;2;0,001;–;–;ROC analysis;–;0,761;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;2;;
C6-carnitine;C6-carnitine;C6-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,05;0,04;1,25;0,728;–;–;ROC analysis;–;0,471;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;3;;
C8-carnitine;C8-carnitine;C8-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,06;0,06;1;0,382;–;–;ROC analysis;–;0,425;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;4;;
C6-carnitine;C6-carnitine;C6-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,06;0,04;1,5;0,291;–;–;ROC analysis;–;0,444;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;5;;
C8-carnitine;C8-carnitine;C8-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,06;0,05;1,2;0,003;–;–;ROC analysis;–;0,34;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;6;;
C5-carnitine;C5-carnitine;C5-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,09;0,12;0,75;0,018;–;–;ROC analysis;–;0,285;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;7;;
4OHE2;4OHE2;4OHE2;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;17;17, 0;–;smoker, non-smoker;healthy;15;15, 0;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;0,1;0,12;0,8333333333;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;8;;
4OHE2;4OHE2;4OHE2;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;18;0, 18;–;smoker, non-smoker;healthy;17;0, 17;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;0,16;0,31;0,5161290323;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;9;;
C5-carnitine;C5-carnitine;C5-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,18;0,09;2;0,001;–;–;ROC analysis;–;0,818;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;10;;
4OHE1;4OHE1;4OHE1;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;17;17, 0;–;smoker, non-smoker;healthy;15;15, 0;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;0,21;0,23;0,9130434783;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;11;;
2OME2;2OME2;2OME2;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;17;17, 0;–;smoker, non-smoker;healthy;15;15, 0;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;0,26;0,32;0,8125;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;12;;
C4-carnitine;C4-carnitine;C4-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,27;0,27;1;0,059;–;–;ROC analysis;–;0,338;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;13;;
C16-carnitine;C16-carnitine;C16-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,28;0,25;1,12;0,08;–;–;ROC analysis;–;0,644;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;14;;
C16-carnitine;C16-carnitine;C16-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,38;0,17;2,2352941176;0,001;–;–;ROC analysis;–;0,858;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;15;;
4OHE1;4OHE1;4OHE1;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;18;0, 18;–;smoker, non-smoker;healthy;17;0, 17;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;0,39;0,7;0,5571428571;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;16;;
2OME1;2OME1;2OME1;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;17;17, 0;–;smoker, non-smoker;healthy;15;15, 0;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;0,51;0,62;0,8225806452;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;17;;
C4-carnitine;C4-carnitine;C4-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,54;0,2;2,7;0,001;–;–;ROC analysis;–;0,879;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;18;;
2OHE2;2OHE2;2OHE2;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;17;17, 0;–;smoker, non-smoker;healthy;15;15, 0;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;0,71;0,76;0,9342105263;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;19;;
C3-carnitine;C3-carnitine;C3-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;0,77;0,77;1;0,429;–;–;ROC analysis;–;0,432;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;20;;
2OME2;2OME2;2OME2;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;18;0, 18;–;smoker, non-smoker;healthy;17;0, 17;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;0,88;1,13;0,7787610619;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;21;;
2OHE2;2OHE2;2OHE2;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;18;0, 18;–;smoker, non-smoker;healthy;17;0, 17;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;1,28;1,82;0,7032967033;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;22;;
C3-carnitine;C3-carnitine;C3-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;1,3;0,55;2,3636363636;0,001;–;–;ROC analysis;–;0,869;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;23;;
2OME1;2OME1;2OME1;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;18;0, 18;–;smoker, non-smoker;healthy;17;0, 17;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;1,47;1,73;0,8497109827;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;24;;
2OHE1;2OHE1;2OHE1;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;17;17, 0;–;smoker, non-smoker;healthy;15;15, 0;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;1,86;1,96;0,9489795918;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;25;;
E3;E3;E3;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;17;17, 0;–;smoker, non-smoker;healthy;15;15, 0;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;2,57;2,88;0,8923611111;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;26;;
2OHE1;2OHE1;2OHE1;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;18;0, 18;–;smoker, non-smoker;healthy;17;0, 17;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;2,69;4,1;0,656097561;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;27;;
E3;E3;E3;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;18;0, 18;–;smoker, non-smoker;healthy;17;0, 17;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;3,53;4,87;0,7248459959;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;28;;
E1;E1;E1;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;17;17, 0;–;smoker, non-smoker;healthy;15;15, 0;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;6,1;5,84;1,0445205479;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;29;;
E1;E1;E1;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;18;0, 18;–;smoker, non-smoker;healthy;17;0, 17;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;8,48;9,79;0,8661899898;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;30;;
C2-carnitine;C2-carnitine;C2-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;8,52;8,31;1,0252707581;0,243;–;–;ROC analysis;–;0,437;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;31;;
C2-carnitine;C2-carnitine;C2-carnitine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;8,69;6,8;1,2779411765;0,205;–;–;ROC analysis;–;0,609;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;32;;
E2;E2;E2;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;17;17, 0;–;smoker, non-smoker;healthy;15;15, 0;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;8,98;9,18;0,9782135076;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;33;;
E2;E2;E2;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC;–;18;0, 18;–;smoker, non-smoker;healthy;17;0, 17;–;smoker, non-smoker;LC;–;–;Triple Quadrupole;MS/MS;Xcalibur;–;–;–;15,12;20,86;0,7248322148;–;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;29290988;Peng et al. 2017;34;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;21,02;32,55;0,6457757296;0,001;–;–;ROC analysis;–;0,076;–;–;–;–;–;–;–;–;China;Y;–;31258653;Ni et al. 2019;35;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;23,41;40,8;0,5737745098;0,001;–;–;ROC analysis;–;0,103;–;–;–;–;–;–;–;–;China;Y;–;31258653;Ni et al. 2019;36;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;27,22;30,24;0,9001322751;0,027;–;–;ROC analysis;–;0,316;–;–;–;–;–;–;–;–;China;Y;–;31258653;Ni et al. 2019;37;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;32;37,12;0,8620689655;0,01;–;–;ROC analysis;–;0,277;–;–;–;–;–;–;–;–;China;Y;–;31258653;Ni et al. 2019;38;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;84,06;104,19;0,8067952779;0,003;–;–;ROC analysis;–;0,242;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;39;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;92,47;94,31;0,9804898738;0,647;–;–;ROC analysis;–;0,481;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;40;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;95,76;102,74;0,9320615145;0,261;–;–;ROC analysis;–;0,398;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;41;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;97,25;67,13;1,4486816624;0,001;–;–;ROC analysis;–;0,841;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;42;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;101,11;120,3;0,840482128;0,001;–;–;ROC analysis;–;0,25;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;43;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;114,95;86,28;1,3322902179;0,001;–;–;ROC analysis;–;0,766;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;44;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;122,48;98;1,2497959184;0,001;–;–;ROC analysis;–;0,754;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;45;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;126,29;127,9;0,9874120407;0,704;–;–;ROC analysis;–;0,467;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;46;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;129,4;115,71;1,1183130239;0,009;–;–;ROC analysis;–;0,642;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;47;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;136,6;165,03;0,8277282918;0,001;–;–;ROC analysis;–;0,183;–;–;–;–;–;–;–;–;China;Y;–;31258653;Ni et al. 2019;48;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;138,6111111111;142,3;0,9740766768;0,557818485;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;49;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;139,6;133,13;1,0485991136;0,822;–;–;ROC analysis;–;0,481;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;50;;
arginine;arginine;arginine;–;–;–;HMDB0000517;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;139,89;119,89;1,1668195846;0,012;–;–;ROC analysis;–;0,716;–;–;–;–;–;–;–;–;China;Y;–;31258653;Ni et al. 2019;51;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;146,5;135,48;1,0813404193;0,934;–;–;ROC analysis;–;0,505;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;52;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;150,73;171,69;0,8779195061;0,009;–;–;ROC analysis;–;0,299;–;–;–;–;–;–;–;–;China;Y;–;31258653;Ni et al. 2019;53;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;168,7272727273;112,3636363636;1,501618123;0,4394342595;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;54;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;197,29;145,11;1,3595892771;0,043;–;–;ROC analysis;–;0,603;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;55;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;218;230,7272727273;0,9448384555;0,9981133161;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;56;;
2-deoxyribonic acid;2-deoxyribonic acid;2-deoxyribonic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;219;302,0909090909;0,7249473367;0,5302363905;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;57;;
arginine;arginine;arginine;–;–;–;HMDB0000517;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;224,94;119,51;1,8821855912;0,001;–;–;ROC analysis;–;0,907;–;–;–;–;–;–;–;–;China;Y;–;31258653;Ni et al. 2019;58;;
2-deoxyribonic acid;2-deoxyribonic acid;2-deoxyribonic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;225,6111111111;292,1;0,7723762791;0,2601908497;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;59;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;234,4444444444;215,25;1,0891727965;0,2782919984;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;60;;
2-oxogluconic acid;2-oxogluconic acid;2-oxogluconic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;236,3636363636;285,5454545455;0,8277618593;0,1146938629;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;61;;
N-acetyl-D-mannosamine;N-acetyl-D-mannosamine;N-acetyl-D-mannosamine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;255,5555555556;278,25;0,9184386543;0,3564105485;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;62;;
N-acetyl-D-mannosamine;N-acetyl-D-mannosamine;N-acetyl-D-mannosamine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;260,7272727273;274,1818181818;0,950928382;0,153847297;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;63;;
2-oxogluconic acid;2-oxogluconic acid;2-oxogluconic acid;NIST;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;271,7222222222;251,5;1,0804064502;0,28932853;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;64;;
glutaric acid;glutaric acid;glutaric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;272,4545454545;977,4545454545;0,2787388393;0,1808306633;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;65;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;II, III, IV;17;13, 4;66.3 (53-77);former, current, non-smoker;healthy;30;23, 7;62.8 (34-85);former, current, non-smoker;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;324,88;364,36;0,8916456252;0,007;–;–;ROC analysis;–;0,267;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;66;;
glycerol-beta-phosphate;glycerol-beta-phosphate;glycerol-beta-phosphate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;350,2727272727;336,4545454545;1,0410699811;0,3335960602;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;67;;
glucose-6-phosphate;glucose-6-phosphate;glucose-6-phosphate;–;–;–;HMDB0001401;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;359,9090909091;379,2727272727;0,94894535;0,5198041862;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;68;;
glucose-6-phosphate;glucose-6-phosphate;glucose-6-phosphate;–;–;–;HMDB0001401;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;366,6666666667;372,25;0,9850011193;0,5191088846;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;69;;
glycerol-beta-phosphate;glycerol-beta-phosphate;glycerol-beta-phosphate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;369,9444444444;319,15;1,1591553954;0,2780452689;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;70;;
2-aminoadipic acid;2-aminoadipic acid;2-aminoadipic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;378,3888888889;429;0,882025382;0,0777617538;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;71;;
erythrose;erythrose;erythrose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;397,7777777778;420,3;0,9464139371;0,2806432775;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;72;;
2-aminoadipic acid;2-aminoadipic acid;2-aminoadipic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;407,0909090909;403;1,0101511392;0,4962615218;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;73;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;–;40;26, 14;66.7 (49-83);–;healthy;100;65, 35;64.1 (41-90);–;LC;ESI;positive;triple quadrupole;MS/MS;–;HMDB, KEGG, SMPDB;SIMCA-P, SPSS;Mann-Whitney U test, Student's t-test, Welch's F test ;408,8;407,44;1,0033379148;0,605;–;–;ROC analysis;–;0,467;–;–;–;–;–;–;–;–;China;–;–;31258653;Ni et al. 2019;74;;
3,6-anhydrogalactose;3,6-anhydrogalactose;3,6-anhydrogalactose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;411,4545454545;439,3636363636;0,9364783778;0,440680733;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;75;;
3,6-anhydrogalactose;3,6-anhydrogalactose;3,6-anhydrogalactose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;417,7222222222;432,4;0,966055093;0,4856691057;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;76;;
erythrose;erythrose;erythrose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;423,4545454545;395,8181818182;1,0698208544;0,4217749282;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;77;;
aconitic acid;aconitic acid;aconitic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;427,5555555556;510;0,8383442266;0,0303872806;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;78;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;438,6363636364;541,8181818182;0,8095637584;0,1786380352;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;79;;
inositol-4-monophosphate;inositol-4-monophosphate;inositol-4-monophosphate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;447,3888888889;425,65;1,0510722163;0,453422558;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;80;;
aconitic acid;aconitic acid;aconitic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;479,0909090909;462,7272727273;1,0353634578;0,8085373655;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;81;;
inositol-4-monophosphate;inositol-4-monophosphate;inositol-4-monophosphate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;484,5454545455;387,3636363636;1,2508800751;0,102295819;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;82;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;500,4545454545;965,8181818182;0,5181664157;0,1795190921;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;83;;
cysteine-glycine;cysteine-glycine;cysteine-glycine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;518,8333333333;660,05;0,7860515618;0,5009661589;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;84;;
azelaic acid;azelaic acid;azelaic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;545,6363636364;4671,4545454546;0,1168022419;0,3438473931;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;85;;
alpha-ketoglutaric acid;alpha-ketoglutaric acid;alpha-ketoglutaric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;564,0909090909;653,5454545455;0,8631242176;0,3040532989;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;86;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;571,7222222222;417,15;1,3705435029;0,1088355109;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;87;;
isolinoleic acid;isolinoleic acid;isolinoleic acid;NIST;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;575,2222222222;571,65;1,0062489674;0,8016041385;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;88;;
1-monostearin;1-monostearin;1-monostearin;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;604;597,8;1,0103713617;0,9966753621;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;89;;
isolinoleic acid;isolinoleic acid;isolinoleic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;609,2727272727;537,3636363636;1,1338183049;0,5076454385;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;90;;
glutaric acid;glutaric acid;glutaric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;635,8888888889;614,75;1,0343861552;0,5308456916;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;91;;
sucrose;sucrose;sucrose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;646,7222222222;1363,2;0,4744147757;0,2908853037;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;92;;
1-monostearin;1-monostearin;1-monostearin;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;652;549,7272727273;1,1860426658;0,3264787762;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;93;;
glycerol-3-galactoside;glycerol-3-galactoside;glycerol-3-galactoside;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;654,5555555556;817,75;0,8004347974;0,29883954;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;94;;
monopalmitin-1-glyceride;monopalmitin-1-glyceride;monopalmitin-1-glyceride;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;664,4545454545;565,6363636364;1,174702668;0,8475610689;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;95;;
2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;NIST;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;670,2777777778;712,55;0,9406747285;0,6767042476;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;96;;
cysteine-glycine;cysteine-glycine;cysteine-glycine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;690,3636363636;496,1818181818;1,3913521436;0,0009553148;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;97;;
alpha ketoglutaric acid;alpha ketoglutaric acid;alpha ketoglutaric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;708,5;519,3;1,364336607;0,09316382;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;98;;
ribitol;ribitol;ribitol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;711,0909090909;845,8181818182;0,8407136715;0,3792854663;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;99;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;714,4444444444;749,9;0,9527196219;0,6413717961;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;100;;
xylulose;xylulose;xylulose;NIST;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;719,8181818182;938,3636363636;0,7670993993;0,0044472295;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;101;;
monopalmitin-1-glyceride;monopalmitin-1-glyceride;monopalmitin-1-glyceride;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;742,2777777778;500,6;1,4827762241;0,0677326278;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;102;;
trehalose;trehalose;trehalose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;758,5;742,55;1,021480035;0,8772665706;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;103;;
ribitol;ribitol;ribitol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;765,7222222222;789,9;0,9693913435;0,7459809804;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;104;;
2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;782,4545454545;602,4545454545;1,2987777275;0,2330420036;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;105;;
glycerol-3-galactoside;glycerol-3-galactoside;glycerol-3-galactoside;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;800,1818181818;680,3636363636;1,1761090326;0,6450058554;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;106;;
biuret;biuret;biuret;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;807,1666666667;848,7;0,9510624092;0,5618678158;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;107;;
hydroxycarbamate;hydroxycarbamate;hydroxycarbamate;NIST;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;844,3888888889;723,5;1,1670889964;0,4450840852;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;108;;
trehalose;trehalose;trehalose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;865,0909090909;635;1,3623478883;0,1794959701;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;109;;
biuret;biuret;biuret;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;867;790,9090909091;1,0962068966;0,3190481843;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;110;;
sucrose;sucrose;sucrose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;895,7272727273;1151,9090909091;0,7776023992;0,6345429348;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;111;;
cellobiose;cellobiose;cellobiose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;903,7272727273;942;0,9593707778;0,4470507777;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;112;;
hydroxycarbamate;hydroxycarbamate;hydroxycarbamate;NIST;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;927,9090909091;633,6363636364;1,4644189383;0,0339020946;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;113;;
cellobiose;cellobiose;cellobiose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;946,9444444444;901,2;1,0507594812;0,9838036545;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;114;;
ribose;ribose;ribose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;949,2727272727;1499,3636363636;0,63311708;0,0134632705;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;115;;
hydrocinnamic acid;hydrocinnamic acid;hydrocinnamic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;966;1256;0,7691082803;0,3985962667;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;116;;
xylulose;xylulose;xylulose;NIST;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;988,0555555556;686,05;1,4402092494;0,1335766176;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;117;;
xylitol;xylitol;xylitol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1008,1818181818;1218,1818181818;0,8276119403;0,4604579786;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;118;;
5-methoxytryptamine;5-methoxytryptamine;5-methoxytryptamine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1034,8181818182;1198,3636363636;0,8635260203;0,704781815;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;119;;
maltose;maltose;maltose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1061,4545454546;988,6363636364;1,0736551724;0,8185796055;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;120;;
phosphoethanolamine;phosphoethanolamine;phosphoethanolamine;–;–;–;HMDB0000224;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1087,5454545455;1265,4545454546;0,8594109195;0,1160593195;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;121;;
hydrocinnamic acid;hydrocinnamic acid;hydrocinnamic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1108,1666666667;1113,75;0,9949869061;0,8123988637;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;122;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1149,0909090909;1557,8181818182;0,7376283847;0,1200360562;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;123;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1203,7272727273;1162,3636363636;1,035585797;0,6812430393;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;124;;
xylitol;xylitol;xylitol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1208,1111111111;1027,75;1,1754912295;0,485714482;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;125;;
phosphoethanolamine;phosphoethanolamine;phosphoethanolamine;–;–;–;HMDB0000224;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1214,7777777778;1142,3;1,0634489869;0,9288644256;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;126;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1230,5555555556;1140,45;1,0790087733;0,3319818565;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;127;;
pyrophosphate;pyrophosphate;pyrophosphate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1241,7777777778;1471,55;0,8438570064;0,464134125;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;128;;
5-methoxytryptamine;5-methoxytryptamine;5-methoxytryptamine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1260,2777777778;987,15;1,2766831563;0,2961353018;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;129;;
quinic acid;quinic acid;quinic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1264,9090909091;1499,7272727273;0,8434260775;0,2337090172;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;130;;
maltose;maltose;maltose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1297,5;779,95;1,6635681774;0,0131538257;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;131;;
allo-inositol;allo-inositol;allo-inositol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1393;2438,2727272727;0,5713060661;0,4551135467;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;132;;
ribose;ribose;ribose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1417,6666666667;1050,5;1,3495161034;0,4007631399;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;133;;
conduritol-beta-epoxide;conduritol-beta-epoxide;conduritol-beta-epoxide;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1427,8181818182;3062,6363636364;0,4662055864;0,3324612081;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;134;;
pyrophosphate;pyrophosphate;pyrophosphate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1431,8181818182;1293,6363636364;1,1068165847;0,1086807379;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;135;;
allo-inositol;allo-inositol;allo-inositol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1443,3333333333;2340,65;0,6166378285;0,2027395226;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;136;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1463,8888888889;1254,1;1,1672824248;0,0856627899;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;137;;
levoglucosan;levoglucosan;levoglucosan;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1476,3888888889;3014,4;0,4897786919;0,542604331;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;138;;
quinic acid;quinic acid;quinic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1520,8333333333;1257,5;1,2094102054;0,7035950338;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;139;;
dihydroabietic acid;dihydroabietic acid;dihydroabietic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1534,3888888889;1709,85;0,8973821615;0,3592296999;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;140;;
gluconic acid;gluconic acid;gluconic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1560,6363636364;1274,1818181818;1,2248144977;0,2671987725;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;141;;
gluconic acid;gluconic acid;gluconic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1576,5;1274,25;1,237198352;0,2596497222;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;142;;
octadecanol;octadecanol;octadecanol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1579,7777777778;1213,75;1,3015676851;0,0902420826;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;143;;
1-hexadecanol;1-hexadecanol;1-hexadecanol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1598;1398,2;1,1428980117;0,1512293232;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;144;;
threitol;threitol;threitol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1619,7272727273;1800,6363636364;0,899530469;0,2121079258;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;145;;
octadecanol;octadecanol;octadecanol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1627,6363636364;1146,4545454546;1,419712949;0,028609143;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;146;;
trans-4-hydroxyproline;trans-4-hydroxyproline;trans-4-hydroxyproline;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1730,8888888889;2104,95;0,8222945385;0,0513287101;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;147;;
1-hexadecanol;1-hexadecanol;1-hexadecanol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1734,9090909091;1250,8181818182;1,3870194055;0,0090155522;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;148;;
adipic acid;adipic acid;adipic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1755,7272727273;3091,2727272727;0,5679625926;0,6349357106;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;149;;
beta-alanine;beta-alanine;beta-alanine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1797,5;1814,65;0,9905491417;0,6988245224;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;150;;
threitol;threitol;threitol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1812,1111111111;1618,4;1,1196929752;0,6751391542;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;151;;
lignoceric acid;lignoceric acid;lignoceric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1819,3888888889;1828,5;0,9950171665;0,7754361191;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;152;;
dihydroabietic acid;dihydroabietic acid;dihydroabietic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1862,1818181818;1391,3636363636;1,3383861483;0,0126740613;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;153;;
lignoceric acid;lignoceric acid;lignoceric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1897,7272727273;1750,7272727273;1,0839651054;0,276547924;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;154;;
2-phenylpropanol;2-phenylpropanol;2-phenylpropanol;NIST;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;1924,9444444444;2055,35;0,9365531148;0,4594413824;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;155;;
adipic acid;adipic acid;adipic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2055,3333333333;2754,8;0,7460916703;0,0285907909;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;156;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2058,5555555556;2571;0,8006828299;0,031054351;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;157;;
beta-alanine;beta-alanine;beta-alanine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2094,7272727273;1518,3636363636;1,3795952581;0,0775283607;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;158;;
2-phenylpropanol;2-phenylpropanol;2-phenylpropanol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2098,2727272727;1888,7272727273;1,1109453215;0,2016082993;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;159;;
behenic acid;behenic acid;behenic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2135,2727272727;2155,5454545455;0,9905950825;0,9990574626;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;160;;
inulobiose;inulobiose;inulobiose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2180,9090909091;2210;0,9868366927;0,9645414807;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;161;;
behenic acid;behenic acid;behenic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2194,3333333333;2101,4;1,0442244853;0,547178758;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;162;;
trans-4-hydroxyproline;trans-4-hydroxyproline;trans-4-hydroxyproline;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2208,4545454546;1647,1818181818;1,3407472819;0,090260394;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;163;;
inulobiose;inulobiose;inulobiose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2278,1111111111;2121,35;1,0738968634;0,8121246452;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;164;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2340,6363636364;2316,0909090909;1,0105977941;0,8574404352;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;165;;
gamma-tocopherol;gamma-tocopherol;gamma-tocopherol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2495,5;2312,9;1,0789485062;0,2911117768;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;166;;
azelaic acid;azelaic acid;azelaic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2522,8333333333;2685,9;0,9392878861;0,5002658351;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;167;;
conduritol-beta-epoxide;conduritol-beta-epoxide;conduritol-beta-epoxide;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2527,1111111111;1991,65;1,2688530169;0,9060207055;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;168;;
arachidic acid;arachidic acid;arachidic acid;–;–;–;HMDB0002212;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2670,5;2741,4;0,9741373021;0,8160314399;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;169;;
levoglucosan;levoglucosan;levoglucosan;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2695,5454545455;1876,1818181818;1,4367186743;0,6063583851;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;170;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2792,8333333333;2829,2;0,9871459541;0,7868754497;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;171;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2800,1666666667;3042,3;0,9204110925;0,273328499;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;172;;
2-hydroxyglutaric acid;2-hydroxyglutaric acid;2-hydroxyglutaric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2842;4118,8181818182;0,6900037522;0,6802823015;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;173;;
erythritol;erythritol;erythritol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2845,0909090909;3462,0909090909;0,8217839981;0,0508928574;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;174;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2912,9090909091;2942,2727272727;0,9900200834;0,7807103902;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;175;;
arachidic acid;arachidic acid;arachidic acid;–;–;–;HMDB0002212;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;2981,4545454546;2434,1818181818;1,2248282044;0,1847641998;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;176;;
sorbitol;sorbitol;sorbitol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3040,2222222222;3537;0,8595482675;0,3835483023;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;177;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3048,0909090909;2575,5454545455;1,1834739331;0,0663876886;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;178;;
glucuronic acid;glucuronic acid;glucuronic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3110,2777777778;3806,5;0,817096487;0,7035089585;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;179;;
erythritol;erythritol;erythritol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3187,7777777778;3122,7;1,0208402273;0,9619247293;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;180;;
xylose;xylose;xylose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3302,8181818182;6454,6363636364;0,5116970184;0,0542660686;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;181;;
gamma-tocopherol;gamma-tocopherol;gamma-tocopherol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3330,1818181818;1468,7272727273;2,267392919;0,0089795742;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;182;;
isothreonic acid;isothreonic acid;isothreonic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3336,7222222222;3483,7;0,9578098637;0,7832548246;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;183;;
2-ketoisocaproic acid;2-ketoisocaproic acid;2-ketoisocaproic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3391,1818181818;3573,1818181818;0,9490650045;0,9472627419;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;184;;
2-hydroxyglutaric acid;2-hydroxyglutaric acid;2-hydroxyglutaric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3436,0555555556;3520,45;0,9760273702;0,9332238377;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;185;;
isothreonic acid;isothreonic acid;isothreonic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3438,7272727273;3389,3636363636;1,0145642786;0,7305332437;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;186;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3445,1818181818;4144;0,8313662689;0,1161247063;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;187;;
2-ketoisocaproic acid;2-ketoisocaproic acid;2-ketoisocaproic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3495,0555555556;3470,75;1,0070029693;0,9234799112;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;188;;
sorbitol;sorbitol;sorbitol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3540,1818181818;3063,2727272727;1,1556861349;0,4850705186;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;189;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3614,6111111111;3956,6;0,9135649576;0,1773114086;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;190;;
aminomalonic acid;aminomalonic acid;aminomalonic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3780,6111111111;4559,65;0,8291450245;0,6585917888;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;191;;
salicylic acid;salicylic acid;salicylic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3811,9090909091;19827,8181818182;0,1922505571;0,3427917738;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;192;;
elaidic acid;elaidic acid;elaidic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3944,8181818182;1937,3636363636;2,0361784994;0,5293903177;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;193;;
elaidic acid;elaidic acid;elaidic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;3969,5555555556;2015,4;1,9696117672;0,1682230264;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;194;;
methioninesulfoxide;methioninesulfoxide;methioninesulfoxide;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;4094,6666666667;5455,55;0,7505506625;0,0326676;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;195;;
aminomalonic acid;aminomalonic acid;aminomalonic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;4157,0909090909;4224,0909090909;0,9841385989;0,6353922784;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;196;;
glucuronic acid;glucuronic acid;glucuronic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;4237;2716,2727272727;1,5598580943;0,3854654891;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;197;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;4617,4545454546;3964,8181818182;1,1646068833;0,8962762156;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;198;;
pseudo uridine;pseudo uridine;pseudo uridine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;4669,6111111111;4566,15;1,0226582813;0,6393144019;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;199;;
fucoserhamnose;fucoserhamnose;fucoserhamnose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;4756,8181818182;6001,5454545455;0,792598876;0,1926887466;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;200;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;4762,3888888889;3867,2;1,2314824392;0,2257056095;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;201;;
1-monoolein;1-monoolein;1-monoolein;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;4842,0909090909;6314,0909090909;0,7668706357;0,1520250933;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;202;;
methioninesulfoxide;methioninesulfoxide;methioninesulfoxide;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;4847,4545454546;4774;1,0153863732;0,9893052867;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;203;;
maleimide;maleimide;maleimide;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;4922,8333333333;4454,55;1,1051247227;0,3731160096;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;204;;
methanolphosphate;methanolphosphate;methanolphosphate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;4945,4444444444;5225,15;0,946469373;0,8590420616;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;205;;
pseudo uridine;pseudo uridine;pseudo uridine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5089,1818181818;4141,1818181818;1,2289201589;0,349691091;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;206;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5261,7272727273;4374,6363636364;1,2027804908;0,9931678209;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;207;;
2-deoxyerythritol;2-deoxyerythritol;2-deoxyerythritol;NIST;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5397,3888888889;6728,65;0,8021503405;0,327679972;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;208;;
methanolphosphate;methanolphosphate;methanolphosphate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5426;4759;1,1401554949;0,1523355042;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;209;;
arabitol;arabitol;arabitol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5453,1818181818;5837,8181818182;0,9341129936;0,5345191716;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;210;;
arabitol;arabitol;arabitol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5478,5555555556;5795,6;0,9452956649;0,2715790265;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;211;;
maleimide;maleimide;maleimide;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5598,5454545455;3754,1818181818;1,4912824487;0,006321079;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;212;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5684,1818181818;6578,2727272727;0,8640842443;0,1150165493;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;213;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5687,8333333333;4035,35;1,4095018606;0,2262655445;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;214;;
2-hydroxyvaleric acid;2-hydroxyvaleric acid;2-hydroxyvaleric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5808,6666666667;5259,4;1,1044352334;0,296193401;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;215;;
2-deoxyerythritol;2-deoxyerythritol;2-deoxyerythritol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5815,3636363636;6380,8181818182;0,9113821254;0,6473685206;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;216;;
2-hydroxyvaleric acid;2-hydroxyvaleric acid;2-hydroxyvaleric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5825,8181818182;5213,3636363636;1,1174778105;0,0177140152;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;217;;
1-monoolein;1-monoolein;1-monoolein;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;5972,1111111111;5223,45;1,1433269412;0,3348974442;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;218;;
arachidonic acid isomer;arachidonic acid isomer;arachidonic acid isomer;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;6028,0909090909;5082,7272727273;1,1859953497;0,8153140123;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;219;;
xylose;xylose;xylose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;6184,6666666667;3703,45;1,6699743932;0,2494246008;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;220;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;6277,6666666667;5999,2;1,0464173001;0,758606079;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;221;;
arachidonic acid isomer;arachidonic acid isomer;arachidonic acid isomer;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;6308,7777777778;4877,5;1,293444957;0,0981284349;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;222;;
methylhexadecanoic acid;methylhexadecanoic acid;methylhexadecanoic acid;–;–;–;HMDB0031067;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;6415,0909090909;5853,2727272727;1,0959835989;0,8902325921;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;223;;
methylhexadecanoic acid;methylhexadecanoic acid;methylhexadecanoic acid;–;–;–;HMDB0031067;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;6680,5;5642,4;1,1839819935;0,0785926233;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;224;;
4-hydroxyproline;4-hydroxyproline;4-hydroxyproline;–;–;–;HMDB0000725;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;7637,3888888889;9685,05;0,7885750604;0,0770067712;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;225;;
cysteine;cysteine;cysteine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;7816,2222222222;9046,7;0,8639860084;0,253422814;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;226;;
3-aminoisobutyric acid;3-aminoisobutyric acid;3-aminoisobutyric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;8321,7777777778;10368,05;0,8026367328;0,0799088103;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;227;;
cysteine;cysteine;cysteine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;8400,9090909091;8526,7272727273;0,9852442587;0,5486006821;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;228;;
4-hydroxyproline;4-hydroxyproline;4-hydroxyproline;–;–;–;HMDB0000725;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;8552,1818181818;8878,0909090909;0,9632906337;0,9799450641;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;229;;
3-aminoisobutyric acid;3-aminoisobutyric acid;3-aminoisobutyric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;8916,7272727273;9881,1818181818;0,9023948184;0,5907988047;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;230;;
benzylalcohol;benzylalcohol;benzylalcohol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;9034,8888888889;9904,75;0,9121773784;0,9690778778;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;231;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;–;–;HMDB0003229;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;9374,2727272727;6484,1818181818;1,4457140454;0,8982155029;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;232;;
hydroxylamine;hydroxylamine;hydroxylamine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;9695,1111111111;8432,35;1,1497519803;0,4633431192;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;233;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;–;–;HMDB0003229;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;10490,7777777778;5624,1;1,8653256126;0,0882440426;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;234;;
glycerol-alpha-phosphate;glycerol-alpha-phosphate;glycerol-alpha-phosphate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;10504,2777777778;10069,05;1,0432243139;0,60494491;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;235;;
glycerol-alpha-phosphate;glycerol-alpha-phosphate;glycerol-alpha-phosphate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;10686,7272727273;9863,9090909091;1,0834170484;0,7025119314;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;236;;
hydroxylamine;hydroxylamine;hydroxylamine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;10725;7336,2727272727;1,4619140262;0,0135654759;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;237;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;10998,6363636364;20003,0909090909;0,5498468419;0,2858922832;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;238;;
benzylalcohol;benzylalcohol;benzylalcohol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;11312,9090909091;7672,6363636364;1,4744487494;0,1492635411;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;239;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;11433,9444444444;14440,4;0,7918024739;0,1847815215;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;240;;
aspartic acid;aspartic acid;aspartic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;11554,1818181818;21026,1818181818;0,5495140258;0,1646948941;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;241;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;12132,6111111111;12177,15;0,9963424209;0,7323951058;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;242;;
salicylic acid;salicylic acid;salicylic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;12247,4444444444;11435,2;1,0710301914;0,2625308291;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;243;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;12300,8181818182;12011,3636363636;1,0240983917;0,8042209486;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;244;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;12571,4545454545;11845,1818181818;1,0613137678;0,3197545383;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;245;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;12947,0909090909;11675;1,1089585361;0,8642850491;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;246;;
threonic acid;threonic acid;threonic acid;–;–;–;HMDB0000943;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;13104,7222222222;18193,75;0,7202870339;0,0608059597;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;247;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;13190,8333333333;11519,1;1,1451270788;0,1222631839;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;248;;
tocopherol alpha;tocopherol alpha;tocopherol alpha;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;13260;14672,2;0,9037499489;0,4904579069;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;249;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;13299,0909090909;11405;1,1660754852;0,3950463477;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;250;;
threonic acid;threonic acid;threonic acid;–;–;–;HMDB0000943;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;13327,0909090909;18239,2727272727;0,7306810479;0,1781776311;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;251;;
asparagine;asparagine;asparagine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;13549,2727272727;16206,2727272727;0,8360511362;0,5419338219;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;252;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;13965,2777777778;10900;1,2812181448;0,1726502614;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;253;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;14108,1818181818;19498,6363636364;0,7235471012;0,2743493451;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;254;;
tocopherol alpha;tocopherol alpha;tocopherol alpha;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;14255,4545454545;13751,0909090909;1,0366780817;0,6035115403;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;255;;
propane-1,3-diol;propane-1,3-diol;propane-1,3-diol;NIST;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;14301,7222222222;12407,35;1,1526814527;0,1868020931;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;256;;
propane-1,3-diol;propane-1,3-diol;propane-1,3-diol;NIST;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;14474,4545454545;12135,2727272727;1,1927588997;0,001495774;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;257;;
asparagine;asparagine;asparagine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;14487,0555555556;15229,3;0,9512620774;0,8575691757;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;258;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;14725,4444444444;16198,9;0,909039777;0,3212857418;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;259;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;14990,0909090909;11042,3636363636;1,3575074506;0,7400105744;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;260;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;15337,9444444444;9391,95;1,6330947721;0,1265962159;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;261;;
capric acid;capric acid;capric acid;–;–;–;HMDB0000511;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;16142,1111111111;15372,55;1,0500607324;0,1970033215;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;262;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;16294,1666666667;17261,85;0,9439409256;0,4890988187;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;263;;
capric acid;capric acid;capric acid;–;–;–;HMDB0000511;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;16447,4545454545;15026,6363636364;1,0945533084;0,5089848282;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;264;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;17391,7272727273;22016,2727272727;0,7899487569;0,2583016888;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;265;;
beta-mannosylglycerate;beta-mannosylglycerate;beta-mannosylglycerate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;17683,7222222222;16626,55;1,0635833785;0,5122690618;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;266;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;17932,8888888889;18974,15;0,9451221208;0,4836271656;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;267;;
beta-mannosylglycerate;beta-mannosylglycerate;beta-mannosylglycerate;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;18067,5454545455;16187,1818181818;1,1161637435;0,2161889782;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;268;;
acetophenone;acetophenone;acetophenone;NIST;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;18387,3888888889;18792,8;0,9784273173;0,9106320048;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;269;;
aspartic acid;aspartic acid;aspartic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;18708,3333333333;14113,75;1,3255395152;0,025122529;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;270;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;19276,2727272727;17685,7272727273;1,089933845;0,6809860124;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;271;;
acetophenone;acetophenone;acetophenone;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;19745,8181818182;17455,6363636364;1,1312001333;0,1566383972;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;272;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;19996,1111111111;19441,15;1,0285456936;0,7324532166;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;273;;
N-methylalanine;N-methylalanine;N-methylalanine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;21216,7777777778;26237,85;0,8086324824;0,065984011;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;274;;
N-methylalanine;N-methylalanine;N-methylalanine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;21672,1818181818;26046,2727272727;0,8320646123;0,2635120099;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;275;;
erythronic acid lactone;erythronic acid lactone;erythronic acid lactone;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;23480,5;43003,5;0,5460136966;0,4726213287;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;276;;
cystine;cystine;cystine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;24613;23835,05;1,0326389078;0,9577081354;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;277;;
cystine;cystine;cystine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;24883,3636363636;23523,7272727273;1,057798509;0,5930874872;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;278;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;30216,1111111111;32116,75;0,9408209458;0,3003340194;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;279;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;30526,0555555556;37025,45;0,8244614328;0,0357542588;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;280;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;30627;31805,5454545455;0,962945284;0,7047054534;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;281;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;31053,4545454545;36840,1818181818;0,8429234877;0,0468013411;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;282;;
erythronic acid lactone;erythronic acid lactone;erythronic acid lactone;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;31082,8181818182;36428,5454545455;0,8532544408;0,0816432077;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;283;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;31486,3636363636;34887,1818181818;0,90251955;0,9143832208;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;284;;
pelargonic acid;pelargonic acid;pelargonic acid;–;–;–;HMDB0000847;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;33678,6363636364;35053,3636363636;0,9607818728;0,8199528388;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;285;;
pelargonic acid;pelargonic acid;pelargonic acid;–;–;–;HMDB0000847;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;34173,3888888889;34539,35;0,9894045166;0,9500701703;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;286;;
inositolmyo;inositolmyo;inositolmyo;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;38940,9090909091;39584,6363636364;0,9837379516;0,7640861894;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;287;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;39179,2222222222;27793,75;1,4096414562;0,0260681903;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;288;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;41161,4444444444;37554,1;1,0960572732;0,6583348518;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;289;;
2-hydroxybutanoic acid;2-hydroxybutanoic acid;2-hydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;46231,1666666667;42560,5;1,0862458539;0,3894640769;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;290;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;48235,0555555556;50490,6;0,9553274383;0,640668948;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;291;;
2-hydroxybutanoic acid;2-hydroxybutanoic acid;2-hydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;48482,7272727273;40115,8181818182;1,2085688257;0,1922376217;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;292;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;50486,8181818182;48357,8181818182;1,044025973;0,6056109716;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;293;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;50740,0909090909;43659,3636363636;1,1621811837;0,7973956455;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;294;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;53763,0555555556;41292,85;1,3019943054;0,047139921;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;295;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;56664,1818181818;61435,7272727273;0,9223327261;0,2264993808;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;296;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;57329,7222222222;60598,1;0,9460646823;0,321911474;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;297;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;60191,4545454545;69059,6363636364;0,8715866129;0,0468109416;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;298;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;66463,1111111111;49061,55;1,3546883682;0,0233850256;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;299;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;67556,5454545455;47052,2727272727;1,4357764575;0,315444354;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;300;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;70127,2222222222;59673,95;1,1751731237;0,0186438044;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;301;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;81830,9090909091;113067,272727273;0,7237364723;0,010401223;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;302;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;83863,3888888889;84542,4;0,9919683956;0,4910659085;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;303;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;84488,0909090909;83953,4545454545;1,0063682473;0,7656305359;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;304;;
threonine;threonine;threonine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;87262,5555555556;101120,55;0,8629557054;0,1189153648;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;305;;
fructose;fructose;fructose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;88402,3888888889;142258,6;0,6214203492;0,2876523209;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;306;;
threonine;threonine;threonine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;91013,3636363636;98098,9090909091;0,9277714144;0,3824171319;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;307;;
1,5-anhydroglucitol;1,5-anhydroglucitol;1,5-anhydroglucitol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;92187,8181818182;88164;1,04564015;0,5310175895;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;308;;
1,5-anhydroglucitol;1,5-anhydroglucitol;1,5-anhydroglucitol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;95587,3888888889;85305,45;1,1205308558;0,4372082284;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;309;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;97409,6111111111;97484,7;0,9992297367;0,6924799134;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;310;;
isoleucine;isoleucine;isoleucine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;109955,111111111;119694,25;0,9186331934;0,5123711104;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;311;;
isoleucine;isoleucine;isoleucine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;115073,090909091;115088,818181818;0,9998633466;0,7163218739;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;312;;
fructose;fructose;fructose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;117303;116192,454545455;1,0095578104;0,8875038134;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;313;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;121513,055555556;143382,65;0,8474739137;0,0050807931;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;314;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;126620,909090909;139425,727272727;0,9081602913;0,3908953217;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;315;;
arginineornithine;arginineornithine;arginineornithine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;128983,545454545;127258,363636364;1,01355653;0,7074160202;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;316;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;134942,888888889;148722,95;0,9073440843;0,2558813212;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;317;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;137603,636363636;146787,454545455;0,9374345838;0,4423936211;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;318;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;143616,727272727;145074,545454545;0,9899512476;0,9113121582;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;319;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;145808,722222222;143028,95;1,019435032;0,800856166;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;320;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;150655;127546,181818182;1,1811800075;0,0058060603;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;321;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;156214;123698,5;1,2628609078;0,0155859449;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;322;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;158494,090909091;215568,636363636;0,7352372478;0,0551499616;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;323;;
lysine;lysine;lysine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;159156,444444444;179325,4;0,8875287296;0,0419849801;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;324;;
lysine;lysine;lysine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;167528,454545455;172015;0,973917708;0,6360909998;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;325;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;175416,944444444;197484,35;0,8882574464;0,2634668061;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;326;;
oxoproline;oxoproline;oxoproline;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;195323,272727273;203595,090909091;0,9593712297;0,9048475488;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;327;;
oxoproline;oxoproline;oxoproline;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;201697,888888889;197444,35;1,021542976;0,6110784593;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;328;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;216130,727272727;326192,818181818;0,6625857935;0,0166120549;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;329;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;260510,388888889;280747,85;0,9279158821;0,5226253082;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;330;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;269250,444444444;313032,4;0,8601360257;0,0381425692;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;331;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;273421,222222222;237344,3;1,15200248;0,0691859826;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;332;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;275601,272727273;233265,090909091;1,1814938603;0,2269215981;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;333;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;294290,444444444;263529,35;1,1167273947;0,2830212508;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;334;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;295018,636363636;289568,454545455;1,0188217388;0,2564509944;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;335;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;296451;259749,636363636;1,1412951492;0,0701518982;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;336;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;309110,611111111;359573,6;0,8596588045;0,0753407571;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;337;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;321619,454545455;349720,636363636;0,9196467726;0,5610519696;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;338;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;365080,222222222;334435,4;1,0916315146;0,1157585473;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;339;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;365106,818181818;332795,909090909;1,0970892616;0,275391748;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;340;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;380753,333333333;301909,2;1,2611518077;0,0550012122;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;341;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;381850,090909091;296662,818181818;1,2871518354;0,1082154513;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;342;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;402769,166666667;437579;0,9204490313;0,7146639772;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;343;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;449419,272727273;576252,636363636;0,7798997252;0,0076542285;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;344;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;476241;365939,181818182;1,3014211751;0,6030549088;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;345;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;494183,5;529623,45;0,9330846283;0,2637496864;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;346;;
glucose;glucose;glucose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;610872,636363636;630890,090909091;0,9682710906;0,5234348503;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;347;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;620351,333333333;630235,1;0,9843173339;0,802285161;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;348;;
glucose;glucose;glucose;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma;unknown (mostly late stage);18;10, 8;67 (50-85) / 62 (53-72);former, current;healthy;20;8, 12;64 (49-80) / 66 (58-82);former, current;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;650817,777777778;593938,65;1,0957659984;0,4223870742;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;349;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;NSCLC, SCLC, mesothelioma, secondary metastasis to lung;I, II, III, IV;11;4, 7;67 (61-73) / 67 (47-76);smoker, non-smoker;healthy;11;5, 6;69 (61-83) / 54 (44-61);unknown;GC;EI;–;TOF;MS/MS;ChromaTOF software (Leco);UC Davis Metabolomics BinBase database;–;Analysis of Covariance;666717,727272727;584389;1,1408800085;0,2246056899;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;MetaMapp mapping;25859693;Miyamoto et al. 2015;350;;
5-hydroxytryptophan;5-hydroxytryptophan;5-hydroxytryptophan;–;–;–;–;–;–;–;Amino acid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;GC;EI;–;–;–;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA; ;–;0,3711308927;0,00772;–;1,19;ROC curve analysis;–;0,7;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;351;;
dihydrosphingosine;dihydrosphingosine;dihydrosphingosine;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.022 uM;0.022 uM;1;0,84;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;352;;
sphingosine;sphingosine;sphingosine;–;–;–;HMDB0000252;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.031 uM;0.03 uM;1,0333333333;0,22;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;353;;
C20:1-ceramide;C20:1-ceramide;C20:1-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.035 uM;0.033 uM;1,0606060606;0,17;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;354;;
C14-carnitine;C14-carnitine;C14-carnitine;–;–;–;–;–;–;–;–;–;428,4;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;0.04 ± 0.02 μmol/L;0.02 ± 0.02 μmol/L;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;355;;
C18:1-ceramide;C18:1-ceramide;C18:1-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.046 uM;0.043 uM;1,0697674419;0,043;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;356;;
dihydroC16-ceramide;dihydroC16-ceramide;dihydroC16-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.049 uM;0.047 uM;1,0425531915;0,32;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;357;;
C26:1-ceramide;C26:1-ceramide;C26:1-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.054 uM;0.052 uM;1,0384615385;0,12;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;358;;
C6-carnitine;C6-carnitine;C6-carnitine;–;–;–;–;–;–;–;–;–;316,4;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;0.06 ± 0.09 μmol/L;0.06 ± 0.06 μmol/L;–;0,9906;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;359;;
C8-carnitine;C8-carnitine;C8-carnitine;–;–;–;–;–;–;–;–;–;344,4;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;0.06 ± 0.11 μmol/L;0.08 ± 0.09 μmol/L;–;0,3164;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;360;;
C14-ceramide;C14-ceramide;C14-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.064 uM;0.066 uM;0,9696969697;0,16;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;361;;
ranitidine;ranitidine;ranitidine;–;–;3001055;HMDB01930;–;–;D00422;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.06633404± 0.2078001;0.08365368± 0.2898363;0,7929602141;0,6052244;0,64176439;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;362;;
D-gluconic acid;D-gluconic acid;D-gluconic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.093606 ± 0.039298;0.089903 ± 0.045331;1,0411888369;0,15103;0,45967;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;363;;
C22:1-ceramide;C22:1-ceramide;C22:1-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.1 uM;0.096 uM;1,0416666667;0,048;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;364;;
C26-ceramide;C26-ceramide;C26-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.101 uM;0.096 uM;1,0520833333;0,049;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;365;;
ibuprofen;ibuprofen;ibuprofen;–;–;3672;HMDB01925;–;–;D00126;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.1068468± 0.2596346;0.3646858± 1.9749426;0,2929831652;0,2084195;0,317556422;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;366;;
dihydroS1P;dihydroS1P;dihydroS1P;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.11 uM;0.11 uM;1;0,12;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;367;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.11147 ± 0.051075;0.11417 ± 0.054058;0,9763510554;0,75974;0,8487;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;368;;
trizma acetate;trizma acetate;trizma acetate;–;–;6503;–;–;–;C07182;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.12058511± 0.2299662;0.08633421± 0.06663499;1,3967245429;0,0584758;0,12243893;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;369;;
C18-ceramide;C18-ceramide;C18-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.15 uM;0.15 uM;1;0,29;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;370;;
triamterene;triamterene;triamterene;–;–;5546;HMDB01940;–;–;D00386;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.156± 0;0.1959789± 0.2169353;0,7960040596;0,0752943;0,145001169;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;371;;
allyl laurate;allyl laurate;allyl laurate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.16995 ± 0.03841;0.21582 ± 0.10258;0,7874617737;0,011757;0,14963;–;ROC curve;–;–;combination of nine metabolites: 100;combination of nine metabolites: 86;–;–;–;–;–;–;Poland;Y;–;28803255;Ro?-Mazurczyk et al. 2017;372;;
atenolol;atenolol;atenolol;–;–;2249;HMDB01924;–;–;D00235;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.1700777± 0.8212973;0.1208495± 0.4227198;1,4073512923;0,5046323;0,575959868;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;373;;
inositol;inositol;inositol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.17334 ± 0.10512;0.22076 ± 0.15748;0,7851965936;0,047971;0,26628;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;374;;
C5-carnitine;C5-carnitine;C5-carnitine;–;–;–;–;–;–;–;–;–;302,4;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;0.18 ± 0.09 μmol/L;0.10 ± 0.04 μmol/L;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;375;;
desmethylnaproxen sulfate;desmethylnaproxen sulfate;desmethylnaproxen sulfate;–;–;184679;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.1893936± 0.6691751;0.2372632± 1.2272296;0,7982426268;0,7241119;0,711604062;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;376;;
gluconic acid;gluconic acid;gluconic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.19286 ± 0.12173;0.25519 ± 0.23889;0,7557506172;0,25478;0,59449;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;377;;
sorbate;sorbate;sorbate;–;–;643460;HMDB29581;–;–;D02411;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.1986± 0;0.2239074± 0.1629141;0,8869738115;0,1338327;0,230821977;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;378;;
oxypurinol;oxypurinol;oxypurinol;–;–;4644;HMDB0000786;–;–;D02365;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.2009787± 0.1965611;0.1866021± 0.175692;1,077044149;0,5333791;0,589381001;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;379;;
D-turanose;D-turanose;D-turanose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.20914 ± 0.1477;0.17504 ± 0.09622;1,1948126143;0,093989;0,39874;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;380;;
pioglitazone;pioglitazone;pioglitazone;–;–;4829;HMDB15264;–;–;C07675;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.2217564± 0.142062;0.2130242± 0.1422255;1,0409915869;0,6267933;0,654932753;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;381;;
desvenlafaxine;desvenlafaxine;desvenlafaxine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.2241128± 0.2503437;0.1995989± 0.3706925;1,1228158071;0,5627714;0,609036179;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;382;;
phosphatidylcholine diacyl C40:2;phosphatidylcholine diacyl C40:2;phosphatidylcholine diacyl C40:2;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I;20;11, 9;62 ± 5;smoker, non-smoker;noncancerous lung diseases;20;8, 16;63 ± 6;smoker, non-smoker;flow infusion;–;–;QTRAP;MS/MS;Analyst;–;MetaboAnalyst 4.0;Wilcoxon rank-sum test;0.24 ± 0.09;0.15 ± 0.04;1,88;0,00381;0,04904;–;ROC analysis;–;0.80 (0.64-0.92);–;–;–;–;–;–;–;–;Poland;Y;–;31264112;Klupczynska et al. 2019;383;;
chenodeoxycholate;chenodeoxycholate;chenodeoxycholate;–;–;10133;HMDB00518;–;–;C02528;Lipid;Primary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.2440351± 0.5320306;0.3940058± 1.2365215;0,6193693088;0,2610997;0,375015714;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;384;;
octadecanoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester;octadecanoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester;octadecanoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.24677 ± 0.12359;0.23489 ± 0.089984;1,0505768658;0,72059;0,85493;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;385;;
hydrochlorothiazide;hydrochlorothiazide;hydrochlorothiazide;–;–;3639;HMDB01928;–;–;C07041;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.2570766± 0.4244386;0.3259442± 0.5918385;0,7887135283;0,3143084;0,42642155;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;386;;
L-threonic acid;L-threonic acid;L-threonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.27756 ± 0.13879;0.29536 ± 0.20327;0,9397345612;0,58199;0,75265;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;387;;
lysophosphatidylcholine acyl C26:1;lysophosphatidylcholine acyl C26:1;lysophosphatidylcholine acyl C26:1;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I;20;11, 9;62 ± 5;smoker, non-smoker;noncancerous lung diseases;20;8, 16;63 ± 6;smoker, non-smoker;flow infusion;–;–;QTRAP;MS/MS;Analyst;–;MetaboAnalyst 4.0;Wilcoxon rank-sum test;0.28 ± 0.07;0.18 ± 0.06;1,52;0,00083;0,04337;–;ROC analysis;–;0.84 (0.68-0.95);–;–;–;–;–;–;–;–;Poland;Y;–;31264112;Klupczynska et al. 2019;388;;
γ-tocopherol;γ-tocopherol;γ-tocopherol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.28104 ± 0.11558;0.40574 ± 0.28152;0,6926603243;0,0097645;0,12427;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;389;;
3-ethylphenylsulfate;3-ethylphenylsulfate;3-ethylphenylsulfate;–;–;–;–;–;–;C14386;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.2839479± 0.2284561;0.81439± 1.8395668;0,348663294;0,0056983;0,024232022;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;390;;
cotinine;cotinine;cotinine;–;–;854019;HMDB0001046;–;–;–;Xenobiotics;Tobacco Metabolite;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.2966096± 0.5117091;0.4955063± 0.6243191;0,5985990491;0,0078334;0,029190502;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;391;;
omeprazole;omeprazole;omeprazole;–;–;4594;HMDB01913;–;–;C07324;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.299116± 0.6665806;0.3392384± 0.9616133;0,8817280119;0,7162076;0,707072359;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;392;;
gabapentin;gabapentin;gabapentin;–;–;3446;6919078;HMDB05015;–;–;D00332;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.304067± 0.2417917;0.2834547± 0.1340012;1,0727181451;0,356411;0,456899309;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;393;;
N-acetylalliin;N-acetylalliin;N-acetylalliin;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.304633± 0.2384756;0.3438247± 0.3610297;0,8860125523;0,3404345;0,444377239;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;394;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.30476 ± 0.18536;0.3389 ± 0.2455;0,8992623193;0,15778;0,46772;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;395;;
N-acetylneuraminic acid;N-acetylneuraminic acid;N-acetylneuraminic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.31266 ± 0.19452;0.44205 ± 0.5918;0,7072955548;0,10599;0,41219;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;396;;
isoleucylthreonine;isoleucylthreonine;isoleucylthreonine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.3164277± 0.6761366;0.2485037± 0.2400918;1,2733319464;0,2163913;0,327216812;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;397;;
gluconic acid lactone;gluconic acid lactone;gluconic acid lactone;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.33681 ± 0.27565;0.52309 ± 0.499;0,6438853735;0,038092;0,2424;–;ROC curve;–;–;combination of nine metabolites: 100;combination of nine metabolites: 86;–;–;–;–;–;–;Poland;Y;–;28803255;Ro?-Mazurczyk et al. 2017;398;;
3-hydroxycotinine glucuronide;3-hydroxycotinine glucuronide;3-hydroxycotinine glucuronide;–;–;183115;–;–;–;–;Xenobiotics;Tobacco Metabolite;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.3435032± 0.4204368;0.4158716± 0.4515586;0,8259837892;0,1942903;0,304519207;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;399;;
carboxyibuprofen;carboxyibuprofen;carboxyibuprofen;–;–;10444113;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.3452372± 1.692852;1.9124995± 8.275412;0,1805162302;0,0701033;0,138737219;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;400;;
hexadecanol;hexadecanol;hexadecanol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.35049 ± 0.18497;0.4707 ± 0.55204;0,7446144041;0,037833;0,26483;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;401;;
warfarin;warfarin;warfarin;–;–;–;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.3583053± 0.2393343;0.3060142± 0.198163;1,1708780181;0,052038;0,114019369;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;402;;
C22-ceramide;C22-ceramide;C22-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.36 uM;0.35 uM;1,0285714286;0,07;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;403;;
furosemide;furosemide;furosemide;–;–;3440;HMDB01933;–;–;D00331;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.3618936± 2.2867777;0.1398642± 0.2902412;2,5874641259;0,1876029;0,297980281;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;404;;
sucralose;sucralose;sucralose;–;–;71485;HMDB31554;–;–;C12285;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.365134± 0.3478445;0.3655058± 0.3046101;0,9989827795;0,9926387;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;405;;
4-acetylphenol sulfate;4-acetylphenol sulfate;4-acetylphenol sulfate;–;–;4684006;–;–;–;C00548;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.3694606± 0.2695673;0.4939837± 0.3849266;0,7479206298;0,0052185;0,023403164;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;406;;
hydroxycotinine;hydroxycotinine;hydroxycotinine;–;–;10219774;HMDB01390;–;–;–;Xenobiotics;Tobacco Metabolite;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.3707489± 1.0482756;0.5312042± 0.9395578;0,697940453;0,1932118;0,303938181;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;407;;
allopurinol riboside;allopurinol riboside;allopurinol riboside;–;–;–;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.3719532± 0.1323726;0.3650547± 0.06673809;1,018897168;0,5605939;0,609036179;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;408;;
C16-carnitine;C16-carnitine;C16-carnitine;–;–;–;–;–;–;–;–;–;456,5;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;0.38 ± 0.21 μmol/L;0.19 ± 0.08 μmol/L;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;409;;
2-hydroxyibuprofen;2-hydroxyibuprofen;2-hydroxyibuprofen;–;–;–;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.389317± 1.620013;2.501071± 8.648568;0,1556601152;0,019569;0,054929141;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;410;;
7-ketodeoxycholate;7-ketodeoxycholate;7-ketodeoxycholate;–;–;188292;HMDB00391;–;–;–;Lipid;Secondary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.3950383± 0.4188813;0.3283289± 0.2638717;1,203178581;0,1026103;0,18994035;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;411;;
C20-ceramide;C20-ceramide;C20-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.4 uM;0.37 uM;1,0810810811;0,06;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;412;;
2,3-dihydroxyisovalerate;2,3-dihydroxyisovalerate;2,3-dihydroxyisovalerate;–;–;677;HMDB12141;–;–;C04039;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4015596± 0.2473656;0.6117021± 1.1269887;0,6564626801;0,0749676;0,145001169;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;413;;
ethyl iso-allocholate;ethyl iso-allocholate;ethyl iso-allocholate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.40573 ± 0.22174;0.4969 ± 0.34458;0,8165224391;0,32894;0,68529;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;414;;
allopurinol;allopurinol;allopurinol;–;–;2094;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4123777± 0.096737;0.41319± 0.09839214;0,9980340763;0,947691;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;415;;
3-methyl catechol sulfate;3-methyl catechol sulfate;3-methyl catechol sulfate;2;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4148532± 0.167443;0.5420979± 0.3617576;0,7652735788;0,0013231;0,015374512;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;416;;
D-talofuranose;D-talofuranose;D-talofuranose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.41546 ± 0.30859;0.45986 ± 0.40101;0,9034488757;0,49554;0,76237;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;417;;
o-cresol sulfate;o-cresol sulfate;o-cresol sulfate;–;–;11615528;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4204436± 0.310361;0.8805158± 1.012468;0,4774969399;0,0000227;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;418;;
ketoleucine;ketoleucine;ketoleucine;–;–;–;HMDB0000695;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.42639 ± 0.26632;0.58974 ± 0.43089;0,7230135314;0,0036184;0,070773;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;419;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.42753 ± 0.19055;0.40801 ± 0.25967;1,0478419647;0,072326;0,33753;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;420;;
C16-ceramide;C16-ceramide;C16-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.43 uM;0.41 uM;1,0487804878;0,14;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;421;;
lipitor;lipitor;lipitor;–;–;60823;HMDB05006;–;–;D00887;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4310564± 0.1349587;0.4123± 0;1,0454921174;0,0571579;0,121517581;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;422;;
gentisate;gentisate;gentisate;–;–;3469;HMDB00152;–;–;C00628;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4325649± 0.7376361;0.6901968± 1.6999354;0,6267268988;0,1607915;0,265585207;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;423;;
1-hydroxy-2-naphthalenecarboxylate;1-hydroxy-2-naphthalenecarboxylate;1-hydroxy-2-naphthalenecarboxylate;–;–;6844;–;–;–;C03203;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4330298± 0.2011362;0.4197426± 0.1650529;1,0316555908;0,5538045;0,606714829;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;424;;
salicylate;salicylate;salicylate;–;–;338;HMDB01895;–;–;C00805;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4369074± 1.744181;2.8833421± 10.837299;0,1515281173;0,0304207;0,076848453;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;425;;
2-ethylphenylsulfate;2-ethylphenylsulfate;2-ethylphenylsulfate;–;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4375191± 0.1019677;0.6461379± 0.5931575;0,6771296034;0,0008099;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;426;;
indol-3-acetic acid;indol-3-acetic acid;indol-3-acetic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.43824 ± 0.26038;0.61811 ± 0.47103;0,7090000162;0,017905;0,17905;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;427;;
7-alpha-hydroxycholesterol;7-alpha-hydroxycholesterol;7-alpha-hydroxycholesterol;–;–;107722;HMDB01496;–;–;C03594;Lipid;Sterol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4390606± 0.3296336;0.4919942± 0.4729913;0,8924101138;0,3304468;0,437996608;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;428;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.44052 ± 0.38849;0.78842 ± 0.56528;0,5587377286;0,00072096;0,020187;–;ROC curve;–;–;combination of nine metabolites: 100;combination of nine metabolites: 86;–;–;–;–;–;–;Poland;Y;–;28803255;Ro?-Mazurczyk et al. 2017;429;;
α-linolenic acid;α-linolenic acid;α-linolenic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.44304 ± 0.48158;0.56977 ± 0.70563;0,777576917;0,42316;0,69016;–;ROC curve;–;–;combination of nine metabolites: 100;combination of nine metabolites: 86;–;–;–;–;–;–;Poland;Y;–;28803255;Ro?-Mazurczyk et al. 2017;430;;
orotate;orotate;orotate;–;–;967;HMDB00226;–;–;C00295;Nucleotide;Pyrimidine Metabolism, Orotate containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4474234± 0.4697187;0.4720668± 0.5870706;0,9477967949;0,7228758;0,711604062;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;431;;
bradykinin;bradykinin;bradykinin;–;–;439201;HMDB04246;–;–;C00306;Peptide;Polypeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4487809± 0.5007939;0.6294832± 0.8174506;0,7129354683;0,0498646;0,110955676;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;432;;
salicyluric glucuronide;salicyluric glucuronide;salicyluric glucuronide;–;–;–;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4491128± 1.282961;1.1200979± 3.163427;0,4009585234;0,048835;0,109230662;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;433;;
L-asparagine;L-asparagine;L-asparagine;–;–;–;HMDB0000168;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.45388 ± 0.46352;0.5809 ± 0.48931;0,7813393011;0,16036;0,46772;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;434;;
5-alpha-pregnan-3alpha,20beta-diol disulfate;5-alpha-pregnan-3alpha,20beta-diol disulfate;5-alpha-pregnan-3alpha,20beta-diol disulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4587436± 0.128391;0.4438426± 0.04056138;1,0335727125;0,146788;0,247209119;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;435;;
phosphatidylcholine diacyl C42:4;phosphatidylcholine diacyl C42:4;phosphatidylcholine diacyl C42:4;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I;20;11, 9;62 ± 5;smoker, non-smoker;noncancerous lung diseases;20;8, 16;63 ± 6;smoker, non-smoker;flow infusion;–;–;QTRAP;MS/MS;Analyst;–;MetaboAnalyst 4.0;Wilcoxon rank-sum test;0.46 ± 0.22;0.26 ± 0.12;1,79;0,00174;0,04529;–;ROC analysis;–;0.81 (0.65-0.93);–;–;–;–;–;–;–;–;Poland;Y;–;31264112;Klupczynska et al. 2019;436;;
1,11-undecanedicarboxylate;1,11-undecanedicarboxylate;1,11-undecanedicarboxylate;–;–;10458;HMDB02327;–;–;–;Lipid;Fatty Acid, Dicarboxylate;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4615404± 0.1791254;0.5304747± 0.2923338;0,8700516726;0,0366199;0,087369234;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;437;;
dihydroferulic acid;dihydroferulic acid;dihydroferulic acid;–;–;14340;–;–;–;–;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4756053± 0.5711514;0.4870005± 0.4792256;0,9766012561;0,859713;0,781510038;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;438;;
bisphenol a monosulfate;bisphenol a monosulfate;bisphenol a monosulfate;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4813128± 0.6786275;0.51732± 0.6359867;0,9303966597;0,660602;0,676690201;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;439;;
2-hydroxyoctanoate;2-hydroxyoctanoate;2-hydroxyoctanoate;–;–;94180;HMDB02264;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.4853606± 0.2898669;0.5300363± 0.3366183;0,9157119993;0,2716737;0,38505184;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;440;;
cholesta-3,5-dien-7-one;cholesta-3,5-dien-7-one;cholesta-3,5-dien-7-one;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.49462 ± 0.23804;0.43776 ± 0.15984;1,1298885234;0,051355;0,26628;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;441;;
ethyl glucuronide;ethyl glucuronide;ethyl glucuronide;–;–;152226;–;–;–;–;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5042426± 0.2753748;0.9088763± 2.7335823;0,5547978311;0,1532484;0,255088325;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;442;;
3-hydroxysebacate;3-hydroxysebacate;3-hydroxysebacate;–;–;3017884;HMDB00350;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5045181± 0.1496998;0.5082263± 0.1856982;0,992703644;0,8664057;0,781510038;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;443;;
phosphoryethanolamine;phosphoryethanolamine;phosphoryethanolamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.50995 ± 0.24888;0.63338 ± 0.31128;0,8051248855;0,022801;0,21281;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;444;;
tartarate;tartarate;tartarate;–;–;444305;HMDB00956;–;–;C00898;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5120149± 1.286982;0.7474205± 2.047028;0,6850426233;0,3083857;0,423120587;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;445;;
sorbose;sorbose;sorbose;–;–;441484;HMDB01266;–;–;C00247;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5134245± 0.9634344;0.5188284± 0.8959057;0,9895844175;0,9627857;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;446;;
2-hydroxyhippurate;2-hydroxyhippurate;2-hydroxyhippurate;(salicylurate);–;10253;HMDB00840;–;–;C07588;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5152872± 1.692007;2.7504126± 8.607883;0,1873490545;0,0131783;0,040458542;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;447;;
phosphatidylcholine acyl-alkyl C44:3;phosphatidylcholine acyl-alkyl C44:3;phosphatidylcholine acyl-alkyl C44:3;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I;20;11, 9;62 ± 5;smoker, non-smoker;noncancerous lung diseases;20;8, 16;63 ± 6;smoker, non-smoker;flow infusion;–;–;QTRAP;MS/MS;Analyst;–;MetaboAnalyst 4.0;Wilcoxon rank-sum test;0.52 ± 0.21;0.33 ± 0.11;1,58;0,00322;0,04789;–;ROC analysis;–;0.80 (0.62-0.92);–;–;–;–;–;–;–;–;Poland;Y;–;31264112;Klupczynska et al. 2019;448;;
glutaric acid;glutaric acid;glutaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 ± 6.9;smoker, non-smoker, unknown;healthy;62;40, 22;62 ± 8.8;smoker, non-smoker, unknown;LC;ESI;negative;triple quadrupole;MS/MS;Analyst software;–;–;Mann-Whitney U test;0.52 ± 0.23 μmol/l;0.52 ± 0.2 μmol/l;1;0,839;–;–;ROC curve analysis ;–;0,515;–;–;–;–;–;–;–;–;Poland;Y;–;27454081;Klupczynska et al. 2016b;449;;
alpha-hydroxyisocaproate;alpha-hydroxyisocaproate;alpha-hydroxyisocaproate;–;–;83697;HMDB00746;–;–;C03264;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5212011± 0.2979558;0.5260658± 0.3071843;0,9907526777;0,8990842;0,790949301;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;450;;
hydroquinone sulfate;hydroquinone sulfate;hydroquinone sulfate;–;–;161220;HMDB02434;–;–;C00530;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5218309± 0.1859336;0.5732405± 0.327446;0,9103175718;0,1584757;0,262770726;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;451;;
5-alpha-androstan-3alpha,17beta-diol disulfate;5-alpha-androstan-3alpha,17beta-diol disulfate;5-alpha-androstan-3alpha,17beta-diol disulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5249947± 0.3729341;0.6095126± 0.6890529;0,8613352702;0,2670756;0,379788191;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;452;;
lysophosphatidylcholine acyl C26:0;lysophosphatidylcholine acyl C26:0;lysophosphatidylcholine acyl C26:0;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I;20;11, 9;62 ± 5;smoker, non-smoker;noncancerous lung diseases;20;8, 16;63 ± 6;smoker, non-smoker;flow infusion;–;–;QTRAP;MS/MS;Analyst;–;MetaboAnalyst 4.0;Wilcoxon rank-sum test;0.53 ± 0.14;0.31 ± 0.14;1,71;0,00011;0,01113;–;ROC analysis;–;0.87 (0.73-0.96);–;–;–;–;–;–;–;–;Poland;Y;–;31264112;Klupczynska et al. 2019;453;;
3-hydroxypyruvic acid;3-hydroxypyruvic acid;3-hydroxypyruvic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.53299 ± 0.56089;0.35277 ± 0.34446;1,5108711058;0,12197;0,42688;–;ROC curve;–;–;combination of nine metabolites: 100;combination of nine metabolites: 86;–;–;–;–;–;–;Poland;Y;–;28803255;Ro?-Mazurczyk et al. 2017;454;;
5-hydroxymethyl-2-furoic acid;5-hydroxymethyl-2-furoic acid;5-hydroxymethyl-2-furoic acid;–;–;80642;HMDB02432;–;–;C20448;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5371777± 1.74813;0.7484653± 1.093724;0,7177055503;0,2134105;0,323849766;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;455;;
3,7-dimethylurate;3,7-dimethylurate;3,7-dimethylurate;–;–;83126;HMDB01982;–;–;C16360;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5399255± 0.3006117;0.6491416± 0.5802655;0,8317530412;0,0873713;0,164611696;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;456;;
C4-carnitine;C4-carnitine;C4-carnitine;–;–;–;–;–;–;–;–;–;288,4;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;0.54 ± 0.40 μmol/L;0.22 ± 0.10 μmol/L;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;457;;
3-phenylpropionate;3-phenylpropionate;3-phenylpropionate;(hydrocinnamate);–;107;HMDB00764;–;–;C05629;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.541133± 0.4391733;0.6736432± 0.5487695;0,8032931973;0,0421008;0,096685851;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;458;;
fluoxetine;fluoxetine;fluoxetine;–;–;3386;–;–;–;D00326;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5413319± 0.0478167;0.54372± 0.07504652;0,9956078496;0,7800593;0,738604005;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;459;;
methyl indole-3-acetate;methyl indole-3-acetate;methyl indole-3-acetate;–;–;74706;HMDB29738;–;–;–;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5425564± 0.5218705;0.5265179± 0.7800068;1,0304614525;0,8568808;0,781510038;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;460;;
methyl-4-hydroxybenzoate;methyl-4-hydroxybenzoate;methyl-4-hydroxybenzoate;–;–;7456;HMDB32572;–;–;D01400;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.546133± 0.8020692;0.4898837± 0.4356353;1,1148217424;0,4439772;0,535580651;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;461;;
5-alpha-androstan-3alpha,17beta-diol disulfate;5-alpha-androstan-3alpha,17beta-diol disulfate;5-alpha-androstan-3alpha,17beta-diol disulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5464543± 0.4148592;0.5235621± 0.4190867;1,0437239441;0,6638586;0,676690201;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;462;;
3-aminophenol;3-aminophenol;3-aminophenol;–;–;11568;–;–;–;C05058;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5471277± 0.3469513;0.94405± 0.758545;0,5795537313;0,00000222;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;463;;
L-cysteine;L-cysteine;L-cysteine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.54811 ± 0.28307;0.77687 ± 0.89885;0,7055363188;0,3094;0,64914;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;464;;
3-methyl catechol sulfate;3-methyl catechol sulfate;3-methyl catechol sulfate;1;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5482138± 0.5799176;1.2148795± 0.8428238;0,4512495272;3,25E-011;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;465;;
estrone 3-sulfate;estrone 3-sulfate;estrone 3-sulfate;–;–;3001028;HMDB01425;–;–;C02538;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5487521± 0.0470431;0.5583032± 0.0960511;0,982892629;0,3650377;0,463804717;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;466;;
3-aminoisobutyrate;3-aminoisobutyrate;3-aminoisobutyrate;–;–;64956;HMDB03911;–;–;C05145;Nucleotide;Pyrimidine Metabolism, Thymine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5518223± 0.5322613;0.5377568± 0.3229472;1,0261558757;0,7825442;0,738604005;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;467;;
metoprolol acid metabolite;metoprolol acid metabolite;metoprolol acid metabolite;–;–;62936;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5543032± 1.877388;0.4672516± 1.665705;1,1863056221;0,691233;0,687155346;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;468;;
lathosterol;lathosterol;lathosterol;–;–;65728;HMDB01170;–;–;C01189;Lipid;Sterol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5577266± 0.39668;0.7702595± 0.5742902;0,7240762366;0,0013861;0,015374512;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;469;;
behenate;behenate;behenate;–;–;8215;HMDB00944;–;–;C08281;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.559816± 0.7282428;0.6217984± 0.7290189;0,9003175306;0,5000764;0,574634604;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;470;;
N-methyl-acetaminophen sulfate 1;N-methyl-acetaminophen sulfate 1;N-methyl-acetaminophen sulfate 1;–;–;–;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5603106± 0.5231164;0.4577042± 0.1273324;1,2241762256;0,0109549;0,036013448;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;471;;
beta-sitosterol;beta-sitosterol;beta-sitosterol;–;–;222284;HMDB00852;–;–;C01753;Lipid;Sterol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5664819± 0.4404987;0.5450616± 0.4616278;1,0392988609;0,7087536;0,70294542;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;472;;
ketopioglitazone;ketopioglitazone;ketopioglitazone;–;–;–;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5675213± 0.1130928;0.5530547± 0.04622068;1,0261576296;0,1300511;0,228896185;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;473;;
N-acetylphenylalanine;N-acetylphenylalanine;N-acetylphenylalanine;–;–;74839;HMDB00512;–;–;C03519;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5712415± 0.4150463;0.5889153± 0.2894286;0,9699892327;0,6767087;0,679003806;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;474;;
7-dehydrocholesterol;7-dehydrocholesterol;7-dehydrocholesterol;–;–;439423;HMDB00032;–;–;C01164;Lipid;Sterol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5723489± 1.4712166;0.4101521± 0.2528413;1,395455247;0,1398844;0,23744492;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;475;;
metformin;metformin;metformin;–;–;4091;HMDB01921;–;–;C07151;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5765915± 0.1089159;0.5993374± 0.1753469;0,9620482553;0,2504486;0,363363304;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;476;;
1,2-dipalmitoylglycerol;1,2-dipalmitoylglycerol;1,2-dipalmitoylglycerol;–;–;99931;HMDB07098;–;–;–;Lipid;Diacylglycerol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5805277± 0.4567087;0.7296679± 0.6776875;0,7956053706;0,0546818;0,117415854;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;477;;
pseudo uridine;pseudo uridine;pseudo uridine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.58723 ± 0.35835;0.62956 ± 0.34589;0,9327625643;0,50208;0,76403;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;478;;
stearamide;stearamide;stearamide;–;–;31292;HMDB0034146;–;–;C13846;Lipid;Fatty Acid, Amide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5885904± 0.3991945;0.5825111± 0.4005045;1,0104363677;0,9040765;0,790949301;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;479;;
N-acetyl-3-methylhistidine;N-acetyl-3-methylhistidine;N-acetyl-3-methylhistidine;–;–;–;–;–;–;–;Amino Acid;Histidine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.5953585± 0.0972044;0.5879068± 0.07486928;1,0126749682;0,4783556;0,55975634;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;480;;
alpha-CEHC glucuronide;alpha-CEHC glucuronide;alpha-CEHC glucuronide;–;–;–;–;–;–;–;Cofactors and Vitamins;Tocopherol Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6020766± 0.325236;0.6406589± 0.7680027;0,9397771575;0,6408544;0,664772809;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;481;;
pyridoxal;pyridoxal;pyridoxal;–;–;1050;HMDB01545;–;–;C00250;Cofactors and Vitamins;Vitamin B6 Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6027011± 0.3797131;0.7735111± 0.599421;0,779175761;0,0121105;0,038763266;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;482;;
leucylglycine;leucylglycine;leucylglycine;–;–;79070;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6172787± 0.4439992;0.7246684± 1.4047482;0,8518084961;0,469775;0,552632262;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;483;;
1,3,7-trimethylurate;1,3,7-trimethylurate;1,3,7-trimethylurate;–;–;79437;HMDB02123;–;–;C16361;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6281543± 0.6598457;1.1192521± 0.85074;0,5612268228;0,00000149;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;484;;
N-ethylglycinexylidide;N-ethylglycinexylidide;N-ethylglycinexylidide;–;–;24415;HMDB60656;–;–;C16561;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6307787± 1.5447672;0.3517405± 0.1455454;1,7933069976;0,0139079;0,041500997;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;485;;
deoxycholate;deoxycholate;deoxycholate;–;–;222528;HMDB00626;–;–;C04483;Lipid;Secondary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6386872± 0.5596977;0.65199± 0.64617;0,9795966196;0,8646471;0,781510038;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;486;;
2-hydroxyacetaminophen sulfate;2-hydroxyacetaminophen sulfate;2-hydroxyacetaminophen sulfate;–;–;–;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6440968± 1.5414878;0.2906505± 0.7458756;2,216052613;0,0095528;0,033552855;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;487;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.6485 ± 0.50829;0.78608 ± 0.4787;0,8249796458;0,034879;0,2424;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;488;;
indoleacetylglutamine;indoleacetylglutamine;indoleacetylglutamine;–;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6494511± 1.1635291;0.4074358± 0.2752601;1,5939961584;0,0068358;0,027175059;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;489;;
2-palmitoleoylglycerophosphocholine;2-palmitoleoylglycerophosphocholine;2-palmitoleoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6545904± 0.4224283;0.77788± 0.5015499;0,8415056307;0,0410686;0,094976057;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;490;;
ibuprofen acyl glucuronide;ibuprofen acyl glucuronide;ibuprofen acyl glucuronide;–;–;163959;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6547777± 0.0346867;0.6824358± 0.1280405;0,959471499;0,0411351;0,094976057;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;491;;
campesterol;campesterol;campesterol;–;–;173183;HMDB02869;–;–;C01789;Lipid;Sterol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.655217± 0.5397038;0.58543± 0.4753031;1,1192063953;0,2663703;0,379788191;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;492;;
3-[3-(sulfooxy)phenyl]propanoic acid;3-[3-(sulfooxy)phenyl]propanoic acid;3-[3-(sulfooxy)phenyl]propanoic acid;–;–;187488;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6555851± 0.2012933;0.6792963± 0.3280622;0,9650944661;0,5203679;0,586078412;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;493;;
tauroursodeoxycholate;tauroursodeoxycholate;tauroursodeoxycholate;–;–;9848818;HMDB00874;–;–;–;Lipid;Secondary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.662917± 1.105139;0.7821795± 1.135068;0,8475254082;0,4008024;0,491786312;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;494;;
maltose;maltose;maltose;–;–;10991489;HMDB00163;–;–;C00208;Carbohydrate;Glycogen Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6658766± 0.5577826;0.6572626± 0.5734163;1,0131058728;0,9043071;0,790949301;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;495;;
N-(2-furoyl)glycine;N-(2-furoyl)glycine;N-(2-furoyl)glycine;–;–;21863;HMDB00439;–;–;–;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6716606± 0.9388018;1.4546716± 1.6501217;0,4617266193;0,0000263;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;496;;
3-hydroxyoctanoate;3-hydroxyoctanoate;3-hydroxyoctanoate;–;–;26613;HMDB01954;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6725383± 0.3899758;0.6304021± 0.3788003;1,0668401961;0,3826594;0,479106922;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;497;;
sarcosine;sarcosine;sarcosine;(N-Methylglycine);–;1088;HMDB00271;–;–;C00213;Amino Acid;Glycine, Serine and Threonine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6758489± 0.3276988;0.8139574± 0.4335298;0,8303246583;0,0067512;0,027175059;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;498;;
quinine;quinine;quinine;–;–;2728270;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6783915± 0.067785;0.6748589± 0.03362434;1,0052345757;0,5630143;0,609036179;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;499;;
phosphatidylcholine acyl-alkyl C42:1;phosphatidylcholine acyl-alkyl C42:1;phosphatidylcholine acyl-alkyl C42:1;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I;20;11, 9;62 ± 5;smoker, non-smoker;noncancerous lung diseases;20;8, 16;63 ± 6;smoker, non-smoker;flow infusion;–;–;QTRAP;MS/MS;Analyst;–;MetaboAnalyst 4.0;Wilcoxon rank-sum test;0.69 ± 0.14;0.53 ± 0.13;1,57;0,00273;0,04729;–;ROC analysis;–;0.80 (0.64-0.94);–;–;–;–;–;–;–;–;Poland;Y;–;31264112;Klupczynska et al. 2019;500;;
paroxetine;paroxetine;paroxetine;–;–;43815;–;–;–;D02362   C07415;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6933± 0;0.6981426± 0.0496479;0,9930635947;0,3553775;0,456899309;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;501;;
beta-hydroxypyruvate;beta-hydroxypyruvate;beta-hydroxypyruvate;–;–;964;HMDB01352;–;–;C00168;Amino Acid;Glycine, Serine and Threonine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6941181± 0.3428237;0.6479216± 0.375231;1,0712995214;0,3157563;0,42642155;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;502;;
ascorbate;ascorbate;ascorbate; (Vitamin C);–;–;HMDB00044;–;–;C00072;Cofactors and Vitamins;Ascorbate and Aldarate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6943213± 0.8740479;1.1995205± 1.1003519;0,5788323751;0,0001253;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;503;;
myristate;myristate;myristate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.69566 ± 0.45751;0.89545 ± 1.0872;0,7768831314;0,28907;0,63233;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;504;;
2-methoxyacetaminophen glucuronide;2-methoxyacetaminophen glucuronide;2-methoxyacetaminophen glucuronide;–;–;–;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6992138± 1.9269981;0.2935253± 0.3749915;2,382124471;0,0053855;0,023524587;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;505;;
N-acetyl-1-methylhistidine;N-acetyl-1-methylhistidine;N-acetyl-1-methylhistidine;–;–;–;–;–;–;–;Amino Acid;Histidine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.6996926± 1.285583;0.6047489± 0.6162848;1,1569968957;0,3999557;0,491786312;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;506;;
7-beta-hydroxycholesterol;7-beta-hydroxycholesterol;7-beta-hydroxycholesterol;–;–;473141;HMDB06119;–;–;–;Lipid;Sterol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7092277± 0.5153432;0.7998505± 0.5473697;0,8867003271;0,1814289;0,291816206;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;507;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.70968 ± 1.9495;0.71993 ± 1.1979;0,9857625047;0,44022;0,69016;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;508;;
octadecanol;octadecanol;octadecanol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.71063 ± 0.27;0.84132 ± 0.66295;0,8446607712;0,36196;0,66677;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;509;;
rosuvastatin;rosuvastatin;rosuvastatin;–;–;446157;HMDB15230;–;–;D01915;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7110011± 0.0538696;0.7239232± 0.1955471;0,9821499021;0,5302622;0,589381001;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;510;;
glutathione, oxidized;glutathione, oxidized;glutathione, oxidized;(GSSG);–;65359;HMDB03337;–;–;C00127;Amino Acid;Glutathione Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7124606± 0.7780699;0.6260258± 0.1903747;1,13806907;0,1481787;0,248576432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;511;;
4-acetamidophenol;4-acetamidophenol;4-acetamidophenol;–;–;1983;HMDB01859;–;–;C06804;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7151638± 1.5846529;0.3297916± 0.9786866;2,1685324914;0,0121678;0,038763266;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;512;;
formic acid;formic acid;formic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.71745 ± 0.47897;0.78942 ± 0.52681;0,9088318006;0,64329;0,78314;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;513;;
norfluoxetine;norfluoxetine;norfluoxetine;–;–;4541;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.719516± 0.0292408;0.7194842± 0.0411345;1,0000441983;0,9947928;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;514;;
eicosapentaenoic acid;eicosapentaenoic acid;eicosapentaenoic acid;–;–;–;HMDB0001999;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.73605 ± 1.0848;0.69884 ± 0.66637;1,0532453781;0,55826;0,73733;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;515;;
sorbitol;sorbitol;sorbitol;–;–;5780;HMDB00247;–;–;C00794;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7408287± 0.4971148;0.8512563± 0.7060983;0,8702769072;0,1749716;0,283554024;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;516;;
pregn-4-ene-3,11,20-trione;pregn-4-ene-3,11,20-trione;pregn-4-ene-3,11,20-trione;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.74349 ± 0.6575;1.3534 ± 3.6854;0,5493497857;0,18032;0,50489;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;517;;
imidazole propionate;imidazole propionate;imidazole propionate;–;–;70630;HMDB02271;–;–;–;Amino Acid;Histidine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7434979± 0.6925624;0.7276916± 0.775276;1,0217211522;0,8670647;0,781510038;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;518;;
isovalerate;isovalerate;isovalerate;–;–;10430;HMDB00718;–;–;C08262;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7437489± 0.4709649;0.7811253± 0.5354198;0,9521505705;0,5650156;0,609665443;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;519;;
celecoxib;celecoxib;celecoxib;–;–;2662;HMDB05014;–;–;C07589;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7441617± 0.0379236;0.7509342± 0.13457169;0,9909812338;0,6334203;0,658652122;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;520;;
gemfibrozil;gemfibrozil;gemfibrozil;–;–;3463;HMDB15371;–;–;D00334;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7461± 0;0.7501089± 0.04110076;0,994655576;0,3599994;0,459562816;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;521;;
valerylcarnitine;valerylcarnitine;valerylcarnitine;–;–;6426903;HMDB0013128;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7506213± 0.4477842;0.6762532± 0.4242761;1,109970792;0,173024;0,281459886;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;522;;
diphenhydramine;diphenhydramine;diphenhydramine;–;–;3100;HMDB01927;–;–;C06960;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7512628± 0.0510798;0.7511858± 0.04913093;1,0001025046;0,9903545;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;523;;
N-palmitoyltaurine;N-palmitoyltaurine;N-palmitoyltaurine;–;–;–;–;–;–;–;Lipid;Endocannabinoid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7524287± 0.4283303;0.6377763± 0.3695217;1,179768988;0,0202874;0,056210382;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;524;;
pseudoephedrine;pseudoephedrine;pseudoephedrine;–;–;7028;HMDB01943;–;–;C02765;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7606± 0;0.7669± 0.04563748;0,9917851089;0,1929233;0,303938181;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;525;;
sebacate;sebacate;sebacate;(decanedioate);–;5192;HMDB00792;–;–;C08277;Lipid;Fatty Acid, Dicarboxylate;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7648638± 0.2837942;0.75812± 0.2991014;1,0088954255;0,855746;0,781510038;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;526;;
9-methyluric acid;9-methyluric acid;9-methyluric acid;–;–;108714;–;–;–;–;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7676947± 0.5621754;0.9725684± 0.6234902;0,7893477724;0,0075035;0,028782416;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;527;;
trigonelline;trigonelline;trigonelline;(N'-methylnicotinate);–;5570;HMDB00875;–;–;C01004;Cofactors and Vitamins;Nicotinate and Nicotinamide Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7678989± 0.9815459;1.1022484± 1.0734746;0,6966659239;0,0115385;0,0376162;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;528;;
1,3-dipalmitoylglycerol;1,3-dipalmitoylglycerol;1,3-dipalmitoylglycerol;–;–;68149;HMDB31011;–;–;–;Lipid;Diacylglycerol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7706074± 0.7195836;0.9575826± 0.8628192;0,8047424838;0,0707479;0,13882663;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;529;;
3-(3-hydroxyphenyl)propionate;3-(3-hydroxyphenyl)propionate;3-(3-hydroxyphenyl)propionate;–;–;91;HMDB00375;–;–;C11457;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7765255± 0.9122703;0.7255616± 0.9434525;1,0702406246;0,6649487;0,676690201;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;530;;
3-(N-acetyl-L-cystein-S-yl) acetaminophen;3-(N-acetyl-L-cystein-S-yl) acetaminophen;3-(N-acetyl-L-cystein-S-yl) acetaminophen;–;–;83967;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7767798± 1.5777617;0.3465342± 0.5995318;2,241567499;0,0010363;0,01536176;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;531;;
cystine;cystine;cystine;–;–;6175;HMDB00089;–;–;C00475;Nucleotide;Pyrimidine Metabolism, Cytidine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7780394± 0.4150007;0.7981379± 0.5462263;0,9748182614;0,7530882;0,728411991;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;532;;
hydroxypioglitazone;hydroxypioglitazone;hydroxypioglitazone;(M-IV);–;–;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7796915± 0.0576105;0.7723221± 0.02354522;1,0095418738;0,1369712;0,233422539;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;533;;
ribitol;ribitol;ribitol;–;–;6912;HMDB00508;–;–;C00474;Carbohydrate;Pentose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7797777± 0.4251764;0.7803847± 0.5507012;0,9992221785;0,9925069;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;534;;
sphingosine 1-phosphate;sphingosine 1-phosphate;sphingosine 1-phosphate;–;–;–;HMDB0000277;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;0.78 uM;0.75 uM;1,04;0,1;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;23749868;Alberg et al. 2013;535;;
gamma-CEHC glucuronide;gamma-CEHC glucuronide;gamma-CEHC glucuronide;–;–;–;–;–;–;–;Cofactors and Vitamins;Tocopherol Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7825138± 0.7532273;0.7120358± 0.4524948;1,0989809782;0,3267142;0,434389878;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;536;;
escitalopram;escitalopram;escitalopram;–;–;146570;HMDB05028;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7840777± 0.0416696;0.7879079± 0.05917278;0,9951387719;0,5786968;0,6211063;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;537;;
metoprolol;metoprolol;metoprolol;–;–;4171;HMDB01932;–;–;D02358;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7861745± 4.1213318;0.2853747± 0.8015676;2,7548850686;0,1065769;0,19567225;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;538;;
quinate;quinate;quinate;–;–;6508;HMDB03072;–;–;C00296;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7863202± 0.8655946;1.2846232± 1.211069;0,612101821;0,0004238;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;539;;
leucylphenylalanine;leucylphenylalanine;leucylphenylalanine;–;–;259325;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7885117± 0.2265696;0.7674153± 0.1745633;1,0274901999;0,3873191;0,48073639;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;540;;
2-methoxyacetaminophen sulfate;2-methoxyacetaminophen sulfate;2-methoxyacetaminophen sulfate;–;–;–;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7957106± 1.7060047;0.3230037± 0.7300487;2,4634720903;0,0012074;0,01536176;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;541;;
caffeine;caffeine;caffeine;–;–;2519;HMDB0001847;–;–;C07481;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7963787± 0.9253227;1.5008963± 1.2752895;0,5306020809;0,00000289;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;542;;
L-urobilin;L-urobilin;L-urobilin;–;–;5280818;HMDB04159;–;–;C05793;Cofactors and Vitamins;Hemoglobin and Porphyrin Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.796817± 2.111713;0.6537253± 1.831288;1,2188865874;0,5562144;0,607804405;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;543;;
N-acetylcarnosine;N-acetylcarnosine;N-acetylcarnosine;–;–;9903482;–;–;–;–;Peptide;Dipeptide Derivative;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.7983755± 0.4907039;1.0048058± 0.4851702;0,7945570179;0,0008715;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;544;;
phenyllactate;phenyllactate;phenyllactate;(PLA);–;3848;HMDB00779;–;–;C05607;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8005553± 0.6170725;0.8109684± 0.5264461;0,9871596723;0,8823228;0,788023204;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;545;;
1-methylxanthine;1-methylxanthine;1-methylxanthine;–;–;80220;HMDB10738;–;–;C16358;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8128883± 0.7619573;1.2638179± 0.9447917;0,6432004959;0,0000722;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;546;;
catechol sulfate;catechol sulfate;catechol sulfate;–;–;3083879;–;–;–;C00090;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8187319± 0.5048314;1.2485226± 0.6983893;0,6557605765;0,000000209;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;547;;
methylphosphate;methylphosphate;methylphosphate;–;–;13130;–;–;–;–;Nucleotide;Purine and Pyrimidine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8196255± 0.387553;0.9053926± 0.4635268;0,9052708184;0,1228316;0,217976199;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;548;;
saccharin;saccharin;saccharin;–;–;5143;HMDB29723;–;–;D01085;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8342255± 2.458275;1.7332053± 5.571154;0,4813194952;0,1360352;0,232751195;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;549;;
paraxanthine;paraxanthine;paraxanthine;–;–;4687;HMDB0001860;–;–;C13747;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8349149± 0.8945667;1.1984211± 0.8908108;0,6966790722;0,0013598;0,015374512;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;550;;
phenylalanyltryptophan;phenylalanyltryptophan;phenylalanyltryptophan;–;–;–;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8427883± 0.4132307;0.9893779± 0.4069964;0,8518365935;0,0047715;0,022906153;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;551;;
1-palmitoylglycerophosphoglycerol;1-palmitoylglycerophosphoglycerol;1-palmitoylglycerophosphoglycerol;–;–;3300276;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8428138± 0.3536023;1.0080384± 0.375692;0,8360929504;0,0004374;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;552;;
delta-tocopherol;delta-tocopherol;delta-tocopherol;–;–;92094;HMDB02902;–;–;C14151;Cofactors and Vitamins;Tocopherol Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8434681± 1.1693359;0.6148732± 0.6572094;1,3717756767;0,035809;0,085911986;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;553;;
beta-tocopherol;beta-tocopherol;beta-tocopherol;–;–;6857447;HMDB06335;–;–;C14152;Cofactors and Vitamins;Tocopherol Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8444245± 0.6633512;0.7318553± 0.5618406;1,1538134656;0,1356722;0,232751195;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;554;;
cinnamoylglycine;cinnamoylglycine;cinnamoylglycine;–;–;709625;–;–;–;–;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8471± 1.110642;0.9137063± 1.039494;0,9271031621;0,6193992;0,650940187;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;555;;
2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.85191 ± 0.29106;0.93478 ± 0.60297;0,9113481247;0,52357;0,73733;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;556;;
2-arachidonoyl glycerol;2-arachidonoyl glycerol;2-arachidonoyl glycerol;–;–;5282280;HMDB04666;–;–;C13856;Lipid;Monoacylglycerol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8570085± 0.564399;0.8433758± 0.6018292;1,0161644429;0,8545244;0,781510038;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;557;;
cyclo(gly-pro);cyclo(gly-pro);cyclo(gly-pro);–;–;7074739;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.858067± 0.6567153;1.208274± 0.8786657;0,7101592851;0,0007103;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;558;;
α-aminoadipic acid;α-aminoadipic acid;α-aminoadipic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;0.86±0.48 ?M;0.88±0.33 ?M;0,98;0,2559;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,554;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;559;;
allantoin;allantoin;allantoin;–;–;204;HMDB00462;–;–;C02350;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8704149± 0.9195377;0.9699774± 0.8099508;0,8973558559;0,3518648;0,45514723;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;560;;
2-aminophenol sulfate;2-aminophenol sulfate;2-aminophenol sulfate;–;–;181670;–;–;–;–;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8746117± 1.048572;1.1621179± 1.34129;0,7526015218;0,0694025;0,13862797;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;561;;
lidocaine;lidocaine;lidocaine;–;–;3676;HMDB14426;–;–;D00358;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8763064± 0.0572489;0.8657521± 0.07525383;1,0121909031;0,2346052;0,348621288;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;562;;
4-acetaminophen sulfate;4-acetaminophen sulfate;4-acetaminophen sulfate;–;–;83939;HMDB59911;–;–;C06804;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8771074± 2.4290968;0.3091968± 0.9095422;2,8367285819;0,0046718;0,022766793;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;563;;
1-myristoylglycerophosphocholine;1-myristoylglycerophosphocholine;1-myristoylglycerophosphocholine;–;–;460604;HMDB10379;–;–;C04230;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8812628± 0.5312323;1.2314353± 0.5784728;0,7156387347;0,00000137;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;564;;
1-eicosapentaenoylglycerophosphoethanolamine;1-eicosapentaenoylglycerophosphoethanolamine;1-eicosapentaenoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8823755± 0.5398115;1.3140168± 1.010291;0,6715100598;0,0001301;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;565;;
N1-methylguanosine;N1-methylguanosine;N1-methylguanosine;–;–;96373;HMDB01563;–;–;–;Nucleotide;Purine Metabolism, Guanine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8850128± 0.3740717;0.77629± 0.305577;1,1400543611;0,0093478;0,033124888;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;566;;
1-pentadecanoylglycerophosphocholine;1-pentadecanoylglycerophosphocholine;1-pentadecanoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8905053± 0.4558914;1.0764168± 0.4878576;0,8272866979;0,0021979;0,017070445;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;567;;
L-alpha-aminobutyric acid;L-alpha-aminobutyric acid;L-alpha-aminobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.89256 ± 0.2562;0.89347 ± 0.36794;0,9989814991;0,66854;0,79319;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;568;;
cysteine;cysteine;cysteine;–;–;5862;HMDB00574;–;–;C00097;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8982138± 0.2592517;1.0673047± 0.2545761;0,8415720459;0,000000316;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;569;;
isoleucylglycine;isoleucylglycine;isoleucylglycine;–;–;342532;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.8994255± 0.452932;0.9178558± 0.4062234;0,9799202663;0,7292088;0,714276942;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;570;;
phenylcarnitine;phenylcarnitine;phenylcarnitine;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9010202± 0.6865131;0.9738121± 0.5143602;0,9252505694;0,3172934;0,427154092;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;571;;
13-octadecenoate (18:1n5);13-octadecenoate (18:1n5);13-octadecenoate (18:1n5);–;–;5312441;HMDB41480;–;–;–;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9067489± 0.7562197;0.7268111± 0.6151441;1,247571618;0,0325457;0,080326516;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;572;;
1-oleoylglycerophosphoethanolamine;1-oleoylglycerophosphoethanolamine;1-oleoylglycerophosphoethanolamine;–;–;9547071;HMDB11506;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9096777± 0.4512945;1.1716358± 0.477344;0,7764167841;0,0000132;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;573;;
cystine;cystine;cystine;–;–;67678;HMDB00192;–;–;C00491;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.911183± 0.3725111;1.050226± 0.4464398;0,8676065913;0,009638;0,033570032;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;574;;
arabinose;arabinose;arabinose;–;–;66308;HMDB00646;–;–;C00216;Carbohydrate;Pentose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9176894± 0.5347307;1.0732979± 0.5508252;0,8550183505;0,0243132;0,065234577;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;575;;
threonate;threonate;threonate;–;–;151152;HMDB00943;–;–;C01620;Cofactors and Vitamins;Ascorbate and Aldarate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9227585± 0.8023379;1.2047447± 0.7880352;0,7659369657;0,0050812;0,023128436;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;576;;
1-eicosenoylglycerophosphocholine;1-eicosenoylglycerophosphocholine;1-eicosenoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.923616± 0.7822634;1.025974± 0.8953461;0,9002333392;0,3453241;0,448224272;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;577;;
cyclo(gly-pro);cyclo(gly-pro);cyclo(gly-pro);–;–;126154;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9244436± 0.6043803;0.9344679± 0.4814062;0,9892727187;0,8796616;0,788023204;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;578;;
2-hydroxydecanoate;2-hydroxydecanoate;2-hydroxydecanoate;–;–;21488;–;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9250043± 0.564878;1.3751063± 1.025125;0,6726783958;0,0000906;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;579;;
histidine;histidine;histidine;–;–;6274;HMDB0000177;–;–;C00135;Amino Acid;Histidine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9254521± 0.1700337;1.0373216± 0.170973;0,8921554318;0,000000387;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;580;;
trimethylamine n-oxide;trimethylamine n-oxide;trimethylamine n-oxide;–;–;1145;HMDB00925;–;–;C01104;Lipid;Phospholipid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9280564± 1.536182;0.7076816± 1.1956;1,3114038856;0,1853021;0,295830112;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;581;;
1-eicosapentaenoylglycerophosphocholine;1-eicosapentaenoylglycerophosphocholine;1-eicosapentaenoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9285436± 0.5808483;1.3117832± 0.9169857;0,7078483701;0,0002553;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;582;;
phosphatidylcholine diacyl C34:4;phosphatidylcholine diacyl C34:4;phosphatidylcholine diacyl C34:4;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I;20;11, 9;62 ± 5;smoker, non-smoker;noncancerous lung diseases;20;8, 16;63 ± 6;smoker, non-smoker;flow infusion;–;–;QTRAP;MS/MS;Analyst;–;MetaboAnalyst 4.0;Wilcoxon rank-sum test;0.93 ± 0.40;1.44 ± 0.43;0,65;0,00162;0,04529;–;ROC analysis;–;0.82 (0.65-0.94);–;–;–;–;–;–;–;–;Poland;Y;–;31264112;Klupczynska et al. 2019;583;;
ectoine;ectoine;ectoine;–;–;126041;HMDB0240650;–;–;C06231;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9304255± 0.6949008;0.9771979± 0.9252615;0,952136205;0,6648203;0,676690201;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;584;;
arachidic acid;arachidic acid;arachidic acid;–;–;–;HMDB0002212;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.93076 ± 0.34941;1.042 ± 0.55174;0,893243762;0,47189;0,71038;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;585;;
1-palmitoylglycerophosphoethanolamine;1-palmitoylglycerophosphoethanolamine;1-palmitoylglycerophosphoethanolamine;–;–;9547069;HMDB11503;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9311149± 0.395417;1.1256047± 0.3861447;0,8272130527;0,0000925;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;586;;
adenosine;adenosine;adenosine;–;–;60961;HMDB00050;–;–;C00212;Nucleotide;Purine Metabolism, Adenine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9329021± 1.946977;0.87674± 1.318514;1,0640578735;0,7743854;0,738604005;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;587;;
isoleucylvaline;isoleucylvaline;isoleucylvaline;–;–;5246011;435949;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.938316± 0.4309972;1.120237± 0.42475;0,8376048997;0,0008171;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;588;;
proline;proline;proline;–;–;145742;HMDB0000162;–;–;C00148;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9385032± 0.3029347;1.1049505± 0.4217501;0,8493622112;0,0007253;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;589;;
azelate;azelate;azelate;(nonanedioate);–;2266;HMDB00784;–;–;C08261;Lipid;Fatty Acid, Dicarboxylate;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9385702± 0.3581637;1.1286984± 0.5664229;0,8315509263;0,0031792;0,019631853;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;590;;
2-stearoylglycerophosphoinositol;2-stearoylglycerophosphoinositol;2-stearoylglycerophosphoinositol;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9432766± 0.6021886;0.9808± 0.5179698;0,9617420473;0,5865898;0,62664657;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;591;;
1-palmitoylglycerophosphocholine;1-palmitoylglycerophosphocholine;1-palmitoylglycerophosphocholine;–;–;86554;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9436638± 0.2811104;1.0361384± 0.2486787;0,910750726;0,005075;0,023128436;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;592;;
pelargonate;pelargonate;pelargonate;–;–;8158;HMDB00847;–;–;C01601;Lipid;Medium Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9449255± 0.1431241;1.0330258± 0.1629988;0,9147162636;0,000012;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;593;;
tryptophan;tryptophan;tryptophan;–;–;6305;HMDB00929;–;–;C00078;Amino Acid;Tryptophan Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.945816± 0.1884884;1.038218± 0.2242702;0,910999424;0,0006709;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;594;;
cholesterol;cholesterol;cholesterol;–;–;11025495;HMDB0000067;–;–;C00187;Lipid;Sterol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9487085± 0.1522138;1.0097426± 0.1682058;0,9395547935;0,0032646;0,019631853;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;595;;
methyl-beta-glucopyranoside;methyl-beta-glucopyranoside;methyl-beta-glucopyranoside;–;–;2108;–;–;–;–;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9509511± 0.8389006;0.9051668± 0.6734048;1,0505810642;0,6199408;0,650940187;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;596;;
inositol 1-phosphate;inositol 1-phosphate;inositol 1-phosphate; (I1P);–;440194;HMDB00213;–;–;C04006;Lipid;Inositol Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9531117± 0.4427782;1.0794205± 0.4084556;0,88298462;0,0176547;0,050549198;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;597;;
riboflavin;riboflavin;riboflavin;(Vitamin B2);–;493570;HMDB0000244;–;–;C00255;Cofactors and Vitamins;Riboflavin Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9552777± 0.5302281;1.2389121± 0.8798746;0,7710617242;0,0042882;0,02226035;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;598;;
N-oleoyltaurine;N-oleoyltaurine;N-oleoyltaurine;–;–;6437033;–;–;–;–;Lipid;Endocannabinoid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.957766± 0.6892129;0.6583605± 0.4942552;1,4547743979;0,0000359;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;599;;
propionylcarnitine;propionylcarnitine;propionylcarnitine;–;–;107738;HMDB0000824;–;–;C03017;Lipid;Fatty Acid Metabolism (also BCAA Metabolism);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9578457± 0.3301857;1.0743± 0.3453522;0,8915998324;0,0070313;0,027598124;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;600;;
alpha-glutamyltyrosine;alpha-glutamyltyrosine;alpha-glutamyltyrosine;–;–;351830;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9595798± 0.4875561;0.9152747± 0.4548508;1,0484063418;0,4509256;0,540032378;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;601;;
valylarginine;valylarginine;valylarginine;–;–;4266827;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9597936± 0.5334278;0.9143842± 0.4817542;1,0496611818;0,4709807;0,552632262;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;602;;
caproate;caproate;caproate;–;–;8892;HMDB00535;–;–;C01585;Lipid;Medium Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9607415± 0.3675058;0.9668232± 0.3341212;0,9937096048;0,8889799;0,788535721;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;603;;
1-linoleoylglycerophosphocholine;1-linoleoylglycerophosphocholine;1-linoleoylglycerophosphocholine;–;–;11988421;HMDB0010386;–;–;C04100;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9610957± 0.3700645;1.0965816± 0.3269616;0,8764470423;0,0018292;0,016307726;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;604;;
pyrophosphate;pyrophosphate;pyrophosphate;(PPi);–;644102;HMDB00250;–;–;C00013;Energy;Oxidative Phosphorylation;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.964233± 0.5382832;1.043674± 0.6082713;0,9238833199;0,2828343;0,396269035;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;605;;
beta-hydroxyisovalerate;beta-hydroxyisovalerate;beta-hydroxyisovalerate;–;–;69362;HMDB00754;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9644128± 0.5639088;1.3361637± 6.883251;0,7217774289;0,6014356;0,639325393;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;606;;
alanine;alanine;alanine;–;–;5950;HMDB00161;–;–;C00041;Amino Acid;Alanine and Aspartate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9644947± 0.2833716;1.0890479± 0.2653567;0,8856311095;0,0003222;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;607;;
1-docosapentaenoylglycerophosphocholine;1-docosapentaenoylglycerophosphocholine;1-docosapentaenoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9646862± 0.4179374;1.1248426± 0.4702664;0,8576188348;0,0054235;0,023524587;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;608;;
gamma-glutamylmethionine;gamma-glutamylmethionine;gamma-glutamylmethionine;–;–;7009567;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9659968± 0.2916682;1.1222005± 0.3709541;0,8608058899;0,0004119;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;609;;
1-linoleoylglycerophosphoethanolamine;1-linoleoylglycerophosphoethanolamine;1-linoleoylglycerophosphoethanolamine;–;–;52925130;HMDB11507;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9665223± 0.4564428;1.1659516± 0.4957366;0,8289557645;0,0011806;0,01536176;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;610;;
3-(cystein-s-yl)acetaminophen;3-(cystein-s-yl)acetaminophen;3-(cystein-s-yl)acetaminophen;–;–;5233914;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9673862± 2.6449852;0.3467458± 0.9121789;2,789900267;0,0038858;0,020958834;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;611;;
1-palmitoylglycerophosphoinositol;1-palmitoylglycerophosphoinositol;1-palmitoylglycerophosphoinositol;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9683777± 0.3660035;1.0869184± 0.4727865;0,890938731;0,0334976;0,08081794;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;612;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.9694 ± 0.53461;0.97646 ± 0.6661;0,9927698011;0,75969;0,87264;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;613;;
N-stearoyltaurine;N-stearoyltaurine;N-stearoyltaurine;–;–;168274;–;–;–;–;Lipid;Endocannabinoid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9699223± 0.5549434;0.8417863± 0.5261781;1,1522191559;0,058661;0,12243893;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;614;;
methionine;methionine;methionine;–;–;6137;HMDB00696;–;–;C00073;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9703404± 0.2671491;1.0918958± 0.2642577;0,8886749084;0,0003276;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;615;;
alpha-ketoglutarate;alpha-ketoglutarate;alpha-ketoglutarate;–;–;51;HMDB00208;–;–;C00026;Energy;TCA Cycle;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9707989± 0.6326111;0.9231879± 0.5633581;1,051572383;0,5202245;0,586078412;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;616;;
2-palmitoylglycerol;2-palmitoylglycerol;2-palmitoylglycerol;(2-monopalmitin);–;123409;HMDB11533;–;–;–;Lipid;Monoacylglycerol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9731266± 0.5868459;1.2149953± 1.8080814;0,800930341;0,2069255;0,317373142;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;617;;
1-stearoylglycerophosphoethanolamine;1-stearoylglycerophosphoethanolamine;1-stearoylglycerophosphoethanolamine;–;–;9547068;HMDB11130;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9731681± 0.3666285;1.0982768± 0.3362096;0,8860863673;0,0044751;0,022695544;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;618;;
2-ethylhexanoate;2-ethylhexanoate;2-ethylhexanoate;–;–;8697;HMDB31230;–;–;–;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9751989± 0.3361686;1.0515621± 0.3555787;0,9273811789;0,0837851;0,1592108;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;619;;
indolelactate;indolelactate;indolelactate;–;–;92904;HMDB00671;–;–;C02043;Amino Acid;Tryptophan Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9761287± 0.4009176;1.1065789± 0.4988518;0,882113964;0,0279858;0,073283815;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;620;;
sphingosine 1-phosphate;sphingosine 1-phosphate;sphingosine 1-phosphate;–;–;5283560;HMDB0000277;–;–;C06124;Lipid;Sphingolipid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9780936± 0.4131693;1.0216247± 0.3886034;0,9573903215;0,3846749;0,480230326;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;621;;
2-oleoylglycerophosphoethanolamine;2-oleoylglycerophosphoethanolamine;2-oleoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9788436± 0.6468944;1.2623211± 0.6415722;0,7754315443;0,0005438;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;622;;
tyrosine;tyrosine;tyrosine;–;–;6057;HMDB0000158;–;–;C00082;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9790851± 0.224101;1.0804332± 0.2889861;0,9061967922;0,0030713;0,01946876;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;623;;
3-hydroxyhippurate;3-hydroxyhippurate;3-hydroxyhippurate;–;–;450268;HMDB06116;–;–;–;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9791053± 1.442961;1.2817411± 1.544195;0,7638869503;0,1130389;0,203969449;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;624;;
3-hydroxyphenylpropionic acid;3-hydroxyphenylpropionic acid;3-hydroxyphenylpropionic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;0.98054 ± 1.1013;1.4376 ± 1.5675;0,6820673344;0,20504;0,52412;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;625;;
4-vinylphenol sulfate;4-vinylphenol sulfate;4-vinylphenol sulfate;–;–;6426766;HMDB04072;–;–;C05627;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9819798± 0.9348394;1.6027011± 1.3796927;0,6127030174;0,0001025;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;626;;
2-linoleoylglycerophosphocholine;2-linoleoylglycerophosphocholine;2-linoleoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.983266± 0.528815;1.137719± 0.4432422;0,8642432798;0,0100597;0,034171522;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;627;;
1-docosahexaenoylglycerophosphocholine;1-docosahexaenoylglycerophosphocholine;1-docosahexaenoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9833436± 0.3660085;1.0874832± 0.4487183;0,9042379689;0,0517788;0,114019369;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;628;;
glutamine;glutamine;glutamine;–;–;5961;HMDB0000641;–;–;C00064;Amino Acid;Glutamate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9834149± 0.1544811;1.0094926± 0.1554955;0,9741675174;0,1838047;0,294534436;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;629;;
valine;valine;valine;–;–;6287;HMDB0000883;–;–;C00183;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9836223± 0.1859707;1.0549163± 0.24668;0,932417387;0,0138691;0,041500997;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;630;;
glycerate;glycerate;glycerate;–;–;752;HMDB00139;–;–;C00258;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9840202± 0.2958047;1.0851216± 0.3362597;0,9068294281;0,0136964;0,041448334;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;631;;
2-linoleoylglycerophosphoethanolamine;2-linoleoylglycerophosphoethanolamine;2-linoleoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.985783± 0.5462642;1.225757± 0.7370529;0,8042238388;0,0054391;0,023524587;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;632;;
gamma-glutamylleucine;gamma-glutamylleucine;gamma-glutamylleucine;–;–;151023;HMDB11171;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9858851± 0.3376543;1.1080621± 0.3724111;0,8897381293;0,0077039;0,029190502;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;633;;
gamma-glutamyltyrosine;gamma-glutamyltyrosine;gamma-glutamyltyrosine;–;–;94340;HMDB11741;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9873574± 0.2674595;1.0852868± 0.319351;0,9097663401;0,0108883;0,036013448;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;634;;
1-margaroylglycerophosphocholine;1-margaroylglycerophosphocholine;1-margaroylglycerophosphocholine;–;–;24779463;HMDB12108;–;–;C04230;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9875989± 0.6679198;1.1383037± 0.6111115;0,8676058068;0,0587317;0,12243893;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;635;;
xylitol;xylitol;xylitol;–;–;6912;HMDB02917;–;–;C00379;Carbohydrate;Pentose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9884213± 0.707863;1.0292874± 1.075835;0,9602967062;0,7382691;0,718936102;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;636;;
pentadecanoate;pentadecanoate;pentadecanoate;–;–;13849;HMDB00826;–;–;C16537;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9888745± 0.3868104;0.9541526± 0.4962982;1,0363903007;0,5521562;0,606456102;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;637;;
lysine;lysine;lysine;–;–;5962;HMDB00182;–;–;C00047;Amino Acid;Lysine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9895128± 0.2804536;1.0610621± 0.2815248;0,9325682257;0,0443819;0,100315203;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;638;;
urate;urate;urate;–;–;1175;HMDB00289;–;–;C00366;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9896947± 0.203009;1.0207974± 0.2102933;0,9695309765;0,2363423;0,349991651;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;639;;
phosphate;phosphate;phosphate;–;–;1061;HMDB0001429;–;–;C00009;Energy;Oxidative Phosphorylation;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9902234± 0.1644398;1.0462695± 0.1990623;0,946432444;0,0189469;0,053533462;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;640;;
benzoate;benzoate;benzoate;–;–;243;HMDB01870;–;–;C00180;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9917489± 0.1451509;1.0149921± 0.1088335;0,9771001173;0,1324616;0,230307092;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;641;;
xylose;xylose;xylose;–;–;135191;HMDB00098;–;–;C00181;Carbohydrate;Pentose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9926883± 1.05832;1.2979132± 1.634773;0,7648341199;0,100322;0,186508322;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;642;;
1-dihomo-linoleoylglycerophosphocholine;1-dihomo-linoleoylglycerophosphocholine;1-dihomo-linoleoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9931787± 0.6732598;1.0754216± 0.6285495;0,9235249692;0,3112443;0,424331352;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;643;;
1-linolenoylglycerophosphocholine;1-linolenoylglycerophosphocholine;1-linolenoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9933649± 0.6456574;1.1884047± 0.6529089;0,8358809924;0,0179632;0,051091457;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;644;;
carnitine;carnitine;carnitine;–;–;10917;HMDB0000062;–;–;C00318;Lipid;Carnitine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.995517± 0.2106721;1.023201± 0.1734553;0,9729437325;0,2401905;0,352048394;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;645;;
acetylphosphate;acetylphosphate;acetylphosphate;–;–;186;HMDB01494;–;–;C00227;Energy;Oxidative Phosphorylation;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9956245± 0.1757046;1.0388458± 0.1806018;0,958394884;0,0565116;0,120741171;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;646;;
glycolate;glycolate;glycolate;(hydroxyacetate);–;757;HMDB00115;–;–;C00160;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9956798± 0.2439497;1.0617837± 0.3093829;0,937742593;0,0709693;0,13882663;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;647;;
stearate, methyl ester;stearate, methyl ester;stearate, methyl ester;–;–;8201;–;–;–;–;Lipid;Fatty Acid, Methyl Ester;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9970372± 0.1920614;1.0453995± 0.5087333;0,9537379729;0,3736515;0,47057246;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;648;;
2-palmitoylglycerophosphocholine;2-palmitoylglycerophosphocholine;2-palmitoylglycerophosphocholine;–;–;15061532;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9975553± 0.4483349;1.1341674± 0.3939895;0,8795485569;0,0090681;0,032434562;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;649;;
phenylalanine;phenylalanine;phenylalanine;–;–;6140;HMDB0000159;–;–;C00079;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9977372± 0.173342;1.0399853± 0.1725929;0,9593762527;0,0535742;0,116789403;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;650;;
sucrose;sucrose;sucrose;–;–;5988;HMDB00258;–;–;C00089;Carbohydrate;Disaccharides and Oligosaccharides;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;0.9980351± 1.330491;1.2360016± 1.710138;0,8074707185;0,237177;0,350020692;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;651;;
C24:1-ceramide;C24:1-ceramide;C24:1-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;1 uM;0.96 uM;1,0416666667;0,07;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;652;;
1-palmitoleoylglycerophosphocholine;1-palmitoleoylglycerophosphocholine;1-palmitoleoylglycerophosphocholine;–;–;24779461;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.000837± 0.5878249;1.16338± 0.5450408;0,8602838282;0,0218185;0,059681845;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;653;;
fucose;fucose;fucose;–;–;19466;HMDB00174;–;–;C01018;Carbohydrate;Pentose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.0018553± 0.6160898;0.9810889± 0.5560693;1,0211666853;0,7751324;0,738604005;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;654;;
succinate;succinate;succinate;–;–;1110;HMDB00254;–;–;C00042;Energy;TCA Cycle;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.001865± 0.3907583;1.048758± 0.485464;0,955287111;0,4154044;0,50394377;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;655;;
palmitoyl sphingomyelin;palmitoyl sphingomyelin;palmitoyl sphingomyelin;–;–;9939941;–;–;–;–;Lipid;Sphingolipid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.002168± 0.2373465;1.004548± 0.2491447;0,9976307752;0,938697;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;656;;
1-palmitoylplasmenylethanolamine;1-palmitoylplasmenylethanolamine;1-palmitoylplasmenylethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.002367± 0.3026432;1.074404± 0.3028707;0,9329516644;0,0600286;0,124538049;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;657;;
gamma-glutamylphenylalanine;gamma-glutamylphenylalanine;gamma-glutamylphenylalanine;–;–;111299;HMDB00594;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.002503± 0.2525121;1.03288± 0.2327206;0,9705900008;0,3149465;0,42642155;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;658;;
leucine;leucine;leucine;–;–;6106;HMDB0000687;–;–;C00123;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.002526± 0.2668922;1.073271± 0.2826482;0,9340846813;0,0440341;0,100055682;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;659;;
threonine;threonine;threonine;–;–;6288;HMDB00167;–;–;C00188;Amino Acid;Glycine, Serine and Threonine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.002537± 0.3298883;1.095235± 0.3449329;0,9153624565;0,0313244;0,078211018;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;660;;
alpha-tocopherol;alpha-tocopherol;alpha-tocopherol;–;–;14985;HMDB01893;–;–;C02477;Cofactors and Vitamins;Tocopherol Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.002835± 0.425534;1.120921± 0.4151652;0,8946527008;0,0259186;0,068287014;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;661;;
isoleucine;isoleucine;isoleucine;–;–;6306;HMDB00172;–;–;C00407;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.00305± 0.2624543;1.068135± 0.287188;0,939066691;0,0654316;0,13444838;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;662;;
5-oxoproline;5-oxoproline;5-oxoproline;–;–;7405;HMDB00267;–;–;C01879;Amino Acid;Glutathione Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.003324± 0.2046687;1.020258± 0.1668089;0,9834022375;0,4566752;0,541767609;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;663;;
ornithine;ornithine;ornithine;–;–;6262;HMDB0000214;–;–;C00077;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.005514± 0.7650679;1.219207± 0.7766344;0,8247278764;0,0289604;0,074922252;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;664;;
1-oleoylglycerophosphocholine;1-oleoylglycerophosphocholine;1-oleoylglycerophosphocholine;–;–;16081932;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.005537± 0.4388026;1.100231± 0.3627992;0,9139326196;0,0546353;0,117415854;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;665;;
2-oleoylglycerophosphocholine;2-oleoylglycerophosphocholine;2-oleoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.006452± 0.4601786;1.100634± 0.378594;0,9144293198;0,0674848;0,136949616;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;666;;
1-eicosatrienoylglycerophosphocholine;1-eicosatrienoylglycerophosphocholine;1-eicosatrienoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.007613± 0.4817879;1.10787± 0.3901111;0,9095047253;0,0606657;0,125254805;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;667;;
gamma-glutamyl-valine;gamma-glutamyl-valine;gamma-glutamyl-valine;–;–;7015683;HMDB11172;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.008617± 0.3220343;1.037207± 0.2817658;0,972435589;0,4434518;0,535580651;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;668;;
4-methylcatechol sulfate;4-methylcatechol sulfate;4-methylcatechol sulfate;–;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.012283± 0.7124231;1.302724± 0.9405676;0,77705101;0,0086376;0,031477991;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;669;;
7-methylguanine;7-methylguanine;7-methylguanine;–;–;11361;HMDB0000897;–;–;C02242;Nucleotide;Purine Metabolism, Guanine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.0123106± 0.2654142;0.9945195± 0.2486145;1,0178891414;0,5791916;0,6211063;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;670;;
glycerophosphorylcholine;glycerophosphorylcholine;glycerophosphorylcholine;(GPC);–;71920;HMDB00086;–;–;C00670;Lipid;Phospholipid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.015002± 0.3717453;1.053725± 0.3773621;0,9632513227;0,4137549;0,503364527;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;671;;
citrulline;citrulline;citrulline;–;–;9750;HMDB00904;–;–;C00327;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.016207± 0.4586533;1.104633± 0.439792;0,9199498838;0,1167183;0,209727511;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;672;;
levulinate;levulinate;levulinate;(4-oxovalerate);–;11579;HMDB00720;–;–;–;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.017714± 1.5268931;1.116871± 0.8924128;0,9112189322;0,4909044;0,568388449;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;673;;
1,5-anhydroglucitol;1,5-anhydroglucitol;1,5-anhydroglucitol;(1,5-AG);–;64960;HMDB02712;–;–;C07326;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.0200968± 0.3469864;0.9498011± 0.3815291;1,0740109692;0,1331728;0,230609873;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;674;;
1-eicosatrienoylglycerophosphoethanolamine;1-eicosatrienoylglycerophosphoethanolamine;1-eicosatrienoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.02061± 0.558327;1.196584± 0.6143779;0,8529363588;0,0198668;0,055402627;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;675;;
guanosine;guanosine;guanosine;–;–;6802;HMDB0000133;–;–;C00387;Nucleotide;Purine Metabolism, Guanine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.021035± 0.7122059;1.200728± 0.7676449;0,850346623;0,0581058;0,12243893;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;676;;
glycerol-2-phosphate;glycerol-2-phosphate;glycerol-2-phosphate;–;–;2526;HMDB02520;–;–;C02979;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.021371± 0.7286407;1.432229± 4.380684;0,7131338634;0,3670498;0,464985544;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;677;;
glucose;glucose;glucose;–;–;79025;HMDB00122;–;–;C00031;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.021545± 0.1987323;1.007043± 0.2346031;1,0144005767;0,6069514;0,642010476;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;678;;
7-alpha-hydroxy-3-oxo-4-cholestenoate;7-alpha-hydroxy-3-oxo-4-cholestenoate;7-alpha-hydroxy-3-oxo-4-cholestenoate; (7-Hoca);–;3081085;HMDB12458;–;–;C17337;Lipid;Sterol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.021951± 0.323089;1.066598± 0.3745664;0,9581407428;0,3236227;0,432960359;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;679;;
2-arachidonoylglycerophosphocholine;2-arachidonoylglycerophosphocholine;2-arachidonoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.02396± 0.4952371;1.098605± 0.424472;0,9320547422;0,1880367;0,297980281;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;680;;
arginine;arginine;arginine;–;–;232;HMDB0000517;–;–;C00062;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.025966± 0.2495975;1.025497± 0.232247;1,0004573392;0,9875386;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;681;;
trans-4-hydroxyproline;trans-4-hydroxyproline;trans-4-hydroxyproline;–;–;5810;HMDB00725;–;–;C01157;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.025967± 0.4244863;1.076351± 0.4068141;0,953189991;0,3333577;0,440495408;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;682;;
gamma-glutamylisoleucine;gamma-glutamylisoleucine;gamma-glutamylisoleucine;–;–;14253342;HMDB11170;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.029013± 0.4134717;1.035691± 0.37993;0,9935521309;0,8923361;0,788535721;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;683;;
theobromine;theobromine;theobromine;–;–;5429;HMDB0002825;–;–;C07480;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.029067± 0.8584048;1.437394± 1.3011977;0,7159254874;0,0061223;0,025297307;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;684;;
N6-acetyllysine;N6-acetyllysine;N6-acetyllysine;–;–;92832;HMDB00206;–;–;C02727;Amino Acid;Lysine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.029109± 0.2356439;1.048779± 0.2207845;0,9812448571;0,4900023;0,568388449;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;685;;
hippurate;hippurate;hippurate;–;–;464;HMDB00714;–;–;C01586;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.029847± 1.063944;1.420652± 1.040638;0,7249115195;0,0033414;0,019631853;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;686;;
7-methylxanthine;7-methylxanthine;7-methylxanthine;–;–;68374;HMDB01991;–;–;C16353;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.029862± 0.8448635;1.422744± 1.4169686;0,723856154;0,0136926;0,041448334;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;687;;
N-acetylalanine;N-acetylalanine;N-acetylalanine;–;–;88064;HMDB00766;–;–;C02847;Amino Acid;Alanine and Aspartate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.0308628± 0.3164823;0.9473979± 0.2181509;1,0880990975;0,0098328;0,033685739;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;688;;
phenylalanylserine;phenylalanylserine;phenylalanylserine;–;–;9859812;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.0327404± 0.6200645;0.9822053± 0.5707889;1,0514506489;0,4952394;0,571724045;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;689;;
ribose;ribose;ribose;–;–;5779;HMDB00283;–;–;C00121;Carbohydrate;Pentose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.0335777± 0.6093635;0.8567974± 0.5141425;1,2063268399;0,0108682;0,036013448;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;690;;
parabanic acid;parabanic acid;parabanic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;1.0337 ± 0.77281;1.6321 ± 2.2193;0,6333557993;0,10485;0,43173;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;691;;
2-methylbutyrylcarnitine;2-methylbutyrylcarnitine;2-methylbutyrylcarnitine;–;–;6426901;HMDB00378;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.034754± 0.4126464;1.06628± 0.3793311;0,9704336572;0,5222912;0,586078412;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;692;;
isovalerylcarnitine;isovalerylcarnitine;isovalerylcarnitine;–;–;6426851;HMDB00688;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.034822± 0.5851652;1.182996± 0.579405;0,8747468292;0,0439539;0,100055682;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;693;;
1-arachidonoylglycerophosphoinositol;1-arachidonoylglycerophosphoinositol;1-arachidonoylglycerophosphoinositol;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.036579± 0.3524492;1.047747± 0.3033808;0,9893409382;0,7822341;0,738604005;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;694;;
glycine;glycine;glycine;–;–;750;HMDB00123;–;–;C00037;Amino Acid;Glycine, Serine and Threonine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.036981± 0.3624612;1.129279± 0.4382136;0,9182682048;0,0783974;0,15030303;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;695;;
p-cresol sulfate;p-cresol sulfate;p-cresol sulfate;–;–;4615423;HMDB11635;–;–;C01468;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.038501± 0.6853826;1.135088± 0.6637929;0,914907919;0,2540876;0,366168809;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;696;;
asparagine;asparagine;asparagine;–;–;6267;HMDB00168;–;–;C00152;Amino Acid;Alanine and Aspartate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.039703± 0.3100665;1.029821± 0.2688859;1,0095958424;0,7819748;0,738604005;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;697;;
uridine;uridine;uridine;–;–;6029;HMDB0000296;–;–;C00299;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.040666± 0.2436918;1.009417± 0.2017137;1,0309574735;0,2530442;0,365892973;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;698;;
3-hydroxypropanoate;3-hydroxypropanoate;3-hydroxypropanoate;–;–;68152;HMDB00700;–;–;C01013;Lipid;Fatty Acid, Monohydroxy;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.041311± 0.5082655;1.143164± 0.680795;0,9109025477;0,1997588;0,309699434;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;699;;
myo-inositol;myo-inositol;myo-inositol;–;–;892;HMDB0000211;–;–;C00137;Lipid;Inositol Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.04179± 0.7075297;1.108779± 0.3917566;0,9395830909;0,3051343;0,420001258;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;700;;
fumarate;fumarate;fumarate;–;–;–;HMDB00134;–;–;C00122;Energy;TCA Cycle;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.042788± 0.480176;1.037012± 0.2996676;1,0055698488;0,901218;0,790949301;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;701;;
3-indoxyl sulfate;3-indoxyl sulfate;3-indoxyl sulfate;–;–;10258;HMDB00682;–;–;–;Amino Acid;Tryptophan Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.042797± 0.7867904;1.138239± 0.7065595;0,9161494203;0,3027919;0,418117174;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;702;;
cortisone;cortisone;cortisone;–;–;222786;HMDB02802;–;–;C00762;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.042866± 0.3049293;0.9794105± 0.2590661;1,0647894831;0,0681638;0,137432102;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;703;;
choline;choline;choline;–;–;305;HMDB0000097;–;–;C00114;Lipid;Phospholipid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.043255± 0.2413635;1.014215± 0.1992124;1,0286329822;0,2826552;0,396269035;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;704;;
myristoylcarnitine;myristoylcarnitine;myristoylcarnitine;–;–;53477791;HMDB05066;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.044735± 0.6959279;1.060916± 1.7073534;0,9847480856;0,9296437;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;705;;
N2,N2-dimethylguanosine;N2,N2-dimethylguanosine;N2,N2-dimethylguanosine;–;–;92919;HMDB04824;–;–;–;Nucleotide;Purine Metabolism, Guanine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.045123± 0.4337455;1.001341± 0.318388;1,043723367;0,3359162;0,441161263;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;706;;
arabitol;arabitol;arabitol;–;–;94154;HMDB01851;–;–;C01904;Carbohydrate;Pentose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.045963± 0.6995286;1.089328± 0.3901972;0,9601910536;0,5029231;0,57594965;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;707;;
creatinine;creatinine;creatinine;–;–;588;HMDB0000562;–;–;C00791;Amino Acid;Creatine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.046573± 0.4178551;1.030508± 0.2445796;1,0155893986;0,6835906;0,68393841;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;708;;
indolepropionate;indolepropionate;indolepropionate;–;–;3744;HMDB02302;–;–;–;Amino Acid;Tryptophan Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.047653± 0.642224;1.310207± 0.9606886;0,7996087641;0,0170575;0,049168508;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;709;;
3-(4-hydroxyphenyl)lactate;3-(4-hydroxyphenyl)lactate;3-(4-hydroxyphenyl)lactate;–;–;9378;HMDB00755;–;–;C03672;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.047986± 0.340083;1.044551± 0.3594686;1,0032884943;0,9385206;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;710;;
1-oleoylglycerophosphoinositol;1-oleoylglycerophosphoinositol;1-oleoylglycerophosphoinositol;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.048283± 0.5200857;1.236761± 0.6639869;0,8476035386;0,0164798;0,047826237;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;711;;
serine;serine;serine;–;–;5951;HMDB0000187;–;–;C00065;Amino Acid;Glycine, Serine and Threonine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.048952± 0.310699;1.013898± 0.2651638;1,0345734975;0,3230135;0,432960359;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;712;;
3-methyl-2-oxovalerate;3-methyl-2-oxovalerate;3-methyl-2-oxovalerate;–;–;47;HMDB03736;–;–;C00671;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.049632± 0.3646107;1.067813± 0.3585741;0,9829736105;0,6892898;0,686813449;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;713;;
pregnenolone sulfate;pregnenolone sulfate;pregnenolone sulfate;–;–;105074;HMDB00774;–;–;–;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.051254± 0.7771951;1.091611± 0.5791136;0,9630298705;0,6230617;0,65262153;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;714;;
stearoylcarnitine;stearoylcarnitine;stearoylcarnitine;–;–;6426855;HMDB0000848;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.052357± 0.4914142;1.005607± 0.4995433;1,0464893343;0,4557282;0,541767609;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;715;;
1-arachidonoylglycerophosphoethanolamine;1-arachidonoylglycerophosphoethanolamine;1-arachidonoylglycerophosphoethanolamine;–;–;42607465;HMDB11517;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.053569± 0.4086245;1.040586± 0.3909532;1,0124766237;0,7953049;0,747363111;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;716;;
4-methyl-2-oxopentanoate;4-methyl-2-oxopentanoate;4-methyl-2-oxopentanoate;–;–;70;HMDB00695;–;–;C00233;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.055456± 0.3916672;1.062205± 0.3537116;0,9936462359;0,8839555;0,788023204;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;717;;
urea;urea;urea;–;–;1176;HMDB00294;–;–;C00086;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.05628± 0.4647057;1.043567± 0.3709509;1,0121822557;0,8030662;0,751368269;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;718;;
succinylcarnitine;succinylcarnitine;succinylcarnitine;–;–;–;–;–;–;–;Energy;TCA Cycle;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.057484± 0.3339085;1.023336± 0.31157;1,0333692942;0,3964158;0,489199445;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;719;;
1-arachidonoylglycerophosphocholine;1-arachidonoylglycerophosphocholine;1-arachidonoylglycerophosphocholine;–;–;–;–;–;–;C05208;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.05872± 0.4048739;1.06516± 0.3522219;0,99395396;0,8903402;0,788535721;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;720;;
2-stearoylglycerophosphocholine;2-stearoylglycerophosphocholine;2-stearoylglycerophosphocholine;–;–;10208382;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.060066± 0.6958314;1.310221± 0.8787484;0,8090741944;0,0164411;0,047826237;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;721;;
arabonate;arabonate;arabonate;–;–;122045;HMDB00539;–;–;C00878;Cofactors and Vitamins;Ascorbate and Aldarate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.060362± 0.8904268;1.097955± 0.5337049;0,9657608918;0,6575724;0,676690201;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;722;;
palmitate, methyl ester;palmitate, methyl ester;palmitate, methyl ester;–;–;8181;–;–;–;C16995;Lipid;Fatty Acid, Methyl Ester;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.061772± 0.6158703;1.215615± 1.1998349;0,873444306;0,2430069;0,354965016;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;723;;
serylleucine;serylleucine;serylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.0639255± 0.7298565;0.8687411± 1.6083761;1,2246749924;0,2630377;0,376539843;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;724;;
deoxycarnitine;deoxycarnitine;deoxycarnitine;–;–;134;HMDB01161;–;–;C01181;Lipid;Carnitine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.063959± 0.6475785;1.016268± 0.2044867;1,0469275821;0,3540752;0,456631114;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;725;;
3-hydroxy-2-ethylpropionate;3-hydroxy-2-ethylpropionate;3-hydroxy-2-ethylpropionate;–;–;188979;HMDB00396;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.0641032± 0.5271901;0.9758226± 0.4911614;1,0904678781;0,1649039;0,271334198;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;726;;
N1-methyladenosine;N1-methyladenosine;N1-methyladenosine;–;–;27476;HMDB03331;–;–;C02494;Nucleotide;Purine Metabolism, Adenine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.064187± 0.2178878;1.007433± 0.2021858;1,05633526;0,0308515;0,077480935;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;727;;
7-methylurate;7-methylurate;7-methylurate;–;–;69160;–;–;–;–;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.064324± 1.080798;1.349526± 1.995551;0,7886650572;0,1961362;0,306294504;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;728;;
1,3-dimethylurate;1,3-dimethylurate;1,3-dimethylurate;–;–;70346;HMDB01857;–;–;–;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.0651277± 2.548831;0.9681158± 1.305916;1,1002069174;0,671205;0,677257468;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;729;;
isobutyrylcarnitine;isobutyrylcarnitine;isobutyrylcarnitine;–;–;168379;HMDB00736;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.066319± 0.6686054;1.180042± 0.7173655;0,9036280065;0,1992346;0,309699434;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;730;;
lactate;lactate;lactate;–;–;612;HMDB00190;–;–;C00186;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.068399± 0.3208461;1.034458± 0.2555639;1,0328104186;0,3347942;0,441036503;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;731;;
betaine;betaine;betaine;–;–;247;HMDB0000043;–;–;C00719;Amino Acid;Glycine, Serine and Threonine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.069745± 0.3258525;1.024067± 0.2985595;1,0446045034;0,239907;0,352048394;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;732;;
2-hydroxystearate;2-hydroxystearate;2-hydroxystearate;–;–;69417;–;–;–;C03045;Lipid;Fatty Acid, Monohydroxy;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.071784± 0.2271114;0.9912795± 0.2379984;1,0812127155;0,0068445;0,027175059;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;733;;
3-methyl-2-oxobutyrate;3-methyl-2-oxobutyrate;3-methyl-2-oxobutyrate;–;–;49;HMDB00019;–;–;C00141;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.07292± 0.2871296;0.99162± 0.2999378;1,0819870515;0,029971;0,076160285;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;734;;
2-palmitoylglycerophosphoethanolamine;2-palmitoylglycerophosphoethanolamine;2-palmitoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.073811± 0.8819952;1.203763± 0.6695664;0,8920451949;0,1679469;0,275286502;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;735;;
xylonate;xylonate;xylonate;–;–;6602431;–;–;–;C05411;Carbohydrate;Pentose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.077705± 0.8978027;1.103347± 0.7607903;0,9767598045;0,8013948;0,751368269;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;736;;
eicosapentaenoate;eicosapentaenoate;eicosapentaenoate;–;–;446284;HMDB01999;–;–;C06428;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.078149± 0.5845547;1.412598± 1.4284136;0,7632383736;0,0298903;0,076160285;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;737;;
1-linoleoylglycerol;1-linoleoylglycerol;1-linoleoylglycerol;(1-monolinolein);–;5283469;–;–;–;–;Lipid;Monoacylglycerol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.079929± 0.5958457;1.052324± 0.4475235;1,0262324151;0,6623427;0,676690201;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;738;;
3-hydroxyisobutyrate;3-hydroxyisobutyrate;3-hydroxyisobutyrate;–;–;87;HMDB00336;–;–;C06001;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.080482± 0.4785197;1.091939± 0.5306763;0,9895076556;0,8596899;0,781510038;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;739;;
1-palmitoylglycerol;1-palmitoylglycerol;1-palmitoylglycerol;(1-monopalmitin);–;14900;HMDB31074;–;–;–;Lipid;Monoacylglycerol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.081152± 0.9683362;1.085895± 0.4250285;0,9956321744;0,9542637;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;740;;
citrate;citrate;citrate;–;–;311;HMDB00094;–;–;C00158;Energy;TCA Cycle;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.082688± 0.3633033;1.065611± 0.295738;1,0160255478;0,6718142;0,677257468;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;741;;
1-stearoylglycerophosphoinositol;1-stearoylglycerophosphoinositol;1-stearoylglycerophosphoinositol;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.083778± 0.5797164;1.120949± 0.4476456;0,9668397046;0,5516525;0,606456102;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;742;;
pro-hydroxy-pro;pro-hydroxy-pro;pro-hydroxy-pro;–;–;11673055;HMDB06695;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.08573± 0.4758494;1.018874± 0.4117314;1,0656175347;0,2223307;0,333847031;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;743;;
kynurenine;kynurenine;kynurenine;–;–;161166;HMDB0000684;–;–;C00328;Amino Acid;Tryptophan Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.086674± 0.3964937;1.008205± 0.2643555;1,0778304016;0,0483843;0,108789023;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;744;;
N-acetylserine;N-acetylserine;N-acetylserine;–;–;65249;HMDB02931;–;–;–;Amino Acid;Glycine, Serine and Threonine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.0869266± 0.6126509;0.9606332± 0.4081916;1,1314689103;0,0397238;0,092975633;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;745;;
2-arachidonoylglycerophosphoethanolamine;2-arachidonoylglycerophosphoethanolamine;2-arachidonoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.08832± 0.5469703;1.047797± 0.4663302;1,0386744761;0,515771;0,584429195;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;746;;
4-androsten-3beta,17beta-diol disulfate;4-androsten-3beta,17beta-diol disulfate;4-androsten-3beta,17beta-diol disulfate;–;–;10634;HMDB03818;–;–;C04295;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.090807± 0.7294603;1.111241± 0.8228299;0,9816115496;0,838103;0,776328456;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;747;;
1-stearoylglycerol;1-stearoylglycerol;1-stearoylglycerol;(1-monostearin);–;24699;HMDB31075;–;–;D01947;Lipid;Monoacylglycerol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.090807± 0.7430408;1.020861± 0.3377913;1,0685166737;0,2757499;0,38954355;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;748;;
xanthine;xanthine;xanthine;–;–;1188;HMDB0000292;–;–;C00385;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.094821± 0.5015046;1.083551± 1.0811354;1,0104009871;0,9234785;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;749;;
1,7-dimethylurate;1,7-dimethylurate;1,7-dimethylurate;–;–;91611;HMDB11103;–;–;C16356;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.096845± 0.8634745;1.007386± 0.7285712;1,0888031003;0,3606289;0,459562816;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;750;;
palmitoyl ethanolamide;palmitoyl ethanolamide;palmitoyl ethanolamide;–;–;4671;HMDB02100;–;–;C16512;Lipid;Endocannabinoid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.097583± 0.359208;0.9805805± 0.2941306;1,1193196275;0,0036803;0,020563785;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;751;;
2-linoleoylglycerol;2-linoleoylglycerol;2-linoleoylglycerol;(2-monolinolein);–;5365676;HMDB11538;–;–;–;Lipid;Monoacylglycerol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.099724± 0.7227947;1.114447± 0.7564963;0,9867889635;0,8755297;0,786605878;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;752;;
2-docosahexaenoylglycerophosphoethanolamine;2-docosahexaenoylglycerophosphoethanolamine;2-docosahexaenoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.100107± 0.7529732;1.089783± 0.6295672;1,0094734456;0,9031185;0,790949301;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;753;;
glutarylcarnitine;glutarylcarnitine;glutarylcarnitine;–;–;71464488;HMDB13130;–;–;–;Amino Acid;Lysine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.103581± 0.4102591;1.005856± 0.320352;1,0971560541;0,0286005;0,074439678;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;754;;
serotonin;serotonin;serotonin;(5HT);–;5202;HMDB00259;–;–;C00780;Amino Acid;Tryptophan Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.107741± 0.6983544;1.079895± 0.6207965;1,0257858403;0,7329997;0,715426967;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;755;;
dihomo-linoleate;dihomo-linoleate;dihomo-linoleate;–;–;5280581;HMDB02925;–;–;C03242;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1092564± 0.3511675;0.9896847± 0.407727;1,1208179736;0,0155611;0,045782746;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;756;;
1-methylurate;1-methylurate;1-methylurate;–;–;69726;HMDB03099;–;–;C16359;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.112953± 0.8297468;1.159881± 0.7929556;0,959540677;0,6439605;0,666385157;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;757;;
3-dehydrocarnitine;3-dehydrocarnitine;3-dehydrocarnitine;–;–;6991982;HMDB12154;–;–;C02636;Lipid;Carnitine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.113691± 0.5923172;1.096739± 0.4428457;1,0154567313;0,7868118;0,741003435;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;758;;
arachidonate;arachidonate;arachidonate;–;–;444899;HMDB01043;–;–;C00219;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.113699± 0.3113646;1.005789± 0.3566317;1,1072889045;0,0129245;0,040458542;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;759;;
homostachydrine;homostachydrine;homostachydrine;–;–;441447;HMDB33433;–;–;C08283;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.117606± 0.5709309;1.173934± 0.6326523;0,9520177455;0,4662893;0,551042217;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;760;;
caprylate;caprylate;caprylate;–;–;379;HMDB00482;–;–;C06423;Lipid;Medium Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.117916± 0.7273599;1.315064± 1.0652386;0,8500848628;0,1066181;0,19567225;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;761;;
aspartate;aspartate;aspartate;–;–;5960;HMDB00191;–;–;C00049;Amino Acid;Alanine and Aspartate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1197606± 0.2316768;0.9907889± 0.2130476;1,1301707155;0,00000478;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;762;;
dimethylglycine;dimethylglycine;dimethylglycine;–;–;673;HMDB0000092;–;–;C01026;Amino Acid;Glycine, Serine and Threonine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.120207± 0.409837;1.0328± 0.4145819;1,0846310999;0,09408;0,175719426;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;763;;
pantothenate;pantothenate;pantothenate;–;–;6613;HMDB00210;–;–;C00864;Cofactors and Vitamins;Pantothenate and CoA Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.123752± 0.7011326;1.439946± 1.3160309;0,7804125988;0,0298841;0,076160285;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;764;;
2-aminobutyrate;2-aminobutyrate;2-aminobutyrate;–;–;439691;HMDB00650;–;–;C02261;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.124172± 0.4246283;1.029227± 0.30986;1,0922488431;0,0330697;0,080458569;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;765;;
dehydroisoandrosterone sulfate;dehydroisoandrosterone sulfate;dehydroisoandrosterone sulfate; (DHEA-S);–;12594;HMDB01032;–;–;C04555;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.124173± 1.0114224;1.194186± 0.8222146;0,9413717796;0,5323421;0,589381001;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;766;;
2-hydroxypalmitate;2-hydroxypalmitate;2-hydroxypalmitate;–;–;92836;HMDB31057;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1243872± 0.245949;0.9808521± 0.2150171;1,1463371491;0,000000809;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;767;;
glutamate;glutamate;glutamate;–;–;611;HMDB00148;–;–;C00025;Amino Acid;Glutamate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.125203± 0.4834663;1.039322± 0.4192745;1,0826317542;0,1236486;0,218522937;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;768;;
leucylalanine;leucylalanine;leucylalanine;–;–;259321;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.125877± 0.6282557;1.102616± 0.5910317;1,0210961931;0,7598659;0,73003491;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;769;;
acetylcarnitine;acetylcarnitine;acetylcarnitine;–;–;1;HMDB0000201;–;–;C02571;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1267415± 0.353238;0.9733468± 0.2791747;1,1575951141;0,0000863;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;770;;
N-acetylthreonine;N-acetylthreonine;N-acetylthreonine;–;–;152204;–;–;–;C01118;Amino Acid;Glycine, Serine and Threonine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1273883± 0.5703726;0.9535426± 0.3460807;1,1823156092;0,0016015;0,015945538;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;771;;
1-docosahexaenoylglycerophosphoethanolamine;1-docosahexaenoylglycerophosphoethanolamine;1-docosahexaenoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.130494± 0.5211683;1.100802± 0.5430441;1,0269730615;0,6603981;0,676690201;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;772;;
pseudo uridine;pseudo uridine;pseudo uridine;–;–;–;HMDB00767;–;–;C02067;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.134551± 0.3924447;1.031103± 0.2584172;1,1003275134;0,0083532;0,030749492;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;773;;
stearoyl sphingomyelin;stearoyl sphingomyelin;stearoyl sphingomyelin;–;–;6453725;HMDB01348;–;–;C00550;Lipid;Sphingolipid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.134978± 0.4245994;1.000518± 0.3315197;1,1343903858;0,0037208;0,020563785;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;774;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;790;HMDB0000157;–;–;C00262;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1361± 0.3282431;0.9941789± 0.2066439;1,1427520741;0,0000126;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;775;;
phenylacetic acid;phenylacetic acid;phenylacetic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;1.1384 ± 0.90942;1.609 ± 1.9907;0,7075201989;0,14817;0,48858;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;776;;
4-acetamidobutanoate;4-acetamidobutanoate;4-acetamidobutanoate;–;–;18189;HMDB03681;–;–;C02946;Amino Acid;Polyamine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.139863± 0.6407716;1.050214± 0.3890295;1,0853626023;0,144754;0,244743448;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;777;;
threitol;threitol;threitol;–;–;169019;HMDB04136;–;–;C16884;Carbohydrate;Pentose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.139887± 0.9612257;1.263906± 0.8927664;0,9018764054;0,283279;0,396269035;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;778;;
inosine;inosine;inosine;–;–;6021;HMDB0000195;–;–;C00294;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.141773± 0.7818268;1.321941± 0.9369812;0,8637094999;0,1086552;0,19856239;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;779;;
1-arachidonylglycerol;1-arachidonylglycerol;1-arachidonylglycerol;–;–;5282281;HMDB11572;–;–;C13857;Lipid;Monoacylglycerol;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.145357± 0.7423133;1.029968± 0.4710747;1,1120316359;0,1121526;0,203224022;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;780;;
3-hydroxydecanoate;3-hydroxydecanoate;3-hydroxydecanoate;–;–;26612;HMDB02203;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1461926± 1.0187571;0.8496374± 0.7202518;1,3490373658;0,0049207;0,022996212;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;781;;
bilirubin (Z,Z);bilirubin (Z,Z);bilirubin (Z,Z);–;–;5280352;HMDB00054;–;–;C00486;Cofactors and Vitamins;Hemoglobin and Porphyrin Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.147686± 1.116875;1.150153± 0.5770102;0,997855068;0,9804009;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;782;;
palmitoylcarnitine;palmitoylcarnitine;palmitoylcarnitine;–;–;461;HMDB0000222;–;–;C02990;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1492904± 0.524511;0.9850884± 0.3857642;1,1666875785;0,0030672;0,01946876;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;783;;
malate;malate;malate;–;–;525;HMDB00156;–;–;C00149;Energy;TCA Cycle;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.151086± 0.6901209;1.061722± 0.5293276;1,0841689256;0,2280164;0,341191697;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;784;;
epiandrosterone sulfate;epiandrosterone sulfate;epiandrosterone sulfate;–;–;–;HMDB00365;–;–;C07635;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.151135± 1.116176;1.296485± 1.11368;0,8878891773;0,3013476;0,417465135;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;785;;
N-formylmethionine;N-formylmethionine;N-formylmethionine;–;–;439750;HMDB01015;–;–;C03145;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.151652± 0.4243536;1.021229± 0.3444315;1,1277118061;0,0058394;0,024511099;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;786;;
2-hydroxyglutarate;2-hydroxyglutarate;2-hydroxyglutarate;–;–;43;HMDB00606;–;–;C02630;Lipid;Fatty Acid, Dicarboxylate;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.151865± 0.8536413;1.066148± 0.7908583;1,0803987814;0,4027454;0,492240258;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;787;;
tryptophan betaine;tryptophan betaine;tryptophan betaine;–;–;442106;HMDB61115;–;–;C09213;Amino Acid;Tryptophan Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.152673± 1.117393;1.421133± 1.196625;0,8110943874;0,0698094;0,138737219;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;788;;
10-undecenoate (11:1n1);10-undecenoate (11:1n1);10-undecenoate (11:1n1);–;–;–;–;–;–;–;Lipid;Medium Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.152781± 0.6260122;1.096009± 0.5822844;1,0517988447;0,4509516;0,540032378;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;789;;
erythronate;erythronate;erythronate;–;–;2781043;HMDB00613;–;–;–;Carbohydrate;Aminosugar Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.154624± 0.7132379;1.147995± 0.630363;1,0057744154;0,9363832;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;790;;
2-aminoheptanoate;2-aminoheptanoate;2-aminoheptanoate;–;–;227939;–;–;–;–;Lipid;Fatty Acid, Amino;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.15549± 0.4888648;1.080297± 0.4598151;1,069604007;0,2047266;0,316259599;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;791;;
biliverdin;biliverdin;biliverdin;–;–;5353439;HMDB01008;–;–;C00500;Cofactors and Vitamins;Hemoglobin and Porphyrin Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.158243± 0.6696873;1.069147± 0.4991139;1,0833337231;0,2085239;0,317556422;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;792;;
arachidate;arachidate;arachidate;–;–;10467;HMDB02212;–;–;C06425;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.160416± 0.515786;1.039558± 0.4101385;1,1162590255;0,0329869;0,080458569;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;793;;
adrenate (22:4n6);adrenate (22:4n6);adrenate (22:4n6);–;–;5497181;HMDB02226;–;–;C16527;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1609915± 0.502184;0.9994289± 0.4941887;1,1616549211;0,0103424;0,034834732;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;794;;
S-methylcysteine;S-methylcysteine;S-methylcysteine;–;–;24417;HMDB02108;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.161684± 0.7826104;1.120363± 0.7589491;1,0368817963;0,6691186;0,677257468;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;795;;
pregnanediol-3-glucuronide;pregnanediol-3-glucuronide;pregnanediol-3-glucuronide;–;–;123796;–;–;–;–;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.16292± 0.7034856;1.001118± 0.5759074;1,1616213074;0,0394656;0,092975633;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;796;;
N-acetylmethionine;N-acetylmethionine;N-acetylmethionine;–;–;448580;HMDB11745;–;–;C02712;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1641053± 0.5503488;0.9748595± 0.354519;1,1941262305;0,0005385;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;797;;
docosahexaenoate;docosahexaenoate;docosahexaenoate;(DHA);–;445580;HMDB02183;–;–;C06429;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.165736± 0.5301326;1.185746± 0.78978;0,9831245478;0,8242501;0,767842753;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;798;;
palmitate;palmitate;palmitate;–;–;985;HMDB00220;–;–;C00249;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1670574± 0.4166779;0.9881837± 0.4866408;1,1810125992;0,0024619;0,01783485;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;799;;
cholesta-4,6-dien-3-ol;cholesta-4,6-dien-3-ol;cholesta-4,6-dien-3-ol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;1.1694 ± 0.8889;1.7972 ± 5.6779;0,6506788337;0,38702;0,67727;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;800;;
indoleacetate;indoleacetate;indoleacetate;–;–;802;HMDB00197;–;–;C00954;Amino Acid;Tryptophan Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.171132± 0.9245894;1.107582± 0.5099506;1,0573772416;0,4557017;0,541767609;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;801;;
1,6-anhydroglucose;1,6-anhydroglucose;1,6-anhydroglucose;–;–;2724705;HMDB00640;–;–;–;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.172119± 1.383641;1.313564± 1.3213;0,8923196738;0,4034647;0,492240258;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;802;;
2-aminooctanoate;2-aminooctanoate;2-aminooctanoate;–;–;69522;HMDB00991;–;–;–;Lipid;Fatty Acid, Amino;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.172518± 0.7960609;1.202206± 0.7188863;0,9753053969;0,7520259;0,728411991;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;803;;
scyllo-inositol;scyllo-inositol;scyllo-inositol;–;–;892;HMDB06088;–;–;C06153;Lipid;Inositol Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.173702± 1.441796;1.483677± 1.585696;0,7910764944;0,1110753;0,202124758;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;804;;
creatine;creatine;creatine;–;–;586;HMDB0000064;–;–;C00300;Amino Acid;Creatine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.174984± 0.8189461;1.251814± 0.8039395;0,9386250673;0,45144;0,540032378;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;805;;
butyryl-carnitine;butyryl-carnitine;butyryl-carnitine;–;–;439829;HDMB02013;–;–;C02862;Lipid;Fatty Acid Metabolism (also BCAA Metabolism);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.175564± 0.6088263;1.088488± 0.5128193;1,0799972071;0,2068233;0,317373142;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;806;;
nonadecanoate (19:0);nonadecanoate (19:0);nonadecanoate (19:0);–;–;12591;HMDB00772;–;–;C16535;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1771947± 0.4140729;0.9891926± 0.3749849;1,1900561124;0,0001501;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;807;;
myristate;myristate;myristate;–;–;11005;HMDB00806;–;–;C06424;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.178252± 0.5712113;1.107921± 0.8465139;1,0634801579;0,4670593;0,551042217;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;808;;
butane-2,3-diol;butane-2,3-diol;butane-2,3-diol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;1.179 ± 1.1028;1.5672 ± 1.6905;0,7522970904;0,13821;0,44998;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;809;;
glycerol-3-phosphate;glycerol-3-phosphate;glycerol-3-phosphate; (G3P);–;754;HMDB00126;–;–;C00093;Lipid;Glycerolipid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.181356± 1.128388;1.94099± 7.755732;0,6086357993;0,3454691;0,448224272;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;810;;
docosahexaenoic acid;docosahexaenoic acid;docosahexaenoic acid;–;–;–;HMDB0002183;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;1.1822 ± 1.6287;1.1189 ± 0.87031;1,0565734203;0,5771;0,76992;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;811;;
stearidonate;stearidonate;stearidonate;–;–;5312508;HMDB06547;–;–;C16300;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.182269± 0.7379454;1.192694± 1.0893123;0,9912592836;0,9332551;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;812;;
dodecanedioate;dodecanedioate;dodecanedioate;–;–;12736;HMDB00623;–;–;C02678;Lipid;Fatty Acid, Dicarboxylate;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.183923± 1.014715;1.182236± 1.084159;1,0014269571;0,9899404;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;813;;
nicotinurate;nicotinurate;nicotinurate;–;–;68499;HMDB03269;–;–;C05380;Cofactors and Vitamins;Nicotinate and Nicotinamide Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.188143± 5.285877;1.048926± 4.102833;1,1327233761;0,807292;0,753680083;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;814;;
N6-carbamoylthreonyladenosine;N6-carbamoylthreonyladenosine;N6-carbamoylthreonyladenosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.190028± 0.9765044;1.007899± 0.3747601;1,1807016378;0,0244562;0,065234577;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;815;;
phenol sulfate;phenol sulfate;phenol sulfate;–;–;74426;HMDB60015;–;–;C02180;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.195339± 1.088053;1.399766± 1.067083;0,8539563041;0,131868;0,230307092;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;816;;
cortisol;cortisol;cortisol;–;–;5754;HMDB00063;–;–;C00735;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.1981351± 0.4646532;0.9698453± 0.3325259;1,23538785;0,00000318;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;817;;
gamma-CEHC;gamma-CEHC;gamma-CEHC;–;–;133098;HMDB01931;–;–;–;Cofactors and Vitamins;Tocopherol Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.199021± 0.9081662;1.220127± 0.7688323;0,9827018007;0,837722;0,776328456;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;818;;
gluconate;gluconate;gluconate;–;–;10690;HMDB00625;–;–;C00257;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.205331± 0.596744;1.080778± 0.4651412;1,1152438336;0,0545955;0,117415854;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;819;;
stearate;stearate;stearate;–;–;5281;HMDB00827;–;–;C01530;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.2064638± 0.3877398;0.9566221± 0.3563258;1,2611707382;0,000000139;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;820;;
taurolithocholate 3-sulfate;taurolithocholate 3-sulfate;taurolithocholate 3-sulfate;–;–;440071;HMDB02580;–;–;C03642;Lipid;Secondary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.210812± 1.687749;1.322713± 1.036868;0,915400393;0,4910265;0,568388449;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;821;;
cis-4-decenoyl carnitine;cis-4-decenoyl carnitine;cis-4-decenoyl carnitine;–;–;–;–;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.215493± 0.6414901;1.048875± 0.4598628;1,1588540102;0,0125903;0,039802692;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;822;;
DSGEGDFXAEGGGVR;DSGEGDFXAEGGGVR;DSGEGDFXAEGGGVR;–;–;–;–;–;–;–;Peptide;Fibrinogen Cleavage Peptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.2156074± 0.5519371;0.9904832± 0.3257576;1,2272872473;0,0000222;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;823;;
4-hydroxyphenylacetate;4-hydroxyphenylacetate;4-hydroxyphenylacetate;–;–;127;HMDB00020;–;–;C00642;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.2224989± 1.5712596;0.9462268± 0.6780978;1,2919723897;0,0393207;0,092975633;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;824;;
linoleate;linoleate;linoleate;–;–;5280450;HMDB00673;–;–;C01595;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.2241117± 0.5623745;0.9794995± 0.5211318;1,2497318273;0,0003374;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;825;;
HWESASXX;HWESASXX;HWESASXX;–;–;–;–;–;–;–;Peptide;Polypeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.224618± 0.6751861;1.029173± 0.5145271;1,1899049042;0,0071361;0,027725921;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;826;;
1-stearoylglycerophosphocholine;1-stearoylglycerophosphocholine;1-stearoylglycerophosphocholine;–;–;497299;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.225807± 1.011201;1.367167± 0.8982341;0,8966037068;0,2320099;0,345961859;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;827;;
L-aspartic acid;L-aspartic acid;L-aspartic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;1.2278 ± 0.77025;1.0937 ± 0.78496;1,1226113194;0,32302;0,68529;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;828;;
C3-carnitine;C3-carnitine;C3-carnitine;–;–;–;–;–;–;–;–;–;274,5;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;1.230 ± 0.72 μmol/L;0.58 ± 0.22 μmol/L;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;829;;
dimethylarginine;dimethylarginine;dimethylarginine; (SDMA + ADMA);–;123831;HMDB01539;–;–;C03626;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.230438± 0.7525733;1.173309± 0.7855822;1,0486904984;0,5587766;0,609036179;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;830;;
N-acetylneuraminate;N-acetylneuraminate;N-acetylneuraminate;–;–;439197;HMDB00230;–;–;C00270;Carbohydrate;Aminosugar Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.2324011± 0.5777806;0.9765911± 0.3560096;1,2619417687;0,00000644;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;26762741;Mazzone et al. 2016;831;;
2-hydroxyisobutyrate;2-hydroxyisobutyrate;2-hydroxyisobutyrate;–;–;11671;HMDB00729;–;–;–;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.232674± 1.0396193;1.070787± 0.4553191;1,1511850629;0,0688955;0,138258416;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;832;;
oleic ethanolamide;oleic ethanolamide;oleic ethanolamide;–;–;5283454;HMDB02088;–;–;–;Lipid;Endocannabinoid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.2343521± 0.4963115;0.9597453± 0.3232153;1,2861246624;4,95E-008;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;833;;
oleoylcarnitine;oleoylcarnitine;oleoylcarnitine;–;–;6441392;53477789;HMDB05065;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.236451± 0.5950513;1.041986± 0.4571983;1,186629187;0,002538;0,01790019;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;834;;
pyruvate;pyruvate;pyruvate;–;–;1060;HMDB00243;–;–;C00022;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.237826± 0.6384399;1.144706± 0.7170382;1,0813483986;0,2863569;0,399274099;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;835;;
15-methylpalmitate;15-methylpalmitate;15-methylpalmitate; (isobar with 2-methylpalmitate);–;–;–;–;–;–;Lipid;Fatty Acid, Branched;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.238347± 0.5173678;1.038687± 0.5772795;1,1922234513;0,0048476;0,022956581;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;836;;
3-methylxanthine;3-methylxanthine;3-methylxanthine;–;–;70639;HMDB01886;–;–;C16357;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.239771± 1.213973;1.347182± 1.312103;0,920269867;0,505989;0,575959868;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;837;;
docosapentaenoate;docosapentaenoate;docosapentaenoate;–;–;6441454;HMDB01976;–;–;C16513;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.240809± 0.6118596;1.08418± 0.7959096;1,1444677083;0,0941095;0,175719426;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;838;;
4-ethylphenylsulfate;4-ethylphenylsulfate;4-ethylphenylsulfate;–;–;–;–;–;–;C13637;Xenobiotics;Benzoate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.241148± 1.498616;2.211468± 4.021845;0,5612326292;0,0243451;0,065234577;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;839;;
heptadecanoic acid;heptadecanoic acid;heptadecanoic acid;–;–;–;HMDB0002259;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;1.2438 ± 0.6796;1.2944 ± 0.57039;0,960908529;0,44367;0,69016;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;840;;
acisoga;acisoga;acisoga;–;–;129397;–;–;–;–;Amino Acid;Polyamine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.244486± 0.5162271;1.005327± 0.4281235;1,2378917506;0,0000467;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;841;;
phenylacetylglutamine;phenylacetylglutamine;phenylacetylglutamine;–;–;92258;HMDB06344;–;–;C04148;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.244585± 1.3117582;1.136857± 0.7772987;1,0947594992;0,3864865;0,48073639;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;842;;
N-delta-acetylornithine;N-delta-acetylornithine;N-delta-acetylornithine;–;–;9920500;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.245204± 1.5735649;1.286697± 0.9375848;0,9677523146;0,781331;0,738604005;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;843;;
beta-alanine;beta-alanine;beta-alanine;–;–;239;HMDB00056;–;–;C00099;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.245561± 1.180895;1.349964± 1.391743;0,9226623821;0,532368;0,589381001;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;844;;
caprate;caprate;caprate;–;–;2969;HMDB00511;–;–;C01571;Lipid;Medium Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.246593± 0.9090358;1.384326± 1.2372062;0,9005053723;0,3380342;0,442589378;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;845;;
pregn steroid monosulfate;pregn steroid monosulfate;pregn steroid monosulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.247439± 0.8840049;1.18116± 0.7232688;1,0561134817;0,5004367;0,574634604;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;846;;
phenylalanylphenylalanine;phenylalanylphenylalanine;phenylalanylphenylalanine;–;–;6993090;6993089;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.2485138± 0.7498722;0.9770753± 0.5108574;1,2778071455;0,00039;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;847;;
1-arachidonoylglyercophosphate;1-arachidonoylglyercophosphate;1-arachidonoylglyercophosphate;–;–;–;–;–;–;–;Lipid;Lysolipid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.250393± 0.7616457;1.053623± 0.5290762;1,1867556042;0,0116941;0,037830494;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;848;;
margarate;margarate;margarate;–;–;10465;HMDB02259;–;–;–;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.2574511± 0.5272238;0.9636958± 0.5179013;1,3048216045;0,000011;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;849;;
glycocholenate sulfate;glycocholenate sulfate;glycocholenate sulfate;–;–;–;–;–;–;–;Lipid;Secondary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.259294± 0.7623709;1.054352± 0.5134749;1,1943772099;0,007779;0,029190502;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;850;;
sarcosine;sarcosine;sarcosine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;1.26±0.64 ?M;1.25±0.52 ?M;1,01;0,8836;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,507;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;851;;
pyroglutamine;pyroglutamine;pyroglutamine;–;–;134508;–;–;–;–;Amino Acid;Glutamate Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.262256± 0.733077;1.017322± 0.5550783;1,2407634947;0,0018742;0,016307726;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;852;;
octadecanoic acid, propyl ester;octadecanoic acid, propyl ester;octadecanoic acid, propyl ester;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;1.2669 ± 0.57273;1.2881 ± 0.77338;0,9835416505;0,9907;0,9907;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;853;;
hexanoylcarnitine;hexanoylcarnitine;hexanoylcarnitine;–;–;6426853;HMDB00705;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.270953± 0.8678851;1.017203± 0.43319;1,2494585643;0,0011161;0,01536176;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;854;;
C-glycosyltryptophan;C-glycosyltryptophan;C-glycosyltryptophan;–;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.27782± 0.6412334;1.018404± 0.2969777;1,2547279861;0,00000473;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;855;;
decanoylcarnitine;decanoylcarnitine;decanoylcarnitine;–;–;10245190;HMDB0000651;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.27854± 0.9771238;1.048468± 0.5154983;1,2194363586;0,0097704;0,033685739;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;856;;
bilirubin (E,E);bilirubin (E,E);bilirubin (E,E);–;–;5315454;–;–;–;–;Cofactors and Vitamins;Hemoglobin and Porphyrin Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.278786± 1.0961254;1.218406± 0.9363659;1,0495565518;0,6292604;0,655914772;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;857;;
N-acetyl-beta-alanine;N-acetyl-beta-alanine;N-acetyl-beta-alanine;–;–;76406;HMDB0061880;–;–;C01073;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.280541± 0.6263652;1.090035± 0.5955121;1,1747705349;0,0131189;0,040458542;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;858;;
i-urobilinogen;i-urobilinogen;i-urobilinogen;–;–;26818;HMDB04157;–;–;C05790;Cofactors and Vitamins;Hemoglobin and Porphyrin Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.2836574± 2.167096;0.6305758± 1.0372;2,0356908717;0,0006654;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;859;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 ± 6.9;smoker, non-smoker, unknown;healthy;62;40, 22;62 ± 8.8;smoker, non-smoker, unknown;LC;ESI;negative;triple quadrupole;MS/MS;Analyst software;–;–;Mann-Whitney U test;1.29 ± 1.15 μmol/l;1.5 ± 1.22 μmol/l;0,86;0,0003;–;–;ROC curve analysis ;–;0,673;–;–;–;–;–;–;–;–;Poland;Y;–;27454081;Klupczynska et al. 2016b;860;;
o-sulfo-l-tyrosine;o-sulfo-l-tyrosine;o-sulfo-l-tyrosine;–;–;514186;–;–;–;–;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.290214± 0.7619987;1.043654± 0.416612;1,2362468788;0,0004885;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;861;;
fructose;fructose;fructose;–;–;5984;HMDB00660;–;–;C00095;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.291498± 1.0778149;1.216686± 0.8741036;1,061488338;0,530664;0,589381001;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;862;;
oleate;oleate;oleate;–;–;445639;HMDB00207;–;–;C00712;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.292579± 0.6680247;1.065943± 0.7456325;1,2126154963;0,0131417;0,040458542;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;863;;
glycolithocholate sulfate;glycolithocholate sulfate;glycolithocholate sulfate;–;–;72222;HMDB02639;–;–;C11301;Lipid;Secondary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.292693± 1.332137;1.379905± 1.207016;0,9367985477;0,5799574;0,6211063;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;864;;
lauroylcarnitine;lauroylcarnitine;lauroylcarnitine;–;–;10427569;HMDB02250;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.2984989± 0.89537;0.9171495± 0.5116314;1,4157985149;0,00000746;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;865;;
laurate;laurate;laurate;–;–;3893;HMDB00638;–;–;C02679;Lipid;Medium Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.298515± 0.7881993;1.359384± 1.3435008;0,9552231011;0,6848118;0,68393841;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;866;;
gamma-tocopherol;gamma-tocopherol;gamma-tocopherol;–;–;14986;HMDB01492;–;–;C02483;Cofactors and Vitamins;Tocopherol Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.3036106± 0.7717303;0.9814279± 0.6415495;1,3282795405;0,0002384;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;867;;
piperine;piperine;piperine;–;–;638024;HMDB29377;–;–;C03882;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.310169± 1.757673;1.539684± 1.805;0,8509336981;0,3094109;0,423175116;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;868;;
cis-vaccenate (18:1n7);cis-vaccenate (18:1n7);cis-vaccenate (18:1n7);–;–;5282761;HMDB03231;–;–;C08367;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.324933± 0.6893607;1.016947± 0.6063136;1,302853541;0,0001455;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;869;;
androsterone sulfate;androsterone sulfate;androsterone sulfate;–;–;159663;HMDB02759;–;–;–;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.326985± 1.3970079;1.173406± 0.8437635;1,1308830874;0,2503904;0,363363304;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;870;;
10-heptadecenoate (17:1n7);10-heptadecenoate (17:1n7);10-heptadecenoate (17:1n7);–;–;5312435;–;–;–;–;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.333939± 0.7715005;1.052413± 0.7856552;1,2675052475;0,0045273;0,022695544;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;871;;
docosapentaenoate;docosapentaenoate;docosapentaenoate;–;–;6441454;HMDB06528;–;–;C16513;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.33738± 0.5699663;1.036585± 0.5635383;1,2901788083;0,0000327;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;872;;
dihomo-linoleate;dihomo-linoleate;dihomo-linoleate;–;–;6439848;HMDB05060;–;–;C16525;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.3407734± 0.6343485;0.9676405± 0.5687728;1,3856110818;0,000000958;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;873;;
aspartylphenylalanine;aspartylphenylalanine;aspartylphenylalanine;–;–;93078;HMDB00706;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.340828± 1.1479631;1.115561± 0.6269617;1,2019315842;0,0331613;0,080458569;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;874;;
mannose;mannose;mannose;–;–;18950;HMDB00169;–;–;C00159;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.347401± 0.5050614;1.007233± 0.4078225;1,3377252334;3,37E-009;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;875;;
17-methylstearate;17-methylstearate;17-methylstearate;–;–;3083779;–;–;–;–;Lipid;Fatty Acid, Branched;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.3487383± 0.661618;0.9728763± 0.5192543;1,3863409973;0,000000325;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;876;;
octanoylcarnitine;octanoylcarnitine;octanoylcarnitine;–;–;123701;HMDB0000791;–;–;C02838;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.349846± 1.1458219;1.083672± 0.5573134;1,2456222916;0,0087722;0,031680219;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;877;;
ADSGEGDFXAEGGGVR;ADSGEGDFXAEGGGVR;ADSGEGDFXAEGGGVR;–;–;16133137;–;–;–;–;Peptide;Fibrinogen Cleavage Peptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.351411± 0.8137344;1.142502± 0.6664687;1,1828521963;0,0216791;0,059680784;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;878;;
eicosenoate;eicosenoate;eicosenoate;–;–;5282768;–;–;–;–;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.360784± 0.7068789;0.9745737± 0.6290958;1,3962863968;0,00000454;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;879;;
phenylalanylleucine;phenylalanylleucine;phenylalanylleucine;–;–;4078229;–;–;–;–;Peptide;Dipeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.364011± 1.0672817;1.032278± 0.4223071;1,3213601375;0,0002206;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;880;;
3-methylhistidine;3-methylhistidine;3-methylhistidine;–;–;64969;HMDB00479;–;–;C01152;Amino Acid;Histidine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.365599± 1.334511;1.574523± 2.046128;0,8673096551;0,3686252;0,465607816;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;881;;
nicotinamide;nicotinamide;nicotinamide;–;–;936;HMDB0001406;–;–;C00153;Cofactors and Vitamins;Nicotinate and Nicotinamide Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.36923± 1.6683087;1.078041± 0.9989875;1,2701093929;0,067506;0,136949616;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;882;;
N-acetylglycine;N-acetylglycine;N-acetylglycine;–;–;10972;HMDB00532;–;–;–;Amino Acid;Glycine, Serine and Threonine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.372749± 0.9398;1.209513± 0.9620726;1,1349601038;0,1757478;0,283741204;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;883;;
bradykinin, des-arg(9);bradykinin, des-arg(9);bradykinin, des-arg(9);–;–;105044;HMDB04246;–;–;C00306;Peptide;Polypeptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.374804± 1.684154;1.238255± 1.462809;1,1102753472;0,4818281;0,562287655;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;884;;
docosadienoate;docosadienoate;docosadienoate;–;–;5282807;–;–;–;C16533;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.3765± 0.6926747;0.94999± 0.4728787;1,4489626207;3,48E-009;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;885;;
pyridoxate;pyridoxate;pyridoxate;–;–;6723;HMDB00017;–;–;C00847;Cofactors and Vitamins;Vitamin B6 Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.382239± 3.050998;3.177348± 9.24473;0,4350291501;0,0676056;0,136949616;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;886;;
gamma-glutamylglutamine;gamma-glutamylglutamine;gamma-glutamylglutamine;–;–;150914;HMDB11738;–;–;C05283;Peptide;Gamma-glutamyl Amino Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.393722± 0.9406742;1.425218± 0.8600186;0,9779009246;0,7783197;0,738604005;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;887;;
tetradecanedioate;tetradecanedioate;tetradecanedioate;–;–;13185;HMDB00872;–;–;–;Lipid;Fatty Acid, Dicarboxylate;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.393862± 1.137943;1.309041± 1.765999;1,0647962898;0,671553;0,677257468;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;888;;
5-alpha-pregnan-3alpha,20beta-diol disulfate;5-alpha-pregnan-3alpha,20beta-diol disulfate;5-alpha-pregnan-3alpha,20beta-diol disulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.397111± 1.834892;1.355694± 2.672026;1,0305504044;0,8923669;0,788535721;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;889;;
10-nonadecenoate (19:1n9);10-nonadecenoate (19:1n9);10-nonadecenoate (19:1n9);–;–;5312513;HMDB13622;–;–;–;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.4019894± 0.7263689;0.9696805± 0.6326986;1,4458261252;0,000000464;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;890;;
2-hydroxybutyrate;2-hydroxybutyrate;2-hydroxybutyrate;(AHB);–;440864;HMDB00008;–;–;C05984;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.403545± 0.7636425;0.99769± 0.5246037;1,4067946957;0,0000003;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;891;;
homocitrulline;homocitrulline;homocitrulline;–;–;65072;HMDB00679;–;–;C02427;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.408464± 1.1977382;1.217225± 0.8359681;1,157110641;0,1187494;0,212488074;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;892;;
ADpSGEGDFXAEGGGVR;ADpSGEGDFXAEGGGVR;ADpSGEGDFXAEGGGVR;–;–;–;–;–;–;–;Peptide;Fibrinogen Cleavage Peptide;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.41656± 1.1987445;1.035354± 0.5972281;1,3681890445;0,0003979;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;893;;
taurocholenate sulfate;taurocholenate sulfate;taurocholenate sulfate;–;–;–;–;–;–;–;Lipid;Secondary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.41708± 1.5698676;1.094168± 0.6632425;1,2951210417;0,0154661;0,045782746;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;894;;
glycerol-3-phosphate;glycerol-3-phosphate;glycerol-3-phosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;1.4266 ± 0.6999;1.4702 ± 1.2486;0,9703441709;0,78202;0,8487;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;895;;
pipecolate;pipecolate;pipecolate;–;–;849;HMDB00070;–;–;C00408;Amino Acid;Lysine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.434802± 2.086915;1.363998± 1.174394;1,051909167;0,7147269;0,707072359;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;896;;
glycodeoxycholate;glycodeoxycholate;glycodeoxycholate;–;–;3035026;HMDB00631;–;–;C05464;Lipid;Secondary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.43858± 3.174931;1.354707± 1.230925;1,0619122807;0,7494643;0,728186896;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;897;;
N1-methyl-2-pyridone-5-carboxamide;N1-methyl-2-pyridone-5-carboxamide;N1-methyl-2-pyridone-5-carboxamide;–;–;69698;HMDB04193;–;–;C05842;Cofactors and Vitamins;Nicotinate and Nicotinamide Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.439143± 2.519597;1.651051± 2.786109;0,8716526625;0,5338651;0,589381001;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;898;;
palmitoleate;palmitoleate;palmitoleate;–;–;445638;HMDB03229;–;–;C08362;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.445518± 1.066521;1.226851± 1.188029;1,1782343577;0,1320389;0,230307092;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;899;;
alpha-hydroxyisovalerate;alpha-hydroxyisovalerate;alpha-hydroxyisovalerate;–;–;99823;HMDB00407;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.446822± 1.9308686;1.275148± 0.8618735;1,1346306468;0,3005911;0,417465135;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;900;;
octadecanedioate;octadecanedioate;octadecanedioate;–;–;70095;HMDB00782;–;–;–;Lipid;Fatty Acid, Dicarboxylate;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.459505± 0.9515637;1.097342± 0.8914816;1,3300365793;0,0017857;0,016307726;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;901;;
erucate;erucate;erucate;–;–;5281116;HMDB02068;–;–;C08316;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.465409± 1.357844;1.403337± 2.965158;1,0442317134;0,8468682;0,780448198;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;902;;
linolenate [alpha or gamma; (18:3n3 or 6)];linolenate [alpha or gamma; (18:3n3 or 6)];linolenate [alpha or gamma; (18:3n3 or 6)];–;–;5280934;–;–;–;C06427;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.469596± 1.0603021;1.110096± 0.8408337;1,3238458656;0,0020912;0,016890877;–;–;–;–;–;–;–;–;–;–;–;–;US;–;903;26762741;Mazzone et al. 2016
glycochenodeoxycholate;glycochenodeoxycholate;glycochenodeoxycholate;–;–;12544;HMDB00637;–;–;C05466;Lipid;Primary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.48203± 3.698873;1.511487± 1.211154;0,9805112449;0,9205976;0,80356114;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;904;;
4-androsten-3beta,17beta-diol disulfate;4-androsten-3beta,17beta-diol disulfate;4-androsten-3beta,17beta-diol disulfate;–;–;10634;HMDB03818;–;–;C04295;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.483126± 1.575373;1.719853± 3.412772;0,8623562595;0,5226853;0,586078412;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;905;;
taurodeoxycholate;taurodeoxycholate;taurodeoxycholate;–;–;2733768;HMDB00896;–;–;C05463;Lipid;Secondary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.484535± 3.144609;1.677809± 1.758627;0,8848057198;0,5069555;0,575959868;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;906;;
cysteine-glutathione disulfide;cysteine-glutathione disulfide;cysteine-glutathione disulfide;–;–;4247235;HMDB00656;–;–;–;Amino Acid;Glutathione Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.493739± 2.191201;1.460251± 1.093311;1,0229330437;0,8634177;0,781510038;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;907;;
pregnen-diol disulfate;pregnen-diol disulfate;pregnen-diol disulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.494456± 1.206241;1.25233± 1.258735;1,1933404135;0,12269;0,217976199;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;908;;
glycerol;glycerol;glycerol;–;–;753;HMDB00131;–;–;C00116;Lipid;Glycerolipid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.499348± 2.8207456;1.119157± 0.4770869;1,3397119439;0,0711183;0,13882663;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;909;;
andro steroid monosulfate;andro steroid monosulfate;andro steroid monosulfate;–;–;–;HMDB02759;–;–;C04555;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.507591± 1.51226;1.30664± 1.166319;1,1537921692;0,2174379;0,327645824;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;910;;
myristoleate;myristoleate;myristoleate;–;–;5281119;HMDB02000;–;–;C08322;Lipid;Long Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.519384± 1.135099;1.199169± 1.197807;1,2670307521;0,0316826;0,078648313;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;911;;
3-methylglutarylcarnitine;3-methylglutarylcarnitine;3-methylglutarylcarnitine;–;–;128145;HMDB00552;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.529246± 1.682068;1.24456± 1.094842;1,2287442952;0,0873939;0,164611696;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;912;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;1.5425 ± 1.0398;1.5055 ± 1.5135;1,0245765526;0,39669;0,67727;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;913;;
adenosine 5'-monophosphate;adenosine 5'-monophosphate;adenosine 5'-monophosphate;(AMP);–;6083;HMDB00045;–;–;C00020;Nucleotide;Purine Metabolism, Adenine containing;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.5438223± 8.7152447;0.4087458± 0.4005822;3,7769740998;0,0734333;0,142697019;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;914;;
5-dodecenoate (12:1n7);5-dodecenoate (12:1n7);5-dodecenoate (12:1n7);–;–;5312378;HMDB00529;–;–;–;Lipid;Medium Chain Fatty Acid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.546729± 1.2764549;1.137816± 0.9975586;1,3593841183;0,0033538;0,019631853;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;915;;
p-acetamidophenylglucuronide;p-acetamidophenylglucuronide;p-acetamidophenylglucuronide;–;–;83944;HMDB10316;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.5924234± 7.647851;0.3280626± 1.023404;4,8540229822;0,0255278;0,067672746;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;916;;
benzaldehyde;benzaldehyde;benzaldehyde;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;1.6015 ± 0.66405;0.9599 ± 0.77073;1,6684029586;0,00000942;0,00065959;–;ROC curve;–;–;combination of nine metabolites: 100;combination of nine metabolites: 86;–;–;–;–;–;–;Poland;Y;–;28803255;Ro?-Mazurczyk et al. 2017;917;;
hydroxybutyrylcarnitine;hydroxybutyrylcarnitine;hydroxybutyrylcarnitine;–;–;53481617;HMDB0013127;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.63519± 1.1995588;1.070692± 0.8167798;1,5272272512;0,0000047;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;918;;
3-methoxytyrosine;3-methoxytyrosine;3-methoxytyrosine;–;–;1670;HMDB01434;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.636636± 5.028283;1.411674± 6.166531;1,1593583221;0,7589816;0,73003491;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;919;;
hexadecanedioate;hexadecanedioate;hexadecanedioate;–;–;10459;HMDB00672;–;–;C19615;Lipid;Fatty Acid, Dicarboxylate;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.662312± 1.364365;1.293999± 1.560202;1,2846315955;0,0519835;0,114019369;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;920;;
chiro-inositol;chiro-inositol;chiro-inositol;–;–;–;–;–;–;–;Lipid;Inositol Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.69613± 4.045633;1.624963± 3.802542;1,0437960741;0,8844471;0,788023204;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;921;;
phosphoric acid, monomethyl ester;phosphoric acid, monomethyl ester;phosphoric acid, monomethyl ester;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;1.7226 ± 1.7763;1.7938 ± 1.4086;0,9603077266;0,61249;0,7963;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;922;;
5-alpha-androstan-3beta,17beta-diol disulfate;5-alpha-androstan-3beta,17beta-diol disulfate;5-alpha-androstan-3beta,17beta-diol disulfate;–;–;242332;HMDB00493;–;–;C12525;Lipid;Steroid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.749784± 2.247959;1.969125± 3.851118;0,8886099156;0,6096254;0,643254517;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;923;;
taurochenodeoxycholate;taurochenodeoxycholate;taurochenodeoxycholate;–;–;387316;HMDB00951;–;–;C05465;Lipid;Primary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.75709± 4.93884;1.848994± 3.168761;0,9502951335;0,8495701;0,781261661;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;924;;
3-carboxy-4-methyl-5-propyl-2-furanpropanoate;3-carboxy-4-methyl-5-propyl-2-furanpropanoate;3-carboxy-4-methyl-5-propyl-2-furanpropanoate; (CMPF);–;123979;HMDB61112;–;–;–;Lipid;Fatty Acid, Dicarboxylate;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.762436± 3.241193;2.725454± 3.90986;0,6466577678;0,0398357;0,092975633;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;925;;
heme;heme;heme;–;–;26945;HMDB03178;–;–;C00032;Cofactors and Vitamins;Hemoglobin and Porphyrin Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.7830511± 4.182296;0.8006479± 1.59717;2,2270102751;0,0046608;0,022766793;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;926;;
theophylline;theophylline;theophylline;–;–;2153;HMDB01889;–;–;C07130;Xenobiotics;Xanthine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.869837± 7.023609;1.361886± 2.547313;1,3729761522;0,3751937;0,471133144;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;927;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 ± 6.9;smoker, non-smoker, unknown;healthy;62;40, 22;62 ± 8.8;smoker, non-smoker, unknown;LC;ESI;negative;triple quadrupole;MS/MS;Analyst software;–;–;Mann-Whitney U test;1.89 ± 0.71 mmol/l;2.2 ± 0.8 mmol/l;0,8590909091;0,00979;–;–;ROC curve analysis ;–;0,624;–;–;–;–;–;–;–;–;Poland;Y;–;27454081;Klupczynska et al. 2016b;928;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;114,0662;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;1.93±0.92 ng/mL;3.32±1.89 ng/mL;2,5315131879;0,00000281;–;1,61;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;929;;
thymol sulfate;thymol sulfate;thymol sulfate;–;–;–;HMDB01878;–;–;C09908;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1.970629± 3.964192;3.01435± 5.109094;0,6537492328;0,0829149;0,158257424;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;930;;
3-methoxytyramine sulfate;3-methoxytyramine sulfate;3-methoxytyramine sulfate;–;–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;931;;
amitriptyline;amitriptyline;amitriptyline;–;–;2160;–;–;–;C06824;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;932;;
carbamazepine;carbamazepine;carbamazepine;–;–;2554;HMDB14704;–;–;D00252;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;933;;
cimetidine;cimetidine;cimetidine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;934;;
codeine;codeine;codeine;–;–;5284371;HMDB04995;–;–;C06174;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;935;;
dexamethasone;dexamethasone;dexamethasone;–;–;5743;HMDB15364;–;–;D00292;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;936;;
diltiazem;diltiazem;diltiazem;–;–;39186;HMDB14487;–;–;C06958;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;937;;
doxylamine;doxylamine;doxylamine;–;–;3162;HMDB01936;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;938;;
equol sulfate;equol sulfate;equol sulfate;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;939;;
famotidine;famotidine;famotidine;–;–;5702160;HMDB01919;–;–;D00318;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;940;;
fexofenadine;fexofenadine;fexofenadine;–;–;3348;HMDB05030;–;–;C06999;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;941;;
homoveratric acid;homoveratric acid;homoveratric acid;–;–;7139;HMDB00434;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;942;;
hydroxybupropion;hydroxybupropion;hydroxybupropion;–;–;446;HMDB12235;–;–;–;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;943;;
indomethecin;indomethecin;indomethecin;–;–;3715;HMDB14473;–;–;C01926;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;944;;
lactose;lactose;lactose;–;–;84571;HMDB00186;–;–;C00243;Carbohydrate;Disaccharides and Oligosaccharides;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;945;;
lansoprazole;lansoprazole;lansoprazole;–;–;3883;HMDB05008;–;–;D00355;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;946;;
meglumine;meglumine;meglumine;–;–;4049;–;–;–;–;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;947;;
meprobamate;meprobamate;meprobamate;–;–;4064;HMDB14515;–;–;D00376;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;948;;
ofloxacin;ofloxacin;ofloxacin;–;–;4583;HMDB01929;–;–;C07321;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;949;;
pantoprazole;pantoprazole;pantoprazole;–;–;4679;HMDB05017;–;–;C11806;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;950;;
phenobarbital;phenobarbital;phenobarbital;–;–;4763;HMDB15305;–;–;C07434;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;951;;
picolinate;picolinate;picolinate;–;–;1018;HMDB02243;–;–;C10164;Amino Acid;Tryptophan Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;952;;
pyridoxine;pyridoxine;pyridoxine;(Vitamin B6);–;1054;HMDB02075;–;–;C00314;Cofactors and Vitamins;Vitamin B6 Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;953;;
topiramate;topiramate;topiramate;–;–;5284627;HMDB05034;–;–;C07502;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;954;;
venlafaxine;venlafaxine;venlafaxine;–;–;5656;HMDB05016;–;–;C07187;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;955;;
verapamil;verapamil;verapamil;–;–;2520;HMDB01850;–;–;D02356;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;1± 0;1± 0;1;1;0,804216432;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;956;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;10.698 ± 5.9459;13.681 ± 8.0682;0,781960383;0,13514;0,44998;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;957;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;–;–;153,0407;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;10.84±4.51 ng/mL;16.48±4.84 ng/mL;4;0,00031;–;1,33;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;958;;
azelaic acid;azelaic acid;azelaic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;100 ± 36;90 ± 46;1,12;0,149;0,529;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;959;;
inosine 5'-monophosphate;inosine 5'-monophosphate;inosine 5'-monophosphate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;100 ± 54;73 ± 27;1,36;0,013;0,168;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;960;;
threonic acid;threonic acid;threonic acid;–;–;–;HMDB0000943;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1000 ± 624;1211 ± 686;0,83;0,257;0,631;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;961;;
arachidic acid;arachidic acid;arachidic acid;–;–;–;HMDB0002212;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1005 ± 327;891 ± 242;1,128;0,079;0,324;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;962;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;100812 ± 51390;81896 ± 35638;1,23;0,244;0,574;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;963;;
rhamnose;rhamnose;rhamnose;–;–;–;HMDB0000849;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1009 ± 599;873 ± 298;1,16;0,612;0,858;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;964;;
PC(16:0/16:0);PC(16:0/16:0);PC(16:0/16:0);–;–;–;–;–;–;–;–;–;778,5564;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;10094.11 ng/mL;8855.64 ng/mL;1,1398509876;0,1;0,1;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;965;;
4-hydroxyphenylacetic acid;4-hydroxyphenylacetic acid;4-hydroxyphenylacetic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;101 ± 172;63 ± 25;1,6;0,244;0,619;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;966;;
3-phosphoglycerate;3-phosphoglycerate;3-phosphoglycerate;–;–;–;–;–;–;–;Organic Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;101 ± 64;141 ± 171;0,72;0,846;0,947;–;random forest;–;"maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=0.699 (0.583, 0.815)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.670 (0.552, 0.789)";"30.2
maltose+maltotriose+cystine+3-Phosphoglycerate=61.6";"72.1
maltose+maltotriose+cystine+3-Phosphoglycerate=76.7";"51.2
maltose+maltotriose+cystine+3-Phosphoglycerate=69.2";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;967;;
saccharic acid;saccharic acid;saccharic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;101 ± 98;117 ± 82;0,86;0,123;0,459;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;968;;
Arg;Arg;Arg;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;101.3 ± 21.6 μM;98.1±17.8 μM;1,0326197757;0,12;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;969;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;10139 ± 3026;10425 ± 3452;0,973;0,775;0,935;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;970;;
beta-alanine;beta-alanine;beta-alanine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;102 ± 61;111 ± 61;0,92;0,297;0,582;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;971;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;102270 ± 19645;98052 ± 20695;1,043;0,229;0,524;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;972;;
arachidic acid;arachidic acid;arachidic acid;–;–;–;HMDB0002212;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1029 ± 388;1137 ± 411;0,91;0,348;0,656;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;973;;
beta-sitosterol;beta-sitosterol;beta-sitosterol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;103 ± 80;115 ± 51;0,9;0,159;0,531;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;974;;
xylose;xylose;xylose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1035 ± 792;1140 ± 729;0,908;0,164;0,439;–;random forest;–;"Bin_225393+aspartate+xylose+glutamate=0.820 (0.729, 0.911)
Bin_225393+aspartate+xylose=0.806 (0.711, 0.901)";"76.7
Bin_225393+aspartate+xylose=74.4";"23.3
Bin_225393+aspartate+xylose=53.5";"50.0
Bin_225393+aspartate+xylose=67.4";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;975;;
PC(24:1/20:4);PC(24:1/20:4);PC(24:1/20:4);–;–;–;–;–;–;–;–;–;936,6615;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;104.6 ng/mL;78.53 ng/mL;1,3319750414;0,0102;0,023;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;976;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1042 ± 1497;1154 ± 924;0,903;0,12;0,368;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;977;;
3-phosphoglycerate;3-phosphoglycerate;3-phosphoglycerate;–;–;–;–;–;–;–;Organic Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;105 ± 116;197 ± 242;0,532;0,048;0,255;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;978;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;105 ± 37;96 ± 36;1,09;0,419;0,669;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;979;;
5-hydroxynorvaline;5-hydroxynorvaline;5-hydroxynorvaline;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;105 ± 50;154 ± 98;0,68;0,003;0,038;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;980;;
nicotinic acid;nicotinic acid;nicotinic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;105 ± 51;138 ± 135;0,76;0,202;0,543;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;981;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;10504 ± 3006;11512 ± 3645;0,91;0,131;0,359;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;982;;
rhamnose;rhamnose;rhamnose;–;–;–;HMDB0000849;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1051 ± 582;1025 ± 350;1,03;0,639;0,821;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;983;;
arginine;arginine;arginine;–;–;–;HMDB0000517;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;106.5±32.7 ?M;94.11±23.52 ?M;1,13;0,0058;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,631;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;984;;
threonine;threonine;threonine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;106.65±30.11 ?M;106.1±28.4 ?M;1,01;0,6753;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,52;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;985;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1063 ± 548;1005 ± 287;1,058;0,872;0,953;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;986;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;106775 ± 26814;97878 ± 26667;1,09;0,168;0,511;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;987;;
cyano-l-alanine;cyano-l-alanine;cyano-l-alanine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;107 ± 84;107 ± 91;1,01;0,969;0,985;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;988;;
PC(15:0/18:3);PC(15:0/18:3);PC(15:0/18:3);–;–;–;–;–;–;–;–;–;786,5243;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;107.03 ng/mL;89.66 ng/mL;1,193731876;0,2;0,17;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;989;;
methylhexadecanoic acid;methylhexadecanoic acid;methylhexadecanoic acid;–;–;–;HMDB0031067;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1072 ± 263;1055 ± 282;1,02;0,666;0,847;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;990;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;107881 ± 39598;106446 ± 35463;1,013;0,932;0,987;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;991;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;108.89±43.22 ?M;113.71±47.39 ?M;0,96;0,5518;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,528;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;992;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;10826 ± 3495;13697 ± 7483;0,79;0,124;0,372;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;993;;
1,5-anhydroglucitol;1,5-anhydroglucitol;1,5-anhydroglucitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;10848 ± 5435;11979 ± 5203;0,91;0,64;0,874;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;994;;
threonine;threonine;threonine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;10933 ± 3275;10687 ± 4073;1,02;0,511;0,74;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;995;;
ribitol;ribitol;ribitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;11.481 ± 5.4321;13.066 ± 7.6992;0,8786927904;0,41979;0,69016;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;996;;
L-serine;L-serine;L-serine;–;–;–;HMDB0000187;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;11.528 ± 4.8431;12.326 ± 6.5947;0,9352588025;0,8135;0,85228;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;997;;
1,5-anhydrosorbitol;1,5-anhydrosorbitol;1,5-anhydrosorbitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;11.743 ± 7.108;11.998 ± 8.638;0,9787464577;0,79547;0,85012;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;998;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;110 ± 57;108 ± 46;1,019;0,729;0,926;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;999;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;11037 ± 3071;10522 ± 2657;1,05;0,476;0,775;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1000;;
2-hydroxyglutaric acid;2-hydroxyglutaric acid;2-hydroxyglutaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1104 ± 433;1358 ± 820;0,813;0,022;0,164;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1001;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;11081 ± 4803;5709 ± 2286;1,941;0;0,001;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1002;;
isothreonic acid;isothreonic acid;isothreonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1109 ± 717;1377 ± 645;0,805;0,006;0,067;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1003;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;111 ± 30;114 ± 37;0,97;0,879;0,952;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1004;;
cystathionine;cystathionine;cystathionine;–;–;–;–;–;–;–;–;–;223,0747;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;1116.98±638.10 ng/mL;634.97±611.20 ng/mL;5,0630263759;0,000000104;–;1,84;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1005;;
cyano-l-alanine;cyano-l-alanine;cyano-l-alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;112 ± 109;130 ± 104;0,87;0,363;0,66;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1006;;
4-hydroxyphenylacetic acid;4-hydroxyphenylacetic acid;4-hydroxyphenylacetic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;112 ± 188;82 ± 26;1,36;0,608;0,803;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1007;;
aconitic acid;aconitic acid;aconitic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;112 ± 46;118 ± 34;0,95;0,208;0,478;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1008;;
L-alanine;L-alanine;L-alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;112.14 ± 45.496;119.19 ± 67.485;0,9408507425;0,85441;0,87954;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1009;;
hydroxylamine;hydroxylamine;hydroxylamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1120 ± 439;1132 ± 399;0,99;0,668;0,896;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1010;;
PC(20:5/20:4);PC(20:5/20:4);PC(20:5/20:4);–;–;–;–;–;–;–;–;–;872,5387;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;113.74 ng/mL;103.25 ng/mL;1,101598063;0,43;0,3;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1011;;
1,5-anhydroglucitol;1,5-anhydroglucitol;1,5-anhydroglucitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;11324 ± 4806;13410 ± 5674;0,84;0,635;0,819;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1012;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;healthy;30;11, 19;60.35 ± 12.48;–;GC;–;–;–;–;GC/MSD ChemStation software (Agilent Technologies);NIST;SIMCA-P+ software, SPSS;independent t-test ;114.92 ± 89.30;183.48 ± 96.63;0,6263352954;0,001;–;–;ROC curve analysis;113,21;0.774 (0.645-0.904);83,33;73,33;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1013;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;before vs. after treatment (operation);30;9, 21;61.58 ± 10.67;–;GC;–;–;–;–;GC/MSD ChemStation software (Agilent Technologies);NIST;SIMCA-P+ software, SPSS;independent t-test ;114.92 ± 89.30;284.16 ± 184.76;0,404420045;0,001;–;–;ROC curve analysis;130,97;0.825 (0.721);80;76,67;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1014;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;238,4;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;114.95 ± 35.17 μmol/L;88.03 ± 16.80 μmol/L;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1015;;
thr;thr;thr;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;115.6 ± 28.6 μM;115.9 ± 25.4 μM;0,9974115617;0,92;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1016;;
capric acid;capric acid;capric acid;–;–;–;HMDB0000511;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1159 ± 464;1117 ± 383;1,04;0,747;0,904;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1017;;
trihydroxypyrazine;trihydroxypyrazine;trihydroxypyrazine;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;116 ± 47;97 ± 38;1,2;0,098;0,494;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1018;;
beta-sitosterol;beta-sitosterol;beta-sitosterol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;116 ± 71;117 ± 60;1;0,942;0,98;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1019;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1162 ± 532;977 ± 393;1,19;0,229;0,6;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1020;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1168 ± 977;885 ± 723;1,32;0,16;0,532;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1021;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;117 ± 56;109 ± 44;1,08;0,733;0,879;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1022;;
1-monopalmitin;1-monopalmitin;1-monopalmitin;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;117 ± 89;111 ± 39;1,05;0,854;0,949;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1023;;
Ser;Ser;Ser;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;117.1 ± 19.9 μM;111.4±17.9 μM;1,0511669659;0,003;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1024;;
3-hydroxybutanoic acid;3-hydroxybutanoic acid;3-hydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;11704 ± 22167;5402 ± 5482;2,17;0,103;0,501;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1025;;
glutaric acid;glutaric acid;glutaric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;118 ± 102;100 ± 36;1,18;0,715;0,895;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1026;;
PC(18:0/20:5);PC(18:0/20:5);PC(18:0/20:5);–;–;–;–;–;–;–;–;–;852,5717;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;11830.36 ng/mL;9044.54 ng/mL;1,3080112421;0,0267;0,0404;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1027;;
levanbiose;levanbiose;levanbiose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;119 ± 222;89 ± 46;1,35;0,535;0,813;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1028;;
PC(20:4/24:0);PC(20:4/24:0);PC(20:4/24:0);–;–;–;–;–;–;–;–;–;938,6787;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;119.34 ng/mL;123.08 ng/mL;0,9696132597;0,74;0,42;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1029;;
deoxytetronic acid;deoxytetronic acid;deoxytetronic acid;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1193 ± 1268;973 ± 654;1,23;0,311;0,695;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1030;;
asparagine;asparagine;asparagine;–;–;–;–;–;–;–;–;–;133,0608;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;11953.05±1494.14 ng/mL;10300.55±1266.10 ng/mL;5,5404378724;1,86E-009;–;1,9;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1031;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;12.631 ± 4.624;14.513 ± 6.8175;0,8703231585;0,18801;0,50619;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1032;;
maleimide;maleimide;maleimide;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1200 ± 536;1116 ± 483;1,08;0,954;0,982;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1033;;
PC(19:0/18:2);PC(19:0/18:2);PC(19:0/18:2);–;–;–;–;–;–;–;–;–;844,6015;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;1200.51 ng/mL;1378.44 ng/mL;0,8709193001;0,093;0,0922;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1034;;
hydroxylamine;hydroxylamine;hydroxylamine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1205 ± 468;1103 ± 449;1,09;0,36;0,735;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1035;;
PC(20:5/15:0);PC(20:5/15:0);PC(20:5/15:0);–;–;–;–;–;–;–;–;–;810,5241;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;121.23 ng/mL;104.1 ng/mL;1,1645533141;0,35;0,26;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1036;;
1-monostearin;1-monostearin;1-monostearin;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;122 ± 32;142 ± 39;0,862;0,039;0,227;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1037;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;212,3;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;122.48 ± 34.12 μmol/L;96.47 ± 20.59 μmol/L;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1038;;
threonic acid;threonic acid;threonic acid;–;–;–;HMDB0000943;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1222 ± 722;2000 ± 1341;0,61;0,002;0,031;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1039;;
1,5-anhydroglucitol;1,5-anhydroglucitol;1,5-anhydroglucitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;12259 ± 6475;15142 ± 7933;0,81;0,053;0,265;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1040;;
6-deoxyglucitol;6-deoxyglucitol;6-deoxyglucitol;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1228 ± 765;1362 ± 656;0,9;0,087;0,472;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1041;;
pipecolic acid;pipecolic acid;pipecolic acid;–;–;–;HMDB0000070;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;123 ± 126;263 ± 462;0,47;0,023;0,127;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1042;;
cysteine;cysteine;cysteine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1230 ± 597;1507 ± 1050;0,82;0,563;0,834;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1043;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1230 ± 780;814 ± 554;1,51;0,015;0,186;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1044;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;12328 ± 4479;14129 ± 5890;0,87;0,342;0,63;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1045;;
linolenic acid;linolenic acid;linolenic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1233 ± 1039;1022 ± 828;1,21;0,873;0,952;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1046;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1239 ± 535;1070 ± 403;1,16;0,257;0,586;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1047;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;166,0863;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;12396.95±2022.94 ng/mL;11365.30±1254.94 ng/mL;2,1287403649;0,0002;–;1,39;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1048;;
lyxose;lyxose;lyxose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;124 ± 107;140 ± 109;0,89;0,438;0,773;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1049;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;124.38±35.64 ?M;117.82±26.8 ?M;1,06;0,4265;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,538;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1050;;
PC(22:0/20:4);PC(22:0/20:4);PC(22:0/20:4);–;–;–;–;–;–;–;–;–;910,6443;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;124.58 ng/mL;175.44 ng/mL;0,7101003192;0,03;0,0441;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1051;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;124011 ± 34021;124422 ± 35741;1;0,795;0,91;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1052;;
γ-linolenic acid;γ-linolenic acid;γ-linolenic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;healthy;30;11, 19;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P+ software, SPSS;independent t-test ;1245.99 ± 595.41;500.34 ± 204.80;2,4902866051;0,001;–;–;ROC curve analysis;805,17;0.889 (0.806-0.972);76,67;93,33;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1053;;
γ-linolenic acid;γ-linolenic acid;γ-linolenic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;before vs. after treatment (operation);30;9, 21;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P+ software, SPSS;independent t-test ;1245.99 ± 595.41;602.06 ± 226.28;2,0695445637;0,001;–;–;ROC curve analysis;808,24;0.847 (0.744–0.949);76,67;90;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1054;;
saccharic acid;saccharic acid;saccharic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;125 ± 140;126 ± 115;0,99;0,66;0,878;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1055;;
aminomalonic acid;aminomalonic acid;aminomalonic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1251 ± 451;1178 ± 519;1,06;0,415;0,768;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1056;;
capric acid;capric acid;capric acid;–;–;–;HMDB0000511;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1254 ± 535;1279 ± 443;0,98;0,272;0,604;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1057;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;12542 ± 3137;12210 ± 3605;1,03;0,491;0,726;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1058;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1257 ± 815;828 ± 658;1,52;0,013;0,175;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1059;;
deoxythreittol;deoxythreittol;deoxythreittol;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1262 ± 744;1251 ± 516;1,01;0,446;0,723;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1060;;
caprylic acid;caprylic acid;caprylic acid;–;–;–;HMDB0000482;–;–;–;Lipid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1268 ± 395;1471 ± 347;0,862;0,016;0,139;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1061;;
pseudo uridine;pseudo uridine;pseudo uridine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1268 ± 763;1099 ± 319;1,15;0,32;0,649;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1062;;
2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;128 ± 116;120 ± 62;1,066;0,93;0,987;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1063;;
PC(24:4/17:2);PC(24:4/17:2);PC(24:4/17:2);–;–;–;–;–;–;–;–;–;892,6127;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;128.19 ng/mL;167.95 ng/mL;0,7632628759;0,00378;0,013;–;ROC curve;–;"0.273 (0.139–0.407),
combination of down-regulated PCs: 0.897 (0.818–0.975),
combination of 12 altered PCs: 1.000 (1.000–1.000) ";"70,
combination of down-regulated PCs: 90.0,
combination of 12 altered PCs: 100";"80,
combination of down-regulated PCs: 76.7,
combination of 12 altered PCs: 100";–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;1064;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;12805 ± 4118;10403 ± 2904;1,23;0,005;0,047;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1065;;
linolenic acid;linolenic acid;linolenic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1282 ± 805;904 ± 674;1,42;0,067;0,399;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1066;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;–;–;188,2;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;129.40 ± 35.12 μmol/L;116.60 ± 23.82 μmol/L;–;0,0141;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1067;;
2-deoxytetronic acid;2-deoxytetronic acid;2-deoxytetronic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1291 ± 745;1180 ± 452;1,094;0,97;0,992;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1068;;
paracetamol;paracetamol;paracetamol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1296 ± 3528;335 ± 729;3,86;0,3;0,622;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1069;;
6-deoxyglucitol;6-deoxyglucitol;6-deoxyglucitol;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1297 ± 531;1815 ± 986;0,71;0,013;0,175;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1070;;
2-hydroxybutanoic acid;2-hydroxybutanoic acid;2-hydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;12996 ± 7017;11486 ± 8094;1,13;0,217;0,589;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1071;;
cytidine-5-diphosphate;cytidine-5-diphosphate;cytidine-5-diphosphate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;130 ± 84;96 ± 32;1,36;0,005;0,093;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1072;;
Leu;Leu;Leu;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;131.8 ± 34.3 μM;122.4±27.6 μM;1,0767973856;0,003;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1073;;
maltotriose;maltotriose;maltotriose;–;–;–;–;–;–;–;Carbohydrate;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;132 ± 114;96 ± 31;1,38;0,039;0,3;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1074;;
phenylacetic acid;phenylacetic acid;phenylacetic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;132 ± 50;148 ± 62;0,892;0,147;0,408;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1075;;
rhamnose;rhamnose;rhamnose;–;–;–;HMDB0000849;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1324 ± 635;1277 ± 476;1,036;0,934;0,987;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1076;;
PC(18:0/16:0);PC(18:0/16:0);PC(18:0/16:0);–;–;–;–;–;–;–;–;–;806,5778;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;13251.6 ng/mL;10152.58 ng/mL;1,3052445782;0,00527;0,0162;–;ROC curve;–;"0.763 (0.641–0.885), 
combination of up-regulated PCs: 0.811 (0.703–0.919),
 combination of 12 altered PCs: 1.000 (1.000–1.000)";"73.3,
combination of up-regulated PCs: 76.7,
 combination of 12 altered PCs: 100";"76.7,
combination of up-regulated PCs: 70.0,
combination of 12 altered PCs: 100";–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;1077;;
PC(18:1/20:4);PC(18:1/20:4);PC(18:1/20:4);–;–;–;–;–;–;–;–;–;852,5709;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;13268.59 ng/mL;13353.05 ng/mL;0,9936748533;0,96;0,49;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1078;;
glutaric acid;glutaric acid;glutaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;133 ± 102;106 ± 51;1,25;0,18;0,534;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1079;;
maltotriose;maltotriose;maltotriose;–;–;–;–;–;–;–;Carbohydrate;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;133 ± 107;97 ± 146;1,36;0,003;0,038;–;random forest;–;"maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=0.699 (0.583, 0.815)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.670 (0.552, 0.789)";"79.1
maltose+maltotriose=67.4";"48.8
maltose+maltotriose=59.3";"64
maltose+maltotriose=63.4";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1080;;
phosphorylcholine;phosphorylcholine;phosphorylcholine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;healthy;30;11, 19;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P+ software, SPSS;independent t-test ;133.28 ± 75.49;72.70 ± 14.16;1,8332874828;0,001;–;–;ROC curve analysis;78,32;0.874 (0.780-0.969);90;80;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1081;;
phosphorylcholine;phosphorylcholine;phosphorylcholine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;before vs. after treatment (operation);30;9, 21;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P+ software, SPSS;independent t-test ;133.28 ± 75.49;82.17 ± 28.31;1,6220031642;0,001;–;–;ROC curve analysis;84,69;0.781 (0.666–0.896);76,67;70;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1082;;
2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;134 ± 53;123 ± 44;1,08;0,445;0,773;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1083;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1347 ± 268;1432 ± 233;0,94;0,063;0,222;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1084;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;193,0343;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;135.09±38.09 ng/mL;29.47±6.40 ng/mL;0,3120826372;0,000000187;–;1,66;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1085;;
hydrogene sulfide;hydrogene sulfide;hydrogene sulfide;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;135.24 ± 109.11;177.52 ± 242.58;0,761829653;0,76044;0,87264;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1086;;
shikimic acid;shikimic acid;shikimic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1350 ± 644;1489 ± 1222;0,906;0,488;0,781;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1087;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;135029 ± 58467;109385 ± 42952;1,23;0,054;0,204;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1088;;
maltotriose;maltotriose;maltotriose;–;–;–;–;–;–;–;Carbohydrate;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;136 ± 54;109 ± 39;1,25;0,003;0,037;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1089;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;174,2;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;136.60 ± 35.57 μmol/L;165.62 ± 28.08 μmol/L;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1090;;
glycerol-alpha-phosphate;glycerol-alpha-phosphate;glycerol-alpha-phosphate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1362 ± 801;1723 ± 761;0,79;0,028;0,137;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1091;;
2-ethyl-1-hexanol;2-ethyl-1-hexanol;2-ethyl-1-hexanol;–;–;–;–;–;–;–;–;–;–;pleural effusion;diagnosis;NSCLC, SCLC;–;20;16, 4;73 (53-85);–;tuberculous pleurisy, pneumonia;20;14, 6;63.6 (44-86);–;GC;EI;positive;single quad;–;–;NIST02 library ; SPSS ;Student's t-test, corrected t-test;1373900 ± 1112200;65000 ± 55500;21,1;0,01;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;24321761;Liu et al. 2014;1092;;
butane-2,3-diol;butane-2,3-diol;butane-2,3-diol;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1374 ± 3896;930 ± 2746;1,48;0,399;0,755;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1093;;
aminomalonic acid;aminomalonic acid;aminomalonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1374 ± 549;1516 ± 607;0,907;0,206;0,5;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1094;;
cysteine;cysteine;cysteine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1378 ± 604;1406 ± 533;0,98;0,663;0,894;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1095;;
N-acetylmannosamine;N-acetylmannosamine;N-acetylmannosamine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;138 ± 51;157 ± 81;0,88;0,451;0,773;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1096;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;138 ± 54;144 ± 55;0,96;0,699;0,886;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1097;;
N-acetylglycine;N-acetylglycine;N-acetylglycine;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;138 ± 76;154 ± 92;0,899;0,296;0,599;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1098;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;13805 ± 5165;12349 ± 5309;1,12;0,209;0,543;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1099;;
PC(16:1/22:6);PC(16:1/22:6);PC(16:1/22:6);–;–;–;–;–;–;–;–;–;848,5395;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;1389.09 ng/mL;1444.44 ng/mL;0,9616806513;0,77;0,43;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1100;;
2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;139 ± 66;162 ± 51;0,86;0,017;0,196;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1101;;
salicylaldehyde;salicylaldehyde;salicylaldehyde;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;139 ± 92;156 ± 88;0,89;0,134;0,516;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1102;;
pseudo uridine;pseudo uridine;pseudo uridine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1396 ± 1140;1182 ± 333;1,18;0,326;0,714;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1103;;
L-isoleucine;L-isoleucine;L-isoleucine;–;–;–;HMDB0000172;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;14.606 ± 10.526;23.197 ± 17.309;0,6296503858;0,00016592;0,0058073;–;ROC curve;–;–;combination of nine metabolites: 100;combination of nine metabolites: 86;–;–;–;–;–;–;Poland;Y;–;28803255;Ro?-Mazurczyk et al. 2017;1104;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;14.939 ± 7.7875;17.369 ± 10.619;0,8600955726;0,3094;0,64914;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1105;;
xylitol;xylitol;xylitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;140 ± 73;207 ± 250;0,68;0,306;0,582;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1106;;
salicylaldehyde;salicylaldehyde;salicylaldehyde;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;140 ± 81;197 ± 263;0,71;0,216;0,543;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1107;;
PC(16:0/18:0);PC(16:0/18:0);PC(16:0/18:0);–;–;–;–;–;–;–;–;–;806,5904;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;140.06 ng/mL;117.01 ng/mL;1,1969917101;0,066;0,0729;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1108;;
PC(14:0/20:4);PC(14:0/20:4);PC(14:0/20:4);–;–;–;–;–;–;–;–;–;798,5252;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;1402.49 ng/mL;1290.82 ng/mL;1,0865109;0,56;0,36;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1109;;
1-monopalmitin;1-monopalmitin;1-monopalmitin;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;141 ± 54;143 ± 44;0,983;0,768;0,935;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1110;;
PC(19:0/20:3);PC(19:0/20:3);PC(19:0/20:3);–;–;–;–;–;–;–;–;–;870,6166;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;141.86 ng/mL;123.29 ng/mL;1,1506204883;0,36;0,26;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1111;;
3-hydroxybutanoic acid;3-hydroxybutanoic acid;3-hydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;14199 ± 25818;6404 ± 6606;2,22;0,094;0,403;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1112;;
gluconic acid;gluconic acid;gluconic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;142 ± 137;158 ± 66;0,9;0,014;0,093;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1113;;
isolinoleic acid;isolinoleic acid;isolinoleic acid;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;142 ± 60;122 ± 32;1,16;0,191;0,541;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1114;;
PC(22:6/21:0);PC(22:6/21:0);PC(22:6/21:0);–;–;–;–;–;–;–;–;–;920,6406;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;142.05 ng/mL;159.1 ng/mL;0,8928346952;0,25;0,2;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1115;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;142.71±39.77 ?M;126.18±32.19 ?M;1,13;0,0071;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,629;alanine+histidine+ornithine+glutamine+lysine+serine=82.2;alanine+histidine+ornithine+glutamine+lysine+serine=58.7;–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1116;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;14276 ± 4817;15614 ± 6000;0,91;0,505;0,74;–;random forest;–;maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.670 (0.552, 0.789);"39.5
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan=60.5";"65.1
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan=93.0";"52.3
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan=76.7";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1117;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1428 ± 597;1613 ± 615;0,89;0,043;0,174;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1118;;
aconitic acid;aconitic acid;aconitic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;144 ± 55;163 ± 47;0,881;0,018;0,148;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1119;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1448 ± 671;1125 ± 259;1,29;0,002;0,034;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1120;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;Nucleotide;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;145 ± 47;121 ± 39;1,2;0,009;0,09;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1121;;
lactamide;lactamide;lactamide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;145 ± 72;86 ± 42;1,69;0;0,001;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1122;;
PC(15:0/18:1);PC(15:0/18:1);PC(15:0/18:1);–;–;–;–;–;–;–;–;–;790,5554;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;1455.64 ng/mL;974.53 ng/mL;1,4936841349;0,00826;0,0207;–;ROC curve;–;"0.717 (0.586–0.848),
combination of up-regulated PCs: 0.811 (0.703–0.919),
 combination of 12 altered PCs: 1.000 (1.000–1.000)";"60,
combination of up-regulated PCs: 76.7,
 combination of 12 altered PCs: 100";"80,
combination of up-regulated PCs: 70.0,
combination of 12 altered PCs: 100";–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;1123;;
pseudo uridine;pseudo uridine;pseudo uridine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1457 ± 1113;1477 ± 453;0,986;0,176;0,466;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1124;;
PC(22:5/22:6);PC(22:5/22:6);PC(22:5/22:6);–;–;–;–;–;–;–;–;–;924,5882;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;1457.7 ng/mL;1282.42 ng/mL;1,1366790911;0,0883;0,0214;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1125;;
capric acid;capric acid;capric acid;–;–;–;HMDB0000511;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1459 ± 335;1399 ± 301;1,043;0,332;0,633;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1126;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;146,2;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;146.50 ± 53.53 μmol/L;141.98 ± 32.66 μmol/L;–;0,5434;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1127;;
methylhexadecanoic acid;methylhexadecanoic acid;methylhexadecanoic acid;–;–;–;HMDB0031067;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1462 ± 407;1340 ± 422;1,09;0,242;0,618;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1128;;
lysine;lysine;lysine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;14622 ± 4376;16035 ± 4028;0,91;0,06;0,217;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1129;;
N-acetylmannosamine;N-acetylmannosamine;N-acetylmannosamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;147 ± 67;173 ± 69;0,85;0,128;0,459;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1130;;
aconitic acid;aconitic acid;aconitic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;148 ± 119;152 ± 60;0,97;0,304;0,69;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1131;;
1-monopalmitin;1-monopalmitin;1-monopalmitin;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;148 ± 136;138 ± 55;1,07;0,782;0,898;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1132;;
shikimic acid;shikimic acid;shikimic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;149 ± 231;171 ± 132;0,87;0,064;0,222;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1133;;
longifolene;longifolene;longifolene;–;–;–;–;–;–;–;–;–;–;pleural effusion;diagnosis;NSCLC, SCLC;–;20;16, 4;73 (53-85);–;tuberculous pleurisy, pneumonia;20;14, 6;63.6 (44-86);–;GC;EI;positive;single quad;–;–;NIST02 library ; SPSS ;Student's t-test, corrected t-test;1500 ± 1400;700 ± 500;2,2;0,04;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;24321761;Liu et al. 2014;1134;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;15000 ± 8116;11063 ± 4099;1,356;0,028;0,188;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1135;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1508 ± 536;1448 ± 577;1,04;0,525;0,806;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1136;;
lyxose;lyxose;lyxose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;151 ± 121;229 ± 282;0,66;0,276;0,604;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1137;;
arabitol;arabitol;arabitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;151 ± 124;133 ± 63;1,137;0,477;0,77;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1138;;
asparagine;asparagine;asparagine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1512 ± 455;1902 ± 651;0,8;0,002;0,034;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1139;;
tocopherol alpha;tocopherol alpha;tocopherol alpha;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1513 ± 1113;1351 ± 921;1,12;0,885;0,959;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1140;;
deoxytetronic acid;deoxytetronic acid;deoxytetronic acid;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1522 ± 1866;1086 ± 599;1,4;0,243;0,574;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1141;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;116,0706;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;1529.22±403.46 ng/mL;1079.66±215.79 ng/mL;2,7702189362;0,0000607;–;1,44;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1142;;
octadecanol;octadecanol;octadecanol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;153 ± 78;148 ± 65;1,04;0,902;0,97;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1143;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;15311 ± 8674;17926 ± 9420;0,85;0,093;0,483;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1144;;
glutamate;glutamate;glutamate;–;–;–;–;–;–;–;–;–;148,0605;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;1532.78±321.05 ng/mL;1092.18±192.11 ng/mL;3,0737503626;0,00000505;–;1,58;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1145;;
PC(15:0/18:2);PC(15:0/18:2);PC(15:0/18:2);–;–;–;–;–;–;–;–;–;788,5397;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;1546.56 ng/mL;1950.71 ng/mL;0,7928190249;0,00715;0,0192;–;ROC curve;–;"0.283 (0.147–0.420),
combination of down-regulated PCs: 0.897 (0.818–0.975),
combination of 12 altered PCs: 1.000 (1.000–1.000) ";"56.7,
combination of down-regulated PCs: 90.0,
combination of 12 altered PCs: 100";"90,
combination of down-regulated PCs: 76.7,
combination of 12 altered PCs: 100";–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;1146;;
PC(22:0/18:1);PC(22:0/18:1);PC(22:0/18:1);–;–;–;–;–;–;–;–;–;888,6631;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;155.05 ng/mL;139.53 ng/mL;1,1112305597;0,3;0,23;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1147;;
glucose;glucose;glucose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;155035 ± 97076;194159 ± 137046;0,8;0,152;0,529;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1148;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;15568 ± 4036;13147 ± 2818;1,18;0,004;0,117;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1149;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;155793 ± 36291;161536 ± 43045;0,96;0,769;0,898;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1150;;
arabitol;arabitol;arabitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;156 ± 141;147 ± 64;1,06;0,962;0,985;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1151;;
methioninesulfoxide;methioninesulfoxide;methioninesulfoxide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;156 ± 50;178 ± 47;0,88;0,013;0,093;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1152;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;15690 ± 6558;16511 ± 7616;0,95;0,639;0,892;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1153;;
beta-glycerolphosphate;beta-glycerolphosphate;beta-glycerolphosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;157 ± 77;168 ± 56;0,938;0,27;0,572;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1154;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;15732 ± 5220;13798 ± 4693;1,14;0,142;0,527;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1155;;
fructose;fructose;fructose;–;–;–;–;–;–;–;Carbohydrate;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1574 ± 1571;3463 ± 6621;0,46;0,242;0,618;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1156;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;157412 ± 102363;196899 ± 84339;0,8;0,02;0,222;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1157;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;157690 ± 42761;152525 ± 48794;1,034;0,492;0,785;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1158;;
isolinoleic acid;isolinoleic acid;isolinoleic acid;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;158 ± 94;131 ± 90;1,21;0,185;0,563;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1159;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;15844 ± 3491;13117 ± 2649;1,208;0;0,004;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1160;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;–;–;106,0499;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;159.17±48.86 ng/mL;64.38±23.19 ng/mL;4,9588307998;0,000000244;–;1,75;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1161;;
PC(20:4/22:4);PC(20:4/22:4);PC(20:4/22:4);–;–;–;–;–;–;–;–;–;902,5857;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;159.63 ng/mL;165.79 ng/mL;0,9628445624;0,7;0,41;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1162;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;15995 ± 5588;15703 ± 4964;1,02;0,908;0,973;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1163;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;160750 ± 77087;102355 ± 52346;1,571;0;0,001;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1164;;
pyruvic acid;pyruvic acid;pyruvic acid;–;–;–;HMDB0000243;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1608 ± 908;2162 ± 1352;0,74;0,066;0,343;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1165;;
octadecanol;octadecanol;octadecanol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;161 ± 67;175 ± 62;0,92;0,246;0,577;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1166;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;161.39±50.88 ?M;183.31±65.84 ?M;0,88;0,0329;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,602;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1167;;
tocopherol alpha;tocopherol alpha;tocopherol alpha;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1617 ± 1265;1430 ± 1238;1,13;0,353;0,734;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1168;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;163 ± 124;272 ± 152;0,6;0;0,011;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1169;;
cellobiotol;cellobiotol;cellobiotol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;163 ± 157;111 ± 47;1,46;0,041;0,3;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1170;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;163 ± 51;194 ± 258;0,84;0,888;0,958;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1171;;
PC(17:2/2:0);PC(17:2/2:0);PC(17:2/2:0);–;–;–;–;–;–;–;–;–;592,3214;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;163.47 ng/mL;340.06 ng/mL;0,4807092866;0,0000186;0,000638;–;ROC curve;–;"0.183 (0.078–0.288),
0.897 (0.818–0.975)
combination of down-regulated PCs";"66.7,
combination of down-regulated PCs: 90.0,
combination of 12 altered PCs: 100";"86.7,
combination of down-regulated PCs: 76.7,
combination of 12 altered PCs: 100";–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;1172;;
PC(18:0/18:2);PC(18:0/18:2);PC(18:0/18:2);–;–;–;–;–;–;–;–;–;830,5879;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;163154.58 ng/mL;176296.51 ng/mL;0,9254555294;0,28;0,22;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1173;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1634 ± 889;1075 ± 1861;1,52;0;0,002;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1174;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;16366 ± 5484;16040 ± 3981;1,02;0,748;0,904;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1175;;
tagatose;tagatose;tagatose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1647 ± 972;2336 ± 974;0,705;0,001;0,016;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1176;;
erythrose;erythrose;erythrose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;165 ± 70;190 ± 65;0,872;0,059;0,265;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1177;;
2-hydroxybutanoic acid;2-hydroxybutanoic acid;2-hydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;16545 ± 8851;12608 ± 6812;1,312;0,006;0,067;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1178;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1655 ± 2046;1058 ± 1210;1,564;0,085;0,324;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1179;;
cysteine;cysteine;cysteine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1659 ± 783;1843 ± 970;0,9;0,45;0,725;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1180;;
3-aminoisobutyric acid;3-aminoisobutyric acid;3-aminoisobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1662 ± 6037;670 ± 359;2,48;0,467;0,77;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1181;;
2-hydroxybutanoic acid;2-hydroxybutanoic acid;2-hydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;16636 ± 8787;14667 ± 9574;1,13;0,295;0,621;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1182;;
3-phosphoglycerate;3-phosphoglycerate;3-phosphoglycerate;–;–;–;–;–;–;–;Organic Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;167 ± 237;108 ± 137;1,54;0,092;0,403;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1183;;
glucose;glucose;glucose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;167237 ± 121193;199282 ± 136738;0,84;0,122;0,457;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1184;;
Pro;Pro;Pro;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;168 ± 43.6 μM;150.9±41.4 μM;1,1133200795;0,001;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1185;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;16800 ± 9460;16469 ± 11660;1,02;0,963;0,982;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1186;;
cGMP;cGMP;cGMP;–;–;–;–;–;–;–;–;–;346,0547;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;16847.50±2023.57 ng/mL;14360.00±2034.44 ng/mL;3,2490095854;0,000117;–;1,4;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1187;;
arabitol;arabitol;arabitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;169 ± 124;170 ± 55;1;0,275;0,604;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1188;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;Nucleotide;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;169 ± 66;128 ± 43;1,32;0,005;0,117;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1189;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;169 ± 66;183 ± 130;0,926;0,574;0,853;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1190;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;16909 ± 5152;16995 ± 5330;1;0,802;0,928;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1191;;
methylhexadecanoic acid;methylhexadecanoic acid;methylhexadecanoic acid;–;–;–;HMDB0031067;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1691 ± 431;1776 ± 720;0,95;0,71;0,861;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1192;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;–;–;HMDB0003229;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1698 ± 1260;1365 ± 1325;1,24;0,081;0,261;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1193;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1698 ± 819;1180 ± 725;1,44;0,002;0,092;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1194;;
PC(20:3/12:0);PC(20:3/12:0);PC(20:3/12:0);–;–;–;–;–;–;–;–;–;772,5085;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;170 ng/mL;112.85 ng/mL;1,5064244572;0,0135;0,0257;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1195;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1708 ± 1527;1555 ± 1348;1,1;0,822;0,936;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1196;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;17099 ± 11268;13854 ± 5198;1,23;0,286;0,672;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1197;;
isoleucine;isoleucine;isoleucine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;17198 ± 5653;16053 ± 5131;1,07;0,284;0,576;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1198;;
threonine;threonine;threonine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;17242 ± 5001;18424 ± 4934;0,94;0,426;0,768;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1199;;
threose;threose;threose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;173 ± 43;193 ± 50;0,897;0,08;0,324;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1200;;
fructose;fructose;fructose;–;–;–;–;–;–;–;Carbohydrate;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1739 ± 1324;4248 ± 7319;0,41;0,017;0,194;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1201;;
fructose;fructose;fructose;–;–;–;–;–;–;–;Carbohydrate;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;17395 ± 12146;26115 ± 10770;0,67;0,003;0,035;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1202;;
2-deoxytetronic acid;2-deoxytetronic acid;2-deoxytetronic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;174 ± 80;141 ± 50;1,23;0,121;0,516;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1203;;
PC(16:1/20:5);PC(16:1/20:5);PC(16:1/20:5);–;–;–;–;–;–;–;–;–;822,5234;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;174.17 ng/mL;119.98 ng/mL;1,4516586098;0,0275;0,0411;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1204;;
levanbiose;levanbiose;levanbiose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;175 ± 101;185 ± 81;0,95;0,309;0,639;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1205;;
behenic acid;behenic acid;behenic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;175 ± 70;178 ± 75;0,984;0,961;0,99;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1206;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;17526 ± 10639;24922 ± 9245;0,7;0,001;0,047;–;random forest;–;maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.883 (0.812, 0.955);–;–;"50.6
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan=77.1";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1207;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1764 ± 1082;1551 ± 1381;1,14;0,256;0,631;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1208;;
PC(23:0/20:4);PC(23:0/20:4);PC(23:0/20:4);–;–;–;–;–;–;–;–;–;924,6615;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;177.55 ng/mL;156.4 ng/mL;1,135230179;0,17;0,15;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1209;;
alpha ketoglutaric acid;alpha ketoglutaric acid;alpha ketoglutaric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;178 ± 76;140 ± 56;1,28;0,009;0,068;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1210;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;178.94 ± 87.797;193.22 ± 163.01;0,9260946072;0,94659;0,9534;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1211;;
benzylalcohol;benzylalcohol;benzylalcohol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1787 ± 2001;1719 ± 1443;1,04;0,509;0,743;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1212;;
methylhexadecanoic acid;methylhexadecanoic acid;methylhexadecanoic acid;–;–;–;HMDB0031067;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1796 ± 363;1742 ± 386;1,031;0,285;0,591;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1213;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;17976 ± 10885;13860 ± 5895;1,3;0,054;0,31;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1214;;
PC(22:6/20:5);PC(22:6/20:5);PC(22:6/20:5);–;–;–;–;–;–;–;–;–;896,5381;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;18.13 ng/mL;19.55 ng/mL;0,9273657289;0,67;0,4;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1215;;
5-methoxytryptamine;5-methoxytryptamine;5-methoxytryptamine;–;–;–;–;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;181 ± 161;136 ± 243;1,33;0,017;0,102;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1216;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;181 ± 62;156 ± 53;1,17;0,068;0,233;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1217;;
shikimic acid;shikimic acid;shikimic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1810 ± 1357;1562 ± 949;1,16;0,46;0,733;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1218;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1813 ± 769;2011 ± 906;0,902;0,5;0,788;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1219;;
2-hydroxyvaleric acid;2-hydroxyvaleric acid;2-hydroxyvaleric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1816 ± 4592;1707 ± 5024;1,06;0,557;0,833;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1220;;
deoxythreittol;deoxythreittol;deoxythreittol;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1822 ± 4291;1185 ± 445;1,54;0,893;0,97;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1221;;
arachidic acid;arachidic acid;arachidic acid;–;–;–;HMDB0002212;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1827 ± 600;2176 ± 1065;0,84;0,252;0,627;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1222;;
maltose;maltose;maltose;–;–;–;–;–;–;–;Carbohydrate;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;183 ± 200;132 ± 169;1,38;0,078;0,258;–;random forest;–;"0.617 (0.496, 0.738)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=0.699 (0.583, 0.815)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.670 (0.552, 0.789)";55,8;69,8;62,8;–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1223;;
glutaric acid;glutaric acid;glutaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;184 ± 102;206 ± 195;0,89;0,404;0,713;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1224;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;184 ± 229;317 ± 497;0,58;0,08;0,386;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1225;;
PC(18:0/24:4);PC(18:0/24:4);PC(18:0/24:4);–;–;–;–;–;–;–;–;–;910,6452;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;184.49 ng/mL;174.66 ng/mL;1,0562807741;0,61;0,38;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1226;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;184523 ± 42921;179532 ± 40525;1,03;0,606;0,813;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1227;;
2-deoxytetronic acid;2-deoxytetronic acid;2-deoxytetronic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;185 ± 89;175 ± 67;1,06;0,987;0,991;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1228;;
PC(24:0/18:1);PC(24:0/18:1);PC(24:0/18:1);–;–;–;–;–;–;–;–;–;916,7178;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;185.51 ng/mL;157.4 ng/mL;1,1785895807;0,18;0,15;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1229;;
arachidic acid;arachidic acid;arachidic acid;–;–;–;HMDB0002212;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1850 ± 651;1897 ± 801;0,98;0,997;0,997;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1230;;
p-cresol;p-cresol;p-cresol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1857 ± 2263;1945 ± 1700;0,96;0,161;0,502;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1231;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;133,0972;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;18747.50±5011.63 ng/mL;12719.00±3260.69 ng/mL;3,3869812495;0,019;–;1,05;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1232;;
4-hydroxyproline;4-hydroxyproline;4-hydroxyproline;–;–;–;HMDB0000725;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1899 ± 686;1952 ± 540;0,97;0,464;0,697;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1233;;
aspartic acid;aspartic acid;aspartic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;19.23±9.5 ?M;12.64±6.01 ?M;1,52;0,0001;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,723;β-alanine+histidine+citrulline+asparagine+phenylalanine+aspartic acid=82.2;β-alanine+histidine+citrulline+asparagine+phenylalanine+aspartic acid=69.8;–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1234;;
γ-aminobutyric acid;γ-aminobutyric acid;γ-aminobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;19.623 ± 9.3508;23.651 ± 11.954;0,8296900765;0,12645;0,45449;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1235;;
linolenic acid;linolenic acid;linolenic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1916 ± 1349;2266 ± 1276;0,846;0,181;0,466;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1236;;
cytidine-5-diphosphate;cytidine-5-diphosphate;cytidine-5-diphosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;192 ± 112;150 ± 62;1,28;0,213;0,543;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1237;;
inulobiose;inulobiose;inulobiose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;192 ± 160;274 ± 731;0,7;0,757;0,9;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1238;;
maleimide;maleimide;maleimide;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1923 ± 540;1804 ± 592;1,066;0,248;0,548;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1239;;
glycerol-3-galactoside;glycerol-3-galactoside;glycerol-3-galactoside;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;193 ± 208;269 ± 168;0,72;0,009;0,161;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1240;;
cysteine-glycine;cysteine-glycine;cysteine-glycine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;193 ± 88;159 ± 45;1,21;0,056;0,208;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1241;;
beta-mannosylglycerate;beta-mannosylglycerate;beta-mannosylglycerate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1934 ± 1112;2115 ± 1300;0,91;0,412;0,669;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1242;;
phosphoethanolamine;phosphoethanolamine;phosphoethanolamine;–;–;–;HMDB0000224;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;195 ± 78;230 ± 82;0,85;0,043;0,304;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1243;;
lysine;lysine;lysine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;196.48±55.51 ?M;190.67±46.22 ?M;1,03;0,4828;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,525;alanine+histidine+ornithine+glutamine+lysine+serine=82.2;alanine+histidine+ornithine+glutamine+lysine+serine=58.7;–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1244;;
tocopherol alpha;tocopherol alpha;tocopherol alpha;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1960 ± 789;2105 ± 921;0,93;0,259;0,554;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1245;;
threitol;threitol;threitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;197 ± 121;206 ± 92;0,96;0,396;0,663;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1246;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;189,4;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;197.29 ± 117.34 μmol/L;152.54 ± 64.60 μmol/L;–;0,0046;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1247;;
threonic acid;threonic acid;threonic acid;–;–;–;HMDB0000943;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;1994 ± 1279;2371 ± 1581;0,84;0,339;0,652;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1248;;
2-keto-3-methylpentanoic acid;2-keto-3-methylpentanoic acid;2-keto-3-methylpentanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;2.0003 ± 1.0415;2.1392 ± 1.4664;0,9350691847;0,63497;0,77978;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1249;;
1,2-propanediol;1,2-propanediol;1,2-propanediol;–;–;1030;HMDB01881;–;–;C00583;Xenobiotics;Chemical;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;2.067623± 4.726577;1.909926± 2.937649;1,0825670733;0,7301582;0,714276942;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1250;;
β-aminoisobutyric acid;β-aminoisobutyric acid;β-aminoisobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;2.11±0.95 ?M;2.19±1.19 ?M;0,96;0,6076;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,525;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1251;;
ethylamine;ethylamine;ethylamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;2.1395 ± 0.68325;2.6158 ± 1.9932;0,8179142136;0,12552;0,45449;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1252;;
12-HETE;12-HETE;12-HETE;–;–;5312983;HMDB06111;–;–;–;Lipid;Eicosanoid;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;2.180786± 2.727428;1.225474± 1.28091;1,7795448945;0,0000735;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1253;;
nicotinylglycine;nicotinylglycine;nicotinylglycine;–;–;–;–;–;–;–;–;–;181,0608;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;2.19±0.59 ng/mL;3.18±0.96 ng/mL;0,366021424;0,00035;–;1,31;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1254;;
β-hydroxybutyric acid;β-hydroxybutyric acid;β-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;2.1996 ± 2.0896;3.8785 ± 3.8139;0,5671264664;0,002942;0,068648;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1255;;
N-methyl proline;N-methyl proline;N-methyl proline;–;–;557;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;2.226495± 3.52901;2.093546± 3.370022;1,0635042172;0,7580427;0,73003491;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;1256;;
palmitelaidic acid;palmitelaidic acid;palmitelaidic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;2.2284 ± 1.4919;2.9179 ± 5.7876;0,7636999212;0,39023;0,67727;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1257;;
2-phosphoglyceric acid;2-phosphoglyceric acid;2-phosphoglyceric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;2.2489 ± 1.1021;2.9713 ± 1.7826;0,7568740955;0,066584;0,33292;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1258;;
glycocholate;glycocholate;glycocholate;–;–;10140;HMDB00138;–;–;C01921;Lipid;Primary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;2.251647± 6.940153;1.789766± 2.00554;1,2580678145;0,3956208;0,489199445;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1259;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;2.263 ± 2.5874;2.2252 ± 2.1857;1,0169872371;0,33941;0,65093;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1260;;
acetoacetate;acetoacetate;acetoacetate;–;–;96;HMDB00060;–;–;C00164;Lipid;Ketone Bodies;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;2.299084± 2.155784;1.186305± 1.122495;1,938020998;2,57E-008;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1261;;
taurocholate;taurocholate;taurocholate;–;–;6675;HMDB00036;–;–;C05122;Lipid;Primary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;2.369297± 6.960538;2.525825± 6.142798;0,9380289608;0,8467373;0,780448198;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1262;;
cadaverine;cadaverine;cadaverine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;2.3988 ± 1.8976;3.4773 ± 3.7539;0,6898455698;0,18859;0,52343;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1263;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;2.6072 ± 2.5057;3.2949 ± 3.15;0,7912834987;0,14451;0,45967;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1264;;
C24-ceramide;C24-ceramide;C24-ceramide;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;2.64 uM;2.48 uM;1,064516129;0,016;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;1265;;
arsenous acid;arsenous acid;arsenous acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;2.7499 ± 2.8011;2.9498 ± 2.6372;0,9322326937;0,50479;0,73733;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1266;;
hydroxylamine;hydroxylamine;hydroxylamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;2.7677 ± 1.0417;3.467 ± 4.2689;0,7982982406;0,34982;0,66183;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1267;;
pyroglutamic acid;pyroglutamic acid;pyroglutamic acid;–;–;–;HMDB0000267;–;–;–;–;–;130,0499;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;2.91±0.84 ng/mL;1.71±0.92 ng/mL;6,36429187;1,23E-009;–;1,98;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1268;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;2.9461 ± 1.3686;3.1191 ± 1.846;0,9445352826;0,53693;0,73733;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1269;;
PC(14:0/20:5);PC(14:0/20:5);PC(14:0/20:5);–;–;–;–;–;–;–;–;–;796,5096;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;200.35 ng/mL;208.58 ng/mL;0,9605427174;0,74;0,42;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1270;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;200181 ± 90481;162301 ± 91842;1,23;0,337;0,652;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1271;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;20025 ± 7215;19100 ± 8864;1,05;0,514;0,799;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1272;;
hydroxylamine;hydroxylamine;hydroxylamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2009 ± 744;2074 ± 898;0,97;0,951;0,982;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1273;;
N-acetylglycine;N-acetylglycine;N-acetylglycine;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;202 ± 139;171 ± 120;1,18;0,359;0,735;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1274;;
threonine;threonine;threonine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;20202 ± 6052;21308 ± 5443;0,95;0,388;0,672;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1275;;
PC(17:0/20:4);PC(17:0/20:4);PC(17:0/20:4);–;–;–;–;–;–;–;–;–;840,5709;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;2040.32 ng/mL;2444.92 ng/mL;0,8345140127;0,0454;0,0564;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1276;;
threonine;threonine;threonine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;20409 ± 6577;19400 ± 7726;1,052;0,298;0,599;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1277;;
2-ketoisocaproic acid;2-ketoisocaproic acid;2-ketoisocaproic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2042 ± 664;1939 ± 701;1,05;0,274;0,572;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1278;;
2-ketoisocaproic acid;2-ketoisocaproic acid;2-ketoisocaproic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2058 ± 962;1734 ± 741;1,187;0,058;0,265;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1279;;
gluconic acid;gluconic acid;gluconic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;207 ± 150;209 ± 71;0,99;0,151;0,496;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1280;;
PC(26:1/16:1);PC(26:1/16:1);PC(26:1/16:1);–;–;–;–;–;–;–;–;–;914,6786;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;207.38 ng/mL;223.27 ng/mL;0,9288305639;0,5;0,33;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1281;;
5-hydroxynorvaline;5-hydroxynorvaline;5-hydroxynorvaline;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;208 ± 86;327 ± 252;0,637;0,006;0,067;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1282;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;119,0339;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;208.88±46.71 ng/mL;1181.10±867.10 ng/mL;0,3609822989;0,00000343;–;1,55;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1283;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2083 ± 1003;1888 ± 614;1,103;0,44;0,749;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1284;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;206,2;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;21.02 ± 6.66 μmol/L;33.09 ± 6.38 μmol/L;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1285;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;21.52±5.7 ?M;22.74±4.98 ?M;0,95;0,1535;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,568;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1286;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;21042 ± 4790;20768 ± 5476;1,013;0,545;0,834;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1287;;
Lys;Lys;Lys;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;211.5 ± 36.2 μM;200.3±34.1 μM;1,0559161258;0,001;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1288;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2119 ± 776;2249 ± 687;0,94;0,494;0,788;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1289;;
N-acetylglycine;N-acetylglycine;N-acetylglycine; NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;213 ± 197;167 ± 108;1,27;0,289;0,621;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1290;;
paracetamol;paracetamol;paracetamol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;213 ± 485;175 ± 370;1,22;0,677;0,847;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1291;;
asparagine;asparagine;asparagine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2140 ± 885;2458 ± 1033;0,87;0,222;0,589;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1292;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2148 ± 1046;2531 ± 1361;0,85;0,297;0,621;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1293;;
xylose;xylose;xylose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;215 ± 138;481 ± 558;0,45;0;0,032;–;random forest;–;"Bin_225393+aspartate+xylose+glutamate=0.874 (0.800, 0.947)
Bin_225393+aspartate+xylose=0.864 (0.787, 0.942)";–;–;"53.8
Bin_225393+aspartate+xylose=68.8";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1294;;
gluconic acid;gluconic acid;gluconic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;215 ± 151;199 ± 61;1,08;0,672;0,878;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1295;;
pyrophosphate;pyrophosphate;pyrophosphate;–;–;–;–;–;–;–;Other;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2153 ± 1526;1108 ± 663;1,94;0;0,015;–;random forest;–;"0.744 (0.637, 0.852)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.883 (0.812, 0.955)";–;–;"66.3
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate=77.1";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1296;;
arabinose;arabinose;arabinose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;216 ± 146;200 ± 63;1,08;0,666;0,847;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1297;;
lysine;lysine;lysine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;21666 ± 8964;27533 ± 8385;0,79;0,003;0,079;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1298;;
PC(18:0/22:6);PC(18:0/22:6);PC(18:0/22:6);–;–;–;–;–;–;–;–;–;878,5878;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;21841.19 ng/mL;20693.65 ng/mL;1,0554537261;0,49;0,33;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1299;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;219059 ± 123529;162676 ± 118384;1,35;0,039;0,341;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1300;;
quinic acid;quinic acid;quinic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2194 ± 10681;887 ± 867;2,475;0,421;0,731;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1301;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;21988 ± 8539;24912 ± 10565;0,883;0,302;0,603;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1302;;
β-alanine;β-alanine;β-alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;22.61±10.27 ?M;15.89±9.1 ?M;1,42;0,0001;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,681;β-alanine+histidine+citrulline+asparagine+phenylalanine+aspartic acid=82.2;β-alanine+histidine+citrulline+asparagine+phenylalanine+aspartic acid=69.8;–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1303;;
pelargonic acid;pelargonic acid;pelargonic acid;–;–;–;HMDB0000847;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2202 ± 441;2271 ± 360;0,97;0,296;0,582;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1304;;
PC(16:0/20:5);PC(16:0/20:5);PC(16:0/20:5);–;–;–;–;–;–;–;–;–;824,5411;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;22087.92 ng/mL;18949.11 ng/mL;1,1656441912;0,32;0,24;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1305;;
cysteine-glycine;cysteine-glycine;cysteine-glycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;222 ± 110;245 ± 90;0,91;0,145;0,495;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1306;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2222 ± 1243;2988 ± 1371;0,74;0,012;0,085;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1307;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2235 ± 1006;1804 ± 447;1,239;0,007;0,069;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1308;;
behenic acid;behenic acid;behenic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;224 ± 115;229 ± 117;0,98;0,919;0,976;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1309;;
isocitric acid;isocitric acid;isocitric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;224 ± 125;264 ± 83;0,85;0,005;0,117;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1310;;
gluconolactone;gluconolactone;gluconolactone;–;–;–;–;–;–;–;–;–;179,055;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;224.84±120.50 ng/mL;112.48±38.85 ng/mL;0,2191514303;5,91E-008;–;1,65;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1311;;
arginine;arginine;arginine;–;–;–;HMDB0000517;–;–;–;–;–;231,1;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;224.94 ± 72.52 μmol/L;123.76 ± 43.14 μmol/L;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1312;;
2-hydroxyvaleric acid;2-hydroxyvaleric acid;2-hydroxyvaleric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2242 ± 10229;594 ± 285;3,77;0,319;0,598;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1313;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;227827 ± 68929;252052 ± 81218;0,904;0,369;0,674;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1314;;
α-amino-n-butyric acid;α-amino-n-butyric acid;α-amino-n-butyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;23.25±8.94 ?M;23.43±7.69 ?M;0,99;0,8355;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,51;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1315;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;–;–;232,1;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;23.41 ± 10.00 μmol/L;42.14 ± 12.77 μmol/L;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1316;;
xylitol;xylitol;xylitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;230 ± 111;263 ± 195;0,871;0,544;0,834;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1317;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;230 ± 500;160 ± 61;1,44;0,329;0,718;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1318;;
5-hydroxynorvaline;5-hydroxynorvaline;5-hydroxynorvaline;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;232 ± 173;228 ± 143;1,02;0,902;0,97;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1319;;
PC(17:0/18:0);PC(17:0/18:0);PC(17:0/18:0);–;–;–;–;–;–;–;–;–;820,6109;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;232.32 ng/mL;271.59 ng/mL;0,8554070474;0,0995;0,0962;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1320;;
alpha ketoglutaric acid;alpha ketoglutaric acid;alpha ketoglutaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;233 ± 184;212 ± 94;1,1;0,758;0,898;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1321;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;233.43±55.25 ?M;226.97±48.97 ?M;1,03;0,7597;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,515;alanine+histidine+ornithine+isoleucine+tryptophan+valine=84.4;alanine+histidine+ornithine+isoleucine+tryptophan+valine=52.4;–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1322;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;23305 ± 10251;23383 ± 10222;1;0,832;0,941;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1323;;
cysteine-glycine;cysteine-glycine;cysteine-glycine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;235 ± 156;236 ± 146;1;0,758;0,904;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1324;;
5-hydroxynorvaline;5-hydroxynorvaline;5-hydroxynorvaline;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;235 ± 185;257 ± 138;0,91;0,117;0,445;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1325;;
PC(18:4/3:0);PC(18:4/3:0);PC(18:4/3:0);–;–;–;–;–;–;–;–;–;616,3219;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;235.84 ng/mL;411.84 ng/mL;0,5726495726;0,00118;0,00607;–;ROC curve;–;"0.233 (0.110–0.356),
0.897 (0.818–0.975)
combination of down-regulated PCs";"66.7,
combination of down-regulated PCs: 90.0,
combination of 12 altered PCs: 100";"83.3,
combination of down-regulated PCs: 76.7,
combination of 12 altered PCs: 100";–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;1326;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2365 ± 1461;2335 ± 352;1,013;0,488;0,781;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1327;;
dihydro-3-coumaric acid;dihydro-3-coumaric acid;dihydro-3-coumaric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;237 ± 82;268 ± 96;0,89;0,148;0,391;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1328;;
galactonic acid;galactonic acid;galactonic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;238 ± 173;231 ± 103;1,03;0,615;0,858;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1329;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;23932 ± 6312;20908 ± 5590;1,15;0,045;0,307;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1330;;
ABA;ABA;ABA;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;24.2 ± 8.4 μM;23.2±6.9 μM;1,0431034483;0,2;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1331;;
2,3,4-trihydroxybutyric acid;2,3,4-trihydroxybutyric acid;2,3,4-trihydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;healthy;30;11, 19;60.35 ± 12.48;–;GC;–;–;–;–;GC/MSD ChemStation software (Agilent Technologies);NIST;SIMCA-P+ software, SPSS;independent t-test ;24.63 ± 24.13;71.89 ± 30.60;0,3426067603;0,001;–;–;ROC curve analysis;45,87;0.88 (0.794-0.966);86,67;83,33;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1332;;
2,3,4-trihydroxybutyric acid;2,3,4-trihydroxybutyric acid;2,3,4-trihydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;before vs. after treatment (operation);30;9, 21;61.58 ± 10.67;–;GC;–;–;–;–;GC/MSD ChemStation software (Agilent Technologies);NIST;SIMCA-P+ software, SPSS;independent t-test ;24.63 ± 24.13;23.02 ± 14.47;1,0699391833;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1333;;
9,12-octadecadienoic acid;9,12-octadecadienoic acid;9,12-octadecadienoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;healthy;30;11, 19;60.35 ± 12.48;–;GC;–;–;–;–;GC/MSD ChemStation software (Agilent Technologies);NIST;SIMCA-P+ software, SPSS;independent t-test ;24.90 ± 18.09;9.88 ± 5.79;2,520242915;0,001;–;–;ROC curve analysis;13,56;0.704 (0.562-0.847);66,67;83,33;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1334;;
9,12-octadecadienoic acid;9,12-octadecadienoic acid;9,12-octadecadienoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;before vs. after treatment (operation);30;9, 21;61.58 ± 10.67;–;GC;–;–;–;–;GC/MSD ChemStation software (Agilent Technologies);NIST;SIMCA-P+ software, SPSS;independent t-test ;24.90 ± 18.09;13.57 ± 9.30;1,8349299926;0,001;–;–;ROC curve analysis;21,29;0.645 (0.499–0.791);53,33;86,67;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1335;;
PC(26:2/13:0);PC(26:2/13:0);PC(26:2/13:0);–;–;–;–;–;–;–;–;–;872,6436;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;240.06 ng/mL;227.89 ng/mL;1,0534029576;0,66;0,4;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1336;;
PC(20:1/20:3);PC(20:1/20:3);PC(20:1/20:3);–;–;–;–;–;–;–;–;–;882,6013;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;242.84 ng/mL;235.42 ng/mL;1,0315181378;0,64;0,39;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1337;;
galactonic acid;galactonic acid;galactonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;244 ± 181;241 ± 143;1,01;0,779;0,898;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1338;;
val;val;val;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;244.8 ± 47.5 μM;239.8±46.1 μM;1,0208507089;0,28;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1339;;
glyoxalurea;glyoxalurea;glyoxalurea;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;245 ± 109;177 ± 108;1,38;0,007;0,123;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1340;;
phenylethylamine;phenylethylamine;phenylethylamine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;245 ± 117;305 ± 254;0,8;0,291;0,582;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1341;;
5-methoxytryptamine;5-methoxytryptamine;5-methoxytryptamine;–;–;–;–;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;245 ± 145;255 ± 171;0,96;0,814;0,935;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1342;;
beta-alanine;beta-alanine;beta-alanine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;246 ± 182;212 ± 136;1,16;0,525;0,806;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1343;;
PC(22:5/7:0);PC(22:5/7:0);PC(22:5/7:0);–;–;–;–;–;–;–;–;–;726,4513;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;246.13 ng/mL;263.28 ng/mL;0,9348602249;0,65;0,39;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1344;;
N-acetylglutamate;N-acetylglutamate;N-acetylglutamate;–;–;–;–;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;247 ± 86;199 ± 69;1,24;0,004;0,041;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1345;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;248 ± 113;173 ± 104;1,43;0,004;0,117;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1346;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;156,0768;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;24879.00±3290.40 ng/mL;15432.00±2151.27 ng/mL;3,6300766213;0,00000072;–;1,66;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1347;;
lactamide;lactamide;lactamide;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;249 ± 109;182 ± 72;1,369;0;0,009;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1348;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;–;–;HMDB0003229;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2496 ± 1609;2447 ± 2245;1,02;0,2;0,492;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1349;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;251 ± 127;216 ± 59;1,17;0,21;0,585;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1350;;
PC(18:2/18:2);PC(18:2/18:2);PC(18:2/18:2);–;–;–;–;–;–;–;–;–;826,5565;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;25110.02 ng/mL;37034.05 ng/mL;0,6780252227;0,00105;0,00581;–;ROC curve;–;"0.254 (0.128–0.381),
combination of down-regulated PCs: 0.897 (0.818–0.975),
combination of 12 altered PCs: 1.000 (1.000–1.000) ";"53.3,
combination of down-regulated PCs: 90.0,
combination of 12 altered PCs: 100";"93.3,
combination of down-regulated PCs: 76.7,
combination of 12 altered PCs: 100";–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;1351;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;25137 ± 13034;38842 ± 14273;0,65;0;0,001;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1352;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2525 ± 828;2551 ± 786;0,99;0,923;0,972;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1353;;
PC(17:0/18:1);PC(17:0/18:1);PC(17:0/18:1);–;–;–;–;–;–;–;–;–;818,5866;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;2536.8 ng/mL;2087.97 ng/mL;1,2149599851;0,0681;0,0745;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1354;;
maleimide;maleimide;maleimide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;254 ± 313;242 ± 117;1,05;0,457;0,695;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1355;;
gluconic acid;gluconic acid;gluconic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;254 ± 366;220 ± 74;1,155;0,766;0,935;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1356;;
methanolphosphate;methanolphosphate;methanolphosphate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;254 ± 84;282 ± 88;0,9;0,096;0,298;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1357;;
dodecanol;dodecanol;dodecanol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;254 ± 94;313 ± 87;0,81;0,001;0,091;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1358;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2557 ± 1453;2335 ± 1796;1,1;0,277;0,573;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1359;;
PC(22:6/20:1);PC(22:6/20:1);PC(22:6/20:1);–;–;–;–;–;–;–;–;–;904,6011;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;256.54 ng/mL;223.9 ng/mL;1,1457793658;0,18;0,15;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1360;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;25744 ± 10769;28168 ± 7676;0,91;0,108;0,506;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1361;;
pyruvic acid;pyruvic acid;pyruvic acid;–;–;–;HMDB0000243;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2576 ± 1598;965 ± 600;2,67;0;0,001;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1362;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;258 ± 101;244 ± 94;1,06;0,503;0,74;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1363;;
4-hydroxyproline;4-hydroxyproline;4-hydroxyproline;–;–;–;HMDB0000725;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2588 ± 1065;2217 ± 708;1,17;0,466;0,774;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1364;;
adenosine-5-phosphate;adenosine-5-phosphate;adenosine-5-phosphate;–;–;–;–;–;–;–;Nucleotide;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;259 ± 174;178 ± 422;1,46;0;0,004;–;random forest;–;maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.670 (0.552, 0.789);"67.4
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=64.0";"76.7
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=90.7";"72.1
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=77.3";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1365;;
PC(16:0/18:1);PC(16:0/18:1);PC(16:0/18:1);–;–;–;–;–;–;–;–;–;804,5624;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;25906.69 ng/mL;29510.92 ng/mL;0,8778679214;0,0549;0,0637;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1366;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;26.13±10.23 ?M;28.1±8.25 ?M;0,93;0,0192;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,611;β-alanine+histidine+citrulline+asparagine+phenylalanine+aspartic acid=82.2;β-alanine+histidine+citrulline+asparagine+phenylalanine+aspartic acid=69.8;–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1367;;
pyroglutamic acid;pyroglutamic acid;pyroglutamic acid;–;–;–;HMDB0000267;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 ± 6.9;smoker, non-smoker, unknown;healthy;62;40, 22;62 ± 8.8;smoker, non-smoker, unknown;LC;ESI;negative;triple quadrupole;MS/MS;Analyst software;–;–;Mann-Whitney U test;26.99 ± 11.56 μmol/l;35.28 ± 10.22 μmol/l;0,7650226757;2,64363E-008;–;–;ROC curve analysis ;"stage I vs. control: 29.6; 
stage II vs. control: 29.6; 
stage III vs. control: 28";"0.766; 
stage I vs. control: 0.752; 
stage II vs. control: 0.748; 
stage III vs. control: 0.799";"stage I vs. control: 0.8; 
stage II vs. control: 0.8; 
stage III vs. control: 0.8";"stage I vs. control: 0.7; 
stage II vs. control: 0.7; 
stage III vs. control: 0.7";–;–;–;–;–;–;Poland;Y;–;27454081;Klupczynska et al. 2016b;1368;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;260 ± 103;259 ± 123;1;0,998;1;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1369;;
adipic acid;adipic acid;adipic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;260 ± 55;292 ± 202;0,89;0,657;0,846;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1370;;
Gly;Gly;Gly;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;263.6 ± 63.2 μM;237±57.3 μM;1,1122362869;0;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1371;;
2-phenyl-2-propanol;2-phenyl-2-propanol;2-phenyl-2-propanol;–;–;–;–;–;–;–;–;–;–;pleural effusion;diagnosis;NSCLC, SCLC;–;20;16, 4;73 (53-85);–;tuberculous pleurisy, pneumonia;20;14, 6;63.6 (44-86);–;GC;EI;positive;single quad;–;–;NIST02 library ; SPSS ;Student's t-test, corrected t-test;26300 ± 26100;1800 ± 1100;14;0,025;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;24321761;Liu et al. 2014;1372;;
niacinamide;niacinamide;niacinamide;–;–;–;HMDB0001406;–;–;–;–;–;123,0553;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;26303.50±4458.58 ng/mL;22834.50±2545.10 ng/mL;0,3763116869;0,008;–;1,03;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1373;;
5-aminovaleric acid lactame;5-aminovaleric acid lactame;5-aminovaleric acid lactame;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;264 ± 254;227 ± 177;1,16;0,766;0,904;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1374;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2642 ± 900;3086 ± 1034;0,856;0,015;0,128;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1375;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;265 ± 109;197 ± 94;1,35;0,002;0,052;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1376;;
dodecanol;dodecanol;dodecanol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;265 ± 112;257 ± 92;1,03;0,894;0,97;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1377;;
threonine;threonine;threonine;–;–;–;–;–;–;–;–;–;120,0655;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;2653.95±739.97 ng/mL;1565.30±260.95 ng/mL;3,2490095854;0,000000298;–;1,76;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1378;;
arabinose;arabinose;arabinose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;266 ± 109;242 ± 97;1,1;0,248;0,579;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1379;;
parabanic acid;parabanic acid;parabanic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;267 ± 143;315 ± 143;0,85;0,063;0,33;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1380;;
cysteine-glycine;cysteine-glycine;cysteine-glycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;267 ± 98;261 ± 80;1,021;0,858;0,949;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1381;;
5-aminovaleric acid lactame;5-aminovaleric acid lactame;5-aminovaleric acid lactame;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;268 ± 267;204 ± 150;1,32;0,682;0,854;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1382;;
PC(16:0/20:3);PC(16:0/20:3);PC(16:0/20:3);–;–;–;–;–;–;–;–;–;828,5618;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;2686.1 ng/mL;4173.25 ng/mL;0,6436470377;0,00142;0,00648;–;ROC curve;–;"0.252 (0.126–0.378),
combination of down-regulated PCs: 0.897 (0.818–0.975),
combination of 12 altered PCs: 1.000 (1.000–1.000) ";"60,
combination of down-regulated PCs: 90.0,
combination of 12 altered PCs: 100";"90,
combination of down-regulated PCs: 76.7,
combination of 12 altered PCs: 100";–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;1383;;
3-phosphoglycerate;3-phosphoglycerate;3-phosphoglycerate;–;–;–;–;–;–;–;Organic Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;269 ± 190;151 ± 84;1,78;0;0,003;–;random forest;–;"maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=0.880 (0.805, 0.954)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.883 (0.812, 0.955)";–;–;"69.9
maltose+maltotriose+cystine+3-Phosphoglycerate=76.5";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1384;;
PC(16:0/18:3);PC(16:0/18:3);PC(16:0/18:3);–;–;–;–;–;–;–;–;–;800,5553;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;269.38 ng/mL;436.53 ng/mL;0,6170938996;0,000113;0,00227;–;ROC curve;–;"0.218 (0.101–0.335),
combination of down-regulated PCs: 0.897 (0.818–0.975),
combination of 12 altered PCs: 1.000 (1.000–1.000) ";"83.8,
combination of down-regulated PCs: 90.0,
combination of 12 altered PCs: 100";"70,
combination of down-regulated PCs: 76.7,
combination of 12 altered PCs: 100";–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;1385;;
beta-alanine;beta-alanine;beta-alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;270 ± 132;214 ± 119;1,259;0,014;0,12;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1386;;
isocitric acid;isocitric acid;isocitric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;270 ± 97;273 ± 93;0,989;0,789;0,935;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1387;;
beta-mannosylglycerate;beta-mannosylglycerate;beta-mannosylglycerate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2714 ± 1462;3128 ± 1611;0,867;0,098;0,334;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1388;;
glycerophospho-N-arachidonoyl ethanolamine;glycerophospho-N-arachidonoyl ethanolamine;glycerophospho-N-arachidonoyl ethanolamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;healthy;30;11, 19;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P+ software, SPSS;independent t-test ;2722.76 ± 769.63;1355.53 ± 282.89;2,0086313103;0,001;–;–;ROC curve analysis;1752,6;0.983 (0.960-1.007);96,67;90;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1389;;
glycerophospho-N-arachidonoyl ethanolamine;glycerophospho-N-arachidonoyl ethanolamine;glycerophospho-N-arachidonoyl ethanolamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;before vs. after treatment (operation);30;9, 21;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P+ software, SPSS;independent t-test ;2722.76 ± 769.63;1714.79 ± 399.47;1,587809586;0,001;–;–;ROC curve analysis;1988,46;0.916 (0.847–0.984);76,67;93,33;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1390;;
PC(16:0/14:1);PC(16:0/14:1);PC(16:0/14:1);–;–;–;–;–;–;–;–;–;748,5089;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;275.77 ng/mL;172.01 ng/mL;1,603220743;0,0533;0,0626;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1391;;
cellobiotol;cellobiotol;cellobiotol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;277 ± 266;144 ± 114;1,93;0;0,015;–;random forest;–;–;–;–;71,1;–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1392;;
tocopherol alpha;tocopherol alpha;tocopherol alpha;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2770 ± 1038;3270 ± 1418;0,847;0,03;0,19;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1393;;
sucrose;sucrose;sucrose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;278 ± 1027;193 ± 226;1,44;0,664;0,878;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1394;;
PC(20:2/22:6);PC(20:2/22:6);PC(20:2/22:6);–;–;–;–;–;–;–;–;–;902,5953;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;279.93 ng/mL;226.7 ng/mL;1,2348037053;0,0346;0,0472;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1395;;
pipecolinic acid;pipecolinic acid;pipecolinic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;28.258 ± 27.926;50.149 ± 89.059;0,5634808271;0,11851;0,45449;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1396;;
levoglucosan;levoglucosan;levoglucosan;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;280 ± 254;276 ± 276;1,02;0,694;0,859;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1397;;
cyclohexanone;cyclohexanone;cyclohexanone;–;–;–;–;–;–;–;–;–;–;pleural effusion;diagnosis;NSCLC, SCLC;–;20;16, 4;73 (53-85);–;tuberculous pleurisy, pneumonia;20;14, 6;63.6 (44-86);–;GC;EI;positive;single quad;–;–;NIST02 library ; SPSS ;Student's t-test, corrected t-test;2800700 ± 2566000;158700 ± 149200;17,5;0,003;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;24321761;Liu et al. 2014;1398;;
lignoceric acid;lignoceric acid;lignoceric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;281 ± 190;284 ± 434;0,99;0,298;0,582;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1399;;
arabinose;arabinose;arabinose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;283 ± 165;238 ± 74;1,19;0,307;0,69;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1400;;
isoleucine;isoleucine;isoleucine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;28327 ± 11452;27809 ± 8433;1,02;0,971;0,985;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1401;;
saccharic acid;saccharic acid;saccharic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;284 ± 1015;118 ± 45;2,41;0,517;0,81;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1402;;
N-acetylglucosamine;N-acetylglucosamine;N-acetylglucosamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2861 ± 2350;2457 ± 1135;1,164;0,52;0,81;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1403;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;28677 ± 16592;33022 ± 17528;0,87;0,256;0,553;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1404;;
lignoceric acid;lignoceric acid;lignoceric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;287 ± 144;232 ± 101;1,23;0,056;0,387;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1405;;
xylose;xylose;xylose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;287 ± 616;357 ± 469;0,8;0,14;0,527;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1406;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2886 ± 803;3026 ± 675;0,95;0,185;0,563;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1407;;
met;met;met;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;29.4 ± 6.1 μM;28±5.2 μM;1,05;0,013;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1408;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2902 ± 3199;2820 ± 1106;1,03;0,419;0,669;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1409;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;291.73±94.86 ?M;275±89.74 ?M;1,06;0,2709;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,552;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1410;;
benzylalcohol;benzylalcohol;benzylalcohol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;29160 ± 2742;29305 ± 2695;1;0,875;0,951;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1411;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2934 ± 750;3145 ± 582;0,93;0,094;0,403;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1412;;
phosphoethanolamine;phosphoethanolamine;phosphoethanolamine;–;–;–;HMDB0000224;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;294 ± 140;216 ± 94;1,36;0,004;0,093;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1413;;
methanolphosphate;methanolphosphate;methanolphosphate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;294 ± 142;302 ± 212;0,98;0,634;0,872;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1414;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;–;–;HMDB0003229;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2954 ± 3083;1678 ± 1506;1,76;0,014;0,178;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1415;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;2955 ± 1404;3510 ± 1602;0,84;0,053;0,202;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1416;;
adipic acid;adipic acid;adipic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;296 ± 111;329 ± 198;0,9;0,649;0,824;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1417;;
pipecolic acid;pipecolic acid;pipecolic acid;–;–;–;HMDB0000070;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;296 ± 242;316 ± 301;0,94;0,775;0,904;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1418;;
lysine;lysine;lysine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;29627 ± 9854;31303 ± 7216;0,95;0,186;0,541;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1419;;
5-methoxytryptamine;5-methoxytryptamine;5-methoxytryptamine;–;–;–;–;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;299 ± 272;187 ± 180;1,6;0,033;0,317;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1420;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;29959 ± 9662;30597 ± 7295;0,98;0,483;0,737;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1421;;
stachydrine;stachydrine;stachydrine;–;–;115244;HMDB04827;–;–;C10172;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;3.168055± 5.162711;2.638223± 3.759305;1,2008291187;0,3257607;0,434389878;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1422;;
3-hydroxybutyrate;3-hydroxybutyrate;3-hydroxybutyrate;(BHBA);–;441;HMDB00357;–;–;C01089;Lipid;Ketone Bodies;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;3.210772± 4.479762;1.303132± 1.82276;2,4638885393;0,000000646;0,015006832;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1423;;
erythritol;erythritol;erythritol;–;–;222285;HMDB02994;–;–;C00503;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;3.376224± 14.49139;4.091527± 32.51451;0,825174562;0,8387824;0,776328456;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1424;;
D-Erythrose;D-Erythrose;D-Erythrose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;3.4437 ± 1.6261;3.802 ± 2.1422;0,9057601262;0,51979;0,73733;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1425;;
2-piperidinone;2-piperidinone;2-piperidinone;–;–;12665;–;–;–;–;Xenobiotics;Food Component/Plant;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;positive;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;3.618559± 5.456544;2.206856± 4.584601;1,6396896762;0,0226162;0,061472279;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1426;;
3-methylhistidine;3-methylhistidine;3-methylhistidine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;3.76±2.08 ?M;3.44±1.23 ?M;1,09;0,8733;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,508;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1427;;
dihydrouracil;dihydrouracil;dihydrouracil;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;3.7831 ± 2.8928;5.8847 ± 7.2572;0,6428704947;0,19068;0,52343;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1428;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;3.8226 ± 2.6189;4.8695 ± 5.9457;0,7850087278;0,79322;0,85012;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1429;;
cholate;cholate;cholate;–;–;221493;HMDB00619;–;–;C00695;Lipid;Primary Bile Acid Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;3.924235± 9.310286;2.636918± 6.343259;1,4881900006;0,1713685;0,279826886;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1430;;
erythrose, O-methyloxime;erythrose, O-methyloxime;erythrose, O-methyloxime;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;30.264 ± 13.462;34.099 ± 19.556;0,8875333587;0,58599;0,75265;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1431;;
PC(20:3/20:4);PC(20:3/20:4);PC(20:3/20:4);–;–;–;–;–;–;–;–;–;876,5634;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;300.11 ng/mL;350.8 ng/mL;0,8555017104;0,11;0,1;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1432;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;30089 ± 7247;29876 ± 7133;1,007;0,979;0,993;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1433;;
isoleucine;isoleucine;isoleucine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;30167 ± 10618;29872 ± 8161;1,01;0,893;0,96;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1434;;
methanolphosphate;methanolphosphate;methanolphosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;302 ± 166;281 ± 165;1,08;0,709;0,861;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1435;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;30212 ± 8962;28440 ± 8545;1,06;0,537;0,75;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1436;;
isoleucine;isoleucine;isoleucine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;30237 ± 9699;26615 ± 7308;1,136;0,036;0,218;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1437;;
sucrose;sucrose;sucrose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;303 ± 862;190 ± 217;1,6;0,775;0,898;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1438;;
4-hydroxyproline;4-hydroxyproline;4-hydroxyproline;–;–;–;HMDB0000725;–;–;–;–;–;132,0655;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;303.28±107.42 ng/mL;131.24±59.38 ng/mL;7,8353623807;0,000505;–;1,33;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1439;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;30367 ± 8595;30696 ± 10252;0,989;0,883;0,96;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1440;;
cystine;cystine;cystine;–;–;–;–;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3044 ± 2748;5050 ± 2468;0,6;0;0,002;–;random forest;–;"maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=0.880 (0.805, 0.954)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.883 (0.812, 0.955)";–;–;"66.3
maltose+maltotriose+cystine=75.9";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1441;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;30547 ± 10083;33738 ± 10507;0,91;0,269;0,6;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1442;;
maltose;maltose;maltose;–;–;–;–;–;–;–;Carbohydrate;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;309 ± 262;139 ± 73;2,218;0;0,001;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1443;;
1-methylhistidine;1-methylhistidine;1-methylhistidine;–;–;–;HMDB0000001;–;–;–;–;–;170,0924;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;3102.10±695.01 ng/mL;1912.36±722.30 ng/mL;2,6944671537;0,000435;–;1,27;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1444;;
2-hydroxyhippuric acid;2-hydroxyhippuric acid;2-hydroxyhippuric acid;–;–;–;–;–;–;–;Organic Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;311 ± 1067;78 ± 40;4,01;0,063;0,33;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1445;;
pimelic acid;pimelic acid;pimelic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;311 ± 220;271 ± 304;1,148;0,426;0,735;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1446;;
lysine;lysine;lysine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;31100 ± 7470;30788 ± 6037;1,01;0,826;0,935;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1447;;
pyrophosphate;pyrophosphate;pyrophosphate;–;–;–;–;–;–;–;Other;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3115 ± 2210;1575 ± 3978;1,98;0;0,001;–;random forest;–;"0.807 (0.710, 0.904)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.670 (0.552, 0.789)";"60.5
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate=64.0";"95.4
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate=87.2";"77.9
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate=75.6";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1448;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;31166 ± 9882;22436 ± 4953;1,389;0;0,002;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1449;;
butane-2,3-diol;butane-2,3-diol;butane-2,3-diol;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3118 ± 9791;1272 ± 3586;2,45;0,36;0,658;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1450;;
PC(16:1/18:3);PC(16:1/18:3);PC(16:1/18:3);–;–;–;–;–;–;–;–;–;798,5238;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;312.25 ng/mL;295.24 ng/mL;1,0576141444;0,64;0,39;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1451;;
hippuric acid;hippuric acid;hippuric acid;–;–;–;HMDB0000714;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3156 ± 1709;1890 ± 805;1,67;0;0,01;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1452;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;–;–;HMDB0003229;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3159 ± 3435;1653 ± 1367;1,91;0,011;0,175;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1453;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;316 ± 117;328 ± 126;0,96;0,51;0,743;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1454;;
quinic acid;quinic acid;quinic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;316 ± 240;646 ± 955;0,49;0,011;0,083;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1455;;
lactamide;lactamide;lactamide;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;317 ± 154;299 ± 135;1,06;0,945;0,98;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1456;;
fucose;fucose;fucose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;317 ± 79;340 ± 75;0,93;0,128;0,356;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1457;;
threonic acid;threonic acid;threonic acid;–;–;–;HMDB0000943;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3196 ± 2751;4221 ± 2967;0,757;0,044;0,242;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1458;;
aspartate;aspartate;aspartate;–;–;–;–;–;–;–;–;–;246,5;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;32.90 ± 11.01 μmol/L;48.33 ± 27.02 μmol/L;–;0,0006;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1459;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;320 ± 147;353 ± 222;0,91;0,457;0,695;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1460;;
lactamide;lactamide;lactamide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;320 ± 184;250 ± 144;1,28;0,125;0,516;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1461;;
threitol;threitol;threitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;321 ± 249;316 ± 148;1,014;0,789;0,935;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1462;;
lignoceric acid;lignoceric acid;lignoceric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;322 ± 286;264 ± 179;1,22;0,225;0,549;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1463;;
AMP;AMP;AMP;–;–;–;–;–;–;–;–;–;348,0704;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;3240.20±1091.67 ng/mL;1211.94±319.08 ng/mL;0,0395548936;0,0000391;–;1,42;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1464;;
4-hydroxyproline;4-hydroxyproline;4-hydroxyproline;–;–;–;HMDB0000725;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3246 ± 1249;3082 ± 969;1,05;0,775;0,898;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1465;;
glucuronic acid;glucuronic acid;glucuronic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;325 ± 386;451 ± 556;0,72;0,055;0,207;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1466;;
malonic acid;malonic acid;malonic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3252 ± 8447;2194 ± 3300;1,48;0,782;0,904;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1467;;
inulobiose;inulobiose;inulobiose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;326 ± 449;257 ± 154;1,265;0,861;0,949;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1468;;
heptadecanoic acid;heptadecanoic acid;heptadecanoic acid;NIST;–;–;HMDB0002259;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;327 ± 99;399 ± 252;0,82;0,035;0,15;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1469;;
PC(16:1/20:4);PC(16:1/20:4);PC(16:1/20:4);–;–;–;–;–;–;–;–;–;824,5403;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;3293.54 ng/mL;3498.54 ng/mL;0,9414041286;0,63;0,38;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1470;;
2-ketoisocaproic acid;2-ketoisocaproic acid;2-ketoisocaproic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3305 ± 1151;3421 ± 1210;0,97;0,647;0,824;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1471;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;331 ± 112;319 ± 102;1,04;0,851;0,943;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1472;;
2-hydroxyglutaric acid;2-hydroxyglutaric acid;2-hydroxyglutaric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;332 ± 184;250 ± 92;1,33;0,004;0,091;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1473;;
gamma-tocopherol;gamma-tocopherol;gamma-tocopherol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;332 ± 235;393 ± 383;0,85;0,941;0,985;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1474;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;333 ± 100;284 ± 73;1,172;0,019;0,15;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1475;;
threitol;threitol;threitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;333 ± 305;341 ± 198;0,98;0,472;0,775;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1476;;
salicylic acid;salicylic acid;salicylic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;334 ± 705;6732 ± 25234;0,05;0,001;0,017;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1477;;
arabinose;arabinose;arabinose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;335 ± 250;329 ± 89;1,017;0,185;0,47;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1478;;
parabanic acid;parabanic acid;parabanic acid;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;336 ± 97;332 ± 102;1,011;0,958;0,99;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1479;;
paracetamol;paracetamol;paracetamol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;337 ± 684;322 ± 721;1,049;0,958;0,99;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1480;;
lignoceric acid;lignoceric acid;lignoceric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;338 ± 145;395 ± 237;0,855;0,455;0,764;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1481;;
behenic acid;behenic acid;behenic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;338 ± 215;289 ± 138;1,17;0,6;0,795;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1482;;
PC(20:4/22:1);PC(20:4/22:1);PC(20:4/22:1);–;–;–;–;–;–;–;–;–;908,6322;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;338.61 ng/mL;311.97 ng/mL;1,0853928262;0,55;0,35;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1483;;
Cit;Cit;Cit;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;34.4 ± 10.6 μM;33.2±8.3 μM;1,0361445783;0,2;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1484;;
PC(16:0/14:0);PC(16:0/14:0);PC(16:0/14:0);–;–;–;–;–;–;–;–;–;750,5466;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;34.86 ng/mL;41.39 ng/mL;0,8422324233;0,0375;0,0494;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1485;;
2-hydroxyglutaric acid;2-hydroxyglutaric acid;2-hydroxyglutaric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;342 ± 108;351 ± 165;0,98;0,915;0,961;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1486;;
PC(22:1/18:1);PC(22:1/18:1);PC(22:1/18:1);–;–;–;–;–;–;–;–;–;886,6485;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;342.73 ng/mL;351.95 ng/mL;0,973803097;0,81;0,44;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1487;;
PC(22:6/18:2);PC(22:6/18:2);PC(22:6/18:2);–;–;–;–;–;–;–;–;–;874,5652;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;343.23 ng/mL;302.29 ng/mL;1,1354328625;0,0714;0,0771;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1488;;
phenylethylamine;phenylethylamine;phenylethylamine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;344 ± 257;323 ± 171;1,07;0,47;0,775;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1489;;
maltotriose;maltotriose;maltotriose;–;–;–;–;–;–;–;Carbohydrate;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;344 ± 295;180 ± 209;1,91;0;0,007;–;random forest;–;"maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=0.880 (0.805, 0.954)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.883 (0.812, 0.955)";–;–;"71.1
maltose+maltotriose=71.7";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1490;;
glycerol-alpha-phosphate;glycerol-alpha-phosphate;glycerol-alpha-phosphate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;345 ± 165;282 ± 98;1,22;0,004;0,093;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1491;;
threitol;threitol;threitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;346 ± 272;387 ± 223;0,89;0,142;0,491;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1492;;
5-methoxytryptamine;5-methoxytryptamine;5-methoxytryptamine;–;–;–;–;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;347 ± 245;370 ± 193;0,94;0,25;0,58;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1493;;
N-acetylglutamate;N-acetylglutamate;N-acetylglutamate;–;–;–;–;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;350 ± 123;347 ± 142;1,011;0,858;0,949;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1494;;
nicotinic acid;nicotinic acid;nicotinic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;350 ± 182;265 ± 115;1,32;0,028;0,137;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1495;;
parabanic acid;parabanic acid;parabanic acid;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;352 ± 187;303 ± 122;1,16;0,301;0,582;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1496;;
methioninesulfoxide;methioninesulfoxide;methioninesulfoxide;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;353 ± 96;396 ± 128;0,892;0,119;0,367;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1497;;
adenosine-5-phosphate;adenosine-5-phosphate;adenosine-5-phosphate;–;–;–;–;–;–;–;Nucleotide;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;356 ± 1439;104 ± 156;3,41;0,707;0,861;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1498;;
isocitric acid;isocitric acid;isocitric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;358 ± 123;348 ± 116;1,03;0,766;0,904;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1499;;
3-aminoisobutyric acid;3-aminoisobutyric acid;3-aminoisobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;358 ± 217;355 ± 220;1,01;0,642;0,822;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1500;;
PC(14:0/18:2);PC(14:0/18:2);PC(14:0/18:2);–;–;–;–;–;–;–;–;–;774,5254;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;3582.98 ng/mL;4360.35 ng/mL;0,82171844;0,11;0,1;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1501;;
N-acetylglutamate;N-acetylglutamate;N-acetylglutamate;–;–;–;–;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;359 ± 133;300 ± 121;1,2;0,042;0,35;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1502;;
2-deoxyerythritol;2-deoxyerythritol;2-deoxyerythritol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;359 ± 151;456 ± 293;0,79;0,035;0,15;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1503;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;359 ± 191;461 ± 169;0,78;0,003;0,037;–;random forest;–;"maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=0.699 (0.583, 0.815)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.670 (0.552, 0.789)";"55.8
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=65.1";"76.7
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=81.4";66,3;–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1504;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;76,0393;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;359.52±138.91 ng/mL;176.19±95.98 ng/mL;4,1124553066;0,0000208;–;1,48;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1505;;
glycerol-3-galactoside;glycerol-3-galactoside;glycerol-3-galactoside;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;360 ± 379;416 ± 478;0,866;0,124;0,372;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1506;;
2-ketoisocaproic acid;2-ketoisocaproic acid;2-ketoisocaproic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3629 ± 1120;3587 ± 1005;1,01;0,951;0,985;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1507;;
PC(18:0/18:1);PC(18:0/18:1);PC(18:0/18:1);–;–;–;–;–;–;–;–;–;832,6138;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;363.14 ng/mL;350.67 ng/mL;1,0355604985;0,74;0,42;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1508;;
4-hydroxyproline;4-hydroxyproline;4-hydroxyproline;–;–;–;HMDB0000725;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3633 ± 1328;3517 ± 1388;1,033;0,575;0,853;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1509;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;365.71 ± 139.16;400.39 ± 186.85;0,9133844502;0,35551;0,68761;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1510;;
PC(18:0/20:3);PC(18:0/20:3);PC(18:0/20:3);–;–;–;–;–;–;–;–;–;856,6022;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;36541.57 ng/mL;28218.05 ng/mL;1,294971481;0,0403;0,052;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1511;;
conduritol-beta-epoxide;conduritol-beta-epoxide;conduritol-beta-epoxide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;368 ± 295;431 ± 385;0,85;0,375;0,65;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1512;;
N-acetylglutamate;N-acetylglutamate;N-acetylglutamate;–;–;–;–;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;369 ± 160;378 ± 120;0,98;0,334;0,652;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1513;;
maltose;maltose;maltose;–;–;–;–;–;–;–;Carbohydrate;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;375 ± 480;198 ± 85;1,89;0,004;0,117;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1514;;
glycerol-3-galactoside;glycerol-3-galactoside;glycerol-3-galactoside;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;376 ± 347;365 ± 252;1,03;0,672;0,878;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1515;;
PC(18:0/22:5);PC(18:0/22:5);PC(18:0/22:5);–;–;–;–;–;–;–;–;–;880,5946;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;3775.85 ng/mL;3660.31 ng/mL;1,0315656324;0,69;0,41;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1516;;
pipecolic acid;pipecolic acid;pipecolic acid;–;–;–;HMDB0000070;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;378 ± 472;569 ± 902;0,664;0,693;0,905;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1517;;
inulobiose;inulobiose;inulobiose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;379 ± 639;267 ± 162;1,42;0,651;0,878;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1518;;
gamma-tocopherol;gamma-tocopherol;gamma-tocopherol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;382 ± 220;314 ± 179;1,22;0,03;0,142;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1519;;
inulobiose;inulobiose;inulobiose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;382 ± 663;272 ± 164;1,41;0,988;0,991;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1520;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3836 ± 2605;2283 ± 1541;1,68;0,02;0,208;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1521;;
2-hydroxyvaleric acid;2-hydroxyvaleric acid;2-hydroxyvaleric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3860 ± 17791;1049 ± 498;3,678;0,565;0,852;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1522;;
cystine;cystine;cystine;–;–;–;–;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3886 ± 1676;4929 ± 1579;0,79;0,052;0,201;–;random forest;–;"maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=0.699 (0.583, 0.815)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.670 (0.552, 0.789)";"58.1
maltose+maltotriose+cystine=69.8";"79.1
maltose+maltotriose+cystine=69.8";"68.6
maltose+maltotriose+cystine=69.8";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1523;;
ribitol;ribitol;ribitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;389 ± 517;454 ± 377;0,86;0,162;0,502;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1524;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;39 ± 9;44 ± 10;0,88;0,025;0,127;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1525;;
N-methylalanine;N-methylalanine;N-methylalanine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3907 ± 2086;3846 ± 2154;1,02;0,664;0,847;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1526;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3919 ± 2555;2543 ± 1869;1,54;0,063;0,395;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1527;;
asparagine;asparagine;asparagine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;3953 ± 938;3627 ± 1064;1,09;0,105;0,416;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1528;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;135,0288;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;398.03±103.15 ng/mL;623.55±63.80 ng/mL;0,1817465647;0,00000929;–;1,57;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1529;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;398.04 ± 274.04;371.49 ± 339.18;1,0714689494;0,55826;0,73733;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1530;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;39853 ± 14977;38360 ± 11275;1,04;0,673;0,878;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1531;;
N,N-Dimethylglycine;N,N-Dimethylglycine;N,N-Dimethylglycine;–;–;–;–;–;–;–;–;–;104,0706;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;4.54±2.62 ng/mL;1.30±1.73 ng/mL;2,4283897688;0,000651;–;1,21;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1532;;
naproxen;naproxen;naproxen;–;–;156391;HMDB01923;–;–;C01517;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;LC;ESI;negative;linear ion-trap;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;4.609601± 36.5105;3.054968± 25.08379;1,5088868361;0,6743782;0,6782501;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1533;;
mannitol;mannitol;mannitol;–;–;6251;HMDB00765;–;–;C00392;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;4.640021± 18.05319;4.316093± 14.01743;1,0750512095;0,868038;0,781510038;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1534;;
L-fucose;L-fucose;L-fucose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;4.8068 ± 2.2044;5.7134 ± 4.1916;0,8413204047;0,5526;0,76992;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1535;;
D-glucose;D-glucose;D-glucose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;400.5 ± 198.36;413.3 ± 220.6;0,9690297605;0,74647;0,8487;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1536;;
pelargonic acid;pelargonic acid;pelargonic acid;–;–;–;HMDB0000847;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4021 ± 852;4085 ± 1024;0,984;0,862;0,949;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1537;;
malonic acid;malonic acid;malonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4031 ± 9788;3164 ± 4678;1,27;0,967;0,982;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1538;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;40374 ± 18318;50335 ± 20356;0,8;0,01;0,162;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1539;;
beta-alanine;beta-alanine;beta-alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;404 ± 327;340 ± 228;1,19;0,49;0,738;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1540;;
pyruvic acid;pyruvic acid;pyruvic acid;–;–;–;HMDB0000243;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4043 ± 1575;3580 ± 1341;1,13;0,677;0,878;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1541;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4070 ± 1522;3213 ± 1694;1,27;0,003;0,038;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1542;;
PC(18:1/22:6);PC(18:1/22:6);PC(18:1/22:6);–;–;–;–;–;–;–;–;–;876,5711;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;4078.03 ng/mL;4084.22 ng/mL;0,9984844107;0,99;0,49;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1543;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;132,2;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;408.80 ± 107.40 μmol/L;420.01 ± 74.52 μmol/L;–;0,4824;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1544;;
ribitol;ribitol;ribitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;409 ± 662;398 ± 287;1,03;0,127;0,516;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1545;;
maleimide;maleimide;maleimide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;411 ± 170;413 ± 205;1;0,853;0,949;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1546;;
PC(19:0/20:4);PC(19:0/20:4);PC(19:0/20:4);–;–;–;–;–;–;–;–;–;868,6016;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;411.12 ng/mL;479.23 ng/mL;0,8578761764;0,0932;0,0923;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1547;;
aspartate;aspartate;aspartate;–;–;–;–;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4110 ± 2000;2631 ± 942;1,56;0;0,032;–;random forest;–;"0.741 (0.633, 0.848)
Bin_225393+aspartate+xylose+glutamate=0.874 (0.800, 0.947)
Bin_225393+aspartate+xylose=0.864 (0.787, 0.942)";–;–;"63.8
Bin_225393+aspartate=68.1";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1548;;
salicylic acid;salicylic acid;salicylic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4114 ± 9743;677 ± 1876;6,08;0,15;0,496;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1549;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4121 ± 2227;4224 ± 2850;0,976;0,649;0,892;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1550;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;41243 ± 15012;42586 ± 15433;0,97;0,864;0,951;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1551;;
conduritol-beta-epoxide;conduritol-beta-epoxide;conduritol-beta-epoxide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;418 ± 416;320 ± 263;1,31;0,395;0,752;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1552;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;41802 ± 23022;50549 ± 23691;0,83;0,175;0,554;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1553;;
pyruvic acid;pyruvic acid;pyruvic acid;–;–;–;HMDB0000243;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;419 ± 490;228 ± 99;1,835;0,001;0,016;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1554;;
xylitol;xylitol;xylitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;419 ± 834;311 ± 273;1,35;0,856;0,949;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1555;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;42.43±13 ?M;45.51±9.94 ?M;0,93;0,0983;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,572;alanine+histidine+ornithine+isoleucine+tryptophan+valine=84.4;alanine+histidine+ornithine+isoleucine+tryptophan+valine=52.4;–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1556;;
L-valine;L-valine;L-valine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;42.645 ± 15.846;55.047 ± 29.244;0,7747016186;0,017197;0,20063;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1557;;
heptadecanoic acid;heptadecanoic acid;heptadecanoic acid;NIST;–;–;HMDB0002259;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;420 ± 266;501 ± 372;0,84;0,374;0,671;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1558;;
Ala;Ala;Ala;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;422.3 ± 97.4 μM;383.7±88.9 μM;1,1005994266;0;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1559;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;424.82±101.12 ?M;473.15±133.12 ?M;0,9;0,0166;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,62;"alanine+histidine+ornithine+isoleucine+tryptophan+valine=84.4
alanine+histidine+ornithine+glutamine+lysine+serine=82.2";"alanine+histidine+ornithine+isoleucine+tryptophan+valine=52.4
alanine+histidine+ornithine+glutamine+lysine+serine=58.7";–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1560;;
1-monoolein;1-monoolein;1-monoolein;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;426 ± 463;321 ± 298;1,33;0,286;0,577;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1561;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;42629 ± 23502;45116 ± 26006;0,95;0,961;0,982;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1562;;
fructose;fructose;fructose;–;–;–;–;–;–;–;Carbohydrate;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;42643 ± 27433;62444 ± 29947;0,683;0,003;0,042;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1563;;
heptadecanoic acid;heptadecanoic acid;heptadecanoic acid;NIST;–;–;HMDB0002259;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;429 ± 165;501 ± 217;0,856;0,057;0,265;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1564;;
glyoxalurea;glyoxalurea;glyoxalurea;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;431 ± 250;327 ± 137;1,32;0,347;0,656;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1565;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;434.61 ± 187.6;479.37 ± 308.42;0,9066274485;0,71978;0,85493;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1566;;
shikimic acid;shikimic acid;shikimic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;437 ± 914;622 ± 1121;0,7;0,345;0,734;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1567;;
NG,NG-dimethylarginine;NG,NG-dimethylarginine;NG,NG-dimethylarginine;–;–;–;–;–;–;–;–;–;203,1503;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;438.06±85.80 ng/mL;342.24±77.10 ng/mL;23,9175879782;9,6E-015;–;2,18;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1568;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;439 ± 1174;193 ± 55;2,27;0,001;0,012;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1569;;
2,3,5-trihydroxypyrazine;2,3,5-trihydroxypyrazine;2,3,5-trihydroxypyrazine;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;44 ± 18;39 ± 15;1,12;0,463;0,697;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1570;;
tagatose;tagatose;tagatose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;440 ± 249;443 ± 185;0,99;0,777;0,904;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1571;;
adenosine-5-phosphate;adenosine-5-phosphate;adenosine-5-phosphate;–;–;–;–;–;–;–;Nucleotide;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;440 ± 346;203 ± 177;2,16;0;0,002;–;random forest;–;maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.883 (0.812, 0.955);–;–;"68.7
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=75.3";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1572;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;44361 ± 19158;63501 ± 20250;0,699;0;0,001;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1573;;
sorbitol;sorbitol;sorbitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;444 ± 305;526 ± 300;0,84;0,188;0,563;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1574;;
2-hydroxyhippuric acid;2-hydroxyhippuric acid;2-hydroxyhippuric acid;–;–;–;–;–;–;–;Organic Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;446 ± 1914;68 ± 45;6,54;0,005;0,093;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1575;;
alpha ketoglutaric acid;alpha ketoglutaric acid;alpha ketoglutaric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;446 ± 285;385 ± 123;1,16;0,212;0,585;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1576;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4479 ± 3495;3871 ± 2659;1,16;0,497;0,788;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1577;;
oxoproline;oxoproline;oxoproline;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;44799 ± 14621;46504 ± 12210;0,96;0,425;0,672;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1578;;
ribose;ribose;ribose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;45 ± 16;54 ± 25;0,82;0,423;0,671;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1579;;
Asn;Asn;Asn;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;45.1 ± 8.2 μM;44.8±7.2 μM;1,0066964286;0,72;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1580;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4523 ± 3090;4172 ± 1539;1,08;0,902;0,961;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1581;;
tagatose;tagatose;tagatose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;453 ± 210;496 ± 203;0,91;0,577;0,783;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1582;;
hippuric acid;hippuric acid;hippuric acid;–;–;–;HMDB0000714;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4536 ± 2435;3213 ± 927;1,412;0,001;0,013;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1583;;
oxoproline;oxoproline;oxoproline;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;45736 ± 9536;39616 ± 8849;1,15;0,005;0,093;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1584;;
2-deoxyerythritol;2-deoxyerythritol;2-deoxyerythritol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;458 ± 209;585 ± 547;0,783;0,113;0,357;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1585;;
glycerol-alpha-phosphate;glycerol-alpha-phosphate;glycerol-alpha-phosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;459 ± 187;360 ± 72;1,27;0,009;0,161;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1586;;
Glu;Glu;Glu;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;46.7 ± 19.4 μM;45.7±19.5 μM;1,0218818381;0,6;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1587;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4608 ± 1673;3755 ± 1419;1,23;0,051;0,31;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1588;;
naproxen;naproxen;naproxen;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4609 ± 14971;7221 ± 19691;0,64;0,729;0,899;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1589;;
benzylalcohol;benzylalcohol;benzylalcohol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;46184 ± 6170;47738 ± 5585;0,967;0,234;0,524;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1590;;
levoglucosan;levoglucosan;levoglucosan;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;463 ± 466;471 ± 488;0,983;0,952;0,99;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1591;;
salicylic acid;salicylic acid;salicylic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4682 ± 11324;603 ± 1692;7,76;0,055;0,387;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1592;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;46959 ± 14628;50007 ± 13515;0,94;0,44;0,721;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1593;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;47048 ± 18468;53187 ± 15925;0,89;0,021;0,122;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1594;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;471 ± 183;632 ± 280;0,75;0;0,011;–;random forest;–;"maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=0.880 (0.805, 0.954)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.883 (0.812, 0.955)";–;–;"67.5
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=79.5";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1595;;
methanolphosphate;methanolphosphate;methanolphosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;471 ± 213;507 ± 172;0,929;0,233;0,524;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1596;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;47341 ± 20146;41933 ± 17945;1,129;0,188;0,472;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1597;;
aspartate;aspartate;aspartate;–;–;–;–;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4741 ± 2976;1524 ± 846;3,11;0;0,001;–;random forest;–;"0.855 (0.771, 0.939)
Bin_225393+aspartate+xylose+glutamate=0.820 (0.729, 0.911)
Bin_225393+aspartate+xylose=0.806 (0.711, 0.901)";"67.4
Bin_225393+aspartate=70.9";"95.4
Bin_225393+aspartate=74.4";"68.1
Bin_225393+aspartate=72.2";–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1598;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4754 ± 4626;4000 ± 3120;1,19;0,545;0,752;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1599;;
heptadecanoic acid;heptadecanoic acid;heptadecanoic acid;NIST;–;–;HMDB0002259;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;477 ± 287;527 ± 368;0,91;0,497;0,788;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1600;;
PC(19:0/18:1);PC(19:0/18:1);PC(19:0/18:1);–;–;–;–;–;–;–;–;–;846,6263;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;477.29 ng/mL;545.53 ng/mL;0,8749106374;0,0966;0,0945;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1601;;
adipic acid;adipic acid;adipic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;478 ± 418;485 ± 328;0,99;0,594;0,851;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1602;;
phenylethylamine;phenylethylamine;phenylethylamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;480 ± 212;476 ± 225;1,01;0,916;0,969;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1603;;
3-aminoisobutyric acid;3-aminoisobutyric acid;3-aminoisobutyric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;480 ± 283;435 ± 272;1,11;0,362;0,735;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1604;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;483 ± 401;367 ± 213;1,32;0,292;0,682;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1605;;
gamma-tocopherol;gamma-tocopherol;gamma-tocopherol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;489 ± 867;412 ± 321;1,19;0,63;0,814;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1606;;
asparagine;asparagine;asparagine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;49.26±11.31 ?M;46.1±8.85 ?M;1,07;0,0649;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,592;β-alanine+histidine+citrulline+asparagine+phenylalanine+aspartic acid=82.2;β-alanine+histidine+citrulline+asparagine+phenylalanine+aspartic acid=69.8;–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1607;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;49.37±16.47 ?M;47.31±13.46 ?M;1,04;0,4287;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,538;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1608;;
asparagine;asparagine;asparagine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;4911 ± 1211;4487 ± 1068;1,094;0,101;0,336;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1609;;
arginine;arginine;arginine;–;–;–;HMDB0000517;–;–;–;–;–;175,119;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;495.84±146.08 ng/mL;346.18±93.95 ng/mL;2,6758551096;0,0000863;–;1,36;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1610;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;4971.8 ± 1409.7;4627.3 ± 1790;1,074449463;0,53309;0,73733;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1611;;
levoglucosan;levoglucosan;levoglucosan;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;498 ± 608;499 ± 542;1;0,616;0,807;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1612;;
glycerol-3-galactoside;glycerol-3-galactoside;glycerol-3-galactoside;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;499 ± 166;489 ± 155;1,02;0,573;0,788;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1613;;
2-deoxyerythritol;2-deoxyerythritol;2-deoxyerythritol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;499 ± 609;414 ± 328;1,21;0,725;0,899;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1614;;
D-mannose;D-mannose;D-mannose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;5.0944 ± 3.0151;5.6794 ± 4.2151;0,8969961616;0,77978;0,8487;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1615;;
N-acetyl-L-lysine;N-acetyl-L-lysine;N-acetyl-L-lysine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;5.1715 ± 2.4718;6.3036 ± 3.5657;0,8204042135;0,17085;0,50893;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1616;;
choline;choline;choline;–;–;–;HMDB0000097;–;–;–;–;–;105,1148;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;5.34±1.52 ng/mL;2.28±1.43 ng/mL;5,9380942825;2,34E-014;–;2,11;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1617;;
α-hydroxybutyric acid;α-hydroxybutyric acid;α-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;5.4432 ± 1.9203;8.5115 ± 8.1791;0,6395112495;0,39668;0,67727;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1618;;
total ceramides;total ceramides;total ceramides;–;–;–;–;–;–;–;–;–;–;plasma;prediagnosis;lung cancer;–;100;54, 46;63,9;former, current, non-smoker;healthy;200;108, 92;63,7;former, current, non-smoker;LC;ESI;–;–;MS/MS;–;–;SAS;–;5.48 uM;5.21 uM;1,0518234165;0,021;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;23749868;Alberg et al. 2013;1619;;
2-propylpentanoate;2-propylpentanoate;2-propylpentanoate; (valproate);–;3121;HMDB01877;–;–;C07185;Xenobiotics;Drug;–;serum;–;adenocarcinoma, squamous cell carcinoma;I, II, III;94;55.3%, 44.7%;68,7;–;at-risk controls ;190;50.5%, 49.5%;66,2;–;GC;EI;–;quadrupole;MS/MS; Metabolon LIMS system; Metabolon LIMS system; Metabolon Inc.;two- sample independent t test ;5.6850606± 50.580659;0.4312479± 0.2322498;13,182813412;0,1520951;0,254153567;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;26762741;Mazzone et al. 2016;1620;;
2-deoxy-erythro-pentonic acid;2-deoxy-erythro-pentonic acid;2-deoxy-erythro-pentonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;5.9952 ± 3.0547;6.5688 ± 3.8418;0,9126781147;0,61026;0,76283;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1621;;
α-tocopherol;α-tocopherol;α-tocopherol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;5.9955 ± 2.8545;7.8236 ± 3.9278;0,766335191;0,031829;0,24145;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1622;;
naproxen;naproxen;naproxen;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;501 ± 2804;1476 ± 3890;0,34;0,022;0,122;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1623;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;502.11±103.48 ?M;489.72±98.95 ?M;1,03;0,4594;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,537;alanine+histidine+ornithine+glutamine+lysine+serine=82.2;alanine+histidine+ornithine+glutamine+lysine+serine=58.7;–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1624;;
PC(22:1/18:2);PC(22:1/18:2);PC(22:1/18:2);–;–;–;–;–;–;–;–;–;884,6233;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;502.72 ng/mL;445.59 ng/mL;1,1282120335;0,0938;0,0221;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1625;;
1,2,4,5-tetramethylbenzene;1,2,4,5-tetramethylbenzene;1,2,4,5-tetramethylbenzene;–;–;–;–;–;–;–;–;–;–;pleural effusion;diagnosis;NSCLC, SCLC;–;20;16, 4;73 (53-85);–;tuberculous pleurisy, pneumonia;20;14, 6;63.6 (44-86);–;GC;EI;positive;single quad;–;–;NIST02 library ; SPSS ;Student's t-test, corrected t-test;50200 ± 50300;6500 ± 5400;7,7;0,005;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;24321761;Liu et al. 2014;1626;;
aspartate;aspartate;aspartate;–;–;–;–;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;503 ± 162;478 ± 768;1,05;0,003;0,038;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1627;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;507 ± 187;516 ± 169;0,98;0,587;0,789;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1628;;
2-hydroxyhippuric acid;2-hydroxyhippuric acid;2-hydroxyhippuric acid;–;–;–;–;–;–;–;Organic Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;51 ± 34;76 ± 87;0,67;0,031;0,142;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1629;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;51087 ± 12154;51041 ± 11967;1;0,91;0,969;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1630;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;512 ± 231;558 ± 167;0,92;0,128;0,516;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1631;;
PC(15:0/22:6);PC(15:0/22:6);PC(15:0/22:6);–;–;–;–;–;–;–;–;–;836,5401;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;512.71 ng/mL;734.49 ng/mL;0,6980489864;0,0004;0,00363;–;ROC curve;–;"0.243 (0.121–0.365),
combination of down-regulated PCs: 0.897 (0.818–0.975),
combination of 12 altered PCs: 1.000 (1.000–1.000) ";"53.5,
combination of down-regulated PCs: 90.0,
combination of 12 altered PCs: 100";"90,
combination of down-regulated PCs: 76.7,
combination of 12 altered PCs: 100";–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;1632;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;517 ± 998;218 ± 73;2,37;0,211;0,543;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1633;;
PC(18:0/20:1);PC(18:0/20:1);PC(18:0/20:1);–;–;–;–;–;–;–;–;–;860,6344;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;518.4 ng/mL;347.2 ng/mL;1,4930875576;0,00196;0,0328;–;ROC curve;–;"0.691 (0.556–0.826),
combination of up-regulated PCs: 0.811 (0.703–0.919),
 combination of 12 altered PCs: 1.000 (1.000–1.000) ";"66.7,
combination of up-regulated PCs: 76.7,
combination of 12 altered PCs: 100";"70,
combination of up-regulated PCs: 70.0,
combination of 12 altered PCs: 100";–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;1634;;
azelaic acid;azelaic acid;azelaic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;520 ± 365;616 ± 1226;0,843;0,828;0,935;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1635;;
levoglucosan;levoglucosan;levoglucosan;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;521 ± 693;444 ± 511;1,17;0,824;0,926;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1636;;
hydroxylamine;hydroxylamine;hydroxylamine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;522 ± 168;529 ± 150;0,99;0,742;0,894;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1637;;
PC(26:2/8:0);PC(26:2/8:0);PC(26:2/8:0);–;–;–;–;–;–;–;–;–;802,555;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;522.14 ng/mL;591.42 ng/mL;0,8828582057;0,59;0,37;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1638;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;5227 ± 3688;7350 ± 3212;0,71;0,002;0,072;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1639;;
isocitric acid;isocitric acid;isocitric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;523 ± 252;456 ± 113;1,15;0,366;0,735;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1640;;
xylitol;xylitol;xylitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;526 ± 1092;350 ± 287;1,5;0,683;0,854;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1641;;
PC(22:6/17:0);PC(22:6/17:0);PC(22:6/17:0);–;–;–;–;–;–;–;–;–;864,5683;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;529.87 ng/mL;647.27 ng/mL;0,8186228313;0,12;0,11;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1642;;
2,3,5-trihydroxypyrazine;2,3,5-trihydroxypyrazine;2,3,5-trihydroxypyrazine;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;53 ± 13;55 ± 16;0,971;0,775;0,935;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1643;;
azelaic acid;azelaic acid;azelaic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;53 ± 15;49 ± 16;1,09;0,284;0,576;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1644;;
sphingosine;sphingosine;sphingosine;–;–;–;HMDB0000252;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;healthy;30;11, 19;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P+ software, SPSS;independent t-test ;53.33 ± 35.95;139.60 ± 38.75;0,3820200573;0,001;–;–;ROC curve analysis;102,76;0.957 (0.894-1.019);90;96,67;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1645;;
sphingosine;sphingosine;sphingosine;–;–;–;HMDB0000252;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;before vs. after treatment (operation);30;9, 21;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P+ software, SPSS;independent t-test ;53.33 ± 35.95;141.78 ± 42.42;0,3761461419;0,001;–;–;ROC curve analysis;86,48;0.966 (0.911);96,67;90;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1646;;
L-glycine;L-glycine;L-glycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;53.529 ± 41.399;67.121 ± 39.885;0,7975000372;0,0088345;0,12368;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1647;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;53193 ± 12343;54802 ± 13674;0,97;0,87;0,951;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1648;;
conduritol-beta-epoxide;conduritol-beta-epoxide;conduritol-beta-epoxide;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;533 ± 544;382 ± 309;1,39;0,293;0,621;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1649;;
sorbitol;sorbitol;sorbitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;534 ± 324;542 ± 303;0,98;0,878;0,953;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1650;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;535 ± 312;610 ± 440;0,877;0,307;0,608;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1651;;
mannitol;mannitol;mannitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;5356 ± 9749;5853 ± 8149;0,92;0,105;0,316;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1652;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;5390 ± 2704;5470 ± 2457;0,99;0,822;0,937;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1653;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;5391 ± 11319;5154 ± 2591;1,05;0,014;0,179;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1654;;
naproxen;naproxen;naproxen;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;5404 ± 16325;7352 ± 20502;0,74;0,628;0,814;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1655;;
glucose;glucose;glucose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;54600 ± 24166;60898 ± 22497;0,9;0,062;0,222;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1656;;
xylose;xylose;xylose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;549 ± 386;637 ± 573;0,86;0,301;0,582;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1657;;
PC(15:0/20:4);PC(15:0/20:4);PC(15:0/20:4);–;–;–;–;–;–;–;–;–;812,5283;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;55.07 ng/mL;42.68 ng/mL;1,2902999063;0,0581;0,0664;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1658;;
2-hydroxyglutaric acid;2-hydroxyglutaric acid;2-hydroxyglutaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;552 ± 292;447 ± 166;1,23;0,156;0,496;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1659;;
3-hydroxybutanoic acid;3-hydroxybutanoic acid;3-hydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;5559 ± 5925;4093 ± 5107;1,36;0,173;0,425;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1660;;
gamma-tocopherol;gamma-tocopherol;gamma-tocopherol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;556 ± 304;463 ± 286;1,199;0,028;0,188;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1661;;
α-hydroxyisobutyric acid;α-hydroxyisobutyric acid;α-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;healthy;30;11, 19;60.35 ± 12.48;–;GC;–;–;–;–;GC/MSD ChemStation software (Agilent Technologies);NIST;SIMCA-P+ software, SPSS;independent t-test ;556.54 ± 220.00;306.84 ± 153.64;1,8137791683;0,001;–;–;ROC curve analysis;365,23;0.86 (0.764-0.956);80;80;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1662;;
α-hydroxyisobutyric acid;α-hydroxyisobutyric acid;α-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;before vs. after treatment (operation);30;9, 21;61.58 ± 10.67;–;GC;–;–;–;–;GC/MSD ChemStation software (Agilent Technologies);NIST;SIMCA-P+ software, SPSS;independent t-test ;556.54 ± 220.00;803.58 ± 329.41;0,6925757236;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1663;;
dihydro-3-coumaric acid;dihydro-3-coumaric acid;dihydro-3-coumaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;558 ± 257;556 ± 205;1,004;0,849;0,949;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1664;;
salicylic acid;salicylic acid;salicylic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;559 ± 1208;13388 ± 45101;0,042;0,002;0,023;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1665;;
L-proline;L-proline;L-proline;–;–;–;HMDB0000162;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;56.388 ± 23.616;72.431 ± 35.646;0,7785064406;0,027879;0,24145;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1666;;
octanoic acid;octanoic acid;octanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;560.9 ± 207.11;609.3 ± 256.11;0,9205645823;0,48339;0,76237;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1667;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;561 ± 177;601 ± 159;0,934;0,245;0,543;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1668;;
PC(22:6/15:0);PC(22:6/15:0);PC(22:6/15:0);–;–;–;–;–;–;–;–;–;836,5329;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;561.26 ng/mL;413.09 ng/mL;1,3586869689;0,2;0,17;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1669;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;56451 ± 41418;51016 ± 38967;1,11;0,209;0,585;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1670;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;566 ± 249;489 ± 160;1,16;0,268;0,653;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1671;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;568 ± 266;652 ± 186;0,87;0,03;0,258;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1672;;
tagatose;tagatose;tagatose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;569 ± 285;753 ± 356;0,76;0,005;0,042;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1673;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;Nucleotide;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;57 ± 16;49 ± 12;1,17;0,024;0,127;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1674;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;57 ± 24;66 ± 22;0,87;0,02;0,222;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1675;;
phenylethylamine;phenylethylamine;phenylethylamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;572 ± 270;661 ± 520;0,865;0,581;0,857;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1676;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;574.66 ± 560.22;486.81 ± 397.39;1,1804605493;0,24283;0,57621;–;ROC curve;–;–;combination of nine metabolites: 100;combination of nine metabolites: 86;–;–;–;–;–;–;Poland;Y;–;28803255;Ro?-Mazurczyk et al. 2017;1677;;
PC(16:0/22:6);PC(16:0/22:6);PC(16:0/22:6);–;–;–;–;–;–;–;–;–;850,5558;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;57560.48 ng/mL;66739.77 ng/mL;0,8624614679;0,035;0,0475;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1678;;
quinic acid;quinic acid;quinic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;576 ± 516;629 ± 561;0,92;0,768;0,904;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1679;;
PC(18:0/20:4);PC(18:0/20:4);PC(18:0/20:4);–;–;–;–;–;–;–;–;–;854,5875;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;57760.34 ng/mL;60476.63 ng/mL;0,9550852949;0,63;0,38;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1680;;
galactose-6-phosphate;galactose-6-phosphate;galactose-6-phosphate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;58 ± 23;61 ± 24;0,95;0,743;0,904;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1681;;
Gln;Gln;Gln;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;580.5 ± 93.3 μM;587.9±83.5 μM;0,9874128253;0,4;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1682;;
PC(17:0/18:2);PC(17:0/18:2);PC(17:0/18:2);–;–;–;–;–;–;–;–;–;816,5711;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;5810.28 ng/mL;7593.07 ng/mL;0,7652082754;0,000572;0,00436;–;ROC curve;–;"0.25 (0.125–0.375),
combination of down-regulated PCs: 0.897 (0.818–0.975),
combination of 12 altered PCs: 1.000 (1.000–1.000) ";"70,
combination of down-regulated PCs: 90.0,
combination of 12 altered PCs: 100";"73.3,
combination of down-regulated PCs: 76.7,
combination of 12 altered PCs: 100";–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;1683;;
caprylic acid;caprylic acid;caprylic acid;–;–;–;HMDB0000482;–;–;–;Lipid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;584 ± 256;735 ± 244;0,8;0,005;0,117;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1684;;
isothreonic acid;isothreonic acid;isothreonic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;584 ± 339;720 ± 347;0,81;0,007;0,055;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1685;;
pelargonic acid;pelargonic acid;pelargonic acid;–;–;–;HMDB0000847;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;5862 ± 2565;6482 ± 2041;0,9;0,084;0,472;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1686;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;587 ± 901;632 ± 558;0,93;0,216;0,487;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1687;;
trp;trp;trp;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;59.3 ± 12 μM;59.8±10.9 μM;0,991638796;0,67;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1688;;
PC(14:0/22:6);PC(14:0/22:6);PC(14:0/22:6);–;–;–;–;–;–;–;–;–;822,5243;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;594.49 ng/mL;667 ng/mL;0,8912893553;0,3;0,23;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1689;;
fucose;fucose;fucose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;595 ± 254;592 ± 103;1,004;0,41;0,72;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1690;;
fucose;fucose;fucose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;597 ± 335;584 ± 406;1,02;0,487;0,781;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1691;;
L-phenylalanine;L-phenylalanine;L-phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;6.3446 ± 2.6528;7.1747 ± 4.454;0,8843017827;0,7028;0,81993;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1692;;
L-threonine;L-threonine;L-threonine;–;–;–;HMDB0000167;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;6.5654 ± 3.2932;7.5102 ± 3.5181;0,8741977577;0,10599;0,41219;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1693;;
oxoproline;oxoproline;oxoproline;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;60393 ± 13891;56530 ± 11065;1,07;0,2;0,543;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1694;;
azelaic acid;azelaic acid;azelaic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;604 ± 1056;236 ± 134;2,56;0,008;0,146;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1695;;
isothreonic acid;isothreonic acid;isothreonic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;604 ± 803;525 ± 146;1,15;0,761;0,904;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1696;;
trans-4-hydroxyproline;trans-4-hydroxyproline;trans-4-hydroxyproline;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;605 ± 490;576 ± 379;1,05;0,674;0,847;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1697;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;healthy;30;11, 19;60.35 ± 12.48;–;GC;–;–;–;–;GC/MSD ChemStation software (Agilent Technologies);NIST;SIMCA-P+ software, SPSS;independent t-test ;605.66 ± 361.44;244.99 ± 131.32;2,4721825381;0,001;–;–;ROC curve analysis;402,22;0.749 (0.614-0.884);70;86,67;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1698;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;before vs. after treatment (operation);30;9, 21;61.58 ± 10.67;–;GC;–;–;–;–;GC/MSD ChemStation software (Agilent Technologies);NIST;SIMCA-P+ software, SPSS;independent t-test ;605.66 ± 361.44;346.58 ± 164.66;1,7475330371;0,001;–;–;ROC curve analysis;489,02;0.694 (0.550–0.838);60;80;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1699;;
quinic acid;quinic acid;quinic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;606 ± 550;724 ± 638;0,84;0,532;0,747;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1700;;
PC(17:0/22:5);PC(17:0/22:5);PC(17:0/22:5);–;–;–;–;–;–;–;–;–;866,5877;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;607.42 ng/mL;627.51 ng/mL;0,967984574;0,69;0,41;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1701;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;61 ± 25;111 ± 197;0,55;0,13;0,516;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1702;;
PC(18:0/20:2);PC(18:0/20:2);PC(18:0/20:2);–;–;–;–;–;–;–;–;–;858,6184;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;6103.35 ng/mL;4748.18 ng/mL;1,2854083038;0,0451;0,0561;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1703;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;6119 ± 3068;5707 ± 2562;1,072;0,753;0,932;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1704;;
2-deoxyerythritol;2-deoxyerythritol;2-deoxyerythritol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;615 ± 846;455 ± 316;1,35;0,85;0,943;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1705;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;62.5±18.5 ?M;56.39±10.03 ?M;1,11;0,0094;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,596;β-alanine+histidine+citrulline+asparagine+phenylalanine+aspartic acid=82.2;β-alanine+histidine+citrulline+asparagine+phenylalanine+aspartic acid=69.8;–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1706;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;629 ± 211;568 ± 199;1,11;0,197;0,573;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1707;;
erythritol;erythritol;erythritol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;629 ± 886;407 ± 156;1,55;0,609;0,813;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1708;;
glutaric acid;glutaric acid;glutaric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;63 ± 38;69 ± 25;0,91;0,09;0,281;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1709;;
1-monostearin;1-monostearin;1-monostearin;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;63 ± 54;67 ± 29;0,93;0,056;0,387;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1710;;
cystine;cystine;cystine;–;–;–;–;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;6358 ± 2545;8312 ± 2735;0,77;0,001;0,091;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1711;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;6388 ± 2461;4183 ± 1343;1,527;0;0,001;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1712;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;639 ± 167;672 ± 219;0,95;0,838;0,945;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1713;;
galactose-6-phosphate;galactose-6-phosphate;galactose-6-phosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;64 ± 29;67 ± 25;0,95;0,61;0,804;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1714;;
isothreonic acid;isothreonic acid;isothreonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;640 ± 716;592 ± 162;1,08;0,514;0,744;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1715;;
adipic acid;adipic acid;adipic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;644 ± 274;815 ± 797;0,79;0,065;0,283;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1716;;
dihydro-3-coumaric acid;dihydro-3-coumaric acid;dihydro-3-coumaric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;644 ± 612;686 ± 733;0,94;0,759;0,904;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1717;;
inosine 5'-monophosphate;inosine 5'-monophosphate;inosine 5'-monophosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;65 ± 26;65 ± 19;1;0,805;0,92;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1718;;
isoleucine;isoleucine;isoleucine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;65.77±19.8 ?M;66.11±15.1 ?M;0,99;0,397;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,54;alanine+histidine+ornithine+isoleucine+tryptophan+valine=84.4;alanine+histidine+ornithine+isoleucine+tryptophan+valine=52.4;–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1719;;
PC(18:0/22:4);PC(18:0/22:4);PC(18:0/22:4);–;–;–;–;–;–;–;–;–;882,6166;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;653.71 ng/mL;652.32 ng/mL;1,002130856;0,98;0,49;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1720;;
caprylic acid;caprylic acid;caprylic acid;–;–;–;HMDB0000482;–;–;–;Lipid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;656 ± 202;682 ± 213;0,96;0,562;0,834;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1721;;
1-monopalmitin;1-monopalmitin;1-monopalmitin;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;66 ± 21;78 ± 30;0,85;0,125;0,356;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1722;;
phenylacetic acid;phenylacetic acid;phenylacetic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;66 ± 26;81 ± 37;0,82;0,011;0,084;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1723;;
1,5-anhydroglucitol;1,5-anhydroglucitol;1,5-anhydroglucitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;6630 ± 3591;8125 ± 3432;0,82;0,017;0,102;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1724;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;66390 ± 14748;65904 ± 19652;1,01;0,711;0,869;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1725;;
nicotinic acid;nicotinic acid;nicotinic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;67 ± 17;71 ± 15;0,949;0,294;0,599;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1726;;
erythrose;erythrose;erythrose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;67 ± 24;80 ± 26;0,84;0,017;0,102;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1727;;
stigmasterol;stigmasterol;stigmasterol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;67 ± 27;90 ± 42;0,74;0,002;0,092;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1728;;
trihydroxypyrazine;trihydroxypyrazine;trihydroxypyrazine;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;67 ± 28;75 ± 36;0,9;0,339;0,652;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1729;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;67.28±19.93 ?M;66.45±14.02 ?M;1,01;0,9616;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,502;"alanine+histidine+ornithine+isoleucine+tryptophan+valine=84.4
alanine+histidine+ornithine+glutamine+lysine+serine=82.2
β-alanine+histidine+citrulline+asparagine+phenylalanine+aspartic acid=82.2";"alanine+histidine+ornithine+isoleucine+tryptophan+valine=52.4
alanine+histidine+ornithine+glutamine+lysine+serine=58.7
β-alanine+histidine+citrulline+asparagine+phenylalanine+aspartic acid=69.8
";–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1730;;
Orn;Orn;Orn;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;67.6 ± 19.7 μM;54.4±12.3 μM;1,2426470588;0,001;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1731;;
Phe;Phe;Phe;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;67.9 ± 12.2 μM;63.9±11.2 μM;1,0625978091;0,001;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1732;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;6703 ± 3653;8239 ± 3295;0,814;0,057;0,265;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1733;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;67220 ± 21747;73742 ± 30099;0,91;0,46;0,695;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1734;;
nicotinic acid;nicotinic acid;nicotinic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;674 ± 352;551 ± 372;1,22;0,127;0,516;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1735;;
glucuronic acid;glucuronic acid;glucuronic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;679 ± 1044;918 ± 1182;0,739;0,09;0,325;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1736;;
lathosterol;lathosterol;lathosterol;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;68 ± 28;63 ± 21;1,08;0,601;0,856;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1737;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;681 ± 266;632 ± 191;1,08;0,363;0,633;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1738;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;6844 ± 6424;5806 ± 2145;1,18;0,665;0,878;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1739;;
parabanic acid;parabanic acid;parabanic acid;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;699 ± 378;569 ± 349;1,23;0,155;0,529;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1740;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;7.475 ± 3.8499;9.7114 ± 6.9109;0,7697139444;0,17959;0,51312;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1741;;
1-methylhistidine;1-methylhistidine;1-methylhistidine;–;–;–;HMDB0000001;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;7±5.85 ?M;8.19±7.61 ?M;0,85;0,7583;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,515;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1742;;
2,3,5-trihydroxypyrazine;2,3,5-trihydroxypyrazine;2,3,5-trihydroxypyrazine;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;70 ± 29;69 ± 25;1,02;0,912;0,969;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1743;;
glycerol-alpha-phosphate;glycerol-alpha-phosphate;glycerol-alpha-phosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;7022 ± 3909;8509 ± 3305;0,825;0,086;0,324;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1744;;
maltose;maltose;maltose;–;–;–;–;–;–;–;Carbohydrate;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;704 ± 718;326 ± 302;2,16;0;0,015;–;random forest;–;"0.741 (0.629, 0.853)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline=0.880 (0.805, 0.954)
maltose+maltotriose+cystine+3-Phosphoglycerate+citrulline+pyrophosphate+tryptophan+adenosine-5-Phosphate=0.883 (0.812, 0.955)";–;–;72,3;–;–;–;–;–;US;Y;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1745;;
acetophenone;acetophenone;acetophenone;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;709 ± 188;714 ± 175;0,99;0,672;0,847;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1746;;
PC(15:1/4:0);PC(15:1/4:0);PC(15:1/4:0);–;–;–;–;–;–;–;–;–;594,3375;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;71.83 ng/mL;101.28 ng/mL;0,7092219589;0,0128;0,0252;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1747;;
prasterone sulfate;prasterone sulfate;prasterone sulfate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;healthy;30;11, 19;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P+ software, SPSS;independent t-test ;71.99 ± 38.72;106.80 ± 31.70;0,6740636704;0,001;–;–;ROC curve analysis;91,07;0.787 (0.670-0.905);76,67;80;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1748;;
prasterone sulfate;prasterone sulfate;prasterone sulfate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma;I, II, III;30;9, 21;61.58 ± 10.67;–;before vs. after treatment (operation);30;9, 21;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P+ software, SPSS;independent t-test ;71.99 ± 38.72;50.93 ± 22.26;1,4135087375;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;CEA, CYFRA21-1;25961003;Chen et al. 2015a;1749;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;7102 ± 3398;5700 ± 1876;1,25;0,016;0,186;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1750;;
mannitol;mannitol;mannitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;7108 ± 9392;10548 ± 12205;0,67;0,087;0,472;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1751;;
cysteine;cysteine;cysteine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;714 ± 337;790 ± 398;0,9;0,356;0,633;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1752;;
fucose;fucose;fucose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;714 ± 462;699 ± 500;1,02;0,653;0,826;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1753;;
pelargonic acid;pelargonic acid;pelargonic acid;–;–;–;HMDB0000847;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;7180 ± 2842;7793 ± 2601;0,92;0,213;0,543;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1754;;
allantoic acid;allantoic acid;allantoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;72 ± 35;90 ± 43;0,8;0,041;0,3;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1755;;
2-hydroxybutyric acid;2-hydroxybutyric acid;2-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 ± 6.9;smoker, non-smoker, unknown;healthy;62;40, 22;62 ± 8.8;smoker, non-smoker, unknown;LC;ESI;negative;triple quadrupole;MS/MS;Analyst software;–;–;Mann-Whitney U test;72.43 ± 33.38 μmol/l;58.99 ± 33.39 μmol/l;1,2278352263;0,00283;–;–;ROC curve analysis ;–;0,643;–;–;–;–;–;–;–;–;Poland;Y;–;27454081;Klupczynska et al. 2016b;1756;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;72125 ± 22812;78639 ± 25158;0,92;0,266;0,598;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1757;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;7223 ± 1694;7220 ± 1722;1;0,936;0,974;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1758;;
lathosterol;lathosterol;lathosterol;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;73 ± 31;77 ± 29;0,95;0,583;0,787;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1759;;
2-oxogluconic acid;2-oxogluconic acid;2-oxogluconic acid;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;73 ± 45;75 ± 28;0,96;0,147;0,529;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1760;;
5-methylcytidine;5-methylcytidine;5-methylcytidine;–;–;–;–;–;–;–;–;–;258,1084;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;73.17±33.40 ng/mL;103.46±35.56 ng/mL;0,3486859166;0,000501;–;1,33;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1761;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;7313 ± 5422;6813 ± 2243;1,07;0,599;0,795;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1762;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;73197 ± 42989;72058 ± 34188;1,016;0,984;0,993;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1763;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;733 ± 340;860 ± 278;0,851;0,02;0,157;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1764;;
erythritol;erythritol;erythritol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;734 ± 631;3882 ± 12616;0,19;0,11;0,51;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1765;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;–;–;176,103;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;735.70±238.92 ng/mL;394.84±95.35 ng/mL;2,3949574092;0,031;–;1,01;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1766;;
1-methyladenosine;1-methyladenosine;1-methyladenosine;–;–;–;–;–;–;–;–;–;282,1197;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;7396.10±1303.52 ng/mL;5521.85±792.75 ng/mL;0,3368083942;4,41E-010;–;1,99;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1767;;
allantoic acid;allantoic acid;allantoic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;74 ± 34;75 ± 35;1;0,983;0,989;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1768;;
PC(22:5/20:4);PC(22:5/20:4);PC(22:5/20:4);–;–;–;–;–;–;–;–;–;900,5603;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;74.62 ng/mL;90.12 ng/mL;0,8280071016;0,3;0,23;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1769;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;74293 ± 15808;84288 ± 15250;0,881;0,006;0,065;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1770;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;7460 ± 8207;7184 ± 1864;1,038;0,113;0,357;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1771;;
trans-4-hydroxyproline;trans-4-hydroxyproline;trans-4-hydroxyproline;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;749 ± 422;857 ± 539;0,88;0,398;0,755;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1772;;
2,3,5-trihydroxypyrazine;2,3,5-trihydroxypyrazine;2,3,5-trihydroxypyrazine;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;75 ± 34;68 ± 24;1,12;0,423;0,768;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1773;;
rhamnose;rhamnose;rhamnose;–;–;–;HMDB0000849;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;753 ± 325;728 ± 276;1,04;0,939;0,974;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1774;;
methioninesulfoxide;methioninesulfoxide;methioninesulfoxide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;758 ± 380;679 ± 285;1,12;0,454;0,773;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1775;;
glutamate;glutamate;glutamate;–;–;–;–;–;–;–;–;–;260,2;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;76.50 ± 21.56 μmol/L;87.55 ± 27.25 μmol/L;–;0,0234;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1776;;
2-deoxytetronic acid;2-deoxytetronic acid;2-deoxytetronic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;762 ± 395;711 ± 310;1,07;0,953;0,974;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1777;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;76204 ± 21657;81099 ± 18314;0,94;0,219;0,589;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1778;;
glucuronic acid;glucuronic acid;glucuronic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;764 ± 1740;487 ± 406;1,57;0,683;0,879;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1779;;
PC(16:0/20:4);PC(16:0/20:4);PC(16:0/20:4);–;–;–;–;–;–;–;–;–;826,5568;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;76576.82 ng/mL;72744.63 ng/mL;1,0526800398;0,62;0,38;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1780;;
glucuronic acid;glucuronic acid;glucuronic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;766 ± 1434;583 ± 390;1,31;0,894;0,96;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1781;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;77 ± 33;79 ± 28;0,97;0,458;0,731;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1782;;
His;His;His;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;77.3 ± 15 μM;80.8±10.7 μM;0,9566831683;0,01;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1783;;
N-methylalanine;N-methylalanine;N-methylalanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;7718 ± 3597;7000 ± 3120;1,103;0,263;0,568;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1784;;
pyrophosphate;pyrophosphate;pyrophosphate;–;–;–;–;–;–;–;Other;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;774 ± 262;852 ± 341;0,908;0,227;0,524;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1785;;
PC(16:0/16:1);PC(16:0/16:1);PC(16:0/16:1);–;–;–;–;–;–;–;–;–;776,5478;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;774.49 ng/mL;944.72 ng/mL;0,8198090439;0,0592;0,0406;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1786;;
capric acid;capric acid;capric acid;–;–;–;HMDB0000511;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;777 ± 159;752 ± 100;1,03;0,437;0,684;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1787;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;78558 ± 20494;78169 ± 23916;1,01;0,855;0,949;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1788;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;789 ± 521;753 ± 315;1,05;0,426;0,768;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1789;;
2-hydroxyhippuric acid;2-hydroxyhippuric acid;2-hydroxyhippuric acid;–;–;–;–;–;–;–;Organic Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;79 ± 26;127 ± 151;0,617;0,043;0,242;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1790;;
stigmasterol;stigmasterol;stigmasterol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;79 ± 32;70 ± 24;1,12;0,358;0,735;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1791;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;Nucleotide;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;79 ± 37;69 ± 32;1,16;0,132;0,516;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1792;;
carbodiimide;carbodiimide;carbodiimide;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;792.53 ± 452.25;928.08 ± 594.15;0,8539457805;0,33502;0,65093;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1793;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 ± 6.9;smoker, non-smoker, unknown;healthy;62;40, 22;62 ± 8.8;smoker, non-smoker, unknown;LC;ESI;negative;triple quadrupole;MS/MS;Analyst software;–;–;Mann-Whitney U test;8.52 ± 2.23 μmol/l;8.9 ± 2.04 μmol/l;0,9573033708;0,17954;–;–;ROC curve analysis ;–;0,564;–;–;–;–;–;–;–;–;Poland;Y;–;27454081;Klupczynska et al. 2016b;1794;;
C2-carnitine;C2-carnitine;C2-carnitine;–;–;–;–;–;–;–;–;–;260,3;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;8.52 ± 4.70 μmol/L;8.76 ± 2.94 μmol/L;–;0,714;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1795;;
L-glutamine;L-glutamine;L-glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;8.8609 ± 3.7115;11.28 ± 7.2898;0,7855407801;0,11645;0,42688;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1796;;
tyr;tyr;tyr;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;80.7 ± 15.6 μM;75.8±15.5 μM;1,0646437995;0,001;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1797;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;80.81±36.92 ?M;72.48±40.75 ?M;1,11;0,0761;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,584;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1798;;
naproxen;naproxen;naproxen;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;802 ± 4411;2610 ± 7032;0,307;0,054;0,265;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1799;;
5’-methylthioadenosine;5’-methylthioadenosine;5’-methylthioadenosine;–;–;–;–;–;–;–;–;–;298,0969;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;802.62±172.27 ng/mL;311.79±67.04 ng/mL;0,3035487211;0,00546;–;1,06;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1800;;
oxoproline;oxoproline;oxoproline;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;80594 ± 21724;83104 ± 16481;0,97;0,386;0,694;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1801;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;807 ± 354;602 ± 238;1,34;0,005;0,117;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1802;;
glucose;glucose;glucose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;80945 ± 29796;91479 ± 31954;0,885;0,022;0,162;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1803;;
ribose;ribose;ribose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;81 ± 49;89 ± 42;0,905;0,212;0,51;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1804;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;81336 ± 27041;84265 ± 30211;0,97;0,845;0,943;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1805;;
N-methylalanine;N-methylalanine;N-methylalanine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;8152 ± 3810;7687 ± 3958;1,06;0,505;0,789;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1806;;
threose;threose;threose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;82 ± 23;94 ± 23;0,88;0,006;0,049;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1807;;
alpha ketoglutaric acid;alpha ketoglutaric acid;alpha ketoglutaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;82 ± 45;70 ± 26;1,168;0,228;0,524;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1808;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;82.832 ± 31.72;92.816 ± 64.789;0,8924323393;0,53118;0,73733;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1809;;
erythritol;erythritol;erythritol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;821 ± 588;4300 ± 13917;0,19;0,356;0,657;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1810;;
mannitol;mannitol;mannitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;8245 ± 8751;11795 ± 13477;0,7;0,171;0,512;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1811;;
methioninesulfoxide;methioninesulfoxide;methioninesulfoxide;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;825 ± 483;917 ± 451;0,9;0,327;0,652;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1812;;
caprylic acid;caprylic acid;caprylic acid;–;–;–;HMDB0000482;–;–;–;Lipid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;829 ± 275;966 ± 272;0,86;0,031;0,143;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1813;;
acetophenone;acetophenone;acetophenone;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;832 ± 392;904 ± 448;0,92;0,47;0,735;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1814;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;83240 ± 24992;78344 ± 30191;1,06;0,355;0,735;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1815;;
2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;2,3-dihydroxybutanoic acid;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;84 ± 38;77 ± 32;1,09;0,379;0,65;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1816;;
gamma-glutamyl-valine;gamma-glutamyl-valine;gamma-glutamyl-valine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;84 ± 41;104 ± 70;0,81;0,044;0,35;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1817;;
Ile;Ile;Ile;–;–;–;–;–;–;–;–;–;–;plasma;–;NSCLC;I, II, III, IV;141;93, 48;62.7 ± 9.2;former, current, non-smoker ;healthy;423;279, 144;61.1 ± 8.7;former, current, non-smoker;LC;ESI;positive ;quadrupole;–;Xcalibur ;–;Matlab; Mann-Whitney U-test, PCA;84.3 ± 22.1 μM;69.7±17.5 μM;1,2094691535;0,001;–;–;ROC curve;–;combination of 21 amino acid: 0.812;–;–;–;–;–;–;–;–;Japan;Y;–;21176209;Maeda et al. 2010;1818;;
dihydro-3-coumaric acid;dihydro-3-coumaric acid;dihydro-3-coumaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;840 ± 894;933 ± 968;0,9;0,476;0,735;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1819;;
pyrophosphate;pyrophosphate;pyrophosphate;–;–;–;–;–;–;–;Other;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;846 ± 536;768 ± 438;1,1;0,484;0,737;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1820;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;84632 ± 39230;46361 ± 32362;1,83;0;0,001;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1821;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;84670 ± 27049;78685 ± 25425;1,076;0,229;0,524;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1822;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;8501 ± 6890;6925 ± 2280;1,228;0,185;0,47;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1823;;
N-methylalanine;N-methylalanine;N-methylalanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;8514 ± 3093;8728 ± 4253;0,98;0,941;0,98;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1824;;
sucrose;sucrose;sucrose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;854 ± 4667;228 ± 364;3,749;0,595;0,862;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1825;;
trans-4-hydroxyproline;trans-4-hydroxyproline;trans-4-hydroxyproline;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;855 ± 498;977 ± 471;0,87;0,02;0,208;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1826;;
hippuric acid;hippuric acid;hippuric acid;–;–;–;HMDB0000714;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;8554 ± 5869;6470 ± 4863;1,32;0,1;0,501;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1827;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;85730 ± 20658;93604 ± 18189;0,92;0,056;0,31;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1828;;
gamma-glutamyl-valine;gamma-glutamyl-valine;gamma-glutamyl-valine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;86 ± 31;93 ± 28;0,92;0,163;0,502;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1829;;
1-monostearin;1-monostearin;1-monostearin;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;86 ± 74;89 ± 51;0,97;0,398;0,674;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1830;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;86.97±31.39 ?M;91.33±28.19 ?M;0,95;0,2385;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,556;"alanine+histidine+ornithine+isoleucine+tryptophan+valine=84.4
alanine+histidine+ornithine+glutamine+lysine+serine=82.2";"alanine+histidine+ornithine+isoleucine+tryptophan+valine=52.4
alanine+histidine+ornithine+glutamine+lysine+serine=58.7";–;–;–;–;–;–;Poland;Y;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1831;;
1-monoolein;1-monoolein;1-monoolein;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;868 ± 748;639 ± 473;1,36;0,204;0,498;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1832;;
beta-glycerolphosphate;beta-glycerolphosphate;beta-glycerolphosphate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;87 ± 34;87 ± 28;1;0,94;0,974;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1833;;
sucrose;sucrose;sucrose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;87 ± 62;223 ± 525;0,39;0,024;0,127;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1834;;
arabitol;arabitol;arabitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;87 ± 64;88 ± 39;0,98;0,215;0,487;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1835;;
cystine;cystine;cystine;–;–;–;–;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;8704 ± 2504;10376 ± 2341;0,839;0,001;0,016;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1836;;
2-hydroxybutanoic acid;2-hydroxybutanoic acid;2-hydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;8718 ± 4691;7190 ± 4294;1,21;0,079;0,258;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1837;;
linolenic acid;linolenic acid;linolenic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;874 ± 510;1120 ± 862;0,78;0,109;0,323;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1838;;
p-cresol;p-cresol;p-cresol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;878 ± 747;877 ± 480;1;0,483;0,781;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1839;;
aspartate;aspartate;aspartate;–;–;–;–;–;–;–;Amino Acid;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;879 ± 837;739 ± 559;1,19;0,127;0,516;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1840;;
1-monostearin;1-monostearin;1-monostearin;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;88 ± 25;106 ± 85;0,83;0,347;0,633;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1841;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;88315 ± 76209;51391 ± 24335;1,72;0,016;0,191;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1842;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;886 ± 233;987 ± 246;0,898;0,099;0,334;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1843;;
saccharic acid;saccharic acid;saccharic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;89 ± 72;89 ± 59;1;0,531;0,762;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1844;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;Amino Acid;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;892 ± 388;999 ± 671;0,89;0,38;0,672;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1845;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;9.0947 ± 6.3865;10.548 ± 6.0754;0,8622203261;0,21339;0,52412;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1846;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;9.4724 ± 4.6332;11.51 ± 8.243;0,8229713293;0,66856;0,83761;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1847;;
L-tyrosine;L-tyrosine;L-tyrosine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;31;17, 14;52-72;–;healthy;92;52, 40;52-73 ;–;GC;–;–;TOF;In-source fragmentation;Leco ChromaTOF-GC; Replib, Mainlib and Fiehn libraries;–;two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach;9.632 ± 4.0878;11.79 ± 7.3324;0,8169635284;0,32347;0,64914;–;ROC curve;–;–;–;–;–;–;–;–;–;–;Poland;–;–;28803255;Ro?-Mazurczyk et al. 2017;1848;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;9.69±2.29 ?M;9.85±2.29 ?M;0,98;0,8573;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,509;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1849;;
hydroxyproline;hydroxyproline;hydroxyproline;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II, III;90;58, 32;64 (48-86);current, non-smoker, unknown;healthy;63;41, 22;62 (43-78);smoker, non-smoker, unknown;LC;–;–;QTRAP;MS/MS;–;–;STATISTICA, MetaboAnalyst 3.0 web portal;t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA;9.79±4.23 ?M;11.91±7.61 ?M;0,82;0,3776;–;–;ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis;–;0,542;–;–;–;–;–;–;–;–;Poland;–;MRM transitions for each amino acid and its corresponding internal standard;27597283;Klupczynska et al. 2016a;1850;;
paracetamol;paracetamol;paracetamol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;901 ± 2421;285 ± 741;3,16;0,222;0,589;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1851;;
PC(23:0/20:5);PC(23:0/20:5);PC(23:0/20:5);–;–;–;–;–;–;–;–;–;922,6566;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;904.67 ng/mL;782.35 ng/mL;1,15634946;0,12;0,11;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1852;;
PC(18:2/20:4);PC(18:2/20:4);PC(18:2/20:4);–;–;–;–;–;–;–;–;–;850,5565;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;9076.63 ng/mL;11530.32 ng/mL;0,7871967127;0,0283;0,0419;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1853;;
3-aminoisobutyric acid;3-aminoisobutyric acid;3-aminoisobutyric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;909 ± 3528;391 ± 206;2,33;0,953;0,974;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1854;;
N-acetylglycine;N-acetylglycine;N-acetylglycine;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;91 ± 48;100 ± 53;0,91;0,348;0,633;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1855;;
N-acetylglucosamine;N-acetylglucosamine;N-acetylglucosamine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;911626 ± 100591;935027 ± 104807;0,98;0,362;0,633;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1856;;
pseudo uridine;pseudo uridine;pseudo uridine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;912 ± 534;937 ± 250;0,97;0,176;0,43;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1857;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;9148 ± 4508;6083 ± 1891;1,5;0;0,037;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1858;;
benzylalcohol;benzylalcohol;benzylalcohol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;918 ± 794;787 ± 433;1,17;0,942;0,985;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1859;;
2-aminoadipic acid;2-aminoadipic acid;2-aminoadipic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;92 ± 52;98 ± 50;0,94;0,755;0,898;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1860;;
adenosine-5-phosphate;adenosine-5-phosphate;adenosine-5-phosphate;–;–;–;–;–;–;–;Nucleotide;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;92 ± 68;112 ± 137;0,818;0,339;0,64;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1861;;
hippuric acid;hippuric acid;hippuric acid;–;–;–;HMDB0000714;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;9219 ± 7597;9261 ± 7425;1;0,957;0,982;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1862;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;927 ± 409;958 ± 498;0,97;0,905;0,961;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1863;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;929 ± 669;937 ± 362;0,99;0,171;0,512;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1864;;
aconitic acid;aconitic acid;aconitic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;93 ± 69;95 ± 58;0,97;0,848;0,943;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1865;;
PC(16:0/18:2);PC(16:0/18:2);PC(16:0/18:2);–;–;–;–;–;–;–;–;–;802,5654;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;930.98 ng/mL;979.69 ng/mL;0,9502801907;0,66;0,39;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1866;;
mannitol;mannitol;mannitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;9313 ± 14442;7955 ± 5567;1,171;0,583;0,857;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1867;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;9388 ± 8914;9072 ± 4845;1,04;0,51;0,743;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1868;;
2-aminoadipic acid;2-aminoadipic acid;2-aminoadipic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;94 ± 40;83 ± 32;1,14;0,305;0,69;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1869;;
trans-4-hydroxyproline;trans-4-hydroxyproline;trans-4-hydroxyproline;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;942 ± 901;915 ± 533;1,029;0,961;0,99;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1870;;
aminomalonic acid;aminomalonic acid;aminomalonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;951 ± 345;829 ± 381;1,15;0,077;0,378;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1871;;
testosterone;testosterone;testosterone;–;–;–;–;–;–;–;–;–;289,2162;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;9562.95±1219.14 ng/mL;8107.15±1450.78 ng/mL;11,313708499;0,0000433;–;1,45;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1872;;
aminomalonic acid;aminomalonic acid;aminomalonic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;957 ± 423;1062 ± 408;0,9;0,089;0,28;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1873;;
2-hydroxyvaleric acid;2-hydroxyvaleric acid;2-hydroxyvaleric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;958 ± 607;943 ± 285;1,02;0,33;0,652;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1874;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;9588 ± 3206;9696 ± 3829;0,99;0,721;0,869;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1875;;
pimelic acid;pimelic acid;pimelic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;96 ± 101;68 ± 36;1,42;0,266;0,56;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1876;;
acetophenone;acetophenone;acetophenone;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;963 ± 914;916 ± 755;1,05;0,697;0,886;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1877;;
PC(17:0/20:3);PC(17:0/20:3);PC(17:0/20:3);–;–;–;–;–;–;–;–;–;842,5858;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;967.08 ng/mL;955.46 ng/mL;1,0121616813;0,92;0,48;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1878;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;222,3;serum;diagnosis;lung cancer;–;40;14, 26;67;–;healthy;100;–;–;–;LC;ESI;positive;Triple quadrupole;MS/MS;–;–;SPSS ;one-way ANOVA;97.25 ± 31.82 μmol/L;68.00 ± 13.33 μmol/L;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27129889;Ni et al. 2016;1879;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;9716 ± 4264;21206 ± 44939;0,46;0,001;0,091;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1880;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;9722 ± 3701;10293 ± 2808;0,95;0,148;0,496;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1881;;
erythritol;erythritol;erythritol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;974 ± 1350;666 ± 249;1,463;0,833;0,937;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1882;;
conduritol-beta-epoxide;conduritol-beta-epoxide;conduritol-beta-epoxide;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;974 ± 2242;676 ± 654;1,44;0,706;0,911;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1883;;
3-hydroxybutanoic acid;3-hydroxybutanoic acid;3-hydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;9752 ± 10721;7082 ± 9138;1,377;0,11;0,352;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1884;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;976 ± 445;1093 ± 461;0,89;0,183;0,441;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1885;;
acetophenone;acetophenone;acetophenone;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;980 ± 398;1089 ± 312;0,9;0,083;0,324;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1886;;
behenic acid;behenic acid;behenic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;99 ± 51;119 ± 68;0,83;0,339;0,627;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1887;;
2-oxogluconic acid;2-oxogluconic acid;2-oxogluconic acid;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;99 ± 59;129 ± 114;0,77;0,214;0,543;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1888;;
PC(17:0/20:5);PC(17:0/20:5);PC(17:0/20:5);–;–;–;–;–;–;–;–;–;838,5456;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;both;Q-TOF;–;Analyst TF, XCMS ;–;SIMCA-P, MetaboAnalystR, SPSS ; Student’s t-test;99.9 ng/mL;126.39 ng/mL;0,7904106338;0,0619;0,0178;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;1889;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;–;–;147,0764;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;994.55±739.86 ng/mL;334.96±233.22 ng/mL;3,0525184179;4,44E-013;–;2,07;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;1890;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;9952 ± 4971;10999 ± 7000;0,91;0,355;0,633;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1891;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;999 ± 898;660 ± 404;1,51;0,019;0,109;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1892;;
pipecolic acid;pipecolic acid;pipecolic acid;–;–;–;HMDB0000070;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;999 ± 988;1076 ± 1199;0,93;0,991;0,991;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;1893;;
prostaglandin E2;prostaglandin E2;prostaglandin E2;–;–;–;–;–;–;–;–;–;–;urine;therapy;NSCLC;–;19;10, 9;–;–;healthy;37;20, 17;–;–;LC;ESI;negative;triple quadrupole;MS/MS;–;–;–;Student’s t test, Wilcoxon signed ranks test, ANOVA;–;–;–;0,05;–;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;15494133;Murphey et al. 2004;1894;;
1,1-difluoroethane;1,1-difluoroethane;1,1-difluoroethane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1895;;
1,3-cyclohexadiene;1,3-cyclohexadiene;1,3-cyclohexadiene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1896;;
1,3-cyclopentadiene;1,3-cyclopentadiene;1,3-cyclopentadiene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1897;;
1,3-cyclopentadiene, 1-Methyl-;1,3-cyclopentadiene, 1-Methyl-;1,3-cyclopentadiene, 1-Methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1898;;
1,4-pentadiene;1,4-pentadiene;1,4-pentadiene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1899;;
1-butanol, 3,3-dimethyl-;1-butanol, 3,3-dimethyl-;1-butanol, 3,3-dimethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1900;;
1-butanol, 3-methyl-;1-butanol, 3-methyl-;1-butanol, 3-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1901;;
1-butene, 2-methyl-;1-butene, 2-methyl-;1-butene, 2-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1902;;
1-butene, 3-methyl-;1-butene, 3-methyl-;1-butene, 3-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1903;;
1-butyne;1-butyne;1-butyne;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1904;;
1-cyclopentene;1-cyclopentene;1-cyclopentene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1905;;
1-pentanol;1-pentanol;1-pentanol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1906;;
1-pentene, 2-methyl-;1-pentene, 2-methyl-;1-pentene, 2-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1907;;
1-pentene, 3-methyl-;1-pentene, 3-methyl-;1-pentene, 3-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1908;;
1-phenyl-1-butene;1-phenyl-1-butene;1-phenyl-1-butene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1909;;
1-propanol;1-propanol;1-propanol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;Y;–;19397483;Ligor et al. 2009;1910;;
2,3-butanedione;2,3-butanedione;2,3-butanedione;–;–;–;HMDB0003407;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1911;;
2-butanol, 2,3-dimethyl-;2-butanol, 2,3-dimethyl-;2-butanol, 2,3-dimethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1912;;
2-butanone;2-butanone;2-butanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;Y;–;19397483;Ligor et al. 2009;1913;;
2-butanone, 3-hydroxy-;2-butanone, 3-hydroxy-;2-butanone, 3-hydroxy-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1914;;
2-butenal, 3-methyl-;2-butenal, 3-methyl-;2-butenal, 3-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1915;;
2-butene (Z+E);2-butene (Z+E);2-butene (Z+E);–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1916;;
2-butene, 2-methyl-;2-butene, 2-methyl-;2-butene, 2-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1917;;
2-butyne;2-butyne;2-butyne;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1918;;
2-indanol, trans-1-amino-;2-indanol, trans-1-amino-;2-indanol, trans-1-amino-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1919;;
2-pentanone;2-pentanone;2-pentanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1920;;
2-pentene (Z+E);2-pentene (Z+E);2-pentene (Z+E);–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1921;;
2-propanol, 1,1,1-trichloro-2-methyl-;2-propanol, 1,1,1-trichloro-2-methyl-;2-propanol, 1,1,1-trichloro-2-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1922;;
2-propanol, 1-methoxy-;2-propanol, 1-methoxy-;2-propanol, 1-methoxy-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1923;;
2-propanone, 1-hydroxy-;2-propanone, 1-hydroxy-;2-propanone, 1-hydroxy-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1924;;
2-propenal, 2-methyl-;2-propenal, 2-methyl-;2-propenal, 2-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1925;;
3-buten-2-one;3-buten-2-one;3-buten-2-one;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1926;;
3-butyn-2-ol;3-butyn-2-ol;3-butyn-2-ol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;Y;–;19397483;Ligor et al. 2009;1927;;
3-pentanol, 2-methyl-;3-pentanol, 2-methyl-;3-pentanol, 2-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1928;;
3-penten-1-yne;3-penten-1-yne;3-penten-1-yne;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1929;;
4-penten-2-one;4-penten-2-one;4-penten-2-one;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1930;;
acetaldehyde;acetaldehyde;acetaldehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1931;;
acetamide, N,N-dimethyl-;acetamide, N,N-dimethyl-;acetamide, N,N-dimethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1932;;
acetic acid;acetic acid;acetic acid;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1933;;
acetic anhydride;acetic anhydride;acetic anhydride;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1934;;
acetone;acetone;acetone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1935;;
acetonitrile;acetonitrile;acetonitrile;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1936;;
acetophenone;acetophenone;acetophenone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1937;;
acetyl bromide;acetyl bromide;acetyl bromide;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1938;;
allyl methyl sulfide;allyl methyl sulfide;allyl methyl sulfide;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1939;;
benzaldehyde;benzaldehyde;benzaldehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;Y;–;19397483;Ligor et al. 2009;1940;;
benzene;benzene;benzene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1941;;
benzene, cyclobutyl-;benzene, cyclobutyl-;benzene, cyclobutyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1942;;
benzene, ethyl-;benzene, ethyl-;benzene, ethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1943;;
butane, 2-methyl-;butane, 2-methyl-;butane, 2-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1944;;
butyl acetate;butyl acetate;butyl acetate;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1945;;
camphene;camphene;camphene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1946;;
cineole;cineole;cineole;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1947;;
cyclohexane, ethyl-;cyclohexane, ethyl-;cyclohexane, ethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1948;;
cyclopropane, 1,1-dimethyl-;cyclopropane, 1,1-dimethyl-;cyclopropane, 1,1-dimethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1949;;
diethyl ether;diethyl ether;diethyl ether;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1950;;
diisopropyl ether;diisopropyl ether;diisopropyl ether;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1951;;
dimethyl ether;dimethyl ether;dimethyl ether;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1952;;
dimethyl sulfide;dimethyl sulfide;dimethyl sulfide;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1953;;
ethanol;ethanol;ethanol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1954;;
ethyl acetate;ethyl acetate;ethyl acetate;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1955;;
ethylene, tetrachloro-;ethylene, tetrachloro-;ethylene, tetrachloro-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1956;;
ethylenimine;ethylenimine;ethylenimine;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1957;;
formamide, N,N-dimethyl-;formamide, N,N-dimethyl-;formamide, N,N-dimethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1958;;
formic acid;formic acid;formic acid;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1959;;
furan;furan;furan;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1960;;
furan, 2,5-dimethyl-;furan, 2,5-dimethyl-;furan, 2,5-dimethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1961;;
furan, 2-methyl-;furan, 2-methyl-;furan, 2-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1962;;
furan, 3-methyl-;furan, 3-methyl-;furan, 3-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1963;;
furfural;furfural;furfural;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1964;;
g-butyrolactone;g-butyrolactone;g-butyrolactone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1965;;
heptane, 2,4-dimethyl-;heptane, 2,4-dimethyl-;heptane, 2,4-dimethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1966;;
heptane, 2-methyl-;heptane, 2-methyl-;heptane, 2-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1967;;
isobutane;isobutane;isobutane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1968;;
isoprene;isoprene;isoprene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1969;;
isoquinoline, 1,2,3,4-tetrahydro-;isoquinoline, 1,2,3,4-tetrahydro-;isoquinoline, 1,2,3,4-tetrahydro-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1970;;
limonene;limonene;limonene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1971;;
menthol mix of isomers;menthol mix of isomers;menthol mix of isomers;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1972;;
methyl acetate;methyl acetate;methyl acetate;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1973;;
methyl propyl sulfide;methyl propyl sulfide;methyl propyl sulfide;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1974;;
n-butane;n-butane;n-butane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1975;;
n-decane;n-decane;n-decane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1976;;
n-heptane;n-heptane;n-heptane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1977;;
n-hexane;n-hexane;n-hexane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;Y;–;19397483;Ligor et al. 2009;1978;;
n-nonane;n-nonane;n-nonane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1979;;
n-octane;n-octane;n-octane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1980;;
n-pentanal;n-pentanal;n-pentanal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1981;;
n-pentane;n-pentane;n-pentane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;Y;–;19397483;Ligor et al. 2009;1982;;
n-undecane;n-undecane;n-undecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1983;;
octane, 2-methyl-;octane, 2-methyl-;octane, 2-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1984;;
p-cymene;p-cymene;p-cymene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1985;;
pentane, 2-methyl-;pentane, 2-methyl-;pentane, 2-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;Y;–;19397483;Ligor et al. 2009;1986;;
pentane, 3-methyl-;pentane, 3-methyl-;pentane, 3-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;Y;–;19397483;Ligor et al. 2009;1987;;
phenol, 2,5-dimethyl-;phenol, 2,5-dimethyl-;phenol, 2,5-dimethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1988;;
p-xylene;p-xylene;p-xylene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1989;;
pyridine;pyridine;pyridine;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1990;;
quinoline;quinoline;quinoline;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1991;;
styrene;styrene;styrene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1992;;
toluene;toluene;toluene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1993;;
trichloroethylene;trichloroethylene;trichloroethylene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1994;;
undecane, 3,7-dimethyl-;undecane, 3,7-dimethyl-;undecane, 3,7-dimethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1995;;
urea, tetramethyl-;urea, tetramethyl-;urea, tetramethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1996;;
urea, thio-, tetramethyl-;urea, thio-, tetramethyl-;urea, thio-, tetramethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC, mesothelioma, carcinoid;–;65;41, 24;–;former, current, non-smoker;healthy;31;–;–;former, current, non-smoker;GC;EI;–;–;–;–;NIST 2005;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Austria;–;–;19397483;Ligor et al. 2009;1997;;
nonanal;nonanal;nonanal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC;–;12;11, 1;–;–;healthy;24;10, 14;–;smoker, non-smoker;GC;EI;–;–;–;–;–;–;Kruskal–Wallis;–;–;–;0,025;–;–;–;8.433 nmol/L;–;33,3;95,8;–;–;–;–;–;–;Germany;–;–;19839051;Fuchs et al. 2010;1998;;
octanal;octanal;octanal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC;–;12;11, 1;–;–;healthy;24;10, 14;–;smoker, non-smoker;GC;EI;–;–;–;–;–;–;Kruskal–Wallis;–;–;–;0,014;–;–;–;1.068 nmol/L;–;58,3;91,7;–;–;–;–;–;–;Germany;–;–;19839051;Fuchs et al. 2010;1999;;
hexanal;hexanal;hexanal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC;–;12;11, 1;–;–;healthy;24;10, 14;–;smoker, non-smoker;GC;EI;–;–;–;–;–;–;Kruskal–Wallis;–;–;–;0,006;–;–;–;1.208 nmol/L;–;8,3;91,7;–;–;–;–;–;–;Germany;–;–;19839051;Fuchs et al. 2010;2000;;
pentanal;pentanal;pentanal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC;–;12;11, 1;–;–;healthy;24;10, 14;–;smoker, non-smoker;GC;EI;–;–;–;–;–;–;Kruskal–Wallis;–;–;–;0,001;–;–;–;0.275 nmol/L;–;75;95,8;–;–;–;–;–;–;Germany;–;–;19839051;Fuchs et al. 2010;2001;;
CEA;CEA;CEA;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC;–;12;11, 1;–;–;healthy;24;10, 14;–;smoker, non-smoker;GC;EI;–;–;–;–;–;–;–;–;–;–;–;–;–;–;5.61 ng/mL;–;58,3;95,7;–;–;–;–;–;–;Germany;–;–;19839051;Fuchs et al. 2010;2002;;
CYFRA 21-1;CYFRA 21-1;CYFRA 21-1;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC;–;12;11, 1;–;–;healthy;24;10, 14;–;smoker, non-smoker;GC;EI;–;–;–;–;–;–;–;–;–;–;–;–;–;–;3.34 ng/mL;–;66,7;100;–;–;–;–;–;–;Germany;–;–;19839051;Fuchs et al. 2010;2003;;
NSE;NSE;NSE;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;NSCLC, SCLC;–;12;11, 1;–;–;healthy;24;10, 14;–;smoker, non-smoker;GC;EI;–;–;–;–;–;–;–;–;–;–;–;–;–;–;22.85 ng/mL;–;50;91,3;–;–;–;–;–;–;Germany;–;–;19839051;Fuchs et al. 2010;2004;;
betaine;betaine;betaine;–;–;–;HMDB0000043;–;–;–;Glycine, serine and threonine metabolism;–;118,157;urine;diagnosis;adenocarcinoma, squamous cell carcinoma;–;35;23, 12;61.8 ± 13.3, 57.4 ± 9.8 ;–;healthy;32;27, 5;57.1 ± 9.9 / 45.6 ± 10.8 ;–;LC;ESI;positive ;QTRAP ;MS/MS;MarkerView ;HMDB, KEGG, Pubchem, mass bank ;SIMCA-P;OSC PLS-DA;–;–;106,6;–;–;2,61;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20309903;Yang et al. 2010;2005;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;Phenylalanine and tyrosine metabolism;–;166,205;urine;diagnosis;adenocarcinoma, squamous cell carcinoma;–;35;23, 12;61.8 ± 13.3, 57.4 ± 9.8 ;–;healthy;32;27, 5;57.1 ± 9.9 / 45.6 ± 10.8 ;–;LC;ESI;positive ;QTRAP ;MS/MS;MarkerView ;HMDB, KEGG, Pubchem, mass bank ;SIMCA-P;OSC PLS-DA;–;–;17,5;–;–;2,58;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20309903;Yang et al. 2010;2006;;
3-hexaprenyl-4-hydroxy-5-methoxybenzoic acid;3-hexaprenyl-4-hydroxy-5-methoxybenzoic acid;3-hexaprenyl-4-hydroxy-5-methoxybenzoic acid;–;–;–;–;–;–;–;Ubiquinone biosynthesis;–;577,298;urine;diagnosis;adenocarcinoma, squamous cell carcinoma;–;35;23, 12;61.8 ± 13.3, 57.4 ± 9.8 ;–;healthy;32;27, 5;57.1 ± 9.9 / 45.6 ± 10.8 ;–;LC;ESI;positive ;QTRAP ;MS/MS;MarkerView ;HMDB, KEGG, Pubchem, mass bank ;SIMCA-P;OSC PLS-DA;–;–;12,4;–;–;3,11;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20309903;Yang et al. 2010;2007;;
proline betaine;proline betaine;proline betaine;–;–;–;HMDB0004827;–;–;–;–;–;144,168;urine;diagnosis;adenocarcinoma, squamous cell carcinoma;–;35;23, 12;61.8 ± 13.3, 57.4 ± 9.8 ;–;healthy;32;27, 5;57.1 ± 9.9 / 45.6 ± 10.8 ;–;LC;ESI;positive ;QTRAP ;MS/MS;MarkerView ;HMDB, KEGG, Pubchem, mass bank ;SIMCA-P;OSC PLS-DA;–;–;4,1;–;–;5,47;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20309903;Yang et al. 2010;2008;;
carnitine;carnitine;carnitine;–;–;–;HMDB0000062;–;–;–;Lysine degradation oxidationof fatty acid;–;162,217;urine;diagnosis;adenocarcinoma, squamous cell carcinoma;–;35;23, 12;61.8 ± 13.3, 57.4 ± 9.8 ;–;healthy;32;27, 5;57.1 ± 9.9 / 45.6 ± 10.8 ;–;LC;ESI;positive ;QTRAP ;MS/MS;MarkerView ;HMDB, KEGG, Pubchem, mass bank ;SIMCA-P;OSC PLS-DA;–;–;3,7;–;–;1,79;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20309903;Yang et al. 2010;2009;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;Bile acids metabolismtaurine and hypotaurinemetabolism;–;126,148;urine;diagnosis;adenocarcinoma, squamous cell carcinoma;–;35;23, 12;61.8 ± 13.3, 57.4 ± 9.8 ;–;healthy;32;27, 5;57.1 ± 9.9 / 45.6 ± 10.8 ;–;LC;ESI;positive ;QTRAP ;MS/MS;MarkerView ;HMDB, KEGG, Pubchem, mass bank ;SIMCA-P;OSC PLS-DA;–;–;2,2;–;–;3,81;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20309903;Yang et al. 2010;2010;;
pipecolic acid;pipecolic acid;pipecolic acid;–;–;–;HMDB0000070;–;–;–;Lysine degradation;–;130,107;urine;diagnosis;adenocarcinoma, squamous cell carcinoma;–;35;23, 12;61.8 ± 13.3, 57.4 ± 9.8 ;–;healthy;32;27, 5;57.1 ± 9.9 / 45.6 ± 10.8 ;–;LC;ESI;positive ;QTRAP ;MS/MS;MarkerView ;HMDB, KEGG, Pubchem, mass bank ;SIMCA-P;OSC PLS-DA;–;–;2;–;–;3,52;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20309903;Yang et al. 2010;2011;;
α-N-phenylacetyl-L-glutamine;α-N-phenylacetyl-L-glutamine;α-N-phenylacetyl-L-glutamine;–;–;–;–;–;–;–;–;–;265,218;urine;diagnosis;adenocarcinoma, squamous cell carcinoma;–;35;23, 12;61.8 ± 13.3, 57.4 ± 9.8 ;–;healthy;32;27, 5;57.1 ± 9.9 / 45.6 ± 10.8 ;–;LC;ESI;positive ;QTRAP ;MS/MS;MarkerView ;HMDB, KEGG, Pubchem, mass bank ;SIMCA-P;OSC PLS-DA;–;–;2;–;–;2,06;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20309903;Yang et al. 2010;2012;;
hippuric acid;hippuric acid;hippuric acid;–;–;–;HMDB0000714;–;–;–;–;–;180,222;urine;diagnosis;adenocarcinoma, squamous cell carcinoma;–;35;23, 12;61.8 ± 13.3, 57.4 ± 9.8 ;–;healthy;32;27, 5;57.1 ± 9.9 / 45.6 ± 10.8 ;–;LC;ESI;positive ;QTRAP ;MS/MS;MarkerView ;HMDB, KEGG, Pubchem, mass bank ;SIMCA-P;OSC PLS-DA;–;–;1,9;–;–;1,87;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20309903;Yang et al. 2010;2013;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;Pantothenate and CoA Biosynthesis propanoatemetabolism valine, leucine and isoleucine degradation;–;118,121;urine;diagnosis;adenocarcinoma, squamous cell carcinoma;–;35;23, 12;61.8 ± 13.3, 57.4 ± 9.8 ;–;healthy;32;27, 5;57.1 ± 9.9 / 45.6 ± 10.8 ;–;LC;ESI;positive ;QTRAP ;MS/MS;MarkerView ;HMDB, KEGG, Pubchem, mass bank ;SIMCA-P;OSC PLS-DA;–;–;1,8;–;–;1,47;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20309903;Yang et al. 2010;2014;;
leucylproline;leucylproline;leucylproline;–;–;–;–;–;–;–;–;–;229,29;urine;diagnosis;adenocarcinoma, squamous cell carcinoma;–;35;23, 12;61.8 ± 13.3, 57.4 ± 9.8 ;–;healthy;32;27, 5;57.1 ± 9.9 / 45.6 ± 10.8 ;–;LC;ESI;positive ;QTRAP ;MS/MS;MarkerView ;HMDB, KEGG, Pubchem, mass bank ;SIMCA-P;OSC PLS-DA;–;–;1,5;–;–;1,89;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20309903;Yang et al. 2010;2015;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;166,0853;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;APCI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,019;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2016;;
succinyladenosine;succinyladenosine;succinyladenosine;–;–;–;–;–;–;–;–;–;384,115;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;ESI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,016;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2017;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;–;–;205,0939;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;APCI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,014;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2018;;
5’-methylthioadenosine;5’-methylthioadenosine;5’-methylthioadenosine;–;–;–;–;–;–;–;–;–;298,0984;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;APPI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,0051;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2019;;
threonylcarbonyl adenosine;threonylcarbonyl adenosine;threonylcarbonyl adenosine;–;–;–;–;–;–;–;–;–;413,1414;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;ESI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,0051;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2020;;
dimethylguanosine;dimethylguanosine;dimethylguanosine;–;–;–;–;–;–;–;–;–;312,1301;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;ESI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,0049;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2021;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;166,0853;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;ESI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,0048;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2022;;
dimethylarginine;dimethylarginine;dimethylarginine;–;–;–;–;–;–;–;–;–;203,1467;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;ESI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,0028;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2023;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;182,0803;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;ESI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,0015;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2024;;
5,6-dihydrouridine;5,6-dihydrouridine;5,6-dihydrouridine;–;–;–;–;–;–;–;–;–;247,0922;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;APCI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,00085;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2025;;
N6,N6,N6-trimethyl-L-lysine;N6,N6,N6-trimethyl-L-lysine;N6,N6,N6-trimethyl-L-lysine;–;–;–;HMDB0001325;–;–;–;–;–;189,157;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;ESI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,00076;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2026;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;182,0803;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;APCI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,00073;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2027;;
indoxyl;indoxyl;indoxyl;–;–;–;–;–;–;–;–;–;134,0596;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;APCI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,00071;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2028;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;–;–;205,0939;urine;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;19;–;61 ± 8.4;–;healthy;22;–;–;–;LC;ESI;positive;Q-TOF;MS/MS;MZmine 2 beta;HMDB, PubChem compound database, METLIN, KEGG ;ParCorA;independent t-test;–;–;–;0,00065;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;20560663;An et al. 2010;2029;;
L-tryptophan;L-tryptophan;L-tryptophan;–;–;–;HMDB0000929;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;4,43;0,019;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2030;;
L-cysteine;L-cysteine;L-cysteine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;3,26;0,019;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2031;;
asparagine;asparagine;asparagine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;3,05;0,092;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2032;;
4-hydroxyphenyllactic acid;4-hydroxyphenyllactic acid;4-hydroxyphenyllactic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,95;0,004;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2033;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,84;0,0007;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2034;;
D-ribose;D-ribose;D-ribose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,66;0,005;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2035;;
L-glutamine;L-glutamine;L-glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,54;0,019;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2036;;
L-tyrosine;L-tyrosine;L-tyrosine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,43;0,012;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2037;;
3-hydroxybutyric acid;3-hydroxybutyric acid;3-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,41;0,0038;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2038;;
α-aminoadipic acid;α-aminoadipic acid;α-aminoadipic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,36;0,01;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2039;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,33;0,0007;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2040;;
aminomalonic acid;aminomalonic acid;aminomalonic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,32;0,014;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2041;;
N-acetyl glucosamine;N-acetyl glucosamine;N-acetyl glucosamine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,31;0,063;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2042;;
L-glutamic acid;L-glutamic acid;L-glutamic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,31;0,003;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2043;;
2-hydroxyglutaric acid;2-hydroxyglutaric acid;2-hydroxyglutaric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,29;0,002;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2044;;
D-glucose;D-glucose;D-glucose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,23;0,062;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2045;;
L-phenylalanine;L-phenylalanine;L-phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,21;0,016;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2046;;
3-hydroxybutyric acid;3-hydroxybutyric acid;3-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,2;0,0029;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2047;;
9h-purine;9h-purine;9h-purine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,18;0,005;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2048;;
4-hydroxyphenylacetic acid;4-hydroxyphenylacetic acid;4-hydroxyphenylacetic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,1;0,024;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2049;;
3-hydroxybutyric acid;3-hydroxybutyric acid;3-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,09;0,104;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2050;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,08;0,18;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2051;;
L-isoleucine;L-isoleucine;L-isoleucine;–;–;–;HMDB0000172;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,07;0,007;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2052;;
5-oxoproline;5-oxoproline;5-oxoproline;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,06;0,005;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2053;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,05;0,013;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2054;;
guanine;guanine;guanine;–;–;–;HMDB0000132;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,02;0,013;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2055;;
L-proline;L-proline;L-proline;–;–;–;HMDB0000162;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,02;0,008;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2056;;
N-acetylaspartic acid;N-acetylaspartic acid;N-acetylaspartic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;2,01;0,009;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2057;;
thiodiglycolic acid;thiodiglycolic acid;thiodiglycolic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,97;0,009;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2058;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,97;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2059;;
pyrimidine;pyrimidine;pyrimidine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,92;0,007;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2060;;
L-threonine;L-threonine;L-threonine;–;–;–;HMDB0000167;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,89;0,023;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2061;;
L-valine;L-valine;L-valine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,88;0,019;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2062;;
uracil;uracil;uracil;–;–;–;HMDB0000300;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,86;0,011;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2063;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,86;0,002;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2064;;
glyoxylic acid;glyoxylic acid;glyoxylic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,85;0,057;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2065;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,84;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2066;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,84;0,006;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2067;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,84;0,0003;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2068;;
butanoic acid;butanoic acid;butanoic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,82;0,04;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2069;;
L-serine;L-serine;L-serine;–;–;–;HMDB0000187;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,82;0,029;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2070;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,77;0,006;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2071;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,76;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2072;;
octanoic acid;octanoic acid;octanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,74;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2073;;
L-leucine;L-leucine;L-leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,74;0,021;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2074;;
D-gluconic acid;D-gluconic acid;D-gluconic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,73;0,005;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2075;;
L-alanine;L-alanine;L-alanine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,7;0,007;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2076;;
adenosine;adenosine;adenosine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,69;0,037;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2077;;
4-hydroxyproline;4-hydroxyproline;4-hydroxyproline;–;–;–;HMDB0000725;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,68;0,056;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2078;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,67;0,092;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2079;;
2-hydroxybutyric acid;2-hydroxybutyric acid;2-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,64;0,022;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2080;;
2-hydroxyisovaleric acid;2-hydroxyisovaleric acid;2-hydroxyisovaleric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,62;0,019;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2081;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,61;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2082;;
ethanimidic acid;ethanimidic acid;ethanimidic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,6;0,007;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2083;;
DL-ornithine;DL-ornithine;DL-ornithine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,59;0,045;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2084;;
aspartic acid;aspartic acid;aspartic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,59;0,016;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2085;;
octanoic acid;octanoic acid;octanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,58;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2086;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,56;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2087;;
malonic acid;malonic acid;malonic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,54;0,049;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2088;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,51;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2089;;
aconitic acid;aconitic acid;aconitic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,49;0,082;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2090;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,48;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2091;;
3-hydroxybutyric acid;3-hydroxybutyric acid;3-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,48;0,423;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2092;;
4-hydroxyphenyllactic acid;4-hydroxyphenyllactic acid;4-hydroxyphenyllactic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,48;0,042;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2093;;
3-hydroxyisobutyric acid;3-hydroxyisobutyric acid;3-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,47;0,428;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2094;;
2-hydroxyisovaleric acid;2-hydroxyisovaleric acid;2-hydroxyisovaleric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,47;0,0091;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2095;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,43;0,033;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2096;;
4-hydroxyproline;4-hydroxyproline;4-hydroxyproline;–;–;–;HMDB0000725;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,43;0,029;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2097;;
L-glycine;L-glycine;L-glycine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,42;0,343;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2098;;
L-lysine;L-lysine;L-lysine;–;–;–;HMDB0000182;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,42;0,095;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2099;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,42;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2100;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,41;0,047;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2101;;
L-proline;L-proline;L-proline;–;–;–;HMDB0000162;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,41;0,0042;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2102;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,4;0,067;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2103;;
L-glycine;L-glycine;L-glycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,4;0,013;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2104;;
2-hydroxyisovaleric acid;2-hydroxyisovaleric acid;2-hydroxyisovaleric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,4;0,114;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2105;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,4;0,0002;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2106;;
2-hydroxyisobutyric acid;2-hydroxyisobutyric acid;2-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,39;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2107;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,39;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2108;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;–;–;HMDB0003229;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,35;0,384;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2109;;
L-proline;L-proline;L-proline;–;–;–;HMDB0000162;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,35;0,101;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2110;;
2-hydroxyisobutyric acid;2-hydroxyisobutyric acid;2-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,35;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2111;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,35;0,0036;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2112;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;–;–;HMDB0003229;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,34;0,229;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2113;;
L-proline;L-proline;L-proline;–;–;–;HMDB0000162;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,34;0,0015;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2114;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,33;0,012;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2115;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;–;–;HMDB0003229;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,33;0,304;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2116;;
4-hydroxyproline;4-hydroxyproline;4-hydroxyproline;–;–;–;HMDB0000725;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,31;0,414;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2117;;
malonic acid;malonic acid;malonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,31;0,0036;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2118;;
glucuronic lactone;glucuronic lactone;glucuronic lactone;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,29;0,101;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2119;;
L-glycine;L-glycine;L-glycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,29;0,052;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2120;;
2-hydroxyisobutyric acid;2-hydroxyisobutyric acid;2-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,29;0,0012;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2121;;
L-isoleucine;L-isoleucine;L-isoleucine;–;–;–;HMDB0000172;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,28;0,024;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2122;;
L-threonine;L-threonine;L-threonine;–;–;–;HMDB0000167;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,27;0,052;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2123;;
glyoxylic acid;glyoxylic acid;glyoxylic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,27;0,164;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2124;;
malonic acid;malonic acid;malonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,27;0,069;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2125;;
L-isoleucine;L-isoleucine;L-isoleucine;–;–;–;HMDB0000172;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,26;0,0042;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2126;;
L-isoleucine;L-isoleucine;L-isoleucine;–;–;–;HMDB0000172;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,25;0,071;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2127;;
sarcosine;sarcosine;sarcosine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,24;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2128;;
L-methionine;L-methionine;L-methionine;–;–;–;HMDB0000696;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,24;0,212;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2129;;
3-hydroxyisobutyric acid;3-hydroxyisobutyric acid;3-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,24;0,165;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2130;;
L-threonine;L-threonine;L-threonine;–;–;–;HMDB0000167;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,24;0,04;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2131;;
4-hydroxyphenyllactic acid;4-hydroxyphenyllactic acid;4-hydroxyphenyllactic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,23;0,402;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2132;;
octanoic acid;octanoic acid;octanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,23;0,039;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2133;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,22;0,017;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2134;;
malonic acid;malonic acid;malonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,22;0,014;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2135;;
α-amino butyric acid;α-amino butyric acid;α-amino butyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,22;0,145;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2136;;
2-hydroxyisobutyric acid;2-hydroxyisobutyric acid;2-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,21;0,06;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2137;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,21;0,012;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2138;;
propanoic acid;propanoic acid;propanoic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,2;0,004;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2139;;
maleic acid;maleic acid;maleic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,2;0,157;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2140;;
3-hydroxyisobutyric acid;3-hydroxyisobutyric acid;3-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,2;0,103;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2141;;
glyoxylic acid;glyoxylic acid;glyoxylic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,19;0,187;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2142;;
glucuronic lactone;glucuronic lactone;glucuronic lactone;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,19;0,15;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2143;;
3-hydroxyisobutyric acid;3-hydroxyisobutyric acid;3-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,18;0,375;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2144;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,18;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2145;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,18;0,254;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2146;;
aconitic acid;aconitic acid;aconitic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,17;0,327;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2147;;
L-methionine;L-methionine;L-methionine;–;–;–;HMDB0000696;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,17;0,209;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2148;;
sarcosine;sarcosine;sarcosine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,17;0,0027;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2149;;
2-propyl-glutaric acid;2-propyl-glutaric acid;2-propyl-glutaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,16;0,024;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2150;;
2-hexenedioic acid;2-hexenedioic acid;2-hexenedioic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,16;0,0008;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2151;;
L-threonine;L-threonine;L-threonine;–;–;–;HMDB0000167;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,16;0,248;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2152;;
glyoxylic acid;glyoxylic acid;glyoxylic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,15;0,62;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2153;;
glucuronic lactone;glucuronic lactone;glucuronic lactone;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,14;0,691;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2154;;
L-methionine;L-methionine;L-methionine;–;–;–;HMDB0000696;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,13;0,677;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2155;;
L-alanine;L-alanine;L-alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,13;0,225;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2156;;
maleic acid;maleic acid;maleic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,13;0,205;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2157;;
2-propyl-glutaric acid;2-propyl-glutaric acid;2-propyl-glutaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,13;0,018;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2158;;
indol-3-acetic acid;indol-3-acetic acid;indol-3-acetic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,12;0,434;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2159;;
3-hydroxypropionic acid;3-hydroxypropionic acid;3-hydroxypropionic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,11;0,803;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2160;;
3-hydroxypropionic acid;3-hydroxypropionic acid;3-hydroxypropionic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,11;0,377;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2161;;
2-hexenedioic acid;2-hexenedioic acid;2-hexenedioic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,11;0,022;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2162;;
α-amino butyric acid;α-amino butyric acid;α-amino butyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,1;0,358;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2163;;
pyruvic acid;pyruvic acid;pyruvic acid;–;–;–;HMDB0000243;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,1;0,274;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2164;;
maleic acid;maleic acid;maleic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,09;0,77;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2165;;
isovalerylglycine;isovalerylglycine;isovalerylglycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,09;0,146;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2166;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,09;0,481;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2167;;
glucuronic lactone;glucuronic lactone;glucuronic lactone;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,09;0,412;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2168;;
2-propyl-glutaric acid;2-propyl-glutaric acid;2-propyl-glutaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,09;0,097;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2169;;
pyruvic acid;pyruvic acid;pyruvic acid;–;–;–;HMDB0000243;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,08;0,463;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2170;;
decanoic acid;decanoic acid;decanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,08;0,24;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2171;;
L-glycine;L-glycine;L-glycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,08;0,645;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2172;;
3-hydroxypropionic acid;3-hydroxypropionic acid;3-hydroxypropionic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,08;0,374;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2173;;
L-alanine;L-alanine;L-alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,08;0,32;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2174;;
pyruvic acid;pyruvic acid;pyruvic acid;–;–;–;HMDB0000243;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,08;0,184;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2175;;
L-alanine;L-alanine;L-alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,07;0,794;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2176;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,07;0,033;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2177;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,07;0,595;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2178;;
7-hydroxyoctanoic acid;7-hydroxyoctanoic acid;7-hydroxyoctanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,07;0,372;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2179;;
isovalerylglycine;isovalerylglycine;isovalerylglycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,07;0,223;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2180;;
3-hydroxypropionic acid;3-hydroxypropionic acid;3-hydroxypropionic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,06;0,795;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2181;;
L-phenylalanine;L-phenylalanine;L-phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,06;0,704;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2182;;
L-valine;L-valine;L-valine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,06;0,581;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2183;;
glucuronic lactone;glucuronic lactone;glucuronic lactone;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,06;0,511;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2184;;
glucuronic lactone;glucuronic lactone;glucuronic lactone;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,05;0,835;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2185;;
L-leucine;L-leucine;L-leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,05;0,672;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2186;;
L-valine;L-valine;L-valine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,05;0,553;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2187;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,04;0,886;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2188;;
L-valine;L-valine;L-valine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,04;0,807;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2189;;
α-amino butyric acid;α-amino butyric acid;α-amino butyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,04;0,794;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2190;;
L-leucine;L-leucine;L-leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,04;0,715;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2191;;
L-leucine;L-leucine;L-leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,03;0,934;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2192;;
isovalerylglycine;isovalerylglycine;isovalerylglycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,03;0,715;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2193;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,02;0,951;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2194;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,02;0,755;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2195;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,02;0,49;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2196;;
aconitic acid;aconitic acid;aconitic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,02;0,471;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2197;;
isocitric acid;isocitric acid;isocitric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,02;0,903;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2198;;
sarcosine;sarcosine;sarcosine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,02;0,866;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2199;;
isocitric acid;isocitric acid;isocitric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,02;0,369;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2200;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,01;0,976;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2201;;
2-hexenedioic acid;2-hexenedioic acid;2-hexenedioic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,01;0,975;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2202;;
decanoic acid;decanoic acid;decanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,01;0,954;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2203;;
7-hydroxyoctanoic acid;7-hydroxyoctanoic acid;7-hydroxyoctanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1,01;0,946;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2204;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1;0,916;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2205;;
ethylmalonic acid;ethylmalonic acid;ethylmalonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1;0,951;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2206;;
2-hydroxybutyric acid;2-hydroxybutyric acid;2-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;1;0,909;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2207;;
margaric acid;margaric acid;margaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,99;0,923;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2208;;
ethylmalonic acid;ethylmalonic acid;ethylmalonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,99;0,881;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2209;;
ethylmalonic acid;ethylmalonic acid;ethylmalonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,99;0,882;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2210;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,99;0,546;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2211;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,99;0,539;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2212;;
7-hydroxyoctanoic acid;7-hydroxyoctanoic acid;7-hydroxyoctanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,98;0,471;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2213;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,98;0,846;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2214;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,98;0,366;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2215;;
pyruvic acid;pyruvic acid;pyruvic acid;–;–;–;HMDB0000243;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,97;0,842;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2216;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,97;0,539;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2217;;
isocitric acid;isocitric acid;isocitric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,97;0,458;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2218;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,97;0,437;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2219;;
margaric acid;margaric acid;margaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,97;0,494;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2220;;
2-hydroxybutyric acid;2-hydroxybutyric acid;2-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,96;0,609;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2221;;
2-hydroxybutyric acid;2-hydroxybutyric acid;2-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,95;0,534;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2222;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,95;0,506;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2223;;
margaric acid;margaric acid;margaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,95;0,373;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2224;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,94;0,595;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2225;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,94;0,471;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2226;;
L-phenylalanine;L-phenylalanine;L-phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,93;0,366;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2227;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,93;0,119;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2228;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,92;0,134;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2229;;
L-serine;L-serine;L-serine;–;–;–;HMDB0000187;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,91;0,328;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2230;;
indol-3-acetic acid;indol-3-acetic acid;indol-3-acetic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,91;0,301;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2231;;
glucuronic lactone;glucuronic lactone;glucuronic lactone;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,9;0,736;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2232;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,9;0,214;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2233;;
L-serine;L-serine;L-serine;–;–;–;HMDB0000187;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,9;0,132;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2234;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,89;0,343;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2235;;
L-serine;L-serine;L-serine;–;–;–;HMDB0000187;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,89;0,248;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2236;;
5-oxoproline;5-oxoproline;5-oxoproline;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,89;0,114;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2237;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,89;0,07;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2238;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,88;0,161;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2239;;
decanoic acid;decanoic acid;decanoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,88;0,25;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2240;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,88;0,086;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2241;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,88;0,081;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2242;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,87;0,106;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2243;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,87;0,013;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2244;;
L-phenylalanine;L-phenylalanine;L-phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,86;0,085;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2245;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,86;0,179;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2246;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,86;0,068;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2247;;
5-oxoproline;5-oxoproline;5-oxoproline;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,85;0,0019;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2248;;
2-ketoglutaric acid;2-ketoglutaric acid;2-ketoglutaric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,84;0,324;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2249;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,83;0,507;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2250;;
5-oxoproline;5-oxoproline;5-oxoproline;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,83;0,0062;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2251;;
L-glutamic acid;L-glutamic acid;L-glutamic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,83;0,371;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2252;;
2-hydroxyphenylacetic acid;2-hydroxyphenylacetic acid;2-hydroxyphenylacetic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,8;0,058;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2253;;
indol-3-acetic acid;indol-3-acetic acid;indol-3-acetic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,8;0,015;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2254;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,79;0,208;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2255;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,77;0,035;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2256;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,77;0,031;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2257;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,74;0,092;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2258;;
4-hydroxyphenyllactic acid;4-hydroxyphenyllactic acid;4-hydroxyphenyllactic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,73;0,099;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2259;;
L-glutamic acid;L-glutamic acid;L-glutamic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,72;0,026;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2260;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,69;0,024;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2261;;
aspartic acid;aspartic acid;aspartic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,68;0,051;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2262;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,67;0,128;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2263;;
isocitric acid;isocitric acid;isocitric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,67;0,117;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2264;;
L-glutamic acid;L-glutamic acid;L-glutamic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,67;0,031;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2265;;
aspartic acid;aspartic acid;aspartic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,65;0,0003;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2266;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,64;0,0089;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2267;;
sarcosine;sarcosine;sarcosine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,62;0,372;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2268;;
aspartic acid;aspartic acid;aspartic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,58;0,0032;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2269;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II;11;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,57;0,0025;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2270;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;33;26, 7;median: 65 (55-81);smoker, non-smoker, unknown;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,47;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176;Hori et al. 2011;2271;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;III, IV;22;–;–;–;healthy;29;23, 6;median: 64 (34-78);smoker, non-smoker, unknown;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,42;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;Y;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2272;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,39;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2273;;
margaric acid;margaric acid;margaric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;–;7;6, 1;median: 61 (53-82);smoker, non-smoker;tumor vs. adjacent normal tissue;7;6, 1;median: 61 (53-82);smoker, non-smoker;GC;–;–;–;–;Shimadzu GCMSsolution software;commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08);SIMCA-P+;student’s t-test, PLS-DA;–;–;0,22;0,345;–;–;–;–;–;–;–;–;–;–;–;–;–;Japan;–;Sensitivity of conventional tumor markers ( CEA, CYFRA, NSE), Sensitivities of the examined metabolites in various histological types;21411176; Hori et al. 2011;2274;;
long chain acyl carnitine;long chain acyl carnitine;long chain acyl carnitine;–;[M+H]+;–;–;–;–;–;–;–;424,3421;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;58;39, 19;52 ± 12 / 52 ± 12;–;healthy;495;251, 244;61 ± 10 / 63 ± 12;–;DI;ESI;positive;FT-ICR;MS/MS ;–;HMDB, Lipid maps;SAS;PLS-DA, ;–;–;–;–;–;–;ROC curve;–;"male
oleamide + long chain acyl carnitine: 0.883,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.983,
female
oleamide + long chain acyl carnitine: 0.879,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.993";"male
oleamide + long chain acyl carnitine:87.2,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100,
female
oleamide + long chain acyl carnitine:78.9,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100";"male
oleamide + long chain acyl carnitine: 84.1,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100,
female
oleamide + long chain acyl carnitine: 92.3,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 93.1";–;–;–;–;–;–;China;Y;–;22906735;Guo et al. 2012;2275;;
LPC(18:0);LPC(18:0);LPC(18:0);–;[M+H]+, [M+Na]+, [M+K]+;–;HMDB0010384;–;–;–;–;–;524.3711, 546.353, 562.3269;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;58;39, 19;52 ± 12 / 52 ± 12;–;healthy;495;251, 244;61 ± 10 / 63 ± 12;–;DI;ESI;positive;FT-ICR;MS/MS ;–;HMDB, Lipid maps;SAS;PLS-DA, ;–;–;–;–;–;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;22906735;Guo et al. 2012;2276;;
LPC(18:1);LPC(18:1);LPC(18:1);–;[M+H]+, [M+Na]+, [M+K]+;–;–;–;–;–;–;–;522.3551, 544.3374, 560.3112;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;58;39, 19;52 ± 12 / 52 ± 12;–;healthy;495;251, 244;61 ± 10 / 63 ± 12;–;DI;ESI;positive;FT-ICR;MS/MS ;–;HMDB, Lipid maps;SAS;PLS-DA, ;–;–;–;–;–;–;ROC curve;–;"male
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 0.753, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.983, 
female
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 0.786, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.993";"male
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 61.5, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100,
female
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 84.2, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100";"male
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 82.9, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 91.7,
female
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 69.9, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 93.1";–;–;–;–;–;–;China;–;–;22906735;Guo et al. 2012;2277;;
LPC(20:3);LPC(20:3);LPC(20:3);–;[M+Na]+;–;–;–;–;–;–;–;568,3374;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;58;39, 19;52 ± 12 / 52 ± 12;–;healthy;495;251, 244;61 ± 10 / 63 ± 12;–;DI;ESI;positive;FT-ICR;MS/MS ;–;HMDB, Lipid maps;SAS;PLS-DA, ;–;–;–;–;–;–;ROC curve;–;"male
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 0.753, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.983,
female
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 0.786, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.993";"male
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 61.5, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100,
female
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 84.2, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100";"male
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 82.9, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 91.7,
female
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 69.9, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 93.1";–;–;–;–;–;–;China;–;–;22906735;Guo et al. 2012;2278;;
LPC(20:4);LPC(20:4);LPC(20:4);–;[M+Na]+;–;–;–;–;–;–;–;566,3217;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;58;39, 19;52 ± 12 / 52 ± 12;–;healthy;495;251, 244;61 ± 10 / 63 ± 12;–;DI;ESI;positive;FT-ICR;MS/MS ;–;HMDB, Lipid maps;SAS;PLS-DA, ;–;–;–;–;–;–;ROC curve;–;"male
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 0.753, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.983,
female
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 0.786, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.993";"male
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 61.5, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100,
female
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 84.2, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100";"male
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 82.9, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 91.7,
female
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 69.9, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 93.1";–;–;–;–;–;–;China;–;–;22906735;Guo et al. 2012;2279;;
LPC(22:6);LPC(22:6);LPC(22:6);–;[M+Na]+;–;–;–;–;–;–;–;590,3217;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;58;39, 19;52 ± 12 / 52 ± 12;–;healthy;495;251, 244;61 ± 10 / 63 ± 12;–;DI;ESI;positive;FT-ICR;MS/MS ;–;HMDB, Lipid maps;SAS;PLS-DA, ;–;–;–;–;–;–;ROC curve;–;"male
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 0.753, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.983,
female
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 0.786, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.993";"male
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 61.5, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100,
female
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 84.2, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100";"male
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 82.9, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 91.7,
female
LPC(18:1)  + LPC(20:4)  + LPC(20:3) + LPC(22:6): 69.9, 
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 93.1";–;–;–;–;–;–;China;–;–;22906735;Guo et al. 2012;2280;;
oleamide;oleamide;oleamide;–;[M+Na]+;–;–;–;–;–;–;–;304,2611;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;58;39, 19;52 ± 12 / 52 ± 12;–;healthy;495;251, 244;61 ± 10 / 63 ± 12;–;DI;ESI;positive;FT-ICR;MS/MS ;–;HMDB, Lipid maps;SAS;PLS-DA, ;–;–;–;–;–;–;ROC curve;–;"male
oleamide + long chain acyl carnitine: 0.883,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.983,
female
oleamide + long chain acyl carnitine: 0.879,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.993";"male
oleamide + long chain acyl carnitine:87.2,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100,
female
oleamide + long chain acyl carnitine:78.9,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100";"male
oleamide + long chain acyl carnitine: 84.1,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100,
female
oleamide + long chain acyl carnitine: 92.3,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 93.1";–;–;–;–;–;–;China;Y;–;22906735;Guo et al. 2012;2281;;
PC(34:2);PC(34:2);PC(34:2);–;[M+Na]+;–;–;–;–;–;–;–;764,5564;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;58;39, 19;52 ± 12 / 52 ± 12;–;healthy;495;251, 244;61 ± 10 / 63 ± 12;–;DI;ESI;positive;FT-ICR;MS/MS ;–;HMDB, Lipid maps;SAS;PLS-DA, ;–;–;–;–;–;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;22906735;Guo et al. 2012;2282;;
PC(36:2);PC(36:2);PC(36:2);–;[M+H]+, [M+Na]+;–;–;–;–;–;–;–;786.6007, 808.5827;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;58;39, 19;52 ± 12 / 52 ± 12;–;healthy;495;251, 244;61 ± 10 / 63 ± 12;–;DI;ESI;positive;FT-ICR;MS/MS ;–;HMDB, Lipid maps;SAS;PLS-DA, ;–;–;–;–;–;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;22906735;Guo et al. 2012;2283;;
PC(36:3);PC(36:3);PC(36:3);–;[M+H]+;–;–;–;–;–;–;–;768,5901;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;58;39, 19;52 ± 12 / 52 ± 12;–;healthy;495;251, 244;61 ± 10 / 63 ± 12;–;DI;ESI;positive;FT-ICR;MS/MS ;–;HMDB, Lipid maps;SAS;PLS-DA, ;–;–;–;–;–;–;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;22906735;Guo et al. 2012;2284;;
SM(16:0/1);SM(16:0/1);SM(16:0/1);–;[M+Na]+;–;–;–;–;–;–;–;725,5568;serum;diagnosis;adenocarcinoma, squamous cell carcinoma, SCLC;I, II, III, IV;58;39, 19;52 ± 12 / 52 ± 12;–;healthy;495;251, 244;61 ± 10 / 63 ± 12;–;DI;ESI;positive;FT-ICR;MS/MS ;–;HMDB, Lipid maps;SAS;PLS-DA, ;–;–;–;–;–;–;ROC curve;–;"male
0.924,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.983,
female 
0.952,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.993";"male
86.2,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100,
female
94.7,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100";"male
88.7,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 91.7,
female
88.9,
Oleamide + Long chain acyl carnitine
 + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 93.1";–;–;–;–;–;–;China;Y;–;22906735;Guo et al. 2012;2285;;
biotin sulfone;biotin sulfone;biotin sulfone;–;[M + H];–;–;–;–;–;–;–;277,084;plasma;diagnosis;lung cancer;I, II, III, IV;100;88, 12;median: 60 (44-76);smoker, non-smoker;healthy;100;89, 11;median: 59 (37-71);smoker, non-smoker;DI;ESI;both;Q-TOF;–;DataAnalysis ;Human Metabolome Database, Metlin Database, NIST Chemistry WebBook Database;"Matlab v.12
program package";odds ratio;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Russia;Y;–;23212094;Lokhov et al. 2012;2286;;
halfenprox;halfenprox;halfenprox;–;[M + H];–;–;–;–;–;–;–;477,086;plasma;diagnosis;lung cancer;I, II, III, IV;100;88, 12;median: 60 (44-76);smoker, non-smoker;healthy;100;89, 11;median: 59 (37-71);smoker, non-smoker;DI;ESI;both;Q-TOF;–;DataAnalysis ;Human Metabolome Database, Metlin Database, NIST Chemistry WebBook Database;"Matlab v.12
program package";odds ratio;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Russia;Y;–;23212094;Lokhov et al. 2012;2287;;
permethrin;permethrin;permethrin;–;[M + H];–;–;–;–;–;–;–;391,079;plasma;diagnosis;lung cancer;I, II, III, IV;100;88, 12;median: 60 (44-76);smoker, non-smoker;healthy;100;89, 11;median: 59 (37-71);smoker, non-smoker;DI;ESI;both;Q-TOF;–;DataAnalysis ;Human Metabolome Database, Metlin Database, NIST Chemistry WebBook Database;"Matlab v.12
program package";odds ratio;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Russia;Y;–;23212094;Lokhov et al. 2012;2288;;
R-benzene;R-benzene;R-benzene;–;[M + H];–;–;–;–;–;–;–;151,081;plasma;diagnosis;lung cancer;I, II, III, IV;100;88, 12;median: 60 (44-76);smoker, non-smoker;healthy;100;89, 11;median: 59 (37-71);smoker, non-smoker;DI;ESI;both;Q-TOF;–;DataAnalysis ;Human Metabolome Database, Metlin Database, NIST Chemistry WebBook Database;"Matlab v.12
program package";odds ratio;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;Russia;Y;–;23212094;Lokhov et al. 2012;2289;;
amylose;amylose;amylose;–;–;–;–;–;–;–;Glycometabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;709,1760476728;4,09E-011;–;1,34;ROC curve analysis;–;0,98;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2290;;
bilirubin;bilirubin;bilirubin;–;–;–;HMDB0000054;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;290,0182746357;3,15E-010;–;1,23;ROC curve analysis;–;0,96;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2291;;
maltitol;maltitol;maltitol;–;–;–;–;–;–;–;Glycometabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;61,8199250512;4,35E-009;–;1,25;ROC curve analysis;–;0,93;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2292;;
N-palmitoleoyl ethanolamide;N-palmitoleoyl ethanolamide;N-palmitoleoyl ethanolamide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;19,02731384;5,14E-009;–;1,03;ROC curve analysis;–;0,93;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2293;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;Fatty acid metabolism ;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;15,6707247614;2,45E-010;–;1,28;ROC curve analysis;–;0,98;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2294;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;Fatty acid metabolism ;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;7,4642639323;4,41E-010;–;1,25;ROC curve analysis;–;0,97;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2295;;
ubiquinone;ubiquinone;ubiquinone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;5,617779503;1,15E-009;–;1,29;ROC curve analysis;–;0,96;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2296;;
ubiquinol;ubiquinol;ubiquinol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;5,5404378724;1,53E-009;–;1,23;ROC curve analysis;–;0,96;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2297;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;Fatty acid metabolism ;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;GC;EI;–;–;–;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;4,2574807298;1,79E-008;–;1,16;ROC curve analysis;–;0,93;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2298;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;Amino acid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;GC;EI;–;–;–;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,4383028607;0,00652;–;1,4;ROC curve analysis;–;0,71;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2299;;
alanine;alanine;alanine;–;–;–;–;–;–;–;Amino acid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;GC;EI;–;–;–;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,3815648022;0,000712;–;1,39;ROC curve analysis;–;0,76;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2300;;
3-hydroxybutyric acid;3-hydroxybutyric acid;3-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;GC;EI;–;–;–;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,3609822989;0,00146;–;1,57;ROC curve analysis;–;0,74;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2301;;
deoxycholic acid glycine conjugate;deoxycholic acid glycine conjugate;deoxycholic acid glycine conjugate;–;–;–;–;–;–;–;Amino acid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,3511112189;0,000476;–;1,05;ROC curve analysis;–;0,76;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2302;;
PE(38:6);PE(38:6);PE(38:6);–;–;–;–;–;–;–;Lipid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,346277367;0,000148;–;1,18;ROC curve analysis;–;0,79;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2303;;
glycine;glycine;glycine;–;–;–;–;–;–;–;Amino acid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;GC;EI;–;–;–;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,3253354639;0,0000319;–;1,51;ROC curve analysis;–;0,82;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2304;;
pipecolic acid;pipecolic acid;pipecolic acid;–;–;–;HMDB0000070;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;GC;EI;–;–;–;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,3253354639;0,0000119;–;1,16;ROC curve analysis;–;0,83;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2305;;
PE(36:2);PE(36:2);PE(36:2);–;–;–;–;–;–;–;Lipid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,3230882077;0,000000944;–;1,12;ROC curve analysis;–;0,87;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2306;;
threonine;threonine;threonine;–;–;–;–;–;–;–;Amino acid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;GC;EI;–;–;–;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,3035487211;0,0045;–;1,44;ROC curve analysis;–;0,71;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2307;;
PE(34:2);PE(34:2);PE(34:2);–;–;–;–;–;–;–;Lipid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,2993696762;0,000000944;–;1,12;ROC curve analysis;–;0,87;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2308;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;GC;EI;–;–;–;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,2660925456;0,0000132;–;1,26;ROC curve analysis;–;0,83;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2309;;
pregnenolone sulfate;pregnenolone sulfate;pregnenolone sulfate;–;–;–;–;–;–;–;Steroids metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,1855654463;0,0000116;–;1,23;ROC curve analysis;–;0,83;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2310;;
N(6)-Methyllysine;N(6)-Methyllysine;N(6)-Methyllysine;–;–;–;HMDB0002038;–;–;–;Amino acid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,1507259785;0,000423;–;1,17;ROC curve analysis;–;0,75;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2311;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;Amino acid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,1455916983;5,49E-008;–;1,03;ROC curve analysis;–;0,9;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2312;;
PC(34:4);PC(34:4);PC(34:4);–;–;–;–;–;–;–;Lipid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,1349035296;0,000000527;–;1,22;ROC curve analysis;–;0,85;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2313;;
L-arginine;L-arginine;L-arginine;–;–;–;HMDB0000517;–;–;–;Amino acid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,1294081155;0,000000179;–;1,13;ROC curve analysis;–;0,89;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2314;;
PE(36:4);PE(36:4);PE(36:4);–;–;–;–;–;–;–;Lipid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,1285142283;0,000000127;–;1,31;ROC curve analysis;–;0,9;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2315;;
androsterone sulfate;androsterone sulfate;androsterone sulfate;–;–;–;–;–;–;–;Steroids metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,1258694438;3,53E-009;–;1,11;ROC curve analysis;–;0,95;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2316;;
PS(38:4);PS(38:4);PS(38:4);–;–;–;–;–;–;–;Lipid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,1029488772;0,0000152;–;1,17;ROC curve analysis;–;0,81;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2317;;
PE(38:4);PE(38:4);PE(38:4);–;–;–;–;–;–;–;Lipid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,1022377573;0,000000001;–;1,23;ROC curve analysis;–;0,96;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2318;;
testosterone sulfate;testosterone sulfate;testosterone sulfate;–;–;–;HMDB0002833;–;–;–;Steroids metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,098755164;4,86E-010;–;1,22;ROC curve analysis;–;0,97;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2319;;
ceramides (42:0);ceramides (42:0);ceramides (42:0);–;–;–;–;–;–;–;Lipid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,0830428634;0,000000893;–;1,08;ROC curve analysis;–;0,86;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2320;;
PE(36:1);PE(36:1);PE(36:1);–;–;–;–;–;–;–;Lipid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,0563281539;1,44E-010;–;1,36;ROC curve analysis;–;0,97;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2321;;
PE(40:5);PE(40:5);PE(40:5);–;–;–;–;–;–;–;Lipid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,0131390065;8,09E-011;–;1,3;ROC curve analysis;–;0,98;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2322;;
PE(40:4);PE(40:4);PE(40:4);–;–;–;–;–;–;–;Lipid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;0,0095518772;3,26E-008;–;1,07;ROC curve analysis;–;0,9;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2323;;
3,4,5-trimethoxycinnamic acid;3,4,5-trimethoxycinnamic acid;3,4,5-trimethoxycinnamic acid;–;–;–;HMDB0002511;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;–;3,16E-012;–;1,62;ROC curve analysis;–;1;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2324;;
5-methoxytryptophan;5-methoxytryptophan;5-methoxytryptophan;–;–;–;–;–;–;–;Amino acid metabolism;–;–;plasma;diagnosis;adenocarcinoma;I;31;15, 16;median: 63 (40-81);smoker, non-smoker;healthy;28;20, 8;median: 37 (29-50);smoker, non-smoker;LC;ESI;–;Q-TOF;MS/MS;MassHunter, Mass Profiler Professional software (Agilent) ;NIST 08, HMDB, METLIN, LIPID MAPS;SIMCA-P;Mann–Whitney–Wilcoxon test, OPLS-DA;–;–;–;3,16E-012;–;1,61;ROC curve analysis;–;1;–;–;–;–;–;–;–;–;China;–;–;23857124;Wen et al. 2013;2325;;
cortisol sulfate;cortisol sulfate;cortisol sulfate;–;–;–;–;–;–;–;–;–;–;urine;diagnosis, prognosis;NSCLC;I, II, III, IV;469;237, 232;66,2;smoker, non-smoker;healthy;536;276, 260;66,6;–;LC;ESI;–;Q-TOF;MS/MS;R package XCMS ;METLIN, HMDB ;STATA, SAS Enterprise Guide;Non-parametric Wilcoxon test;–;–;–;–;–;–;random forest;–;"all case: 0.64 (0.61, 0.68)
stage I~II: 0.59 (0.55, 0.64)
all case: creatine riboside+N- acetylneuraminic acid+cortisol sulfate+561+=0.78 (0.75, 0.81)
stage I~II: creatine riboside+N- acetylneuraminic acid+cortisol sulfate+561+=0.71 (0.67, 0.75)";–;–;–;Cox proportional hazards regression;–;"univariate: 1.53 (1.21, 1.94)
multivariate: 1.63 (1.27, 2.08)";"univariate: 0.0004
multivariate: 0.0001";"univariate: 0.01
multivariate: 0.02";US;Y;–;24736543;Mathe et al. 2014;2326;;
creatine riboside;creatine riboside;creatine riboside;–;–;–;–;–;–;–;–;–;–;urine;diagnosis, prognosis;NSCLC;I, II, III, IV;469;237, 232;66,2;smoker, non-smoker;healthy;536;276, 260;66,6;–;LC;ESI;–;Q-TOF;MS/MS;R package XCMS ;METLIN, HMDB ;STATA, SAS Enterprise Guide;Non-parametric Wilcoxon test;–;–;–;–;–;–;random forest;–;"all case: 0.76 (0.73, 0.79)
stage I~II: 0.70 (0.66, 0.74)
all case: creatine riboside+N- acetylneuraminic acid+cortisol sulfate+561+=0.78 (0.75, 0.81)
stage I~II: creatine riboside+N- acetylneuraminic acid+cortisol sulfate+561+=0.71 (0.67, 0.75)";–;–;–;Cox proportional hazards regression;45 months;"univariate: 2.05 (1.54, 2.71) / 0.86 (0.38, 1.95)
multivariate: 1.81 (1.33, 2.45) / 0.78 (0.34, 1.83)";"univariate: < 0.0001 / 0.72
multivariate: 0.0002 / 0.57";"univariate: 0.0005
multivariate: 0.002";US;Y;–;24736543;Mathe et al. 2014;2327;;
N-acetylneuraminic acid;N-acetylneuraminic acid;N-acetylneuraminic acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis, prognosis;NSCLC;I, II, III, IV;469;237, 232;66,2;smoker, non-smoker;healthy;536;276, 260;66,6;–;LC;ESI;–;Q-TOF;MS/MS;R package XCMS ;METLIN, HMDB ;STATA, SAS Enterprise Guide;Non-parametric Wilcoxon test;–;–;–;–;–;–;random forest;–;"all case: 0.67 (0.64, 0.70)
stage I~II: 0.60 (0.56, 0.65)
all case: creatine riboside+N- acetylneuraminic acid+cortisol sulfate+561+=0.78 (0.75, 0.81)
stage I~II: creatine riboside+N- acetylneuraminic acid+cortisol sulfate+561+=0.71 (0.67, 0.75)";–;–;–;Cox proportional hazards regression;15 months;"univariate: 1.74 (1.22, 2.48) / 1.14 (0.82, 1.57)
multivariate: 1.54 (1.06, 2.25) / 1.27 (0.90, 1.80)";"univariate: 0.002 / 0.44
multivariate: 0.025 / 0.17";"univariate: 0.06
multivariate: 0.09";US;Y;–;24736543;Mathe et al. 2014;2328;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;Methionine metabolism;–;125,9869;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, METLIN, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;3,47;0,000418;–;4,91;ROC curve analysis ;–;"Taurine+Hippuric Acid+Tyrosine+Uric Acid= 0.970 (0.924-1.016)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2329;;
acylcarnitine C3;acylcarnitine C3;acylcarnitine C3;–;–;–;–;–;–;–;Fatty acid metabolism;–;218,1383;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;2,83;0,0243;–;1,32;ROC curve analysis ;–;"Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=0.958 (0.902-1.013)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2330;;
carnitine;carnitine;carnitine;–;–;–;HMDB0000062;–;–;–;Fatty acid metabolism;–;162,112;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;2,83;0,0106;–;2,82;ROC curve analysis ;–;"Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=0.958 (0.902-1.013)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2331;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;Tyrosine metabolism;–;180,0509;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;negative;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;2,44;0,000562;–;1,41;ROC curve analysis ;–;"Taurine+Hippuric Acid+Tyrosine+Uric Acid= 0.970 (0.924-1.016)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2332;;
o-phosphotyrosine;o-phosphotyrosine;o-phosphotyrosine;–;–;–;–;–;–;–;Tyrosine metabolism;–;260,022;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;negative;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;1,49;0,0164;–;2,31;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2333;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;Purine metabolism;–;167,0192;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;negative;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;1,44;0,00109;–;7,77;ROC curve analysis ;–;"Taurine+Hippuric Acid+Tyrosine+Uric Acid= 0.970 (0.924-1.016)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2334;;
N-acryloylglycine;N-acryloylglycine;N-acryloylglycine;–;–;–;–;–;–;–;–;–;130,05;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;1,43;0,000292;–;1,71;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2335;;
threonylcarbonyl adenosine;threonylcarbonyl adenosine;threonylcarbonyl adenosine;–;–;–;–;–;–;–;–;–;413,1412;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;1,37;0,000144;–;1,49;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2336;;
dimethylarginine;dimethylarginine;dimethylarginine;–;–;–;–;–;–;–;–;–;203,1486;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;1,32;0,000249;–;1,93;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2337;;
hippuric acid;hippuric acid;hippuric acid;–;–;–;HMDB0000714;–;–;–;–;–;180,0882;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;1,31;0,000446;–;2,63;ROC curve analysis ;–;"Taurine+Hippuric Acid+Tyrosine+Uric Acid= 0.970 (0.924-1.016)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2338;;
acylcarnitine C10:1+OH;acylcarnitine C10:1+OH;acylcarnitine C10:1+OH;–;–;–;–;–;–;–;Fatty acid metabolism;–;330,2272;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,62;0,0394;–;2,09;ROC curve analysis ;–;"Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=0.958 (0.902-1.013)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2339;;
acylcarnitine C8:1;acylcarnitine C8:1;acylcarnitine C8:1;–;–;–;–;–;–;–;Fatty acid metabolism;–;286,2006;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,58;0,0172;–;6,85;ROC curve analysis ;–;"Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=0.958 (0.902-1.013)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2340;;
acylcarnitine C10:3;acylcarnitine C10:3;acylcarnitine C10:3;–;–;–;–;–;–;–;Fatty acid metabolism;–;310,2003;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,58;0,0102;–;4,39;ROC curve analysis ;–;"Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=0.958 (0.902-1.013)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2341;;
acylcarnitine C12:4;acylcarnitine C12:4;acylcarnitine C12:4;–;–;–;–;–;–;–;Fatty acid metabolism;–;336,2163;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,51;0,0243;–;1,04;ROC curve analysis ;–;"Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=0.958 (0.902-1.013)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2342;;
acylcarnitine C10:3;acylcarnitine C10:3;acylcarnitine C10:3;–;–;–;–;–;–;–;Fatty acid metabolism;–;310,2003;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,49;0,00307;–;5,31;ROC curve analysis ;–;"Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=0.958 (0.902-1.013)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2343;;
acylcarnitine C7:1;acylcarnitine C7:1;acylcarnitine C7:1;–;–;–;–;–;–;–;Fatty acid metabolism;–;272,1863;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,48;0,00611;–;1,16;ROC curve analysis ;–;"Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=0.958 (0.902-1.013)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2344;;
acylcarnitine C8:2;acylcarnitine C8:2;acylcarnitine C8:2;–;–;–;–;–;–;–;Fatty acid metabolism;–;284,186;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,45;0,00391;–;1,54;ROC curve analysis ;–;"Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=0.958 (0.902-1.013)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2345;;
acylcarnitine C10:2+OH;acylcarnitine C10:2+OH;acylcarnitine C10:2+OH;–;–;–;–;–;–;–;Fatty acid metabolism;–;328,2115;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,35;0,00395;–;1,37;ROC curve analysis ;–;"Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=0.958 (0.902-1.013)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2346;;
acylcarnitine C9:1;acylcarnitine C9:1;acylcarnitine C9:1;–;–;–;–;–;–;–;Fatty acid metabolism;–;300,2166;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,32;0,0114;–;2,34;ROC curve analysis ;–;"Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=0.958 (0.902-1.013)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2347;;
acylcarnitine C8;acylcarnitine C8;acylcarnitine C8;–;–;–;–;–;–;–;Fatty acid metabolism;–;288,2174;urine;diagnosis;NSCLC ;–;20;10, 10;38-74;–;healthy;20;10, 10;35-66;–;LC;ESI;positive;Q-TOF;MS/MS;MassLynx;HMDB, metlin, lipidmaps;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,27;0,012;–;1,15;ROC curve analysis ;–;"Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=0.958 (0.902-1.013)
Taurine+Hippuric Acid+Tyrosine+Uric Acid+Carnitine+Acylcarnitine C3+Acylcarnitine C7:1+Acylcarnitine C8:2+Acylcarnitine C8:1+Acylcarnitine C8+Acylcarnitine C9:1+Acylcarnitine C10:3+Acylcarnitine C10:3+[Acylcarnitine C10:2+OH]+[Acylcarnitine C10:1+OH]+Acylcarnitine C12:4=1.000 (1.000-1.000)";–;–;–;–;–;–;–;–;China;Y;–;24771673;Wu et al. 2014;2348;;
1-arachidonoyl glycerol;1-arachidonoyl glycerol;1-arachidonoyl glycerol;–;–;–;–;–;–;–;Eicosanoid;–;379,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,5;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2349;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;Fatty acid;–;303,2;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;both;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,5;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2350;;
carnitine 10:1;carnitine 10:1;carnitine 10:1;–;–;–;–;–;–;–;Fatty acid ester;–;314,2;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,4;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2351;;
carnitine 8:1;carnitine 8:1;carnitine 8:1;–;–;–;–;–;–;–;Fatty acid ester;–;286,2;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,1;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2352;;
choline;choline;choline;–;–;–;HMDB0000097;–;–;–;Alcohol and Polyol;–;104,1;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,2;ROC curve analysis ;–;choline+linoleic acid=1;1;0,96;–;–;–;–;–;–;China;Y;–;24856296;Li et al. 2014;2353;;
DG (38:8);DG (38:8);DG (38:8);–;–;–;–;–;–;–;DG;–;637,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;3,2;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2354;;
fatty acid amide C20:0;fatty acid amide C20:0;fatty acid amide C20:0;–;–;–;–;–;–;–;Fatty acid amide;–;312,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,7;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2355;;
fatty acid amide C20:1;fatty acid amide C20:1;fatty acid amide C20:1;–;–;–;–;–;–;–;Fatty acid amide;–;310,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;3,9;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2356;;
fatty acid amide C22:1;fatty acid amide C22:1;fatty acid amide C22:1;–;–;–;–;–;–;–;Fatty acid amide;–;338,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,3;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2357;;
fatty acid amide C22:2;fatty acid amide C22:2;fatty acid amide C22:2;–;–;–;–;–;–;–;Fatty acid amide;–;336,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,3;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2358;;
fatty acid amide C24:1;fatty acid amide C24:1;fatty acid amide C24:1;–;–;–;–;–;–;–;Fatty acid amide;–;366,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;8,7;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2359;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;Fatty acid;–;279,2;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;both;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;6,3;ROC curve analysis ;–;choline+linoleic acid=1;1;0,96;–;–;–;–;–;–;China;Y;–;24856296;Li et al. 2014;2360;;
LPC(16:0);LPC(16:0);LPC(16:0);–;–;–;–;–;–;–;Lysophosphatidylcholine;–;496,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;8,6;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2361;;
LPC 16:0 isomer;LPC 16:0 isomer;LPC 16:0 isomer;–;–;–;–;–;–;–;Lysophosphatidylcholine;–;496,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;3,7;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2362;;
LPC(18:0);LPC(18:0);LPC(18:0);–;–;–;HMDB0010384;–;–;–;Lysophosphatidylcholine;–;524,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;6,3;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2363;;
LPC(18:2);LPC(18:2);LPC(18:2);–;–;–;HMDB0010386;–;–;–;Lysophosphatidylcholine;–;520,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;6,4;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2364;;
LPC(20:4);LPC(20:4);LPC(20:4);–;–;–;–;–;–;–;Lysophosphatidylcholine;–;544,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;2,4;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2365;;
LPC(20:5);LPC(20:5);LPC(20:5);–;–;–;–;–;–;–;Lysophosphatidylcholine;–;542,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;2,3;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2366;;
LPC(22:3);LPC(22:3);LPC(22:3);–;–;–;–;–;–;–;Lysophosphatidylcholine;–;546,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,4;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2367;;
LPC C16 1;LPC C16 1;LPC C16 1;–;–;–;–;–;–;–;Lysophosphatidylcholine;–;407,2;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;negative;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,3;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2368;;
LPC C20 3;LPC C20 3;LPC C20 3;–;–;–;–;–;–;–;Lysophosphatidylcholine;–;459,2;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;negative;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,1;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2369;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;Fatty acid;–;281,2;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;both;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;7,4;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2370;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;Fatty acid;–;255,2;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;both;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;6;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2371;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;–;–;HMDB0003229;–;–;–;Fatty acid;–;253,2;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;negative;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,5;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2372;;
SM(d18:1/14:0);SM(d18:1/14:0);SM(d18:1/14:0);–;–;–;–;–;–;–;SM;–;675,7;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;positive;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;1,6;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2373;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;Fatty acid;–;283,3;serum;diagnosis;NSCLC, SCLC;–;23;12, 11;63.0 ± 9.8 / 59.4 ± 5.8;–;healthy;23;11, 12;51.0 ± 11.1 / 56.3 ± 14.3;–;LC;–;negative;Q-TOF;MS/MS;MarkerLynx;METLIN, HMDB, KEGG;SIMCA-P, SPSS;PCA, PLS-DA, OSC-PLS-DA, student’s t-test;–;–;–;0,05;–;2,6;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;24856296;Li et al. 2014;2374;;
1(R)-a-pinene;1(R)-a-pinene;1(R)-a-pinene;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2375;;
1(R)-a-pinene;1(R)-a-pinene;1(R)-a-pinene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2376;;
2,3,4-trimethylpentane;2,3,4-trimethylpentane;2,3,4-trimethylpentane;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2377;;
2,3,4-trimethylpentane;2,3,4-trimethylpentane;2,3,4-trimethylpentane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2378;;
2,4-dimethyl-1-heptene;2,4-dimethyl-1-heptene;2,4-dimethyl-1-heptene;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2379;;
2,4-dimethyl-1-heptene;2,4-dimethyl-1-heptene;2,4-dimethyl-1-heptene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2380;;
2,4-dimethylheptane;2,4-dimethylheptane;2,4-dimethylheptane;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2381;;
2,4-dimethylheptane;2,4-dimethylheptane;2,4-dimethylheptane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2382;;
2-butanon;2-butanon;2-butanon;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2383;;
2-butanon;2-butanon;2-butanon;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2384;;
2-butenal;2-butenal;2-butenal;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2385;;
2-butenal;2-butenal;2-butenal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2386;;
2-hexanone;2-hexanone;2-hexanone;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2387;;
2-hexanone;2-hexanone;2-hexanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2388;;
2-methyl-1-pentene;2-methyl-1-pentene;2-methyl-1-pentene;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2389;;
2-methyl-1-pentene;2-methyl-1-pentene;2-methyl-1-pentene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2390;;
2-methylbutanal;2-methylbutanal;2-methylbutanal;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2391;;
2-methylbutanal;2-methylbutanal;2-methylbutanal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2392;;
2-methylpentane;2-methylpentane;2-methylpentane;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2393;;
2-methylpentane;2-methylpentane;2-methylpentane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2394;;
2-methylpropanal;2-methylpropanal;2-methylpropanal;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2395;;
2-methylpropanal;2-methylpropanal;2-methylpropanal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2396;;
2-pentanone;2-pentanone;2-pentanone;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2397;;
2-pentanone;2-pentanone;2-pentanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2398;;
2-propanol;2-propanol;2-propanol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2399;;
2-propanol;2-propanol;2-propanol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2400;;
2-propenal;2-propenal;2-propenal;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2401;;
2-propenal;2-propenal;2-propenal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2402;;
3-methylbutanal;3-methylbutanal;3-methylbutanal;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2403;;
3-methylbutanal;3-methylbutanal;3-methylbutanal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2404;;
3-methylhexane;3-methylhexane;3-methylhexane;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2405;;
3-methylhexane;3-methylhexane;3-methylhexane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2406;;
4-methylheptane;4-methylheptane;4-methylheptane;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2407;;
4-methylheptane;4-methylheptane;4-methylheptane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2408;;
4-methyloctane;4-methyloctane;4-methyloctane;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2409;;
4-methyloctane;4-methyloctane;4-methyloctane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2410;;
6-methyl-5-heptene-2-one;6-methyl-5-heptene-2-one;6-methyl-5-heptene-2-one;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2411;;
6-methyl-5-heptene-2-one;6-methyl-5-heptene-2-one;6-methyl-5-heptene-2-one;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2412;;
acetaldehyde;acetaldehyde;acetaldehyde;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2413;;
acetaldehyde;acetaldehyde;acetaldehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2414;;
acetic acid;acetic acid;acetic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2415;;
acetic acid;acetic acid;acetic acid;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2416;;
acetone;acetone;acetone;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2417;;
acetone;acetone;acetone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2418;;
acetonitrile;acetonitrile;acetonitrile;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2419;;
acetonitrile;acetonitrile;acetonitrile;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2420;;
benzaldehyde;benzaldehyde;benzaldehyde;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2421;;
benzaldehyde;benzaldehyde;benzaldehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2422;;
butanedione;butanedione;butanedione;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2423;;
butanedione;butanedione;butanedione;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2424;;
decanal;decanal;decanal;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2425;;
decanal;decanal;decanal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2426;;
ethanol;ethanol;ethanol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;Y;–;24862102;Filipiak et al. 2014;2427;;
ethanol;ethanol;ethanol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2428;;
hexanal;hexanal;hexanal;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2429;;
hexanal;hexanal;hexanal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2430;;
hexane;hexane;hexane;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2431;;
hexane;hexane;hexane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2432;;
methanol;methanol;methanol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2433;;
methanol;methanol;methanol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2434;;
methyl acetate;methyl acetate;methyl acetate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2435;;
methyl acetate;methyl acetate;methyl acetate;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2436;;
N-dodecan;N-dodecan;N-dodecan;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2437;;
N-dodecan;N-dodecan;N-dodecan;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2438;;
nonane;nonane;nonane;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2439;;
nonane;nonane;nonane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2440;;
octanal;octanal;octanal;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;Y;–;24862102;Filipiak et al. 2014;2441;;
octanal;octanal;octanal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2442;;
octane;octane;octane;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2443;;
octane;octane;octane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2444;;
propanal;propanal;propanal;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2445;;
propanal;propanal;propanal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2446;;
propene;propene;propene;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2447;;
propene;propene;propene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2448;;
pyridine;pyridine;pyridine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2449;;
pyridine;pyridine;pyridine;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2450;;
pyrrole;pyrrole;pyrrole;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;NSCLC, SCLC;I, II, III, IV;14;6, 8;67.7, 63.4;smoker, non-smoker;tumor vs. adjacent normal tissue;13;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2451;;
pyrrole;pyrrole;pyrrole;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	;–;36;25, 11;63 ± 7;former, non-smokers;healthy;28;12, 16;52 ± 17;former, non-smokers;GC;–;–;–;–;–;NIST 2005;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;Kruskal–Wallis test, Spearman;–;–;–;–;–;–;–;–;–;–;Austria;–;–;24862102;Filipiak et al. 2014;2452;;
ceramide;ceramide;ceramide;–;–;–;–;–;–;–;–;–;–;pleural effusion;diagnosis;NSCLC, SCLC, anaplastic carcinoma;–;32;13, 19;72.8 ± 11.4;smoker, non-smoker; pulmonary tuberculosis;18;10, 8;59.7 ± 25.2 ;smoker, non-smoker;LC;ESI;both;TripleTOF;MS/MS;PeakView, LipidView (AB SCIEX),  XCMS;HMDB;SIMCA-P13, MedCalc ;t-test, OPLS-DA;–;–;–;0,0000172;–;–;ROC curve analysis ;–;0.726–0.938;72,2;90,6;–;–;–;–;–;–;China;–;–;25117182;Lam et al. 2014;2453;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;pleural effusion;diagnosis;NSCLC, SCLC, anaplastic carcinoma;–;32;13, 19;72.8 ± 11.4;smoker, non-smoker; pulmonary tuberculosis;18;10, 8;59.7 ± 25.2 ;smoker, non-smoker;LC;ESI;both;TripleTOF;MS/MS;PeakView, LipidView (AB SCIEX),  XCMS;HMDB;SIMCA-P13, MedCalc ;t-test, OPLS-DA;–;–;–;8,23E-008;–;–;ROC curve analysis ;–;0.866–0.996;84,4;100;–;–;–;–;–;–;China;–;–;25117182;Lam et al. 2014;2454;;
β-hydroxybutyric acid;β-hydroxybutyric acid;β-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;117;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;5,2053674218;0,001;–;1,14;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2455;;
L-adrenaline;L-adrenaline;L-adrenaline;–;–;–;–;–;–;–;–;–;183,0865;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;3,3473049707;0,001;–;1,366;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2456;;
ferulic acid;ferulic acid;ferulic acid;–;–;–;–;–;–;–;–;–;194,057;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,9342666883;0,001;–;1,112;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2457;;
bilirubin;bilirubin;bilirubin;–;–;–;HMDB0000054;–;–;–;–;–;584,2619;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,6982050687;0,001;–;1,421;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2458;;
α-hydroxyisobutyric acid;α-hydroxyisobutyric acid;α-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;131;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,6207868077;0,001;–;1,98;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2459;;
9,12-octadecadienoic acid;9,12-octadecadienoic acid;9,12-octadecadienoic acid;–;–;–;–;–;–;–;–;–;122;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,514026749;0,001;–;1,5;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2460;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;–;–;132;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,4794153999;0,001;–;1,46;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2461;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;117;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,4622888267;0,001;–;1,72;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2462;;
γ-linolenic acid;γ-linolenic acid;γ-linolenic acid;–;–;–;–;–;–;–;–;–;278,2241;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,3982798276;0,001;–;1,334;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2463;;
adrenosterone;adrenosterone;adrenosterone;–;–;–;–;–;–;–;–;–;300,1658;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,3375544971;0,001;–;1,437;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2464;;
α-hydroxyvaleric acid;α-hydroxyvaleric acid;α-hydroxyvaleric acid;–;–;–;–;–;–;–;–;–;145;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,158456473;0,001;–;1,43;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2465;;
phosphorylcholine;phosphorylcholine;phosphorylcholine;–;–;–;–;–;–;–;–;–;169,0481;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,1331715617;0,001;–;1,116;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2466;;
galactitol 1-phosphate;galactitol 1-phosphate;galactitol 1-phosphate;–;–;–;–;–;–;–;–;–;262,0483;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,1199055668;0,001;–;1,91;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2467;;
1,25-hydroxyvitamin D3;1,25-hydroxyvitamin D3;1,25-hydroxyvitamin D3;–;–;–;–;–;–;–;–;–;416,3266;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,1199055668;0,001;–;1,831;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2468;;
3-hydroxy-3-methyl-glutaric acid;3-hydroxy-3-methyl-glutaric acid;3-hydroxy-3-methyl-glutaric acid;–;–;–;–;–;–;–;–;–;162,0524;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,0748398731;0,001;–;1,06;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2469;;
γ-linolenic acid;γ-linolenic acid;γ-linolenic acid;–;–;–;–;–;–;–;–;–;278,2241;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,069095163;0,001;–;1,468;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2470;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;–;–;246;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,0562276533;0,001;–;1,37;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2471;;
lauroylcarnitine;lauroylcarnitine;lauroylcarnitine;–;–;–;–;–;–;–;–;–;343,2715;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,0505344758;0,001;–;1,194;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2472;;
glycerophospho-N-arachidonoyl ethanolamine;glycerophospho-N-arachidonoyl ethanolamine;glycerophospho-N-arachidonoyl ethanolamine;–;–;–;–;–;–;–;–;–;501,2862;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;2,0083350865;0,001;–;1,781;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2473;;
α-hydroxyisobutyric acid;α-hydroxyisobutyric acid;α-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;131;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,9861849909;0,001;–;1,89;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2474;;
1,25-hydroxyvitamin D3;1,25-hydroxyvitamin D3;1,25-hydroxyvitamin D3;–;–;–;–;–;–;–;–;–;416,3266;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,9793133128;0,001;–;1,428;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2475;;
sphinganine;sphinganine;sphinganine;–;–;–;HMDB0000269;–;–;–;–;–;301,2973;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,972465409;0,001;–;1,919;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2476;;
2-hydroxyglutarate;2-hydroxyglutarate;2-hydroxyglutarate;–;–;–;–;–;–;–;–;–;148,0363;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,9683680441;0,001;–;1,256;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2477;;
dimethyl fumarate;dimethyl fumarate;dimethyl fumarate;–;–;–;–;–;–;–;–;–;144,0417;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,9385796339;0,001;–;1,317;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2478;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;120;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,9318726578;0,001;–;1,03;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2479;;
L-adrenaline;L-adrenaline;L-adrenaline;–;–;–;–;–;–;–;–;–;183,0865;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,8634808586;0,002;–;1,108;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2480;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;73;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,8531761238;0,001;–;2,3;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2481;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;179;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,8531761238;0,001;–;1,68;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2482;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;–;–;280,24;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,8276629005;0,001;–;1,247;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2483;;
phosphorylcholine;phosphorylcholine;phosphorylcholine;–;–;–;–;–;–;–;–;–;169,0481;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,8251309771;0,001;–;1,155;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2484;;
pyroglutamic acid;pyroglutamic acid;pyroglutamic acid;–;–;–;HMDB0000267;–;–;–;–;–;232;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,8150383106;0,001;–;1,35;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2485;;
traumatic acid;traumatic acid;traumatic acid;–;–;–;–;–;–;–;–;–;228,1325;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,8137806579;0,001;–;1,55;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2486;;
adrenosterone;adrenosterone;adrenosterone;–;–;–;–;–;–;–;–;–;300,1658;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,811267966;0,001;–;1,727;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2487;;
L-adrenaline;L-adrenaline;L-adrenaline;–;–;–;–;–;–;–;–;–;183,0865;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,7962647458;0,004;–;1,022;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2488;;
oxalosuccinic acid;oxalosuccinic acid;oxalosuccinic acid;–;–;–;–;–;–;–;–;–;190,0093;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,7629603158;0,001;–;1,56;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2489;;
palmitoyl-L-carnitine;palmitoyl-L-carnitine;palmitoyl-L-carnitine;–;–;–;–;–;–;–;–;–;399,3345;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,7218983767;0,001;–;1,245;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2490;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;–;–;247;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,7171308729;0,001;–;1,03;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2491;;
glutamylphenylalanine;glutamylphenylalanine;glutamylphenylalanine;–;–;–;–;–;–;–;–;–;294,1205;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,7171308729;0,001;–;1,615;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2492;;
L-carnitine;L-carnitine;L-carnitine;–;–;–;HMDB0000062;–;–;–;–;–;161,1047;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6958399293;0,001;–;1,57;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2493;;
acetylcarnitine;acetylcarnitine;acetylcarnitine;–;–;–;HMDB0000201;–;–;–;–;–;203,1152;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6876315923;0,001;–;1,184;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2494;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;–;–;244,0706;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6841259072;0,001;–;1,488;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2495;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;–;–;280,24;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6829589646;0,001;–;1,335;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2496;;
caffeic acid 3-sulfate;caffeic acid 3-sulfate;caffeic acid 3-sulfate;–;–;–;–;–;–;–;–;–;260,0036;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6597891712;0,001;–;1,563;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2497;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;168,0283;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,657489809;0,001;–;1,52;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2498;;
arachidyl carnitine;arachidyl carnitine;arachidyl carnitine;–;–;–;–;–;–;–;–;–;455,3962;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6494670972;0,001;–;1,199;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2499;;
α-hydroxyvaleric acid;α-hydroxyvaleric acid;α-hydroxyvaleric acid;–;–;–;–;–;–;–;–;–;145;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6471820345;0,001;–;1,09;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2500;;
acetylcarnitine;acetylcarnitine;acetylcarnitine;–;–;–;HMDB0000201;–;–;–;–;–;203,1152;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6437603746;0,001;–;1,297;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2501;;
corticosterone;corticosterone;corticosterone;–;–;–;–;–;–;–;–;–;346,2129;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6369383632;0,006;–;1,001;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2502;;
18-hydroxycorticosterone;18-hydroxycorticosterone;18-hydroxycorticosterone;–;–;–;–;–;–;–;–;–;362,2087;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6324060923;0,001;–;1,494;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2503;;
cortisol;cortisol;cortisol;–;–;–;–;–;–;–;–;–;362,2087;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6278863701;0,001;–;1,135;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2504;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;174;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6132835184;0,001;–;1,36;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2505;;
glycerophospho-N-oleoyl ethanolamine;glycerophospho-N-oleoyl ethanolamine;glycerophospho-N-oleoyl ethanolamine;–;–;–;–;–;–;–;–;–;479,3012;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6099322752;0,001;–;1,022;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2506;;
L-pipecolic acid;L-pipecolic acid;L-pipecolic acid;–;–;–;–;–;–;–;–;–;129,0786;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,6077019815;0,001;–;1,331;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2507;;
glycerophospho-N-arachidonoyl ethanolamine;glycerophospho-N-arachidonoyl ethanolamine;glycerophospho-N-arachidonoyl ethanolamine;–;–;–;–;–;–;–;–;–;501,2862;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,5877678619;0,001;–;1,813;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2508;;
phenylglyoxylic acid;phenylglyoxylic acid;phenylglyoxylic acid;–;–;–;–;–;–;–;–;–;150,0274;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,5800826237;0,001;–;1,333;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2509;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;179;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,5691681958;0,001;–;1,14;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2510;;
dimethyl fumarate;dimethyl fumarate;dimethyl fumarate;–;–;–;–;–;–;–;–;–;144,0417;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,5443502662;0,001;–;1,202;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2511;;
oxalosuccinic acid;oxalosuccinic acid;oxalosuccinic acid;–;–;–;–;–;–;–;–;–;190,0093;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,5390072202;0,001;–;1,174;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2512;;
glucose;glucose;glucose;–;–;–;–;–;–;–;–;–;311;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,5368751813;0,001;–;1,61;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2513;;
L-phenylalanine;L-phenylalanine;L-phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;218;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,526259209;0,001;–;1,09;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2514;;
L-ornithine;L-ornithine;L-ornithine;–;–;–;–;–;–;–;–;–;174;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,5052467474;0,01;–;1;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2515;;
L-valine;L-valine;L-valine;–;–;–;–;–;–;–;–;–;117,0783;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,5000389893;0,001;–;1,418;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2516;;
8-hydroxy guanine;8-hydroxy guanine;8-hydroxy guanine;–;–;–;–;–;–;–;–;–;167,0416;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,4917440267;0,001;–;1,246;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2517;;
L-pipecolic acid;L-pipecolic acid;L-pipecolic acid;–;–;–;–;–;–;–;–;–;129,0786;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,4845235706;0,001;–;1,108;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2518;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;–;–;244,0705;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,4845235706;0,001;–;1,281;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2519;;
oleamide;oleamide;oleamide;–;–;–;–;–;–;–;–;–;281,2712;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,4671333442;0,001;–;1,392;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2520;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;168,0271;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,4439291955;0,001;–;1,049;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2521;;
α-hydroxyisobutyric acid;α-hydroxyisobutyric acid;α-hydroxyisobutyric acid;–;–;–;–;–;–;–;–;–;131;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,4439291955;0,001;–;1,18;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2522;;
glycerophospho-N-oleoyl ethanolamine;glycerophospho-N-oleoyl ethanolamine;glycerophospho-N-oleoyl ethanolamine;–;–;–;–;–;–;–;–;–;479,3012;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,4429286869;0,004;–;1,045;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2523;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;329;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,4240501956;0,001;–;1,62;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2524;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;179;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3947436664;0,001;–;1,14;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2525;;
L-carnitine;L-carnitine;L-carnitine;–;–;–;HMDB0000062;–;–;–;–;–;161,1047;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3918463918;0,001;–;1,388;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2526;;
L-valine;L-valine;L-valine;–;–;–;–;–;–;–;–;–;117,0783;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3774500464;0,001;–;1,402;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2527;;
arachidyl carnitine;arachidyl carnitine;arachidyl carnitine;–;–;–;–;–;–;–;–;–;455,3962;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3764956016;0,002;–;1,077;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2528;;
L-lysine;L-lysine;L-lysine;–;–;–;HMDB0000182;–;–;–;–;–;146,1052;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3660402568;0,001;–;1,52;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2529;;
oleamide;oleamide;oleamide;–;–;–;–;–;–;–;–;–;281,2712;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3537862791;0,001;–;1,384;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2530;;
palmitoyl-L-carnitine;palmitoyl-L-carnitine;palmitoyl-L-carnitine;–;–;–;–;–;–;–;–;–;399,3345;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3528482311;0,001;–;1,173;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2531;;
caffeic acid 3-sulfate;caffeic acid 3-sulfate;caffeic acid 3-sulfate;–;–;–;–;–;–;–;–;–;260,0036;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3379275548;0,001;–;1,616;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2532;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;–;–;217;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3379275548;0,001;–;1,19;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2533;;
gluconic acid;gluconic acid;gluconic acid;–;–;–;–;–;–;–;–;–;217;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3195079108;0,001;–;1,37;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2534;;
glycerophospho-N-palmitoyl ethanolamine;glycerophospho-N-palmitoyl ethanolamine;glycerophospho-N-palmitoyl ethanolamine;–;–;–;–;–;–;–;–;–;453,2854;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,315854525;0,001;–;1,213;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2535;;
sphinganine;sphinganine;sphinganine;–;–;–;HMDB0000269;–;–;–;–;–;301,2973;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3149427602;0,001;–;1,027;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2536;;
glucose;glucose;glucose;–;–;–;–;–;–;–;–;–;311;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3103934039;0,001;–;1,14;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2537;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;105;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3103934039;0,001;–;1,03;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2538;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;113,0587;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,3040507353;0,004;–;1,054;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2539;;
phenylglyoxylic acid;phenylglyoxylic acid;phenylglyoxylic acid;–;–;–;–;–;–;–;–;–;150,0274;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,2941456545;0,001;–;1,296;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2540;;
tetradecanoic acid;tetradecanoic acid;tetradecanoic acid;–;–;–;–;–;–;–;–;–;132;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,2923528306;0,001;–;1,21;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2541;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;73;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,265756594;0,001;–;1,33;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2542;;
glycerophospho-N-arachidonoyl ethanolamine;glycerophospho-N-arachidonoyl ethanolamine;glycerophospho-N-arachidonoyl ethanolamine;–;–;–;–;–;–;–;–;–;501,2862;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,2648795424;0,001;–;1,281;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2543;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;140;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,2483305489;0,01;–;1,07;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2544;;
PC(15:0);PC(15:0);PC(15:0);–;–;–;–;–;–;–;–;–;481,3169;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,2414274915;0,001;–;1,356;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2545;;
caffeic acid 3-sulfate;caffeic acid 3-sulfate;caffeic acid 3-sulfate;–;–;–;–;–;–;–;–;–;260,0036;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,2414274915;0,006;–;1,016;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2546;;
ribitol;ribitol;ribitol;–;–;–;–;–;–;–;–;–;218;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,2311444133;0,001;–;1,18;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2547;;
galactose;galactose;galactose;–;–;–;–;–;–;–;–;–;219;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,2226402777;0,001;–;1,52;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2548;;
L-proline;L-proline;L-proline;–;–;–;HMDB0000162;–;–;–;–;–;142;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,2226402777;0,001;–;1,19;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2549;;
L-carnitine;L-carnitine;L-carnitine;–;–;–;HMDB0000062;–;–;–;–;–;161,1047;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,2175660187;0,001;–;1,165;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2550;;
1-linoleoylglycerophosphocholine;1-linoleoylglycerophosphocholine;1-linoleoylglycerophosphocholine;–;–;–;HMDB0010386;–;–;–;–;–;519,3329;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,2091556758;0,001;–;1,178;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2551;;
8-hydroxy guanine;8-hydroxy guanine;8-hydroxy guanine;–;–;–;–;–;–;–;–;–;167,0416;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,2066439197;0,004;–;1,021;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2552;;
tetradecanedioic acid;tetradecanedioic acid;tetradecanedioic acid;–;–;–;–;–;–;–;–;–;258,1826;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,1415547071;0,003;–;1,052;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2553;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;73;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;1,1407637159;0,1;–;1,22;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2554;;
PC(18:0);PC(18:0);PC(18:0);–;–;–;–;–;–;–;–;–;523,364;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,8962666996;0,001;–;1,054;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2555;;
L-valine;L-valine;L-valine;–;–;–;–;–;–;–;–;–;73;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,8350879194;0,001;–;1,28;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2556;;
pyroglutamic acid;pyroglutamic acid;pyroglutamic acid;–;–;–;HMDB0000267;–;–;–;–;–;73;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,8235910173;0,001;–;1,09;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2557;;
pyroglutamic acid;pyroglutamic acid;pyroglutamic acid;–;–;–;HMDB0000267;–;–;–;–;–;73;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,8235910173;0,02;–;1;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2558;;
PC(16:0);PC(16:0);PC(16:0);–;–;–;–;–;–;–;–;–;495,3325;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,8145075631;0,001;–;1,635;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2559;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;73;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,8066417592;0,001;–;1,3;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2560;;
phosphate;phosphate;phosphate;–;–;–;HMDB0001429;–;–;–;–;–;299;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,8010698776;0,001;–;1,52;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2561;;
L-isoleucine;L-isoleucine;L-isoleucine;–;–;–;HMDB0000172;–;–;–;–;–;73;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,7900413119;0,001;–;1,47;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2562;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;73;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,7845840979;0,001;–;1,38;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2563;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;–;–;217;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,7791645797;0,001;–;1,19;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2564;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;73;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,7791645797;0,001;–;1,16;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2565;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;313;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,7631296045;0,001;–;1,56;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2566;;
α-D-glucopyranoside;α-D-glucopyranoside;α-D-glucopyranoside;–;–;–;–;–;–;–;–;–;190;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,7578582833;0,01;–;1,1;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2567;;
PC(16:0);PC(16:0);PC(16:0);–;–;–;–;–;–;–;–;–;495,3325;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,7381572028;0,001;–;1,309;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2568;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;168,0283;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,7366238429;0,002;–;1,08;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2569;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;73;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,732042848;0,001;–;1,14;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2570;;
phosphate;phosphate;phosphate;–;–;–;HMDB0001429;–;–;–;–;–;103;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,732042848;0,001;–;1,01;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2571;;
α-D-glucopyranoside;α-D-glucopyranoside;α-D-glucopyranoside;–;–;–;–;–;–;–;–;–;190;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,732042848;0,001;–;1,21;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2572;;
L-leucine;L-leucine;L-leucine;–;–;–;HMDB0000687;–;–;–;–;–;158;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,7219645978;0,001;–;1,38;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2573;;
L-phenylalanine;L-phenylalanine;L-phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;218;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,7219645978;0,001;–;1,35;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2574;;
aminomalonic acid;aminomalonic acid;aminomalonic acid;–;–;–;–;–;–;–;–;–;218;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,716977624;0,001;–;1,31;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2575;;
tetradecanoic acid;tetradecanoic acid;tetradecanoic acid;–;–;–;–;–;–;–;–;–;132;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,7120250978;0,001;–;1,3;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2576;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;329;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,7071067812;0,001;–;1,32;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2577;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;116;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,6877709091;0,001;–;1,28;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2578;;
2-deoxy-galactopyranose;2-deoxy-galactopyranose;2-deoxy-galactopyranose;–;–;–;–;–;–;–;–;–;218;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,6830201284;0,01;–;1,04;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2579;;
glycocholic acid;glycocholic acid;glycocholic acid;–;–;–;–;–;–;–;–;–;465,3219;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,6671115848;0,001;–;1,319;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2580;;
sphinganine;sphinganine;sphinganine;–;–;–;HMDB0000269;–;–;–;–;–;301,2973;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,6666493385;0,001;–;1,979;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2581;;
L-proline;L-proline;L-proline;–;–;–;HMDB0000162;–;–;–;–;–;142;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,664342907;0,01;–;1,11;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2582;;
glycocholic acid;glycocholic acid;glycocholic acid;–;–;–;–;–;–;–;–;–;465,3219;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,6620444552;0,001;–;1,553;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2583;;
L-threonine;L-threonine;L-threonine;–;–;–;HMDB0000167;–;–;–;–;–;219;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,6551967019;0,001;–;1,76;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2584;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;73;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,6506709277;0,001;–;1,97;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2585;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;–;–;132;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,6372803137;0,01;–;1,01;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2586;;
galactitol 1-phosphate;galactitol 1-phosphate;galactitol 1-phosphate;–;–;–;–;–;–;–;–;–;262,0483;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,62981499;0,001;–;1,399;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2587;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;174;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,6155722067;0,001;–;1,63;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2588;;
PC(15:0);PC(15:0);PC(15:0);–;–;–;–;–;–;–;–;–;481,3159;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,5904963307;0,001;–;1,167;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2589;;
PC(14:0);PC(14:0);PC(14:0);–;–;–;–;–;–;–;–;–;467,3008;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,5868240891;0,001;–;1,249;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2590;;
2-hydroxyglutarate;2-hydroxyglutarate;2-hydroxyglutarate;–;–;–;–;–;–;–;–;–;148,0363;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,5759438212;0,003;–;1,082;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2591;;
bilirubin;bilirubin;bilirubin;–;–;–;HMDB0000054;–;–;–;–;–;584,2619;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,5735535121;0,001;–;1,303;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2592;;
9,12-octadecadienoic acid;9,12-octadecadienoic acid;9,12-octadecadienoic acid;–;–;–;–;–;–;–;–;–;94;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,5703818579;0,001;–;1,19;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2593;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;117;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,5703818579;0,001;–;1,29;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2594;;
prasterone sulfate;prasterone sulfate;prasterone sulfate;–;–;–;–;–;–;–;–;–;368,1655;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,5578696612;0,001;–;1,221;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2595;;
PC(17:0);PC(17:0);PC(17:0);–;–;–;–;–;–;–;–;–;509,3476;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,4876777308;0,001;–;1,267;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2596;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;329;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,4863274737;0,001;–;2,14;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2597;;
octanoylcarnitine;octanoylcarnitine;octanoylcarnitine;–;–;–;HMDB0000791;–;–;–;–;–;287,2086;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,471065637;0,002;–;1,059;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2598;;
traumatic acid;traumatic acid;traumatic acid;–;–;–;–;–;–;–;–;–;228,1325;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,4665164958;0,001;–;1,908;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2599;;
ubiquinone;ubiquinone;ubiquinone;–;–;–;–;–;–;–;–;–;250,1198;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,4328682828;0,001;–;1,293;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2600;;
ferulic acid;ferulic acid;ferulic acid;–;–;–;–;–;–;–;–;–;194,057;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,392020227;0,004;–;1,057;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2601;;
sphingosine;sphingosine;sphingosine;–;–;–;HMDB0000252;–;–;–;–;–;299,2816;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,342458245;0,001;–;1,788;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2602;;
decanoyl-L-Carnitine;decanoyl-L-Carnitine;decanoyl-L-Carnitine;–;–;–;HMDB0000651;–;–;–;–;–;315,2403;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,3389160817;0,001;–;1,403;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2603;;
sphingosine;sphingosine;sphingosine;–;–;–;HMDB0000252;–;–;–;–;–;299,2816;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;before vs. after treatment (operation);30;–;61.58 ± 10.67;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,3372756336;0,001;–;2,164;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2604;;
prasterone sulfate;prasterone sulfate;prasterone sulfate;–;–;–;–;–;–;–;–;–;368,1655;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;LC;ESI;positive;Q-TOF;–;Mass Hunter Qualitative Analysis Software (Agilent Technologies);METLIN;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,3289636313;0,001;–;2,087;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25293627;Chen et al. 2015b;2605;;
2,3,4-trihydroxybutyric acid;2,3,4-trihydroxybutyric acid;2,3,4-trihydroxybutyric acid;–;–;–;–;–;–;–;–;–;292;serum;–;lung cancer;–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,3253354639;0,001;–;2,07;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2606;;
2,3,4-trihydroxybutyric acid;2,3,4-trihydroxybutyric acid;2,3,4-trihydroxybutyric acid;–;–;–;–;–;–;–;–;–;292;serum;–;lung cancer (postoperative);–;30;–;61.58 ± 10.67;–;healthy;30;–;60.35 ± 12.48;–;GC;EI;–;quadrupole;–;ChemStation;NIST;SIMCA-P;PCA, PLS-DA,  independent t test ;–;–;0,3208564744;0,001;–;2,04;–;–;–;–;–;–;–;–;–;–;–;China;Y;" Box plots of the most 
important potential biomarkers ";25293627;Chen et al. 2015b;2607;;
cyclooctanemethanol;cyclooctanemethanol;cyclooctanemethanol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;1663,4929077376;0,0000586;–;1,8178;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2608;;
2-hydroxy-iso-butyrophenone;2-hydroxy-iso-butyrophenone;2-hydroxy-iso-butyrophenone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;278,2041248067;0,000273;–;1,179;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2609;;
2,2-dimethyldecane;2,2-dimethyldecane;2,2-dimethyldecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;50,2133822654;0,000566;–;1,327;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2610;;
propanoic acid, 2-methyl-, 3-hydroxy-2,4, 4-trimethylpentyl ester;propanoic acid, 2-methyl-, 3-hydroxy-2,4, 4-trimethylpentyl ester;propanoic acid, 2-methyl-, 3-hydroxy-2,4, 4-trimethylpentyl ester;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;29,44600482;0,000293;–;1,4871;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2611;;
sulfurous acid, 2-ethylhexyl nonyl ester;sulfurous acid, 2-ethylhexyl nonyl ester;sulfurous acid, 2-ethylhexyl nonyl ester;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;28,6408022697;0,000162;–;1,5626;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2612;;
isopropylbenzene;isopropylbenzene;isopropylbenzene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;24,0839479586;0,003739;–;1,1221;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2613;;
propanoic acid, 2-methyl-, 2,2-dimethyl-1-(2-hydroxy-1-methylethyl)propyl ester;propanoic acid, 2-methyl-, 2,2-dimethyl-1-(2-hydroxy-1-methylethyl)propyl ester;propanoic acid, 2-methyl-, 2,2-dimethyl-1-(2-hydroxy-1-methylethyl)propyl ester;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;19,1596592739;0,00154;–;1,2266;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2614;;
nonane, 3-methyl-5-propyl;nonane, 3-methyl-5-propyl;nonane, 3-methyl-5-propyl;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;16,4498212265;0,000698;–;1,4836;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2615;;
2,3’-bifuran, octahydro;2,3’-bifuran, octahydro;2,3’-bifuran, octahydro;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;16,1112888009;0,00734;–;1,1345;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2616;;
4-methyltoluene;4-methyltoluene;4-methyltoluene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;15,4549812628;0,0000568;–;1,6122;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2617;;
cyclopentanone;cyclopentanone;cyclopentanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;14,4200074018;0,000201;–;1,3522;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2618;;
2-butanone;2-butanone;2-butanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;12,5533455663;0,00341;–;1,2879;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2619;;
ethylaniline;ethylaniline;ethylaniline;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;5,5789746654;0,00666;–;1,2958;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2620;;
2,3,4-trimethyldecane;2,3,4-trimethyldecane;2,3,4-trimethyldecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;4,7239706457;0,00161;–;1,2848;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2621;;
3,4,5,6-tetramethyloctane;3,4,5,6-tetramethyloctane;3,4,5,6-tetramethyloctane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;4;0,000133;–;1,6552;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2622;;
2,2-dimethyldecane;2,2-dimethyldecane;2,2-dimethyldecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;3,9723699817;0,00376;–;1,1814;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2623;;
tetradecane;tetradecane;tetradecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;3,944930818;0,000443;–;1,4729;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2624;;
ethylene carbonate;ethylene carbonate;ethylene carbonate;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;3,8105519922;0,0096;–;1,107;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2625;;
tetradecane;tetradecane;tetradecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;3,7842305869;0,0000287;–;1,7265;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2626;;
dimethylphenylcarbinol;dimethylphenylcarbinol;dimethylphenylcarbinol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;3,4581489252;0,000456;–;1,5584;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2627;;
hexadecane;hexadecane;hexadecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;3,0104934948;0,0027;–;1,365;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2628;;
butyl glycol;butyl glycol;butyl glycol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;2,9690471413;0,00376;–;1,1917;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2629;;
3-phenyl-2-oxazolidinone;3-phenyl-2-oxazolidinone;3-phenyl-2-oxazolidinone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;2,5491212546;0,001611;–;1,6739;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2630;;
butyl glycol;butyl glycol;butyl glycol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;2,3949574092;0,0027;–;1,4783;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2631;;
benzothiazole;benzothiazole;benzothiazole;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;2,3456698985;0,00136;–;1,2373;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2632;;
caprolactam;caprolactam;caprolactam;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;2,2815274317;0,0088;–;1,1532;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;25482491;Wang et al. 2014;2633;;
benzothiazole;benzothiazole;benzothiazole;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;2,1885874025;0,00443;–;1,1968;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2634;;
3-methyl-4-heptanone;3-methyl-4-heptanone;3-methyl-4-heptanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;2,0994333672;0,00135;–;1,0678;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2635;;
ethylaniline;ethylaniline;ethylaniline;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;2,0705298477;0,001611;–;2,1212;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2636;;
ethylaniline;ethylaniline;ethylaniline;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;2,0139111001;0,009605;–;1,4794;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2637;;
caprolactam;caprolactam;caprolactam;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,8408964153;0,004425;–;1,6282;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;25482491;Wang et al. 2014;2638;;
benzothiazole;benzothiazole;benzothiazole;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,6830201284;0,000941;–;1,4415;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2639;;
cyclooctanemethanol;cyclooctanemethanol;cyclooctanemethanol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,5904963307;0,00228;–;1,191;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2640;;
1,6-dioxacyclododecane-7,12-dione;1,6-dioxacyclododecane-7,12-dione;1,6-dioxacyclododecane-7,12-dione;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,5904963307;0,001128;–;1,7674;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2641;;
butyl glycol;butyl glycol;butyl glycol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,554784736;0,00257;–;1,3227;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2642;;
caprolactam;caprolactam;caprolactam;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,5285090203;0,001128;–;2,4544;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;25482491;Wang et al. 2014;2643;;
ethylhexanol;ethylhexanol;ethylhexanol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,5105060629;0,00827;–;1,0584;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2644;;
isolongifolene-5-ol;isolongifolene-5-ol;isolongifolene-5-ol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,4475125355;0,00656;–;1,923;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2645;;
isolongifolene-5-ol;isolongifolene-5-ol;isolongifolene-5-ol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,4263174459;0,000649;–;1,836;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2646;;
tetradecane;tetradecane;tetradecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,3842187953;0,000782;–;1,7512;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2647;;
dimethylphenylcarbinol;dimethylphenylcarbinol;dimethylphenylcarbinol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,3164391485;0,000782;–;1,4897;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2648;;
cyclohexanone;cyclohexanone;cyclohexanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,2973017788;0,00291;–;1,407;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2649;;
dimethylphenylcarbinol;dimethylphenylcarbinol;dimethylphenylcarbinol;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,277392368;0,001128;–;1,7;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2650;;
2,2,4,6,6-pentamethylheptane;2,2,4,6,6-pentamethylheptane;2,2,4,6,6-pentamethylheptane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,2300469127;0,0000366;–;1,004;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2651;;
2,2-dimethyldecane;2,2-dimethyldecane;2,2-dimethyldecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,2284578626;0,000108;–;2,1988;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2652;;
2,2,4,6,6-pentamethylheptane;2,2,4,6,6-pentamethylheptane;2,2,4,6,6-pentamethylheptane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,2176376408;0,000133;–;2,1969;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2653;;
cyclohexanone;cyclohexanone;cyclohexanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,1842836522;0,000246;–;1,216;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2654;;
tetramethylurea;tetramethylurea;tetramethylurea;–;–;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;0,0014699675;0,000403;–;1,608;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2655;;
1,6-dioxacyclododecane-7,12-dione;1,6-dioxacyclododecane-7,12-dione;1,6-dioxacyclododecane-7,12-dione;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2656;;
1,6-dioxacyclododecane-7,12-dione;1,6-dioxacyclododecane-7,12-dione;1,6-dioxacyclododecane-7,12-dione;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2657;;
2,2,4,6,6-pentamethylheptane;2,2,4,6,6-pentamethylheptane;2,2,4,6,6-pentamethylheptane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2658;;
2,3,4-trimethyldecane;2,3,4-trimethyldecane;2,3,4-trimethyldecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2659;;
2,3,4-trimethyldecane;2,3,4-trimethyldecane;2,3,4-trimethyldecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2660;;
2,3’-bifuran, octahydro;2,3’-bifuran, octahydro;2,3’-bifuran, octahydro;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2661;;
2,3’-bifuran, octahydro;2,3’-bifuran, octahydro;2,3’-bifuran, octahydro;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2662;;
2-butanone;2-butanone;2-butanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2663;;
2-butanone;2-butanone;2-butanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2664;;
2-hydroxy-iso-butyrophenone;2-hydroxy-iso-butyrophenone;2-hydroxy-iso-butyrophenone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2665;;
2-hydroxy-iso-butyrophenone;2-hydroxy-iso-butyrophenone;2-hydroxy-iso-butyrophenone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2666;;
3,4,5,6-tetramethyloctane;3,4,5,6-tetramethyloctane;3,4,5,6-tetramethyloctane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2667;;
3,4,5,6-tetramethyloctane;3,4,5,6-tetramethyloctane;3,4,5,6-tetramethyloctane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2668;;
3-methyl-4-heptanone;3-methyl-4-heptanone;3-methyl-4-heptanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2669;;
3-methyl-4-heptanone;3-methyl-4-heptanone;3-methyl-4-heptanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2670;;
3-phenyl-2-oxazolidinone;3-phenyl-2-oxazolidinone;3-phenyl-2-oxazolidinone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2671;;
3-phenyl-2-oxazolidinone;3-phenyl-2-oxazolidinone;3-phenyl-2-oxazolidinone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2672;;
4-methyltoluene;4-methyltoluene;4-methyltoluene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2673;;
4-methyltoluene;4-methyltoluene;4-methyltoluene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2674;;
caprolactam;caprolactam;caprolactam;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;25482491;Wang et al. 2014;2675;;
cyclohexanone;cyclohexanone;cyclohexanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2676;;
cyclooctanemethanol;cyclooctanemethanol;cyclooctanemethanol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2677;;
cyclopentanone;cyclopentanone;cyclopentanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2678;;
cyclopentanone;cyclopentanone;cyclopentanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2679;;
dimethylphenylcarbinol;dimethylphenylcarbinol;dimethylphenylcarbinol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2680;;
ethylaniline;ethylaniline;ethylaniline;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2681;;
ethylene carbonate;ethylene carbonate;ethylene carbonate;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2682;;
ethylene carbonate;ethylene carbonate;ethylene carbonate;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2683;;
ethylhexanol;ethylhexanol;ethylhexanol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2684;;
ethylhexanol;ethylhexanol;ethylhexanol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2685;;
hexadecane;hexadecane;hexadecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2686;;
hexadecane;hexadecane;hexadecane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2687;;
isolongifolene-5-ol;isolongifolene-5-ol;isolongifolene-5-ol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2688;;
isolongifolene-5-ol;isolongifolene-5-ol;isolongifolene-5-ol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2689;;
isopropylbenzene;isopropylbenzene;isopropylbenzene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2690;;
isopropylbenzene;isopropylbenzene;isopropylbenzene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2691;;
nonane, 3-methyl-5-propyl;nonane, 3-methyl-5-propyl;nonane, 3-methyl-5-propyl;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2692;;
nonane, 3-methyl-5-propyl;nonane, 3-methyl-5-propyl;nonane, 3-methyl-5-propyl;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2693;;
propanoic acid, 2-methyl-, 2,2-dimethyl-1-(2-hydroxy-1-methylethyl)propyl ester;propanoic acid, 2-methyl-, 2,2-dimethyl-1-(2-hydroxy-1-methylethyl)propyl ester;propanoic acid, 2-methyl-, 2,2-dimethyl-1-(2-hydroxy-1-methylethyl)propyl ester;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2694;;
propanoic acid, 2-methyl-, 2,2-dimethyl-1-(2-hydroxy-1-methylethyl)propyl ester;propanoic acid, 2-methyl-, 2,2-dimethyl-1-(2-hydroxy-1-methylethyl)propyl ester;propanoic acid, 2-methyl-, 2,2-dimethyl-1-(2-hydroxy-1-methylethyl)propyl ester;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2695;;
propanoic acid, 2-methyl-, 3-hydroxy-2,4, 4-trimethylpentyl ester;propanoic acid, 2-methyl-, 3-hydroxy-2,4, 4-trimethylpentyl ester;propanoic acid, 2-methyl-, 3-hydroxy-2,4, 4-trimethylpentyl ester;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (postoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2696;;
propanoic acid, 2-methyl-, 3-hydroxy-2,4, 4-trimethylpentyl ester;propanoic acid, 2-methyl-, 3-hydroxy-2,4, 4-trimethylpentyl ester;propanoic acid, 2-methyl-, 3-hydroxy-2,4, 4-trimethylpentyl ester;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2697;;
sulfurous acid, 2-ethylhexyl nonyl ester;sulfurous acid, 2-ethylhexyl nonyl ester;sulfurous acid, 2-ethylhexyl nonyl ester;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;tumor vs. adjacent normal tissue (preoperative contralateral vs. ipsilateral);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2698;;
sulfurous acid, 2-ethylhexyl nonyl ester;sulfurous acid, 2-ethylhexyl nonyl ester;sulfurous acid, 2-ethylhexyl nonyl ester;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma;I, II, IV;18;13, 5;58.67 ± 6.34;smoker;before vs. after treatment (operation);18;13, 5;58.67 ± 6.34;smoker;GC;EI;–;–;–;XCMS;–; SIMCA-P;PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;25482491;Wang et al. 2014;2699;;
arachidic acid;arachidic acid;arachidic acid;–;–;–;HMDB0002212;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;3,5;–;0,136;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2700;;
inosine 5'-monophosphate;inosine 5'-monophosphate;inosine 5'-monophosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;3,5;–;0,00085;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2701;;
lysine;lysine;lysine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;2,7;–;0,000065;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2702;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;2,7;–;0,00038;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;25657018;Wikoff et al. 2015b;2703;;
adenosine-5-phosphate;adenosine-5-phosphate;adenosine-5-phosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;2,5;–;0,001;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2704;;
5,6-dihydrouracil;5,6-dihydrouracil;5,6-dihydrouracil;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;2,4;–;0,00000024;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;25657018;Wikoff et al. 2015b;2705;;
UDP GlcNAc;UDP GlcNAc;UDP GlcNAc;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;2,3;–;0,000022;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2706;;
3-phosphoglycerate;3-phosphoglycerate;3-phosphoglycerate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;2,2;–;0,001;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2707;;
alpha-tocopherol;alpha-tocopherol;alpha-tocopherol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;2,2;–;0,00000041;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;25657018;Wikoff et al. 2015b;2708;;
glycerol-3-galactoside;glycerol-3-galactoside;glycerol-3-galactoside;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;2,2;–;0,003;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2709;;
gluconic acid;gluconic acid;gluconic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;2,1;–;0,00038;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2710;;
octadecanol;octadecanol;octadecanol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;2,1;–;0,38;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2711;;
glucose;glucose;glucose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;2;–;0,00037;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;25657018;Wikoff et al. 2015b;2712;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,9;–;0,0000096;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2713;;
5'-deoxy-5'-methylthioadenosine;5'-deoxy-5'-methylthioadenosine;5'-deoxy-5'-methylthioadenosine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,8;–;0,000065;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;25657018;Wikoff et al. 2015b;2714;;
cytidine-5-monophosphate;cytidine-5-monophosphate;cytidine-5-monophosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,8;–;0,001;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2715;;
methioninesulfoxide;methioninesulfoxide;methioninesulfoxide;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,8;–;0,045;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2716;;
ribitol;ribitol;ribitol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,8;–;0,00000066;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2717;;
2-hydroxyglutaric acid;2-hydroxyglutaric acid;2-hydroxyglutaric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,7;–;0,003;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2718;;
4-hydroxyproline;4-hydroxyproline;4-hydroxyproline;–;–;–;HMDB0000725;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,7;–;0,47;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2719;;
maltotriose;maltotriose;maltotriose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,7;–;0,615;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2720;;
trehalose;trehalose;trehalose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,7;–;0,523;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2721;;
238267 trisaccharide;238267 trisaccharide;238267 trisaccharide;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,6;–;0,177;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2722;;
5-aminovaleric acid;5-aminovaleric acid;5-aminovaleric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,6;–;0,313;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2723;;
allantoic acid;allantoic acid;allantoic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,6;–;0,005;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2724;;
ascorbic acid;ascorbic acid;ascorbic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,6;–;0,739;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2725;;
biuret;biuret;biuret;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,6;–;0,002;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2726;;
cellobiotol;cellobiotol;cellobiotol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,6;–;0,443;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2727;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,6;–;0,007;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2728;;
cysteine;cysteine;cysteine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,6;–;0,003;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2729;;
erythronic acid lactone;erythronic acid lactone;erythronic acid lactone;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,6;–;0,006;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2730;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,6;–;0,012;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2731;;
maltose;maltose;maltose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,6;–;0,47;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2732;;
adenine;adenine;adenine;–;–;–;HMDB0000034;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,5;–;0,00037;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2733;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,5;–;0,007;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2734;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,5;–;0,004;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2735;;
dihydrosphingosine;dihydrosphingosine;dihydrosphingosine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,5;–;0,00054;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2736;;
fucose;fucose;fucose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,5;–;0,008;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2737;;
N-acetyl-D-mannosamine;N-acetyl-D-mannosamine;N-acetyl-D-mannosamine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,5;–;0,00033;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2738;;
3-phenyllactic acid;3-phenyllactic acid;3-phenyllactic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,152;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2739;;
arabitol;arabitol;arabitol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,003;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2740;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,011;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2741;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,002;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2742;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,017;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2743;;
inositol-4-monophosphate;inositol-4-monophosphate;inositol-4-monophosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,02;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2744;;
mannitol;mannitol;mannitol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,017;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2745;;
nicotinamide;nicotinamide;nicotinamide;–;–;–;HMDB0001406;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,006;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2746;;
phosphoethanolamine;phosphoethanolamine;phosphoethanolamine;–;–;–;HMDB0000224;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,289;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2747;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,008;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2748;;
sorbitol;sorbitol;sorbitol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,837;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2749;;
spermidine;spermidine;spermidine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,002;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2750;;
triethanolamine;triethanolamine;triethanolamine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,002;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2751;;
uracil;uracil;uracil;–;–;–;HMDB0000300;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,037;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2752;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,019;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2753;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,002;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2754;;
xylitol;xylitol;xylitol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,4;–;0,00094;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2755;;
2-phenylpropanol;2-phenylpropanol;2-phenylpropanol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,052;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2756;;
4-hydroxybutyric acid;4-hydroxybutyric acid;4-hydroxybutyric acid;–;–;–;HMDB0000710;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,004;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2757;;
acetophenone;acetophenone;acetophenone;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,178;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2758;;
adenosine;adenosine;adenosine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,057;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2759;;
adipic acid;adipic acid;adipic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,163;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2760;;
aminomalonic acid;aminomalonic acid;aminomalonic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,03;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2761;;
arabinose;arabinose;arabinose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,00045;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2762;;
caprylic acid;caprylic acid;caprylic acid;–;–;–;HMDB0000482;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,002;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2763;;
cystine;cystine;cystine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,178;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2764;;
digalacturonic acid;digalacturonic acid;digalacturonic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,47;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2765;;
dodecanol;dodecanol;dodecanol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,002;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2766;;
fructose-6-phosphate;fructose-6-phosphate;fructose-6-phosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,193;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2767;;
hydroxylamine;hydroxylamine;hydroxylamine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,013;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2768;;
isothreonic acid;isothreonic acid;isothreonic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,008;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2769;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,116;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2770;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,045;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2771;;
phenylethylamine;phenylethylamine;phenylethylamine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,51;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2772;;
quinic acid;quinic acid;quinic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,02;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2773;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,726;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2774;;
sucrose;sucrose;sucrose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,313;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2775;;
tagatose;tagatose;tagatose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,022;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2776;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,095;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2777;;
trans-4-hydroxyproline;trans-4-hydroxyproline;trans-4-hydroxyproline;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,3;–;0,008;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2778;;
1,5-anhydroglucitol;1,5-anhydroglucitol;1,5-anhydroglucitol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,037;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2779;;
1-monostearin;1-monostearin;1-monostearin;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,047;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2780;;
2-ketoisocaproic acid;2-ketoisocaproic acid;2-ketoisocaproic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,285;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2781;;
2-monopalmitin;2-monopalmitin;2-monopalmitin;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,129;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2782;;
alanine;alanine;alanine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,013;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2783;;
asparagine;asparagine;asparagine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,18;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2784;;
azelaic acid;azelaic acid;azelaic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,178;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2785;;
capric acid;capric acid;capric acid;–;–;–;HMDB0000511;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,004;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2786;;
cysteine-glycine;cysteine-glycine;cysteine-glycine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,097;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2787;;
erythronic acid;erythronic acid;erythronic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,048;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2788;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,17;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2789;;
FAD;FAD;FAD;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,092;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2790;;
fructose;fructose;fructose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,562;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2791;;
galactose-6-phosphate;galactose-6-phosphate;galactose-6-phosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,152;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2792;;
gamma-tocopherol;gamma-tocopherol;gamma-tocopherol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,01;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;25657018;Wikoff et al. 2015b;2793;;
glucose-6-phosphate;glucose-6-phosphate;glucose-6-phosphate;–;–;–;HMDB0001401;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,19;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2794;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,019;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2795;;
glycerol-alpha-phosphate;glycerol-alpha-phosphate;glycerol-alpha-phosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,231;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2796;;
glycerol-beta-phosphate;glycerol-beta-phosphate;glycerol-beta-phosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,201;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2797;;
glycocyamine;glycocyamine;glycocyamine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,392;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2798;;
isoleucine;isoleucine;isoleucine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,124;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2799;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,035;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2800;;
orotic acid;orotic acid;orotic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,389;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2801;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,027;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2802;;
pelargonic acid;pelargonic acid;pelargonic acid;–;–;–;HMDB0000847;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,033;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2803;;
pentadecanoic acid (C15:0);pentadecanoic acid (C15:0);pentadecanoic acid (C15:0);–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,015;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2804;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,18;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2805;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,047;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2806;;
threonic acid;threonic acid;threonic acid;–;–;–;HMDB0000943;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,648;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2807;;
thymine;thymine;thymine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,306;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2808;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,837;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2809;;
UDP-glucuronic acid;UDP-glucuronic acid;UDP-glucuronic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,2;–;0,007;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2810;;
1-monopalmitin;1-monopalmitin;1-monopalmitin;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,047;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2811;;
2-aminoadipic acid;2-aminoadipic acid;2-aminoadipic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,77;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2812;;
2-hydroxybutanoic acid;2-hydroxybutanoic acid;2-hydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,178;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2813;;
2-monoolein;2-monoolein;2-monoolein;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,361;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2814;;
3-aminoisobutyric acid;3-aminoisobutyric acid;3-aminoisobutyric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,275;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2815;;
3-hydroxybutanoic acid;3-hydroxybutanoic acid;3-hydroxybutanoic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,523;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2816;;
5-hydroxynorvaline;5-hydroxynorvaline;5-hydroxynorvaline;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,457;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2817;;
5-methoxytryptamine;5-methoxytryptamine;5-methoxytryptamine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,725;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2818;;
allo-inositol;allo-inositol;allo-inositol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,19;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2819;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,039;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2820;;
beta-alanine;beta-alanine;beta-alanine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,375;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2821;;
dihydroabietic acid;dihydroabietic acid;dihydroabietic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,873;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2822;;
dodecane;dodecane;dodecane;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,275;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2823;;
ethanol phosphate N;ethanol phosphate N;ethanol phosphate N;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,837;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2824;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,647;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2825;;
glycine;glycine;glycine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,202;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2826;;
guanine;guanine;guanine;–;–;–;HMDB0000132;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,249;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2827;;
homoserine;homoserine;homoserine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,392;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2828;;
hydroxycarbamate;hydroxycarbamate;hydroxycarbamate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,19;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2829;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,386;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2830;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,392;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2831;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,394;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2832;;
isoheptadecanoic acid (methyl-C16:0);isoheptadecanoic acid (methyl-C16:0);isoheptadecanoic acid (methyl-C16:0);–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,178;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2833;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,377;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2834;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,416;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2835;;
mannose;mannose;mannose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,542;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2836;;
methanolphosphate;methanolphosphate;methanolphosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,204;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2837;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,405;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2838;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,084;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2839;;
N-methylalanine;N-methylalanine;N-methylalanine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,826;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2840;;
octadecane-1,12-diol N;octadecane-1,12-diol N;octadecane-1,12-diol N;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,129;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2841;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,663;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2842;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,429;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2843;;
oxoproline;oxoproline;oxoproline;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,094;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2844;;
pantothenic acid;pantothenic acid;pantothenic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,725;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2845;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,328;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2846;;
phenylpyruvic acid;phenylpyruvic acid;phenylpyruvic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,202;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2847;;
pipecolic acid;pipecolic acid;pipecolic acid;–;–;–;HMDB0000070;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,123;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2848;;
putrescine;putrescine;putrescine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,73;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2849;;
salicylaldehyde;salicylaldehyde;salicylaldehyde;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,372;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2850;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,758;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2851;;
shikimic acid;shikimic acid;shikimic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,845;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2852;;
threitol;threitol;threitol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,18;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2853;;
threonine;threonine;threonine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,291;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2854;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,429;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2855;;
uridine-5'-monophosphate;uridine-5'-monophosphate;uridine-5'-monophosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,555;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2856;;
xanthosine;xanthosine;xanthosine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1,1;–;0,826;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2857;;
1-hexadecanol;1-hexadecanol;1-hexadecanol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,441;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2858;;
alpha-ketoglutaric acid;alpha-ketoglutaric acid;alpha-ketoglutaric acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,845;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2859;;
aspartic acid;aspartic acid;aspartic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,644;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2860;;
behenic acid;behenic acid;behenic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,644;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2861;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,655;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2862;;
conduritol-beta-epoxide;conduritol-beta-epoxide;conduritol-beta-epoxide;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,694;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2863;;
cytidine-5-diphosphate;cytidine-5-diphosphate;cytidine-5-diphosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,926;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2864;;
eicosenoic acid;eicosenoic acid;eicosenoic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,635;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2865;;
erythritol;erythritol;erythritol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,81;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2866;;
fructose-1-phosphate;fructose-1-phosphate;fructose-1-phosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,696;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2867;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,845;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2868;;
glucuronic acid;glucuronic acid;glucuronic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,846;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2869;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,507;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2870;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,845;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2871;;
levoglucosan;levoglucosan;levoglucosan;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,846;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2872;;
maleimide;maleimide;maleimide;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,837;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2873;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,837;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2874;;
pseudo uridine;pseudo uridine;pseudo uridine;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,846;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2875;;
pyrophosphate;pyrophosphate;pyrophosphate;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,67;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2876;;
ribonic acid;ribonic acid;ribonic acid;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,38;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2877;;
ribose;ribose;ribose;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,696;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2878;;
stigmasterol;stigmasterol;stigmasterol;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,954;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2879;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,615;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2880;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;39;15, 24;72.33 ± 8.78;smoker, non-smoker;tumor vs. adjacent normal tissue;39;15, 24;72.33 ± 8.78;smoker, non-smoker;GC;EI;–;TOF;–;BinBase;NIST11, BinBase;–;OPLS-DA;–;–;1;–;0,846;–;–;–;–;–;–;–;–;–;–;–;–;US;–;–;25657018;Wikoff et al. 2015b;2881;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;plasma;–;adenocarcinoma, squamous cell carcinoma, NSCLC, SCLC, lung cancer;I, II, III;96;–;–;–;healthy;96;–;–;non-smoker;GC;EI;–;triple quadrupole;–;Agilent Mass Hunter Qualitative Analysis,  Mass Hunter;Wiley registry NIST 11,  Fiehn RTL libraries; MPP software;one way ANOVA, Turkey’s honest Significance Difference;–;–;364785,78854355;0,001;–;–;Hierarchical clustering, Partial Least Square Discrimination;–;–;96,2;92;93,1;–;–;–;–;–;Pakistan;–;Heat map, Pathway analysis;25712604;Musharraf et al. 2015;2882;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;plasma;–;adenocarcinoma, squamous cell carcinoma, NSCLC, SCLC, lung cancer;I, II, III;96;–;–;–;healthy;96;–;–;non-smoker;GC;EI;–;triple quadrupole;–;Agilent Mass Hunter Qualitative Analysis,  Mass Hunter;Wiley registry NIST 11,  Fiehn RTL libraries; MPP software;one way ANOVA, Turkey’s honest Significance Difference;–;–;357826,324090908;0,001;–;–;Hierarchical clustering, Partial Least Square Discrimination;–;–;96,2;92;93,1;–;–;–;–;–;Pakistan;–;Heat map, Pathway analysis;25712604;Musharraf et al. 2015;2883;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;–;plasma;–;adenocarcinoma, squamous cell carcinoma, NSCLC, SCLC, lung cancer;I, II, III;96;–;–;–;healthy;96;–;–;non-smoker;GC;EI;–;triple quadrupole;–;Agilent Mass Hunter Qualitative Analysis,  Mass Hunter;Wiley registry NIST 11,  Fiehn RTL libraries; MPP software;one way ANOVA, Turkey’s honest Significance Difference;–;–;175648,289281136;0,001;–;–;Hierarchical clustering, Partial Least Square Discrimination;–;–;96,2;92;93,1;–;–;–;–;–;Pakistan;–;Heat map, Pathway analysis;25712604;Musharraf et al. 2015;2884;;
D-glucose;D-glucose;D-glucose;–;–;–;–;–;–;–;–;–;–;plasma;–;adenocarcinoma, squamous cell carcinoma, NSCLC, SCLC, lung cancer;I, II, III;96;–;–;–;healthy;96;–;–;non-smoker;GC;EI;–;triple quadrupole;–;Agilent Mass Hunter Qualitative Analysis,  Mass Hunter;Wiley registry NIST 11,  Fiehn RTL libraries; MPP software;one way ANOVA, Turkey’s honest Significance Difference;–;–;111939,524579634;0,001;–;–;Hierarchical clustering, Partial Least Square Discrimination;–;–;96,2;92;93,1;–;–;–;–;–;Pakistan;–;Heat map, Pathway analysis;25712604;Musharraf et al. 2015;2885;;
altrose;altrose;altrose;–;–;–;–;–;–;–;–;–;–;plasma;–;adenocarcinoma, squamous cell carcinoma, NSCLC, SCLC, lung cancer;I, II, III;96;–;–;–;healthy;96;–;–;non-smoker;GC;EI;–;triple quadrupole;–;Agilent Mass Hunter Qualitative Analysis,  Mass Hunter;Wiley registry NIST 11,  Fiehn RTL libraries; MPP software;one way ANOVA, Turkey’s honest Significance Difference;–;–;51519,4653027583;0,001;–;–;Hierarchical clustering, Partial Least Square Discrimination;–;–;96,2;92;93,1;–;–;–;–;–;Pakistan;–;Heat map, Pathway analysis;25712604;Musharraf et al. 2015;2886;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;plasma;–;adenocarcinoma, squamous cell carcinoma, NSCLC, SCLC, lung cancer;I, II, III;96;–;–;–;healthy;96;–;–;non-smoker;GC;EI;–;triple quadrupole;–;Agilent Mass Hunter Qualitative Analysis,  Mass Hunter;Wiley registry NIST 11,  Fiehn RTL libraries; MPP software;one way ANOVA, Turkey’s honest Significance Difference;–;–;33086,8424909471;0,001;–;–;Hierarchical clustering, Partial Least Square Discrimination;–;–;96,2;92;93,1;–;–;–;–;–;Pakistan;–;Heat map, Pathway analysis;25712604;Musharraf et al. 2015;2887;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;plasma;–;adenocarcinoma, squamous cell carcinoma, NSCLC, SCLC, lung cancer;I, II, III;96;–;–;–;healthy;96;–;–;non-smoker;GC;EI;–;triple quadrupole;–;Agilent Mass Hunter Qualitative Analysis,  Mass Hunter;Wiley registry NIST 11,  Fiehn RTL libraries; MPP software;one way ANOVA, Turkey’s honest Significance Difference;–;–;30348,3403082544;0,001;–;–;Hierarchical clustering, Partial Least Square Discrimination;–;–;96,2;92;93,1;–;–;–;–;–;Pakistan;–;Heat map, Pathway analysis;25712604;Musharraf et al. 2015;2888;;
octadecanoic acid;octadecanoic acid;octadecanoic acid;–;–;–;–;–;–;–;–;–;–;plasma;–;adenocarcinoma, squamous cell carcinoma, NSCLC, SCLC, lung cancer;I, II, III;96;–;–;–;healthy;96;–;–;non-smoker;GC;EI;–;triple quadrupole;–;Agilent Mass Hunter Qualitative Analysis,  Mass Hunter;Wiley registry NIST 11,  Fiehn RTL libraries; MPP software;one way ANOVA, Turkey’s honest Significance Difference;–;–;8233,1568738695;0,001;–;–;Hierarchical clustering, Partial Least Square Discrimination;–;–;96,2;92;93,1;–;–;–;–;–;Pakistan;–;Heat map, Pathway analysis;25712604;Musharraf et al. 2015;2889;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;plasma;–;adenocarcinoma, squamous cell carcinoma, NSCLC, SCLC, lung cancer;I, II, III;96;–;–;–;healthy;96;–;–;non-smoker;GC;EI;–;triple quadrupole;–;Agilent Mass Hunter Qualitative Analysis,  Mass Hunter;Wiley registry NIST 11,  Fiehn RTL libraries; MPP software;one way ANOVA, Turkey’s honest Significance Difference;–;–;2669,4558995907;0,001;–;–;Hierarchical clustering, Partial Least Square Discrimination;–;–;96,2;92;93,1;–;–;–;–;–;Pakistan;–;Heat map, Pathway analysis;25712604;Musharraf et al. 2015;2890;;
naphthalene;naphthalene;naphthalene;–;–;–;–;–;–;–;–;–;–;plasma;–;adenocarcinoma, squamous cell carcinoma, NSCLC, SCLC, lung cancer;I, II, III;96;–;–;–;healthy;96;–;–;non-smoker;GC;EI;–;triple quadrupole;–;Agilent Mass Hunter Qualitative Analysis,  Mass Hunter;Wiley registry NIST 11,  Fiehn RTL libraries; MPP software;one way ANOVA, Turkey’s honest Significance Difference;–;–;38,4119686461;0,001;–;–;Hierarchical clustering, Partial Least Square Discrimination;–;–;96,2;92;93,1;–;–;–;–;–;Pakistan;–;Heat map, Pathway analysis;25712604;Musharraf et al. 2015;2891;;
1-propene;1-propene;1-propene;–;–;–;–;–;–;–;–;–;–;plasma;–;adenocarcinoma, squamous cell carcinoma, NSCLC, SCLC, lung cancer;I, II, III;96;–;–;–;healthy;96;–;–;non-smoker;GC;EI;–;triple quadrupole;–;Agilent Mass Hunter Qualitative Analysis,  Mass Hunter;Wiley registry NIST 11,  Fiehn RTL libraries; MPP software;one way ANOVA, Turkey’s honest Significance Difference;–;–;0,2064994723;0,001;–;–;Hierarchical clustering, Partial Least Square Discrimination;–;–;96,2;92;93,1;–;–;–;–;–;Pakistan;–;Heat map, Pathway analysis;25712604;Musharraf et al. 2015;2892;;
2-butanone;2-butanone;2-butanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;85;43, 42;42.15 ± 14.2;current, non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;2,36;0,901;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2893;;
2-butanone;2-butanone;2-butanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;45;–;–;current;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;2,365;0,931;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2894;;
2-butanone;2-butanone;2-butanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;40;–;–;non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;2,255;0,934;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2895;;
3-hydroxy-2-butanone;3-hydroxy-2-butanone;3-hydroxy-2-butanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;85;43, 42;42.15 ± 14.2;current, non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;0,1695;0,821;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2896;;
3-hydroxy-2-butanone;3-hydroxy-2-butanone;3-hydroxy-2-butanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;45;–;–;current;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;0,1695;0,946;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2897;;
3-hydroxy-2-butanone;3-hydroxy-2-butanone;3-hydroxy-2-butanone;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;40;–;–;non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;0,1595;0,962;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2898;;
4-hydroxy-2-hexenal;4-hydroxy-2-hexenal;4-hydroxy-2-hexenal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;85;43, 42;42.15 ± 14.2;current, non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;0,0073;0,694;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2899;;
4-hydroxy-2-hexenal;4-hydroxy-2-hexenal;4-hydroxy-2-hexenal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;45;–;–;current;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;0,00734;0,728;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2900;;
4-hydroxy-2-hexenal;4-hydroxy-2-hexenal;4-hydroxy-2-hexenal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;40;–;–;non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;0,00672;0,771;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2901;;
4-hydroxy-2-nonenal;4-hydroxy-2-nonenal;4-hydroxy-2-nonenal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;85;43, 42;42.15 ± 14.2;current, non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;0,00175;0,696;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2902;;
4-hydroxy-2-nonenal;4-hydroxy-2-nonenal;4-hydroxy-2-nonenal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;45;–;–;current;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;0,000285;0,826;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2903;;
4-hydroxy-2-nonenal;4-hydroxy-2-nonenal;4-hydroxy-2-nonenal;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;40;–;–;non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;0,000255;0,842;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2904;;
acetaldehyde;acetaldehyde;acetaldehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;85;43, 42;42.15 ± 14.2;current, non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;–;0,538;–;–;–;–;–;–;–;–;US;–;–;26233567;Li et al. 2015;2905;;
acetaldehyde;acetaldehyde;acetaldehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;45;–;–;current;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;–;0,572;–;–;–;–;–;–;–;–;US;–;–;26233567;Li et al. 2015;2906;;
acetaldehyde;acetaldehyde;acetaldehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;40;–;–;non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;–;0,766;–;–;–;–;–;–;–;–;US;–;–;26233567;Li et al. 2015;2907;;
acrolein;acrolein;acrolein;–;–;–;HMDB0041822;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;85;43, 42;42.15 ± 14.2;current, non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;–;0,625;–;–;–;–;–;–;–;–;US;–;–;26233567;Li et al. 2015;2908;;
acrolein;acrolein;acrolein;–;–;–;HMDB0041822;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;45;–;–;current;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;–;0,598;–;–;–;–;–;–;–;–;US;–;–;26233567;Li et al. 2015;2909;;
acrolein;acrolein;acrolein;–;–;–;HMDB0041822;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;40;–;–;non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;–;0,69;–;–;–;–;–;–;–;–;US;–;–;26233567;Li et al. 2015;2910;;
hydroxyacetaldehyde;hydroxyacetaldehyde;hydroxyacetaldehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;85;43, 42;42.15 ± 14.2;current, non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;0,357;0,793;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2911;;
hydroxyacetaldehyde;hydroxyacetaldehyde;hydroxyacetaldehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;45;–;–;current;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;0,3575;0,82;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2912;;
hydroxyacetaldehyde;hydroxyacetaldehyde;hydroxyacetaldehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;40;–;–;non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;0,3875;0,753;–;–;–;–;–;–;–;–;US;Y;–;26233567;Li et al. 2015;2913;;
malondialdehyde;malondialdehyde;malondialdehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;85;43, 42;42.15 ± 14.2;current, non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;–;0,66;–;–;–;–;–;–;–;–;US;–;–;26233567;Li et al. 2015;2914;;
malondialdehyde;malondialdehyde;malondialdehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;45;–;–;current;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;–;0,672;–;–;–;–;–;–;–;–;US;–;–;26233567;Li et al. 2015;2915;;
malondialdehyde;malondialdehyde;malondialdehyde;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;lung cancer;I, II, III, IV;85;46, 39;66.12 ± 10.1;former, current, non-smoker;healthy;40;–;–;non-smoker;DI;nano-ESI;–;LTQ-FT-ICR;MS/MS;–;–;R packages caret, pROC;Kruskal-Wallis test;–;–;–;–;–;–;ROC curve;–;0,764;–;–;–;–;–;–;–;–;US;–;–;26233567;Li et al. 2015;2916;;
1-monoolein;1-monoolein;1-monoolein;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2917;;
1-monoolein;1-monoolein;1-monoolein;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2918;;
2-aminoadipic acid;2-aminoadipic acid;2-aminoadipic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2919;;
2-aminoadipic acid;2-aminoadipic acid;2-aminoadipic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2920;;
2-oxogluconic acid;2-oxogluconic acid;2-oxogluconic acid;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2921;;
2-oxogluconic acid;2-oxogluconic acid;2-oxogluconic acid;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2922;;
4-hydroxyphenylacetic acid;4-hydroxyphenylacetic acid;4-hydroxyphenylacetic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2923;;
4-hydroxyphenylacetic acid;4-hydroxyphenylacetic acid;4-hydroxyphenylacetic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2924;;
5-aminovaleric acid lactame;5-aminovaleric acid lactame;5-aminovaleric acid lactame;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2925;;
5-aminovaleric acid lactame;5-aminovaleric acid lactame;5-aminovaleric acid lactame;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2926;;
6-deoxyglucitol;6-deoxyglucitol;6-deoxyglucitol;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2927;;
6-deoxyglucitol;6-deoxyglucitol;6-deoxyglucitol;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2928;;
allantoic acid;allantoic acid;allantoic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2929;;
allantoic acid;allantoic acid;allantoic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2930;;
beta-glycerolphosphate;beta-glycerolphosphate;beta-glycerolphosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2931;;
beta-glycerolphosphate;beta-glycerolphosphate;beta-glycerolphosphate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2932;;
beta-mannosylglycerate;beta-mannosylglycerate;beta-mannosylglycerate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2933;;
beta-mannosylglycerate;beta-mannosylglycerate;beta-mannosylglycerate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2934;;
beta-sitosterol;beta-sitosterol;beta-sitosterol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2935;;
beta-sitosterol;beta-sitosterol;beta-sitosterol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2936;;
butane-2,3-diol;butane-2,3-diol;butane-2,3-diol;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2937;;
butane-2,3-diol;butane-2,3-diol;butane-2,3-diol;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2938;;
cellobiotol;cellobiotol;cellobiotol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2939;;
cellobiotol;cellobiotol;cellobiotol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2940;;
cyano-l-alanine;cyano-l-alanine;cyano-l-alanine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2941;;
cyano-l-alanine;cyano-l-alanine;cyano-l-alanine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2942;;
cytidine-5-diphosphate;cytidine-5-diphosphate;cytidine-5-diphosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2943;;
cytidine-5-diphosphate;cytidine-5-diphosphate;cytidine-5-diphosphate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2944;;
deoxytetronic acid;deoxytetronic acid;deoxytetronic acid;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2945;;
deoxytetronic acid;deoxytetronic acid;deoxytetronic acid;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2946;;
deoxythreittol;deoxythreittol;deoxythreittol;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2947;;
deoxythreittol;deoxythreittol;deoxythreittol;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2948;;
dodecanol;dodecanol;dodecanol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2949;;
dodecanol;dodecanol;dodecanol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2950;;
erythrose;erythrose;erythrose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2951;;
erythrose;erythrose;erythrose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2952;;
galactonic acid;galactonic acid;galactonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2953;;
galactonic acid;galactonic acid;galactonic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2954;;
galactose-6-phosphate;galactose-6-phosphate;galactose-6-phosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2955;;
galactose-6-phosphate;galactose-6-phosphate;galactose-6-phosphate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2956;;
gamma-glutamyl-valine;gamma-glutamyl-valine;gamma-glutamyl-valine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2957;;
gamma-glutamyl-valine;gamma-glutamyl-valine;gamma-glutamyl-valine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2958;;
glyoxalurea;glyoxalurea;glyoxalurea;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2959;;
glyoxalurea;glyoxalurea;glyoxalurea;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2960;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2961;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2962;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2963;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2964;;
inosine 5'-monophosphate;inosine 5'-monophosphate;inosine 5'-monophosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2965;;
inosine 5'-monophosphate;inosine 5'-monophosphate;inosine 5'-monophosphate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2966;;
isolinoleic acid;isolinoleic acid;isolinoleic acid;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2967;;
isolinoleic acid;isolinoleic acid;isolinoleic acid;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2968;;
lathosterol;lathosterol;lathosterol;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2969;;
lathosterol;lathosterol;lathosterol;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2970;;
levanbiose;levanbiose;levanbiose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2971;;
levanbiose;levanbiose;levanbiose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2972;;
lyxose;lyxose;lyxose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2973;;
lyxose;lyxose;lyxose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2974;;
malonic acid;malonic acid;malonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2975;;
malonic acid;malonic acid;malonic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2976;;
N-acetylglucosamine;N-acetylglucosamine;N-acetylglucosamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2977;;
N-acetylglucosamine;N-acetylglucosamine;N-acetylglucosamine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2978;;
N-acetylmannosamine;N-acetylmannosamine;N-acetylmannosamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2979;;
N-acetylmannosamine;N-acetylmannosamine;N-acetylmannosamine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2980;;
octadecanol;octadecanol;octadecanol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2981;;
octadecanol;octadecanol;octadecanol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2982;;
p-cresol;p-cresol;p-cresol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2983;;
p-cresol;p-cresol;p-cresol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2984;;
phenylacetic acid;phenylacetic acid;phenylacetic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2985;;
phenylacetic acid;phenylacetic acid;phenylacetic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2986;;
phosphoethanolamine;phosphoethanolamine;phosphoethanolamine;–;–;–;HMDB0000224;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2987;;
phosphoethanolamine;phosphoethanolamine;phosphoethanolamine;–;–;–;HMDB0000224;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2988;;
pimelic acid;pimelic acid;pimelic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2989;;
pimelic acid;pimelic acid;pimelic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2990;;
ribitol;ribitol;ribitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2991;;
ribitol;ribitol;ribitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2992;;
ribose;ribose;ribose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2993;;
ribose;ribose;ribose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2994;;
salicylaldehyde;salicylaldehyde;salicylaldehyde;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2995;;
salicylaldehyde;salicylaldehyde;salicylaldehyde;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2996;;
sorbitol;sorbitol;sorbitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2997;;
sorbitol;sorbitol;sorbitol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2998;;
stigmasterol;stigmasterol;stigmasterol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;2999;;
stigmasterol;stigmasterol;stigmasterol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;3000;;
threose;threose;threose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;49;17, 32;65.9 ± 9.87;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;3001;;
threose;threose;threose;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;52;17, 35;65.9 ± 9.66;–;healthy;31;11, 20;64.1 ± 8.97;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;3002;;
trihydroxypyrazine;trihydroxypyrazine;trihydroxypyrazine;NIST;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;3003;;
trihydroxypyrazine;trihydroxypyrazine;trihydroxypyrazine;NIST;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;43;21, 22;67.3 ± 10.10;–;healthy;43;21, 22;65.9 ± 8.05;–;GC;EI;–;TOF;–;–;UC Davis Metabolomics BinBase database;–;regress (by the covariates: age, gender and smoking history [packs per year]), permutation test;–;–;–;–;–;–;random forest;–;–;–;–;–;–;–;–;–;–;US;–;Pearson's correlation coefficients between metabolites;26282632;Fahrmann et al. 2015;3004;;
diacetylspermine;diacetylspermine;diacetylspermine;–;–;–;HMDB0002172;–;–;–;–;–;–;serum;prediagnosis;NSCLC;I, II, III, IV;100;75, 25;61.1 ± 5.8;former, current;healthy ;199;149, 50;60.9 ± 5.9;former, current;LC;ESI;both;Q-TOF;MS/MS;XCMS;METLIN, LIPID MAPS, HMDB, Pubchem, SciFinder Scholar;Prism, R;Mann-Whitney U test, Kruskal-Wallis test;–;–;–;0,001;–;–;ROC curve;–;0.657 (0.586-0.727);–;–;–;–;–;–;–;–;US;Y;–;26282655;Wikoff et al. 2015a;3005;;
diacetylspermine;diacetylspermine;diacetylspermine;–;–;–;HMDB0002172;–;–;–;–;–;–;serum;prediagnosis;NSCLC;I, II, III, IV;108;75, 33;61.9 ± 5.7;former, current;healthy ;216;150, 66;61.9 ± 5.9;former, current;LC;ESI;both;Q-TOF;MS/MS;XCMS;METLIN, LIPID MAPS, HMDB, Pubchem, SciFinder Scholar;Prism, R;Mann-Whitney U test, Kruskal-Wallis test;–;–;–;0,001;–;–;ROC curve;–;"0.650 (0.585-0.716)
Pro-SFTPB + DAS: 0.732 (0.673-0.791)";–;–;–;–;–;–;–;–;US;Y;–;26282655;Wikoff et al. 2015a;3006;;
pro-surfactant protein B;pro-surfactant protein B;pro-surfactant protein B;–;–;–;–;–;–;–;–;–;–;serum;prediagnosis;NSCLC;I, II, III, IV;108;75, 33;61.9 ± 5.7;former, current;healthy ;216;150, 66;61.9 ± 5.9;former, current;LC;ESI;both;Q-TOF;MS/MS;XCMS;METLIN, LIPID MAPS, HMDB, Pubchem, SciFinder Scholar;Prism, R;Mann-Whitney U test, Kruskal-Wallis test;–;–;–;0,001;–;–;ROC curve;–;"0.699 (0.639-0.760)
Pro-SFTPB + DAS: 0.732 (0.673-0.791)";–;–;–;–;–;–;–;–;US;Y;–;26282655;Wikoff et al. 2015a;3007;;
betaine;betaine;betaine;–;–;–;HMDB0000043;–;–;–;–;–;118,0862;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;2,55;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3008;;
choline;choline;choline;–;–;–;HMDB0000097;–;–;–;–;–;104,1067;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;14;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;Y;–;26404114;Li et al. 2015;3009;;
L-carnitine;L-carnitine;L-carnitine;–;–;–;HMDB0000062;–;–;–;–;–;162,1113;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;3,72;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3010;;
PC(16:0/18:1);PC(16:0/18:1);PC(16:0/18:1);–;–;–;–;–;–;–;–;–;760,585;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;14,08;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3011;;
PC(16:0/18:1);PC(16:0/18:1);PC(16:0/18:1);–;[PC(16:0/18:1)+Na]+;–;–;–;–;–;–;–;782,5695;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;13,36;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3012;;
PC(16:0/18:2);PC(16:0/18:2);PC(16:0/18:2);–;–;–;–;–;–;–;–;–;758,5699;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;8,58;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3013;;
PC(16:0/18:2);PC(16:0/18:2);PC(16:0/18:2);–;[PC(16:0/18:2)+Na]+;–;–;–;–;–;–;–;780,5509;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;6,35;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3014;;
PC(16:0/20:4);PC(16:0/20:4);PC(16:0/20:4);–;[PC(16:0/20:4)+Na]+;–;–;–;–;–;–;–;804,5521;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;6,23;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;Y;–;26404114;Li et al. 2015;3015;;
PC(18:0/18:1);PC(18:0/18:1);PC(18:0/18:1);–;[PC(18:0/18:1)+Na]+;–;–;–;–;–;–;–;810,5997;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;8,36;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3016;;
PC(18:0/18:2);PC(18:0/18:2);PC(18:0/18:2);–;–;–;–;–;–;–;–;–;786,6022;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;8,83;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3017;;
PC(18:1/18:1);PC(18:1/18:1);PC(18:1/18:1);–;[PC(18:1/18:1)+Na]+;–;–;–;–;–;–;–;808,5854;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;8,21;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3018;;
PC(18:1/20:3);PC(18:1/20:3);PC(18:1/20:3);–;[PC(18:1/20:3)+Na]+;–;–;–;–;–;–;–;832,5839;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;5,89;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;Y;–;26404114;Li et al. 2015;3019;;
PC(32:1);PC(32:1);PC(32:1);–;–;–;–;–;–;–;–;–;732,5535;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;7,32;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3020;;
PC(32:1);PC(32:1);PC(32:1);–;[PC(32:1)+Na]+;–;–;–;–;–;–;–;754,5375;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;5,06;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3021;;
PC(34:0);PC(34:0);PC(34:0);–;[PC(34:0)+Na]+;–;–;–;–;–;–;–;784,5832;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;8,94;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3022;;
PC(34:1);PC(34:1);PC(34:1);–;[PC(34:1)+K]+;–;–;–;–;–;–;–;798,543;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;9,24;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;Y;–;26404114;Li et al. 2015;3023;;
PC(36:1);PC(36:1);PC(36:1);–;–;–;–;–;–;–;–;–;788,6147;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;6,47;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3024;;
PC(36:3);PC(36:3);PC(36:3);–;[PC(36:3)+Na]+;–;–;–;–;–;–;–;806,5667;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;7,05;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;Y;–;26404114;Li et al. 2015;3025;;
PC(38:2);PC(38:2);PC(38:2);–;[PC(38:2)+Na]+;–;–;–;–;–;–;–;820,6174;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;5,13;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;Y;–;26404114;Li et al. 2015;3026;;
PC(O-16:0/18:1);PC(O-16:0/18:1);PC(O-16:0/18:1);–;[PC(O-16:0/18:1)+Na]+;–;–;–;–;–;–;–;768,5853;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;5,74;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3027;;
PC(O-34:1);PC(O-34:1);PC(O-34:1);–;–;–;–;–;–;–;–;–;746,6058;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;5,11;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3028;;
PC(P-18:0/18:0);PC(P-18:0/18:0);PC(P-18:0/18:0);–;[PC(P-18:0/18:0)+Na]+;–;–;–;–;–;–;–;796,6155;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;6,78;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3029;;
PC(P-34:1);PC(P-34:1);PC(P-34:1);–;–;–;–;–;–;–;–;–;744,5914;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;3,37;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3030;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;116,0709;tissue;diagnosis;adenocarcinoma, squamous cell carcinoma;–;52;–;–;–;tumor vs. adjacent normal tissue;21;–;–;–;LC;AFADESI;both;Q-Orbitrap, Q-TOF;MS/MS;Markerview (AB SCIEX);LIPID MAPS, Massbank, HMDB, METLIN;SIMCA-P 11.0, PASW Statistics 18.0;t-test, PLS-DA, OPLS-DA;–;–;–;–;–;2,01;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;26404114;Li et al. 2015;3031;;
1-decanol, 2-methyl-;1-decanol, 2-methyl-;1-decanol, 2-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,957;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3032;;
octane, 2,2,6-trimethyl-;octane, 2,2,6-trimethyl-;octane, 2,2,6-trimethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,9392;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3033;;
decane, 3,7-dimethyl-;decane, 3,7-dimethyl-;decane, 3,7-dimethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,9087;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3034;;
2-butanone;2-butanone;2-butanone;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,8942;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3035;;
1-hexanol, 2-ethyl-;1-hexanol, 2-ethyl-;1-hexanol, 2-ethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,8933;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3036;;
undecane;undecane;undecane;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,8313;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3037;;
pentane, 1-(1-ethoxyethoxy)-;pentane, 1-(1-ethoxyethoxy)-;pentane, 1-(1-ethoxyethoxy)-;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,7931;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3038;;
4-heptanone;4-heptanone;4-heptanone;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,6961;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3039;;
acetic acid, (acetyloxy)-;acetic acid, (acetyloxy)-;acetic acid, (acetyloxy)-;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,621;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3040;;
bicyclo[3.1.0]hexane, 4-methyl-1-(1-methylethyl)-, didehydro deriv.;bicyclo[3.1.0]hexane, 4-methyl-1-(1-methylethyl)-, didehydro deriv.;bicyclo[3.1.0]hexane, 4-methyl-1-(1-methylethyl)-, didehydro deriv.;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,4218;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3041;;
cyclohexanone;cyclohexanone;cyclohexanone;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,4125;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3042;;
thiophene;thiophene;thiophene;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,3214;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3043;;
thymol;thymol;thymol;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,2814;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3044;;
ethanol;ethanol;ethanol;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,2278;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3045;;
hexanal, 2,2-dimethyl-;hexanal, 2,2-dimethyl-;hexanal, 2,2-dimethyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,0738;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3046;;
butanoic acid, ethyl ester;butanoic acid, ethyl ester;butanoic acid, ethyl ester;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,0678;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3047;;
butane, 1,1-diethoxy-3-methyl-;butane, 1,1-diethoxy-3-methyl-;butane, 1,1-diethoxy-3-methyl-;–;–;–;–;–;–;–;–;–;–;exhaled breath (air);–;adenocarcinoma, squamous cell carcinoma;–;20;13, 7;67 ± 9;former, current, non-smoker;other lung diseases;10;4, 6;64 ± 7;former, current, non-smoker;GC;EI;–;quadrupole;–;GC-MS solutions software;NIST 127, NIST 147;Matlab;Kruskal-Wallis rank test, PLS-DA;–;–;–;0,0399;–;–;–;–;–;–;–;–;–;–;–;–;–;Italy;Y;–;26559776;Capuano et al. 2015;3048;;
monostearin;monostearin;monostearin;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma, NSCLC, SCLC;–;48;45, 3;63  ±  7 ;–;at-risk controls;130;107, 23;61±8;former, active smokers;GC;EI;–;Q-TOF;–;Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent);NIST 11, KEGG ;–;unpaired t-test, Fisher's exact, Mann–Whitney tests;–;–;8,1037631002;0,000107;–;–;Support-vector machine, ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;Spain;Y;–;26866403;Peralbo-Molina et al. 2016;3049;;
monopalmitin;monopalmitin;monopalmitin;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma, NSCLC, SCLC;–;48;45, 3;63  ±  7 ;–;at-risk controls;130;107, 23;61±8;former, active smokers;GC;EI;–;Q-TOF;–;Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent);NIST 11, KEGG ;–;unpaired t-test, Fisher's exact, Mann–Whitney tests;–;–;6,1905946626;0,003899;–;–;Support-vector machine, ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;Spain;Y;–;26866403;Peralbo-Molina et al. 2016;3050;;
monostearin;monostearin;monostearin;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma, NSCLC, SCLC;–;48;45, 3;63  ±  7 ;–;healthy;61;53, 8;60  ±  9;non-smoker;GC;EI;–;Q-TOF;–;Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent);NIST 11, KEGG ;–;unpaired t-test, Fisher's exact, Mann–Whitney tests;–;–;6,097238586;0,003911;–;–;Support-vector machine, ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;Spain;Y;–;26866403;Peralbo-Molina et al. 2016;3051;;
squalene;squalene;squalene;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma, NSCLC, SCLC;–;48;45, 3;63  ±  7 ;–;at-risk controls;130;107, 23;61±8;former, active smokers;GC;EI;–;Q-TOF;–;Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent);NIST 11, KEGG ;–;unpaired t-test, Fisher's exact, Mann–Whitney tests;–;–;5,3929512778;0,000212;–;–;Support-vector machine, ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;Spain;Y;–;26866403;Peralbo-Molina et al. 2016;3052;;
triethyl citrate;triethyl citrate;triethyl citrate;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma, NSCLC, SCLC;–;48;45, 3;63  ±  7 ;–;healthy;61;53, 8;60  ±  9;non-smoker;GC;EI;–;Q-TOF;–;Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent);NIST 11, KEGG ;–;unpaired t-test, Fisher's exact, Mann–Whitney tests;–;–;4,7016136762;0,009728;–;–;Support-vector machine, ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;Spain;Y;–;26866403;Peralbo-Molina et al. 2016;3053;;
11-eicosenamide;11-eicosenamide;11-eicosenamide;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma, NSCLC, SCLC;–;48;45, 3;63  ±  7 ;–;healthy;61;53, 8;60  ±  9;non-smoker;GC;EI;–;Q-TOF;–;Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent);NIST 11, KEGG ;–;unpaired t-test, Fisher's exact, Mann–Whitney tests;–;–;4,4761860428;0,0000313;–;–;Support-vector machine, ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;Spain;Y;–;26866403;Peralbo-Molina et al. 2016;3054;;
n-hexadecylindane;n-hexadecylindane;n-hexadecylindane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma, NSCLC, SCLC;–;48;45, 3;63  ±  7 ;–;healthy;61;53, 8;60  ±  9;non-smoker;GC;EI;–;Q-TOF;–;Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent);NIST 11, KEGG ;–;unpaired t-test, Fisher's exact, Mann–Whitney tests;–;–;3,8705833052;0,002707;–;–;Support-vector machine, ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;Spain;–;–;26866403;Peralbo-Molina et al. 2016;3055;;
n-hexadecylindane;n-hexadecylindane;n-hexadecylindane;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma, NSCLC, SCLC;–;48;45, 3;63  ±  7 ;–;at-risk controls;130;107, 23;61±8;former, active smokers;GC;EI;–;Q-TOF;–;Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent);NIST 11, KEGG ;–;unpaired t-test, Fisher's exact, Mann–Whitney tests;–;–;3,5195207702;0,000481;–;–;Support-vector machine, ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;Spain;–;–;26866403;Peralbo-Molina et al. 2016;3056;;
13-heptadecyn-1-ol;13-heptadecyn-1-ol;13-heptadecyn-1-ol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma, NSCLC, SCLC;–;48;45, 3;63  ±  7 ;–;at-risk controls;130;107, 23;61±8;former, active smokers;GC;EI;–;Q-TOF;–;Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent);NIST 11, KEGG ;–;unpaired t-test, Fisher's exact, Mann–Whitney tests;–;–;2,7128325504;0,002017;–;–;Support-vector machine, ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;Spain;–;–;26866403;Peralbo-Molina et al. 2016;3057;;
benzoic acid 4-ethoxy-ethyl ester;benzoic acid 4-ethoxy-ethyl ester;benzoic acid 4-ethoxy-ethyl ester;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma, NSCLC, SCLC;–;48;45, 3;63  ±  7 ;–;healthy;61;53, 8;60  ±  9;non-smoker;GC;EI;–;Q-TOF;–;Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent);NIST 11, KEGG ;–;unpaired t-test, Fisher's exact, Mann–Whitney tests;–;–;0,3337037953;0,003489;–;–;Support-vector machine, ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;Spain;Y;–;26866403;Peralbo-Molina et al. 2016;3058;;
indole;indole;indole;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma, NSCLC, SCLC;–;48;45, 3;63  ±  7 ;–;healthy;61;53, 8;60  ±  9;non-smoker;GC;EI;–;Q-TOF;–;Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent);NIST 11, KEGG ;–;unpaired t-test, Fisher's exact, Mann–Whitney tests;–;–;0,1458674611;0,000351;–;–;Support-vector machine, ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;Spain;–;–;26866403;Peralbo-Molina et al. 2016;3059;;
p-cresol;p-cresol;p-cresol;–;–;–;–;–;–;–;–;–;–;exhaled breath;diagnosis;adenocarcinoma, squamous cell carcinoma, large cell carcinoma, NSCLC, SCLC;–;48;45, 3;63  ±  7 ;–;healthy;61;53, 8;60  ±  9;non-smoker;GC;EI;–;Q-TOF;–;Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent);NIST 11, KEGG ;–;unpaired t-test, Fisher's exact, Mann–Whitney tests;–;–;0,116253012;0,0009;–;–;Support-vector machine, ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;Spain;–;–;26866403;Peralbo-Molina et al. 2016;3060;;
diethyl glutarate;diethyl glutarate;diethyl glutarate;–;–;–;–;–;–;–;–;–;–;sputum;diagnosis;NSCLC, SCLC, clinic-radiological diagnosis;I, II, III, IV;23;11, 12;66,6;former, current, non-smoker;healthy;33;20, 13;55,3;current, non-smoker;flow infusion;–;negative;FT-ICR;–;–;HMDB;PyChem (Version 3.0.5g Beta) package, MetaboAnalyst 2.0;ANOVA, Random Forest;–;–;8;1,42E-018;–;–;ROC curve analysis;–;0.99 (0.979–1.000);–;–;–;–;–;–;–;–;UK;Y;–;26973212;Cameron et al. 2016;3061;;
cysteamine;cysteamine;cysteamine;–;–;–;–;–;–;–;–;–;–;sputum;diagnosis;NSCLC, SCLC, clinic-radiological diagnosis;I, II, III, IV;23;11, 12;66,6;former, current, non-smoker;healthy;33;20, 13;55,3;current, non-smoker;flow infusion;–;negative;FT-ICR;–;–;HMDB;PyChem (Version 3.0.5g Beta) package, MetaboAnalyst 2.0;ANOVA, Random Forest;–;–;5,0982425093;3,03E-020;–;–;ROC curve analysis;–;0.99 (0.980–1.000);–;–;–;–;–;–;–;–;UK;Y;–;26973212;Cameron et al. 2016;3062;;
CE(22:5(4Z,7Z,10Z,13Z,16Z));CE(22:5(4Z,7Z,10Z,13Z,16Z));CE(22:5(4Z,7Z,10Z,13Z,16Z));–;–;–;–;–;–;–;–;–;–;sputum;diagnosis;NSCLC, SCLC, clinic-radiological diagnosis;I, II, III, IV;23;11, 12;66,6;former, current, non-smoker;at-risk controls (not diagnosed with lung cancer at least one-year follow-up);11;10, 1;66,5;former, current;flow infusion;–;negative;FT-ICR;–;–;HMDB;PyChem (Version 3.0.5g Beta) package, MetaboAnalyst 2.0;ANOVA, Random Forest;–;–;1;0,0128;–;–;ROC curve analysis;–;0.82 (0.644–0.947);–;–;–;–;–;–;–;–;UK;Y;–;26973212;Cameron et al. 2016;3063;;
ganglioside GM1 (18:1/12:0);ganglioside GM1 (18:1/12:0);ganglioside GM1 (18:1/12:0);–;–;–;–;–;–;–;–;–;–;sputum;diagnosis;NSCLC, SCLC, clinic-radiological diagnosis;I, II, III, IV;23;11, 12;66,6;former, current, non-smoker;at-risk controls (not diagnosed with lung cancer at least one-year follow-up);11;10, 1;66,5;former, current;flow infusion;–;negative;FT-ICR;–;–;HMDB;PyChem (Version 3.0.5g Beta) package, MetaboAnalyst 2.0;ANOVA, Random Forest;–;–;0,9794202976;0,00293;–;–;ROC curve analysis;–;0.85 (0.709–0.953);–;–;–;–;–;–;–;–;UK;Y;–;26973212;Cameron et al. 2016;3064;;
2-aminobutyrate;2-aminobutyrate;2-aminobutyrate;–;–;–;HMDB00452;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;–;–;–;NMR;–;Chenomx NMR Suite 7.1, Metabolite Detector;–;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;–;–;27073350;Hao et al. 2016;3065;;
2-oxoglutarate;2-oxoglutarate;2-oxoglutarate;–;–;–;HMDB00208;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;–;–;–;NMR;–;Chenomx NMR Suite 7.1, Metabolite Detector;–;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;–;–;27073350;Hao et al. 2016;3066;;
4-hydroxybutyrate;4-hydroxybutyrate;4-hydroxybutyrate;–;–;–;HMDB00710;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;–;–;–;NMR;–;Chenomx NMR Suite 7.1, Metabolite Detector;–;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;–;–;27073350;Hao et al. 2016;3067;;
butanoic acid, 2-hydroxy;butanoic acid, 2-hydroxy;butanoic acid, 2-hydroxy;–;–;–;HMDB00008;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;GC;–;–;TOF;–;Chenomx NMR Suite 7.1, Metabolite Detector;HMDB;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;Y;–;27073350;Hao et al. 2016;3068;;
citrate;citrate;citrate;–;–;–;HMDB00452;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;–;–;–;NMR;–;Chenomx NMR Suite 7.1, Metabolite Detector;–;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;–;–;27073350;Hao et al. 2016;3069;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;GC;–;–;TOF;–;Chenomx NMR Suite 7.1, Metabolite Detector;HMDB;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;Y;–;27073350;Hao et al. 2016;3070;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;–;–;–;NMR;–;Chenomx NMR Suite 7.1, Metabolite Detector;–;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;–;–;27073350;Hao et al. 2016;3071;;
dimethylamine;dimethylamine;dimethylamine;–;–;–;HMDB00087;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;–;–;–;NMR;–;Chenomx NMR Suite 7.1, Metabolite Detector;–;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;–;–;27073350;Hao et al. 2016;3072;;
erythritol;erythritol;erythritol;–;–;–;HMDB02994;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;GC;–;–;TOF;–;Chenomx NMR Suite 7.1, Metabolite Detector;HMDB;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;–;–;27073350;Hao et al. 2016;3073;;
glucopyranose;glucopyranose;glucopyranose;–;–;–;HMDB01514;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;GC;–;–;TOF;–;Chenomx NMR Suite 7.1, Metabolite Detector;HMDB;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;Y;–;27073350;Hao et al. 2016;3074;;
isopropanol;isopropanol;isopropanol;–;–;–;HMDB00863;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;–;–;–;NMR;–;Chenomx NMR Suite 7.1, Metabolite Detector;–;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;–;–;27073350;Hao et al. 2016;3075;;
methionine;methionine;methionine;–;–;–;HMDB00696;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;–;–;–;NMR;–;Chenomx NMR Suite 7.1, Metabolite Detector;–;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;–;–;27073350;Hao et al. 2016;3076;;
ribitol;ribitol;ribitol;–;–;–;HMDB00508;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;GC;–;–;TOF;–;Chenomx NMR Suite 7.1, Metabolite Detector;HMDB;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;–;–;27073350;Hao et al. 2016;3077;;
threonine;threonine;threonine;–;–;–;HMDB00167;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;25;15, 10;64 (42–77);smoker, non-smoker;before vs. after treatment (radiation treatment);–;–;–;smoker, non-smoker;–;–;–;NMR;–;Chenomx NMR Suite 7.1, Metabolite Detector;–;–;OPLS-DA, CV-ANOVA;–;–;–;–;–;>1;–;–;–;–;–;–;–;–;–;–;–;Canada;–;–;27073350;Hao et al. 2016;3078;;
Arg;Arg;Arg;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;lung cancer;–;222;94, 128;median: 57.47 (27-81);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27217771;Huang et al. 2016;3079;;
Arg;Arg;Arg;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;benign lung disease;–;118;55, 63;median: 59.61 (32-80);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27217771;Huang et al. 2016;3080;;
C10:1;C10:1;C10:1;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;lung cancer;–;222;94, 128;median: 57.47 (27-81);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27217771;Huang et al. 2016;3081;;
C12;C12;C12;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;lung cancer;–;222;94, 128;median: 57.47 (27-81);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;27217771;Huang et al. 2016;3082;;
C14;C14;C14;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;lung cancer;–;222;94, 128;median: 57.47 (27-81);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;27217771;Huang et al. 2016;3083;;
C14:1;C14:1;C14:1;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;lung cancer;–;222;94, 128;median: 57.47 (27-81);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;27217771;Huang et al. 2016;3084;;
C5DC;C5DC;C5DC;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;lung cancer;–;222;94, 128;median: 57.47 (27-81);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;27217771;Huang et al. 2016;3085;;
C5-OH/C0;C5-OH/C0;C5-OH/C0;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;lung cancer;–;222;94, 128;median: 57.47 (27-81);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27217771;Huang et al. 2016;3086;;
Pro;Pro;Pro;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;lung cancer;–;222;94, 128;median: 57.47 (27-81);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27217771;Huang et al. 2016;3087;;
C12;C12;C12;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;benign lung disease;–;118;55, 63;median: 59.61 (32-80);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,042;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;27217771;Huang et al. 2016;3088;;
Pro;Pro;Pro;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;benign lung disease;–;118;55, 63;median: 59.61 (32-80);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,042;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27217771;Huang et al. 2016;3089;;
C14:1;C14:1;C14:1;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;benign lung disease;–;118;55, 63;median: 59.61 (32-80);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,032;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;27217771;Huang et al. 2016;3090;;
C10:1;C10:1;C10:1;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;benign lung disease;–;118;55, 63;median: 59.61 (32-80);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,03;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27217771;Huang et al. 2016;3091;;
C14;C14;C14;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;benign lung disease;–;118;55, 63;median: 59.61 (32-80);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,023;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;27217771;Huang et al. 2016;3092;;
Pip;Pip;Pip;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;benign lung disease;–;118;55, 63;median: 59.61 (32-80);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,023;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;27217771;Huang et al. 2016;3093;;
C5DC;C5DC;C5DC;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;benign lung disease;–;118;55, 63;median: 59.61 (32-80);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,02;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;27217771;Huang et al. 2016;3094;;
Hcy;Hcy;Hcy;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;benign lung disease;–;118;55, 63;median: 59.61 (32-80);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,009;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;27217771;Huang et al. 2016;3095;;
C5-OH/C0;C5-OH/C0;C5-OH/C0;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;benign lung disease;–;118;55, 63;median: 59.61 (32-80);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,005;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;27217771;Huang et al. 2016;3096;;
Pip;Pip;Pip;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;lung cancer;–;222;94, 128;median: 57.47 (27-81);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,003;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;27217771;Huang et al. 2016;3097;;
Hcy;Hcy;Hcy;–;–;–;–;–;–;–;–;–;–;dried blood spot;diagnosis;lung cancer;–;222;94, 128;median: 57.47 (27-81);–;healthy;96;30, 66;median: 56.07 (32-80);–;LC;ESI;positive;QTrap;MS/MS;Analyst software, ChemoView software;–;SIMCA-P;PLS-DA, ANOVA, student’s t-test;–;–;–;0,002;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;–;27217771;Huang et al. 2016;3098;;
adenine;adenine;adenine;–;[M + H];–;HMDB0000034;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,92;0,043;–;1,27;ROC curve analysis ;–;0,82;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3099;;
acetic acid;acetic acid;acetic acid;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,71;0,047;–;1,93;ROC curve analysis ;–;0,52;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3100;;
phosphocholine;phosphocholine;phosphocholine;–;[M + H];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,48;0,046;–;2,09;ROC curve analysis ;–;0,67;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3101;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,37;0,008;–;2,11;ROC curve analysis ;–;0,69;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3102;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,36;0,022;–;1,88;ROC curve analysis ;–;0,64;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3103;;
carnitine;carnitine;carnitine;–;[M + H];–;HMDB0000062;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,92;0,023;–;2,67;ROC curve analysis ;–;0,87;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3104;;
PE(16:0/18:0);PE(16:0/18:0);PE(16:0/18:0);–;[M + H];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,9;0,023;–;1,04;ROC curve analysis ;–;0,59;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3105;;
PE(18:1/18:0);PE(18:1/18:0);PE(18:1/18:0);–;[M + H];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,88;0,024;–;1,36;ROC curve analysis ;–;0,59;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3106;;
PPE(18:0/20:4);PPE(18:0/20:4);PPE(18:0/20:4);–;[M + H];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,86;0,047;–;1,24;ROC curve analysis ;–;0,52;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3107;;
PPE(18:1/20:4);PPE(18:1/20:4);PPE(18:1/20:4);–;[M + H];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,86;0,028;–;1,41;ROC curve analysis ;–;0,55;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3108;;
LPC(18:2);LPC(18:2);LPC(18:2);–;[M + H];–;HMDB0010386;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,86;0,024;–;1,1;ROC curve analysis ;–;0,5;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3109;;
PE(18:0/18:0);PE(18:0/18:0);PE(18:0/18:0);–;[M + H];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,85;0,006;–;1,64;ROC curve analysis ;–;0,56;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3110;;
L-glutamate;L-glutamate;L-glutamate;–;[M + H];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,84;0,019;–;1,58;ROC curve analysis ;–;0,51;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3111;;
pyroglutamate;pyroglutamate;pyroglutamate;–;[M + H];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,83;0,042;–;1,01;ROC curve analysis ;–;0,57;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3112;;
PC(18:1/18:1);PC(18:1/18:1);PC(18:1/18:1);–;[M + Na];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,8;0,041;–;1,14;ROC curve analysis ;–;0,51;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3113;;
L-arginine;L-arginine;L-arginine;–;[M + H];–;HMDB0000517;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,8;0,036;–;1,43;ROC curve analysis ;–;0,53;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3114;;
L-serine;L-serine;L-serine;–;[M + H];–;HMDB0000187;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,78;0,044;–;1,31;ROC curve analysis ;–;0,53;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3115;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,78;0,023;–;1,45;ROC curve analysis ;–;0,54;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3116;;
creatine;creatine;creatine;–;[M + H];–;HMDB0000064;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,76;0,032;–;1,53;ROC curve analysis ;–;0,6;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3117;;
urea;urea;urea;–;[M + H];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,74;0,048;–;1,3;ROC curve analysis ;–;0,54;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3118;;
LPS(18:0);LPS(18:0);LPS(18:0);–;[M + H];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,72;0,001;–;1,63;ROC curve analysis ;–;0,58;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3119;;
acetylcarnitine;acetylcarnitine;acetylcarnitine;–;[M + H];–;HMDB0000201;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,71;0,011;–;1,71;ROC curve analysis ;–;0,71;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3120;;
glycerophosphocholine;glycerophosphocholine;glycerophosphocholine;–;[M + H];–;HMDB0000086;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,7;0,019;–;1,14;ROC curve analysis ;–;0,52;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3121;;
L-proline;L-proline;L-proline;–;–;–;HMDB0000162;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,68;0,042;–;1,01;ROC curve analysis ;–;0,63;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3122;;
LPC(22:5);LPC(22:5);LPC(22:5);–;[M + H];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,68;0,038;–;1,6;ROC curve analysis ;–;0,61;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3123;;
choline;choline;choline;–;[M + H];–;HMDB0000097;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,68;0,014;–;2,41;ROC curve analysis ;–;0,78;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3124;;
galactose;galactose;galactose;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,63;0,043;–;2,1;ROC curve analysis ;–;0,68;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3125;;
inosytol;inosytol;inosytol;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,63;0,028;–;1,17;ROC curve analysis ;–;0,58;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3126;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,62;0,012;–;1,96;ROC curve analysis ;–;0,65;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3127;;
acetylcholine;acetylcholine;acetylcholine;–;[M + H];–;HMDB0000895;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,61;0,027;–;1,67;ROC curve analysis ;–;0,57;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3128;;
PC(16:0/16:0);PC(16:0/16:0);PC(16:0/16:0);–;[M + Na];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,6;0,047;–;1,69;ROC curve analysis ;–;0,56;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3129;;
L-glycine;L-glycine;L-glycine;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,6;0,017;–;1,49;ROC curve analysis ;–;0,74;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3130;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,59;0,004;–;2,18;ROC curve analysis ;–;0,88;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3131;;
fructose;fructose;fructose;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,58;0,017;–;1,66;ROC curve analysis ;–;0,6;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3132;;
L-valine;L-valine;L-valine;–;[M + H];–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;DI;ESI;positive;Q-TOF;MS/MS;Markerview;HMDB, METLIN;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,57;0,04;–;1,87;ROC curve analysis ;–;0,66;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3133;;
isocitric acid;isocitric acid;isocitric acid;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,53;0,023;–;1,67;ROC curve analysis ;–;0,57;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3134;;
L-glutamine;L-glutamine;L-glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,5;0,033;–;1,44;ROC curve analysis ;–;0,66;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3135;;
L-aspartate;L-aspartate;L-aspartate;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,48;0,047;–;1,35;ROC curve analysis ;–;0,74;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3136;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,47;0,019;–;1,55;ROC curve analysis ;–;0,72;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3137;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,42;0,047;–;2,12;ROC curve analysis ;–;0,79;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3138;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,36;0,038;–;1,02;ROC curve analysis ;–;0,63;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3139;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;lung cancer;–;24;16, 8;66 ± 11;–;noncancerous lung diseases;31;23, 8;56 ± 13;–;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,21;0,048;–;1,01;ROC curve analysis ;–;0,52;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;27255828;Callejon-Leblic et al. 2016;3140;;
cysteamine;cysteamine;cysteamine;–;–;–;–;–;–;–;–;–;–;sputum;diagnosis;NSCLC, SCLC, radiological;–;23;11, 12;66.6 ± 8.1;former, current, non-smoker ;healthy;33;20, 13;55.3 ± 14.6;former, current;flow infusion;ESI;–;–;–;–;–;–;PCA, 50–50 MANOVA test, ;–;–;–;–;–;–;ROC curve;–;0,99;96;94;–;–;–;–;–;–;UK;–;–;27423423;O'Shea et al. 2016;3141;;
diethyl glutarate;diethyl glutarate;diethyl glutarate;–;–;–;–;–;–;–;–;–;–;sputum;diagnosis;NSCLC, SCLC, radiological;–;23;11, 12;66.6 ± 8.1;former, current, non-smoker ;healthy;33;20, 13;55.3 ± 14.6;former, current;flow infusion;ESI;–;–;–;–;–;–;PCA, 50–50 MANOVA test, ;–;–;–;–;–;–;ROC curve;–;0,99;96;94;–;–;–;–;–;–;UK;–;–;27423423;O'Shea et al. 2016;3142;;
isobutyl decanoate;isobutyl decanoate;isobutyl decanoate;–;–;–;–;–;–;–;–;–;–;sputum;diagnosis;NSCLC, SCLC, radiological;–;23;11, 12;66.6 ± 8.1;former, current, non-smoker ;healthy;33;20, 13;55.3 ± 14.6;former, current;flow infusion;ESI;–;–;–;–;–;–;PCA, 50–50 MANOVA test, ;–;–;–;–;–;–;ROC curve;–;0,99;96;94;–;–;–;–;–;–;UK;–;–;27423423;O'Shea et al. 2016;3143;;
putrescine;putrescine;putrescine;–;–;–;–;–;–;–;–;–;–;sputum;diagnosis;SCLC, NSCLC, radiological;–;23;11, 12;66.6 ± 8.1;former, current, non-smoker ;healthy;33;20, 13;55.3 ± 14.6;former, current;flow infusion;ESI;–;–;–;–;–;–;PCA, 50–50 MANOVA test, ;–;–;–;–;–;–;ROC curve;–;0,99;96;94;–;–;–;–;–;–;UK;–;–;27423423;O'Shea et al. 2016;3144;;
carnitine;carnitine;carnitine;–;–;–;HMDB0000062;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;1,12;0,00249;0,01772;–;ROC curve analysis (Monte-Carlo cross validation);–;0.656 (0.511–0.776);0,52;0,76;–;–;–;–;–;–;Poland;Y;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3145;;
leucine;leucine;leucine;–;[M–HCOOH];–;HMDB0000687;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;0,9;0,00612;0,03867;–;ROC curve analysis (Monte-Carlo cross validation);–;0.628 (0.494–0.765);0,65;0,6;–;–;–;–;–;–;Poland;Y;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3146;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;0,9;0,00127;0,01002;–;ROC curve analysis (Monte-Carlo cross validation);–;0.687 (0.549–0.813);0,56;0,68;–;–;–;–;–;–;Poland;Y;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3147;;
tyrosine;tyrosine;tyrosine;–;[M–NH3–H2O];–;HMDB0000158;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;0,89;0,00266;0,01838;–;ROC curve analysis (Monte-Carlo cross validation);–;–;–;–;–;–;–;–;–;–;Poland;–;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3148;;
tyrosine;tyrosine;tyrosine;–;[M–NH3];–;HMDB0000158;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;0,88;0,00022;0,00318;–;ROC curve analysis (Monte-Carlo cross validation);–;–;–;–;–;–;–;–;–;–;Poland;–;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3149;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;0,87;0,00007;0,0013;–;ROC curve analysis (Monte-Carlo cross validation);–;0.681 (0.545–0.799);0,58;0,72;–;–;–;–;–;–;Poland;Y;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3150;;
tyrosine;tyrosine;tyrosine;–;[M–NH3–HCOOH];–;HMDB0000158;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;0,85;0,00063;0,00668;–;ROC curve analysis (Monte-Carlo cross validation);–;–;–;–;–;–;–;–;–;–;Poland;–;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3151;;
methionine;methionine;methionine;–;[M–HCOOH];–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;0,84;0,00427;0,02859;–;ROC curve analysis (Monte-Carlo cross validation);–;–;–;–;–;–;–;–;–;–;Poland;–;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3152;;
methionine;methionine;methionine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;0,83;0,00121;0,01002;–;ROC curve analysis (Monte-Carlo cross validation);–;0.685 (0.541–0.795);0,6;0,68;–;–;–;–;–;–;Poland;Y;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3153;;
methionine;methionine;methionine;–;[M–NH3];–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;0,82;0,00079;0,00794;–;ROC curve analysis (Monte-Carlo cross validation);–;–;–;–;–;–;–;–;–;–;Poland;–;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3154;;
malic acid;malic acid;malic acid;–;[M+NH4] ;–;HMDB0000156;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;HMDB;MetaboAnalyst 3.0 web server;t-test;–;–;0,81;0,00049;0,00565;–;ROC curve analysis (Monte-Carlo cross validation);–;0.717 (0.599–0.843);0,71;0,64;–;–;–;–;–;–;Poland;Y;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3155;;
5-oxo-l-proline;5-oxo-l-proline;5-oxo-l-proline;(pyroglutamic acid);–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;0,79;0,00035;0,00454;–;ROC curve analysis (Monte-Carlo cross validation);–;0.705 (0.560–0.813);0,63;0,72;–;–;–;–;–;–;Poland;Y;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3156;;
5-oxo-l-proline;5-oxo-l-proline;5-oxo-l-proline;(pyroglutamic acid);[M+Na];–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library, HMDB;MetaboAnalyst 3.0 web server;t-test;–;–;0,78;0,00126;0,01002;–;ROC curve analysis (Monte-Carlo cross validation);–;–;–;–;–;–;–;–;–;–;Poland;–;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3157;;
tyrosine;tyrosine;tyrosine;–;[M+Na];–;HMDB0000158;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library, HMDB;MetaboAnalyst 3.0 web server;t-test;–;–;0,78;0,00126;0,01002;–;ROC curve analysis (Monte-Carlo cross validation);–;–;–;–;–;–;–;–;–;–;Poland;–;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3158;;
propionylcarnitine;propionylcarnitine;propionylcarnitine;–;–;–;HMDB0000824;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;0,77;0,00221;0,01652;–;ROC curve analysis (Monte-Carlo cross validation);–;0.727 (0.598–0.837);0,67;0,72;–;–;–;–;–;–;Poland;Y;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3159;;
thiomorpholine 3-carboxylate;thiomorpholine 3-carboxylate;thiomorpholine 3-carboxylate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;HMDB;MetaboAnalyst 3.0 web server;t-test;–;–;0,72;0,00045;0,00553;–;ROC curve analysis (Monte-Carlo cross validation);–;0.734 (0.588–0.853);0,75;0,68;–;–;–;–;–;–;Poland;Y;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3160;;
valerylcarnitine;valerylcarnitine;valerylcarnitine;–;–;–;HMDB0013128;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;In-house library;MetaboAnalyst 3.0 web server;t-test;–;–;0,66;0,00005;0,00103;–;ROC curve analysis (Monte-Carlo cross validation);–;0.754 (0.616–0.865);0,71;0,68;–;–;–;–;–;–;Poland;Y;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3161;;
alpha-N-phenylacetyl-L-glutamine;alpha-N-phenylacetyl-L-glutamine;alpha-N-phenylacetyl-L-glutamine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;HMDB, mzCloud;MetaboAnalyst 3.0 web server;t-test;–;–;0,58;0,0011;0,01002;–;ROC curve analysis (Monte-Carlo cross validation);–;0.731 (0.608–0.835);0,56;0,8;–;–;–;–;–;–;Poland;Y;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3162;;
1-amino-propan-2-ol;1-amino-propan-2-ol;1-amino-propan-2-ol; (2-Amino-1-propanol, Tri- methylamine N-oxide);–;–;–;–;–;–;–;–;–;serum;diagnosis;adenocarcinoma, squamous cell carcinoma;I, II;50;28, 22;65 (53-86);–;healthy;25;14, 11;64 (50-78);–;LC;ESI;positive;Q-Orbitrap;MS/MS ;MZmine 2.19 software;HMDB, mzCloud;MetaboAnalyst 3.0 web server;t-test;–;–;0,57;0,00004;0,00087;–;ROC curve analysis (Monte-Carlo cross validation);–;0.799 (0.686–0.892);0,71;0,76;–;–;–;–;–;–;Poland;Y;Boxplots of the identified metabolites.;28168355;Klupczynska et al. 2017;3163;;
4-androsten-19-ol-3,17-dione;4-androsten-19-ol-3,17-dione;4-androsten-19-ol-3,17-dione;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;11,59;–;–;3,67;ROC curve;–;0.692 (0.612–0.771);91,1;56,7;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3164;;
galactonic acid;galactonic acid;galactonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;6,64;–;–;4,26;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3165;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;267,0736;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;4,17;–;–;1,72;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3166;;
5,10-methylenetrahydrofolate;5,10-methylenetrahydrofolate;5,10-methylenetrahydrofolate;–;–;–;–;–;–;–;–;–;440,1747;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;3,8;–;–;1,11;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3167;;
PC(18:3/0:0);PC(18:3/0:0);PC(18:3/0:0);–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;518,3369;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;2,11;–;–;1,57;ROC curve;–;Combined effects of PCs: 0.996 (0.987–1.000) ;Combined effects of PCs: 98.9;Combined effects of PCs: 98.9;–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;3168;;
DL-lactate;DL-lactate;DL-lactate;–;–;–;–;–;–;–;–;–;89,024;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;2,03;–;–;2,41;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3169;;
D-(glycerol-1-phosphate);D-(glycerol-1-phosphate);D-(glycerol-1-phosphate);–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,9;–;–;2,91;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3170;;
PC(O-16:0/0:0);PC(O-16:0/0:0);PC(O-16:0/0:0);–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;504,3452;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,83;–;–;1,29;ROC curve;–;Combined effects of PCs: 0.996 (0.987–1.000) ;Combined effects of PCs: 98.9;Combined effects of PCs: 98.9;–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;3171;;
mannose;mannose;mannose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,74;–;–;1,59;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3172;;
PC(18:4/22:6);PC(18:4/22:6);PC(18:4/22:6);–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;826,5287;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,69;–;–;1,03;ROC curve;–;Combined effects of PCs: 0.996 (0.987–1.000) ;Combined effects of PCs: 98.9;Combined effects of PCs: 98.9;–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;3173;;
prostaglandin E2;prostaglandin E2;prostaglandin E2;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,68;–;–;1,06;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3174;;
PE(18:1/0:0);PE(18:1/0:0);PE(18:1/0:0);–;–;–;–;–;–;–;–;–;478,293;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,67;–;–;1,11;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3175;;
PC(18:0/22:6);PC(18:0/22:6);PC(18:0/22:6);–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;834,5778;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,64;–;–;1,57;ROC curve;–;Combined effects of PCs: 0.996 (0.987–1.000) ;Combined effects of PCs: 98.9;Combined effects of PCs: 98.9;–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;3176;;
PC(16:1/0:0);PC(16:1/0:0);PC(16:1/0:0);–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;494,3326;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,62;–;–;1,08;ROC curve;–;Combined effects of PCs: 0.996 (0.987–1.000) ;Combined effects of PCs: 98.9;Combined effects of PCs: 98.9;–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;3177;;
3-hydroxybutyric acid;3-hydroxybutyric acid;3-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,6;–;–;3,29;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3178;;
PC(15:1/22:6);PC(15:1/22:6);PC(15:1/22:6);–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;790,5513;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,57;–;–;1,54;ROC curve;–;Combined effects of PCs: 0.996 (0.987–1.000) ;Combined effects of PCs: 98.9;Combined effects of PCs: 98.9;–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;3179;;
PE(18:2/0:0);PE(18:2/0:0);PE(18:2/0:0);–;–;–;–;–;–;–;–;–;476,2775;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,57;–;–;1,26;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3180;;
L-prolyl-L-phenylalanine;L-prolyl-L-phenylalanine;L-prolyl-L-phenylalanine;–;–;–;–;–;–;–;–;–;263,1366;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,5;–;–;1,67;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3181;;
PC(O-16:1/0:0);PC(O-16:1/0:0);PC(O-16:1/0:0);–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;502,3333;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,49;–;–;1,34;ROC curve;–;Combined effects of PCs: 0.996 (0.987–1.000) ;Combined effects of PCs: 98.9;Combined effects of PCs: 98.9;–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;3182;;
PE(16:0/0:0);PE(16:0/0:0);PE(16:0/0:0);–;–;–;–;–;–;–;–;–;452,2774;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,48;–;–;1,35;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3183;;
PC(19:0/0:0);PC(19:0/0:0);PC(19:0/0:0);–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;538,3695;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,45;–;–;1,34;ROC curve;–;Combined effects of PCs: 0.996 (0.987–1.000) ;Combined effects of PCs: 98.9;Combined effects of PCs: 98.9;–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;3184;;
2-hydroxy-3-methylbutyric acid;2-hydroxy-3-methylbutyric acid;2-hydroxy-3-methylbutyric acid;–;–;–;–;–;–;–;–;–;117,0554;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,39;–;–;1,09;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3185;;
PC(17:2/24:4);PC(17:2/24:4);PC(17:2/24:4);–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;848,593;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,39;–;–;1,35;ROC curve;–;Combined effects of PCs: 0.996 (0.987–1.000) ;Combined effects of PCs: 98.9;Combined effects of PCs: 98.9;–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;3186;;
PE(18:0/0:0);PE(18:0/0:0);PE(18:0/0:0);–;–;–;–;–;–;–;–;–;480,3087;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,34;–;–;1,04;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3187;;
4-acetylbutyric acid;4-acetylbutyric acid;4-acetylbutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,32;–;–;1,56;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3188;;
PE(22:2/12:0);PE(22:2/12:0);PE(22:2/12:0);–;–;–;–;–;–;–;–;–;716,5143;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,29;–;–;1,15;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3189;;
glycochenodeoxycholate;glycochenodeoxycholate;glycochenodeoxycholate;–;–;–;–;–;–;–;–;–;450,3173;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,28;–;–;1,07;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3190;;
PA(18:2/18:0);PA(18:2/18:0);PA(18:2/18:0);–;–;–;–;–;–;–;–;–;699,477;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,21;–;–;1,81;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3191;;
2-oxoadipic acid;2-oxoadipic acid;2-oxoadipic acid;–;–;–;–;–;–;–;–;–;141,0165;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;1,18;–;–;1,79;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3192;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,88;–;–;1,32;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3193;;
β-glycerophosphoric acid;β-glycerophosphoric acid;β-glycerophosphoric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,87;–;–;1,39;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3194;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;255,2322;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,86;–;–;1,04;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3195;;
lyxose;lyxose;lyxose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,85;–;–;1,45;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3196;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;303,2327;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,84;–;–;1,26;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3197;;
2-deoxyerythritol;2-deoxyerythritol;2-deoxyerythritol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,83;–;–;1,3;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3198;;
2-hydroxypyridine;2-hydroxypyridine;2-hydroxypyridine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,83;–;–;1,1;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3199;;
glucose 1-phosphate;glucose 1-phosphate;glucose 1-phosphate;–;–;–;–;–;–;–;Starch and sucrose metabolism, Galactose metabolism, Amino sugar and nucleotide sugar metabolism;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,82;–;–;1,52;ROC curve;–;0.316 (0.238–0.394);86,7;50;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3200;;
3-(2-hydroxyphenyl)propionic acid;3-(2-hydroxyphenyl)propionic acid;3-(2-hydroxyphenyl)propionic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,81;–;–;1,5;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3201;;
cis-(6,9,12)-linolenic acid;cis-(6,9,12)-linolenic acid;cis-(6,9,12)-linolenic acid;–;–;–;–;–;–;–;–;–;277,2175;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,8;–;–;1,25;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3202;;
sedoheptulose;sedoheptulose;sedoheptulose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,77;–;–;1,28;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3203;;
aspartic acid;aspartic acid;aspartic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,76;–;–;1,21;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3204;;
isoleucine;isoleucine;isoleucine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,74;–;–;1,37;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3205;;
4-aminobutyric acid;4-aminobutyric acid;4-aminobutyric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,67;–;–;1,24;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3206;;
1-methylxanthine;1-methylxanthine;1-methylxanthine;–;–;–;–;–;–;–;–;–;203,0023;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,63;–;–;1,01;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3207;;
p-cresol;p-cresol;p-cresol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;GC;EI;–;TOF;–;Chroma TOF;LECO-Fiehn Rtx 5 ;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,6;–;–;1,17;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3208;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;Caffeine metabolism;–;188,9864;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,52;–;–;1,29;ROC curve;–;0.264 (0.191–0.337);77,8;60;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3209;;
PC(20:0/0:0);PC(20:0/0:0);PC(20:0/0:0);–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;552,3926;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,51;–;–;1,48;ROC curve;–;Combined effects of PCs: 0.996 (0.987–1.000) ;Combined effects of PCs: 98.9;Combined effects of PCs: 98.9;–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;3210;;
3-hydroxybutyric acid;3-hydroxybutyric acid;3-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;169,1228;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,5;–;–;1,54;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3211;;
L-palmitoylcarnitine;L-palmitoylcarnitine;L-palmitoylcarnitine;–;–;–;HMDB0000222;–;–;–;–;–;444,3168;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,5;–;–;1,62;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3212;;
theophylline;theophylline;theophylline;–;–;–;–;–;–;–;Caffeine metabolism;–;179,0544;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,42;–;–;1,19;ROC curve;–;0.251 (0.181–0.322);67,8;76,7;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3213;;
hippuric acid;hippuric acid;hippuric acid;–;–;–;HMDB0000714;–;–;–;–;–;178,051;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;negative;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,41;–;–;1,22;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3214;;
β-octylglucoside;β-octylglucoside;β-octylglucoside;–;–;–;–;–;–;–;–;–;310,2229;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,39;–;–;1,73;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3215;;
PC(O-18:3/0:0);PC(O-18:3/0:0);PC(O-18:3/0:0);–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;504,3374;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,37;–;–;1,62;ROC curve;–;Combined effects of PCs: 0.996 (0.987–1.000) ;Combined effects of PCs: 98.9;Combined effects of PCs: 98.9;–;–;–;–;–;–;China;Y;–;29740076;Chen et al. 2018;3216;;
PC(10:0/22:2);PC(10:0/22:2);PC(10:0/22:2);–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;730,5311;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,36;–;–;1,49;ROC curve;–;Combined effects of PCs: 0.996 (0.987–1.000) ;Combined effects of PCs: 98.9;Combined effects of PCs: 98.9;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3217;;
isovaleric acid;isovaleric acid;isovaleric acid;–;–;–;–;–;–;–;–;–;103,0755;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,35;–;–;1,6;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3218;;
biliverdin;biliverdin;biliverdin;–;–;–;–;–;–;–;–;–;583,2549;serum;diagnosis;NSCLC ;I, II;90;40, 50; 58.1 ± 9.0;–;healthy;90;42, 48;53.0 ± 11.8;–;LC;ESI;positive;Q-TOF;MS/MS;Analyst TF, XCMS; in-house;SIMCA-P, MetaboAnalystR, SPSS ;PCA, OPLS-DA;–;–;0,29;–;–;1,11;ROC curve;–;–;–;–;–;–;–;–;–;–;China;–;–;29740076;Chen et al. 2018;3219;;
testosterone;testosterone;testosterone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;31,845;3,261E-015;–;2,138;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3220;;
tetradecanedioic acid;tetradecanedioic acid;tetradecanedioic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;26,598;1,176E-018;–;1,562;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3221;;
dodecanoic acid;dodecanoic acid;dodecanoic acid;–;–;–;HMDB0000638;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;24,153;8,675E-024;–;2,095;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3222;;
testosterone;testosterone;testosterone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;23,367;4,114E-009;–;1,425;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3223;;
tetradecanedioic acid;tetradecanedioic acid;tetradecanedioic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;21,204;5,234E-018;–;1,158;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3224;;
tetradecanedioic acid;tetradecanedioic acid;tetradecanedioic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;20,99;6,615E-017;–;1,804;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3225;;
palmitoyl-Dl-carnitine chloride free;palmitoyl-Dl-carnitine chloride free;palmitoyl-Dl-carnitine chloride free;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;19,569;1,421E-023;–;2,016;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3226;;
indoleacetic acid;indoleacetic acid;indoleacetic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;19,568;3,838E-019;–;1,275;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3227;;
cortisone;cortisone;cortisone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;16,716;1,123E-023;–;2,316;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;29896992;Xiang et al. 2018;3228;;
palmitoyl-Dl-carnitine chloride free;palmitoyl-Dl-carnitine chloride free;palmitoyl-Dl-carnitine chloride free;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;14,573;2,846E-020;–;2,2;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3229;;
cortisol;cortisol;cortisol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;14,568;1,819E-025;–;2,518;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;29896992;Xiang et al. 2018;3230;;
palmitoyl-Dl-carnitine chloride free;palmitoyl-Dl-carnitine chloride free;palmitoyl-Dl-carnitine chloride free;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;13,219;3,006E-020;–;1,872;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3231;;
sodium glycodeoxycholate bioxtra;sodium glycodeoxycholate bioxtra;sodium glycodeoxycholate bioxtra;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;12,835;7,623E-010;–;1,654;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3232;;
hexadecanedioic  Acid;hexadecanedioic  Acid;hexadecanedioic  Acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;11,767;6,06E-020;–;1,932;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3233;;
indoleacetic acid;indoleacetic acid;indoleacetic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;11,541;2,902E-017;–;1,814;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3234;;
tetradecanedioic acid;tetradecanedioic acid;tetradecanedioic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;11,281;6,474E-016;–;1,337;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3235;;
cortisone;cortisone;cortisone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;11,26;4,305E-022;–;2,226;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;29896992;Xiang et al. 2018;3236;;
indoleacetic acid;indoleacetic acid;indoleacetic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;10,553;2,525E-017;–;1,468;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3237;;
sodium glycodeoxycholate bioxtra;sodium glycodeoxycholate bioxtra;sodium glycodeoxycholate bioxtra;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;9,341;6,039E-008;–;1,336;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3238;;
dodecanoic acid;dodecanoic acid;dodecanoic acid;–;–;–;HMDB0000638;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;9,239;4,674E-019;–;1,83;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3239;;
octadecanedioic acid;octadecanedioic acid;octadecanedioic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;9,22;3,514E-014;–;1,66;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3240;;
cortisol;cortisol;cortisol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;8,871;1,091E-025;–;2,183;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;29896992;Xiang et al. 2018;3241;;
hexadecanedioic  Acid;hexadecanedioic  Acid;hexadecanedioic  Acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;8,702;3,938E-016;–;2,004;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3242;;
cortisone;cortisone;cortisone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;8,676;4,121E-020;–;2,551;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;29896992;Xiang et al. 2018;3243;;
testosterone;testosterone;testosterone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;8,554;7,165E-009;–;1,636;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3244;;
hexadecanedioic  Acid;hexadecanedioic  Acid;hexadecanedioic  Acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;8,311;6,607E-017;–;1,697;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3245;;
indoleacetic acid;indoleacetic acid;indoleacetic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;8,143;4,724E-016;–;2,026;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3246;;
octadecanedioic acid;octadecanedioic acid;octadecanedioic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;6,533;7,271E-014;–;1,888;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3247;;
cortisol;cortisol;cortisol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;6,359;1,516E-023;–;2,416;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;29896992;Xiang et al. 2018;3248;;
cuminaldehyde;cuminaldehyde;cuminaldehyde;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;6,111;4,932E-014;–;1,988;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3249;;
trans-ferulic acid;trans-ferulic acid;trans-ferulic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;5,97;3,061E-010;–;1,299;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3250;;
dodecanoic acid;dodecanoic acid;dodecanoic acid;–;–;–;HMDB0000638;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;5,888;4,938E-018;–;2,142;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3251;;
cortisol;cortisol;cortisol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;5,841;9,084E-021;–;2,582;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;29896992;Xiang et al. 2018;3252;;
octadecanedioic acid;octadecanedioic acid;octadecanedioic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;5,741;7,626E-013;–;1,869;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3253;;
hexadecanedioic  Acid;hexadecanedioic  Acid;hexadecanedioic  Acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;5,549;9,15E-017;–;2,063;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3254;;
indoleacrylic acid;indoleacrylic acid;indoleacrylic acid;–;–;–;HMDB0000734;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;5,128;7,214E-007;–;1,258;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3255;;
trans-ferulic acid;trans-ferulic acid;trans-ferulic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;5,111;4,931E-008;–;1,672;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3256;;
4-methylcatechol;4-methylcatechol;4-methylcatechol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;4,753;4,4E-011;–;1,749;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3257;;
4-methylcatechol;4-methylcatechol;4-methylcatechol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;4,725;3,225E-010;–;2,051;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3258;;
indoleacrylic acid;indoleacrylic acid;indoleacrylic acid;–;–;–;HMDB0000734;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;4,542;0,00001328;–;1,425;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3259;;
trans-ferulic acid;trans-ferulic acid;trans-ferulic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;4,472;2,129E-008;–;1,46;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3260;;
trans-ferulic acid;trans-ferulic acid;trans-ferulic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;4,446;3,382E-007;–;1,391;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3261;;
4-8-dihydroxyquinoline-2-carboxylic;4-8-dihydroxyquinoline-2-carboxylic;4-8-dihydroxyquinoline-2-carboxylic;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;4,378;7,302E-009;–;1,686;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3262;;
palmitoyl-Dl-carnitine chloride free;palmitoyl-Dl-carnitine chloride free;palmitoyl-Dl-carnitine chloride free;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;4,22;9,919E-017;–;1,897;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3263;;
cortisone;cortisone;cortisone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;4,132;1,49E-017;–;2,154;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;29896992;Xiang et al. 2018;3264;;
testosterone;testosterone;testosterone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;4,003;0,0003046;–;1,295;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3265;;
sodium glycodeoxycholate bioxtra;sodium glycodeoxycholate bioxtra;sodium glycodeoxycholate bioxtra;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;3,959;6,017E-007;–;1,103;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3266;;
octadecanedioic acid;octadecanedioic acid;octadecanedioic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;3,906;8,896E-011;–;1,437;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3267;;
L-aspartyl-L-phenylalanine;L-aspartyl-L-phenylalanine;L-aspartyl-L-phenylalanine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;3,861;4,887E-008;–;1,356;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3268;;
indoleacrylic acid;indoleacrylic acid;indoleacrylic acid;–;–;–;HMDB0000734;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;3,502;1,345E-007;–;1,618;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3269;;
dodecanoic acid;dodecanoic acid;dodecanoic acid;–;–;–;HMDB0000638;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;3,31;9,207E-016;–;1,475;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3270;;
cuminaldehyde;cuminaldehyde;cuminaldehyde;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;3,207;3,398E-007;–;1,302;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3271;;
4-8-dihydroxyquinoline-2-carboxylic;4-8-dihydroxyquinoline-2-carboxylic;4-8-dihydroxyquinoline-2-carboxylic;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;3,132;0,000001932;–;1,744;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3272;;
cuminaldehyde;cuminaldehyde;cuminaldehyde;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;3,09;8,792E-012;–;1,224;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3273;;
sodium glycodeoxycholate bioxtra;sodium glycodeoxycholate bioxtra;sodium glycodeoxycholate bioxtra;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;2,976;0,00000792;–;1,168;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3274;;
4-methylcatechol;4-methylcatechol;4-methylcatechol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;2,833;2,876E-007;–;1,876;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3275;;
indoleacrylic acid;indoleacrylic acid;indoleacrylic acid;–;–;–;HMDB0000734;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;2,707;0,00005826;–;1,211;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3276;;
4-methylcatechol;4-methylcatechol;4-methylcatechol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;2,696;0,000002051;–;1,515;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3277;;
cuminaldehyde;cuminaldehyde;cuminaldehyde;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;2,684;7,324E-007;–;1,344;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3278;;
4-8-dihydroxyquinoline-2-carboxylic;4-8-dihydroxyquinoline-2-carboxylic;4-8-dihydroxyquinoline-2-carboxylic;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;2,654;1,134E-007;–;1,488;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3279;;
L-aspartyl-L-phenylalanine;L-aspartyl-L-phenylalanine;L-aspartyl-L-phenylalanine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;2,166;0,0000464;–;1,079;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3280;;
L-aspartyl-L-phenylalanine;L-aspartyl-L-phenylalanine;L-aspartyl-L-phenylalanine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;1,991;0,00001122;–;1,164;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3281;;
L-aspartyl-L-phenylalanine;L-aspartyl-L-phenylalanine;L-aspartyl-L-phenylalanine;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;1,988;0,0001188;–;1,053;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3282;;
4-8-dihydroxyquinoline-2-carboxylic;4-8-dihydroxyquinoline-2-carboxylic;4-8-dihydroxyquinoline-2-carboxylic;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;1,981;0,00001472;–;1,388;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3283;;
DL-glyceraldehyde;DL-glyceraldehyde;DL-glyceraldehyde;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,615;0,00000547;–;2,126;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3284;;
DL-glyceraldehyde;DL-glyceraldehyde;DL-glyceraldehyde;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,6;4,243E-008;–;1,99;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3285;;
DL-glyceraldehyde;DL-glyceraldehyde;DL-glyceraldehyde;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,556;0,000002562;–;1,812;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3286;;
DL-glyceraldehyde;DL-glyceraldehyde;DL-glyceraldehyde;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,53;6,713E-008;–;2,252;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3287;;
transtrans-farnesol;transtrans-farnesol;transtrans-farnesol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,47;0,00004746;–;1,578;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3288;;
2,3-dihydroxypropyl decanoate;2,3-dihydroxypropyl decanoate;2,3-dihydroxypropyl decanoate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,45;3,821E-010;–;1,899;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3289;;
2,3-dihydroxypropyl decanoate;2,3-dihydroxypropyl decanoate;2,3-dihydroxypropyl decanoate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,449;3,832E-009;–;1,688;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3290;;
2,3-dihydroxypropyl decanoate;2,3-dihydroxypropyl decanoate;2,3-dihydroxypropyl decanoate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,433;1,095E-007;–;2,187;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3291;;
transtrans-farnesol;transtrans-farnesol;transtrans-farnesol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,351;1,864E-008;–;1,849;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3292;;
octadecanamide;octadecanamide;octadecanamide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,348;2,082E-007;–;1,902;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3293;;
transtrans-farnesol;transtrans-farnesol;transtrans-farnesol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,321;3,159E-008;–;1,799;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3294;;
2,3-dihydroxypropyl decanoate;2,3-dihydroxypropyl decanoate;2,3-dihydroxypropyl decanoate;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,318;1,564E-007;–;2,078;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3295;;
2-methoxycinnamic acid;2-methoxycinnamic acid;2-methoxycinnamic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,29;9,126E-008;–;1,525;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3296;;
octadecanamide;octadecanamide;octadecanamide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,287;0,000000016;–;2,338;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3297;;
serotonin hydrochloride;serotonin hydrochloride;serotonin hydrochloride;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,276;1,431E-008;–;1,36;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3298;;
transtrans-farnesol;transtrans-farnesol;transtrans-farnesol;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,266;0,000001475;–;1,894;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3299;;
2-methoxycinnamic acid;2-methoxycinnamic acid;2-methoxycinnamic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,263;0,000001181;–;2,252;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3300;;
retinoic acid;retinoic acid;retinoic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,224;0,000001223;–;2,012;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3301;;
dehydroepiandrosterone;dehydroepiandrosterone;dehydroepiandrosterone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,217;2,752E-008;–;1,664;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3302;;
dehydroepiandrosterone;dehydroepiandrosterone;dehydroepiandrosterone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,209;1,929E-008;–;1,587;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3303;;
serotonin hydrochloride;serotonin hydrochloride;serotonin hydrochloride;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,198;3,016E-010;–;1,646;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3304;;
homovanillic acid;homovanillic acid;homovanillic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,185;3,256E-007;–;1,721;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3305;;
serotonin hydrochloride;serotonin hydrochloride;serotonin hydrochloride;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,179;2,669E-007;–;1,836;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3306;;
2-methoxycinnamic acid;2-methoxycinnamic acid;2-methoxycinnamic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,177;9,717E-009;–;1,942;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3307;;
retinoic acid;retinoic acid;retinoic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,173;1,758E-009;–;2,044;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3308;;
2-methoxycinnamic acid;2-methoxycinnamic acid;2-methoxycinnamic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,163;9,222E-010;–;1,569;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3309;;
octadecanamide;octadecanamide;octadecanamide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,149;5,821E-016;–;2,739;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3310;;
dehydroepiandrosterone;dehydroepiandrosterone;dehydroepiandrosterone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,135;4,03E-012;–;2,057;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3311;;
dehydroepiandrosterone;dehydroepiandrosterone;dehydroepiandrosterone;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,128;2,452E-007;–;1,938;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3312;;
octadecanamide;octadecanamide;octadecanamide;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,127;1,464E-017;–;3,417;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3313;;
4-methoxyphenylacetic acid;4-methoxyphenylacetic acid;4-methoxyphenylacetic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,121;1,688E-013;–;2,272;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;29896992;Xiang et al. 2018;3314;;
homovanillic acid;homovanillic acid;homovanillic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,112;1,658E-007;–;2,052;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3315;;
retinoic acid;retinoic acid;retinoic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,108;1,21E-010;–;1,501;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3316;;
3,4,5-trimethoxycinnamic acid;3,4,5-trimethoxycinnamic acid;3,4,5-trimethoxycinnamic acid;–;–;–;HMDB0002511;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,104;7,72E-016;–;1,875;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3317;;
homovanillic acid;homovanillic acid;homovanillic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,092;8,517E-011;–;1,919;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3318;;
homovanillic acid;homovanillic acid;homovanillic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,085;2,46E-011;–;1,775;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3319;;
4-methoxyphenylacetic acid;4-methoxyphenylacetic acid;4-methoxyphenylacetic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,082;7,772E-013;–;2,072;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;29896992;Xiang et al. 2018;3320;;
serotonin hydrochloride;serotonin hydrochloride;serotonin hydrochloride;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,081;8,191E-014;–;1,997;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3321;;
3,4,5-trimethoxycinnamic acid;3,4,5-trimethoxycinnamic acid;3,4,5-trimethoxycinnamic acid;–;–;–;HMDB0002511;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,075;4,442E-015;–;1,59;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3322;;
4-methoxyphenylacetic acid;4-methoxyphenylacetic acid;4-methoxyphenylacetic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,061;9,236E-014;–;2,049;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;29896992;Xiang et al. 2018;3323;;
4-methoxyphenylacetic acid;4-methoxyphenylacetic acid;4-methoxyphenylacetic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,05;9,34E-013;–;2,654;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;29896992;Xiang et al. 2018;3324;;
retinoic acid;retinoic acid;retinoic acid;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,046;4,469E-007;–;1,328;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3325;;
1-palmitoyl-palmitoyl;1-palmitoyl-palmitoyl;1-palmitoyl-palmitoyl;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,039;7,521E-015;–;1,944;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3326;;
1-palmitoyl-palmitoyl;1-palmitoyl-palmitoyl;1-palmitoyl-palmitoyl;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;25;21, 4;59.8 (43-83);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,036;3,802E-013;–;1,788;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3327;;
3,4,5-trimethoxycinnamic acid;3,4,5-trimethoxycinnamic acid;3,4,5-trimethoxycinnamic acid;–;–;–;HMDB0002511;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,034;4,975E-015;–;2,644;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3328;;
1-palmitoyl-palmitoyl;1-palmitoyl-palmitoyl;1-palmitoyl-palmitoyl;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;28;16, 12;59 (44-80);former, current, non-smoker;healthy;56;35, 21;58 (47-80);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,032;2,567E-013;–;2,124;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3329;;
1-palmitoyl-palmitoyl;1-palmitoyl-palmitoyl;1-palmitoyl-palmitoyl;–;–;–;–;–;–;–;–;–;–;plasma;diagnosis;adenocarcinoma;I, II, III, IV;24;10, 14;59 (43-71);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,029;6,739E-012;–;1,922;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3330;;
3,4,5-trimethoxycinnamic acid;3,4,5-trimethoxycinnamic acid;3,4,5-trimethoxycinnamic acid;–;–;–;HMDB0002511;–;–;–;–;–;–;plasma;diagnosis;squamous cell carcinoma;I, II, III, IV;22;16, 6;60.5 (42-73);former, current, non-smoker;healthy;56;35, 21;59 (42-79);former, current, non-smoker;LC;ESI;both;LTQ-FT;–;Analyst software;–;SIMCA-P;independent sample t-tests, OPLS-DA;–;–;0,028;1,316E-016;–;2,071;–;–;–;–;–;–;–;–;–;–;–;China;–;–;29896992;Xiang et al. 2018;3331;;
ascorbate;ascorbate;ascorbate;(Vitamin C);–;–;–;–;–;–;Cofactors and Vitamins;Ascorbate and Aldarate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;17,1264108839;6,39990145194888E-010;3,1721250674877E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3332;;
isoleucylleucine;isoleucylleucine;isoleucylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;15,508267408;3,26535813948717E-014;7,66398763326695E-013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3333;;
glutathione, reduced;glutathione, reduced;glutathione, reduced;(GSH);–;–;–;–;–;–;Amino Acid;Glutathione Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;15,3396710109;5,74314247936219E-011;3,91711769105216E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3334;;
cytidine 5'-diphosphocholine;cytidine 5'-diphosphocholine;cytidine 5'-diphosphocholine;–;–;–;–;–;–;–;Lipid;Phospholipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;14,9556515376;5,03299315346869E-017;5,02041067058502E-015;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3335;;
UDP-N-acetylglucosamine;UDP-N-acetylglucosamine;UDP-N-acetylglucosamine;–;–;–;–;–;–;–;Carbohydrate;Nucleotide Sugar;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;13,9740919683;1,26097093485248E-011;1,02679061837987E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3336;;
phenylalanylleucine;phenylalanylleucine;phenylalanylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;11,9969614455;2,61971779290389E-013;3,80097236134055E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3337;;
leucylleucine;leucylleucine;leucylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;11,2060052024;2,01483405369343E-012;2,08810074655501E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3338;;
isoleucylvaline;isoleucylvaline;isoleucylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;11,0279534957;8,15247548045909E-016;4,06604714587897E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3339;;
xanthosine 5'-monophosphate;xanthosine 5'-monophosphate;xanthosine 5'-monophosphate;(xmp);–;–;–;–;–;–;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;10,7833798283;1,09142475784655E-017;2,15867183357571E-015;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3340;;
N(1)-acetylspermine;N(1)-acetylspermine;N(1)-acetylspermine;–;–;–;–;–;–;–;Amino Acid;Polyamine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;10,6347973517;9,38966586871831E-013;1,11835124824436E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3341;;
valylphenylalanine;valylphenylalanine;valylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;10,4140059135;3,89739341438343E-013;5,4563507801368E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3342;;
alanylphenylalanine;alanylphenylalanine;alanylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;10,4041522949;4,50102242256403E-015;1,43672635728244E-013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3343;;
threonylphenylalanine;threonylphenylalanine;threonylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;10,3647156983;5,66669314765329E-014;1,1694823414515E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3344;;
UDP-glucuronate;UDP-glucuronate;UDP-glucuronate;–;–;–;–;–;–;–;Carbohydrate;Nucleotide Sugar;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;10,3348220051;1,32565094238717E-011;1,06855500204542E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3345;;
UDP-N-acetylgalactosamine;UDP-N-acetylgalactosamine;UDP-N-acetylgalactosamine;–;–;–;–;–;–;–;Carbohydrate;Nucleotide Sugar;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;10,1767869533;3,65931779087777E-011;2,67902348359675E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3346;;
valylthreonine;valylthreonine;valylthreonine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;9,4667039411;1,26980833314196E-013;1,986876568328E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3347;;
ascorbate;ascorbate;ascorbate;(Vitamin C);–;–;–;–;–;–;Cofactors and vitamins;Ascorbate and aldarate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;9,2089636512;2,51909586414027E-008;5,26610992551227E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3348;;
isoleucylalanine;isoleucylalanine;isoleucylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;9,0911118244;1,49816735245331E-012;1,66046881563575E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3349;;
alanyltyrosine;alanyltyrosine;alanyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;8,825415667;1,37583154530734E-015;5,73887402892974E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3350;;
dehydroascorbate;dehydroascorbate;dehydroascorbate;–;–;–;–;–;–;–;Cofactors and Vitamins;Ascorbate and Aldarate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;8,7346232657;5,52052339244084E-014;1,1694823414515E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3351;;
aspartylphenylalanine;aspartylphenylalanine;aspartylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;8,7027290615;1,02771009798607E-012;1,18856906984476E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3352;;
2'-deoxycytidine 5'-monophosphate;2'-deoxycytidine 5'-monophosphate;2'-deoxycytidine 5'-monophosphate;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Cytidine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;8,3325643039;5,99441206473829E-011;4,05384815903488E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3353;;
isoleucylserine;isoleucylserine;isoleucylserine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;8,3050510355;5,77649063492928E-012;4,95660164158448E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3354;;
serylphenyalanine;serylphenyalanine;serylphenyalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;8,2209975825;2,61933875951033E-014;6,3340373639068E-013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3355;;
threonylvaline;threonylvaline;threonylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;7,9088568077;5,36526248564494E-012;4,65378202559202E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3356;;
valylisoleucine;valylisoleucine;valylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;7,8591859229;3,84701114333527E-011;2,79083172034686E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3357;;
aspartyltryptophan;aspartyltryptophan;aspartyltryptophan;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;7,8209059653;2,48711894360285E-009;1,07282211729463E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3358;;
tyrosylleucine;tyrosylleucine;tyrosylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;7,1247390296;1,78922310610437E-012;1,87868426140958E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3359;;
2'-deoxyadenosine 5'-monophosphate;2'-deoxyadenosine 5'-monophosphate;2'-deoxyadenosine 5'-monophosphate;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;7,0613622947;2,30966259379457E-010;1,31650767846291E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3360;;
leucylglutamine;leucylglutamine;leucylglutamine;*;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;6,8316645121;9,16461808543724E-014;1,55603515578275E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3361;;
gamma-glutamylcysteine;gamma-glutamylcysteine;gamma-glutamylcysteine;–;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;6,7366691975;1,4307988118979E-010;8,85098799918235E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3362;;
2'-o-methylguanosine;2'-o-methylguanosine;2'-o-methylguanosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Guanine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;6,6983714287;6,37083275762662E-014;1,23998159526489E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3363;;
isoleucylglutamine;isoleucylglutamine;isoleucylglutamine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;6,5996808316;7,65869036648871E-012;6,50173926857233E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3364;;
bilirubin (Z,Z);bilirubin (Z,Z);bilirubin (Z,Z);–;–;–;–;–;–;–;Cofactors and Vitamins;Hemoglobin and Porphyrin Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;6,5932462225;1,35255127417025E-017;2,15867183357571E-015;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3365;;
eicosenoylglycerol;eicosenoylglycerol;eicosenoylglycerol;(monoeicosenoin);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;6,4607004867;6,32308120595694E-006;1,41748641205509E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3366;;
phenylalanylvaline;phenylalanylvaline;phenylalanylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;6,4515015185;3,90238980647528E-012;3,62105472740381E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3367;;
uridine-5'-monophosphate;uridine-5'-monophosphate;uridine-5'-monophosphate;(UMP);–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;6,105483597;9,2835674775245E-010;4,41884180605928E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3368;;
alanylleucine;alanylleucine;alanylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;5,9769570427;2,1473287661117E-011;1,66365859743411E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3369;;
docosadienoate;docosadienoate;docosadienoate;(22:2n6);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;5,699563111;2,85413023300636E-017;3,48378223061133E-015;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3370;;
2'-deoxyguanosine;2'-deoxyguanosine;2'-deoxyguanosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Guanine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;5,6932608365;1,23201866388023E-013;1,986876568328E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3371;;
galactonate;galactonate;galactonate;–;–;–;–;–;–;–;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;5,6616698713;0,000000002;9,12824161256529E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3372;;
5-methylthioadenosine;5-methylthioadenosine;5-methylthioadenosine;(MTA);–;–;–;–;–;–;Amino Acid;Polyamine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;5,5969570657;5,60286018197686E-010;2,8478232007755E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3373;;
docosatrienoate;docosatrienoate;docosatrienoate;(22:3n3);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;5,486937338;1,18815071124238E-016;9,48144267571422E-015;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3374;;
valylvaline;valylvaline;valylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;5,4430407012;1,14440074375851E-014;3,14907515006653E-013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3375;;
gulonic acid;gulonic acid;gulonic acid;*;–;–;–;–;–;–;Cofactors and Vitamins;Ascorbate and Aldarate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;5,3195184035;1,77714416680907E-013;2,62622415761785E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3376;;
2'-deoxyinosine;2'-deoxyinosine;2'-deoxyinosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;5,2993627938;8,09458651028481E-014;1,45241686401175E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3377;;
guanosine 5'- monophosphate;guanosine 5'- monophosphate;guanosine 5'- monophosphate;(5'-GMP);–;–;–;–;–;–;Nucleotide;Purine Metabolism, Guanine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;5,1044950544;0,000023656;4,81503588307916E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3378;;
methionylphenylalanine;methionylphenylalanine;methionylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;5,0980116652;8,26051139713936E-006;1,7912739388362E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3379;;
leucyltyrosine;leucyltyrosine;leucyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,9974651627;1,86381583981758E-007;5,46810676534715E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3380;;
adenylosuccinate;adenylosuccinate;adenylosuccinate;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,9855888041;8,64100883919182E-008;2,70412747202944E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3381;;
tyrosylisoleucine;tyrosylisoleucine;tyrosylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,8975816098;4,17711706297145E-011;3,0030084831092E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3382;;
methionylalanine;methionylalanine;methionylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,8167676023;2,08483569938652E-009;9,23371706776171E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3383;;
thymidine;thymidine;thymidine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Thymine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,7109240074;9,03677134992143E-012;7,51181618462219E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3384;;
tyrosylphenylalanine;tyrosylphenylalanine;tyrosylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,7100936764;0,000000009;3,36158597403767E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3385;;
glycerophosphoethanolamine;glycerophosphoethanolamine;glycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Phospholipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,704829114;2,23018329201861E-015;8,47469650967073E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3386;;
erucate;erucate;erucate;(22:1n9);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,6270773481;5,87098436824262E-015;1,73520204661393E-013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3387;;
leucylphenylalanine;leucylphenylalanine;leucylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,6029820589;0,000000173;5,13120479491946E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3388;;
N-acetylputrescine;N-acetylputrescine;N-acetylputrescine;–;–;–;–;–;–;–;Amino Acid;Polyamine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,596393309;4,88949577135704E-015;1,50069908674728E-013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3389;;
seryltyrosine;seryltyrosine;seryltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,5914809371;2,35390639592526E-012;2,31903370857822E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3390;;
2-arachidonoylglycerophosphoinositol;2-arachidonoylglycerophosphoinositol;2-arachidonoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,5576107123;8,3532487998102E-011;5,46384634610536E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3391;;
serylmethionine;serylmethionine;serylmethionine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,5417427639;3,46906099776081E-012;3,2568360896625E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3392;;
alpha-glutamylaspartate;alpha-glutamylaspartate;alpha-glutamylaspartate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,5323772214;5,85563103310973E-008;1,89181925685084E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3393;;
N-methylnicotinamide;N-methylnicotinamide;N-methylnicotinamide;–;–;–;–;–;–;–;Cofactors and Vitamins;Nicotinate and Nicotinamide Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,5311092012;7,23777767736843E-014;1,3751777587E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3394;;
asparagylisoleucine;asparagylisoleucine;asparagylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,5024516607;7,2013623706575E-011;4,74932824114437E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3395;;
cytidine 5'-diphosphocholine;cytidine 5'-diphosphocholine;cytidine 5'-diphosphocholine;–;–;–;–;–;–;–;Lipid;Glycerolipid metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,465597131;2,47997817321852E-014;9,08571851853235E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3396;;
dihydrobiopterin;dihydrobiopterin;dihydrobiopterin;–;–;–;–;–;–;–;Cofactors and Vitamins;Tetrahydrobiopterin Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,4139689311;4,74744847583359E-007;1,29741913825863E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3397;;
threonylleucine;threonylleucine;threonylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,4051723528;1,88317494780019E-014;4,69616752607671E-013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3398;;
alpha-glutamyltyrosine;alpha-glutamyltyrosine;alpha-glutamyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,3815499922;1,41533115884198E-010;8,82370519340549E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3399;;
glutamine-leucine;glutamine-leucine;glutamine-leucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,371290553;1,14243023202647E-009;5,30034491370421E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3400;;
dihomo-linoleate;dihomo-linoleate;dihomo-linoleate;(20:2n6);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,3037574083;1,43831429296485E-015;5,73887402892974E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3401;;
valylleucine;valylleucine;valylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,2727741869;2,36827880179667E-009;1,02711221947486E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3402;;
thymine;thymine;thymine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Thymine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,2587557184;4,89102785507509E-012;4,38543845882014E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3403;;
aspartylvaline;aspartylvaline;aspartylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,215260522;1,60493484688975E-011;1,28073800781802E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3404;;
cytosine-2',3'-cyclic monophosphate;cytosine-2',3'-cyclic monophosphate;cytosine-2',3'-cyclic monophosphate;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Cytidine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,2132524736;2,00623052382697E-006;4,82220469281302E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3405;;
phenylalanylalanine;phenylalanylalanine;phenylalanylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,1863003164;1,6917235415234E-011;1,33662909518384E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3406;;
5-methyluridine;5-methyluridine;5-methyluridine;(ribothymidine);–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,1537444736;1,93510991638975E-020;1,54421771327902E-017;–;–;–;–;–;–;–;–;–;–;–;–;Spain;Y;–;30099851;Moreno et al. 2018;3407;;
adrenate (22:4n6);adrenate (22:4n6);adrenate (22:4n6);(22:4n6);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,0744789764;1,76647717688308E-016;1,17470732262725E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3408;;
isoleucylasparagine;isoleucylasparagine;isoleucylasparagine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,053247385;3,11255150696702E-006;7,34856835076829E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3409;;
2'-deoxyuridine;2'-deoxyuridine;2'-deoxyuridine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;4,0521693917;2,57203742944107E-015;9,32948122133625E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3410;;
putrescine;putrescine;putrescine;–;–;–;–;–;–;–;Amino Acid;Polyamine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,9625554879;8,65138722827051E-013;1,04603136487271E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3411;;
eicosenoate;eicosenoate;eicosenoate;(20:1n9 or 11);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,9479833528;8,52525752060808E-013;1,04603136487271E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3412;;
asparagylleucine;asparagylleucine;asparagylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,9270897236;3,04013828581205E-011;2,24632440007223E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3413;;
aspartate-glutamate;aspartate-glutamate;aspartate-glutamate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,9097437752;9,86169636347012E-013;1,15729907324252E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3414;;
leucylserine;leucylserine;leucylserine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,8975398345;4,98491294572577E-012;4,41995614521018E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3415;;
leucylglycine;leucylglycine;leucylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,8945701971;1,17561779869178E-010;7,386952782331E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3416;;
stearoylcarnitine;stearoylcarnitine;stearoylcarnitine;–;–;–;HMDB0000848;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,8880608455;3,71022882308717E-006;8,65720058720339E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3417;;
imidazole lactate;imidazole lactate;imidazole lactate;–;–;–;–;–;–;–;Amino Acid;Histidine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,8847309166;7,45129109371459E-015;2,12361796170866E-013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3418;;
alanylvaline;alanylvaline;alanylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,8615023295;2,97190381309143E-012;2,87956221263963E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3419;;
arginylphenylalanine;arginylphenylalanine;arginylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,8567860506;6,8346974822952E-008;2,18163543634863E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3420;;
isoleucyltyrosine;isoleucyltyrosine;isoleucyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,8369584929;7,93543256326392E-009;3,01546437404029E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3421;;
5,6-dihydrouracil;5,6-dihydrouracil;5,6-dihydrouracil;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,7832518129;1,60338418444302E-014;4,12742122317914E-013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3422;;
oxaloacetate;oxaloacetate;oxaloacetate;–;–;–;–;–;–;–;Energy;TCA Cycle;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,764954984;5,75739147487077E-006;1,30152929091979E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3423;;
N6-carbamoylthreonyladenosine;N6-carbamoylthreonyladenosine;N6-carbamoylthreonyladenosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,683212839;7,37999125999335E-016;3,92615535031646E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3424;;
tryptophylasparagine;tryptophylasparagine;tryptophylasparagine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,6732892871;1,2343656203686E-006;3,11716381346247E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3425;;
coenzyme A;coenzyme A;coenzyme A;–;–;–;–;–;–;–;Cofactors and Vitamins;Pantothenate and CoA Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,63733502;7,23751657027195E-006;1,60878502035572E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3426;;
valylarginine;valylarginine;valylarginine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,6203831508;5,96773916991373E-010;0,000000003;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3427;;
dihomo-linoleate;dihomo-linoleate;dihomo-linoleate;(20:3n3 or n6);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,5882170522;2,81495402079211E-015;9,76666655909611E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3428;;
mead acid;mead acid;mead acid;(20:3n9);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,5735923247;4,56735884736053E-013;6,28405579343742E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3429;;
valylserine;valylserine;valylserine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,5682575614;4,80166425083068E-012;4,35423644563964E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3430;;
aspartylleucine;aspartylleucine;aspartylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,5261508001;4,94764771214559E-010;2,53091209890524E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3431;;
5,6-dihydrothymine;5,6-dihydrothymine;5,6-dihydrothymine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Thymine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,5012291478;1,28912368557494E-015;5,71511500604891E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3432;;
1-methylnicotinamide;1-methylnicotinamide;1-methylnicotinamide;–;–;–;–;–;–;–;Cofactors and Vitamins;Nicotinate and Nicotinamide Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,480473018;3,05594932509765E-017;3,48378223061133E-015;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3433;;
leucylglutamate;leucylglutamate;leucylglutamate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,4439085529;3,19972664219496E-009;1,3509956933712E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3434;;
imidazole propionate;imidazole propionate;imidazole propionate;–;–;–;–;–;–;–;Amino Acid;Histidine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,4199673757;7,7013667302899E-009;2,94052184247433E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3435;;
homocysteine;homocysteine;homocysteine;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,4055685382;4,99183419367561E-014;1,10652324626476E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3436;;
pyridoxal;pyridoxal;pyridoxal;–;–;–;–;–;–;–;Cofactors and Vitamins;Vitamin B6 Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,3973635366;7,76745014959623E-008;0,000000246;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3437;;
2-stearoylglycerol;2-stearoylglycerol;2-stearoylglycerol;(2-monostearin);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,3950831988;3,79137240311563E-005;7,39734762270482E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3438;;
cysteine;cysteine;cysteine;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,3688822629;5,88529329653381E-010;0,000000003;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3439;;
serylvaline;serylvaline;serylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,3638297873;0,000000072;0,000000229;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3440;;
10-nonadecenoate (19:1n9);10-nonadecenoate (19:1n9);10-nonadecenoate (19:1n9);(19:1n9);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,3370276296;2,17825063770712E-012;2,22851796011575E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3441;;
leucylisoleucine;leucylisoleucine;leucylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,3273350692;2,21063636404655E-007;6,34563963492498E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3442;;
2-methylcitrate;2-methylcitrate;2-methylcitrate;–;–;–;–;–;–;–;Energy;TCA Cycle;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,3231145461;9,82681386093113E-006;2,10235856863889E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3443;;
putrescine;putrescine;putrescine;–;–;–;–;–;–;–;Amino acid;Polyamine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,2725500961;4,31341941430522E-008;7,01330045511108E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3444;;
glycerophosphorylcholine;glycerophosphorylcholine;glycerophosphorylcholine;(GPC);–;–;–;–;–;–;Lipid;Phospholipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,246489919;8,31352148193538E-013;1,03659220977882E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3445;;
lysylphenylalanine;lysylphenylalanine;lysylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,2242591934;4,92448374531751E-007;1,34120751834928E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3446;;
valylglycine;valylglycine;valylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,1918454802;2,46974011434446E-008;8,53182948591723E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3447;;
2-eicosatrienoylglycerophosphocholine;2-eicosatrienoylglycerophosphocholine;2-eicosatrienoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,161442176;0,0002111154;0,0003718987;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3448;;
alanylmethionine;alanylmethionine;alanylmethionine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,1544102566;1,95021417168102E-006;0,000004716;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3449;;
serylleucine;serylleucine;serylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,1531059788;0,0002229474;0,0003910155;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3450;;
docosadienoate;docosadienoate;docosadienoate;(22:2n6);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,1452073749;2,01144025861737E-008;4,64748565017382E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3451;;
lysyltyrosine;lysyltyrosine;lysyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,1260501394;1,9679909606661E-005;4,06854089795739E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3452;;
5,6-dihydrouracil;5,6-dihydrouracil;5,6-dihydrouracil;–;–;–;–;–;–;–;Nucleotide;Pyrimidine metabolism, uracil containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,1211473786;2,60704859352441E-012;3,81498110852405E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;Y;–;30099851;Moreno et al. 2018;3453;;
1-methylhistamine;1-methylhistamine;1-methylhistamine;–;–;–;–;–;–;–;Amino Acid;Histidine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,0921269679;4,97841455428566E-013;6,7335166344406E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3454;;
phenylalanylarginine;phenylalanylarginine;phenylalanylarginine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,0918863348;4,73905171406646E-006;0,000010836;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3455;;
isoleucylthreonine;isoleucylthreonine;isoleucylthreonine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,0911932582;4,54947710858405E-011;3,24150243986614E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3456;;
2-palmitoleoylglycerophosphoethanolamine;2-palmitoleoylglycerophosphoethanolamine;2-palmitoleoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,0505611299;0,0005794402;0,000957336;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3457;;
1-eicosenoylglycerophosphocholine;1-eicosenoylglycerophosphocholine;1-eicosenoylglycerophosphocholine;(20:1n9)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,0303251771;3,96846766341386E-005;7,72399315952259E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3458;;
nervonate;nervonate;nervonate;(24:1n9);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,0278477683;4,91261663141638E-011;3,38506782435503E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3459;;
N6,N6-dimethyladenosine;N6,N6-dimethyladenosine;N6,N6-dimethyladenosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,013671706;0,000000001;4,7974979391497E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3460;;
aspartylphenylalanine;aspartylphenylalanine;aspartylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,0061194347;3,89401721184526E-010;2,4421050800001E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3461;;
1-dihomo-linoleoylglycerophosphocholine;1-dihomo-linoleoylglycerophosphocholine;1-dihomo-linoleoylglycerophosphocholine;(20:2n6)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;3,0008854311;0,0004023466;0,0006816828;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3462;;
phenylalanylserine;phenylalanylserine;phenylalanylserine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,9966009552;1,07999882248507E-009;0,000000005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3463;;
3-hydroxy-3-methylglutarate;3-hydroxy-3-methylglutarate;3-hydroxy-3-methylglutarate;–;–;–;–;–;–;–;Lipid;Mevalonate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,991452406;1,77431099499117E-012;1,87868426140958E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3464;;
leucylalanine;leucylalanine;leucylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,9839840592;1,92567919636216E-008;6,82974221643111E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3465;;
isoleucylphenylalanine;isoleucylphenylalanine;isoleucylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,9743894409;1,72965064257698E-005;3,59443024160529E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3466;;
2-eicosenoylglycerophosphocholine;2-eicosenoylglycerophosphocholine;2-eicosenoylglycerophosphocholine;(20:1n9)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,9739050199;0,000252779;0,0004356753;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3467;;
alpha-hydroxyisocaproate;alpha-hydroxyisocaproate;alpha-hydroxyisocaproate;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,9716158971;7,7138483938074E-010;3,77647301733638E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3468;;
phenylalanylglycine;phenylalanylglycine;phenylalanylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,9576300905;2,27499410054805E-009;9,92046607779969E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3469;;
aspartylleucine;aspartylleucine;aspartylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,9502582666;0,000000017;4,15594673867642E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3470;;
N2-methylguanosine;N2-methylguanosine;N2-methylguanosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Guanine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,94600666;8,94561818285988E-014;1,55187028476569E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3471;;
tryptophylglycine;tryptophylglycine;tryptophylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,9330218991;0,0002393696;0,0004152542;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3472;;
quinolinate;quinolinate;quinolinate;–;–;–;–;–;–;–;Cofactors and Vitamins;Nicotinate and Nicotinamide Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,9306492587;5,60469936322587E-007;1,51611867520483E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3473;;
cytidine-5'-diphosphoethanolamine;cytidine-5'-diphosphoethanolamine;cytidine-5'-diphosphoethanolamine;–;–;–;–;–;–;–;Lipid;Phospholipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,9187162327;8,96285954794138E-010;4,30865175858869E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3474;;
oleic ethanolamide;oleic ethanolamide;oleic ethanolamide;–;–;–;–;–;–;–;Lipid;Endocannabinoid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,9127271544;2,244244663026E-009;9,84014967634475E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3475;;
N1-methylguanosine;N1-methylguanosine;N1-methylguanosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Guanine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,879025845;5,74099837471038E-014;1,1694823414515E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3476;;
pro-hydroxy-pro;pro-hydroxy-pro;pro-hydroxy-pro;–;–;–;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,8623270557;9,44233593094557E-016;4,43234357229092E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3477;;
docosapentaenoate;docosapentaenoate;docosapentaenoate;(n6 DPA; 22:5n6);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,8392452687;8,43030832985347E-012;7,08145899707691E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3478;;
phenyllactate;phenyllactate;phenyllactate;(PLA);–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,8255814865;3,58019147416276E-015;1,19041366515912E-013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3479;;
ribitol;ribitol;ribitol;–;–;–;–;–;–;–;Carbohydrate;Pentose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,8233720871;1,97207827574382E-010;1,1571459294438E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3480;;
leucylmethionine;leucylmethionine;leucylmethionine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,792891486;1,94098206851757E-005;4,02312646929096E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3481;;
adenosine 5'-diphosphate;adenosine 5'-diphosphate;adenosine 5'-diphosphate;(ADP);–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,7825241407;1,246976300155E-007;3,76926927092307E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3482;;
N-acetylmannosamine;N-acetylmannosamine;N-acetylmannosamine;–;–;–;–;–;–;–;Carbohydrate;Aminosugar Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,7460517872;3,79225607799684E-010;0,000000002;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3483;;
docosatrienoate;docosatrienoate;docosatrienoate;(22:3n3);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,7198968382;4,51907392881334E-005;0,000176036;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3484;;
threonylisoleucine;threonylisoleucine;threonylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,7059866441;4,33507283806113E-010;2,26103799004757E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3485;;
docosapentaenoate;docosapentaenoate;docosapentaenoate;(n3 DPA; 22:5n3);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,7044257954;1,09547681859922E-012;1,23125422710166E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3486;;
glycylisoleucine;glycylisoleucine;glycylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,7042837503;1,26995267990461E-008;4,67014856481051E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3487;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,7028156113;2,99503337906126E-012;2,87956221263963E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3488;;
tiglyl carnitine;tiglyl carnitine;tiglyl carnitine;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,697261295;0,000000036;1,19848471506294E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3489;;
2-palmitoylglycerol;2-palmitoylglycerol;2-palmitoylglycerol;(2-monopalmitin);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,6731084435;2,41286520429786E-010;1,36557903051751E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3490;;
1-dihomo-linolenylglycerol;1-dihomo-linolenylglycerol;1-dihomo-linolenylglycerol;(alpha, gamma);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,6655075698;1,37185265942435E-013;2,10526619657813E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3491;;
dihomo-linoleate;dihomo-linoleate;dihomo-linoleate;(20:2n6);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,660677242;2,71789977490032E-007;2,84085238376486E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3492;;
glycerophosphorylcholine;glycerophosphorylcholine;glycerophosphorylcholine;(GPC);–;–;–;–;–;–;Lipid;Glycerolipid metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,659584325;4,69362012999067E-010;2,57562404633238E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3493;;
glutathione, oxidized;glutathione, oxidized;glutathione, oxidized;(GSSG);–;–;–;–;–;–;Amino Acid;Glutathione Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,651533378;0,0002452539;0,0004244418;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3494;;
adenosine 5'-monophosphate;adenosine 5'-monophosphate;adenosine 5'-monophosphate;(AMP);–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,6465315886;2,35876384571995E-007;6,67715286300278E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3495;;
prolylphenylalanine;prolylphenylalanine;prolylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,6399700013;1,28317839332694E-005;2,70893216369021E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3496;;
histidylisoleucine;histidylisoleucine;histidylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,6395293698;2,38201012485312E-005;4,81904820982878E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3497;;
leucylthreonine;leucylthreonine;leucylthreonine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,6263051513;2,2882785354938E-007;6,54496871442313E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3498;;
dihomo-linoleate;dihomo-linoleate;dihomo-linoleate;(20:3n3 or n6);–;–;–;–;–;–;Lipid;Essential fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,6149297821;0,00000001;2,74598387531254E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3499;;
serylphenyalanine;serylphenyalanine;serylphenyalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,6114052656;3,98538314088834E-006;2,33277759846664E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3500;;
creatine;creatine;creatine;–;–;–;HMDB0000064;–;–;–;Amino Acid;Creatine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,6072102338;7,42762115893875E-014;1,3784282987984E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3501;;
1-docosapentaenoylglycerophosphocholine;1-docosapentaenoylglycerophosphocholine;1-docosapentaenoylglycerophosphocholine;(22:5n3)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5935216403;0,0147317624;0,0203390076;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3502;;
glycerol-3-phosphate;glycerol-3-phosphate;glycerol-3-phosphate;(G3P);–;–;–;–;–;–;Lipid;Glycerolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5904964403;3,41398823671003E-014;7,78389317969887E-013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3503;;
2'-deoxyguanosine;2'-deoxyguanosine;2'-deoxyguanosine;–;–;–;–;–;–;–;Nucleotide;Purine metabolism, guanine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,590319884;1,41398351957619E-008;3,65140450055264E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3504;;
glycylleucine;glycylleucine;glycylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5850319883;9,83744657055128E-009;2,74598387531254E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3505;;
alanylleucine;alanylleucine;alanylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5772357555;0,000000143;0,00000161;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3506;;
S-adenosylhomocysteine;S-adenosylhomocysteine;S-adenosylhomocysteine;(SAH);–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5630464421;1,71653799082349E-010;0,000000001;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3507;;
threonylleucine;threonylleucine;threonylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5592529318;3,69570664984751E-009;1,47492292662096E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3508;;
tyrosylvaline;tyrosylvaline;tyrosylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5496546293;2,09150929964984E-008;7,35253048951792E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3509;;
ribulose;ribulose;ribulose;–;–;–;–;–;–;–;Carbohydrate;Pentose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,544265525;6,53238589909142E-009;2,53050677061891E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3510;;
tyrosyltyrosine;tyrosyltyrosine;tyrosyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5413297707;6,44380408380883E-009;2,50836861408753E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3511;;
xylitol;xylitol;xylitol;–;–;–;–;–;–;–;Carbohydrate;Pentose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5282710171;2,27241293649713E-012;2,26673190415589E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3512;;
2-linoleoylglycerol;2-linoleoylglycerol;2-linoleoylglycerol;(2-monolinolein);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5238878123;1,1391875256217E-005;5,32024812497792E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3513;;
2-oleoylglycerophosphocholine;2-oleoylglycerophosphocholine;2-oleoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,520501967;0,0005083885;0,0008451958;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3514;;
nicotinamide adenine dinucleotide phosphate;nicotinamide adenine dinucleotide phosphate;nicotinamide adenine dinucleotide phosphate;(NADP+);–;–;–;–;–;–;Cofactors and vitamins;Nicotinate and nicotinamide metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5197758553;1,16162052393881E-005;5,36790957904358E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3515;;
flavin adenine dinucleotide;flavin adenine dinucleotide;flavin adenine dinucleotide;(FAD);–;–;–;–;–;–;Cofactors and Vitamins;Riboflavin Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5173684359;4,1062552375299E-008;1,35404614857391E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3516;;
inosine 5'-monophosphate;inosine 5'-monophosphate;inosine 5'-monophosphate;(IMP);–;–;–;–;–;–;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,5132005974;0,0034149327;0,0050936753;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3517;;
S-methylglutathione;S-methylglutathione;S-methylglutathione;–;–;–;–;–;–;–;Amino Acid;Glutathione Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4779583552;6,08410548185221E-005;0,0001150501;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3518;;
S-lactoylglutathione;S-lactoylglutathione;S-lactoylglutathione;–;–;–;–;–;–;–;Amino Acid;Glutathione Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4647565183;3,12825763159818E-005;6,20982485078446E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3519;;
N-acetyl-glucosamine 1-phosphate;N-acetyl-glucosamine 1-phosphate;N-acetyl-glucosamine 1-phosphate;–;–;–;–;–;–;–;Carbohydrate;Aminosugar Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4626566748;6,80091718875645E-009;2,62180285827423E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3520;;
2'-deoxyinosine;2'-deoxyinosine;2'-deoxyinosine;–;–;–;–;–;–;–;Nucleotide;Purine metabolism, (hypo)xanthine/inosine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4585579415;1,25456020375561E-007;1,48851872823977E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3521;;
glycylphenylalanine;glycylphenylalanine;glycylphenylalanine;–;–;–;HMDB0028848;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4567526342;9,30282485486164E-010;4,41884180605928E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3522;;
ribonate;ribonate;ribonate;–;–;–;–;–;–;–;Carbohydrate;Pentose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,453481345;7,13930797813767E-010;3,51677022626782E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3523;;
aspartylvaline;aspartylvaline;aspartylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4489501849;5,82041837324803E-008;8,2424634382448E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3524;;
tyrosylglutamine;tyrosylglutamine;tyrosylglutamine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4301088303;0,000000006;2,37908140411897E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3525;;
arginylleucine;arginylleucine;arginylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4263440099;0,0002383257;0,000414344;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3526;;
glycyltryptophan;glycyltryptophan;glycyltryptophan;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4181154998;0,000000012;4,45774229528155E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3527;;
5-methyltetrahydrofolate;5-methyltetrahydrofolate;5-methyltetrahydrofolate;(5MeTHF);–;–;–;–;–;–;Cofactors and Vitamins;Folate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4118793171;2,46888042128459E-007;6,9617193504774E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3528;;
prolylglutamine;prolylglutamine;prolylglutamine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4096514278;2,3867028781419E-006;5,65159910016984E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3529;;
2-docosahexaenoylglycerophosphocholine;2-docosahexaenoylglycerophosphocholine;2-docosahexaenoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4081355811;0,0095482062;0,013344078;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3530;;
N6-succinyladenosine;N6-succinyladenosine;N6-succinyladenosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,4004386016;4,54362204445351E-009;1,84051288907305E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3531;;
ribose;ribose;ribose;–;–;–;–;–;–;–;Carbohydrate;Pentose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3946145827;3,66813627873695E-010;0,000000002;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3532;;
gamma-glutamylisoleucine;gamma-glutamylisoleucine;gamma-glutamylisoleucine;*;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3848364619;5,30741122096958E-012;4,65378202559202E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3533;;
S-lactoylglutathione;S-lactoylglutathione;S-lactoylglutathione;–;–;–;–;–;–;–;Amino acid;Glutathione metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3835221884;0,0001393585;0,0004531733;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3534;;
adrenate (22:4n6);adrenate (22:4n6);adrenate (22:4n6);(22:4n6);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3798262659;4,84972965490036E-008;7,60368328036163E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3535;;
valylaspartate;valylaspartate;valylaspartate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3735299958;2,69223645340603E-007;7,56480524583808E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3536;;
1-methylhistidine;1-methylhistidine;1-methylhistidine;–;–;–;HMDB0000001;–;–;–;Amino Acid;Histidine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3716023876;0,000000005;1,9911901704305E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3537;;
valylglutamate;valylglutamate;valylglutamate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3668854067;0,0007228548;0,0011724353;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3538;;
UDP-glucuronate;UDP-glucuronate;UDP-glucuronate;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3635896728;6,55834495107086E-006;3,38719227472954E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3539;;
isoleucylglycine;isoleucylglycine;isoleucylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3525900433;0,00000002;7,07439525957057E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3540;;
phenylalanyltyrosine;phenylalanyltyrosine;phenylalanyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,347414468;1,67008525286178E-005;3,47970765478774E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3541;;
xylulose;xylulose;xylulose;–;–;–;–;–;–;–;Carbohydrate;Pentose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3466022535;2,09751158235702E-010;1,22176222096416E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3542;;
adenosine 2'-monophosphate;adenosine 2'-monophosphate;adenosine 2'-monophosphate;(2'-AMP);–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3456347691;1,79398735780341E-010;1,068359635468E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3543;;
galactose;galactose;galactose;–;–;–;–;–;–;–;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,342003329;7,42980264383796E-009;2,85047236047245E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3544;;
N2,N2-dimethylguanosine;N2,N2-dimethylguanosine;N2,N2-dimethylguanosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Guanine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3272062643;2,21446106076019E-012;2,23688598289447E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3545;;
valylmethionine;valylmethionine;valylmethionine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3193422975;2,21789026309222E-005;4,53814469217331E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3546;;
3-hydroxyindolin-2-one;3-hydroxyindolin-2-one;3-hydroxyindolin-2-one;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3175388651;3,39519672583871E-012;3,22543688954678E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3547;;
fucose;fucose;fucose;–;–;–;–;–;–;–;Carbohydrate;Aminosugars metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3105193747;5,2589876445107E-009;1,92391297995016E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3548;;
tyrosyllysine;tyrosyllysine;tyrosyllysine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3061195703;0,0001034078;0,0001875442;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3549;;
erucate;erucate;erucate;(22:1n9);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3024439656;1,60216333606732E-006;1,0766518195009E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3550;;
N-acetylputrescine;N-acetylputrescine;N-acetylputrescine;–;–;–;–;–;–;–;Amino acid;Polyamine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,3010979078;3,39249216954901E-005;0,0001378985;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3551;;
1-eicosatrienoylglycerophosphocholine;1-eicosatrienoylglycerophosphocholine;1-eicosatrienoylglycerophosphocholine;(20:3)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,296967423;0,0054989449;0,0079208629;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3552;;
glycyltyrosine;glycyltyrosine;glycyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2896352636;2,47575640252679E-010;1,39130535860308E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3553;;
2-margaroylglycerophosphocholine;2-margaroylglycerophosphocholine;2-margaroylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2815532739;0,0053860609;0,0077863706;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3554;;
palmitoylcarnitine;palmitoylcarnitine;palmitoylcarnitine;–;–;–;HMDB0000222;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2802219043;0,0010880602;0,0017365441;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3555;;
adenine;adenine;adenine;–;–;–;HMDB0000034;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2643418554;1,88081500257296E-008;6,74558515407686E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3556;;
alanylphenylalanine;alanylphenylalanine;alanylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2586225823;4,84452931163202E-006;2,69208654152716E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3557;;
N-acetylglucosamine;N-acetylglucosamine;N-acetylglucosamine;–;–;–;–;–;–;–;Carbohydrate;Aminosugar Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2570477;4,86360784760366E-011;3,38506782435503E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3558;;
lactate;lactate;lactate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2536813;6,0056389269892E-017;5,32499984859709E-015;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3559;;
glycylleucine;glycylleucine;glycylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2527072519;4,677342844658E-009;1,88511090405913E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3560;;
thiamin diphosphate;thiamin diphosphate;thiamin diphosphate;–;–;–;–;–;–;–;Cofactors and Vitamins;Thiamine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2508045622;1,17217292621739E-007;0,000000357;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3561;;
pyroglutamylvaline;pyroglutamylvaline;pyroglutamylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2502824965;2,2869545567534E-010;1,31294225632318E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3562;;
1-palmitoleoylglycerophosphoethanolamine;1-palmitoleoylglycerophosphoethanolamine;1-palmitoleoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2325478415;0,0014130979;0,0022241658;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3563;;
sorbitol;sorbitol;sorbitol;–;–;–;–;–;–;–;Carbohydrate;Fructose, mannose, galactose, starch, and sucrose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2273895059;0,000009784;4,71996747324224E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3564;;
isoleucylaspartate;isoleucylaspartate;isoleucylaspartate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,219327696;1,28883387784866E-007;3,86650163354597E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3565;;
prostaglandin E1;prostaglandin E1;prostaglandin E1;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2192032829;4,52588835290988E-005;8,68187236928386E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3566;;
6-oxopiperidine-2-carboxylic acid;6-oxopiperidine-2-carboxylic acid;6-oxopiperidine-2-carboxylic acid;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2190345511;9,15616007061254E-006;1,974761009824E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3567;;
pyroglutamine;pyroglutamine;pyroglutamine;*;–;–;–;–;–;–;Amino Acid;Glutamate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2180175686;2,35208884038797E-011;1,80477586022077E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3568;;
glutarate;glutarate;glutarate;(pentanedioate);–;–;–;–;–;–;Amino Acid;Lysine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2171770844;0,0001521094;0,0002733858;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3569;;
fucose;fucose;fucose;–;–;–;–;–;–;–;Carbohydrate;Pentose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2164901608;6,23605232929517E-009;2,45141367427465E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3570;;
2-hydroxyadipate;2-hydroxyadipate;2-hydroxyadipate;–;–;–;–;–;–;–;Lipid;Fatty Acid, Dicarboxylate;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,2025718759;3,52254456754629E-008;1,18108847264788E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3571;;
2-linoleoylglycerophosphoinositol;2-linoleoylglycerophosphoinositol;2-linoleoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1977879818;1,99575505330302E-006;4,81151822518372E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3572;;
N-acetylgalactosamine;N-acetylgalactosamine;N-acetylgalactosamine;–;–;–;–;–;–;–;Carbohydrate;Aminosugar Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,194898375;2,74787654392632E-008;9,33108715767322E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3573;;
serylleucine;serylleucine;serylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,185631474;5,39464673293134E-006;2,95568068531493E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3574;;
UDP-galactose;UDP-galactose;UDP-galactose;–;–;–;–;–;–;–;Carbohydrate;Nucleotide Sugar;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1849081224;0,0010467578;0,0016739734;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3575;;
butyryl-carnitine;butyryl-carnitine;butyryl-carnitine;–;–;–;–;–;–;–;Lipid;Fatty Acid Metabolism (also BCAA Metabolism);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1818271536;2,76255937047508E-009;1,17888897199953E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3576;;
docosahexaenoate;docosahexaenoate;docosahexaenoate;(DHA; 22:6n3);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1787829946;5,60284408066284E-013;7,45178262728158E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3577;;
docosapentaenoate;docosapentaenoate;docosapentaenoate;(n3 DPA; 22:5n3);–;–;–;–;–;–;Lipid;Essential fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,177104933;6,05765497924954E-007;5,21433438409912E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3578;;
2-palmitoleoylglycerophosphocholine;2-palmitoleoylglycerophosphocholine;2-palmitoleoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1765083275;0,0020703787;0,0031895023;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3579;;
asparagylvaline;asparagylvaline;asparagylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1739159514;1,351139152602E-008;4,92332896701551E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3580;;
glycerophosphoinositol;glycerophosphoinositol;glycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Phospholipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1671647651;8,04728231447092E-013;1,01932242649965E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3581;;
spermine;spermine;spermine;–;–;–;–;–;–;–;Amino Acid;Polyamine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1650213562;0,0050710958;0,007371101;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3582;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1647293571;5,2274965518423E-006;1,18847357503423E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3583;;
glycylmethionine;glycylmethionine;glycylmethionine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1636384841;3,74410819936436E-006;8,7107823413783E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3584;;
ribose 5-phosphate;ribose 5-phosphate;ribose 5-phosphate;–;–;–;–;–;–;–;Carbohydrate;Pentose Phosphate Pathway;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1512131365;0,000004168;9,61291889735174E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3585;;
alanylalanine;alanylalanine;alanylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1482030884;7,36611551278038E-006;1,63282227199965E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3586;;
3-methylhistamine;3-methylhistamine;3-methylhistamine;–;–;–;–;–;–;–;Amino acid;Histidine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1438284655;3,45496636914177E-010;2,4421050800001E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3587;;
1-palmitoylplasmenylethanolamine;1-palmitoylplasmenylethanolamine;1-palmitoylplasmenylethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,134796554;1,00779550052145E-010;6,43302421857355E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3588;;
prolylvaline;prolylvaline;prolylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1339722845;0,0002966121;0,0005057616;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3589;;
assymetric dimethylarginine;assymetric dimethylarginine;assymetric dimethylarginine;(ADMA);–;–;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1331324473;2,6300538852029E-008;9,00765236219705E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3590;;
homoserine;homoserine;homoserine;–;–;–;–;–;–;–;Amino Acid;Glycine, Serine and Threonine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1312582093;5,71103818890725E-010;2,88443574351139E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3591;;
cystathionine;cystathionine;cystathionine;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1249725886;4,66746739484944E-008;1,52649138569256E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3592;;
N-acetylaspartate;N-acetylaspartate;N-acetylaspartate;(NAA);–;–;–;–;–;–;Amino acid;Alanine and aspartate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1248307541;0,000000559;4,90825868319962E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3593;;
pipecolate;pipecolate;pipecolate;–;–;–;–;–;–;–;Amino Acid;Lysine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1238340453;1,57181047787187E-010;0,000000001;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3594;;
3-(4-hydroxyphenyl)lactate;3-(4-hydroxyphenyl)lactate;3-(4-hydroxyphenyl)lactate;–;–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1231666621;1,26936892505018E-013;1,986876568328E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3595;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;Amino acid;Tryptophan metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1188523077;8,14386903587192E-009;2,74598387531254E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3596;;
thymine;thymine;thymine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine metabolism, thymine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1173049195;1,0563239712433E-005;0,000049863;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3597;;
2'-deoxycytidine;2'-deoxycytidine;2'-deoxycytidine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Cytidine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1135632872;0,006396206;0,0091308987;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3598;;
docosapentaenoate;docosapentaenoate;docosapentaenoate;(n6 DPA; 22:5n6);–;–;–;–;–;–;Lipid;Essential fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1129917537;3,25668224321665E-007;3,28806130220941E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3599;;
cis-vaccenate (18:1n7);cis-vaccenate (18:1n7);cis-vaccenate (18:1n7);(18:1n7);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1100422157;1,51328470149895E-010;9,28923993689354E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3600;;
adenosine 5'-diphosphoribose;adenosine 5'-diphosphoribose;adenosine 5'-diphosphoribose;(ADP-ribose);–;–;–;–;–;–;Cofactors and Vitamins;Nicotinate and Nicotinamide Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1013149735;2,51327021067951E-005;5,03916991990514E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3601;;
7-hydroxycholesterol;7-hydroxycholesterol;7-hydroxycholesterol;(alpha or beta);–;–;–;–;–;–;Lipid;Sterol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,1012061473;0,0049245564;0,0071842705;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3602;;
anserine;anserine;anserine;–;–;–;–;–;–;–;Peptide;Dipeptide Derivative;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,100269269;6,15047130342519E-005;0,0001157565;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3603;;
gamma-glutamyl-valine;gamma-glutamyl-valine;gamma-glutamyl-valine;–;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,099221491;2,03795300955302E-007;5,91376909681204E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3604;;
methionine sulfone;methionine sulfone;methionine sulfone;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,098869088;7,07326598364792E-007;1,88148875165035E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3605;;
gamma-glutamyltryptophan;gamma-glutamyltryptophan;gamma-glutamyltryptophan;–;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0987743456;2,32009625022795E-006;5,52667703785644E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3606;;
ribitol;ribitol;ribitol;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0919983809;0,000000042;7,01330045511108E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3607;;
uridine monophosphate;uridine monophosphate;uridine monophosphate;(5' or 3');–;–;–;–;–;–;Nucleotide;Pyrimidine metabolism, uracil containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0919479245;0,0060920247;0,0126941844;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3608;;
1-oleoylglycerophosphocholine;1-oleoylglycerophosphocholine;1-oleoylglycerophosphocholine;(18:1);–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0884150547;0,0042680553;0,0062839634;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3609;;
fucose-1-phosphate;fucose-1-phosphate;fucose-1-phosphate;–;–;–;–;–;–;–;Carbohydrate;Pentose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,083850456;1,89349758710929E-008;6,74558515407686E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3610;;
ribose;ribose;ribose;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,080049002;4,41710819886413E-007;4,14632275936669E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3611;;
leucylglycine;leucylglycine;leucylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,079932589;5,58173076947392E-006;2,95668207626814E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3612;;
erythronate;erythronate;erythronate;*;–;–;–;–;–;–;Carbohydrate;Aminosugar Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0783250893;8,1903206617204E-014;1,45241686401175E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3613;;
2-arachidonoyl glycerol;2-arachidonoyl glycerol;2-arachidonoyl glycerol;–;–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0716558392;1,50375519280798E-009;6,81816274920889E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3614;;
myristoleate;myristoleate;myristoleate;(14:1n5);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0661480459;0,000000002;8,83434823161372E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3615;;
2-linoleoylglycerol;2-linoleoylglycerol;2-linoleoylglycerol;(2-monolinolein);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0641831662;3,81189740593497E-009;1,57611094815342E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3616;;
10-nonadecenoate (19:1n9);10-nonadecenoate (19:1n9);10-nonadecenoate (19:1n9);(19:1n9);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0605379764;0,000016692;7,47733951609422E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3617;;
N-acetyl-beta-alanine;N-acetyl-beta-alanine;N-acetyl-beta-alanine;–;–;–;HMDB0061880;–;–;–;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0549542844;5,5594607917047E-009;2,20718891133351E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3618;;
N-acetylhistidine;N-acetylhistidine;N-acetylhistidine;–;–;–;–;–;–;–;Amino Acid;Histidine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0503064496;1,2043833525206E-006;3,05110449305218E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3619;;
arginylisoleucine;arginylisoleucine;arginylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0461709576;1,19233492365707E-005;2,53728871754225E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3620;;
uridine-3'-monophosphate;uridine-3'-monophosphate;uridine-3'-monophosphate;(3'-UMP);–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0445504252;1,53669386448367E-006;3,796537782842E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3621;;
adenosine 5'-monophosphate;adenosine 5'-monophosphate;adenosine 5'-monophosphate;(AMP);–;–;–;–;–;–;Nucleotide;Purine metabolism, adenine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0442992127;0,0003187315;0,0009205469;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3622;;
xanthosine;xanthosine;xanthosine;–;–;–;–;–;–;–;Nucleotide;Purine metabolism, (hypo)xanthine/inosine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0368559632;1,61173073140069E-006;1,0766518195009E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3623;;
erythronate;erythronate;erythronate;*;–;–;–;–;–;–;Carbohydrate;Aminosugars metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,033758408;9,74277723685123E-009;2,74598387531254E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3624;;
mannose-6-phosphate;mannose-6-phosphate;mannose-6-phosphate;–;–;–;–;–;–;–;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0292359022;7,19186600853979E-007;1,90668075575241E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3625;;
arginyltyrosine;arginyltyrosine;arginyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0171639999;2,12507536251881E-006;5,07727586613776E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3626;;
1-stearoylglycerophosphoinositol;1-stearoylglycerophosphoinositol;1-stearoylglycerophosphoinositol;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0133849005;0,000000003;1,26825071664739E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3627;;
cysteine;cysteine;cysteine;–;–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0119567357;1,12207273763795E-006;8,3116633361038E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3628;;
glutamine-leucine;glutamine-leucine;glutamine-leucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0046489323;1,76145772748213E-005;7,81090850873391E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3629;;
3'-dephosphocoenzyme A;3'-dephosphocoenzyme A;3'-dephosphocoenzyme A;–;–;–;–;–;–;–;Cofactors and Vitamins;Pantothenate and CoA Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;2,0027843524;0,0004238095;0,0007150105;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3630;;
histidylphenylalanine;histidylphenylalanine;histidylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9990380797;0,0004259104;0,0007170391;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3631;;
sarcosine;sarcosine;sarcosine;(N-Methylglycine);–;–;–;–;–;–;Amino Acid;Glycine, Serine and Threonine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9934774591;8,93135745239529E-009;3,36158597403767E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3632;;
lysylisoleucine;lysylisoleucine;lysylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9932324817;0,0028819265;0,0043722003;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3633;;
guanosine 5'- monophosphate;guanosine 5'- monophosphate;guanosine 5'- monophosphate;–;–;–;–;–;–;–;Carbohydrate;Nucleotide Sugar;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9923370099;8,37539373690895E-008;2,63132448899738E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3634;;
cytidine-3'-monophosphate;cytidine-3'-monophosphate;cytidine-3'-monophosphate;(3'-CMP);–;–;–;–;–;–;Nucleotide;Pyrimidine metabolism, cytidine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,989736551;1,71085525713365E-007;1,85981739525283E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3635;;
2-aminoadipate;2-aminoadipate;2-aminoadipate;–;–;–;–;–;–;–;Amino Acid;Lysine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9873418837;9,91712183778073E-008;3,05554564731623E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3636;;
leucylhistidine;leucylhistidine;leucylhistidine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9618455303;8,009426911718E-006;1,75591282295356E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3637;;
adenosine-5'-diphosphoglucose;adenosine-5'-diphosphoglucose;adenosine-5'-diphosphoglucose;–;–;–;–;–;–;–;Nucleotide;Purine metabolism, adenine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9510255709;2,24963830786943E-005;9,68226683484981E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3638;;
2-oleoylglycerol;2-oleoylglycerol;2-oleoylglycerol;(2-monoolein);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9475114143;3,30597225212759E-008;1,11786688864314E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3639;;
1-arachidonoylglycerophosphoinositol;1-arachidonoylglycerophosphoinositol;1-arachidonoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9445297346;8,15744987954147E-006;1,77859153111314E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3640;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;Lipid;Glycerolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9440954593;2,09436439757502E-009;9,23371706776171E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3641;;
eicosenoate;eicosenoate;eicosenoate;(20:1n9 or 11);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,94163717;0,000090367;0,0003148502;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3642;;
xylitol;xylitol;xylitol;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9405807158;3,2955511912805E-007;3,28806130220941E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3643;;
serylisoleucine;serylisoleucine;serylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9399397493;0,0222354995;0,0296721214;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3644;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9384996257;1,81765590280212E-011;1,42204844160401E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3645;;
1-stearoylglycerophosphoinositol;1-stearoylglycerophosphoinositol;1-stearoylglycerophosphoinositol;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9383376037;3,95431949082225E-008;6,947777558546E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3646;;
palmitoyl ethanolamide;palmitoyl ethanolamide;palmitoyl ethanolamide;–;–;–;–;–;–;–;Lipid;Endocannabinoid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9311603453;6,60631375457165E-006;1,4725805519967E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3647;;
trans-4-hydroxyproline;trans-4-hydroxyproline;trans-4-hydroxyproline;–;–;–;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,930073292;1,69739351927638E-013;2,55569816675953E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3648;;
4-hydroxyphenylpyruvate;4-hydroxyphenylpyruvate;4-hydroxyphenylpyruvate;–;–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9277775635;1,87941612120963E-007;5,49367789276661E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3649;;
mead acid;mead acid;mead acid;(20:3n9);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9263367979;0,0001086272;0,0003725573;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3650;;
pro-hydroxy-pro;pro-hydroxy-pro;pro-hydroxy-pro;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9254667924;5,81918787724278E-008;8,2424634382448E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3651;;
prostaglandin E2;prostaglandin E2;prostaglandin E2;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9179454401;0,0006097167;0,000999084;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3652;;
glutamate, gamma-methyl ester;glutamate, gamma-methyl ester;glutamate, gamma-methyl ester;–;–;–;–;–;–;–;Amino Acid;Glutamate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9154366604;7,94961883786635E-010;3,86816819062033E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3653;;
lignocerate;lignocerate;lignocerate;(24:0);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9129828121;1,06121190565035E-007;3,25710423349608E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3654;;
2-linoleoylglycerophosphocholine;2-linoleoylglycerophosphocholine;2-linoleoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9127525659;0,010753971;0,0149506426;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3655;;
N-acetyl-aspartyl-glutamate;N-acetyl-aspartyl-glutamate;N-acetyl-aspartyl-glutamate;(NAAG);–;–;–;–;–;–;Amino acid;Glutamate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9120039587;4,40779912917673E-006;2,54608397066919E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3656;;
4-hydroxyphenylpyruvate;4-hydroxyphenylpyruvate;4-hydroxyphenylpyruvate;–;–;–;–;–;–;–;Amino acid;Phenylalanine & tyrosine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9078702297;1,76423980356473E-006;1,12246561415205E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3657;;
3-(4-hydroxyphenyl)lactate;3-(4-hydroxyphenyl)lactate;3-(4-hydroxyphenyl)lactate;–;–;–;–;–;–;–;Amino acid;Phenylalanine & tyrosine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9041785783;3,93032482108395E-008;6,947777558546E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3658;;
N-stearoyltaurine;N-stearoyltaurine;N-stearoyltaurine;–;–;–;–;–;–;–;Lipid;Endocannabinoid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9011821107;8,5241475212211E-005;0,000156374;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3659;;
1-linoleoylglycerophosphocholine;1-linoleoylglycerophosphocholine;1-linoleoylglycerophosphocholine;(18:2n6);–;–;HMDB0010386;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,9010849695;0,0081353544;0,0115311063;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3660;;
xanthosine;xanthosine;xanthosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8984050191;0,00000012;3,64151696757049E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3661;;
guanidinoacetate;guanidinoacetate;guanidinoacetate;–;–;–;–;–;–;–;Amino Acid;Creatine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,897251311;2,09414222665409E-007;6,05480252489118E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3662;;
1-palmitoylplasmenylethanolamine;1-palmitoylplasmenylethanolamine;1-palmitoylplasmenylethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8972182952;1,3233577613991E-006;9,37022672990651E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3663;;
phenylalanylglycine;phenylalanylglycine;phenylalanylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8938688221;6,83972144023704E-005;0,0002481519;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3664;;
phenylalanylleucine;phenylalanylleucine;phenylalanylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8848526676;0,0001169392;0,0003918802;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3665;;
N1-methylguanosine;N1-methylguanosine;N1-methylguanosine;–;–;–;–;–;–;–;Nucleotide;Purine metabolism, guanine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8846885766;5,58546770073458E-007;4,90825868319962E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3666;;
phenylalanylhistidine;phenylalanylhistidine;phenylalanylhistidine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8817824719;0,0172302619;0,0233839269;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3667;;
prolylalanine;prolylalanine;prolylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8804737307;5,05580941733089E-006;1,15272454715144E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3668;;
palmitoleate;palmitoleate;palmitoleate;(16:1n7);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8792687198;5,67143355708675E-007;0,000001529;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3669;;
isoleucylmethionine;isoleucylmethionine;isoleucylmethionine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8784203724;2,95387046857311E-005;5,89297158480335E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3670;;
S-methylcysteine;S-methylcysteine;S-methylcysteine;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8699508829;9,69585532252241E-012;7,97659025502359E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3671;;
S-adenosylhomocysteine;S-adenosylhomocysteine;S-adenosylhomocysteine;(SAH);–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8675968263;1,7369592985277E-007;1,85981739525283E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3672;;
cysteinyl-glycine;cysteinyl-glycine;cysteinyl-glycine;–;–;–;–;–;–;–;Amino Acid;Glutathione Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8671373375;3,02623037531983E-005;6,02227391397811E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3673;;
thymidine 3'-monophosphate;thymidine 3'-monophosphate;thymidine 3'-monophosphate;–;–;–;–;–;–;–;Nucleotide;Pyrimidine metabolism, thymine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8667972524;4,37378169462966E-005;0,0001729811;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3674;;
1-pentadecanoylglycerophosphocholine;1-pentadecanoylglycerophosphocholine;1-pentadecanoylglycerophosphocholine;(15:0)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8611797925;0,0243215321;0,0322938146;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3675;;
prolylglutamate;prolylglutamate;prolylglutamate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8598725906;1,5372402862299E-007;4,59444849592307E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3676;;
docosahexaenoate;docosahexaenoate;docosahexaenoate;(DHA; 22:6n3);–;–;–;–;–;–;Lipid;Essential fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,859189522;0,000000072;0,000000987;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3677;;
glucose 1-phosphate;glucose 1-phosphate;glucose 1-phosphate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8584845431;1,33551261530169E-006;3,32005939878737E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3678;;
prolyltryptophan;prolyltryptophan;prolyltryptophan;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8558553216;0,0004407421;0,0007373422;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3679;;
oleoylcarnitine;oleoylcarnitine;oleoylcarnitine;–;–;–;–;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8535115708;0,0154056561;0,0211641438;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3680;;
lactate;lactate;lactate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, gluconeogenesis, pyruvate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8534232251;4,13927950730403E-014;9,08571851853235E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3681;;
asparagine;asparagine;asparagine;–;–;–;–;–;–;–;Amino acid;Alanine and aspartate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8474191335;2,1124802258393E-005;9,18196850637083E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3682;;
valerylcarnitine;valerylcarnitine;valerylcarnitine;–;–;–;HMDB0013128;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8454377996;7,62151164872285E-006;1,68475520655979E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3683;;
cytidine-3'-monophosphate;cytidine-3'-monophosphate;cytidine-3'-monophosphate;(3'-CMP);–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Cytidine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8451249052;6,05280914354389E-011;4,0589426021412E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3684;;
eicosapentaenoate;eicosapentaenoate;eicosapentaenoate;(EPA; 20:5n3);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8386114881;1,75219487321794E-007;0,000000516;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3685;;
2-hydroxyglutarate;2-hydroxyglutarate;2-hydroxyglutarate;–;–;–;–;–;–;–;Lipid;Fatty acid, dicarboxylate;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8345496293;1,61865649401046E-006;1,0766518195009E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3686;;
tyrosylglycine;tyrosylglycine;tyrosylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8320116417;1,54212588056186E-006;3,79819892805051E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3687;;
3'-dephosphocoenzyme A;3'-dephosphocoenzyme A;3'-dephosphocoenzyme A;–;–;–;–;–;–;–;Cofactors and vitamins;Pantothenate and CoA metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,831448071;0,0002605434;0,0007780853;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3688;;
leucylserine;leucylserine;leucylserine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,829866837;5,03187183156113E-005;0,0001888027;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3689;;
leucylglutamate;leucylglutamate;leucylglutamate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8297214581;4,75518542439829E-005;0,000181524;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3690;;
alpha-glutamyltyrosine;alpha-glutamyltyrosine;alpha-glutamyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8294787494;0,0003743723;0,0010401864;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3691;;
asparagylleucine;asparagylleucine;asparagylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8276122709;2,60682143316619E-005;0,00010899;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3692;;
prostaglandin F2alpha;prostaglandin F2alpha;prostaglandin F2alpha;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8220903551;6,5607534443637E-005;0,0001223243;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3693;;
2-methylbutyrylcarnitine;2-methylbutyrylcarnitine;2-methylbutyrylcarnitine;(C5);–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,820687844;9,15501684983463E-007;2,39531260530099E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3694;;
3-methoxytyrosine;3-methoxytyrosine;3-methoxytyrosine;–;–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8205464214;4,6339375489525E-011;3,27246209209212E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3695;;
UDP-glucose;UDP-glucose;UDP-glucose;–;–;–;–;–;–;–;Carbohydrate;Nucleotide Sugar;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8201475157;0,018505319;0,0249446698;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3696;;
leucylleucine;leucylleucine;leucylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8181741525;0,0001232567;0,0004068398;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3697;;
adenosine 2'-monophosphate;adenosine 2'-monophosphate;adenosine 2'-monophosphate;(2'-AMP);–;–;–;–;–;–;Nucleotide;Purine metabolism, adenine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8119358546;1,36949632409663E-006;0,000009543;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3698;;
3-methylhistidine;3-methylhistidine;3-methylhistidine;–;–;–;–;–;–;–;Amino Acid;Histidine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8091153252;8,63643692899636E-011;5,57923306559752E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3699;;
glutathione, reduced;glutathione, reduced;glutathione, reduced;(GSH);–;–;–;–;–;–;Amino acid;Glutathione metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8079690327;0,0221201305;0,038998945;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3700;;
homocysteine;homocysteine;homocysteine;–;–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8034636605;5,02062810908023E-007;4,59178279142963E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3701;;
cytidine 5'-monophosphate;cytidine 5'-monophosphate;cytidine 5'-monophosphate;(5'-CMP);–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Cytidine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8027122788;5,11253479769609E-008;1,65845640998434E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3702;;
1-oleoylglycerol;1-oleoylglycerol;1-oleoylglycerol;(1-monoolein);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,8023152032;1,12512490045722E-006;0,000002887;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3703;;
1-stearoylglycerophosphoserine;1-stearoylglycerophosphoserine;1-stearoylglycerophosphoserine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7946579833;3,45258921441404E-008;1,16251738105587E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3704;;
N-acetylaspartate;N-acetylaspartate;N-acetylaspartate;(NAA);–;–;–;–;–;–;Amino Acid;Alanine and Aspartate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7944471174;8,26048065197976E-006;1,7912739388362E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3705;;
7-methylguanine;7-methylguanine;7-methylguanine;–;–;–;HMDB0000897;–;–;–;Nucleotide;Purine Metabolism, Guanine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7935885459;2,956677546007E-016;1,68530620122399E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3706;;
2-docosapentaenoylglycerophosphocholine;2-docosapentaenoylglycerophosphocholine;2-docosapentaenoylglycerophosphocholine;(22:5n3)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7934233884;0,0951376818;0,1167998002;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3707;;
N-acetylglutamine;N-acetylglutamine;N-acetylglutamine;–;–;–;–;–;–;–;Amino Acid;Glutamate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7904905929;3,10484857249718E-007;8,60301791962761E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3708;;
choline phosphate;choline phosphate;choline phosphate;–;–;–;–;–;–;–;Lipid;Glycerolipid metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7893627638;4,43911548269327E-007;4,14632275936669E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3709;;
spermidine;spermidine;spermidine;–;–;–;–;–;–;–;Amino Acid;Polyamine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7815346918;1,6105669288861E-005;3,36448274673066E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3710;;
2-stearoylglycerophosphoinositol;2-stearoylglycerophosphoinositol;2-stearoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7760349723;8,04171879543483E-005;0,0001485484;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3711;;
10-heptadecenoate (17:1n7);10-heptadecenoate (17:1n7);10-heptadecenoate (17:1n7);(17:1n7);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7754996698;9,52283780327603E-008;2,9454358786877E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3712;;
isoleucyltryptophan;isoleucyltryptophan;isoleucyltryptophan;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7718589893;0,0015984295;0,0024961777;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3713;;
leucylalanine;leucylalanine;leucylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7714291616;4,77615054898178E-006;2,6881155012859E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3714;;
fructose-6-phosphate;fructose-6-phosphate;fructose-6-phosphate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7678788016;1,00132358909122E-005;2,1365139681679E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3715;;
phenylalanylglutamate;phenylalanylglutamate;phenylalanylglutamate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7673455957;0,0043230866;0,0063532654;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3716;;
glycylproline;glycylproline;glycylproline;–;–;–;HMDB0000721;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7663293337;1,0107319048966E-006;7,7844088815721E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3717;;
S-adenosylmethionine;S-adenosylmethionine;S-adenosylmethionine;(SAM);–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7652416032;0,0002687529;0,0004622087;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3718;;
arachidonate;arachidonate;arachidonate;(20:4n6);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,762851278;2,6785691802629E-010;1,49475399010475E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3719;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;Nucleotide;Purine Metabolism, Guanine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7599556014;4,13724221873175E-008;1,35864991380574E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3720;;
N1-methyladenosine;N1-methyladenosine;N1-methyladenosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7538681488;4,9206499702404E-011;3,38506782435503E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3721;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7508931074;3,9969893415907E-012;3,6662040167694E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3722;;
2-myristoylglycerophosphocholine;2-myristoylglycerophosphocholine;2-myristoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7497067303;0,0496148348;0,0636537591;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3723;;
1-docosapentaenoylglycerophosphocholine;1-docosapentaenoylglycerophosphocholine;1-docosapentaenoylglycerophosphocholine;(22:5n6)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7432055532;0,0009739022;0,0015668829;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3724;;
ethylmalonate;ethylmalonate;ethylmalonate;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7376720642;4,36115999790574E-009;1,78472086068142E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3725;;
myristoylcarnitine;myristoylcarnitine;myristoylcarnitine;–;–;–;–;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7348122125;0,0346847151;0,045300168;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3726;;
lysylleucine;lysylleucine;lysylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7347139013;0,0103285264;0,0143842305;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3727;;
adenosine 3'-monophosphate;adenosine 3'-monophosphate;adenosine 3'-monophosphate;(3'-AMP);–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7327961158;1,99098751754321E-005;4,10544712919764E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3728;;
prolylglycine;prolylglycine;prolylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7230228495;0,00004965;9,50135748647134E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3729;;
oleoyl-linoleoyl-glycerol;oleoyl-linoleoyl-glycerol;oleoyl-linoleoyl-glycerol;–;–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7226087054;9,40075898373193E-005;0,0001712741;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3730;;
2'-deoxyadenosine 3'-monophosphate;2'-deoxyadenosine 3'-monophosphate;2'-deoxyadenosine 3'-monophosphate;–;–;–;–;–;–;–;Nucleotide;Purine metabolism, adenine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,722257993;0,0006887248;0,0017997036;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3731;;
1-palmitoylglycerophosphoinositol;1-palmitoylglycerophosphoinositol;1-palmitoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7219568909;0,0002049434;0,0006293707;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3732;;
isoleucylalanine;isoleucylalanine;isoleucylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7134466574;8,15800322244365E-007;0,00000657;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3733;;
pantothenate;pantothenate;pantothenate;–;–;–;–;–;–;–;Cofactors and Vitamins;Pantothenate and CoA Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7088223438;3,57811756525812E-009;1,49494126548481E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3734;;
cytidine;cytidine;cytidine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Cytidine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,708532283;0,000043152;8,33783517420738E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3735;;
beta-alanine;beta-alanine;beta-alanine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,7026946891;7,82690092908352E-006;1,72062450176547E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3736;;
valerylcarnitine;valerylcarnitine;valerylcarnitine;–;–;–;HMDB0013128;–;–;–;Lipid;Fatty acid metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,702350207;3,52946818582869E-005;0,0001421501;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3737;;
2-myristoylglycerophosphoethanolamine;2-myristoylglycerophosphoethanolamine;2-myristoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6996380334;0,0009395585;0,0015146822;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3738;;
N2-methylguanosine;N2-methylguanosine;N2-methylguanosine;–;–;–;–;–;–;–;Nucleotide;Purine metabolism, guanine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6954337172;5,9881326241047E-006;3,12951216902614E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3739;;
5-dodecenoate (12:1n7);5-dodecenoate (12:1n7);5-dodecenoate (12:1n7);(12:1n7);–;–;–;–;–;–;Lipid;Medium Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6885716415;8,76135208747767E-010;4,23730846412556E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3740;;
phenylalanylalanine;phenylalanylalanine;phenylalanylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6809558887;9,04659974478124E-007;7,09188801421243E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3741;;
histidylleucine;histidylleucine;histidylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6767791166;0,0005402035;0,0008962211;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3742;;
1-linoleoylglycerol;1-linoleoylglycerol;1-linoleoylglycerol;(1-monolinolein);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6749915513;1,15737583595753E-008;4,31582204249583E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3743;;
isoleucylisoleucine;isoleucylisoleucine;isoleucylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6747825911;0,000197058;0,0003486747;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3744;;
2-linoleoylglycerophosphoethanolamine;2-linoleoylglycerophosphoethanolamine;2-linoleoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6745256933;3,12831110427741E-006;0,000007364;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3745;;
1-oleoylplasmenylethanolamine;1-oleoylplasmenylethanolamine;1-oleoylplasmenylethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,66789681;0,0001298857;0,0002339703;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3746;;
leucylasparagine;leucylasparagine;leucylasparagine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6663268765;0,0010353434;0,0016590443;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3747;;
2-methylbutyrylcarnitine;2-methylbutyrylcarnitine;2-methylbutyrylcarnitine;(C5);–;–;–;–;–;–;Amino acid;Valine, leucine and isoleucine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6656646763;1,19687719251748E-005;5,47321966161638E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3748;;
arachidonate;arachidonate;arachidonate;(20:4n6);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6656124825;6,68179699340984E-007;5,5741285415015E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3749;;
1-myristoylglycerophosphocholine;1-myristoylglycerophosphocholine;1-myristoylglycerophosphocholine;(14:0);–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6618389913;0,0957150395;0,117328113;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3750;;
2-oleoylglycerophosphoinositol;2-oleoylglycerophosphoinositol;2-oleoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6594932495;0,0292780442;0,0385542562;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3751;;
arabitol;arabitol;arabitol;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6579770796;4,05053374330359E-005;0,0001616531;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3752;;
cytidine 5'-monophospho-N-acetylneuraminic acid;cytidine 5'-monophospho-N-acetylneuraminic acid;cytidine 5'-monophospho-N-acetylneuraminic acid;–;–;–;–;–;–;–;Carbohydrate;Nucleotide Sugar;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6522116016;3,56223841644227E-007;9,80229743558941E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3753;;
2-hydroxyglutarate;2-hydroxyglutarate;2-hydroxyglutarate;–;–;–;–;–;–;–;Lipid;Fatty Acid, Dicarboxylate;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,652120575;6,57418185158327E-007;1,76046883139713E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3754;;
butyryl-carnitine;butyryl-carnitine;butyryl-carnitine;–;–;–;–;–;–;–;Lipid;Fatty acid metabolism (also BCAA metabolism);–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6513392082;7,21387316736048E-005;0,0002574708;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3755;;
xylonate;xylonate;xylonate;–;–;–;–;–;–;–;Carbohydrate;Pentose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6461554064;8,79070574079169E-005;0,0001608941;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3756;;
erythritol;erythritol;erythritol;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6426384436;2,41190998568413E-008;8,36827899380843E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3757;;
2-aminoadipate;2-aminoadipate;2-aminoadipate;–;–;–;–;–;–;–;Amino acid;Lysine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6424851639;0,0009144318;0,0023475763;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3758;;
2-oleoylglycerophosphoethanolamine;2-oleoylglycerophosphoethanolamine;2-oleoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6402688872;8,70532962236298E-007;2,3002824631277E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3759;;
5-hydroxytryptophan;5-hydroxytryptophan;5-hydroxytryptophan;–;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6397845355;6,54151735856627E-005;0,0001222513;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3760;;
C-glycosyltryptophan;C-glycosyltryptophan;C-glycosyltryptophan;*;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6395734433;4,41939195420415E-009;0,000000018;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3761;;
alpha-tocopherol;alpha-tocopherol;alpha-tocopherol;–;–;–;–;–;–;–;Cofactors and vitamins;Tocopherol metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6387010236;1,10548227120056E-007;1,34807421404735E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3762;;
anthranilate;anthranilate;anthranilate;–;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6371950097;0,0004704585;0,0007837701;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3763;;
ribulose;ribulose;ribulose;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6354846223;3,12485745620377E-005;0,0001294163;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3764;;
malate;malate;malate;–;–;–;–;–;–;–;Energy;Krebs cycle;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6343960217;0,000002726;1,63933367640985E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3765;;
4-hydroxybutyrate;4-hydroxybutyrate;4-hydroxybutyrate;(GHB);–;–;–;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,632537518;8,97231004260176E-005;0,0001638422;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3766;;
isoleucylglycine;isoleucylglycine;isoleucylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6303563945;5,59008228542723E-006;2,95668207626814E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3767;;
N-acetylglucosamine 6-phosphate;N-acetylglucosamine 6-phosphate;N-acetylglucosamine 6-phosphate;–;–;–;–;–;–;–;Carbohydrate;Aminosugar Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6296711405;2,04624904277972E-006;4,9036238322469E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3768;;
1-linoleoylglycerol;1-linoleoylglycerol;1-linoleoylglycerol;(1-monolinolein);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6292781508;0,0013023127;0,0032118835;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3769;;
alpha-tocopherol;alpha-tocopherol;alpha-tocopherol;–;–;–;–;–;–;–;Cofactors and Vitamins;Tocopherol Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,628355801;1,2574108462465E-007;3,78646737850832E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3770;;
1-myristoylglycerol;1-myristoylglycerol;1-myristoylglycerol;(1-monomyristin);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6277569087;8,68931568594917E-008;2,70862262397947E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3771;;
2-stearoylglycerophosphoinositol;2-stearoylglycerophosphoinositol;2-stearoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6275709838;5,45353383850819E-006;2,95568068531493E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3772;;
N-acetylneuraminate;N-acetylneuraminate;N-acetylneuraminate;–;–;–;–;–;–;–;Carbohydrate;Aminosugar Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6256133131;3,29027865877774E-006;7,72247755795482E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3773;;
cysteine-glutathione disulfide;cysteine-glutathione disulfide;cysteine-glutathione disulfide;–;–;–;–;–;–;–;Amino Acid;Glutathione Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6240657249;0,0001557197;0,0002779962;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3774;;
pyruvate;pyruvate;pyruvate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6214723288;0,0002457295;0,0004244418;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3775;;
2-hydroxypalmitate;2-hydroxypalmitate;2-hydroxypalmitate;–;–;–;–;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6175820329;2,8405747091347E-007;7,95360918557715E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3776;;
histidylvaline;histidylvaline;histidylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6167119693;0,0184521516;0,0249150879;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3777;;
2-docosahexaenoylglycerophosphoethanolamine;2-docosahexaenoylglycerophosphoethanolamine;2-docosahexaenoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6163186682;2,3986370608456E-005;4,82144174950829E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3778;;
4-hydroxybutyrate;4-hydroxybutyrate;4-hydroxybutyrate;(GHB);–;–;–;–;–;–;Lipid;Fatty acid, monohydroxy;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6102413041;0,000058543;0,0002159696;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3779;;
uracil;uracil;uracil;–;–;–;HMDB0000300;–;–;–;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6100621463;3,51626383220112E-007;9,70926829791174E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3780;;
arabitol;arabitol;arabitol;–;–;–;–;–;–;–;Carbohydrate;Pentose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6087566214;4,51731237877423E-006;1,03885166520514E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3781;;
arachidate;arachidate;arachidate;(20:0);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6068468218;2,64144138422048E-009;1,13326356161717E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3782;;
prolyltyrosine;prolyltyrosine;prolyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6065976473;3,73463906791851E-005;7,32246185798273E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3783;;
2-aminooctanoate;2-aminooctanoate;2-aminooctanoate;–;–;–;–;–;–;–;Lipid;Fatty Acid, Amino;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6062189284;0,0010105587;0,0016225873;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3784;;
N-palmitoyl-sphingosine;N-palmitoyl-sphingosine;N-palmitoyl-sphingosine;*;–;–;–;–;–;–;Lipid;Sphingolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6053776302;1,19073849317447E-006;3,0358125161445E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3785;;
2-palmitoylglycerol;2-palmitoylglycerol;2-palmitoylglycerol;(2-monopalmitin);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6053365622;0,0030307355;0,0066809044;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3786;;
phenylpyruvate;phenylpyruvate;phenylpyruvate;–;–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6043155659;5,04745231488439E-005;9,63604532841565E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3787;;
2-aminoheptanoate;2-aminoheptanoate;2-aminoheptanoate;–;–;–;–;–;–;–;Lipid;Fatty Acid, Amino;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,601768472;0,000000161;4,79478474936393E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3788;;
15-methylpalmitate;15-methylpalmitate;15-methylpalmitate;(isobar with 2-methylpalmitate);–;–;–;–;–;–;Lipid;Fatty Acid, Branched;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,6013037835;2,11949961395722E-008;7,41824864885027E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3789;;
arginylvaline;arginylvaline;arginylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5930535428;0,0352991708;0,0460273502;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3790;;
N-acetylthreonine;N-acetylthreonine;N-acetylthreonine;–;–;–;–;–;–;–;Amino Acid;Glycine, Serine and Threonine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5928888889;2,34020789885274E-008;8,15496027635148E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3791;;
1-margaroylglycerophosphocholine;1-margaroylglycerophosphocholine;1-margaroylglycerophosphocholine;(17:0);–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5799407495;0,1861891492;0,2181775933;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3792;;
eicosapentaenoate;eicosapentaenoate;eicosapentaenoate;(EPA; 20:5n3);–;–;–;–;–;–;Lipid;Essential fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5788914413;0,0002007448;0,0006250139;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3793;;
5-methyltetrahydrofolate;5-methyltetrahydrofolate;5-methyltetrahydrofolate;(5MeTHF);–;–;–;–;–;–;Cofactors and vitamins;Folate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5735743618;9,392671615371E-006;4,58153648794208E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3794;;
1-arachidonoylglycerophosphocholine;1-arachidonoylglycerophosphocholine;1-arachidonoylglycerophosphocholine;(20:4n6)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,573412783;0,1331659762;0,1610097713;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3795;;
gamma-aminobutyrate;gamma-aminobutyrate;gamma-aminobutyrate;(GABA);–;–;–;–;–;–;Amino Acid;Glutamate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5707358962;2,3713146642232E-005;4,81503588307916E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3796;;
threonylphenylalanine;threonylphenylalanine;threonylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,568437049;0,0018573017;0,0043601895;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3797;;
phytosphingosine;phytosphingosine;phytosphingosine;–;–;–;HMDB0004610;–;–;–;Lipid;Sphingolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5655229368;0,0535867524;0,0679844649;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3798;;
phosphoethanolamine;phosphoethanolamine;phosphoethanolamine;–;–;–;HMDB0000224;–;–;–;Lipid;Glycerolipid metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,561736089;0,0006024882;0,0016094211;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3799;;
stearoylcarnitine;stearoylcarnitine;stearoylcarnitine;–;–;–;HMDB0000848;–;–;–;Lipid;Carnitine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5590610428;0,0926249941;0,1378385505;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3800;;
phenylalanylisoleucine;phenylalanylisoleucine;phenylalanylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5545627305;0,0025324035;0,0038713754;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3801;;
1-docosahexaenoylglycerophosphocholine;1-docosahexaenoylglycerophosphocholine;1-docosahexaenoylglycerophosphocholine;(22:6n3)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5544140728;0,1088672119;0,1324329803;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3802;;
glycylproline;glycylproline;glycylproline;–;–;–;HMDB0000721;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5543805451;1,06876152585789E-006;2,76010258134174E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3803;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;Nucleotide;Purine metabolism, (hypo)xanthine/inosine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5539323753;2,70480097940764E-006;1,63933367640985E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3804;;
2-hydroxy-3-methylvalerate;2-hydroxy-3-methylvalerate;2-hydroxy-3-methylvalerate;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5534775152;0,0001930265;0,0003430626;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3805;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;Nucleotide;Purine metabolism, guanine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5527879753;2,29961991410264E-005;9,80129264360253E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3806;;
pro-pro-pro;pro-pro-pro;pro-pro-pro;–;–;–;–;–;–;–;Peptide;Polypeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5523010532;0,0002347366;0,0004089953;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3807;;
1-stearoylplasmenylethanolamine;1-stearoylplasmenylethanolamine;1-stearoylplasmenylethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5511885058;0,2715963053;0,3105069508;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3808;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;Lipid;Phospholipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5503672057;6,3162895521287E-005;0,0001184524;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3809;;
cystathionine;cystathionine;cystathionine;–;–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5491092542;0,0010862892;0,002725034;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3810;;
biopterin;biopterin;biopterin;–;–;–;–;–;–;–;Cofactors and Vitamins;Tetrahydrobiopterin Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5476787129;0,0029925807;0,0045058101;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3811;;
sorbitol;sorbitol;sorbitol;–;–;–;–;–;–;–;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5458079739;0,0001957162;0,0003470701;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3812;;
pseudo uridine;pseudo uridine;pseudo uridine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Uracil containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5451995666;1,52521131813829E-012;1,66728579708816E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3813;;
stearoyl-arachidonoyl-glycerophosphoinositol;stearoyl-arachidonoyl-glycerophosphoinositol;stearoyl-arachidonoyl-glycerophosphoinositol;(1)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5442216766;3,00263956524169E-011;2,23935175052604E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3814;;
alanine;alanine;alanine;–;–;–;–;–;–;–;Amino Acid;Alanine and Aspartate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5427245702;5,56876518898235E-006;1,26246438091134E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3815;;
1-arachidonylglycerol;1-arachidonylglycerol;1-arachidonylglycerol;–;–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5400042972;1,10022572242998E-006;2,8321939564488E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3816;;
riboflavin;riboflavin;riboflavin;(Vitamin B2);–;–;HMDB0000244;–;–;–;Cofactors and vitamins;Riboflavin metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5389854696;8,23123888955484E-007;0,00000657;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3817;;
orotate;orotate;orotate;–;–;–;–;–;–;–;Nucleotide;Pyrimidine metabolism, orotate containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5374574066;0,0003211826;0,0009215632;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3818;;
glycylvaline;glycylvaline;glycylvaline;–;–;–;HMDB0028854;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5336335642;0,0001074595;0,0001944506;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3819;;
1-palmitoylglycerophosphoinositol;1-palmitoylglycerophosphoinositol;1-palmitoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5330212365;0,0007172319;0,0011656844;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3820;;
beta-hydroxyisovaleroylcarnitine;beta-hydroxyisovaleroylcarnitine;beta-hydroxyisovaleroylcarnitine;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5274113887;8,0885486626369E-006;0,000017684;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3821;;
1-linoleoylglycerophosphoethanolamine;1-linoleoylglycerophosphoethanolamine;1-linoleoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5264302072;0,0002776567;0,0008180622;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3822;;
anserine;anserine;anserine;–;–;–;–;–;–;–;Peptide;Dipeptide derivative;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5249184834;0,0001516644;0,0004824687;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3823;;
prolylproline;prolylproline;prolylproline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5222436107;0,001345032;0,0032803836;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3824;;
dimethylarginine;dimethylarginine;dimethylarginine;(SDMA + ADMA);–;–;–;–;–;–;Amino acid;"Urea cycle; arginine-, proline-, metabolism";–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5185109439;9,14594090983554E-005;0,0003161471;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3825;;
uracil;uracil;uracil;–;–;–;HMDB0000300;–;–;–;Nucleotide;Pyrimidine metabolism, uracil containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5158175546;3,32844829123505E-005;0,0001365597;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3826;;
2-palmitoleoylglycerophosphocholine;2-palmitoleoylglycerophosphocholine;2-palmitoleoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5124096968;0,0318364769;0,0525421555;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3827;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;Nucleotide;Purine metabolism, (hypo)xanthine/inosine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5011011126;0,0010706001;0,0027011118;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3828;;
glucuronate;glucuronate;glucuronate;–;–;–;–;–;–;–;Carbohydrate;Aminosugar Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,5000394423;0,000000004;1,66368355619861E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3829;;
coenzyme A;coenzyme A;coenzyme A;–;–;–;–;–;–;–;Cofactors and vitamins;Pantothenate and CoA metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4992339239;0,0009601918;0,0024365561;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3830;;
1-linoleoylglycerophosphocholine;1-linoleoylglycerophosphocholine;1-linoleoylglycerophosphocholine;–;–;–;HMDB0010386;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4952868949;0,0736718702;0,1103820854;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3831;;
phenylalanylserine;phenylalanylserine;phenylalanylserine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4947257395;0,0003351165;0,0009491363;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3832;;
N-acetylalanine;N-acetylalanine;N-acetylalanine;–;–;–;–;–;–;–;Amino Acid;Alanine and Aspartate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4946484347;1,35048850646155E-008;4,92332896701551E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3833;;
fumarate;fumarate;fumarate;–;–;–;–;–;–;–;Energy;TCA Cycle;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4929253444;9,2624622919522E-007;2,41550487221498E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3834;;
erythritol;erythritol;erythritol;–;–;–;–;–;–;–;Xenobiotics;Sugar, sugar substitute, starch;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4904379025;1,03207051007304E-006;7,8117061021046E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3835;;
1-linoleoylglycerophosphoinositol;1-linoleoylglycerophosphoinositol;1-linoleoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4887652123;0,0220094337;0,029419645;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3836;;
2-linolenoylglycerophosphocholine;2-linolenoylglycerophosphocholine;2-linolenoylglycerophosphocholine;(18:3n3)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4886383295;0,0614789103;0,0772601109;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3837;;
1-oleoylglycerophosphoethanolamine;1-oleoylglycerophosphoethanolamine;1-oleoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4874202601;3,673583505235E-005;7,23832009179637E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3838;;
N-acetylglutamate;N-acetylglutamate;N-acetylglutamate;–;–;–;–;–;–;–;Amino acid;Glutamate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4871179357;0,0015619194;0,0037674869;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3839;;
N-octanoylglycine;N-octanoylglycine;N-octanoylglycine;–;–;–;–;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Glycine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4855393541;0,0017975703;0,0027962205;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3840;;
2-myristoylglycerophosphocholine;2-myristoylglycerophosphocholine;2-myristoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4854686733;0,0205742086;0,0368656227;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3841;;
prostaglandin E2;prostaglandin E2;prostaglandin E2;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4849886787;0,0425642162;0,0675493723;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3842;;
histidyltryptophan;histidyltryptophan;histidyltryptophan;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,484394273;0,0087066411;0,0122107198;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3843;;
1-linoleoylglycerophosphoethanolamine;1-linoleoylglycerophosphoethanolamine;1-linoleoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4840464237;1,23743980242574E-005;2,62626851685038E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3844;;
myristoleate;myristoleate;myristoleate;(14:1n5);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4828091169;0,0030436922;0,0066809044;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3845;;
tyrosylleucine;tyrosylleucine;tyrosylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4823007345;0,0017939198;0,0042340364;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3846;;
linoleoylcarnitine;linoleoylcarnitine;linoleoylcarnitine;*;–;–;HMDB0006469;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4816665149;0,1423764468;0,1708517362;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3847;;
isobutyrylcarnitine;isobutyrylcarnitine;isobutyrylcarnitine;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4804243749;0,0021850039;0,0033596014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3848;;
N-acetyl-aspartyl-glutamate;N-acetyl-aspartyl-glutamate;N-acetyl-aspartyl-glutamate;(NAAG);–;–;–;–;–;–;Amino Acid;Glutamate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4744476699;0,005731884;0,0082415197;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3849;;
methionylphenylalanine;methionylphenylalanine;methionylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4733848777;0,0022504758;0,0051725596;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3850;;
homoarginine;homoarginine;homoarginine;–;–;–;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4730733055;0,0010902746;0,001736605;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3851;;
nicotinamide;nicotinamide;nicotinamide;–;–;–;HMDB0001406;–;–;–;Cofactors and Vitamins;Nicotinate and Nicotinamide Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4716351834;5,69599432571955E-007;1,53043887943576E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3852;;
tyrosylglycine;tyrosylglycine;tyrosylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4672593799;0,0003886029;0,001072935;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3853;;
N-acetylarginine;N-acetylarginine;N-acetylarginine;–;–;–;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4662220259;8,94529057715495E-006;1,93450999473432E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3854;;
N-acetylvaline;N-acetylvaline;N-acetylvaline;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4648670232;1,88996920545159E-008;6,74558515407686E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3855;;
5-aminovalerate;5-aminovalerate;5-aminovalerate;–;–;–;–;–;–;–;Amino Acid;Lysine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4590888912;0,000082707;0,0001524255;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3856;;
2-arachidonoylglycerophosphocholine;2-arachidonoylglycerophosphocholine;2-arachidonoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4582082379;0,1376096998;0,1658799705;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3857;;
adenosine;adenosine;adenosine;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4573179484;0,000226577;0,0003965097;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3858;;
ergothioneine;ergothioneine;ergothioneine;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4571031405;0,0004526413;0,0007556648;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3859;;
glycine;glycine;glycine;–;–;–;–;–;–;–;Amino Acid;Glycine, Serine and Threonine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4568298631;1,19462038517829E-006;0,000003036;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3860;;
glutamate;glutamate;glutamate;–;–;–;–;–;–;–;Amino Acid;Glutamate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4558808931;2,9640688263024E-010;1,6200869338283E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3861;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;Amino Acid;Glutamate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4530435255;2,10499157900829E-007;6,06419956696253E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3862;;
fructose;fructose;fructose;–;–;–;–;–;–;–;Carbohydrate;Fructose, mannose, galactose, starch, and sucrose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4527011827;0,0011051718;0,0027566502;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3863;;
leucylproline;leucylproline;leucylproline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4509933017;0,0040921687;0,0087206895;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3864;;
10-heptadecenoate (17:1n7);10-heptadecenoate (17:1n7);10-heptadecenoate (17:1n7);(17:1n7);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4496222383;0,0027952897;0,0061976373;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3865;;
1-palmitoylglycerol;1-palmitoylglycerol;1-palmitoylglycerol;(1-monopalmitin);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4486796362;0,0002758882;0,0004734598;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3866;;
N1-methyladenosine;N1-methyladenosine;N1-methyladenosine;–;–;–;–;–;–;–;Nucleotide;Purine metabolism, adenine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4484141849;0,000075646;0,0002678112;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3867;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4469253862;6,83071083403821E-008;2,18163543634863E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3868;;
isoleucine;isoleucine;isoleucine;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4462703896;2,48724059820525E-008;8,55524998865427E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3869;;
asparagine;asparagine;asparagine;–;–;–;–;–;–;–;Amino Acid;Alanine and Aspartate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4451915856;4,85378117093504E-009;1,9463906404051E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3870;;
Ac-Ser-Asp-Lys-Pro-OH;Ac-Ser-Asp-Lys-Pro-OH;Ac-Ser-Asp-Lys-Pro-OH;–;–;–;–;–;–;–;Peptide;Polypeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,441267148;0,0004044355;0,0006837702;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3871;;
galactose 1-phosphate;galactose 1-phosphate;galactose 1-phosphate;–;–;–;–;–;–;–;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4406411095;0,0003768781;0,0006398909;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3872;;
stearate;stearate;stearate;(18:0);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4393950523;1,73748657476167E-010;0,000000001;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3873;;
creatine;creatine;creatine;–;–;–;HMDB0000064;–;–;–;Amino acid;Creatine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4354241937;4,71445030324095E-005;0,000181524;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3874;;
gamma-glutamylphenylalanine;gamma-glutamylphenylalanine;gamma-glutamylphenylalanine;–;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4347695607;7,37108681240832E-005;0,0001367937;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3875;;
norophthalmate;norophthalmate;norophthalmate;*;–;–;–;–;–;–;Amino Acid;Glutathione Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4343260209;0,0061091431;0,0087681586;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3876;;
1-margaroylglycerophosphoethanolamine;1-margaroylglycerophosphoethanolamine;1-margaroylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4322486317;0,0561031422;0,0708390941;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3877;;
mannose-6-phosphate;mannose-6-phosphate;mannose-6-phosphate;–;–;–;–;–;–;–;Carbohydrate;Fructose, mannose, galactose, starch, and sucrose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4298772719;0,0126149844;0,0243963795;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3878;;
bilirubin (E,E);bilirubin (E,E);bilirubin (E,E);*;–;–;–;–;–;–;Cofactors and Vitamins;Hemoglobin and Porphyrin Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,426837876;0,0519639241;0,0663475383;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3879;;
1-nonadecanoylglycerophosphocholine;1-nonadecanoylglycerophosphocholine;1-nonadecanoylglycerophosphocholine;(19:0);–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,425252547;0,0269459286;0,0355655939;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3880;;
2-oleoylglycerophosphoserine;2-oleoylglycerophosphoserine;2-oleoylglycerophosphoserine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4238225958;0,0054976303;0,0079208629;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3881;;
1-docosahexaenoylglycerophosphoethanolamine;1-docosahexaenoylglycerophosphoethanolamine;1-docosahexaenoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4238191948;0,0003339317;0,0005681823;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3882;;
myristate;myristate;myristate;(14:0);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4208698826;0,0007196862;0,0018584838;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3883;;
methionine;methionine;methionine;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4177197409;6,32362359262674E-006;1,41748641205509E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3884;;
dihydroxyacetone phosphate;dihydroxyacetone phosphate;dihydroxyacetone phosphate;(DHAP);–;–;–;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4098776289;2,38536847478994E-005;4,81904820982878E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3885;;
1-docosahexaenoylglycerol;1-docosahexaenoylglycerol;1-docosahexaenoylglycerol;–;–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4094192664;0,000061367;0,0001157565;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3886;;
15-methylpalmitate (isobar with 2-methylpalmitate);15-methylpalmitate (isobar with 2-methylpalmitate);15-methylpalmitate (isobar with 2-methylpalmitate);–;–;–;–;–;–;–;Lipid;Fatty acid, branched;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,408942834;0,001323907;0,0032469003;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3887;;
stearoyl-arachidonoyl-glycerophosphocholine;stearoyl-arachidonoyl-glycerophosphocholine;stearoyl-arachidonoyl-glycerophosphocholine;(1)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4043653832;2,39165779593562E-005;4,81955283120361E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3888;;
isovalerylcarnitine;isovalerylcarnitine;isovalerylcarnitine;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4041496429;0,0048956637;0,0071552008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3889;;
3-hydroxyoctanoate;3-hydroxyoctanoate;3-hydroxyoctanoate;–;–;–;–;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4028961263;6,84559791807365E-007;0,000001827;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3890;;
tyrosylalanine;tyrosylalanine;tyrosylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4018761937;0,0031473361;0,0047121467;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3891;;
nicotinamide;nicotinamide;nicotinamide;–;–;–;HMDB0001406;–;–;–;Cofactors and vitamins;Nicotinate and nicotinamide metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,401823893;9,13524964627134E-006;4,50603887046418E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3892;;
2-eicosatrienoylglycerophosphocholine;2-eicosatrienoylglycerophosphocholine;2-eicosatrienoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,40132259;0,0247889267;0,0425091359;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3893;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,4004132867;0,000000049;1,59670828040639E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3894;;
1-stearoylglycerophosphocholine;1-stearoylglycerophosphocholine;1-stearoylglycerophosphocholine;(18:0);–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3996400694;0,2217304171;0,2575558557;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3895;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;Lipid;Glycerolipid metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,39839795;0,0009553315;0,0024365561;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3896;;
N-acetylmethionine;N-acetylmethionine;N-acetylmethionine;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3967673149;9,64121414428181E-006;0,000020682;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3897;;
valylaspartate;valylaspartate;valylaspartate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3961097304;0,000605188;0,0016094211;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3898;;
N-formylmethionine;N-formylmethionine;N-formylmethionine;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3960956279;0,000060818;0,0001150501;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3899;;
threonine;threonine;threonine;–;–;–;–;–;–;–;Amino Acid;Glycine, Serine and Threonine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3949541041;0,000000036;1,19848471506294E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3900;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3944499758;0,0017883271;0,0042340364;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3901;;
C-glycosyltryptophan;C-glycosyltryptophan;C-glycosyltryptophan;*;–;–;–;–;–;–;Amino acid;Tryptophan metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3940306506;1,90269841130503E-006;1,19326371794701E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3902;;
orotate;orotate;orotate;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Orotate containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3934626158;0,0085001916;0,0119548492;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3903;;
oleate;oleate;oleate;(18:1n9);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3927604808;2,87262750385473E-005;5,74525500770946E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3904;;
N-acetylisoleucine;N-acetylisoleucine;N-acetylisoleucine;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3906037022;0,0019440305;0,0030064657;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3905;;
ribose 5-phosphate;ribose 5-phosphate;ribose 5-phosphate;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3900614798;0,0270128672;0,0456101873;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3906;;
2-palmitoleoylglycerophosphoethanolamine;2-palmitoleoylglycerophosphoethanolamine;2-palmitoleoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3900397259;0,0232664365;0,0406930901;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3907;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3869130234;0,000001294;3,25740116716164E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3908;;
phosphoethanolamine;phosphoethanolamine;phosphoethanolamine;–;–;–;HMDB0000224;–;–;–;Lipid;Phospholipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3850217826;1,32125318912599E-006;3,29487514038293E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3909;;
methyl glucopyranoside;methyl glucopyranoside;methyl glucopyranoside;(alpha + beta);–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3811805181;0,020014925;0,026798507;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3910;;
N-formylmethionine;N-formylmethionine;N-formylmethionine;–;–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3796889948;0,0001256589;0,0004116735;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3911;;
arabinose;arabinose;arabinose;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3768128153;0,0206840543;0,0369117879;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3912;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3725351976;6,24332987849815E-008;2,00894243671029E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3913;;
indolelactate;indolelactate;indolelactate;–;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3700290965;1,99903809073478E-005;4,11142370207823E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3914;;
tyrosylarginine;tyrosylarginine;tyrosylarginine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3683273625;0,0269638901;0,0355655939;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3915;;
glycylglycine;glycylglycine;glycylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3682762033;7,85971845647176E-005;0,0001455233;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3916;;
margarate;margarate;margarate;(17:0);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3676094306;0,0003376771;0,0009502581;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3917;;
homocitrulline;homocitrulline;homocitrulline;–;–;–;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3674759355;4,25477318673708E-005;8,24104126945678E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3918;;
beta-tocopherol;beta-tocopherol;beta-tocopherol;–;–;–;–;–;–;–;Cofactors and Vitamins;Tocopherol Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3653003864;0,0159277037;0,0218015567;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3919;;
myristate;myristate;myristate;(14:0);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3638539466;4,37012790190674E-005;8,42357986889269E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3920;;
alpha-hydroxyisovaleroyl carnitine;alpha-hydroxyisovaleroyl carnitine;alpha-hydroxyisovaleroyl carnitine;*;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3631371392;0,0097721316;0,0136331487;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3921;;
alpha-glutamylglutamate;alpha-glutamylglutamate;alpha-glutamylglutamate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3608471739;0,0083607193;0,0117877279;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3922;;
gamma-glutamylleucine;gamma-glutamylleucine;gamma-glutamylleucine;–;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3604020191;0,0022972054;0,0035253267;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3923;;
Isobar: ribulose 5-phosphate, xylulose 5-phosphate;Isobar: ribulose 5-phosphate, xylulose 5-phosphate;Isobar: ribulose 5-phosphate, xylulose 5-phosphate;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3603383673;0,0046013634;0,0097584471;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3924;;
cytidine-5'-diphosphoethanolamine;cytidine-5'-diphosphoethanolamine;cytidine-5'-diphosphoethanolamine;–;–;–;–;–;–;–;Lipid;Glycerolipid metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,355995909;0,0006085738;0,0016094211;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3925;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3541368919;0,000001314;3,28715989050242E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3926;;
alanylarginine;alanylarginine;alanylarginine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3540440467;0,0523208966;0,0666966062;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3927;;
N2-acetyllysine;N2-acetyllysine;N2-acetyllysine;–;–;–;–;–;–;–;Amino Acid;Lysine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3530508186;0,0010942175;0,0017394135;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3928;;
oleoyl-linoleoyl-glycerophosphoinositol;oleoyl-linoleoyl-glycerophosphoinositol;oleoyl-linoleoyl-glycerophosphoinositol;(1)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3526184145;2,28615812303071E-005;4,66586747360232E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3929;;
guanosine 5'- monophosphate;guanosine 5'- monophosphate;guanosine 5'- monophosphate;–;–;–;–;–;–;–;Nucleotide;Purine metabolism, guanine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3500632511;0,0079895072;0,0160154962;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3930;;
adenosine;adenosine;adenosine;–;–;–;–;–;–;–;Nucleotide;Purine metabolism, adenine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3483966789;0,0003508322;0,0009809895;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3931;;
gamma-aminobutyrate;gamma-aminobutyrate;gamma-aminobutyrate;(GABA);–;–;–;–;–;–;Amino acid;Glutamate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3470059686;0,0067488912;0,0137802942;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3932;;
2-aminobutyrate;2-aminobutyrate;2-aminobutyrate;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3467392879;0,000000236;6,67715286300278E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3933;;
squalene;squalene;squalene;–;–;–;–;–;–;–;Lipid;Sterol/Steroid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3457563002;0,0031546993;0,0068901144;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3934;;
xylulose;xylulose;xylulose;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3443696391;0,0355216828;0,0575425046;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3935;;
allo-isoleucine;allo-isoleucine;allo-isoleucine;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,342284333;0,0007744551;0,0012535805;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3936;;
phenylalanylproline;phenylalanylproline;phenylalanylproline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3419368584;0,0023496688;0,0053724199;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3937;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3411848154;6,60289730921034E-006;1,4725805519967E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3938;;
arginylproline;arginylproline;arginylproline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3404419049;0,0155206787;0,0212809306;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3939;;
3-methylhistidine;3-methylhistidine;3-methylhistidine;–;–;–;–;–;–;–;Amino acid;Histidine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3403725464;0,0165189139;0,0305983258;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3940;;
oleoyl-linoleoyl-glycerophosphocholine;oleoyl-linoleoyl-glycerophosphocholine;oleoyl-linoleoyl-glycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3400052163;0,000063234;0,0001184524;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3941;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;Lipid;Glycerolipid metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3398468188;0,0003038448;0,0008833634;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3942;;
pro-pro-pro;pro-pro-pro;pro-pro-pro;–;–;–;–;–;–;–;Peptide;Polypeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3389066683;0,0003027434;0,0008833634;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3943;;
tryptophylglutamate;tryptophylglutamate;tryptophylglutamate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3365192671;0,0082648996;0,0116732565;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3944;;
hypotaurine;hypotaurine;hypotaurine;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3362704235;0,0030583583;0,0045875375;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3945;;
cyclo(L-phe-L-pro);cyclo(L-phe-L-pro);cyclo(L-phe-L-pro);–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3356412573;0,0018994386;0,0029432077;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3946;;
stearoyl-arachidonoyl-glycerophosphocholine;stearoyl-arachidonoyl-glycerophosphocholine;stearoyl-arachidonoyl-glycerophosphocholine;(2)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3349020749;9,0281713066624E-007;2,36989496799888E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3947;;
N-acetylthreonine;N-acetylthreonine;N-acetylthreonine;–;–;–;–;–;–;–;Amino acid;Glycine, serine and threonine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,334281769;4,85028066023443E-005;0,000183558;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3948;;
2-oleoylglycerophosphoserine;2-oleoylglycerophosphoserine;2-oleoylglycerophosphoserine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3305959524;0,0237791363;0,0412127494;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3949;;
spermidine;spermidine;spermidine;–;–;–;–;–;–;–;Amino acid;Polyamine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3297885884;0,0035005207;0,0075700916;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3950;;
alpha-hydroxyisovalerate;alpha-hydroxyisovalerate;alpha-hydroxyisovalerate;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3295250196;1,93593638718052E-007;5,63823809113158E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3951;;
glycerol-2-phosphate;glycerol-2-phosphate;glycerol-2-phosphate;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3294483083;0,0004364611;0,00119754;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3952;;
palmitate;palmitate;palmitate;(16:0);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3273194919;5,94017502185681E-006;1,33905640323213E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3953;;
valylglycine;valylglycine;valylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3262252647;0,0183114433;0,0334946817;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3954;;
trans-4-hydroxyproline;trans-4-hydroxyproline;trans-4-hydroxyproline;–;–;–;–;–;–;–;Amino acid;"Urea cycle; arginine-, proline-, metabolism";–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3261799315;0,0002637407;0,000782312;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3955;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;Amino Acid;Glycine, Serine and Threonine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3254070045;0,0002214649;0,0003892709;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3956;;
N-acetylalanine;N-acetylalanine;N-acetylalanine;–;–;–;–;–;–;–;Amino acid;Alanine and aspartate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3242811626;0,000110395;0,0003756854;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3957;;
quinolinate;quinolinate;quinolinate;–;–;–;–;–;–;–;Cofactors and vitamins;Nicotinate and nicotinamide metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3229260349;0,1215961745;0,1727531411;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3958;;
linoleate;linoleate;linoleate;(18:2n6);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3228113084;0,0018472732;0,0028679455;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3959;;
1-stearoylglycerol;1-stearoylglycerol;1-stearoylglycerol;(1-monostearin);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3218079842;0,0026997;0,0060160828;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3960;;
palmitoleate;palmitoleate;palmitoleate;(16:1n7);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3203465309;0,0352382168;0,0572947303;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3961;;
1-arachidonoylglycerophosphoinositol;1-arachidonoylglycerophosphoinositol;1-arachidonoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3197827382;0,0189380765;0,0340730147;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3962;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3188270656;1,59405655583762E-005;3,347518767259E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3963;;
1-stearoylglycerol;1-stearoylglycerol;1-stearoylglycerol;(1-monostearin);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3182411477;9,95133036754031E-005;0,0001808921;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3964;;
fructose;fructose;fructose;–;–;–;–;–;–;–;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3180146263;0,0023877811;0,0036572924;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3965;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;Lipid;Sterol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,317515453;3,69583587620852E-005;7,26422913599606E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3966;;
1-stearoylglycerophosphoethanolamine;1-stearoylglycerophosphoethanolamine;1-stearoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3171239167;0,0215682469;0,0381792757;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3967;;
glutamate, gamma-methyl ester;glutamate, gamma-methyl ester;glutamate, gamma-methyl ester;–;–;–;–;–;–;–;Amino acid;Glutamate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3144141825;0,0005366689;0,0014453844;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3968;;
N4-acetylcytidine;N4-acetylcytidine;N4-acetylcytidine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Cytidine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3128372089;5,36578980362947E-007;1,45642866098514E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3969;;
adenosine 3',5'-cyclic monophosphate;adenosine 3',5'-cyclic monophosphate;adenosine 3',5'-cyclic monophosphate;(cAMP);–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3110141567;0,0196517454;0,0263564586;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3970;;
1,3-dihydroxyacetone;1,3-dihydroxyacetone;1,3-dihydroxyacetone;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, gluconeogenesis, pyruvate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,309915548;0,0025394898;0,0057171078;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3971;;
myristoyl sphingomyelin;myristoyl sphingomyelin;myristoyl sphingomyelin;*;–;–;–;–;–;–;Lipid;Sphingolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3098966598;9,49830549754246E-006;2,043031748528E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3972;;
flavin adenine dinucleotide;flavin adenine dinucleotide;flavin adenine dinucleotide;(FAD);–;–;–;–;–;–;Cofactors and vitamins;Riboflavin metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3094481037;0,0012481035;0,0030955787;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3973;;
N6-methyladenosine;N6-methyladenosine;N6-methyladenosine;–;–;–;HMDB0004044;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3040032404;0,0307763065;0,0403983347;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3974;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;Amino acid;"Urea cycle; arginine-, proline-, metabolism";–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,302936351;3,43778967942469E-006;2,03944549901005E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3975;;
1-stearoylglycerophosphoethanolamine;1-stearoylglycerophosphoethanolamine;1-stearoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3026855764;0,017188284;0,0233666961;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3976;;
glycylphenylalanine;glycylphenylalanine;glycylphenylalanine;–;–;–;HMDB0028848;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3025233681;0,0622795403;0,0942783385;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3977;;
margarate;margarate;margarate;(17:0);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3016264431;1,75476557614322E-006;4,2822719564596E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3978;;
palmitoyl-linoleoyl-glycerophosphoinositol;palmitoyl-linoleoyl-glycerophosphoinositol;palmitoyl-linoleoyl-glycerophosphoinositol;(1)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,3008016352;0,0006350336;0,0010384361;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3979;;
N-acetylglutamate;N-acetylglutamate;N-acetylglutamate;–;–;–;–;–;–;–;Amino Acid;Glutamate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2990784254;0,0071474051;0,0101668971;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3980;;
mannitol;mannitol;mannitol;–;–;–;–;–;–;–;Carbohydrate;Fructose, mannose, galactose, starch, and sucrose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2966675424;0,0461597861;0,0728926118;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3981;;
tryptophylglutamate;tryptophylglutamate;tryptophylglutamate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2959983534;0,0184421208;0,0335937388;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3982;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;Amino acid;Phenylalanine & tyrosine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2951034817;4,53122169549464E-005;0,000176036;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3983;;
isoleucine;isoleucine;isoleucine;–;–;–;–;–;–;–;Amino acid;Valine, leucine and isoleucine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2950701056;1,519330985397E-005;6,87614744937406E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3984;;
1-oleoylglycerophosphocholine;1-oleoylglycerophosphocholine;1-oleoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2934715202;0,2908183946;0,3546368757;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3985;;
phosphate;phosphate;phosphate;–;–;–;HMDB0001429;–;–;–;Energy;Oxidative Phosphorylation;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2932252492;1,74503506507419E-007;5,15754808121927E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3986;;
N-acetylneuraminate;N-acetylneuraminate;N-acetylneuraminate;–;–;–;–;–;–;–;Carbohydrate;Aminosugars metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2900267087;0,0129276501;0,0248913965;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3987;;
methionine;methionine;methionine;–;–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2892037585;0,0003264587;0,0009306193;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3988;;
oleoyl-linoleoyl-glycerophosphocholine;oleoyl-linoleoyl-glycerophosphocholine;oleoyl-linoleoyl-glycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2875998726;8,93057767816528E-008;2,77299649306455E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3989;;
malate;malate;malate;–;–;–;–;–;–;–;Energy;TCA Cycle;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2874257237;2,32941977013598E-006;5,53237195407296E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3990;;
dehydroascorbate;dehydroascorbate;dehydroascorbate;–;–;–;–;–;–;–;Cofactors and vitamins;Ascorbate and aldarate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,286723118;0,116994751;0,167298683;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3991;;
pyroglutamine;pyroglutamine;pyroglutamine;–;–;–;–;–;–;–;Amino acid;Glutamate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2840485429;7,91663212345019E-005;0,0002780321;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3992;;
adenosine 3'-monophosphate;adenosine 3'-monophosphate;adenosine 3'-monophosphate;(3'-AMP);–;–;–;–;–;–;Nucleotide;Purine metabolism, adenine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2824691168;0,0163917306;0,0304913972;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3993;;
2-oleoylglycerophosphoinositol;2-oleoylglycerophosphoinositol;2-oleoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2806499242;0,0358106786;0,0577973821;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3994;;
palmitoyl-oleoyl-glycerophosphocholine;palmitoyl-oleoyl-glycerophosphocholine;palmitoyl-oleoyl-glycerophosphocholine;(1)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2803705021;4,18384470351257E-005;8,12337730754996E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3995;;
N-delta-acetylornithine;N-delta-acetylornithine;N-delta-acetylornithine;–;–;–;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2787192043;0,0082566305;0,0116732565;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;3996;;
1-heptadecanoylglycerophosphocholine;1-heptadecanoylglycerophosphocholine;1-heptadecanoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2778821517;0,0935196876;0,1386998069;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3997;;
o-sulfo-l-tyrosine;o-sulfo-l-tyrosine;o-sulfo-l-tyrosine;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2777812257;1,62040823677806E-006;3,96652077591686E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3998;;
palmitoyl-arachidonoyl-glycerophosphocholine;palmitoyl-arachidonoyl-glycerophosphocholine;palmitoyl-arachidonoyl-glycerophosphocholine;(1)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2760166836;0,003326318;0,0049707898;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;3999;;
3-methylxanthine;3-methylxanthine;3-methylxanthine;–;–;–;–;–;–;–;Xenobiotics;Xanthine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2754582736;0,0570259876;0,0718648924;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4000;;
cis-vaccenate (18:1n7);cis-vaccenate (18:1n7);cis-vaccenate (18:1n7);(18:1n7);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2748438982;0,0082038483;0,0162963322;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4001;;
cytidine;cytidine;cytidine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine metabolism, cytidine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2731496539;0,0231873875;0,0406930901;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4002;;
valylhistidine;valylhistidine;valylhistidine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2704536504;0,2460870087;0,2829646008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4003;;
2-hydroxystearate;2-hydroxystearate;2-hydroxystearate;–;–;–;–;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2698893457;0,0532200732;0,0677346387;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4004;;
choline phosphate;choline phosphate;choline phosphate;–;–;–;–;–;–;–;Lipid;Phospholipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2684473207;0,0112508307;0,0156141963;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4005;;
2-stearoylglycerophosphocholine;2-stearoylglycerophosphocholine;2-stearoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2672451095;0,5022344541;0,5401389412;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4006;;
2-hydroxypalmitate;2-hydroxypalmitate;2-hydroxypalmitate;–;–;–;–;–;–;–;Lipid;Fatty acid, monohydroxy;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2670168868;0,0020634898;0,0047677474;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4007;;
spermine;spermine;spermine;–;–;–;–;–;–;–;Amino acid;Polyamine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2669852638;0,0048641026;0,0102660627;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4008;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;Amino acid;Phenylalanine & tyrosine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2664453259;0,0002447249;0,0007358509;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4009;;
cytidine 5'-monophosphate;cytidine 5'-monophosphate;cytidine 5'-monophosphate;(5'-CMP);–;–;–;–;–;–;Nucleotide;Pyrimidine metabolism, cytidine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2658016094;0,0015980955;0,0038336826;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4010;;
acetyl CoA;acetyl CoA;acetyl CoA;–;–;–;–;–;–;–;Cofactors and vitamins;Pantothenate and CoA metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2647603089;0,0120568396;0,0236292525;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4011;;
2-palmitoylglycerophosphocholine;2-palmitoylglycerophosphocholine;2-palmitoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2635802087;0,3705894343;0,411307884;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4012;;
5-dodecenoate (12:1n7);5-dodecenoate (12:1n7);5-dodecenoate (12:1n7);(12:1n7);–;–;–;–;–;–;Lipid;Medium chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2633595397;0,0365615314;0,0587930853;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4013;;
fructose-6-phosphate;fructose-6-phosphate;fructose-6-phosphate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, gluconeogenesis, pyruvate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2629231331;0,0238451898;0,0412127494;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4014;;
adenine;adenine;adenine;–;–;–;HMDB0000034;–;–;–;Nucleotide;Purine metabolism, adenine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2624149044;0,0063837217;0,0132191218;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4015;;
beta-alanine;beta-alanine;beta-alanine;–;–;–;–;–;–;–;Amino acid;Alanine and aspartate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,262324639;0,0255833718;0,0435313962;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4016;;
N-acetyltaurine;N-acetyltaurine;N-acetyltaurine;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2615663837;0,0040436263;0,0059866675;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4017;;
orotidine;orotidine;orotidine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Orotate containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2582329946;0,0733665151;0,0914788736;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4018;;
glycylvaline;glycylvaline;glycylvaline;–;–;–;HMDB0028854;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2572903024;0,0544009451;0,0840916018;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4019;;
1-palmitoleoylglycerophosphocholine;1-palmitoleoylglycerophosphocholine;1-palmitoleoylglycerophosphocholine;(16:1)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2563067679;0,5985345311;0,6292892698;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4020;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;Amino acid;Valine, leucine and isoleucine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2556262597;0,0002351154;0,0007118322;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4021;;
1-myristoylglycerophosphocholine;1-myristoylglycerophosphocholine;1-myristoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2536521962;0,1273831306;0,1786619628;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4022;;
alpha-hydroxyisocaproate;alpha-hydroxyisocaproate;alpha-hydroxyisocaproate;–;–;–;–;–;–;–;Amino acid;Valine, leucine and isoleucine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2527910221;0,0145655577;0,0275615511;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4023;;
sarcosine;sarcosine;sarcosine;(N-Methylglycine);–;–;–;–;–;–;Amino acid;Glycine, serine and threonine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2521258704;0,0081503639;0,0162636807;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4024;;
pentadecanoate;pentadecanoate;pentadecanoate;(15:0);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2515396085;0,0077290625;0,0156993493;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4025;;
1-palmitoylglycerol;1-palmitoylglycerol;1-palmitoylglycerol;(1-monopalmitin);–;–;–;–;–;–;Lipid;Monoacylglycerol;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2500366113;0,0349205105;0,0569892345;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4026;;
gamma-glutamylthreonine;gamma-glutamylthreonine;gamma-glutamylthreonine;*;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2500332836;0,004988211;0,0072638547;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4027;;
2-aminobutyrate;2-aminobutyrate;2-aminobutyrate;–;–;–;–;–;–;–;Amino acid;Butanoate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2443970642;0,0002066456;0,000629982;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4028;;
gamma-glutamylleucine;gamma-glutamylleucine;gamma-glutamylleucine;–;–;–;–;–;–;–;Peptide;gamma-glutamyl;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2422386047;0,0160698836;0,0300199103;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4029;;
glutamate;glutamate;glutamate;–;–;–;–;–;–;–;Amino acid;Glutamate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2407262648;0,0001958931;0,0006142649;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4030;;
squalene;squalene;squalene;–;–;–;–;–;–;–;Lipid;Sterol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2405898304;0,0183666581;0,0248416833;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4031;;
1-oleoylglycerophosphoethanolamine;1-oleoylglycerophosphoethanolamine;1-oleoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2402271621;0,0376260645;0,060284096;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4032;;
oleic ethanolamide;oleic ethanolamide;oleic ethanolamide;–;–;–;–;–;–;–;Lipid;Endocannabinoid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2396671585;0,161008608;0,2168183403;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4033;;
o-tyrosine;o-tyrosine;o-tyrosine;–;–;–;HMDB0006050;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2389241932;0,0543507363;0,0688442659;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4034;;
glycerol-3-phosphate;glycerol-3-phosphate;glycerol-3-phosphate;(G3P);–;–;–;–;–;–;Lipid;Glycerolipid metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2356192383;0,0189220477;0,0340730147;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4035;;
methioninesulfoxide;methioninesulfoxide;methioninesulfoxide;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,234959452;0,0048248459;0,0070646368;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4036;;
phenylalanylproline;phenylalanylproline;phenylalanylproline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2347547826;0,0395964883;0,0513788579;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4037;;
1-palmitoylglycerophosphocholine;1-palmitoylglycerophosphocholine;1-palmitoylglycerophosphocholine;(16:0);–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2338298106;0,3773406245;0,4176391378;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4038;;
argininosuccinate;argininosuccinate;argininosuccinate;–;–;–;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2332647734;0,0261454466;0,0346579176;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;4039;;
stearate;stearate;stearate;(18:0);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2303765809;0,0037252134;0,0079804505;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4040;;
2-hydroxybutyrate;2-hydroxybutyrate;2-hydroxybutyrate;(AHB);–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2280636925;0,00001604;3,35955255689518E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4041;;
alanine;alanine;alanine;–;–;–;–;–;–;–;Amino acid;Alanine and aspartate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2266598575;0,0023992971;0,0054574684;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4042;;
gamma-tocopherol;gamma-tocopherol;gamma-tocopherol;–;–;–;–;–;–;–;Cofactors and vitamins;Tocopherol metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,225193536;0,0171135094;0,0314344378;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4043;;
2-piperidinone;2-piperidinone;2-piperidinone;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2240471626;0,1446480428;0,1733170242;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4044;;
alpha-hydroxyisovalerate;alpha-hydroxyisovalerate;alpha-hydroxyisovalerate;–;–;–;–;–;–;–;Amino acid;Valine, leucine and isoleucine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2195226057;0,0085067351;0,0168218771;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4045;;
threonine;threonine;threonine;–;–;–;–;–;–;–;Amino acid;Glycine, serine and threonine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2165294567;0,0002050114;0,0006293707;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4046;;
pantothenate;pantothenate;pantothenate;–;–;–;–;–;–;–;Cofactors and vitamins;Pantothenate and CoA metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2138641034;0,0149799276;0,0281033685;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4047;;
N-acetyl-3-methylhistidine;N-acetyl-3-methylhistidine;N-acetyl-3-methylhistidine;*;–;–;–;–;–;–;Amino Acid;Histidine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2133371487;0,0307796836;0,0403983347;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4048;;
3-aminoisobutyrate;3-aminoisobutyrate;3-aminoisobutyrate;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Thymine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2126508953;0,0120043554;0,0166310341;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4049;;
sedoheptulose-7-phosphate;sedoheptulose-7-phosphate;sedoheptulose-7-phosphate;–;–;–;–;–;–;–;Carbohydrate;Pentose Phosphate Pathway;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2104616839;0,0148419493;0,0204557435;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4050;;
3-hydroxydecanoate;3-hydroxydecanoate;3-hydroxydecanoate;–;–;–;–;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,210248099;0,0004352956;0,0007297602;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4051;;
flavin mononucleotide;flavin mononucleotide;flavin mononucleotide;(FMN);–;–;–;–;–;–;Cofactors and vitamins;Riboflavin metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2075654175;0,006687401;0,0137185469;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4052;;
phenylalanylaspartate;phenylalanylaspartate;phenylalanylaspartate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2070901194;0,0214549124;0,0381324151;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4053;;
urea;urea;urea;–;–;–;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2060602514;1,90081271884074E-006;4,62453826108204E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;4054;;
glycodeoxycholate;glycodeoxycholate;glycodeoxycholate;–;–;–;–;–;–;–;Lipid;Secondary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2057353565;0,1335347587;0,1612114031;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4055;;
1-arachidoylglycerophosphocholine;1-arachidoylglycerophosphocholine;1-arachidoylglycerophosphocholine;(20:0);–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2056867364;0,3930161101;0,4337854161;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4056;;
methioninesulfoxide;methioninesulfoxide;methioninesulfoxide;–;–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2046543833;0,0318040774;0,0525421555;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4057;;
2-docosahexaenoylglycerophosphocholine;2-docosahexaenoylglycerophosphocholine;2-docosahexaenoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2044836575;0,1983693275;0,2615139182;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4058;;
glycine;glycine;glycine;–;–;–;–;–;–;–;Amino acid;Glycine, serine and threonine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2040825521;0,0053845444;0,0113101195;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4059;;
2-docosapentaenoylglycerophosphocholine;2-docosapentaenoylglycerophosphocholine;2-docosapentaenoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2039498014;0,0649831081;0,0980329363;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4060;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;Amino acid;Valine, leucine and isoleucine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2033555892;0,0004826808;0,0013080054;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4061;;
Ac-Ser-Asp-Lys-Pro-OH;Ac-Ser-Asp-Lys-Pro-OH;Ac-Ser-Asp-Lys-Pro-OH;–;–;–;–;–;–;–;Peptide;Polypeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2027366245;0,058887799;0,0903907125;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4062;;
ergothioneine;ergothioneine;ergothioneine;–;–;–;–;–;–;–;Xenobiotics;Food component/Plant;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,2025227094;0,0674767499;0,1014462095;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4063;;
palmitoylcarnitine;palmitoylcarnitine;palmitoylcarnitine;–;–;–;HMDB0000222;–;–;–;Lipid;Carnitine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1967692874;0,4974624324;0,5542792077;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4064;;
phytosphingosine;phytosphingosine;phytosphingosine;–;–;–;HMDB0004610;–;–;–;Lipid;Sphingolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1938795066;0,3492086471;0,4132145447;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4065;;
glycyltyrosine;glycyltyrosine;glycyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1937724012;0,1042330504;0,1500272431;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4066;;
2-linoleoylglycerophosphoethanolamine;2-linoleoylglycerophosphoethanolamine;2-linoleoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1931110877;0,3791679504;0,4380387637;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4067;;
cyclo(gly-pro);cyclo(gly-pro);cyclo(gly-pro);–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1919982762;0,0026012214;0,0039614021;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4068;;
dihydroxyacetone phosphate;dihydroxyacetone phosphate;dihydroxyacetone phosphate;(DHAP);–;–;–;–;–;–;Carbohydrate;Glycolysis, gluconeogenesis, pyruvate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1918083125;0,0533737896;0,0830889846;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4069;;
gamma-glutamyllysine;gamma-glutamyllysine;gamma-glutamyllysine;–;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1900899989;0,1769853965;0,2083102455;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4070;;
beta-hydroxyisovalerate;beta-hydroxyisovalerate;beta-hydroxyisovalerate;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1900341534;0,0061619311;0,0088280449;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4071;;
pipecolate;pipecolate;pipecolate;–;–;–;–;–;–;–;Amino acid;Lysine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1897627457;0,0019579985;0,0045721348;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4072;;
palmitoyl-arachidonoyl-glycerophosphocholine;palmitoyl-arachidonoyl-glycerophosphocholine;palmitoyl-arachidonoyl-glycerophosphocholine;(2)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1895676709;0,0265780552;0,0351729487;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4073;;
mannitol;mannitol;mannitol;–;–;–;–;–;–;–;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1887127723;0,0823967069;0,1022590546;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4074;;
glucose-6-phosphate;glucose-6-phosphate;glucose-6-phosphate;(G6P);–;–;HMDB0001401;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1880214592;0,0698353069;0,0873488635;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4075;;
gamma-glutamyl-valine;gamma-glutamyl-valine;gamma-glutamyl-valine;–;–;–;–;–;–;–;Peptide;gamma-glutamyl;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1816575358;0,1024028857;0,148857175;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4076;;
phosphoglycolate;phosphoglycolate;phosphoglycolate;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1795023944;0,0143443252;0,0198384255;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4077;;
methionylleucine;methionylleucine;methionylleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1790237494;0,1118534266;0,1604694584;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4078;;
tyrosylglutamate;tyrosylglutamate;tyrosylglutamate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1787319272;0,083785412;0,1036600911;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4079;;
urate;urate;urate;–;–;–;–;–;–;–;Nucleotide;Purine metabolism, urate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1784060605;0,0141255877;0,0270791835;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4080;;
dihydroorotate;dihydroorotate;dihydroorotate;–;–;–;–;–;–;–;Nucleotide;Pyrimidine Metabolism, Orotate containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1778174807;0,4043129478;0,4456377519;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4081;;
prostaglandin B2;prostaglandin B2;prostaglandin B2;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1756905042;0,0311823303;0,0518524357;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4082;;
phenylalanylaspartate;phenylalanylaspartate;phenylalanylaspartate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1746754439;0,1814234423;0,2129057455;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4083;;
4-guanidinobutanoate;4-guanidinobutanoate;4-guanidinobutanoate;–;–;–;–;–;–;–;Amino Acid;Guanidino and Acetamido Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1744752004;0,0459545966;0,0594356047;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4084;;
tyrosylvaline;tyrosylvaline;tyrosylvaline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1744726288;0,0277219299;0,0464501039;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4085;;
cystine;cystine;cystine;–;–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,173085724;0,329088855;0,3925815417;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4086;;
palmitoyl ethanolamide;palmitoyl ethanolamide;palmitoyl ethanolamide;–;–;–;–;–;–;–;Lipid;Endocannabinoid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1717763889;0,191044319;0,2526158314;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4087;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;Amino acid;Glycine, serine and threonine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1703878943;0,0300353832;0,0501351073;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4088;;
N-acetylserine;N-acetylserine;N-acetylserine;–;–;–;–;–;–;–;Amino Acid;Glycine, Serine and Threonine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1701447012;0,0095275075;0,0133385105;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4089;;
guanosine 3'-monophosphate;guanosine 3'-monophosphate;guanosine 3'-monophosphate;(3'-GMP);–;–;–;–;–;–;Nucleotide;Purine metabolism, guanine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1700634954;0,3518015254;0,4151636281;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4090;;
isobutyrylcarnitine;isobutyrylcarnitine;isobutyrylcarnitine;–;–;–;–;–;–;–;Amino acid;Valine, leucine and isoleucine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1697579876;0,152464423;0,207219448;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4091;;
gamma-glutamyl-2-aminobutyrate;gamma-glutamyl-2-aminobutyrate;gamma-glutamyl-2-aminobutyrate;–;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1683015225;0,3292120475;0,3679428766;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4092;;
5-oxoproline;5-oxoproline;5-oxoproline;–;–;–;–;–;–;–;Amino Acid;Glutathione Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1682651643;0,0642613996;0,0805032918;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4093;;
2-linoleoylglycerophosphocholine;2-linoleoylglycerophosphocholine;2-linoleoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1680399534;0,4747653801;0,5330485981;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4094;;
1-stearoylglycerophosphocholine;1-stearoylglycerophosphocholine;1-stearoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1667908023;0,5224557139;0,5762765286;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4095;;
prolylserine;prolylserine;prolylserine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1647792306;0,425871409;0,4655416224;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4096;;
palmitate;palmitate;palmitate;(16:0);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1639912073;0,0593981569;0,0905409406;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4097;;
7-beta-hydroxycholesterol;7-beta-hydroxycholesterol;7-beta-hydroxycholesterol;–;–;–;–;–;–;–;Lipid;Sterol/Steroid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1637081559;0,0421669407;0,0673137707;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4098;;
prolylproline;prolylproline;prolylproline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1632825546;0,1701865127;0,2016408033;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4099;;
cyclo(L-phe-D-pro);cyclo(L-phe-D-pro);cyclo(L-phe-D-pro);*;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1620614614;0,2969197913;0,3375622916;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4100;;
1-palmitoleoylglycerophosphocholine;1-palmitoleoylglycerophosphocholine;1-palmitoleoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1615636817;0,3706581612;0,4327631191;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4101;;
N-acetylglucosamine 6-phosphate;N-acetylglucosamine 6-phosphate;N-acetylglucosamine 6-phosphate;–;–;–;–;–;–;–;Carbohydrate;Aminosugars metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1609163584;0,3274117138;0,3916450746;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4102;;
5-aminovalerate;5-aminovalerate;5-aminovalerate;–;–;–;–;–;–;–;Amino acid;"Urea cycle; arginine-, proline-, metabolism";–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1607768962;0,1814521443;0,2421200345;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4103;;
indolelactate;indolelactate;indolelactate;–;–;–;–;–;–;–;Amino acid;Tryptophan metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1571053315;0,1656663414;0,2224083299;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4104;;
palmitoleoyl sphingomyelin;palmitoleoyl sphingomyelin;palmitoleoyl sphingomyelin;*;–;–;–;–;–;–;Lipid;Sphingolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,156944043;0,0052696721;0,0076319389;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4105;;
S-methylcysteine;S-methylcysteine;S-methylcysteine;–;–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1568403032;0,03218883;0,0529247056;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4106;;
urea;urea;urea;–;–;–;–;–;–;–;Amino acid;"Urea cycle; arginine-, proline-, metabolism";–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1543306051;0,0604991484;0,0919000904;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4107;;
palmitoyl sphingomyelin;palmitoyl sphingomyelin;palmitoyl sphingomyelin;–;–;–;–;–;–;–;Lipid;Sphingolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1522288074;0,0185220397;0,0335998986;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4108;;
mannose;mannose;mannose;–;–;–;–;–;–;–;Carbohydrate;Fructose, Mannose and Galactose Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1506052432;0,2420599093;0,2787356531;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4109;;
phosphate;phosphate;phosphate;–;–;–;HMDB0001429;–;–;–;Energy;Oxidative phosphorylation;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1487308686;0,0006966636;0,0018096765;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4110;;
adenosine 5'-diphosphate;adenosine 5'-diphosphate;adenosine 5'-diphosphate;(ADP);–;–;–;–;–;–;Nucleotide;Purine metabolism, adenine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1465972624;0,3491374924;0,4132145447;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4111;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;Amino Acid;Histidine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1464843048;0,0052441075;0,0076087232;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4112;;
hypotaurine;hypotaurine;hypotaurine;–;–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1456034937;0,2643606399;0,3325338708;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4113;;
gamma-glutamylphenylalanine;gamma-glutamylphenylalanine;gamma-glutamylphenylalanine;–;–;–;–;–;–;–;Peptide;gamma-glutamyl;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1429364061;0,1002474113;0,1469255106;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4114;;
N-acetylglucosamine 6-sulfate;N-acetylglucosamine 6-sulfate;N-acetylglucosamine 6-sulfate;–;–;–;–;–;–;–;Carbohydrate;Aminosugars metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1426719234;0,2698557762;0,3378926189;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4115;;
1-pentadecanoylglycerophosphocholine;1-pentadecanoylglycerophosphocholine;1-pentadecanoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1382707375;0,1040101898;0,1500272431;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4116;;
isovalerylcarnitine;isovalerylcarnitine;isovalerylcarnitine;–;–;–;–;–;–;–;Amino acid;Valine, leucine and isoleucine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1381286289;0,2211825316;0,2872755366;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4117;;
glutarylcarnitine;glutarylcarnitine;glutarylcarnitine;(C5);–;–;–;–;–;–;Amino acid;Lysine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,13502665;0,1278473881;0,1787420489;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4118;;
1-palmitoylglycerophosphoethanolamine;1-palmitoylglycerophosphoethanolamine;1-palmitoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1332537794;0,2737358848;0,3397673351;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4119;;
3-hydroxybutyrate;3-hydroxybutyrate;3-hydroxybutyrate;(BHBA);–;–;–;–;–;–;Lipid;Ketone bodies;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1327218012;0,0951413291;0,140157864;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4120;;
N-acetylglycine;N-acetylglycine;N-acetylglycine;–;–;–;–;–;–;–;Amino acid;Glycine, serine and threonine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1322027584;0,1254453757;0,1770756268;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4121;;
1-methylurate;1-methylurate;1-methylurate;–;–;–;–;–;–;–;Xenobiotics;Xanthine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1316433337;0,4206273497;0,4808734544;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4122;;
1-eicosapentaenoylglycerophosphocholine;1-eicosapentaenoylglycerophosphocholine;1-eicosapentaenoylglycerophosphocholine;(20:5n3)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1316209825;0,4417514285;0,4822402735;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4123;;
hydroxybutyrylcarnitine;hydroxybutyrylcarnitine;hydroxybutyrylcarnitine;*;–;–;HMDB0013127;–;–;–;Lipid;Fatty acid metabolism (also BCAA metabolism);–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1294377625;0,273980949;0,3397673351;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4124;;
N-acetylleucine;N-acetylleucine;N-acetylleucine;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1283391547;0,0069880282;0,0099579402;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4125;;
1-oleoylglycerophosphoinositol;1-oleoylglycerophosphoinositol;1-oleoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1275691139;0,2331820992;0,2692898917;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4126;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;Nucleotide;Purine metabolism, (hypo)xanthine/inosine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1265607475;0,0037266341;0,0079804505;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4127;;
arabonate;arabonate;arabonate;–;–;–;–;–;–;–;Cofactors and vitamins;Ascorbate and aldarate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1263302158;0,1308181284;0,1817378429;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4128;;
biliverdin;biliverdin;biliverdin;–;–;–;–;–;–;–;Cofactors and Vitamins;Hemoglobin and Porphyrin Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1221841366;0,3138485874;0,3552498904;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4129;;
pseudo uridine;pseudo uridine;pseudo uridine;–;–;–;–;–;–;–;Nucleotide;Pyrimidine metabolism, uracil containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1196375898;0,0078814773;0,0158714154;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4130;;
lathosterol;lathosterol;lathosterol;–;–;–;–;–;–;–;Lipid;Sterol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1194021397;0,289675626;0,3302302137;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4131;;
phosphoglycolate;phosphoglycolate;phosphoglycolate;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,11811569;0,2876142491;0,3528358511;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4132;;
symmetric dimethylarginine;symmetric dimethylarginine;symmetric dimethylarginine;(SDMA);–;–;HMDB0003334;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1173443532;0,4763847651;0,5165150034;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;4133;;
N-methyl proline;N-methyl proline;N-methyl proline;–;–;–;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1171588489;0,001956484;0,0030198728;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;4134;;
2-oleoylglycerophosphocholine;2-oleoylglycerophosphocholine;2-oleoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1164344395;0,6173911864;0,6643008108;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4135;;
2-docosahexaenoylglycerophosphoethanolamine;2-docosahexaenoylglycerophosphoethanolamine;2-docosahexaenoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1157007723;0,5859372776;0,6366991705;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4136;;
2-stearoylglycerophosphoethanolamine;2-stearoylglycerophosphoethanolamine;2-stearoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1140992683;0,3114233616;0,3530054582;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4137;;
1-oleoylglycerophosphoserine;1-oleoylglycerophosphoserine;1-oleoylglycerophosphoserine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1134465808;0,1764424138;0,2079779117;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4138;;
prostaglandin A2;prostaglandin A2;prostaglandin A2;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,113344919;0,0426222691;0,0675493723;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4139;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;Nucleotide;Pyrimidine metabolism, uracil containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,109699813;0,0096183612;0,0189348007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4140;;
cysteine sulfinic acid;cysteine sulfinic acid;cysteine sulfinic acid;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1093229349;0,4089763235;0,4501560085;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4141;;
2-arachidonoylglycerophosphoethanolamine;2-arachidonoylglycerophosphoethanolamine;2-arachidonoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1044502693;0,1690103772;0,200699823;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4142;;
methylphosphate;methylphosphate;methylphosphate;–;–;–;–;–;–;–;Nucleotide;Purine and pyrimidine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1031347867;0,1521387542;0,207219448;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4143;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;Amino acid;Glutamate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1030497916;0,0272584935;0,0458485771;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4144;;
caproate;caproate;caproate;(6:0);–;–;–;–;–;–;Lipid;Medium Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1016673851;0,0163473098;0,0222994072;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4145;;
tyrosylglutamate;tyrosylglutamate;tyrosylglutamate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,101424529;0,2709298448;0,3378926189;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4146;;
N6-acetyllysine;N6-acetyllysine;N6-acetyllysine;–;–;–;–;–;–;–;Amino Acid;Lysine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1009659937;0,3005953112;0,3412162992;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4147;;
adenosine 3',5'-diphosphate;adenosine 3',5'-diphosphate;adenosine 3',5'-diphosphate;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, Adenine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,1008047542;0,6635552788;0,6903743318;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4148;;
leucylhistidine;leucylhistidine;leucylhistidine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,100164927;0,0542107918;0,0840916018;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4149;;
arginine;arginine;arginine;–;–;–;HMDB0000517;–;–;–;Amino acid;"Urea cycle; arginine-, proline-, metabolism";–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0981707182;0,2512504337;0,3198882803;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4150;;
glycylglycine;glycylglycine;glycylglycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0981387397;0,3678403911;0,4306184845;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4151;;
linoleate;linoleate;linoleate;(18:2n6);–;–;–;–;–;–;Lipid;Essential fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0971711678;0,2513928399;0,3198882803;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4152;;
carnosine;carnosine;carnosine;–;–;–;–;–;–;–;Peptide;Dipeptide Derivative;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0949459858;0,542005392;0,5766937371;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4153;;
adenosine 5'-diphosphoribose;adenosine 5'-diphosphoribose;adenosine 5'-diphosphoribose;–;–;–;–;–;–;–;Cofactors and vitamins;Nicotinate and nicotinamide metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0948605514;0,572970624;0,6270639595;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4154;;
N6-acetyllysine;N6-acetyllysine;N6-acetyllysine;–;–;–;–;–;–;–;Amino acid;Lysine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,094529728;0,2877340198;0,3528358511;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4155;;
N-methylpipecolate;N-methylpipecolate;N-methylpipecolate;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0933339751;0,0017493139;0,0027264697;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4156;;
gamma-tocopherol;gamma-tocopherol;gamma-tocopherol;–;–;–;–;–;–;–;Cofactors and Vitamins;Tocopherol Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0917429224;0,479696366;0,5175748662;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4157;;
2-methylmalonyl carnitine;2-methylmalonyl carnitine;2-methylmalonyl carnitine;–;–;–;–;–;–;–;Lipid;Fatty Acid Synthesis;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0914380409;0,4143063192;0,4541434652;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4158;;
ophthalmate;ophthalmate;ophthalmate;–;–;–;–;–;–;–;Amino Acid;Glutathione Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0910280326;0,5801162901;0,6123449729;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4159;;
linolenate;linolenate;linolenate;[alpha or gamma; (18:3n3 or 6)];–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0890902674;0,3754333494;0,4161052956;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;4160;;
1-palmitoylglycerophosphoethanolamine;1-palmitoylglycerophosphoethanolamine;1-palmitoylglycerophosphoethanolamine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0888949606;0,4120642536;0,45293013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4161;;
xylonate;xylonate;xylonate;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0886706471;0,365621522;0,4291653694;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4162;;
ranitidine;ranitidine;ranitidine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0886341249;0,3148739841;0,3807980138;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4163;;
fumarate;fumarate;fumarate;–;–;–;–;–;–;–;Energy;Krebs cycle;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0881463133;0,2412466496;0,3087675778;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4164;;
pentadecanoate;pentadecanoate;pentadecanoate;(15:0);–;–;–;–;–;–;Lipid;Long Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0879321303;0,0343041196;0,0448765368;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4165;;
pterin;pterin;pterin;–;–;–;–;–;–;–;Cofactors and Vitamins;Pterin Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,087019547;0,4802329168;0,5175748662;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4166;;
3-hydroxyisobutyrate;3-hydroxyisobutyrate;3-hydroxyisobutyrate;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0870045139;0,3175354449;0,3589140014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4167;;
3-hydroxybutyrate;3-hydroxybutyrate;3-hydroxybutyrate;(BHBA);–;–;–;–;–;–;Lipid;Ketone Bodies;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0849322073;0,1098295554;0,1334002819;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4168;;
acisoga;acisoga;acisoga;–;–;–;–;–;–;–;Amino Acid;Polyamine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0844867362;0,0185549338;0,0249693713;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4169;;
N-acetylglycine;N-acetylglycine;N-acetylglycine;–;–;–;–;–;–;–;Amino Acid;Glycine, Serine and Threonine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0841146908;0,0181181602;0,0245471848;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4170;;
glycylalanine;glycylalanine;glycylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0840389136;0,4613733928;0,5016021355;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4171;;
tryptophan betaine;tryptophan betaine;tryptophan betaine;–;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0832435529;0,2142067791;0,2495430799;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4172;;
histidylisoleucine;histidylisoleucine;histidylisoleucine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0830892216;0,5826917504;0,6347436189;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4173;;
gamma-glutamyltyrosine;gamma-glutamyltyrosine;gamma-glutamyltyrosine;–;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0816113751;0,7122250444;0,7390839863;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4174;;
1-methylurate;1-methylurate;1-methylurate;–;–;–;–;–;–;–;Xenobiotics;Xanthine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0803758012;0,174595279;0,2064104187;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4175;;
2-hydroxystearate;2-hydroxystearate;2-hydroxystearate;–;–;–;–;–;–;–;Lipid;Fatty acid, monohydroxy;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0799865117;0,1889700892;0,2506280035;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4176;;
lidocaine;lidocaine;lidocaine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,079933155;0,2595013202;0,3283028229;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4177;;
N-acetylserine;N-acetylserine;N-acetylserine;–;–;–;–;–;–;–;Amino acid;Glycine, serine and threonine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0795331428;0,2609141333;0,3291416797;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4178;;
1,7-dimethylurate;1,7-dimethylurate;1,7-dimethylurate;–;–;–;–;–;–;–;Xenobiotics;Xanthine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0774968675;0,2208250299;0,2568780959;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4179;;
inosine 5'-monophosphate;inosine 5'-monophosphate;inosine 5'-monophosphate;(IMP);–;–;–;–;–;–;Nucleotide;Purine metabolism, (hypo)xanthine/inosine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0752371168;0,4084195953;0,4693617862;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4180;;
1,2-propanediol;1,2-propanediol;1,2-propanediol;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0748689838;0,4642143364;0,5040041367;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4181;;
myristoleoyl sphingomyelin;myristoleoyl sphingomyelin;myristoleoyl sphingomyelin;*;–;–;–;–;–;–;Lipid;Sphingolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0740649137;0,3524528276;0,3928175369;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4182;;
glucose-6-phosphate;glucose-6-phosphate;glucose-6-phosphate;(G6P);–;–;HMDB0001401;–;–;–;Carbohydrate;Glycolysis, gluconeogenesis, pyruvate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0727443166;0,453208595;0,5101501877;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4183;;
glycylthreonine;glycylthreonine;glycylthreonine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0727396251;0,418017614;0,4791376829;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4184;;
palmitoyl-linoleoyl-glycerophosphocholine;palmitoyl-linoleoyl-glycerophosphocholine;palmitoyl-linoleoyl-glycerophosphocholine;(1)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,072140691;0,2002082935;0,234261317;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4185;;
laurate;laurate;laurate;(12:0);–;–;–;–;–;–;Lipid;Medium Chain Fatty Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0715452175;0,0979756676;0,1197313672;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4186;;
1,2-propanediol;1,2-propanediol;1,2-propanediol;–;–;–;–;–;–;–;Lipid;Ketone bodies;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0715439426;0,3632734297;0,4275523744;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4187;;
palmitoyl sphingomyelin;palmitoyl sphingomyelin;palmitoyl sphingomyelin;–;–;–;–;–;–;–;Lipid;Sphingolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0713968391;0,0225651118;0,0300115987;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4188;;
nicotinamide adenine dinucleotide;nicotinamide adenine dinucleotide;nicotinamide adenine dinucleotide;(NAD+);–;–;–;–;–;–;Cofactors and Vitamins;Nicotinate and Nicotinamide Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0708128604;0,5927712174;0,6240520204;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4189;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;Lipid;Sterol/Steroid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,070534872;0,1484901407;0,2037099118;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4190;;
guanosine 3'-monophosphate;guanosine 3'-monophosphate;guanosine 3'-monophosphate;(3'-GMP);–;–;–;–;–;–;Nucleotide;Purine Metabolism, Guanine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0690801836;0,5381811744;0,5741558518;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4191;;
2-palmitoylglycerophosphoethanolamine;2-palmitoylglycerophosphoethanolamine;2-palmitoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0690033041;0,4459434092;0,4861514215;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4192;;
alpha-ketoglutarate;alpha-ketoglutarate;alpha-ketoglutarate;–;–;–;–;–;–;–;Energy;TCA Cycle;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,068588995;0,3633774651;0,4038652049;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4193;;
3-(cystein-s-yl)acetaminophen;3-(cystein-s-yl)acetaminophen;3-(cystein-s-yl)acetaminophen;*;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0673063019;0,2331203001;0,2692898917;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4194;;
2-hydroxybutyrate;2-hydroxybutyrate;2-hydroxybutyrate;(AHB);–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0633038885;0,2897840771;0,354359916;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4195;;
escitalopram;escitalopram;escitalopram;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0629202656;0,2341016182;0,3004988608;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4196;;
alpha-hydroxycaproate;alpha-hydroxycaproate;alpha-hydroxycaproate;–;–;–;–;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0625867295;0,6522386455;0,6803744302;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4197;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;Amino acid;Creatine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0615722341;0,0472567806;0,0743574432;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4198;;
4-acetamidophenol;4-acetamidophenol;4-acetamidophenol;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0600749487;0,2566621464;0,3256493708;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4199;;
N-acetylmethionine;N-acetylmethionine;N-acetylmethionine;–;–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0538717524;0,5349596912;0,5871182611;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4200;;
riboflavin;riboflavin;riboflavin;(Vitamin B2);–;–;HMDB0000244;–;–;–;Cofactors and Vitamins;Riboflavin Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0527259653;0,4806052329;0,5175748662;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4201;;
flavin mononucleotide;flavin mononucleotide;flavin mononucleotide;(FMN);–;–;–;–;–;–;Cofactors and Vitamins;Riboflavin Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0525281953;0,4576360154;0,4982176539;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4202;;
4-acetaminophen sulfate;4-acetaminophen sulfate;4-acetaminophen sulfate;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,050400317;0,3718235858;0,4329722922;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4203;;
N-6-trimethyllysine;N-6-trimethyllysine;N-6-trimethyllysine;–;–;–;–;–;–;–;Amino Acid;Lysine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,048744884;0,5640477887;0,5969630442;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4204;;
cholate;cholate;cholate;–;–;–;–;–;–;–;Lipid;Primary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0466814415;0,4132734477;0,4536344034;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4205;;
sedoheptulose-7-phosphate;sedoheptulose-7-phosphate;sedoheptulose-7-phosphate;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0445531032;0,6890289507;0,7266881786;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4206;;
leukotriene B4;leukotriene B4;leukotriene B4;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0390362222;0,8401550119;0,8606465976;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4207;;
gamma-glutamylmethionine;gamma-glutamylmethionine;gamma-glutamylmethionine;–;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0379740059;0,7302993518;0,7568556918;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4208;;
hydroxybutyrylcarnitine;hydroxybutyrylcarnitine;hydroxybutyrylcarnitine;*;–;–;HMDB0013127;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0343317369;0,6160296248;0,6442878644;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4209;;
lidocaine;lidocaine;lidocaine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0333077888;0,5417625796;0,5766937371;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4210;;
succinylcarnitine;succinylcarnitine;succinylcarnitine;–;–;–;–;–;–;–;Energy;Krebs cycle;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0329486877;0,7000450165;0,7317137197;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4211;;
1-palmitoylglycerophosphocholine;1-palmitoylglycerophosphocholine;1-palmitoylglycerophosphocholine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0301859835;0,9010861129;0,9178116092;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4212;;
7-alpha-hydroxycholesterol;7-alpha-hydroxycholesterol;7-alpha-hydroxycholesterol;–;–;–;–;–;–;–;Lipid;Sterol/Steroid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0291652043;0,7598004365;0,7848291567;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4213;;
oleate;oleate;oleate;(18:1n9);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0286372824;0,6941344314;0,7283337309;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4214;;
N-acetyl-1-methylhistidine;N-acetyl-1-methylhistidine;N-acetyl-1-methylhistidine;*;–;–;–;–;–;–;Amino Acid;Histidine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0282575442;0,8167799362;0,8388550696;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4215;;
N-delta-acetylornithine;N-delta-acetylornithine;N-delta-acetylornithine;*;–;–;–;–;–;–;Amino acid;"Urea cycle; arginine-, proline-, metabolism";–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0279032952;0,6860399688;0,7266881786;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4216;;
caprate;caprate;caprate;(10:0);–;–;–;–;–;–;Lipid;Medium chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0268483597;0,6902710034;0,7266881786;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4217;;
16-hydroxypalmitate;16-hydroxypalmitate;16-hydroxypalmitate;–;–;–;–;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0259276641;0,6050599141;0,6344780702;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4218;;
diltiazem;diltiazem;diltiazem;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0236026656;0,4193370745;0,4590274149;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4219;;
N-oleoyltaurine;N-oleoyltaurine;N-oleoyltaurine;–;–;–;–;–;–;–;Lipid;Endocannabinoid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0226432977;0,8543083063;0,8740231133;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4220;;
hydrochlorothiazide;hydrochlorothiazide;hydrochlorothiazide;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0214439455;0,2106937044;0,2745417197;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4221;;
choline;choline;choline;–;–;–;HMDB0000097;–;–;–;Lipid;Phospholipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0199759717;0,5596106203;0,593842121;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4222;;
paraxanthine;paraxanthine;paraxanthine;–;–;–;HMDB0001860;–;–;–;Xenobiotics;Xanthine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0173674122;0,9135837465;0,9287131588;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4223;;
3-methylxanthine;3-methylxanthine;3-methylxanthine;–;–;–;–;–;–;–;Xenobiotics;Xanthine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0158407283;0,6722359678;0,7145559076;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4224;;
1-linolenoylglycerophosphocholine;1-linolenoylglycerophosphocholine;1-linolenoylglycerophosphocholine;(18:3n3)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0158178965;0,9362318711;0,9433245368;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4225;;
anthranilate;anthranilate;anthranilate;–;–;–;–;–;–;–;Amino acid;Tryptophan metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0152181018;0,3248127137;0,3895977631;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4226;;
chenodeoxycholate;chenodeoxycholate;chenodeoxycholate;–;–;–;–;–;–;–;Lipid;Primary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,014275592;0,9276228734;0,938204123;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4227;;
arginine;arginine;arginine;–;–;–;HMDB0000517;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,01312334;0,8122890247;0,8353178372;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;4228;;
choline;choline;choline;–;–;–;HMDB0000097;–;–;–;Lipid;Glycerolipid metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0106211656;0,7867018335;0,8069208058;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4229;;
cortisol;cortisol;cortisol;–;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0104578716;0,9335828518;0,9430368553;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4230;;
2-stearoylglycerophosphocholine;2-stearoylglycerophosphocholine;2-stearoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0093205584;0,9601397807;0,9689686523;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4231;;
palmitoyl-linoleoyl-glycerophosphocholine;palmitoyl-linoleoyl-glycerophosphocholine;palmitoyl-linoleoyl-glycerophosphocholine;(2)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,008940244;0,8059322899;0,8298502804;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4232;;
1-arachidonoylglycerophosphoethanolamine;1-arachidonoylglycerophosphoethanolamine;1-arachidonoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0072243963;0,9185932108;0,9303630432;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4233;;
celecoxib;celecoxib;celecoxib;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0070569491;0,3243747105;0,3630449074;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4234;;
4-methylcatechol sulfate;4-methylcatechol sulfate;4-methylcatechol sulfate;–;–;–;–;–;–;–;Xenobiotics;Benzoate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,006831194;0,9141126778;0,9289246887;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4235;;
4-guanidinobutanoate;4-guanidinobutanoate;4-guanidinobutanoate;–;–;–;–;–;–;–;Amino acid;Guanidino and acetamido metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0063829334;0,94833241;0,9592578986;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4236;;
theobromine;theobromine;theobromine;–;–;–;HMDB0002825;–;–;–;Xenobiotics;Xanthine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0059543329;0,916920078;0,9303630432;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4237;;
hexanoylcarnitine;hexanoylcarnitine;hexanoylcarnitine;–;–;–;–;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0042875467;0,9618329993;0,9654625578;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4238;;
theophylline;theophylline;theophylline;–;–;–;–;–;–;–;Xenobiotics;Xanthine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0020895492;0,9405172214;0,9535497926;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4239;;
mannose;mannose;mannose;–;–;–;–;–;–;–;Carbohydrate;Fructose, mannose, galactose, starch, and sucrose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0011416778;0,9923677792;0,9923677792;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4240;;
5-oxoproline;5-oxoproline;5-oxoproline;–;–;–;–;–;–;–;Amino acid;Glutathione metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0008853941;0,987970499;0,9902261394;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4241;;
metformin;metformin;metformin;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;1,0004139698;0,6654574886;0,7090675668;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4242;;
taurodeoxycholate;taurodeoxycholate;taurodeoxycholate;–;–;–;–;–;–;–;Lipid;Secondary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9991786888;0,9944476443;0,9944476443;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4243;;
cysteine-glutathione disulfide;cysteine-glutathione disulfide;cysteine-glutathione disulfide;–;–;–;–;–;–;–;Amino acid;Glutathione metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9962742757;0,9761623609;0,9806299232;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4244;;
escitalopram;escitalopram;escitalopram;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9962528414;0,3243747105;0,3630449074;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4245;;
3-hydroxyquinine;3-hydroxyquinine;3-hydroxyquinine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9960810721;0,3248127137;0,3895977631;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4246;;
3-aminoisobutyrate;3-aminoisobutyrate;3-aminoisobutyrate;–;–;–;–;–;–;–;Nucleotide;"Pyrimidine metabolism, thymine containing; Valine, leucine and isoleucine metabolism/";–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9959217734;0,9675817765;0,9742394493;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4247;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;Amino Acid;Tryptophan Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,995910169;0,9717918317;0,9730111439;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4248;;
piperine;piperine;piperine;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9946027765;0,964026548;0,9664487253;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4249;;
2-hydroxyacetaminophen sulfate;2-hydroxyacetaminophen sulfate;2-hydroxyacetaminophen sulfate;*;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9942615426;0,7224627421;0,7533518854;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4250;;
cotinine;cotinine;cotinine;–;–;–;HMDB0001046;–;–;–;Xenobiotics;Tobacco metabolite;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9938330616;0,3248127137;0,3895977631;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4251;;
2-methoxyacetaminophen sulfate;2-methoxyacetaminophen sulfate;2-methoxyacetaminophen sulfate;*;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9936807611;0,729839111;0,7556588909;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4252;;
4-acetamidophenol;4-acetamidophenol;4-acetamidophenol;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9904426803;0,9484987791;0,9532771104;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4253;;
glycocholate;glycocholate;glycocholate;–;–;–;–;–;–;–;Lipid;Primary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9897367002;0,9402412296;0,9461696106;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4254;;
desvenlafaxine;desvenlafaxine;desvenlafaxine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9895147444;0,3067721584;0,3730553395;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4255;;
7-methylxanthine;7-methylxanthine;7-methylxanthine;–;–;–;–;–;–;–;Xenobiotics;Xanthine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,989313735;0,9187043585;0,9303630432;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4256;;
N,O-didesmethylvenlafaxine glucuronide;N,O-didesmethylvenlafaxine glucuronide;N,O-didesmethylvenlafaxine glucuronide;*;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9887077501;0,161733869;0,1927593072;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4257;;
trigonelline;trigonelline;trigonelline;(N'-methylnicotinate);–;–;–;–;–;–;Cofactors and Vitamins;Nicotinate and Nicotinamide Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9857750136;0,783805342;0,8081093836;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4258;;
hydrochlorothiazide;hydrochlorothiazide;hydrochlorothiazide;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9850945951;0,2711388222;0,3104286658;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4259;;
3-methyl-2-oxovalerate;3-methyl-2-oxovalerate;3-methyl-2-oxovalerate;–;–;–;–;–;–;–;Amino acid;Valine, leucine and isoleucine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9840208034;0,689605461;0,7266881786;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4260;;
urate;urate;urate;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9834085615;0,5629720659;0,5966158149;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4261;;
hexanoylglycine;hexanoylglycine;hexanoylglycine;–;–;–;–;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Glycine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9827056741;0,8736775967;0,8926949067;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4262;;
sphinganine;sphinganine;sphinganine;–;–;–;HMDB0000269;–;–;–;Lipid;Sphingolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9804805299;0,9361106986;0,9433245368;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4263;;
stachydrine;stachydrine;stachydrine;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9796908657;0,6083278054;0,6370677017;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4264;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;Amino Acid;Creatine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9795455296;0,5211676303;0,5574956688;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4265;;
indolin-2-one;indolin-2-one;indolin-2-one;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9780963677;0,7384114278;0,7642701938;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4266;;
glucosamine-6-phosphate;glucosamine-6-phosphate;glucosamine-6-phosphate;–;–;–;–;–;–;–;Carbohydrate;Aminosugar Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9777577593;0,775312862;0,8013207372;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4267;;
p-acetamidophenylglucuronide;p-acetamidophenylglucuronide;p-acetamidophenylglucuronide;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9776640711;0,2261092355;0,2928081251;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4268;;
tetraethylene glycol;tetraethylene glycol;tetraethylene glycol;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9776051011;0,6629666964;0,7081323107;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4269;;
gamma-glutamylmethionine;gamma-glutamylmethionine;gamma-glutamylmethionine;–;–;–;–;–;–;–;Peptide;gamma-glutamyl;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9761573143;0,7772900338;0,7991342502;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4270;;
desmethylnaproxen sulfate;desmethylnaproxen sulfate;desmethylnaproxen sulfate;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9759868255;0,3243747105;0,3630449074;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4271;;
nicotinamide adenine dinucleotide;nicotinamide adenine dinucleotide;nicotinamide adenine dinucleotide;(NAD+);–;–;–;–;–;–;Cofactors and vitamins;Nicotinate and nicotinamide metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9748609934;0,7677529293;0,7911820093;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4272;;
valyltyrosine;valyltyrosine;valyltyrosine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9738709578;0,8913129904;0,9072292938;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4273;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;Amino acid;Histidine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9719732559;0,5942047107;0,6440885629;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4274;;
metformin;metformin;metformin;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9718362881;0,1575344494;0,1881923513;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4275;;
gamma-glutamylalanine;gamma-glutamylalanine;gamma-glutamylalanine;–;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,970845037;0,7762167041;0,8013207372;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4276;;
quinine;quinine;quinine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9703332988;0,1018408188;0,1485319584;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4277;;
15-HETE;15-HETE;15-HETE;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9664664903;0,8841144934;0,9010515526;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4278;;
2,3-dihydroxyisovalerate;2,3-dihydroxyisovalerate;2,3-dihydroxyisovalerate;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9636229003;0,4770411144;0,516524843;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4279;;
indoleacrylate;indoleacrylate;indoleacrylate;–;–;–;–;–;–;–;Xenobiotics;Food component/Plant;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9636026904;0,6344300448;0,6809652559;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4280;;
3-hydroxyhippurate;3-hydroxyhippurate;3-hydroxyhippurate;–;–;–;–;–;–;–;Xenobiotics;Benzoate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9635142256;0,120877868;0,1722902079;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4281;;
ranitidine;ranitidine;ranitidine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9632978911;0,3220635859;0,3624918781;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4282;;
indoleacetate;indoleacetate;indoleacetate;–;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9631433592;0,5063403188;0,543821769;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4283;;
methylprednisolone;methylprednisolone;methylprednisolone;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9625586971;0,178632124;0,2390838489;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4284;;
hexaethylene glycol;hexaethylene glycol;hexaethylene glycol;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9608373023;0,512181774;0,5677974717;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4285;;
valylalanine;valylalanine;valylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9589249311;0,8832234593;0,9010515526;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4286;;
triethyleneglycol;triethyleneglycol;triethyleneglycol;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9581502333;0,3148561212;0,3807980138;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4287;;
caproate;caproate;caproate;(6:0);–;–;–;–;–;–;Lipid;Medium chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9564699146;0,4921735034;0,5511841021;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4288;;
naproxen;naproxen;naproxen;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9560871819;0,3243747105;0,3630449074;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4289;;
tryptophan betaine;tryptophan betaine;tryptophan betaine;–;–;–;–;–;–;–;Amino acid;Tryptophan metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9545835041;0,5103019697;0,5671457335;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4290;;
linolenate;linolenate;linolenate;[alpha or gamma; (18:3n3 or 6)];–;–;–;–;–;–;Lipid;Essential fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,952634265;0,6398774599;0,6851370851;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;4291;;
1,3,7-trimethylurate;1,3,7-trimethylurate;1,3,7-trimethylurate;–;–;–;–;–;–;–;Xenobiotics;Xanthine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9525025954;0,1657976265;0,1971781012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4292;;
2-oleoylglycerophosphoethanolamine;2-oleoylglycerophosphoethanolamine;2-oleoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9521405044;0,8404734422;0,8580647468;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4293;;
sulfate;sulfate;sulfate;*;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,951563312;0,6563649326;0,6837848776;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4294;;
1,3-dimethylurate;1,3-dimethylurate;1,3-dimethylurate;–;–;–;–;–;–;–;Xenobiotics;Xanthine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9508125071;0,123994188;0,1755917695;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4295;;
lysine;lysine;lysine;–;–;–;–;–;–;–;Amino acid;Lysine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9505451883;0,3779413167;0,4377737151;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4296;;
chiro-inositol;chiro-inositol;chiro-inositol;–;–;–;–;–;–;–;Lipid;Inositol metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9504738044;0,4331238883;0,490055121;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4297;;
aspartate;aspartate;aspartate;–;–;–;–;–;–;–;Amino Acid;Alanine and Aspartate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9498245062;0,321976356;0,3624918781;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4298;;
gamma-glutamylglutamine;gamma-glutamylglutamine;gamma-glutamylglutamine;–;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9496921557;0,5995386321;0,6295155637;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4299;;
N,O-didesmethyl venlafaxine;N,O-didesmethyl venlafaxine;N,O-didesmethyl venlafaxine;*;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9471924199;0,107145881;0,1305380351;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4300;;
inositol 1-phosphate;inositol 1-phosphate;inositol 1-phosphate;(I1P);–;–;–;–;–;–;Lipid;Inositol metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9470933096;0,5342788465;0,5871182611;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4301;;
heptaethylene glycol;heptaethylene glycol;heptaethylene glycol;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9429545439;0,3821428134;0,440316785;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4302;;
2-arachidonoylglycerophosphocholine;2-arachidonoylglycerophosphocholine;2-arachidonoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9427970325;0,8071142635;0,8259281158;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4303;;
o-desmethylvenlafaxine;o-desmethylvenlafaxine;o-desmethylvenlafaxine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9422335565;0,1153944602;0,1397341111;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4304;;
3-(N-acetyl-L-cystein-S-yl) acetaminophen;3-(N-acetyl-L-cystein-S-yl) acetaminophen;3-(N-acetyl-L-cystein-S-yl) acetaminophen;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9408836614;0,0855780841;0,1055507127;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4305;;
theophylline;theophylline;theophylline;–;–;–;–;–;–;–;Xenobiotics;Xanthine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9407625868;0,5105499128;0,5468709133;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4306;;
phenylalanylglutamate;phenylalanylglutamate;phenylalanylglutamate;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9398662003;0,614027416;0,6623047559;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4307;;
1,5-anhydroglucitol;1,5-anhydroglucitol;1,5-anhydroglucitol;(1,5-AG);–;–;–;–;–;–;Carbohydrate;Glycolysis, gluconeogenesis, pyruvate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9379429139;0,1504304272;0,2057288398;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4308;;
2-hydroxyoctanoate;2-hydroxyoctanoate;2-hydroxyoctanoate;–;–;–;–;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9369812065;0,5568911184;0,5917431591;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4309;;
theobromine;theobromine;theobromine;–;–;–;HMDB0002825;–;–;–;Xenobiotics;Xanthine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9352423721;0,2272263017;0,2933892542;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4310;;
gamma-glutamyltyrosine;gamma-glutamyltyrosine;gamma-glutamyltyrosine;–;–;–;–;–;–;–;Peptide;gamma-glutamyl;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9340240692;0,2820508497;0,3478098961;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4311;;
1,5-anhydroglucitol;1,5-anhydroglucitol;1,5-anhydroglucitol;(1,5-AG);–;–;–;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9333257015;0,0389948812;0,0506806436;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4312;;
15-HETE;15-HETE;15-HETE;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9331104392;0,725884724;0,7551265257;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4313;;
isocitrate;isocitrate;isocitrate;–;–;–;–;–;–;–;Energy;TCA Cycle;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9310242482;0,6906691235;0,7176483861;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4314;;
myristoleoylcarnitine;myristoleoylcarnitine;myristoleoylcarnitine;*;–;–;–;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9310038272;0,8205433119;0,8416369703;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4315;;
2-stearoylglycerophosphoglycerol;2-stearoylglycerophosphoglycerol;2-stearoylglycerophosphoglycerol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9290469999;0,6183133405;0,6458299028;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4316;;
kynurenate;kynurenate;kynurenate;–;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9273424175;0,2792692428;0,3188223974;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4317;;
2-eicosapentaenoylglycerophosphoethanolamine;2-eicosapentaenoylglycerophosphoethanolamine;2-eicosapentaenoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9240796106;0,6951522398;0,7283337309;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4318;;
hexanoylcarnitine;hexanoylcarnitine;hexanoylcarnitine;–;–;–;–;–;–;–;Lipid;Carnitine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,922301702;0,4246550834;0,4842170951;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4319;;
chiro-inositol;chiro-inositol;chiro-inositol;–;–;–;–;–;–;–;Lipid;Inositol Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9213703398;0,2594690296;0,2974946632;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4320;;
lysine;lysine;lysine;–;–;–;–;–;–;–;Amino Acid;Lysine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9205318526;0,1618405211;0,1927593072;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4321;;
pentaethylene glycol;pentaethylene glycol;pentaethylene glycol;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,920511415;0,210752983;0,2745417197;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4322;;
2-docosapentaenoylglycerophosphoethanolamine;2-docosapentaenoylglycerophosphoethanolamine;2-docosapentaenoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9177847276;0,729322823;0,7556588909;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4323;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9171699985;0,1058424641;0,1291472269;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;4324;;
glutarylcarnitine;glutarylcarnitine;glutarylcarnitine;(C5);–;–;–;–;–;–;Amino Acid;Lysine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9168851519;0,2297916303;0,266233332;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4325;;
succinylcarnitine;succinylcarnitine;succinylcarnitine;–;–;–;–;–;–;–;Energy;TCA Cycle;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9167313941;0,5230849623;0,5587975903;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4326;;
tyrosylhistidine;tyrosylhistidine;tyrosylhistidine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9161634937;0,5837080412;0,6153223472;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4327;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;Lipid;Inositol metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9160523139;0,2705047202;0,3378926189;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4328;;
benzoate;benzoate;benzoate;–;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9146070079;0,0639267351;0,0802099601;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4329;;
2-methoxyacetaminophen sulfate;2-methoxyacetaminophen sulfate;2-methoxyacetaminophen sulfate;*;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9126545424;0,041359153;0,0535789028;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4330;;
caffeine;caffeine;caffeine;–;–;–;HMDB0001847;–;–;–;Xenobiotics;Xanthine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9117650764;0,0532122753;0,0830889846;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4331;;
3-methoxytyramine sulfate;3-methoxytyramine sulfate;3-methoxytyramine sulfate;–;–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9113712766;0,1406654019;0,1690526968;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4332;;
2-methoxyacetaminophen glucuronide;2-methoxyacetaminophen glucuronide;2-methoxyacetaminophen glucuronide;*;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9108805395;0,0732794225;0,0914788736;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4333;;
2-hydroxyacetaminophen sulfate;2-hydroxyacetaminophen sulfate;2-hydroxyacetaminophen sulfate;*;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9080042005;0,0041509249;0,0061341445;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4334;;
4-acetylphenol sulfate;4-acetylphenol sulfate;4-acetylphenol sulfate;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9059788392;0,0029543745;0,0044651342;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4335;;
1,2-dipalmitoylglycerol;1,2-dipalmitoylglycerol;1,2-dipalmitoylglycerol;–;–;–;–;–;–;–;Lipid;Diacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9054237419;0,1703081472;0,2016408033;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4336;;
p-acetamidophenylglucuronide;p-acetamidophenylglucuronide;p-acetamidophenylglucuronide;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,902625024;0,0026268742;0,0039928489;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4337;;
glycerol-2-phosphate;glycerol-2-phosphate;glycerol-2-phosphate;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9014949676;0,3781449523;0,4179496841;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4338;;
1,2-dipalmitoylglycerol;1,2-dipalmitoylglycerol;1,2-dipalmitoylglycerol;–;–;–;–;–;–;–;Lipid;Diacylglycerol;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9004433507;0,4299614248;0,4877340194;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4339;;
4-acetaminophen sulfate;4-acetaminophen sulfate;4-acetaminophen sulfate;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,9002244733;0,2079258183;0,2429352899;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4340;;
3-hydroxy-2-ethylpropionate;3-hydroxy-2-ethylpropionate;3-hydroxy-2-ethylpropionate;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8973606842;0,0015105572;0,0023682213;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4341;;
ornithine;ornithine;ornithine;–;–;–;HMDB0000214;–;–;–;Amino acid;"Urea cycle; arginine-, proline-, metabolism";–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8964755792;0,210084086;0,2745417197;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4342;;
octaethylene glycol;octaethylene glycol;octaethylene glycol;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,894905975;0,100404677;0,1469255106;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4343;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;Amino Acid;Urea cycle; Arginine and Proline Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8936938859;0,3301006479;0,3684200239;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;4344;;
phenylalanylphenylalanine;phenylalanylphenylalanine;phenylalanylphenylalanine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8930441048;0,5744236078;0,6071391245;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4345;;
gluconate;gluconate;gluconate;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8927861516;0,3743885619;0,4348057637;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4346;;
hippurate;hippurate;hippurate;–;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8805443092;0,0006615722;0,0010796209;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4347;;
arabonate;arabonate;arabonate;–;–;–;–;–;–;–;Cofactors and Vitamins;Ascorbate and Aldarate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8779593854;0,2298681275;0,266233332;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4348;;
quinine;quinine;quinine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8765981597;0,0533404799;0,0677797817;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4349;;
caffeine;caffeine;caffeine;–;–;–;HMDB0001847;–;–;–;Xenobiotics;Xanthine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,876194859;0,0223501128;0,0297752755;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4350;;
1,3-dimethylurate;1,3-dimethylurate;1,3-dimethylurate;–;–;–;–;–;–;–;Xenobiotics;Xanthine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8752453235;0,0154089819;0,0211641438;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4351;;
1-oleoylglycerophosphoinositol;1-oleoylglycerophosphoinositol;1-oleoylglycerophosphoinositol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8735609045;0,231881975;0,2985225426;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4352;;
scyllo-inositol;scyllo-inositol;scyllo-inositol;–;–;–;–;–;–;–;Lipid;Inositol metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8715731964;0,187843316;0,2498885325;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4353;;
hippurate;hippurate;hippurate;–;–;–;–;–;–;–;Xenobiotics;Benzoate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8709899556;0,0017484068;0,0041714707;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4354;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;Amino acid;"Urea cycle; arginine-, proline-, metabolism";–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,865745931;0,1607964444;0,2168183403;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4355;;
cyclo(gly-pro);cyclo(gly-pro);cyclo(gly-pro);–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8638862925;0,2969532942;0,3375622916;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4356;;
maltohexaose;maltohexaose;maltohexaose;–;–;–;–;–;–;–;Carbohydrate;Fructose, mannose, galactose, starch, and sucrose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8630893555;0,5140986963;0,5684869715;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4357;;
pantoprazole;pantoprazole;pantoprazole;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8626753151;0,0485184949;0,0624479982;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4358;;
1-arachidonoylglycerophosphoethanolamine;1-arachidonoylglycerophosphoethanolamine;1-arachidonoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,861996572;0,0266883132;0,0452361756;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4359;;
6-keto prostaglandin F1alpha;6-keto prostaglandin F1alpha;6-keto prostaglandin F1alpha;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8619749057;0,4295481086;0,4877340194;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4360;;
7-alpha-hydroxy-3-oxo-4-cholestenoate;7-alpha-hydroxy-3-oxo-4-cholestenoate;7-alpha-hydroxy-3-oxo-4-cholestenoate;(7-Hoca);–;–;–;–;–;–;Lipid;Sterol/Steroid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8612267654;0,1569200083;0,2126169248;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4361;;
deoxycarnitine;deoxycarnitine;deoxycarnitine;–;–;–;–;–;–;–;Lipid;Carnitine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8597742594;0,0493831433;0,077425714;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4362;;
cystine;cystine;cystine;–;–;–;–;–;–;–;Amino Acid;Methionine, Cysteine, SAM and Taurine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8595527424;0,5098563803;0,5468620854;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4363;;
2-arachidonoylglycerophosphoethanolamine;2-arachidonoylglycerophosphoethanolamine;2-arachidonoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8584667206;0,4460212811;0,5033504946;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4364;;
2-palmitoylglycerophosphoethanolamine;2-palmitoylglycerophosphoethanolamine;2-palmitoylglycerophosphoethanolamine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8580538401;0,347417848;0,4132145447;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4365;;
4-acetamidobutanoate;4-acetamidobutanoate;4-acetamidobutanoate;–;–;–;–;–;–;–;Amino Acid;Polyamine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8570685399;0,3211799889;0,3624918781;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4366;;
N-acetylalliin;N-acetylalliin;N-acetylalliin;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8568859804;0,0062263688;0,0089043769;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4367;;
1-oleoylglycerophosphoserine;1-oleoylglycerophosphoserine;1-oleoylglycerophosphoserine;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,855996086;0,0833719256;0,1244907325;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4368;;
threonylproline;threonylproline;threonylproline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8542813558;0,2513983278;0,2886559217;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4369;;
N-acetylphenylalanine;N-acetylphenylalanine;N-acetylphenylalanine;–;–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8518278771;0,0041818688;0,0061684498;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4370;;
inositol 1-phosphate;inositol 1-phosphate;inositol 1-phosphate;(I1P);–;–;–;–;–;–;Lipid;Inositol Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8509603236;0,2379819028;0,2744357781;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4371;;
lauroylcarnitine;lauroylcarnitine;lauroylcarnitine;–;–;–;–;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8504772507;0,353016402;0,3928969161;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4372;;
N1-methyl-2-pyridone-5-carboxamide;N1-methyl-2-pyridone-5-carboxamide;N1-methyl-2-pyridone-5-carboxamide;–;–;–;–;–;–;–;Cofactors and Vitamins;Nicotinate and Nicotinamide Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8476513194;3,62714532237626E-005;7,16450981994122E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4373;;
4-androsten-3beta,17beta-diol monosulfate;4-androsten-3beta,17beta-diol monosulfate;4-androsten-3beta,17beta-diol monosulfate;-2;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8458328989;0,0025645173;0,0039129729;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4374;;
taurochenodeoxycholate;taurochenodeoxycholate;taurochenodeoxycholate;–;–;–;–;–;–;–;Lipid;Primary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8430714607;0,154913381;0,1853386477;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4375;;
isovalerate;isovalerate;isovalerate;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8404338802;0,0947008487;0,116442646;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4376;;
2-palmitoylglycerophosphocholine;2-palmitoylglycerophosphocholine;2-palmitoylglycerophosphocholine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8402185767;0,5742134663;0,6270639595;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4377;;
oleoylcarnitine;oleoylcarnitine;oleoylcarnitine;–;–;–;–;–;–;–;Lipid;Carnitine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8399267711;0,4968659406;0,5542792077;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4378;;
stearidonate;stearidonate;stearidonate;(18:4n3);–;–;–;–;–;–;Lipid;Polyunsaturated Fatty Acid (n3 and n6);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8395240708;0,1762159036;0,2079779117;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4379;;
1,3-dipalmitoylglycerol;1,3-dipalmitoylglycerol;1,3-dipalmitoylglycerol;–;–;–;–;–;–;–;Lipid;Diacylglycerol;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8393432624;0,1453668148;0,200679345;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4380;;
2-hydroxydecanoate;2-hydroxydecanoate;2-hydroxydecanoate;–;–;–;–;–;–;–;Lipid;Fatty Acid, Monohydroxy;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8367846355;0,0004288825;0,0007205226;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4381;;
glycochenodeoxycholate;glycochenodeoxycholate;glycochenodeoxycholate;–;–;–;–;–;–;–;Lipid;Primary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8358335914;0,0559623916;0,0707733574;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4382;;
betaine;betaine;betaine;–;–;–;HMDB0000043;–;–;–;Amino Acid;Glycine, Serine and Threonine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8336434496;0,0029729787;0,004484758;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4383;;
N,N-dimethylsphingosine;N,N-dimethylsphingosine;N,N-dimethylsphingosine;–;–;–;HMDB0013645;–;–;–;Lipid;Sphingolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,832559776;0,1294517772;0,180410572;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4384;;
glycoursodeoxycholate;glycoursodeoxycholate;glycoursodeoxycholate;–;–;–;–;–;–;–;Lipid;Secondary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8288466455;0,0497841205;0,063768424;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4385;;
aspartate;aspartate;aspartate;–;–;–;–;–;–;–;Amino acid;Alanine and aspartate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8278340878;0,0170535228;0,0314344378;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4386;;
carnitine;carnitine;carnitine;–;–;–;HMDB0000062;–;–;–;Lipid;Carnitine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8267482994;0,0144979796;0,0275524374;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4387;;
methylphosphate;methylphosphate;methylphosphate;–;–;–;–;–;–;–;Nucleotide;Purine and Pyrimidine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8260186001;0,0855445151;0,1055507127;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4388;;
catechol sulfate;catechol sulfate;catechol sulfate;–;–;–;–;–;–;–;Xenobiotics;Benzoate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8257461671;0,0001417912;0,0004576936;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4389;;
3-dehydrocarnitine;3-dehydrocarnitine;3-dehydrocarnitine;*;–;–;–;–;–;–;Lipid;Carnitine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8246651379;0,0125883206;0,0243963795;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4390;;
4-methyl-2-oxopentanoate;4-methyl-2-oxopentanoate;4-methyl-2-oxopentanoate;–;–;–;–;–;–;–;Amino acid;Valine, leucine and isoleucine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8227700912;0,006101305;0,0126941844;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4391;;
taurocholate;taurocholate;taurocholate;–;–;–;–;–;–;–;Lipid;Primary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8217519016;0,1380806692;0,1661966425;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4392;;
3-methylglutarylcarnitine;3-methylglutarylcarnitine;3-methylglutarylcarnitine;-2;–;–;–;–;–;–;Amino Acid;Lysine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8214768139;0,051713406;0,0661334904;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4393;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;Lipid;Inositol Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8209742335;0,0005822519;0,0009583293;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4394;;
quinate;quinate;quinate;–;–;–;–;–;–;–;Xenobiotics;Food component/Plant;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8194634208;0,0241159213;0,0415172135;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4395;;
tartarate;tartarate;tartarate;–;–;–;–;–;–;–;Xenobiotics;Food component/Plant;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8174699789;0,0146968792;0,0276906865;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4396;;
cysteinyl-glycine;cysteinyl-glycine;cysteinyl-glycine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8161485899;0,0578311079;0,0890801979;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4397;;
phenylacetylglutamine;phenylacetylglutamine;phenylacetylglutamine;–;–;–;–;–;–;–;Amino acid;Phenylalanine & tyrosine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8159037762;1,72519924450312E-006;1,11376833578951E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4398;;
3-hydroxyhippurate;3-hydroxyhippurate;3-hydroxyhippurate;–;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8150400493;0,0164650124;0,022421638;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4399;;
2-stearoylglycerophosphoglycerol;2-stearoylglycerophosphoglycerol;2-stearoylglycerophosphoglycerol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,810201826;0,0593169936;0,0905409406;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4400;;
guanine;guanine;guanine;–;–;–;HMDB0000132;–;–;–;Nucleotide;Purine metabolism, guanine containing;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8100977015;0,2758179128;0,3410818697;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4401;;
acetylcarnitine;acetylcarnitine;acetylcarnitine;–;–;–;HMDB0000201;–;–;–;Lipid;Carnitine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8033286478;0,0064253646;0,0132428877;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4402;;
isovalerylglycine;isovalerylglycine;isovalerylglycine;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,8008969224;0,0001542878;0,0002760576;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4403;;
gamma-glutamylglutamine;gamma-glutamylglutamine;gamma-glutamylglutamine;–;–;–;–;–;–;–;Peptide;gamma-glutamyl;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7967684014;0,0334364841;0,0547709572;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4404;;
glycolithocholate sulfate;glycolithocholate sulfate;glycolithocholate sulfate;*;–;–;–;–;–;–;Lipid;Bile acid metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7966091973;0,0004416896;0,0012043585;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4405;;
p-cresol sulfate;p-cresol sulfate;p-cresol sulfate;–;–;–;–;–;–;–;Amino acid;Phenylalanine & tyrosine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7955232564;3,49051870849457E-007;3,40519491784248E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4406;;
phenylcarnitine;phenylcarnitine;phenylcarnitine;*;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,795227143;0,0570956664;0,0718648924;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4407;;
betaine;betaine;betaine;–;–;–;HMDB0000043;–;–;–;Amino acid;Glycine, serine and threonine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7941464401;0,0020345645;0,0047257874;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4408;;
azelate;azelate;azelate;(nonanedioate);–;–;–;–;–;–;Lipid;Fatty acid, dicarboxylate;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7937356969;0,0001477652;0,0004734959;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4409;;
saccharin;saccharin;saccharin;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7919334542;0,0012488766;0,0019734724;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4410;;
phenylacetylglutamine;phenylacetylglutamine;phenylacetylglutamine;–;–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7918749277;3,73854015277172E-009;1,55383075099575E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4411;;
acetylcarnitine;acetylcarnitine;acetylcarnitine;–;–;–;HMDB0000201;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7887263598;0,000007683;1,69364727571727E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4412;;
pelargonate;pelargonate;pelargonate;(9:0);–;–;–;–;–;–;Lipid;Medium chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7827941256;4,52683711872277E-006;2,58088505859649E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4413;;
maltose;maltose;maltose;–;–;–;–;–;–;–;Carbohydrate;Fructose, mannose, galactose, starch, and sucrose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7746402603;0,1479370579;0,2035873618;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4414;;
7-alpha-hydroxy-3-oxo-4-cholestenoate;7-alpha-hydroxy-3-oxo-4-cholestenoate;7-alpha-hydroxy-3-oxo-4-cholestenoate;(7-Hoca);–;–;–;–;–;–;Lipid;Sterol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7731308825;0,0778147154;0,0968738578;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4415;;
N-palmitoyltaurine;N-palmitoyltaurine;N-palmitoyltaurine;–;–;–;–;–;–;–;Lipid;Endocannabinoid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7649845752;0,0790699315;0,0982831858;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4416;;
carnitine;carnitine;carnitine;–;–;–;HMDB0000062;–;–;–;Lipid;Carnitine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7621095031;1,28278078810102E-005;2,70893216369021E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4417;;
N-ethylglycinexylidide;N-ethylglycinexylidide;N-ethylglycinexylidide;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7597729696;0,0011718022;0,0018590421;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4418;;
deoxycholate;deoxycholate;deoxycholate;–;–;–;–;–;–;–;Lipid;Secondary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7587968237;0,0037567821;0,0055827041;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4419;;
N-acetyltyrosine;N-acetyltyrosine;N-acetyltyrosine;–;–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7571164194;0,0008788837;0,0014197352;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4420;;
16a-hydroxy dhea 3-sulfate;16a-hydroxy dhea 3-sulfate;16a-hydroxy dhea 3-sulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7541094271;0,008509216;0,0119548492;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4421;;
3-phenylpropionate;3-phenylpropionate;3-phenylpropionate;(hydrocinnamate);–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7538290825;0,0035449625;0,0052777613;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4422;;
maltose;maltose;maltose;–;–;–;–;–;–;–;Carbohydrate;Glycogen Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7533180324;0,0476639483;0,0614472226;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4423;;
pyridoxate;pyridoxate;pyridoxate;–;–;–;–;–;–;–;Cofactors and Vitamins;Vitamin B6 Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7531724259;8,62880066396768E-009;3,2634042321546E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4424;;
octanoylcarnitine;octanoylcarnitine;octanoylcarnitine;–;–;–;HMDB0000791;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7530066822;0,0959344901;0,1174167532;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4425;;
4-methyl-2-oxopentanoate;4-methyl-2-oxopentanoate;4-methyl-2-oxopentanoate;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7524487395;0,0045081213;0,0066130161;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4426;;
4-hydroxyhippurate;4-hydroxyhippurate;4-hydroxyhippurate;–;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7522365509;0,0030418042;0,004571299;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4427;;
stearidonate;stearidonate;stearidonate;(18:4n3);–;–;–;–;–;–;Lipid;Long chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7518232835;0,0234364104;0,040827715;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4428;;
catechol sulfate;catechol sulfate;catechol sulfate;–;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7499193322;2,8456483864535E-011;2,14229001168858E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4429;;
scyllo-inositol;scyllo-inositol;scyllo-inositol;–;–;–;–;–;–;–;Lipid;Inositol Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7485616096;0,0015543294;0,0024320683;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4430;;
phenol sulfate;phenol sulfate;phenol sulfate;–;–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7482115266;2,77956104640459E-010;1,52971704484887E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4431;;
gamma-glutamylglutamate;gamma-glutamylglutamate;gamma-glutamylglutamate;–;–;–;–;–;–;–;Peptide;gamma-glutamyl;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7479058146;0,0121410757;0,0236885877;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4432;;
6-keto prostaglandin F1alpha;6-keto prostaglandin F1alpha;6-keto prostaglandin F1alpha;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7478940855;0,1806309367;0,212287905;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4433;;
1-palmitoylglycerophosphoserine;1-palmitoylglycerophosphoserine;1-palmitoylglycerophosphoserine;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,747654192;0,0921755378;0,1135124678;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4434;;
indolepropionate;indolepropionate;indolepropionate;–;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7474157668;0,0161532501;0,0220724204;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4435;;
5-alpha-androstan-3alpha,17beta-diol disulfate;5-alpha-androstan-3alpha,17beta-diol disulfate;5-alpha-androstan-3alpha,17beta-diol disulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7473168601;0,0011821382;0,0018717189;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4436;;
laurate;laurate;laurate;(12:0);–;–;–;–;–;–;Lipid;Medium chain fatty acid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7466791271;1,02723370804987E-005;4,9016912808032E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4437;;
benzoate;benzoate;benzoate;–;–;–;–;–;–;–;Xenobiotics;Benzoate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7407865464;3,95659314267996E-008;6,947777558546E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4438;;
pseudoephedrine;pseudoephedrine;pseudoephedrine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7403644559;0,0143171104;0,0273270064;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4439;;
phenol sulfate;phenol sulfate;phenol sulfate;–;–;–;–;–;–;–;Amino acid;Phenylalanine & tyrosine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7397585652;3,08939056390354E-009;1,35624245755365E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4440;;
gluconate;gluconate;gluconate;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7367868372;0,0314559683;0,0412181654;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4441;;
1,3-dipalmitoylglycerol;1,3-dipalmitoylglycerol;1,3-dipalmitoylglycerol;–;–;–;–;–;–;–;Lipid;Diacylglycerol;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7358442807;0,0039502522;0,005859296;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4442;;
3-indoxyl sulfate;3-indoxyl sulfate;3-indoxyl sulfate;–;–;–;–;–;–;–;Amino acid;Tryptophan metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,734189035;2,06249207053073E-005;9,05434018962989E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4443;;
3-indoxyl sulfate;3-indoxyl sulfate;3-indoxyl sulfate;–;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7313343705;3,88710118431222E-006;0,000008991;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4444;;
androsterone sulfate;androsterone sulfate;androsterone sulfate;–;–;–;–;–;–;–;Lipid;Sterol/Steroid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7301288626;2,09644184826227E-006;1,29625066392554E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4445;;
p-cresol sulfate;p-cresol sulfate;p-cresol sulfate;–;–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7280468552;3,81924696185136E-010;0,000000002;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4446;;
sphingosine;sphingosine;sphingosine;–;–;–;HMDB0000252;–;–;–;Lipid;Sphingolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7248445813;0,2088985804;0,2437150104;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4447;;
malonylcarnitine;malonylcarnitine;malonylcarnitine;–;–;–;–;–;–;–;Lipid;Fatty Acid Synthesis;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7240406897;0,0002770798;0,0004744843;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4448;;
quinate;quinate;quinate;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7235485957;1,9178847526415E-006;4,6518906766198E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4449;;
prostaglandin D2;prostaglandin D2;prostaglandin D2;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,722435825;0,0383171404;0,0498810409;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4450;;
sphinganine;sphinganine;sphinganine;–;–;–;HMDB0000269;–;–;–;Lipid;Sphingolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,722190741;0,1349590664;0,1868991488;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4451;;
o-methylcatechol sulfate;o-methylcatechol sulfate;o-methylcatechol sulfate;–;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,721421932;1,87176084997721E-010;1,10641863576431E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4452;;
DSGEGDFXAEGGGVR;DSGEGDFXAEGGGVR;DSGEGDFXAEGGGVR;–;–;–;–;–;–;–;Peptide;Fibrinogen Cleavage Peptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7153140597;0,0195791449;0,0263032957;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4453;;
N-ethylglycinexylidide;N-ethylglycinexylidide;N-ethylglycinexylidide;*;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7141652838;6,23168009579443E-005;0,0002279756;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4454;;
taurolithocholate 3-sulfate;taurolithocholate 3-sulfate;taurolithocholate 3-sulfate;–;–;–;–;–;–;–;Lipid;Secondary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7139321262;0,0002918602;0,0004987246;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4455;;
3-methylglutarylcarnitine;3-methylglutarylcarnitine;3-methylglutarylcarnitine;-1;–;–;–;–;–;–;Amino Acid;Lysine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7117446504;9,59929152867991E-007;2,49519043644514E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4456;;
lauroylcarnitine;lauroylcarnitine;lauroylcarnitine;–;–;–;–;–;–;–;Lipid;Carnitine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7066944976;0,0034783792;0,0075594478;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4457;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;Amino acid;Tryptophan metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7052205337;0,0026246768;0,0058787404;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4458;;
pregnen-diol disulfate;pregnen-diol disulfate;pregnen-diol disulfate;*;–;–;–;–;–;–;Lipid;Sterol/Steroid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7014065091;8,62690394548497E-006;4,30364867280443E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4459;;
propionylcarnitine;propionylcarnitine;propionylcarnitine;–;–;–;HMDB0000824;–;–;–;Lipid;Fatty acid metabolism (also BCAA metabolism);–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,7011218459;0,0024518696;0,0055483029;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4460;;
creatine phosphate;creatine phosphate;creatine phosphate;–;–;–;–;–;–;–;Amino Acid;Creatine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6987040446;0,0494038411;0,0634851292;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4461;;
4-androsten-3beta,17beta-diol monosulfate;4-androsten-3beta,17beta-diol monosulfate;4-androsten-3beta,17beta-diol monosulfate;-1;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,697768344;3,50315563968411E-005;6,93676972820823E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4462;;
pregn steroid monosulfate;pregn steroid monosulfate;pregn steroid monosulfate;*;–;–;–;–;–;–;Lipid;Sterol/Steroid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6971251359;0,0001115198;0,0003765938;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4463;;
maltopentaose;maltopentaose;maltopentaose;–;–;–;–;–;–;–;Carbohydrate;Fructose, mannose, galactose, starch, and sucrose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6960459701;0,1993236915;0,2619853311;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4464;;
3-methyl-2-oxovalerate;3-methyl-2-oxovalerate;3-methyl-2-oxovalerate;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6917166616;0,0029414052;0,0044539684;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4465;;
maltopentaose;maltopentaose;maltopentaose;–;–;–;–;–;–;–;Carbohydrate;Glycogen Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6907542135;0,0833259812;0,1032517594;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4466;;
androsterone sulfate;androsterone sulfate;androsterone sulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,690083101;1,26573756789402E-008;4,67014856481051E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4467;;
deoxycarnitine;deoxycarnitine;deoxycarnitine;–;–;–;–;–;–;–;Lipid;Carnitine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6895003697;1,43170085288443E-006;3,54812820062664E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4468;;
glutathione, oxidized;glutathione, oxidized;glutathione, oxidized;(GSSG);–;–;–;–;–;–;Amino acid;Glutathione metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6880512827;0,0944665557;0,1396323836;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4469;;
allantoin;allantoin;allantoin;–;–;–;–;–;–;–;Nucleotide;Purine metabolism, urate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6879891514;0,0014842884;0,0036000144;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4470;;
pregnenolone sulfate;pregnenolone sulfate;pregnenolone sulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6863466791;0,0002310155;0,0004033925;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4471;;
glucose;glucose;glucose;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,686209598;1,5526591806776E-006;3,81237546517146E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4472;;
3-carboxy-4-methyl-5-propyl-2-furanpropanoate;3-carboxy-4-methyl-5-propyl-2-furanpropanoate;3-carboxy-4-methyl-5-propyl-2-furanpropanoate;(CMPF);–;–;–;–;–;–;Lipid;Fatty acid, dicarboxylate;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6845064945;7,41933459076102E-008;0,000000987;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4473;;
5-alpha-pregnan-3alpha,20beta-diol disulfate;5-alpha-pregnan-3alpha,20beta-diol disulfate;5-alpha-pregnan-3alpha,20beta-diol disulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6841951293;5,39371026499182E-005;0,0001027251;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4474;;
3-methyl catechol sulfate;3-methyl catechol sulfate;3-methyl catechol sulfate;-1;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6778717719;0,000000236;6,67715286300278E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4475;;
4-androsten-3beta,17beta-diol disulfate;4-androsten-3beta,17beta-diol disulfate;4-androsten-3beta,17beta-diol disulfate;*;–;–;–;–;–;–;Lipid;Sterol/Steroid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6633782313;2,42791441839529E-008;5,26610992551227E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4476;;
cysteine sulfinic acid;cysteine sulfinic acid;cysteine sulfinic acid;–;–;–;–;–;–;–;Amino acid;Cysteine, methionine, SAM, taurine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6629706715;0,00068746;0,0017997036;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4477;;
dehydroisoandrosterone sulfate;dehydroisoandrosterone sulfate;dehydroisoandrosterone sulfate;(DHEA-S);–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6626389052;3,75082467953446E-008;1,24197431297448E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4478;;
3-methyl-2-oxobutyrate;3-methyl-2-oxobutyrate;3-methyl-2-oxobutyrate;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,657625225;0,0005824432;0,0009583293;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4479;;
epiandrosterone sulfate;epiandrosterone sulfate;epiandrosterone sulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6554252044;8,99581700980562E-007;2,3691953708993E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4480;;
pregn steroid monosulfate;pregn steroid monosulfate;pregn steroid monosulfate;*;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6473547383;8,31913658862289E-008;2,6239806315103E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4481;;
4-allylphenol sulfate;4-allylphenol sulfate;4-allylphenol sulfate;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6473273964;4,58889266661175E-006;1,05228055975752E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4482;;
4-methylcatechol sulfate;4-methylcatechol sulfate;4-methylcatechol sulfate;–;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6469058143;4,38179057899356E-010;2,27056420911485E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4483;;
glucose;glucose;glucose;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, gluconeogenesis, pyruvate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6439387178;5,82827335532788E-005;0,0002159696;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4484;;
3-carboxy-4-methyl-5-propyl-2-furanpropanoate;3-carboxy-4-methyl-5-propyl-2-furanpropanoate;3-carboxy-4-methyl-5-propyl-2-furanpropanoate;(CMPF);–;–;–;–;–;–;Lipid;Fatty Acid, Dicarboxylate;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6418594693;3,39476630860028E-010;1,84287313895444E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4485;;
glycolithocholate sulfate;glycolithocholate sulfate;glycolithocholate sulfate;*;–;–;–;–;–;–;Lipid;Secondary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6389912448;1,41719468084238E-008;5,14055161505553E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4486;;
pregnen-diol disulfate;pregnen-diol disulfate;pregnen-diol disulfate;*;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6384492835;6,38690886671776E-009;0,000000025;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4487;;
stearoyl sphingomyelin;stearoyl sphingomyelin;stearoyl sphingomyelin;–;–;–;–;–;–;–;Lipid;Sphingolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6374763827;0,000001702;1,11376833578951E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4488;;
oleoyl sphingomyelin;oleoyl sphingomyelin;oleoyl sphingomyelin;–;–;–;–;–;–;–;Lipid;Sphingolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6361942723;1,0622594679989E-006;2,75221771254261E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4489;;
sphingosine;sphingosine;sphingosine;–;–;–;HMDB0000252;–;–;–;Lipid;Sphingolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,632421952;0,1041264801;0,1500272431;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4490;;
5-alpha-androstan-3beta,17beta-diol disulfate;5-alpha-androstan-3beta,17beta-diol disulfate;5-alpha-androstan-3beta,17beta-diol disulfate;–;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6317300779;1,08763950876675E-007;3,32542654404548E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4491;;
citrate;citrate;citrate;–;–;–;–;–;–;–;Energy;TCA Cycle;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6296459865;0,0013663875;0,0021548957;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4492;;
gamma-glutamylglutamate;gamma-glutamylglutamate;gamma-glutamylglutamate;–;–;–;–;–;–;–;Peptide;Gamma-glutamyl Amino Acid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,62728797;2,11717262695523E-005;0,000043432;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4493;;
citrate;citrate;citrate;–;–;–;–;–;–;–;Energy;Krebs cycle;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,625915471;0,0001573867;0,0004970703;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4494;;
glycocholenate sulfate;glycocholenate sulfate;glycocholenate sulfate;*;–;–;–;–;–;–;Lipid;Secondary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6257134665;2,87552667918477E-007;8,0233226922708E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4495;;
valyllysine;valyllysine;valyllysine;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6213050564;0,0473552117;0,0611479918;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4496;;
4-androsten-3beta,17beta-diol disulfate;4-androsten-3beta,17beta-diol disulfate;4-androsten-3beta,17beta-diol disulfate;-1;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6178749716;4,24078089348816E-010;2,22640996908128E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4497;;
6-phosphogluconate;6-phosphogluconate;6-phosphogluconate;–;–;–;–;–;–;–;Carbohydrate;Nucleotide sugars, pentose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,614901049;7,20931224000715E-005;0,0002574708;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4498;;
maltotriose;maltotriose;maltotriose;–;–;–;–;–;–;–;Carbohydrate;Fructose, mannose, galactose, starch, and sucrose metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6102185859;0,0250176277;0,0427343913;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4499;;
2-oleoylglycerophosphoglycerol;2-oleoylglycerophosphoglycerol;2-oleoylglycerophosphoglycerol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,608340417;4,51355452527363E-005;8,67907593052617E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4500;;
4-androsten-3beta,17beta-diol disulfate;4-androsten-3beta,17beta-diol disulfate;4-androsten-3beta,17beta-diol disulfate;-2;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6068216759;1,05568834600397E-009;0,000000005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4501;;
pseudoephedrine;pseudoephedrine;pseudoephedrine;–;–;–;–;–;–;–;Xenobiotics;Drug;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6066708144;1,5782296359828E-005;3,32302704357328E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4502;;
ophthalmate;ophthalmate;ophthalmate;–;–;–;–;–;–;–;Amino acid;Glutathione metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6039541268;7,55368720336307E-006;3,85589381660045E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4503;;
taurocholenate sulfate;taurocholenate sulfate;taurocholenate sulfate;–;–;–;–;–;–;–;Lipid;Secondary Bile Acid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,6003037164;3,39286516089334E-006;7,93990146156271E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4504;;
propionylcarnitine;propionylcarnitine;propionylcarnitine;–;–;–;HMDB0000824;–;–;–;Lipid;Fatty Acid Metabolism (also BCAA Metabolism);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5995030763;3,79037026729948E-005;7,39734762270482E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4505;;
acetylphosphate;acetylphosphate;acetylphosphate;–;–;–;–;–;–;–;Energy;Oxidative Phosphorylation;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5988628707;2,28338833207648E-010;1,31294225632318E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4506;;
palmitoyl-oleoyl-glycerophosphoglycerol;palmitoyl-oleoyl-glycerophosphoglycerol;palmitoyl-oleoyl-glycerophosphoglycerol;(2)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5920347564;1,80970448516762E-008;6,53458904598986E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4507;;
cinnamoylglycine;cinnamoylglycine;cinnamoylglycine;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5858880061;1,45246047625161E-009;6,62321977170732E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4508;;
2-palmitoylglycerophosphoglycerol;2-palmitoylglycerophosphoglycerol;2-palmitoylglycerophosphoglycerol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5798823482;0,0073742153;0,0104708608;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4509;;
maltotetraose;maltotetraose;maltotetraose;–;–;–;–;–;–;–;Carbohydrate;Oligosaccharide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5780187049;0,0077602706;0,0156993493;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4510;;
tartronate;tartronate;tartronate;(hydroxymalonate);–;–;–;–;–;–;Xenobiotics;Bacterial/Fungal;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5766102291;0,0006775669;0,0011034661;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4511;;
corticosterone;corticosterone;corticosterone;–;–;–;–;–;–;–;Lipid;Steroid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5751686714;0,0001538931;0,00027597;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4512;;
isobutyrylglycine;isobutyrylglycine;isobutyrylglycine;–;–;–;–;–;–;–;Amino Acid;Leucine, Isoleucine and Valine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5748512026;2,92853263237753E-007;8,14274927051312E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4513;;
dehydroisoandrosterone sulfate;dehydroisoandrosterone sulfate;dehydroisoandrosterone sulfate;(DHEA-S);–;–;–;–;–;–;Lipid;Sterol/Steroid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5694900856;0,000000673;5,5741285415015E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4514;;
2-aminophenol sulfate;2-aminophenol sulfate;2-aminophenol sulfate;–;–;–;–;–;–;–;Xenobiotics;Chemical;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,551050582;1,43272879884539E-009;6,57079069815302E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4515;;
nervonoyl sphingomyelin;nervonoyl sphingomyelin;nervonoyl sphingomyelin;*;–;–;–;–;–;–;Lipid;Sphingolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5454855383;8,66948496408638E-011;5,57923306559752E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4516;;
histamine;histamine;histamine;–;–;–;–;–;–;–;Amino acid;Histidine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5445950221;0,0001192708;0,0003966657;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4517;;
6-phosphogluconate;6-phosphogluconate;6-phosphogluconate;–;–;–;–;–;–;–;Carbohydrate;Pentose Phosphate Pathway;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5428746719;0,0002059207;0,0003635502;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4518;;
VGAHAGEYGAEALER;VGAHAGEYGAEALER;VGAHAGEYGAEALER;*;–;–;–;–;–;–;Peptide;Polypeptide;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5382315216;0,000023377;0,000098678;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4519;;
octanoylcarnitine;octanoylcarnitine;octanoylcarnitine;–;–;–;HMDB0000791;–;–;–;Lipid;Carnitine metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5334261468;0,000001136;8,3116633361038E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4520;;
palmitoyl-palmitoyl-glycerophosphocholine;palmitoyl-palmitoyl-glycerophosphocholine;palmitoyl-palmitoyl-glycerophosphocholine;(1)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5332638423;4,56294095081861E-010;2,34917863145371E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4521;;
tartarate;tartarate;tartarate;–;–;–;–;–;–;–;Xenobiotics;Food Component/Plant;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5328930795;3,4699443412564E-010;1,87095647589365E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4522;;
glycerate;glycerate;glycerate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, gluconeogenesis, pyruvate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5303366565;9,88342216069701E-008;1,23966352244171E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4523;;
4-ethylphenylsulfate;4-ethylphenylsulfate;4-ethylphenylsulfate;–;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5282392472;6,21350178390268E-013;8,12848266156449E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4524;;
lysylproline;lysylproline;lysylproline;–;–;–;–;–;–;–;Peptide;Dipeptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5167680791;0,0005736987;0,0009498164;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4525;;
allantoin;allantoin;allantoin;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5163282555;1,04995342383349E-012;1,19694690317018E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4526;;
1-stearoylglycerophosphoglycerol;1-stearoylglycerophosphoglycerol;1-stearoylglycerophosphoglycerol;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5138235881;8,32829153556098E-005;0,0001531331;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4527;;
nicotinamide adenine dinucleotide reduced;nicotinamide adenine dinucleotide reduced;nicotinamide adenine dinucleotide reduced;(NADH);–;–;–;–;–;–;Cofactors and vitamins;Nicotinate and nicotinamide metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5054477434;8,25358751876337E-006;4,16474128820359E-005;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4528;;
maltotetraose;maltotetraose;maltotetraose;–;–;–;–;–;–;–;Carbohydrate;Glycogen Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,5019778854;0,0014530931;0,0022826147;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4529;;
stearoyl sphingomyelin;stearoyl sphingomyelin;stearoyl sphingomyelin;–;–;–;–;–;–;–;Lipid;Sphingolipid Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,4983787836;7,89947179642542E-013;1,01673846670121E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4530;;
o-cresol sulfate;o-cresol sulfate;o-cresol sulfate;–;–;–;–;–;–;–;Amino Acid;Phenylalanine and Tyrosine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,4923031281;1,01574066609056E-010;6,43302421857355E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4531;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;Amino Acid;Histidine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,4911561983;0,000168031;0,0002993053;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4532;;
decanoylcarnitine;decanoylcarnitine;decanoylcarnitine;–;–;–;HMDB0000651;–;–;–;Lipid;Fatty Acid Metabolism(Acyl Carnitine);–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,4837512947;1,30272679172472E-006;3,26910685470542E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4533;;
palmitoyl-palmitoyl-glycerophosphocholine;palmitoyl-palmitoyl-glycerophosphocholine;palmitoyl-palmitoyl-glycerophosphocholine;(2)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,4772638997;1,18629171366313E-014;3,15553595834393E-013;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4534;;
inosine 5'-triphosphate;inosine 5'-triphosphate;inosine 5'-triphosphate;–;–;–;–;–;–;–;Nucleotide;Purine Metabolism, (Hypo)Xanthine/Inosine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,465163205;3,36442905689547E-009;1,4130602038961E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4535;;
maltotriose;maltotriose;maltotriose;–;–;–;–;–;–;–;Carbohydrate;Glycogen Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,4611922386;0,0005959052;0,0009784617;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4536;;
cys-gly, oxidized;cys-gly, oxidized;cys-gly, oxidized;–;–;–;–;–;–;–;Amino Acid;Glutathione Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,4581372035;6,79043864483813E-005;0,0001263117;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4537;;
1-palmitoylglycerophosphoglycerol;1-palmitoylglycerophosphoglycerol;1-palmitoylglycerophosphoglycerol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,4524084806;5,65416835152723E-005;0,0001074292;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4538;;
maltohexaose;maltohexaose;maltohexaose;–;–;–;–;–;–;–;Carbohydrate;Glycogen Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,4366001548;0,0001131197;0,0002042297;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4539;;
1-oleoylglycerophosphoglycerol;1-oleoylglycerophosphoglycerol;1-oleoylglycerophosphoglycerol;*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,4356005713;2,69104590052904E-008;9,1771565325734E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4540;;
4-vinylphenol sulfate;4-vinylphenol sulfate;4-vinylphenol sulfate;–;–;–;–;–;–;–;Xenobiotics;Benzoate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,4284427779;2,69851249950439E-010;1,49542567680868E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4541;;
threonate;threonate;threonate;–;–;–;–;–;–;–;Cofactors and vitamins;Ascorbate and aldarate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,4260357876;0,000000002;9,97085195082397E-008;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4542;;
betaine aldehyde;betaine aldehyde;betaine aldehyde;–;–;–;–;–;–;–;Amino Acid;Glycine, Serine and Threonine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,3816952526;1,53379156045018E-009;6,91506025558893E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4543;;
glycerate;glycerate;glycerate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,377588261;1,47604218950956E-016;1,07080151566239E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4544;;
1-stearoylglycerophosphoglycerol;1-stearoylglycerophosphoglycerol;1-stearoylglycerophosphoglycerol;–;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,3693254075;9,41106097516241E-008;1,21513404944009E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4545;;
12-HETE;12-HETE;12-HETE;–;–;–;–;–;–;–;Lipid;Eicosanoid;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,3521888318;3,11568328629035E-008;6,21720437582483E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4546;;
3-phosphoglycerate;3-phosphoglycerate;3-phosphoglycerate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, gluconeogenesis, pyruvate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,3494012365;8,66971070566599E-011;7,61200599957474E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4547;;
threonate;threonate;threonate;–;–;–;–;–;–;–;Cofactors and Vitamins;Ascorbate and Aldarate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,3434578383;3,41338187648438E-013;4,86406917399024E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4548;;
palmitoyl-oleoyl-glycerophosphoglycerol;palmitoyl-oleoyl-glycerophosphoglycerol;palmitoyl-oleoyl-glycerophosphoglycerol;(1)*;–;–;–;–;–;–;Lipid;Lysolipid;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,3142195017;1,69996161960067E-012;1,83320185465045E-011;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4549;;
N-methylglutamate;N-methylglutamate;N-methylglutamate;–;–;–;–;–;–;–;Amino Acid;Glutamate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,3023250285;1,16596601645301E-009;5,37827098918789E-009;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4550;;
2-phosphoglycerate;2-phosphoglycerate;2-phosphoglycerate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, gluconeogenesis, pyruvate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,2960458876;5,51565582447168E-008;8,2424634382448E-007;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4551;;
heme;heme;heme;–;–;–;–;–;–;–;Cofactors and vitamins;Hemoglobin and porphyrin metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,2769787299;0,00000013;1,50230618640656E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4552;;
ADSGEGDFXAEGGGVR;ADSGEGDFXAEGGGVR;ADSGEGDFXAEGGGVR;*;–;–;–;–;–;–;Peptide;Fibrinogen Cleavage Peptide;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,2598821407;3,76493694798493E-006;8,73377815259296E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4553;;
2-phosphoglycerate;2-phosphoglycerate;2-phosphoglycerate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,2464932062;2,59182556879984E-016;1,5909821568479E-014;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4554;;
phosphoenolpyruvate;phosphoenolpyruvate;phosphoenolpyruvate;(PEP);–;–;–;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,2385083505;5,86206687444359E-014;1,1694823414515E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4555;;
5-hydroxyindoleacetate;5-hydroxyindoleacetate;5-hydroxyindoleacetate;–;–;–;–;–;–;–;Amino Acid;Tryptophan Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,2270587589;6,41815057547901E-011;4,26807013269354E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4556;;
phosphoenolpyruvate;phosphoenolpyruvate;phosphoenolpyruvate;(PEP);–;–;–;–;–;–;Carbohydrate;Glycolysis, gluconeogenesis, pyruvate metabolism;–;tissue;therapy, diagnosis;adenocarcinoma;I, II, III;33;24, 9;62.11 ± 9.73;–;tumor vs. adjacent normal tissue;33;24, 9;62.11 ± 9.73;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,2230905378;8,13190519901077E-012;8,92476595591432E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4557;;
3-phosphoglycerate;3-phosphoglycerate;3-phosphoglycerate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,210463356;1,07265202611819E-013;1,78328399342149E-012;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4558;;
guanine;guanine;guanine;–;–;–;HMDB0000132;–;–;–;Nucleotide;Purine Metabolism, Guanine containing;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,1916543513;1,14064277146172E-006;2,91741324239246E-006;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4559;;
heme;heme;heme;–;–;–;–;–;–;–;Cofactors and Vitamins;Hemoglobin and Porphyrin Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,1705151424;2,59608629571183E-011;1,97302558474099E-010;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4560;;
2,3-diphosphoglycerate;2,3-diphosphoglycerate;2,3-diphosphoglycerate;–;–;–;–;–;–;–;Carbohydrate;Glycolysis, Gluconeogenesis, and Pyruvate Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,1573718838;1,90113511937762E-019;7,5855291263167E-017;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4561;;
4-imidazoleacetate;4-imidazoleacetate;4-imidazoleacetate;–;–;–;–;–;–;–;Amino Acid;Histidine Metabolism;–;tissue;therapy, diagnosis;squamous cell carcinoma;I, II, III;35;35, 0;68.71 ± 7.46;–;tumor vs. adjacent normal tissue;35;35, 0;68.71 ± 7.46;–;LC, GC;ESI, EI;both;LC: linear ion-trap, GC: single-quadrupole ;LC: MS/MS ;–;KEGG, HMDB;pheatmap 1.0.8, ggplot2 2.2.1, mixOmics 6.3.1, MetaboAnalyztR 0.0.0.9;paired two-sample t-test, PLS-DA;–;–;0,1309491332;1,01817756686521E-017;2,15867183357571E-015;–;–;–;–;–;–;–;–;–;–;–;–;Spain;–;–;30099851;Moreno et al. 2018;4562;;
reduced glutathione;reduced glutathione;reduced glutathione;–;–;–;–;–;–;–;–;–;–;lymph node aspirates;diagnosis;adenocarcinoma, squamous cell carcinoma;II, III, IV;50;31, 19;–;–;non-malignant;29;15, 14;–;–;LC;ESI;positive;Q-TOF;MS/MS;MassHunter, MassProfilerProfessional;HMDB;R package;OPLS-DA, PLS-DA;–;–;4,62;0,043;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;30104001;Sappington et al. 2018;4563;;
oxidized glutathione;oxidized glutathione;oxidized glutathione;–;–;–;HMDB0003337;–;–;–;–;–;–;lymph node aspirates;diagnosis;adenocarcinoma, squamous cell carcinoma;II, III, IV;50;31, 19;–;–;non-malignant;29;15, 14;–;–;LC;ESI;positive;Q-TOF;MS/MS;MassHunter, MassProfilerProfessional;HMDB;R package;OPLS-DA, PLS-DA;–;–;2,53;0,0009;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;30104001;Sappington et al. 2018;4564;;
oxidized glutathione;oxidized glutathione;oxidized glutathione;–;–;–;HMDB0003337;–;–;–;–;–;–;lymph node aspirates;diagnosis;adenocarcinoma;II, III, IV;31;17, 14;–;–;squamous cell carcinoma;19;14, 5;–;–;LC;ESI;positive;Q-TOF;MS/MS;MassHunter, MassProfilerProfessional;HMDB;R package;OPLS-DA, PLS-DA;–;–;1,57;0,17;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;30104001;Sappington et al. 2018;4565;;
reduced glutathione;reduced glutathione;reduced glutathione;–;–;–;–;–;–;–;–;–;–;lymph node aspirates;diagnosis;adenocarcinoma;II, III, IV;31;17, 14;–;–;squamous cell carcinoma;19;14, 5;–;–;LC;ESI;positive;Q-TOF;MS/MS;MassHunter, MassProfilerProfessional;HMDB;R package;OPLS-DA, PLS-DA;–;–;1,54;0,57;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;30104001;Sappington et al. 2018;4566;;
glutamate;glutamate;glutamate;–;–;–;–;–;–;–;–;–;–;lymph node aspirates;diagnosis;adenocarcinoma, squamous cell carcinoma;II, III, IV;50;31, 19;–;–;non-malignant;29;15, 14;–;–;LC;ESI;positive;Q-TOF;MS/MS;MassHunter, MassProfilerProfessional;HMDB;R package;OPLS-DA, PLS-DA;–;–;1,44;0,045;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;30104001;Sappington et al. 2018;4567;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;–;–;–;lymph node aspirates;diagnosis;adenocarcinoma, squamous cell carcinoma;II, III, IV;50;31, 19;–;–;non-malignant;29;15, 14;–;–;LC;ESI;positive;Q-TOF;MS/MS;MassHunter, MassProfilerProfessional;HMDB;R package;OPLS-DA, PLS-DA;–;–;1,36;0,139;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;30104001;Sappington et al. 2018;4568;;
glutamate;glutamate;glutamate;–;–;–;–;–;–;–;–;–;–;lymph node aspirates;diagnosis;adenocarcinoma;II, III, IV;31;17, 14;–;–;squamous cell carcinoma;19;14, 5;–;–;LC;ESI;positive;Q-TOF;MS/MS;MassHunter, MassProfilerProfessional;HMDB;R package;OPLS-DA, PLS-DA;–;–;1,1;0,74;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;30104001;Sappington et al. 2018;4569;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;–;–;–;lymph node aspirates;diagnosis;adenocarcinoma;II, III, IV;31;17, 14;–;–;squamous cell carcinoma;19;14, 5;–;–;LC;ESI;positive;Q-TOF;MS/MS;MassHunter, MassProfilerProfessional;HMDB;R package;OPLS-DA, PLS-DA;–;–;0,98;0,92;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;30104001;Sappington et al. 2018;4570;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;–;–;–;lymph node aspirates;diagnosis;adenocarcinoma;II, III, IV;31;17, 14;–;–;squamous cell carcinoma;19;14, 5;–;–;LC;ESI;positive;Q-TOF;MS/MS;MassHunter, MassProfilerProfessional;HMDB;R package;OPLS-DA, PLS-DA;–;–;0,97;0,92;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;30104001;Sappington et al. 2018;4571;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;lymph node aspirates;diagnosis;adenocarcinoma;II, III, IV;31;17, 14;–;–;squamous cell carcinoma;19;14, 5;–;–;LC;ESI;positive;Q-TOF;MS/MS;MassHunter, MassProfilerProfessional;HMDB;R package;OPLS-DA, PLS-DA;–;–;0,92;0,7;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;30104001;Sappington et al. 2018;4572;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;lymph node aspirates;diagnosis;adenocarcinoma, squamous cell carcinoma;II, III, IV;50;31, 19;–;–;non-malignant;29;15, 14;–;–;LC;ESI;positive;Q-TOF;MS/MS;MassHunter, MassProfilerProfessional;HMDB;R package;OPLS-DA, PLS-DA;–;–;0,69;0,0076;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;30104001;Sappington et al. 2018;4573;;
tryptophan;tryptophan;tryptophan;–;–;–;–;–;–;–;–;–;–;lymph node aspirates;diagnosis;adenocarcinoma, squamous cell carcinoma;II, III, IV;50;31, 19;–;–;non-malignant;29;15, 14;–;–;LC;ESI;positive;Q-TOF;MS/MS;MassHunter, MassProfilerProfessional;HMDB;R package;OPLS-DA, PLS-DA;–;–;0,59;0,0027;–;–;–;–;–;–;–;–;–;–;–;–;–;US;Y;–;30104001;Sappington et al. 2018;4574;;
urea;urea;urea;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;8,84;0,011;–;1,85;ROC curve analysis ;–;0,7;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4575;;
L-alanine;L-alanine;L-alanine;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;8,6;0,031;–;1,19;ROC curve analysis ;–;0,59;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4576;;
succinic acid;succinic acid;succinic acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;7,21;0,033;–;1,42;ROC curve analysis ;–;0,81;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4577;;
butanoic acid;butanoic acid;butanoic acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;5,17;0,01;–;1,52;ROC curve analysis ;–;0,68;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4578;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;4,25;0,044;–;1,99;ROC curve analysis ;–;0,75;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4579;;
deoxy-glucose;deoxy-glucose;deoxy-glucose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;4,24;0,046;–;2,31;ROC curve analysis ;–;0,8;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4580;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;4,12;0,013;–;1,79;ROC curve analysis ;–;0,74;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4581;;
L-threonine;L-threonine;L-threonine;–;–;–;HMDB0000167;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;4,07;0,029;–;1,74;ROC curve analysis ;–;0,82;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4582;;
adipic acid;adipic acid;adipic acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;3,96;0,017;–;2,21;ROC curve analysis ;–;0,75;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4583;;
purine;purine;purine;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;3,72;0;–;1,87;ROC curve analysis ;–;0,54;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4584;;
gluconic acid;gluconic acid;gluconic acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;3,35;0,021;–;2,01;ROC curve analysis ;–;0,74;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4585;;
malonic acid;malonic acid;malonic acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;3,31;0,005;–;1,73;ROC curve analysis ;–;0,79;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4586;;
galactaric acid;galactaric acid;galactaric acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;3,26;0,019;–;1,56;ROC curve analysis ;–;0,67;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4587;;
acetic acid;acetic acid;acetic acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;3,17;0,043;–;1,72;ROC curve analysis ;–;0,59;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4588;;
ribonic acid;ribonic acid;ribonic acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;2,91;0,043;–;2;ROC curve analysis ;–;0,66;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4589;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;2,79;0;–;2,1;ROC curve analysis ;–;0,88;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4590;;
ribitol;ribitol;ribitol;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;2,76;0,003;–;1,29;ROC curve analysis ;–;0,79;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4591;;
arabitol;arabitol;arabitol;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;2,72;0,02;–;1,36;ROC curve analysis ;–;0,63;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4592;;
L-serine;L-serine;L-serine;–;–;–;HMDB0000187;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;2,71;0,033;–;1,29;ROC curve analysis ;–;0,61;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4593;;
L-aspartate;L-aspartate;L-aspartate;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;2,41;0,047;–;1,23;ROC curve analysis ;–;0,73;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4594;;
sorbitol;sorbitol;sorbitol;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;2,37;0,003;–;1,24;ROC curve analysis ;–;0,67;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4595;;
glucose;glucose;glucose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;2,29;0,001;–;2,74;ROC curve analysis ;–;0,82;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4596;;
aconitic acid;aconitic acid;aconitic acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;2,09;0;–;1,51;ROC curve analysis ;–;0,81;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4597;;
threonic acid;threonic acid;threonic acid;–;–;–;HMDB0000943;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;2,03;0,009;–;1,93;ROC curve analysis ;–;0,7;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4598;;
L-cysteine;L-cysteine;L-cysteine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,9;0,039;–;1,28;ROC curve analysis ;–;0,64;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4599;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,85;0,032;–;1,53;ROC curve analysis ;–;0,7;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4600;;
glucuronic acid;glucuronic acid;glucuronic acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,84;0,003;–;1,28;ROC curve analysis ;–;0,73;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4601;;
acetic acid;acetic acid;acetic acid;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,71;0,047;–;1,93;ROC curve analysis ;–;0,52;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4602;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,71;0,029;–;1,94;ROC curve analysis ;–;0,67;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4603;;
L-threonine;L-threonine;L-threonine;–;–;–;HMDB0000167;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,54;0,009;–;1,38;ROC curve analysis ;–;0,69;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4604;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,37;0,008;–;2,11;ROC curve analysis ;–;0,69;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4605;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,36;0,022;–;1,88;ROC curve analysis ;–;0,64;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4606;;
L-phenylalanine;L-phenylalanine;L-phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,03;0,022;–;7,53;ROC curve analysis ;–;0,73;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4607;;
malonic acid;malonic acid;malonic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;1,02;0,002;–;1,02;ROC curve analysis ;–;0,75;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4608;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,94;0,037;–;2,01;ROC curve analysis ;–;0,53;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4609;;
L-glycine;L-glycine;L-glycine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,91;0,022;–;1,33;ROC curve analysis ;–;0,76;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4610;;
L-cysteine;L-cysteine;L-cysteine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,91;0,009;–;1,48;ROC curve analysis ;–;0,54;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4611;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,82;0,005;–;1,63;ROC curve analysis ;–;0,77;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4612;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,78;0,023;–;1,45;ROC curve analysis ;–;0,54;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4613;;
isocitric acid;isocitric acid;isocitric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,77;0,013;–;2,27;ROC curve analysis ;–;0,61;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4614;;
L-ornithine;L-ornithine;L-ornithine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,7;0,018;–;8,97;ROC curve analysis ;–;0,65;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4615;;
fructose;fructose;fructose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,69;0,009;–;2,24;ROC curve analysis ;–;0,75;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4616;;
L-proline;L-proline;L-proline;–;–;–;HMDB0000162;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,68;0,042;–;1,01;ROC curve analysis ;–;0,63;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4617;;
L-serine;L-serine;L-serine;–;–;–;HMDB0000187;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,67;0,012;–;1,12;ROC curve analysis ;–;0,67;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4618;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,65;0,02;–;1,98;ROC curve analysis ;–;0,67;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4619;;
L-proline;L-proline;L-proline;–;–;–;HMDB0000162;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,64;0,002;–;1,39;ROC curve analysis ;–;0,71;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4620;;
galactose;galactose;galactose;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,63;0,043;–;2,1;ROC curve analysis ;–;0,68;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4621;;
inositol;inositol;inositol;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,63;0,028;–;1,17;ROC curve analysis ;–;0,58;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4622;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,62;0,012;–;1,96;ROC curve analysis ;–;0,65;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4623;;
L-glutamine;L-glutamine;L-glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,61;0,043;–;1,57;ROC curve analysis ;–;0,67;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4624;;
L-glycine;L-glycine;L-glycine;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,6;0,017;–;1,49;ROC curve analysis ;–;0,74;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4625;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,6;0,004;–;5,82;ROC curve analysis ;–;0,76;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4626;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,59;0,004;–;2,18;ROC curve analysis ;–;0,88;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4627;;
fructose;fructose;fructose;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,58;0,017;–;1,66;ROC curve analysis ;–;0,6;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4628;;
inositol;inositol;inositol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,56;0,002;–;1,66;ROC curve analysis ;–;0,74;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4629;;
tartaric acid;tartaric acid;tartaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,54;0,01;–;1,2;ROC curve analysis ;–;0,72;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4630;;
isocitric acid;isocitric acid;isocitric acid;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,53;0,023;–;1,67;ROC curve analysis ;–;0,57;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4631;;
L-valine;L-valine;L-valine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,53;0,001;–;1,5;ROC curve analysis ;–;0,75;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4632;;
L-asparagine;L-asparagine;L-asparagine;–;–;–;HMDB0000168;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,52;0;–;2,57;ROC curve analysis ;–;0,83;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4633;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,5;0,042;–;2,42;ROC curve analysis ;–;0,73;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4634;;
L-glutamine;L-glutamine;L-glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,5;0,033;–;1,44;ROC curve analysis ;–;0,66;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4635;;
L-aspartate;L-aspartate;L-aspartate;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,48;0,047;–;1,35;ROC curve analysis ;–;0,74;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4636;;
hippuric acid;hippuric acid;hippuric acid;–;–;–;HMDB0000714;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,47;0,035;–;2,37;ROC curve analysis ;–;0,69;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4637;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,42;0,047;–;2,12;ROC curve analysis ;–;0,79;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4638;;
margaric acid;margaric acid;margaric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,42;0,012;–;2,24;ROC curve analysis ;–;0,78;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4639;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,41;0,001;–;11,38;ROC curve analysis ;–;0,8;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4640;;
isocitric acid;isocitric acid;isocitric acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,4;0,034;–;1,44;ROC curve analysis ;–;0,75;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4641;;
phosphoric acid;phosphoric acid;phosphoric acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,39;0,011;–;1,61;ROC curve analysis ;–;0,75;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4642;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;serum;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,38;0,003;–;2,64;ROC curve analysis ;–;0,79;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4643;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;bronchoalveolar lavage fluid ;diagnosis;NSCLC, SCLC;–;24;16, 8;65± 12;former, current;noncancerous lung diseases;30;25, 5;55 ± 15;former, current, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,36;0,038;–;1,02;ROC curve analysis ;–;0,63;–;–;–;–;–;–;–;–;Spain;–;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4644;;
L-glycine;L-glycine;L-glycine;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,29;0,005;–;2,46;ROC curve analysis ;–;0,82;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4645;;
inositol;inositol;inositol;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,17;0,005;–;1,59;ROC curve analysis ;–;0,76;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4646;;
glucaric acid;glucaric acid;glucaric acid;–;–;–;–;–;–;–;–;–;–;urine;diagnosis;NSCLC, SCLC;–;32;22, 8;66 ± 12;former, current, non-smoker;healthy;29;18, 11;56 ± 13;former, non-smoker;GC;EI;–;ion trap;–;XCMS;NIST Mass Spectral Library;SIMCA- P, STATISTICA;PLS-LDA, one-way ANOVA;–;–;0,11;0,048;–;2,07;ROC curve analysis ;–;0,93;–;–;–;–;–;–;–;–;Spain;Y;Metabolic pathway analysis;30292984;Callejon-Leblic et al. 2019;4647;;
PC(18:1/20:3);PC(18:1/20:3);PC(18:1/20:3);–;[M + H]+;–;–;–;–;–;–;–;810,505;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;3,16;0,013;–;1,73;ROC curve;–;0,51;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4648;;
inosine;inosine;inosine;–;[M - H]-;–;HMDB0000195;–;–;–;–;–;267,265;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;negative;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;3,14;0,0001;–;2,89;ROC curve;–;0,69;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4649;;
PC(18:0/22:6);PC(18:0/22:6);PC(18:0/22:6);–;[M + Na]+;–;–;–;–;–;–;–;856,547;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;2,99;0,001;–;1,67;ROC curve;–;0,61;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4650;;
adenosine;adenosine;adenosine;–;[M + H]+;–;–;–;–;–;–;–;268,111;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;2,86;0,026;–;1,81;ROC curve;–;0,65;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4651;;
propionylcarnitine;propionylcarnitine;propionylcarnitine;–;[M + H]+;–;HMDB0000824;–;–;–;–;–;204,231;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;2,55;0,0015;–;1,51;ROC curve;–;0,57;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4652;;
butyryl-carnitine;butyryl-carnitine;butyryl-carnitine;–;[M + H]+;–;–;–;–;–;–;–;232,145;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;2,28;0,044;–;1,26;ROC curve;–;0,66;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4653;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;[M - H]-;–;HMDB0003229;–;–;–;–;–;253,208;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;negative;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,97;0,0016;–;1,39;ROC curve;–;0,62;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4654;;
xanthine;xanthine;xanthine;–;[M - H]-;–;HMDB0000292;–;–;–;–;–;151,028;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;negative;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,86;0,022;–;1,83;ROC curve;–;0,52;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4655;;
pentanoyl-carrnitine;pentanoyl-carrnitine;pentanoyl-carrnitine;–;[M + H]+;–;–;–;–;–;–;–;246,117;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,81;0,032;–;2,3;ROC curve;–;0,61;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4656;;
TAG(16:0/18:2/22:6);TAG(16:0/18:2/22:6);TAG(16:0/18:2/22:6);–;[M + NH4]+;–;–;–;–;–;–;–;1024,78;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,69;0,0014;–;1,3;ROC curve;–;0,61;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4657;;
oleic acid;oleic acid;oleic acid;–;[M - H]-;–;HMDB0000207;–;–;–;–;–;281,236;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;negative;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,68;0,012;–;1,48;ROC curve;–;0,64;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4658;;
PC(16:0/18:0);PC(16:0/18:0);PC(16:0/18:0);–;[M + Na]+;–;–;–;–;–;–;–;784,579;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,67;0,014;–;1,17;ROC curve;–;0,67;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4659;;
TAG(16:0/16:0/18:2);TAG(16:0/16:0/18:2);TAG(16:0/16:0/18:2);–;[M + NH4]+;–;–;–;–;–;–;–;948,736;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,67;0,0001;–;1,21;ROC curve;–;0,66;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4660;;
TAG(18:2/18:2/18:1);TAG(18:2/18:2/18:1);TAG(18:2/18:2/18:1);–;[M + NH4]+;–;–;–;–;–;–;–;998,709;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,66;0,001;–;1,22;ROC curve;–;0,55;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4661;;
LPC(16:0);LPC(16:0);LPC(16:0);–;[M + H]+;–;–;–;–;–;–;–;496,346;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,66;0,0005;–;1,01;ROC curve;–;0,72;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4662;;
TAG(14:0/16:0/18:1);TAG(14:0/16:0/18:1);TAG(14:0/16:0/18:1);–;[M + NH4]+;–;–;–;–;–;–;–;922,701;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,62;0,0013;–;1,16;ROC curve;–;0,63;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4663;;
glucose;glucose;glucose;–;[M + Na]+;–;–;–;–;–;–;–;203,53;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,62;0,0005;–;1,73;ROC curve;–;0,65;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4664;;
stearic acid;stearic acid;stearic acid;–;[M - H]-;–;HMDB0000827;–;–;–;–;–;283,247;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;negative;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,57;0,011;–;1,14;ROC curve;–;0,55;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4665;;
PC(18:2/18:2);PC(18:2/18:2);PC(18:2/18:2);–;[M + Na]+;–;–;–;–;–;–;–;804,567;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,52;0,0002;–;1,11;ROC curve;–;0,62;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4666;;
TAG(18:2/18:2/18:2);TAG(18:2/18:2/18:2);TAG(18:2/18:2/18:2);–;[M + NH4]+;–;–;–;–;–;–;–;996,792;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,51;0,0005;–;1,38;ROC curve;–;0,72;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4667;;
PC(16:0/20:5);PC(16:0/20:5);PC(16:0/20:5);–;[M + Na]+;–;–;–;–;–;–;–;802,579;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,5;0,0002;–;1,01;ROC curve;–;0,72;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4668;;
choline;choline;choline;–;[M + H]+;–;HMDB0000097;–;–;–;–;–;104,105;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14 ;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,49;0,0006;–;1,2;ROC curve;–;0,66;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4669;;
TAG(16:0/16:0/16:0);TAG(16:0/16:0/16:0);TAG(16:0/16:0/16:0);–;[M + NH4]+;–;–;–;–;–;–;–;924,715;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,45;0,0003;–;1,1;ROC curve;–;0,64;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4670;;
carnitine;carnitine;carnitine;–;[M + H]+;–;HMDB0000062;–;–;–;–;–;162,107;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,44;0,0002;–;2,11;ROC curve;–;0,73;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4671;;
TAG(16:0/18:1/18:1);TAG(16:0/18:1/18:1);TAG(16:0/18:1/18:1);–;[M + NH4]+;–;–;–;–;–;–;–;976,757;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,43;0,0017;–;1,12;ROC curve;–;0,67;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4672;;
PC(16:0/18:3);PC(16:0/18:3);PC(16:0/18:3);–;[M + Na]+;–;–;–;–;–;–;–;778,597;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,43;0,0004;–;1,1;ROC curve;–;0,65;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4673;;
PC(16:0/16:0);PC(16:0/16:0);PC(16:0/16:0);–;[M + Na]+;–;–;–;–;–;–;–;756,574;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,43;0,0003;–;1,25;ROC curve;–;0,68;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4674;;
PC(16:0/16:1);PC(16:0/16:1);PC(16:0/16:1);–;[M + Na]+;–;–;–;–;–;–;–;754,581;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,43;0,0002;–;1,4;ROC curve;–;0,74;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4675;;
TAG(16:0/16:0/18:1);TAG(16:0/16:0/18:1);TAG(16:0/16:0/18:1);–;[M + NH4]+;–;–;–;–;–;–;–;950,736;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,43;0,0001;–;1,39;ROC curve;–;0,72;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4676;;
threonine;threonine;threonine;–;[M + H]+;–;–;–;–;–;–;–;120,059;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,43;0,0001;–;2,15;ROC curve;–;0,76;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4677;;
TAG(18:3/18:2/18:2);TAG(18:3/18:2/18:2);TAG(18:3/18:2/18:2);–;[M + NH4]+;–;–;–;–;–;–;–;994,712;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,4;0,0011;–;1,07;ROC curve;–;0,69;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4678;;
phosphocholine;phosphocholine;phosphocholine;–;[M + H]+;–;–;–;–;–;–;–;184,111;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,4;0,0001;–;1,81;ROC curve;–;0,71;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4679;;
LPC(18:0);LPC(18:0);LPC(18:0);–;[M + H]+;–;HMDB0010384;–;–;–;–;–;524,388;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,38;0,019;–;1,14;ROC curve;–;0,64;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4680;;
acetic acid;acetic acid;acetic acid;–;[M - H]-;–;–;–;–;–;–;–;59,014;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14 ;former, non-smoker;DI;ESI;negative;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,36;0,003;–;1,27;ROC curve;–;0,54;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4681;;
glutamate;glutamate;glutamate;–;[M + H]+;–;–;–;–;–;–;–;148,035;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,35;0,0002;–;1,35;ROC curve;–;0,71;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4682;;
TAG(16:0/18:2/18:2);TAG(16:0/18:2/18:2);TAG(16:0/18:2/18:2);–;[M + NH4]+;–;–;–;–;–;–;–;972,728;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,35;0,0001;–;1,01;ROC curve;–;0,6;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4683;;
docosatetraenoic acid;docosatetraenoic acid;docosatetraenoic acid;–;[M - H]-;–;–;–;–;–;–;–;330,236;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;negative;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,34;0,004;–;1,68;ROC curve;–;0,55;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4684;;
creatine;creatine;creatine;–;[M - H]+;–;HMDB0000064;–;–;–;–;–;132,071;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,33;0,0012;–;1,89;ROC curve;–;0,7;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4685;;
DAG(18:3/18:1);DAG(18:3/18:1);DAG(18:3/18:1);–;[M + NH4]+;–;–;–;–;–;–;–;634,545;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,32;0,014;–;1,12;ROC curve;–;0,65;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4686;;
docopentaenoic acid;docopentaenoic acid;docopentaenoic acid;–;[M - H]-;–;–;–;–;–;–;–;329,227;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;negative;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,32;0,014;–;1,44;ROC curve;–;0,53;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4687;;
aspartic acid;aspartic acid;aspartic acid;–;[M - H]-;–;–;–;–;–;–;–;132,03;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;negative;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,32;0,004;–;1,02;ROC curve;–;0,53;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4688;;
adenine;adenine;adenine;–;[M - H]-;–;HMDB0000034;–;–;–;–;–;134,05;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;negative;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;1,1;0,005;–;1,35;ROC curve;–;0,58;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4689;;
phosphoethanolamine;phosphoethanolamine;phosphoethanolamine;–;[M + H]+;–;HMDB0000224;–;–;–;–;–;142,128;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;0,77;0,0021;–;1,01;ROC curve;–;0,74;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4690;;
docohexaenoic acid;docohexaenoic acid;docohexaenoic acid;–;[M - H]-;–;–;–;–;–;–;–;327,218;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;negative;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;0,72;0,03;–;1,43;ROC curve;–;0,65;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4691;;
tyrosine;tyrosine;tyrosine;–;[M + H]+;–;HMDB0000158;–;–;–;–;–;182,036;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;0,66;0,0013;–;1,55;ROC curve;–;0,73;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4692;;
phenylalanine;phenylalanine;phenylalanine;–;[M + H]+;–;HMDB0000159;–;–;–;–;–;166,09;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;0,56;0,015;–;2,07;ROC curve;–;0,65;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4693;;
glutathione;glutathione;glutathione;–;[M + H]+;–;HMDB0000125;–;–;–;–;–;308,151;blood;diagnosis;NSCLC, SCLC ;II, III, IV;30;25, 5; 67 ± 12;former, current, non-smoker;healthy;30;14, 16;56 ± 14;former, non-smoker;DI;ESI;positive;Q-TOF;MS/MS;–;HMDB, Metlin;SIMCA-P;PCA, PLS-DA, one-way ANOVA;–;–;0,48;0,0014;–;1,64;ROC curve;–;0,6;–;–;–;–;–;–;–;–;Spain;–;–;30439409;Callej?n-Leblic et al. 2019;4694;;
2-phenylacetamide;2-phenylacetamide;2-phenylacetamide;–;–;–;–;–;–;–;–;–;136,0757;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;–;–;7,2100037009;0,00359;–;1,12;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;4695;;
N1-methyl-2-pyridone-5-carboxamide;N1-methyl-2-pyridone-5-carboxamide;N1-methyl-2-pyridone-5-carboxamide;–;–;–;–;–;–;–;–;–;153,0659;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;–;–;3,7321319661;0,000388;–;1,29;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;4696;;
5-acetamidopentanoate;5-acetamidopentanoate;5-acetamidopentanoate;–;–;–;–;–;–;–;–;–;160,0968;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,4146597729;0,000436;–;1,28;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;4697;;
carnitine C7-COOH;carnitine C7-COOH;carnitine C7-COOH;–;–;–;–;–;–;–;–;–;304,1775;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,3868912484;0,00104;–;1,27;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;4698;;
spermidine;spermidine;spermidine;–;–;–;–;–;–;–;–;–;146,1652;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,3868912484;0,000184;–;1,4;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;4699;;
carnitine C11:1;carnitine C11:1;carnitine C11:1;–;–;–;–;–;–;–;–;–;328,2482;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,2482731239;0,000291;–;1,32;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;4700;;
carnitine C11:2;carnitine C11:2;carnitine C11:2;–;–;–;–;–;–;–;–;–;326,2326;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,2448550744;0,000275;–;1,32;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;4701;;
N-acetylisatin;N-acetylisatin;N-acetylisatin;–;–;–;–;–;–;–;–;–;190,0499;plasma;diagnosis;SCLC;–;20;–;–;–;healthy;20;–;–;–;LC;ESI;both;QTRAP;MS/MS;Analyst, MultiQuant;–;SIMCA-P;OPLS-DA, student’s t-test;–;–;0,1367867127;0,00312;–;1,09;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30473010;Yue et al. 2018;4702;;
salicylic acid;salicylic acid;salicylic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;5,8081310278;0,0000646;0,000909;0,83921;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4703;;
paracetamol;paracetamol;paracetamol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;4,7296420458;2,86E-011;1,21E-010;1,2319;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4704;;
threitol;threitol;threitol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;4,0533619264;1,06E-010;3,58E-009;1,3488;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4705;;
adenosine-5-phosphate;adenosine-5-phosphate;adenosine-5-phosphate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;3,8640774198;2,2E-011;1,21E-009;1,3045;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4706;;
2-hydroxyhippuric acid;2-hydroxyhippuric acid;2-hydroxyhippuric acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;3,8336695854;3,07E-008;0,000000742;0,8596;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4707;;
azelaic acid;azelaic acid;azelaic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;2,3940827185;0,000455;0,004052;0,65377;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4708;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;2,2033107747;0,00000895;0,000151;0,73145;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4709;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;–;–;HMDB0003229;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;2,129112231;0,000105;0,001368;0,73193;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4710;;
butane-2,3-diol;butane-2,3-diol;butane-2,3-diol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;2,1230038684;0,0000581;0,000893;0,7573;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4711;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;Tryptophan metabolism;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;1,8658021362;0,00022;0,002408;0,54953;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4712;;
maltose;maltose;maltose;–;–;–;–;–;–;–;Starch and sucrose metabolism;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;1,7197799733;0,000228;0,002408;0,51667;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4713;;
3-phosphoglycerate;3-phosphoglycerate;3-phosphoglycerate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;1,5997517006;0,004035;0,030999;0,23804;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4714;;
urea;urea;urea;–;–;–;–;–;–;–;Arginine and proline metabolism, Urea cycle;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;1,5299431013;0,000276;0,002596;0,15879;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4715;;
dodecanol;dodecanol;dodecanol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;0,732555515;0,001641;0,013205;1,0168;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4716;;
naproxen;naproxen;naproxen;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;0,7185946004;0,000128;0,001542;1,1766;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4717;;
cystine;cystine;cystine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;0,7172907841;0,004624;0,033975;1,047;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4718;;
caprylic acid;caprylic acid;caprylic acid;–;–;–;HMDB0000482;–;–;–;Beta oxidation of very long chain fatty acids;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;0,6652737431;0,001293;0,010923;1,0126;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4719;;
lyxose;lyxose;lyxose;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;0,5420846273;0,000262;0,002596;1,0744;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4720;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;Purine metabolism;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;0,5399283966;0,00000673;0,000126;1,2696;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4721;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;0,4474970261;1,93E-009;5,43E-008;1,4044;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4722;;
fructose;fructose;fructose;–;–;–;–;–;–;–;Galactose metabolism, Fructose and mannose degradation, Starch and sucrose metabolism;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;0,4018920655;0,0000045;0,0000951;1,2899;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4723;;
indole-3-acetate;indole-3-acetate;indole-3-acetate;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;0,2470200412;3,62E-018;6,12E-016;1,6853;ROC curve analysis ;–;–;–;–;–;–;–;–;–;–;China;–;–;30805978;Sun et al. 2019;4724;;
erythritol;erythritol;erythritol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;lung cancer;I, II, III, IV;31;21, 10;54.1 ± 9.9 ;smoker, non-smoker;healthy;29;15, 14;52.1 ± 14.6;smoker, non-smoker;GC;–;–;–;–;–;BinBase, KEGG;–;Student t test, PLS-DA;–;–;0,2060790853;2,58E-017;2,18E-015;1,6743;ROC curve analysis ;–;(0.914, 1.000);93,1;100;–;–;–;–;–;–;China;Y;–;30805978;Sun et al. 2019;4725;;
oxalic acid;oxalic acid;oxalic acid;–;–;–;–;–;–;–;Glyoxylate and dicarboxylate metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;3,953;0,001;0,001;1,564;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4726;;
phosphate;phosphate;phosphate;–;–;–;HMDB0001429;–;–;–;–;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;3,396;0,001;0,001;2,152;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4727;;
isocitrate;isocitrate;isocitrate;–;–;–;–;–;–;–;TCA cycle;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;3,347;0,001;0,001;1,591;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4728;;
pyruvic acid;pyruvic acid;pyruvic acid;–;–;–;HMDB0000243;–;–;–;Glycolysis, Pyruvate metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;2,558;0,001;0,001;1,815;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4729;;
glycolic acid;glycolic acid;glycolic acid;–;–;–;HMDB0000115;–;–;–;Glyoxylate and dicarboxylate metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;1,501;0,001;0,001;1,356;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4730;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;TCA cycle;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;1,154;0,02;0,04;1,379;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4731;;
hydroxylamine;hydroxylamine;hydroxylamine;–;–;–;–;–;–;–;Nitrogen metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;1,152;0,006;0,014;1,073;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4732;;
porphine;porphine;porphine;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;1,148;0,001;0,003;1,03;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4733;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;Valine, leucine and isoleucine metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,892;0,001;0,001;1,473;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4734;;
cholesta-3,5-diene;cholesta-3,5-diene;cholesta-3,5-diene;–;–;–;–;–;–;–;Steroids metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,861;0,002;0,006;1,06;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4735;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;Fatty acid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,849;0,001;0,001;1,209;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4736;;
hydroxyurea;hydroxyurea;hydroxyurea;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,847;0,001;0,001;1,137;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4737;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;Steroids metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,838;0,001;0,001;1,513;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4738;;
beta-alanine;beta-alanine;beta-alanine;–;–;–;–;–;–;–;beta-Alanine metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,831;0,001;0,003;1,094;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4739;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;Fatty acid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,818;0,001;0,001;1,164;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4740;;
2-hydroxyglutaric acid;2-hydroxyglutaric acid;2-hydroxyglutaric acid;–;–;–;–;–;–;–;Organic acid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,809;0,001;0,001;1,175;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4741;;
docosahexaenoic acid;docosahexaenoic acid;docosahexaenoic acid;–;–;–;HMDB0002183;–;–;–;Fatty acid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,789;0,003;0,008;1,079;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4742;;
2-monopalmitoylglycerol;2-monopalmitoylglycerol;2-monopalmitoylglycerol;–;–;–;–;–;–;–;Glycerolipid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,788;0,001;0,001;1,122;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4743;;
11,14-eicosadienoic acid;11,14-eicosadienoic acid;11,14-eicosadienoic acid;–;–;–;–;–;–;–;Fatty acid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,786;0,008;0,017;1,077;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4744;;
myristic acid;myristic acid;myristic acid;–;–;–;HMDB0000806;–;–;–;Fatty acid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,77;0,001;0,016;1,027;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4745;;
pyroglutamic acid;pyroglutamic acid;pyroglutamic acid;–;–;–;HMDB0000267;–;–;–;Alanine, aspartate and glutamate metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,77;0,001;0,001;1,467;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4746;;
lauric acid;lauric acid;lauric acid;–;–;–;–;–;–;–;Fatty acid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,769;0,001;0,001;1,109;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4747;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;Fatty acid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,768;0,001;0,001;1,374;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4748;;
glyceric acid;glyceric acid;glyceric acid;–;–;–;–;–;–;–;Glycerolipid metabolism, Pentose phosphate pathway;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,744;0,001;0,001;1,385;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4749;;
glycerol;glycerol;glycerol;–;–;–;–;–;–;–;Glycerolipid metabolism, Pentose and glucuronate interconversions;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,741;0,001;0,001;1,34;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4750;;
7,10,13,16-docosatetraenoic acid;7,10,13,16-docosatetraenoic acid;7,10,13,16-docosatetraenoic acid;–;–;–;–;–;–;–;Fatty acid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,728;0,001;0,001;1,114;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4751;;
L-threonic acid;L-threonic acid;L-threonic acid;–;–;–;–;–;–;–;Ascorbate and aldarate metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,723;0,001;0,001;1,255;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4752;;
citrulline;citrulline;citrulline;–;–;–;–;–;–;–;Urea cycle;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,684;0,001;0,001;1,457;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4753;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;Phenylalanine metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,681;0,001;0,001;1,756;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4754;;
9-octadecenoic acid, methyl ester;9-octadecenoic acid, methyl ester;9-octadecenoic acid, methyl ester;–;–;–;–;–;–;–;Lipid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,677;0,001;0,001;1,039;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4755;;
linolenic acid;linolenic acid;linolenic acid;–;–;–;–;–;–;–;Fatty acid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,665;0,001;0,003;1,222;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4756;;
glycine;glycine;glycine;–;–;–;–;–;–;–;Glycine, serine and threonine metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,65;0,001;0,001;1,364;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4757;;
cysteine;cysteine;cysteine;–;–;–;–;–;–;–;Cysteine and methionine metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,645;0,001;0,001;1,903;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;30892048;Mu et al. 2019;4758;;
8,11,14-eicosatrienoic acid, methyl ester;8,11,14-eicosatrienoic acid, methyl ester;8,11,14-eicosatrienoic acid, methyl ester;–;–;–;–;–;–;–;Lipid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,574;0,001;0,001;1,283;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4759;;
5,8,11,14-eicosatetraenoic acid, methyl ester;5,8,11,14-eicosatetraenoic acid, methyl ester;5,8,11,14-eicosatetraenoic acid, methyl ester;–;–;–;–;–;–;–;Lipid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,569;0,001;0,001;1,332;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4760;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;Glycine, serine and threonine metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,569;0,001;0,001;1,901;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;30892048;Mu et al. 2019;4761;;
9,12-octadecadienoic acid (Z,Z)-, methyl ester;9,12-octadecadienoic acid (Z,Z)-, methyl ester;9,12-octadecadienoic acid (Z,Z)-, methyl ester;–;–;–;–;–;–;–;Lipid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,568;0,001;0,001;1,297;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4762;;
ethanolamine;ethanolamine;ethanolamine;–;–;–;–;–;–;–;Glycerophospholipid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,559;0,001;0,001;1,882;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4763;;
hexadecanoic acid, methyl ester;hexadecanoic acid, methyl ester;hexadecanoic acid, methyl ester;–;–;–;–;–;–;–;Lipid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,522;0,001;0,001;1,357;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4764;;
methyl stearate;methyl stearate;methyl stearate;–;–;–;–;–;–;–;Lipid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,474;0,001;0,001;1,454;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4765;;
1,2-propanediol;1,2-propanediol;1,2-propanediol;–;–;–;–;–;–;–;–;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,441;0,001;0,001;1,026;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4766;;
glycerol-1-phosphate;glycerol-1-phosphate;glycerol-1-phosphate;–;–;–;–;–;–;–;Glycerolipid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,389;0,001;0,001;1,766;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4767;;
1-monolinoleoylglycerol;1-monolinoleoylglycerol;1-monolinoleoylglycerol;–;–;–;–;–;–;–;Glycerolipid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,385;0,001;0,001;1,567;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4768;;
hypotaurine;hypotaurine;hypotaurine;–;–;–;–;–;–;–;Taurine and hypotaurine metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,385;0,001;0,001;1,661;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4769;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;Alanine, aspartate and glutamate metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,381;0,001;0,001;1,721;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4770;;
4,7,10,13,16,19-docosahexaenoic acid, methyl ester;4,7,10,13,16,19-docosahexaenoic acid, methyl ester;4,7,10,13,16,19-docosahexaenoic acid, methyl ester;–;–;–;–;–;–;–;Lipid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,366;0,001;0,001;1,825;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4771;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;Purine metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,311;0,001;0,001;1,875;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4772;;
benzoic acid;benzoic acid;benzoic acid;–;–;–;–;–;–;–;Phenylalanine metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,272;0,001;0,001;1,961;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4773;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;Purine metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,249;0,001;0,001;1,615;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4774;;
1-monooleoylglycerol;1-monooleoylglycerol;1-monooleoylglycerol;–;–;–;–;–;–;–;Glycerolipid metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,24;0,001;0,001;1,431;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;30892048;Mu et al. 2019;4775;;
ethylene glycol;ethylene glycol;ethylene glycol;–;–;–;–;–;–;–;Glyoxylate and dicarboxylate metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,231;0,001;0,001;1,937;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4776;;
ribose;ribose;ribose;–;–;–;–;–;–;–;Pentose phosphate pathway;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,093;0,001;0,001;1,672;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4777;;
aspartic acid;aspartic acid;aspartic acid;–;–;–;–;–;–;–;Alanine, aspartate and glutamate metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,076;0,001;0,001;1,809;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4778;;
serotonin;serotonin;serotonin;–;–;–;–;–;–;–;Tryptophan metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,065;0,001;0,001;1,939;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4779;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;Purine metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,05;0,001;0,001;1,436;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4780;;
glycylglycine;glycylglycine;glycylglycine;–;–;–;–;–;–;–;Glycine, serine and threonine metabolism;–;–;serum;diagnosis;NSCLC;I, II, III, IV;30;0, 30;60.4 ± 9.7;non-smoker;healthy;30;0, 30;54.7 ± 14.3;non-smoker;GC;–;–;–;–;–;–;SIMCA, SPSS;PCA, PLS-DA, Mann-Whitney U test;–;–;0,037;0,001;0,001;1,975;–;–;–;–;–;–;–;–;–;–;–;China;–;–;30892048;Mu et al. 2019;4781;;
SM(42:2);SM(42:2);SM(42:2);–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;25;–;46-82;–;tumor vs. adjacent normal tissue;25;–;46-82;–;LC;ESI;positive;Q-TOF;MS/MS;Progenesis QI;LIPID MAPS, HMDB;Ezinfo, JMP;Student's t test;–;–;–;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;confirmed by MALDI;31222099;Muranishi et al. 2019;4782;;
PC(16:0/18:1);PC(16:0/18:1);PC(16:0/18:1);–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;25;–;46-82;–;tumor vs. adjacent normal tissue;25;–;46-82;–;LC;ESI;positive;Q-TOF;MS/MS;Progenesis QI;LIPID MAPS, HMDB;Ezinfo, JMP;Student's t test;–;–;–;0,2879;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;confirmed by MALDI;31222099;Muranishi et al. 2019;4783;;
PC(36:4);PC(36:4);PC(36:4);–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;25;–;46-82;–;tumor vs. adjacent normal tissue;25;–;46-82;–;LC;ESI;positive;Q-TOF;MS/MS;Progenesis QI;LIPID MAPS, HMDB;Ezinfo, JMP;Student's t test;–;–;–;0,2545;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;confirmed by MALDI;31222099;Muranishi et al. 2019;4784;;
PC(16:0/16:0);PC(16:0/16:0);PC(16:0/16:0);–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;adenocarcinoma;I;25;–;46-82;–;tumor vs. adjacent normal tissue;25;–;46-82;–;LC;ESI;positive;Q-TOF;MS/MS;Progenesis QI;LIPID MAPS, HMDB;Ezinfo, JMP;Student's t test;–;–;–;0,0432;–;–;–;–;–;–;–;–;–;–;–;–;–;China;Y;confirmed by MALDI;31222099;Muranishi et al. 2019;4785;;
L-cysteine-glutathione gisulfide;L-cysteine-glutathione gisulfide;L-cysteine-glutathione gisulfide;–;–;–;–;–;–;–;–;–;427,09401;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;3,19338309;2,00993E-006;–;1,944981349;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4786;;
2, 4-diacetylphloroglucinol;2, 4-diacetylphloroglucinol;2, 4-diacetylphloroglucinol;–;–;–;–;–;–;–;–;–;209,04515;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;2,782323957;1,16835E-011;–;2,650923461;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4787;;
glycoursodeoxycholic acid;glycoursodeoxycholic acid;glycoursodeoxycholic acid;–;–;–;HMDB0000708;–;–;–;–;–;450,32006;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;1,876314921;0,007349588;–;1,264252383;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4788;;
glycoursodeoxycholic acid;glycoursodeoxycholic acid;glycoursodeoxycholic acid;–;–;–;HMDB0000708;–;–;–;–;–;448,30613;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;1,700960285;0,008749063;–;1,201569872;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4789;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;166,07215;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;1,582829571;0,000114873;–;1,321042679;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4790;;
2,3-dihydroxybenzoic acid;2,3-dihydroxybenzoic acid;2,3-dihydroxybenzoic acid;–;–;–;–;–;–;–;–;–;153,03027;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;1,534582177;0,00017606;–;1,524855204;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4791;;
stearamide;stearamide;stearamide;–;–;–;HMDB0034146;–;–;–;–;–;284,29412;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;1,462385265;0,001424559;–;1,288763243;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4792;;
6-thioxanthine;6-thioxanthine;6-thioxanthine;–;–;–;–;–;–;–;–;–;169,03539;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;1,364016088;0,000242097;–;1,270514797;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4793;;
D-mannose;D-mannose;D-mannose;–;–;–;–;–;–;–;–;–;215,03249;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;1,354467152;6,98593E-005;–;1,816157601;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4794;;
Dl-P-hydroxyphenyl lactic acid;Dl-P-hydroxyphenyl lactic acid;Dl-P-hydroxyphenyl lactic acid;–;–;–;–;–;–;–;–;–;181,05032;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;1,323866602;0,004044825;–;1,399169427;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4795;;
D(-)-arginine;D(-)-arginine;D(-)-arginine;–;–;–;–;–;–;–;–;–;175,11874;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;1,302705232;0,000455747;–;1,288341008;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4796;;
hydroxyphenyllactic acid;hydroxyphenyllactic acid;hydroxyphenyllactic acid;–;–;–;–;–;–;–;–;–;181,05997;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;1,295350147;0,010051256;–;1,299205089;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4797;;
3-carboxybenzadehyde;3-carboxybenzadehyde;3-carboxybenzadehyde;–;–;–;–;–;–;–;–;–;151,03912;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;1,254857949;0,00149003;–;1,42112953;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4798;;
L-tyrosine;L-tyrosine;L-tyrosine;–;–;–;–;–;–;–;–;–;180,05915;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;1,245820884;0,01320715;–;1,303787108;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4799;;
2-methylmercaptobenzothiazole;2-methylmercaptobenzothiazole;2-methylmercaptobenzothiazole;–;–;–;–;–;–;–;–;–;182,00897;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,889589966;0,001681058;–;1,224463159;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4800;;
alpha-pinene;alpha-pinene;alpha-pinene;–;–;–;–;–;–;–;–;–;136,02145;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,878106567;5,50723E-005;–;1,738504047;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4801;;
dodecylamine;dodecylamine;dodecylamine;–;–;–;–;–;–;–;–;–;186,22136;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,85706084;0,001824798;–;1,483622325;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4802;;
cholesteryl laurate;cholesteryl laurate;cholesteryl laurate;–;–;–;–;–;–;–;–;–;283,26375;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,826107645;0,006373954;–;1,217285682;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4803;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;–;–;151,02585;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,797313073;3,12694E-007;–;1,894062845;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;31442449;Huang et al. 2019;4804;;
calcifediol;calcifediol;calcifediol;–;–;–;–;–;–;–;–;–;401,34447;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,755455381;0,001286877;–;1,321397073;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4805;;
D-pantothenic acid;D-pantothenic acid;D-pantothenic acid;–;–;–;–;–;–;–;–;–;220,11757;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,727377226;0,00367764;–;1,303604931;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4806;;
pyroglutamic acid;pyroglutamic acid;pyroglutamic acid;–;–;–;HMDB0000267;–;–;–;–;–;128,03514;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,694724052;0,000946801;–;1,722675621;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4807;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;133,01398;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,690930505;0,000749386;–;1,414421201;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4808;;
uridine;uridine;uridine;–;–;–;HMDB0000296;–;–;–;–;–;243,06172;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,678407802;0,000110994;–;1,837043807;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4809;;
4-pyridoxate;4-pyridoxate;4-pyridoxate;–;–;–;–;–;–;–;–;–;182,00921;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,661078952;7,46679E-005;–;1,314529694;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;31442449;Huang et al. 2019;4810;;
cis-11,14-eicosadienoic acid;cis-11,14-eicosadienoic acid;cis-11,14-eicosadienoic acid;–;–;–;–;–;–;–;–;–;307,26376;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,660491997;0,001675464;–;1,512008485;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4811;;
D-(+)-Malic acid;D-(+)-Malic acid;D-(+)-Malic acid;–;–;–;–;–;–;–;–;–;133,01405;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,642011412;9,16168E-008;–;2,031293883;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4812;;
cis-8,11,14-eicosatrienoic acid;cis-8,11,14-eicosatrienoic acid;cis-8,11,14-eicosatrienoic acid;–;–;–;–;–;–;–;–;–;305,24804;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,63649831;0,00044142;–;1,42041064;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4813;;
docosahexaenoic acid;docosahexaenoic acid;docosahexaenoic acid;–;–;–;HMDB0002183;–;–;–;–;–;327,23239;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,57646401;0,000273125;–;1,6699338;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4814;;
threonate;threonate;threonate;–;–;–;–;–;–;–;–;–;135,02967;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,572612662;1,02323E-006;–;2,057371232;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4815;;
3-aminopentanedioic acid;3-aminopentanedioic acid;3-aminopentanedioic acid;–;–;–;–;–;–;–;–;–;146,04567;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,560226725;2,20851E-008;–;2,128440434;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4816;;
10-hydroxydecanoic acid;10-hydroxydecanoic acid;10-hydroxydecanoic acid;–;–;–;–;–;–;–;–;–;187,13363;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,548424223;3,93911E-005;–;1,849863176;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4817;;
7z,10z,13z-hexadecatrienoic acid;7z,10z,13z-hexadecatrienoic acid;7z,10z,13z-hexadecatrienoic acid;–;–;–;–;–;–;–;–;–;249,18557;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,545164249;0,000795892;–;1,459792894;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4818;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;303,23244;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,544997905;5,10525E-006;–;1,97396854;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4819;;
Dl-glutamic acid;Dl-glutamic acid;Dl-glutamic acid;–;–;–;–;–;–;–;–;–;148,06023;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,543732383;1,15301E-008;–;2,167167711;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4820;;
All-cis-4,7,10,13,16-docosapentaenoic acid;All-cis-4,7,10,13,16-docosapentaenoic acid;All-cis-4,7,10,13,16-docosapentaenoic acid;–;–;–;–;–;–;–;–;–;329,24811;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,534849795;0,000421658;–;1,587974127;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4821;;
canthaxanthine;canthaxanthine;canthaxanthine;–;–;–;–;–;–;–;–;–;565,40074;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,53040919;0,000128243;–;1,681768078;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4822;;
L-pyroglutamic acid;L-pyroglutamic acid;L-pyroglutamic acid;–;–;–;–;–;–;–;–;–;130,04976;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,515379615;7,9959E-007;–;2,070554307;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4823;;
Phe-Phe;Phe-Phe;Phe-Phe;–;–;–;–;–;–;–;–;–;313,15381;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,493355581;9,42322E-005;–;1,819868675;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4824;;
10-undecenoic acid;10-undecenoic acid;10-undecenoic acid;–;–;–;–;–;–;–;–;–;183,1387;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,443330387;1,91015E-006;–;2,138219656;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4825;;
2-aminopropanol;2-aminopropanol;2-aminopropanol;–;–;–;–;–;–;–;–;–;76,07552;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,44040153;0,018410496;–;1,478057758;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4826;;
D-Glu;D-Glu;D-Glu;–;–;–;–;–;–;–;–;–;146,02788;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,421108896;0,004054526;–;1,748671325;–;–;–;–;–;–;–;–;–;–;–;China;Y;–;31442449;Huang et al. 2019;4827;;
5-pregnane-3,20-dione;5-pregnane-3,20-dione;5-pregnane-3,20-dione;–;–;–;–;–;–;–;–;–;315,23254;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,415479209;0,03737452;–;1,581416078;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4828;;
butylamine;butylamine;butylamine;–;–;–;–;–;–;–;–;–;74,09626;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,40517454;2,37637E-008;–;2,082762857;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4829;;
glycerophosphoric acid;glycerophosphoric acid;glycerophosphoric acid;–;–;–;–;–;–;–;–;–;171,00763;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,321746844;1,16738E-008;–;2,591199813;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4830;;
3-methylcrotonyl glycine;3-methylcrotonyl glycine;3-methylcrotonyl glycine;–;–;–;–;–;–;–;–;–;180,06525;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,287351272;0,009854803;–;1,589611045;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4831;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;–;–;137,04566;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,2794885;1,82856E-007;–;2,434019335;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4832;;
8(R)-hydroxy-(5Z,9E,11Z,14Z)-eicosatetraenoic acid;8(R)-hydroxy-(5Z,9E,11Z,14Z)-eicosatetraenoic acid;8(R)-hydroxy-(5Z,9E,11Z,14Z)-eicosatetraenoic acid;–;–;–;–;–;–;–;–;–;319,22732;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,272021655;0,000108324;–;2,330052744;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4833;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;–;–;135,03098;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,240092536;2,12398E-007;–;2,691477624;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4834;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;267,07303;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,201411207;6,4414E-006;–;2,336002592;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4835;;
N-oleoylethanolamine;N-oleoylethanolamine;N-oleoylethanolamine;–;–;–;–;–;–;–;–;–;326,30452;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,050983505;1,06882E-007;–;2,559131211;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4836;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;537,16717;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,027173159;0,00019946;–;2,009511896;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4837;;
N-acetyl-5-hydroxytryptamine;N-acetyl-5-hydroxytryptamine;N-acetyl-5-hydroxytryptamine;–;–;–;–;–;–;–;–;–;219,11582;plasma;diagnosis;lung cancer;–;31;19, 12;28-64;–;healthy;35;24, 11;23-60;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;OSI-SMMS;SIMCA, SPSS;OPLS-DA, Mann-Whitney U test;–;–;0,018885012;5,36577E-008;–;2,437850449;–;–;–;–;–;–;–;–;–;–;–;China;–;–;31442449;Huang et al. 2019;4838;;
HpOTrE;HpOTrE;HpOTrE;–;–;–;–;–;–;–;–;–;293,2105;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;3,51;–;0,000526;3,02;ROC analysis;–;0,779;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4839;;
HOTrE;HOTrE;HOTrE;–;–;–;–;–;–;–;–;–;277,2157;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;3,5;–;0,0000161;3,21;ROC analysis;–;0,845;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4840;;
DiHOME;DiHOME;DiHOME;–;–;–;–;–;–;–;–;–;313,2387;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;3,24;–;0,0000805;2,35;ROC analysis;–;0,793;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4841;;
HODE;HODE;HODE;–;–;–;–;–;–;–;–;–;279,2313;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;3,08;–;0,00449;1,94;ROC analysis;–;0,759;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4842;;
HpODE;HpODE;HpODE;–;–;–;–;–;–;–;–;–;295,2261;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;2,83;–;0,00127;2,81;ROC analysis;–;0,787;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4843;;
octadecadienoic acid;octadecadienoic acid;octadecadienoic acid;–;–;–;–;–;–;–;–;–;281,2469;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;2,81;–;0,0000204;2,95;ROC analysis;–;0,837;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4844;;
OxoOTrE;OxoOTrE;OxoOTrE;–;–;–;–;–;–;–;–;–;293,2105;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;2,63;–;0,000158;3,7;ROC analysis;–;0,805;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4845;;
OxoODE;OxoODE;OxoODE;–;–;–;–;–;–;–;–;–;295,2262;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;2,6;–;0,000302;2,93;ROC analysis;–;0,801;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4846;;
PC(15:0/20:2);PC(15:0/20:2);PC(15:0/20:2);–;–;–;–;–;–;–;–;–;772,5851;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;2,03;–;0,000238;1,73;ROC analysis;–;0,782;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4847;;
glutamate;glutamate;glutamate;–;–;–;–;–;–;–;–;–;148,0602;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;1,84;–;0,00012;1,69;ROC analysis;–;0,839;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4848;;
ChE(16:1);ChE(16:1);ChE(16:1);–;–;–;–;–;–;–;–;–;640,6027;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;1,59;–;0,00369;1,18;ROC analysis;–;0,73;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4849;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;191,0188;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;1,53;–;0,00882;1,24;ROC analysis;–;0,728;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4850;;
PI(18:0/20:3);PI(18:0/20:3);PI(18:0/20:3);–;–;–;–;–;–;–;–;–;887,5655;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;1,52;–;0,000112;1,19;ROC analysis;–;0,763;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4851;;
ChE(18:3);ChE(18:3);ChE(18:3);–;–;–;–;–;–;–;–;–;664,6027;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;1,49;–;0,00197;1,1;ROC analysis;–;0,731;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4852;;
PC(16:0/22:4);PC(16:0/22:4);PC(16:0/22:4);–;–;–;–;–;–;–;–;–;854,5917;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;1,47;–;0,00109;1,17;ROC analysis;–;0,738;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4853;;
arginine;arginine;arginine;–;–;–;HMDB0000517;–;–;–;–;–;175,1187;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;1,38;–;0,00009;1,04;ROC analysis;–;0,81;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4854;;
PC(18:1p/22:6);PC(18:1p/22:6);PC(18:1p/22:6);–;–;–;–;–;–;–;–;–;816,5902;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;1,34;–;0,00935;1,1;ROC analysis;–;0,715;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4855;;
PC(19:0/18:2);PC(19:0/18:2);PC(19:0/18:2);–;–;–;–;–;–;–;–;–;844,6073;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;1,23;–;0,00919;0,8;ROC analysis;–;0,643;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4856;;
phSM(d42:1);phSM(d42:1);phSM(d42:1);–;–;–;–;–;–;–;–;–;875,6859;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;1,23;–;0,00684;0,72;ROC analysis;–;0,673;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4857;;
PC(40:6e);PC(40:6e);PC(40:6e);–;–;–;–;–;–;–;–;–;820,6215;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,71;–;0,00026;1,2;ROC analysis;–;0,816;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4858;;
TG(18:3/18:2/20:4);TG(18:3/18:2/20:4);TG(18:3/18:2/20:4);–;–;–;–;–;–;–;–;–;918,7545;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,71;–;0,0106;1,04;ROC analysis;–;0,716;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4859;;
N1-Acetyl-spermidine;N1-Acetyl-spermidine;N1-Acetyl-spermidine;–;–;–;–;–;–;–;–;–;188,1755;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,7;–;0,0151;1,14;ROC analysis;–;0,734;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4860;;
PC(42:1);PC(42:1);PC(42:1);–;–;–;–;–;–;–;–;–;872,7103;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,69;–;0,000601;1,21;ROC analysis;–;0,781;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4861;;
PC(33:0);PC(33:0);PC(33:0);–;–;–;–;–;–;–;–;–;748,5851;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,68;–;0,00162;1,24;ROC analysis;–;0,763;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4862;;
PC(16:0e/20:4);PC(16:0e/20:4);PC(16:0e/20:4);–;–;–;–;–;–;–;–;–;812,5811;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,67;–;1,54E-008;1,39;ROC analysis;–;0,892;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4863;;
PC(18:0p/22:5);PC(18:0p/22:5);PC(18:0p/22:5);–;–;–;–;–;–;–;–;–;864,6124;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,67;–;0,0000548;1,17;ROC analysis;–;0,782;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4864;;
PC(36:4e);PC(36:4e);PC(36:4e);–;–;–;–;–;–;–;–;–;768,5902;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,67;–;1,16E-008;1,55;ROC analysis;–;0,912;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4865;;
LPC(18:0p);LPC(18:0p);LPC(18:0p);–;–;–;–;–;–;–;–;–;508,3762;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,66;–;0,00352;1,2;ROC analysis;–;0,733;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4866;;
PC(34:2e);PC(34:2e);PC(34:2e);–;–;–;–;–;–;–;–;–;744,5902;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,66;–;0,00000495;1,46;ROC analysis;–;0,861;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4867;;
phSM(d34:2);phSM(d34:2);phSM(d34:2);–;–;–;–;–;–;–;–;–;761,545;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,66;–;0,00000238;1,37;ROC analysis;–;0,813;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4868;;
Cer(d18:1/16:0);Cer(d18:1/16:0);Cer(d18:1/16:0);–;–;–;HMDB0004949;–;–;–;–;–;538,5194;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,65;–;0,00935;1,17;ROC analysis;–;0,696;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4869;;
dodecanoyl-carnitine;dodecanoyl-carnitine;dodecanoyl-carnitine;–;–;–;–;–;–;–;–;–;344,2788;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,63;–;0,00776;1,19;ROC analysis;–;0,744;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4870;;
PC(40:7p);PC(40:7p);PC(40:7p);–;–;–;–;–;–;–;–;–;816,5902;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,63;–;0,000343;1,38;ROC analysis;–;0,804;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4871;;
SM(d32:0);SM(d32:0);SM(d32:0);–;–;–;–;–;–;–;–;–;677,5592;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,63;–;0,000163;1,39;ROC analysis;–;0,817;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4872;;
PE(18:1p/18:1);PE(18:1p/18:1);PE(18:1p/18:1);–;–;–;–;–;–;–;–;–;728,5589;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,62;–;0,00312;1,27;ROC analysis;–;0,714;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4873;;
Cer(d18:2/24:1);Cer(d18:2/24:1);Cer(d18:2/24:1);–;–;–;–;–;–;–;–;–;646,6133;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,61;–;0,00000552;1,6;ROC analysis;–;0,861;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4874;;
LPC(26:0);LPC(26:0);LPC(26:0);–;–;–;–;–;–;–;–;–;636,4963;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,6;–;0,0000496;1,52;ROC analysis;–;0,813;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4875;;
TG(18:2/18:2/22:6);TG(18:2/18:2/22:6);TG(18:2/18:2/22:6);–;–;–;–;–;–;–;–;–;944,7702;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,6;–;0,00011;1,54;ROC analysis;–;0,784;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4876;;
PC(30:0e);PC(30:0e);PC(30:0e);–;–;–;–;–;–;–;–;–;692,5589;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,59;–;0,0000227;1,56;ROC analysis;–;0,83;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4877;;
PC(34:0e);PC(34:0e);PC(34:0e);–;–;–;–;–;–;–;–;–;748,6215;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,59;–;0,00000166;1,68;ROC analysis;–;0,884;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4878;;
PC(44:7e);PC(44:7e);PC(44:7e);–;–;–;–;–;–;–;–;–;874,6684;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,58;–;0,0000478;1,56;ROC analysis;–;0,821;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4879;;
PE(16:0p/20:4);PE(16:0p/20:4);PE(16:0p/20:4);–;–;–;–;–;–;–;–;–;724,5276;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,58;–;0,000000953;1,74;ROC analysis;–;0,868;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4880;;
LPC(26:1);LPC(26:1);LPC(26:1);–;–;–;–;–;–;–;–;–;634,4806;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,57;–;0,0000334;1,63;ROC analysis;–;0,833;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4881;;
LPC(20:4);LPC(20:4);LPC(20:4);–;–;–;–;–;–;–;–;–;588,3307;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,56;–;0,00155;1,28;ROC analysis;–;0,733;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4882;;
PC(38:6e);PC(38:6e);PC(38:6e);–;–;–;–;–;–;–;–;–;792,5902;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,56;–;0,00000821;1,7;ROC analysis;–;0,839;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4883;;
2-methylbutyrylcarnitine;2-methylbutyrylcarnitine;2-methylbutyrylcarnitine;–;–;–;–;–;–;–;–;–;246,1696;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,54;–;0,00461;1,32;ROC analysis;–;0,733;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4884;;
PC(44:6e);PC(44:6e);PC(44:6e);–;–;–;–;–;–;–;–;–;876,6841;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,54;–;0,000000412;1,85;ROC analysis;–;0,877;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4885;;
PC(40:3p);PC(40:3p);PC(40:3p);–;–;–;–;–;–;–;–;–;824,6528;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,53;–;2,43E-011;2,05;ROC analysis;–;0,953;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4886;;
PE(18:0p/18:1);PE(18:0p/18:1);PE(18:0p/18:1);–;–;–;–;–;–;–;–;–;730,5745;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,53;–;0,005;1,37;ROC analysis;–;0,721;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4887;;
LPC(20:2);LPC(20:2);LPC(20:2);–;–;–;–;–;–;–;–;–;592,362;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,52;–;0,0000319;1,58;ROC analysis;–;0,793;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4888;;
PC(36:0e);PC(36:0e);PC(36:0e);–;–;–;–;–;–;–;–;–;776,6528;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,52;–;0,0000138;1,75;ROC analysis;–;0,864;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4889;;
PC(42:3p);PC(42:3p);PC(42:3p);–;–;–;–;–;–;–;–;–;852,6841;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,52;–;5,52E-008;1,94;ROC analysis;–;0,902;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4890;;
PC(18:0e/22:4);PC(18:0e/22:4);PC(18:0e/22:4);–;–;–;–;–;–;–;–;–;868,6437;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,51;–;3,92E-009;1,86;ROC analysis;–;0,892;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4891;;
LPC(20:0e);LPC(20:0e);LPC(20:0e);–;–;–;–;–;–;–;–;–;538,4231;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,5;–;0,000000533;1,95;ROC analysis;–;0,858;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4892;;
PC(40:5e);PC(40:5e);PC(40:5e);–;–;–;–;–;–;–;–;–;822,6371;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,48;–;0,000000917;1,97;ROC analysis;–;0,894;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4893;;
PC(35:0);PC(35:0);PC(35:0);–;–;–;–;–;–;–;–;–;776,6164;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,47;–;0,00162;1,63;ROC analysis;–;0,767;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4894;;
cortisol;cortisol;cortisol;–;–;–;–;–;–;–;–;–;363,2158;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,43;–;0,0372;1,42;ROC analysis;–;0,859;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4895;;
LPC(18:0e);LPC(18:0e);LPC(18:0e);–;–;–;–;–;–;–;–;–;554,3827;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;negative;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,41;–;3,51E-010;2,19;ROC analysis;–;0,935;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4896;;
myristoylcarnitine;myristoylcarnitine;myristoylcarnitine;–;–;–;–;–;–;–;–;–;372,3097;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,4;–;0,000388;1,74;ROC analysis;–;0,79;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4897;;
PE(16:0p/22:4);PE(16:0p/22:4);PE(16:0p/22:4);–;–;–;–;–;–;–;–;–;752,5589;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,4;–;0,00000227;2,11;ROC analysis;–;0,909;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4898;;
LPC(16:0e);LPC(16:0e);LPC(16:0e);–;–;–;–;–;–;–;–;–;482,3599;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,38;–;0,000000284;2,09;ROC analysis;–;0,889;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4899;;
glycocholic acid;glycocholic acid;glycocholic acid;–;–;–;–;–;–;–;–;–;466,3155;pleural effusion;diagnosis;adenocarcinoma;–;46;15, 31;63 ± 12;–;pulmonary tuberculosis, other pulmonary diseases;32;26, 6;49 ± 19;–;LC;ESI;positive;Q-Orbitrap;MS/MS;XCMS;HMDB, METLIN, LipidSearch ;MetaX;PLS-DA;–;–;0,3;–;0,047;1,52;ROC analysis;–;0,744;–;–;–;–;–;–;–;–;China;–;–;31884394;Yang et al. 2020;4900;;
2-propylpent-3-enoic acid;2-propylpent-3-enoic acid;2-propylpent-3-enoic acid;–;–;–;HMDB0013904;–;–;–;–;–;160,1328;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;50;<0.0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4901;;
13,14-Dihydro PGE1/Prostaglandin F1a;13,14-Dihydro PGE1/Prostaglandin F1a;13,14-Dihydro PGE1/Prostaglandin F1a;–;–;–;HMDB0005076;–;–;–;–;–;713,493;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;5;0,047;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4902;;
2-hexenoylcarnitine;2-hexenoylcarnitine;2-hexenoylcarnitine;–;–;–;HMDB0013161;–;–;–;–;–;258,1654;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;16;0,013;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4903;;
2-octenoylcarnitine;2-octenoylcarnitine;2-octenoylcarnitine;–;–;–;HMDB0013324;–;–;–;–;–;286,2013;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;3;0,026;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4904;;
chenodeoxycholic;chenodeoxycholic;chenodeoxycholic;–;–;–;HMDB0000518;–;–;–;–;–;450,3208;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;28;0,0005;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4905;;
deoxycholic acid glycine conjugate;deoxycholic acid glycine conjugate;deoxycholic acid glycine conjugate;–;–;–;–;–;–;–;–;–;450,3208;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;28;0,0005;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4906;;
glycoursodeoxycholic acid;glycoursodeoxycholic acid;glycoursodeoxycholic acid;–;–;–;HMDB0000708;–;–;–;–;–;450,3208;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;28;0,0005;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4907;;
cholic acid;cholic acid;cholic acid;–;[M + NH4]+;–;HMDB0000619;–;–;–;–;–;426,3246;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;4;0,026;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4908;;
cis-5-Tetradecenoylcarnitine;cis-5-Tetradecenoylcarnitine;cis-5-Tetradecenoylcarnitine;–;–;–;HMDB0002014;–;–;–;–;–;370,2948;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;4;0,033;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4909;;
decanoylcarnitine;decanoylcarnitine;decanoylcarnitine;–;–;–;HMDB0000651;–;–;–;–;–;316,2481;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;2;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4910;;
dodecanoylcarnitine;dodecanoylcarnitine;dodecanoylcarnitine;–;–;–;HMDB0002250;–;–;–;–;–;344,2792;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;6;0,0009;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4911;;
L-carnitine;L-carnitine;L-carnitine;–;–;–;HMDB0000062;–;–;–;–;–;162,1124;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;3;<0.0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4912;;
L-octanoylcarnitine;L-octanoylcarnitine;L-octanoylcarnitine;–;–;–;HMDB0000791;–;–;–;–;–;288,2166;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;2;0,0008;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4913;;
LysoPC(P-18:1);LysoPC(P-18:1);LysoPC(P-18:1);–;–;–;HMDB0011507;–;–;–;–;–;522,3552;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;3;0,026;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4914;;
PG(18:1/18:2);PG(18:1/18:2);PG(18:1/18:2);–;–;–;HMDB0010620;–;–;–;–;–;773,536;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;6;0,0087;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4915;;
PI(16:0/18:1);PI(16:0/18:1);PI(16:0/18:1);–;[M + NH4]+;–;HMDB0009782;–;–;–;–;–;854,5691;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;7;0,0002;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4916;;
4-guanidinobutanoic acid;4-guanidinobutanoic acid;4-guanidinobutanoic acid;–;[M + NH4]+;–;HMDB0003464;–;–;–;–;–;163,1156;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;4;0,029;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4917;;
isodesmosine;isodesmosine;isodesmosine;–;–;–;HMDB0000739;–;–;–;–;–;527,296;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;19;0,043;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4918;;
L-isoleucyl-L-proline;L-isoleucyl-L-proline;L-isoleucyl-L-proline;–;–;–;HMDB0011174;–;–;–;–;–;229,152;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;2;0,0005;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4919;;
myo-inositol;myo-inositol;myo-inositol;–;[M + Na]+;–;HMDB0000211;–;–;–;–;–;203,0524;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;2;0,0002;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4920;;
glyceraldehyde;glyceraldehyde;glyceraldehyde;–;[M + Na]+;–;HMDB0001051;–;–;–;–;–;203,0524;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;2;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4921;;
beta-cortol;beta-cortol;beta-cortol;–;–;–;HMDB0005821;–;–;–;–;–;–;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;8;0,013;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4922;;
5-Acetylamino-6-formylamino-3-methyluracil;5-Acetylamino-6-formylamino-3-methyluracil;5-Acetylamino-6-formylamino-3-methyluracil;–;[M + Na]+;–;HMDB0011105;–;–;–;–;–;249,0608;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;3;0,029;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4923;;
4-hydroxycyclohexylcarboxylic acid;4-hydroxycyclohexylcarboxylic acid;4-hydroxycyclohexylcarboxylic acid;–;[M + NH4]+;–;HMDB0001988;–;–;–;–;–;162,1126;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;3;<0.0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4924;;
guanidinosuccinic acid;guanidinosuccinic acid;guanidinosuccinic acid;–;–;–;HMDB0003157;–;–;–;–;–;176,0654;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;3;0,023;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4925;;
proline betaine;proline betaine;proline betaine;–;–;–;HMDB0004827;–;–;–;–;–;144,1014;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;2;0,024;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4926;;
androstanediol;androstanediol;androstanediol;–;[2M + NH4]+;–;HMDB0000495;–;–;–;–;–;623,4382;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;54;<0.0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4927;;
dopamine;dopamine;dopamine;–;–;–;HMDB0000073;–;–;–;–;–;154,0823;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;5;<0.0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4928;;
epinephrine;epinephrine;epinephrine;–;–;–;HMDB0000068;–;–;–;–;–;184,0944;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;134;<0.0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4929;;
androstenedione;androstenedione;androstenedione;–;–;–;HMDB0000053;–;–;–;–;–;287,2041;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;8;0,023;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4930;;
tetrahydrobiopterin/sapropterin (BH4, THB);tetrahydrobiopterin/sapropterin (BH4, THB);tetrahydrobiopterin/sapropterin (BH4, THB);–;[2M + K]+;–;HMDB0000027;–;–;–;–;–;500,2767;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;8;0,0031;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4931;;
N-desmethylaminopyrine;N-desmethylaminopyrine;N-desmethylaminopyrine;–;–;–;HMDB0013839;–;–;–;–;–;218,1378;Serum;diagnosis;NSCLC pre-surgery;I, II;32;12,2;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;32;12,2;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;10;0,0003;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4932;;
isopentenyladenine;isopentenyladenine;isopentenyladenine;–;–;–;HMDB0245646;–;–;–;–;–;204,1242;Urine;diagnosis;NSCLC pre-surgery;I, II;29;11,18;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;29;11,18;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;31;0,0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4933;;
aspartyl glycine;aspartyl glycine;aspartyl glycine;–;–;–;HMDB0028753;–;–;–;–;–;248,0938;Urine;diagnosis;NSCLC pre-surgery;I, II;29;11,18;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;29;11,18;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;50;0,0006;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4934;;
Asymmetric dimethylarginine (ADMA);Asymmetric dimethylarginine (ADMA);Asymmetric dimethylarginine (ADMA);–;–;–;–;–;–;–;–;–;203,1505;Urine;diagnosis;NSCLC pre-surgery;I, II;29;11,18;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;29;11,18;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;16;0,044;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4935;;
hypoglycin;hypoglycin;hypoglycin;–;–;–;HMDB0029427;–;–;–;–;–;142,0875;Urine;diagnosis;NSCLC pre-surgery;I, II;29;11,18;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;29;11,18;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;442;<0.0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4936;;
L-glutamic acid n-butyl ester;L-glutamic acid n-butyl ester;L-glutamic acid n-butyl ester;–;–;–;–;–;–;–;–;–;204,1233;Urine;diagnosis;NSCLC pre-surgery;I, II;29;11,18;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;29;11,18;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;65;0,0009;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4937;;
N(alpha)-t-Butoxycarbonyl-L-leucine;N(alpha)-t-Butoxycarbonyl-L-leucine;N(alpha)-t-Butoxycarbonyl-L-leucine;–;–;–;–;–;–;–;–;–;232,1547;Urine;diagnosis;NSCLC pre-surgery;I, II;29;11,18;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;29;11,18;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;161;<0.0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4938;;
Pro Leu;Pro Leu;Pro Leu;–;–;–;–;–;–;–;–;–;229,1548;Urine;diagnosis;NSCLC pre-surgery;I, II;29;11,18;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;29;11,18;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;625;<0.0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4939;;
1-methyladenine;1-methyladenine;1-methyladenine;–;[M + Na]+;–;HMDB0011599;–;–;–;–;–;321,1307;Urine;diagnosis;NSCLC pre-surgery;I, II;29;11,18;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;29;11,18;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;59;<0.0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4940;;
3-methyluric acid;3-methyluric acid;3-methyluric acid;–;–;–;HMDB0001970;–;–;–;–;–;183,0515;Urine;diagnosis;NSCLC pre-surgery;I, II;29;11,18;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;29;11,18;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;198;<0.0001;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4941;;
N6-methyladenosine;N6-methyladenosine;N6-methyladenosine;–;–;–;HMDB0004044;–;–;–;–;–;282,1199;Urine;diagnosis;NSCLC pre-surgery;I, II;29;11,18;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;29;11,18;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;27;0,0085;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4942;;
fumaric acid;fumaric acid;fumaric acid;–;–;–;HMDB0000134;–;–;–;–;–;139,0026;Urine;diagnosis;NSCLC pre-surgery;I, II;29;11,18;63.8 ± 7.0;former, current, non-smoker;NSCLC post-surgery;29;11,18;63.8 ± 7.0;former, current, non-smoker;LC;ESI;both;Q-TOF;–;MassHunter, Mass Profiler Professional;HMDB, METLIN;MPP;Pair t-test;–;–;17;0,011;–;–;–;–;–;–;–;–;–;–;–;–;–;Canada;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34208545;Ahmed et al. 2021;4943;;
4-oxoproline;4-oxoproline;4-oxoproline;–;[M+H]+, [M-H]-;–;HMDB0304793;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA, Compound Discoverer;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,61;1,3E-015;–;2,57;ROC analysis;–;Discriminating healthy controls and lung cancer patients 0.83,  Discriminating healthy controls, early-stage patients, and advanced-stage 0.73;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4944;;
4-oxoproline;4-oxoproline;4-oxoproline;–;[M+H]+, [M-H]-;–;HMDB0304793;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,42;2,65E-010;–;3,75;ROC analysis;–;Discriminating healthy controls and lung cancer patients 0.83,  Discriminating healthy controls, early-stage patients, and advanced-stage 0.73;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4945;;
heptadecanoic acid;heptadecanoic acid;heptadecanoic acid;–;[M+H]+, [M-H]-;–;HMDB0002259;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,73;1,67E-009;–;2,01;ROC analysis;–;Discriminating healthy controls and lung cancer patients 0.84,  Discriminating healthy controls, early-stage patients, and advanced-stage 0.75, Distinguishing lung cancer types 0.75;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4946;;
ornithine;ornithine;ornithine;–;[M+H]+, [M-H]-;–;HMDB0000214;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,33;0,0000688;–;1,65;ROC analysis;–;Discriminating healthy controls and lung cancer patients 0.81,  Discriminating healthy controls, early-stage patients, and advanced-stage 0.72, Distinguishing lung cancer types 0.73;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4947;;
ornithine;ornithine;ornithine;–;[M+H]+, [M-H]-;–;HMDB0000214;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,42;4,6E-010;–;5,14;ROC analysis;–;Discriminating healthy controls and lung cancer patients 0.81,  Discriminating healthy controls, early-stage patients, and advanced-stage 0.72, Distinguishing lung cancer types 0.73;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4948;;
4-oxoproline;4-oxoproline;4-oxoproline;–;[M+H]+, [M-H]-;–;HMDB0304793;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,33;1,86E-010;–;2,6;ROC analysis;–;Discriminating healthy controls and lung cancer patients 0.83,  Discriminating healthy controls, early-stage patients, and advanced-stage 0.73;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4949;;
heptadecanoic acid;heptadecanoic acid;heptadecanoic acid;–;[M+H]+, [M-H]-;–;HMDB0002259;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,68;5,28E-012;–;6,02;ROC analysis;–;Discriminating healthy controls and lung cancer patients 0.84,  Discriminating healthy controls, early-stage patients, and advanced-stage 0.75, Distinguishing lung cancer types 0.75;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4950;;
palmitic acid;palmitic acid;palmitic acid;–;[M+H]+, [M-H]-;–;HMDB0000220;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,76;5,94E-014;–;40,05;ROC analysis;–;Discriminating healthy controls and lung cancer patients 0.86,  Discriminating healthy controls, early-stage patients, and advanced-stage 0.77, Distinguishing lung cancer types 0.78;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4951;;
11-aminoundecanoic acid;11-aminoundecanoic acid;11-aminoundecanoic acid;–;[M+H]+, [M-H]-;–;HMDB0032669;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,35;1,98E-028;–;1,98;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4952;;
1-methylhistidine;1-methylhistidine;1-methylhistidine;–;[M+H]+, [M-H]-;–;HMDB0000001;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,65;0,0343;–;1,04;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4953;;
3-hydroxyhexade cadienoylcarnitine;3-hydroxyhexade cadienoylcarnitine;3-hydroxyhexade cadienoylcarnitine;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,72;0,000232;–;1,65;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4954;;
3-hydroxyoctanoylcarnitine;3-hydroxyoctanoylcarnitine;3-hydroxyoctanoylcarnitine;–;[M+H]+, [M-H]-;–;HMDB0061634;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,8;0,00919;–;1,52;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4955;;
4-hydroxy-2-oxo glutaric acid;4-hydroxy-2-oxo glutaric acid;4-hydroxy-2-oxo glutaric acid;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,84;0,0084;–;1,37;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4956;;
5-methylthioribose;5-methylthioribose;5-methylthioribose;–;[M+H]+, [M-H]-;–;HMDB0001087;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,55;0,000737;–;2,37;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4957;;
7-methylguanine;7-methylguanine;7-methylguanine;–;[M+H]+, [M-H]-;–;HMDB0000897;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,23;0,0000627;–;1,09;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4958;;
acetylcholine;acetylcholine;acetylcholine;–;[M+H]+, [M-H]-;–;HMDB0000895;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,16;0,000104;–;2,43;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4959;;
acylcarnitine C12:0;acylcarnitine C12:0;acylcarnitine C12:0;–;[M+H]+, [M-H]-;–;HMDB0002250;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,76;0,00884;–;1,13;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4960;;
acylcarnitine C14:2;acylcarnitine C14:2;acylcarnitine C14:2;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,8;0,00751;–;1,01;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4961;;
acylcarnitine C18:2;acylcarnitine C18:2;acylcarnitine C18:2;–;[M+H]+, [M-H]-;–;HMDB0006469;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,33;0,000000603;–;1,03;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4962;;
acylcarnitine C8:2;acylcarnitine C8:2;acylcarnitine C8:2;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,88;0,000277;–;1,26;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4963;;
aspartyl-leucine;aspartyl-leucine;aspartyl-leucine;–;[M+H]+, [M-H]-;–;HMDB0028757;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,84;0,000909;–;2,7;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4964;;
betaine;betaine;betaine;–;[M+H]+, [M-H]-;–;HMDB0000043;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,13;0,00109;–;10,28;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4965;;
butyrylcarnitine;butyrylcarnitine;butyrylcarnitine;–;[M+H]+, [M-H]-;–;HMDB0002013;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,24;0,0209;–;2,27;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4966;;
caprylic acid;caprylic acid;caprylic acid;–;[M+H]+, [M-H]-;–;HMDB0000482;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,63;0,000449;–;1,23;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4967;;
choline;choline;choline;–;[M+H]+, [M-H]-;–;HMDB0000097;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,13;0,0000397;–;7,91;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4968;;
cis-4-Hydroxy-D-proline;cis-4-Hydroxy-D-proline;cis-4-Hydroxy-D-proline;–;[M+H]+, [M-H]-;–;HMDB0060460;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,86;0,0266;–;3,47;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4969;;
cotinine;cotinine;cotinine;–;[M+H]+, [M-H]-;–;HMDB0001046;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,42;0,0153;–;1,22;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4970;;
cotinine;cotinine;cotinine;–;[M+H]+, [M-H]-;–;HMDB0001046;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,54;0,0248;–;1,26;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4971;;
creatine;creatine;creatine;–;[M+H]+, [M-H]-;–;HMDB0000064;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,2;0,0498;–;1,58;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4972;;
dehydroepiandrosterone sulfate;dehydroepiandrosterone sulfate;dehydroepiandrosterone sulfate;–;[M+H]+, [M-H]-;–;HMDB0001032;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,7;0,00266;–;2,32;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4973;;
dimethylglycine;dimethylglycine;dimethylglycine;–;[M+H]+, [M-H]-;–;HMDB0000092;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,73;0,00762;–;2,07;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4974;;
D-Xylonic acid;D-Xylonic acid;D-Xylonic acid;–;[M+H]+, [M-H]-;–;HMDB0059750;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,8;0,00531;–;1,1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4975;;
ectoine;ectoine;ectoine;–;[M+H]+, [M-H]-;–;HMDB0240650;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,76;0,00347;–;1,17;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4976;;
formiminoglutamic acid;formiminoglutamic acid;formiminoglutamic acid;–;[M+H]+, [M-H]-;–;HMDB0000854;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,71;0,033;–;1,67;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4977;;
gamma-Aminobutyryllysine;gamma-Aminobutyryllysine;gamma-Aminobutyryllysine;–;[M+H]+, [M-H]-;–;HMDB0001959;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,08;7,48E-010;–;1,08;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4978;;
gamma-Glutamyl serine;gamma-Glutamyl serine;gamma-Glutamyl serine;–;[M+H]+, [M-H]-;–;HMDB0029158;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,17;0,00163;–;5,4;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4979;;
glycerophosphocholine;glycerophosphocholine;glycerophosphocholine;–;[M+H]+, [M-H]-;–;HMDB0000086;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,33;2,01E-008;–;1,77;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4980;;
glycoursodeoxycholic acid;glycoursodeoxycholic acid;glycoursodeoxycholic acid;–;[M+H]+, [M-H]-;–;HMDB0000708;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,52;0,00565;–;2,86;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4981;;
glycoursodeoxycholic acid;glycoursodeoxycholic acid;glycoursodeoxycholic acid;–;[M+H]+, [M-H]-;–;HMDB0000708;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,56;0,00256;–;3,56;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4982;;
glycylhydroxyproline;glycylhydroxyproline;glycylhydroxyproline;–;[M+H]+, [M-H]-;–;HMDB0011173;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,44;0,0000551;–;1,83;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4983;;
glycylproline;glycylproline;glycylproline;–;[M+H]+, [M-H]-;–;HMDB0000721;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,36;0,0000445;–;5,78;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4984;;
glycylproline;glycylproline;glycylproline;–;[M+H]+, [M-H]-;–;HMDB0000721;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,37;0,0000461;–;7,18;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4985;;
glycylvaline;glycylvaline;glycylvaline;–;[M+H]+, [M-H]-;–;HMDB0028854;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,38;0,0000232;–;2,32;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4986;;
hypoxanthine;hypoxanthine;hypoxanthine;–;[M+H]+, [M-H]-;–;HMDB0000157;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,58;1,51E-010;–;5,41;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4987;;
imidazoleacetic acid;imidazoleacetic acid;imidazoleacetic acid;–;[M+H]+, [M-H]-;–;HMDB0002024;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,15;0,00125;–;1,2;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4988;;
inosinic acid;inosinic acid;inosinic acid;–;[M+H]+, [M-H]-;–;HMDB0000175;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,22;0,0191;–;8,21;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4989;;
L-arginine;L-arginine;L-arginine;–;[M+H]+, [M-H]-;–;HMDB0000517;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,87;0,000749;–;1,09;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4990;;
L-arginine;L-arginine;L-arginine;–;[M+H]+, [M-H]-;–;HMDB0000517;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,71;0,00406;–;2,5;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4991;;
L-asparagine;L-asparagine;L-asparagine;–;[M+H]+, [M-H]-;–;HMDB0000168;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,18;0,000129;–;1,2;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4992;;
L-carnitine;L-carnitine;L-carnitine;–;[M+H]+, [M-H]-;–;HMDB0000062;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,17;0,00000217;–;8,75;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4993;;
L-cystine;L-cystine;L-cystine;–;[M+H]+, [M-H]-;–;HMDB0000192;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,72;0,000000237;–;1,29;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4994;;
L-glutamine;L-glutamine;L-glutamine;–;[M+H]+, [M-H]-;–;HMDB0000641;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,86;0,000538;–;1,07;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4995;;
L-histidine;L-histidine;L-histidine;–;[M+H]+, [M-H]-;–;HMDB0000177;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,12;0,00592;–;3,61;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4996;;
L-histidine;L-histidine;L-histidine;–;[M+H]+, [M-H]-;–;HMDB0000177;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,1;0,027;–;1,73;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4997;;
linolenelaidic acid;linolenelaidic acid;linolenelaidic acid;–;[M+H]+, [M-H]-;–;HMDB0030964;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,82;0,001;–;2,3;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4998;;
L-kynurenine;L-kynurenine;L-kynurenine;–;[M+H]+, [M-H]-;–;HMDB0000684;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,2;0,000228;–;1,02;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;4999;;
L-leucine;L-leucine;L-leucine;–;[M+H]+, [M-H]-;–;HMDB0000687;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,45;0,0000602;–;1,25;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5000;;
L-lysine;L-lysine;L-lysine;–;[M+H]+, [M-H]-;–;HMDB0000182;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,1;0,0188;–;2,5;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5001;;
L-norleucine;L-norleucine;L-norleucine;–;[M+H]+, [M-H]-;–;HMDB0001645;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,07;0,0402;–;1,98;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5002;;
L-phenylalanine;L-phenylalanine;L-phenylalanine;–;[M+H]+, [M-H]-;–;HMDB0000159;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,09;0,0118;–;2,37;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5003;;
L-proline;L-proline;L-proline;–;[M+H]+, [M-H]-;–;HMDB0000162;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,11;0,0148;–;2,07;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5004;;
L-serine;L-serine;L-serine;–;[M+H]+, [M-H]-;–;HMDB0000187;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,14;0,000945;–;1,21;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5005;;
L-theanine;L-theanine;L-theanine;–;[M+H]+, [M-H]-;–;HMDB0034365;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,63;0,00442;–;1,97;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5006;;
L-threonine;L-threonine;L-threonine;–;[M+H]+, [M-H]-;–;HMDB0000167;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,23;0,0000853;–;2,33;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5007;;
L-threonine;L-threonine;L-threonine;–;[M+H]+, [M-H]-;–;HMDB0000167;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,17;0,00137;–;1,32;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5008;;
methylhexadecanoic acid;methylhexadecanoic acid;methylhexadecanoic acid;–;[M+H]+, [M-H]-;–;HMDB0031067;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,36;0,0183;–;1,69;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5009;;
methylimidazoleacetic acid;methylimidazoleacetic acid;methylimidazoleacetic acid;–;[M+H]+, [M-H]-;–;HMDB0002820;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,39;0,0000705;–;6,15;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5010;;
N(6)-Methyllysin;N(6)-Methyllysin;N(6)-Methyllysin;–;[M+H]+, [M-H]-;–;HMDB0002038;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,84;0,0041;–;1,31;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5011;;
N(6)-Methyllysine;N(6)-Methyllysine;N(6)-Methyllysine;–;[M+H]+, [M-H]-;–;HMDB0002038;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,78;0,000000438;–;1,86;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5012;;
N2-Acetylornithine;N2-Acetylornithine;N2-Acetylornithine;–;[M+H]+, [M-H]-;–;HMDB0003357;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,73;0,00366;–;1,62;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5013;;
N2-gamma-Glutamylglutamine;N2-gamma-Glutamylglutamine;N2-gamma-Glutamylglutamine;–;[M+H]+, [M-H]-;–;HMDB0011738;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,28;0,000035;–;1,03;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5014;;
N6,N6,N6-trimethyl-L-lysine;N6,N6,N6-trimethyl-L-lysine;N6,N6,N6-trimethyl-L-lysine;–;[M+H]+, [M-H]-;–;HMDB0001325;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,17;0,00183;–;1,57;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5015;;
N-acetyl-beta-alanine;N-acetyl-beta-alanine;N-acetyl-beta-alanine;–;[M+H]+, [M-H]-;–;HMDB0061880;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,74;0,000145;–;2,68;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5016;;
Ne,Ne dimethyllysine;Ne,Ne dimethyllysine;Ne,Ne dimethyllysine;–;[M+H]+, [M-H]-;–;HMDB0013287;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,58;0,00000124;–;2,21;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5017;;
Ne,Ne dimethyllysine;Ne,Ne dimethyllysine;Ne,Ne dimethyllysine;–;[M+H]+, [M-H]-;–;HMDB0013287;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,55;0,0000186;–;2,29;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5018;;
N-LINOLEOYL- 4-AMINOBUTYRIC ACID;N-LINOLEOYL- 4-AMINOBUTYRIC ACID;N-LINOLEOYL- 4-AMINOBUTYRIC ACID;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,45;1,41E-022;–;3,07;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5019;;
N-OLEOYL-4-A MINOBUTYRIC ACID;N-OLEOYL-4-A MINOBUTYRIC ACID;N-OLEOYL-4-A MINOBUTYRIC ACID;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,48;5,06E-023;–;7,37;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5020;;
N-undecanoylglycine;N-undecanoylglycine;N-undecanoylglycine;–;[M+H]+, [M-H]-;–;HMDB0013286;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;2,07;0,0000045;–;1,4;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5021;;
o-tyrosine;o-tyrosine;o-tyrosine;–;[M+H]+, [M-H]-;–;HMDB0006050;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,47;0,0441;–;1,42;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5022;;
pelargonic acid;pelargonic acid;pelargonic acid;–;[M+H]+, [M-H]-;–;HMDB0000847;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,84;0,000358;–;1,18;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5023;;
pipecolic acid;pipecolic acid;pipecolic acid;–;[M+H]+, [M-H]-;–;HMDB0000070;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,09;0,026;–;2,15;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5024;;
proline betaine;proline betaine;proline betaine;–;[M+H]+, [M-H]-;–;HMDB0004827;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,72;0,0238;–;7,74;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5025;;
pseudouridine;pseudouridine;pseudouridine;–;[M+H]+, [M-H]-;–;HMDB0000767;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,13;0,00068;–;1,11;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5026;;
pyroglutamylglycine;pyroglutamylglycine;pyroglutamylglycine;–;[M+H]+, [M-H]-;–;HMDB0061890;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,31;0,000000056;–;1,67;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5027;;
stearic acid;stearic acid;stearic acid;–;[M+H]+, [M-H]-;–;HMDB0000827;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,81;0,0000151;–;8,63;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5028;;
symmetric dimethylarginine;symmetric dimethylarginine;symmetric dimethylarginine;–;[M+H]+, [M-H]-;–;HMDB0003334;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,16;0,0225;–;1,44;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5029;;
taurine;taurine;taurine;–;[M+H]+, [M-H]-;–;HMDB0000251;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,07;0,0263;–;1,13;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5030;;
threonic acid;threonic acid;threonic acid;–;[M+H]+, [M-H]-;–;HMDB0000943;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,38;0,000000577;–;2,1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5031;;
uridine;uridine;uridine;–;[M+H]+, [M-H]-;–;HMDB0000296;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,87;0,000471;–;3,71;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5032;;
xanthine;xanthine;xanthine;–;[M+H]+, [M-H]-;–;HMDB0000292;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,41;0,0000053;–;1,62;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5033;;
3',5'-Cyclic IMP;3',5'-Cyclic IMP;3',5'-Cyclic IMP;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,21;0,000000922;–;11,97;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5034;;
3-oxopalmitic acid;3-oxopalmitic acid;3-oxopalmitic acid;–;[M+H]+, [M-H]-;–;HMDB0010733;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,7;1,47E-008;–;1,01;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5035;;
arachidic acid;arachidic acid;arachidic acid;–;[M+H]+, [M-H]-;–;HMDB0002212;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,6;0,00000221;–;4,49;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5036;;
capric acid;capric acid;capric acid;–;[M+H]+, [M-H]-;–;HMDB0000511;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,83;0,00445;–;1,35;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5037;;
caprylic acid;caprylic acid;caprylic acid;–;[M+H]+, [M-H]-;–;HMDB0000482;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,8;0,0113;–;1,99;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5038;;
Cer(d18:1/16:0);Cer(d18:1/16:0);Cer(d18:1/16:0);–;[M+H]+, [M-H]-;–;HMDB0004949;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,63;0,000011;–;1,01;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5039;;
citric acid;citric acid;citric acid;–;[M+H]+, [M-H]-;–;HMDB0000094;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,13;0,0217;–;2,79;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5040;;
dehydroascorbic acid;dehydroascorbic acid;dehydroascorbic acid;–;[M+H]+, [M-H]-;–;HMDB0001264;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,28;0,0000506;–;1,24;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5041;;
deoxycholic acid;deoxycholic acid;deoxycholic acid;–;[M+H]+, [M-H]-;–;HMDB0000626;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,74;0,00794;–;1,31;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5042;;
docosahexaenoic acid;docosahexaenoic acid;docosahexaenoic acid;–;[M+H]+, [M-H]-;–;HMDB0002183;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,82;0,00875;–;1,98;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5043;;
dodecanoic acid;dodecanoic acid;dodecanoic acid;–;[M+H]+, [M-H]-;–;HMDB0000638;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,66;0,000000006;–;5,08;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5044;;
glutamylglycine;glutamylglycine;glutamylglycine;–;[M+H]+, [M-H]-;–;HMDB0028819;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;2,4;2,21E-008;–;1,27;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5045;;
glycolic acid;glycolic acid;glycolic acid;–;[M+H]+, [M-H]-;–;HMDB0000115;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,28;0,0000123;–;1,89;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5046;;
glycoursodeoxycholic acid;glycoursodeoxycholic acid;glycoursodeoxycholic acid;–;[M+H]+, [M-H]-;–;HMDB0000708;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,5;0,00865;–;1,5;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5047;;
hydroxypropionic acid;hydroxypropionic acid;hydroxypropionic acid;–;[M+H]+, [M-H]-;–;HMDB0000700;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,66;3,72E-010;–;2,57;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5048;;
juniperic acid;juniperic acid;juniperic acid;–;[M+H]+, [M-H]-;–;HMDB0006294;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,62;1,82E-012;–;1,14;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5049;;
L-histidine;L-histidine;L-histidine;–;[M+H]+, [M-H]-;–;HMDB0000177;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;2,09;0,000139;–;1,27;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5050;;
L-leucine;L-leucine;L-leucine;–;[M+H]+, [M-H]-;–;HMDB0000687;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,35;0,011;–;1,33;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5051;;
LysoPC(0:0/18:0);LysoPC(0:0/18:0);LysoPC(0:0/18:0);–;[M+H]+, [M-H]-;–;HMDB0011128;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,2;0,00137;–;1,49;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5052;;
LysoPC(16:0/0:0);LysoPC(16:0/0:0);LysoPC(16:0/0:0);–;[M+H]+, [M-H]-;–;HMDB0010382;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,11;0,0152;–;4,4;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5053;;
LysoPC(16:1(9Z)/0:0);LysoPC(16:1(9Z)/0:0);LysoPC(16:1(9Z)/0:0);–;[M+H]+, [M-H]-;–;HMDB0010383;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,25;0,00229;–;1,13;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5054;;
LysoPC(18:0/0:0);LysoPC(18:0/0:0);LysoPC(18:0/0:0);–;[M+H]+, [M-H]-;–;HMDB0010384;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,18;0,0123;–;3,57;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5055;;
LysoPC(18:1(9Z)/0:0);LysoPC(18:1(9Z)/0:0);LysoPC(18:1(9Z)/0:0);–;[M+H]+, [M-H]-;–;HMDB0002815;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,16;0,00603;–;2,68;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5056;;
LysoPC(20:4(5Z,8Z,11Z,14Z)/0:0);LysoPC(20:4(5Z,8Z,11Z,14Z)/0:0);LysoPC(20:4(5Z,8Z,11Z,14Z)/0:0);–;[M+H]+, [M-H]-;–;HMDB0010395;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,19;0,0041;–;1,77;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5057;;
LysoPE(18:0/0:0);LysoPE(18:0/0:0);LysoPE(18:0/0:0);–;[M+H]+, [M-H]-;–;HMDB0011130;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,22;0,0009;–;1,05;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5058;;
LysoPE(18:2(9Z,12Z)/0:0);LysoPE(18:2(9Z,12Z)/0:0);LysoPE(18:2(9Z,12Z)/0:0);–;[M+H]+, [M-H]-;–;HMDB0011507;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,16;0,042;–;1,03;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5059;;
myristic acid;myristic acid;myristic acid;–;[M+H]+, [M-H]-;–;HMDB0000806;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,53;0,0124;–;1,85;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5060;;
nonadecanoic acid;nonadecanoic acid;nonadecanoic acid;–;[M+H]+, [M-H]-;–;HMDB0000772;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,68;0,0000157;–;1,42;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5061;;
O-acetylserine;O-acetylserine;O-acetylserine;–;[M+H]+, [M-H]-;–;HMDB0003011;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,38;2,59E-012;–;3,15;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5062;;
oleic acid;oleic acid;oleic acid;–;[M+H]+, [M-H]-;–;HMDB0000207;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,86;0,0209;–;1,82;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5063;;
oxoglutaric acid;oxoglutaric acid;oxoglutaric acid;–;[M+H]+, [M-H]-;–;HMDB0000208;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,13;0,0314;–;2,66;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5064;;
pelargonic acid;pelargonic acid;pelargonic acid;–;[M+H]+, [M-H]-;–;HMDB0000847;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,81;0,000409;–;2,9;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5065;;
pentadecanoic acid;pentadecanoic acid;pentadecanoic acid;–;[M+H]+, [M-H]-;–;HMDB0000826;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,8;0,000000156;–;3,69;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5066;;
phosphate;phosphate;phosphate;–;[M+H]+, [M-H]-;–;HMDB0001429;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,11;0,0246;–;1,08;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5067;;
PI(16:0/20:4(5Z,8Z,11Z,14Z));PI(16:0/20:4(5Z,8Z,11Z,14Z));PI(16:0/20:4(5Z,8Z,11Z,14Z));–;[M+H]+, [M-H]-;–;HMDB0009789;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,28;0,0135;–;1,04;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5068;;
PI(18:0/18:2(9Z,12Z));PI(18:0/18:2(9Z,12Z));PI(18:0/18:2(9Z,12Z));–;[M+H]+, [M-H]-;–;HMDB0009809;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,28;0,013;–;1,63;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5069;;
PI(18:0/20:4(5Z,8Z,11Z,14Z));PI(18:0/20:4(5Z,8Z,11Z,14Z));PI(18:0/20:4(5Z,8Z,11Z,14Z));–;[M+H]+, [M-H]-;–;HMDB0009815;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,36;0,000379;–;4,13;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5070;;
rhamnose;rhamnose;rhamnose;–;[M+H]+, [M-H]-;–;HMDB0000849;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,44;0,00002;–;2,84;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5071;;
stearic acid;stearic acid;stearic acid;–;[M+H]+, [M-H]-;–;HMDB0000827;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,75;2,19E-009;–;29,93;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5072;;
testosterone sulfate;testosterone sulfate;testosterone sulfate;–;[M+H]+, [M-H]-;–;HMDB0002833;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,71;0,00359;–;2,27;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5073;;
tridecylic acid;tridecylic acid;tridecylic acid;–;[M+H]+, [M-H]-;–;HMDB0000910;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,74;6,59E-013;–;2,05;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5074;;
undecanoic acid;undecanoic acid;undecanoic acid;–;[M+H]+, [M-H]-;–;HMDB0000947;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,75;8,62E-008;–;1,71;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5075;;
Undecylenic acid;Undecylenic acid;Undecylenic acid;–;[M+H]+, [M-H]-;–;HMDB0033724;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,69;0,0000153;–;1,11;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5076;;
3-hydroxyoctanoyl carnitine;3-hydroxyoctanoyl carnitine;3-hydroxyoctanoyl carnitine;–;[M+H]+, [M-H]-;–;HMDB0061634;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,74;0,000703;–;1,01;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5077;;
3-oxooctadecanoic acid;3-oxooctadecanoic acid;3-oxooctadecanoic acid;–;[M+H]+, [M-H]-;–;HMDB0010736;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,57;1,11E-011;–;1,76;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5078;;
4-hydroxyproline;4-hydroxyproline;4-hydroxyproline;–;[M+H]+, [M-H]-;–;HMDB0000725;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,79;3,21E-009;–;2,38;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5079;;
acetylcholine;acetylcholine;acetylcholine;–;[M+H]+, [M-H]-;–;HMDB0000895;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,23;0,0000172;–;1,3;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5080;;
acylcarnitine C10:1;acylcarnitine C10:1;acylcarnitine C10:1;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,46;0,00206;–;4,2;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5081;;
acylcarnitine C10:1;acylcarnitine C10:1;acylcarnitine C10:1;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,69;0,00595;–;1,21;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5082;;
acylcarnitine C12:0;acylcarnitine C12:0;acylcarnitine C12:0;–;[M+H]+, [M-H]-;–;HMDB0002250;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,73;0,00223;–;1,26;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5083;;
acylcarnitine C12:1;acylcarnitine C12:1;acylcarnitine C12:1;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,7;0,00306;–;1,35;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5084;;
acylcarnitine C14:1;acylcarnitine C14:1;acylcarnitine C14:1;–;[M+H]+, [M-H]-;–;HMDB0002014;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,74;0,00579;–;1,3;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5085;;
acylcarnitine C14:1;acylcarnitine C14:1;acylcarnitine C14:1;–;[M+H]+, [M-H]-;–;HMDB0002014;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,8;0,00966;–;1,13;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5086;;
acylcarnitine C14:2;acylcarnitine C14:2;acylcarnitine C14:2;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,59;0,0000287;–;1,24;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5087;;
acylcarnitine C18:2;acylcarnitine C18:2;acylcarnitine C18:2;–;[M+H]+, [M-H]-;–;HMDB0006469;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,75;0,00000606;–;4,57;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5088;;
acylcarnitine C8:0;acylcarnitine C8:0;acylcarnitine C8:0;–;[M+H]+, [M-H]-;–;HMDB0000791;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,82;0,0285;–;2,01;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5089;;
acylcarnitine C9:1;acylcarnitine C9:1;acylcarnitine C9:1;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,73;0,000127;–;1,16;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5090;;
alpha-Linolenic acid;alpha-Linolenic acid;alpha-Linolenic acid;–;[M+H]+, [M-H]-;–;HMDB0001388;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,85;0,00465;–;1,85;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5091;;
bilirubin;bilirubin;bilirubin;–;[M+H]+, [M-H]-;–;HMDB0000054;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,85;0,0231;–;1,49;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5092;;
caffeine;caffeine;caffeine;–;[M+H]+, [M-H]-;–;HMDB0001847;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,29;0,00519;–;4,39;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5093;;
choline;choline;choline;–;[M+H]+, [M-H]-;–;HMDB0000097;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,22;2,74E-008;–;3,76;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5094;;
cotinine;cotinine;cotinine;–;[M+H]+, [M-H]-;–;HMDB0001046;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,38;0,00647;–;1,58;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5095;;
creatinine;creatinine;creatinine;–;[M+H]+, [M-H]-;–;HMDB0000562;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,89;0,00053;–;2,98;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5096;;
decanoylcarnitine;decanoylcarnitine;decanoylcarnitine;–;[M+H]+, [M-H]-;–;HMDB0000651;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,77;0,0274;–;2,38;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5097;;
glycochenodeoxycholic acid;glycochenodeoxycholic acid;glycochenodeoxycholic acid;–;[M+H]+, [M-H]-;–;HMDB0000637;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,47;0,0144;–;1,86;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5098;;
glycylhydroxyproline;glycylhydroxyproline;glycylhydroxyproline;–;[M+H]+, [M-H]-;–;HMDB0011173;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,93;0,0448;–;1,55;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5099;;
glycylproline;glycylproline;glycylproline;–;[M+H]+, [M-H]-;–;HMDB0000721;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,65;0,00023;–;2,38;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5100;;
hippuric acid;hippuric acid;hippuric acid;–;[M+H]+, [M-H]-;–;HMDB0000714;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,46;0,00307;–;1,12;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5101;;
hypoxanthine;hypoxanthine;hypoxanthine;–;[M+H]+, [M-H]-;–;HMDB0000157;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,43;3,76E-008;–;1,73;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5102;;
indole-3-carboxal dehyde;indole-3-carboxal dehyde;indole-3-carboxal dehyde;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,34;0,000391;–;1,24;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5103;;
indoleacrylic acid;indoleacrylic acid;indoleacrylic acid;–;[M+H]+, [M-H]-;–;HMDB0000734;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,92;0,0172;–;4,18;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5104;;
L-Acetylcarnitine;L-Acetylcarnitine;L-Acetylcarnitine;–;[M+H]+, [M-H]-;–;HMDB0000201;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,92;0,0441;–;3,26;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5105;;
L-arginine;L-arginine;L-arginine;–;[M+H]+, [M-H]-;–;HMDB0000517;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,74;0,00000111;–;1,86;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5106;;
L-leucine;L-leucine;L-leucine;–;[M+H]+, [M-H]-;–;HMDB0000687;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,93;0,0015;–;5,76;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5107;;
L-methionine;L-methionine;L-methionine;–;[M+H]+, [M-H]-;–;HMDB0000696;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,91;0,00114;–;2,38;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5108;;
L-tryptophan;L-tryptophan;L-tryptophan;–;[M+H]+, [M-H]-;–;HMDB0000929;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,92;0,0145;–;4,29;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5109;;
LysoPC(0:0/18:0);LysoPC(0:0/18:0);LysoPC(0:0/18:0);–;[M+H]+, [M-H]-;–;HMDB0011128;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,14;0,0196;–;1,98;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5110;;
LysoPC(18:0/0:0);LysoPC(18:0/0:0);LysoPC(18:0/0:0);–;[M+H]+, [M-H]-;–;HMDB0010384;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,1;0,0273;–;4,73;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5111;;
N,N-dimethylsphingosine;N,N-dimethylsphingosine;N,N-dimethylsphingosine;–;[M+H]+, [M-H]-;–;HMDB0013645;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,71;0,00000023;–;5,12;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5112;;
prenisteine;prenisteine;prenisteine;–;[M+H]+, [M-H]-;–;HMDB0012286;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,54;1,24E-018;–;1,46;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5113;;
proline betaine;proline betaine;proline betaine;–;[M+H]+, [M-H]-;–;HMDB0004827;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,68;0,00724;–;3,88;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5114;;
S-Allyl-L-cysteine;S-Allyl-L-cysteine;S-Allyl-L-cysteine;–;[M+H]+, [M-H]-;–;–;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,51;4,42E-015;–;1,53;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5115;;
sphingosine 1-phosphate;sphingosine 1-phosphate;sphingosine 1-phosphate;–;[M+H]+, [M-H]-;–;HMDB0000277;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;1,26;3,57E-009;–;2,35;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5116;;
Vitamin A;Vitamin A;Vitamin A;–;[M+H]+, [M-H]-;–;HMDB0000305;–;–;–;–;–;–;blood;diagnosis;adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types;I, II, III, IV;98;51, 47;Median: 50 (32-69);–;healthy;75;36, 39;Median: 50 (31-69);–;LC;ESI;both;Q-Orbitrap;MS/MS;ProteoWizard, XCMS, Xcalibur, CAMERA;mzCloud, ChemSpider, LipidBlast and Fiehn HILIC;SIMCA;PCA, OPLS-DA, Student’s t test ;–;–;0,74;0,00263;–;1,92;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways.;34083687;Qi et al. 2021;5117;;
LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z));LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z));LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z));–;–;–;HMDB0010404;–;–;–;–;–;568,3383944;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3 ;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L1 detection.;34136379;Wan et al., 2021;5118;;
LysoPC(20:4(8Z,11Z,14Z,17Z));LysoPC(20:4(8Z,11Z,14Z,17Z));LysoPC(20:4(8Z,11Z,14Z,17Z));–;–;–;HMDB0010396;–;–;–;–;–;544,3388767;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3 ;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L2 detection.;34136379;Wan et al., 2021;5119;;
LysoPC(16:1(9Z));LysoPC(16:1(9Z));LysoPC(16:1(9Z));–;–;–;HMDB0010383;–;–;–;–;–;494,3233547;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L3 detection.;34136379;Wan et al., 2021;5120;;
PC(18:2(9Z,12Z)/18:2(9Z,12Z));PC(18:2(9Z,12Z)/18:2(9Z,12Z));PC(18:2(9Z,12Z)/18:2(9Z,12Z));–;–;–;HMDB0008138;–;–;–;–;–;782,5676741;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L4 detection.;34136379;Wan et al., 2021;5121;;
PC(18:0/20:4(8Z,11Z,14Z,17Z));PC(18:0/20:4(8Z,11Z,14Z,17Z));PC(18:0/20:4(8Z,11Z,14Z,17Z));–;–;–;HMDB0008049;–;–;–;–;–;810,599091;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;ROC analysis;–;0,979;0,9333;0,9333;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L5 detection.;34136379;Wan et al., 2021;5122;;
1-linoleoylglycerophosphocholine;1-linoleoylglycerophosphocholine;1-linoleoylglycerophosphocholine;–;–;–;HMDB0010386;–;–;–;–;–;520,3385644;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L6 detection.;34136379;Wan et al., 2021;5123;;
PC(16:0/20:4(5Z,8Z,11Z,14Z));PC(16:0/20:4(5Z,8Z,11Z,14Z));PC(16:0/20:4(5Z,8Z,11Z,14Z));–;–;–;HMDB0007982;–;–;–;–;–;804,5499407;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;ROC analysis;–;1;1;1;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L7 detection.;34136379;Wan et al., 2021;5124;;
PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z));PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z));PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z));–;–;–;HMDB0008945;–;–;–;–;–;730,5235003;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L8 detection.;34136379;Wan et al., 2021;5125;;
PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));–;–;–;HMDB0007991;–;–;–;–;–;806,5674193;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;ROC analysis;–;0,968;0,9;0,9667;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L9 detection.;34136379;Wan et al., 2021;5126;;
LysoPC(18:0);LysoPC(18:0);LysoPC(18:0);–;–;–;HMDB0010384;–;–;–;–;–;546,3524004;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;ROC analysis;–;0,933;0,9333;0,8;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L10 detection.;34136379;Wan et al., 2021;5127;;
L-palmitoylcarnitine;L-palmitoylcarnitine;L-palmitoylcarnitine;–;–;–;HMDB0000222;–;–;–;–;–;400,3415326;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;ROC analysis;–;0,993;0,9333;1;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L11 detection.;34136379;Wan et al., 2021;5128;;
PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));–;–;–;HMDB0008847;–;–;–;–;–;718,4873528;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L12 detection.;34136379;Wan et al., 2021;5129;;
PE(14:0/20:4(5Z,8Z,11Z,14Z));PE(14:0/20:4(5Z,8Z,11Z,14Z));PE(14:0/20:4(5Z,8Z,11Z,14Z));–;–;–;HMDB0008838;–;–;–;–;–;676,4758311;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L13 detection.;34136379;Wan et al., 2021;5130;;
12(R)-HETE;12(R)-HETE;12(R)-HETE;–;–;–;–;–;–;–;–;–;319,2265323;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L14 detection.;34136379;Wan et al., 2021;5131;;
LysoPC(18:3(9Z,12Z,15Z));LysoPC(18:3(9Z,12Z,15Z));LysoPC(18:3(9Z,12Z,15Z));–;–;–;HMDB0010388;–;–;–;–;–;562,3134118;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L15 detection.;34136379;Wan et al., 2021;5132;;
LysoPC(16:1(9Z)/0:0);LysoPC(16:1(9Z)/0:0);LysoPC(16:1(9Z)/0:0);–;–;–;HMDB0010383;–;–;–;–;–;538,3134614;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;ROC analysis;–;0,951;0,9667;0,8388;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L16 detection.;34136379;Wan et al., 2021;5133;;
PC(18:1(11Z)/18:3(6Z,9Z,12Z));PC(18:1(11Z)/18:3(6Z,9Z,12Z));PC(18:1(11Z)/18:3(6Z,9Z,12Z));–;–;–;HMDB0008073;–;–;–;–;–;826,5586321;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L17 detection.;34136379;Wan et al., 2021;5134;;
PE(15:0/22:1(13Z));PE(15:0/22:1(13Z));PE(15:0/22:1(13Z));–;–;–;HMDB0008908;–;–;–;–;–;804,5749688;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L18 detection.;34136379;Wan et al., 2021;5135;;
PE(15:0/24:1(15Z));PE(15:0/24:1(15Z));PE(15:0/24:1(15Z));–;–;–;HMDB0008915;–;–;–;–;–;832,6063319;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L19 detection.;34136379;Wan et al., 2021;5136;;
PC(20:2(11Z,14Z)/18:1(11Z));PC(20:2(11Z,14Z)/18:1(11Z));PC(20:2(11Z,14Z)/18:1(11Z));–;–;–;HMDB0008334;–;–;–;–;–;856,6065374;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L20 detection.;34136379;Wan et al., 2021;5137;;
PC(16:0/20:3(5Z,8Z,11Z));PC(16:0/20:3(5Z,8Z,11Z));PC(16:0/20:3(5Z,8Z,11Z));–;–;–;HMDB0007980;–;–;–;–;–;828,5748635;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L21 detection.;34136379;Wan et al., 2021;5138;;
PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z));PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z));PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z));–;–;–;HMDB0008945;–;–;–;–;–;730,5235003;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;ROC analysis;–;1;1;1;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L22 detection.;34136379;Wan et al., 2021;5139;;
PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));–;–;–;HMDB0008847;–;–;–;–;–;718,4873528;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;ROC analysis;–;1;1;1;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L23 detection.;34136379;Wan et al., 2021;5140;;
PE(14:0/20:4(5Z,8Z,11Z,14Z));PE(14:0/20:4(5Z,8Z,11Z,14Z));PE(14:0/20:4(5Z,8Z,11Z,14Z));–;–;–;HMDB0008838;–;–;–;–;–;676,4758311;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;ROC analysis;–;1;1;1;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L24 detection.;34136379;Wan et al., 2021;5141;;
PE(15:0/22:1(13Z));PE(15:0/22:1(13Z));PE(15:0/22:1(13Z));–;–;–;HMDB0008908;–;–;–;–;–;804,5749688;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L25 detection.;34136379;Wan et al., 2021;5142;;
PE(15:0/24:1(15Z));PE(15:0/24:1(15Z));PE(15:0/24:1(15Z));–;–;–;HMDB0008915;–;–;–;–;–;832,6063319;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L26 detection.;34136379;Wan et al., 2021;5143;;
LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z));LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z));LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z));–;–;–;HMDB0010404;–;–;–;–;–;568,3383944;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L27 detection.;34136379;Wan et al., 2021;5144;;
LysoPC(20:4(8Z,11Z,14Z,17Z));LysoPC(20:4(8Z,11Z,14Z,17Z));LysoPC(20:4(8Z,11Z,14Z,17Z));–;–;–;HMDB0010396;–;–;–;–;–;544,3388767;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L28 detection.;34136379;Wan et al., 2021;5145;;
LysoPC(16:1(9Z));LysoPC(16:1(9Z));LysoPC(16:1(9Z));–;–;–;HMDB0010383;–;–;–;–;–;494,3233547;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L29 detection.;34136379;Wan et al., 2021;5146;;
PC(18:2(9Z,12Z)/18:2(9Z,12Z));PC(18:2(9Z,12Z)/18:2(9Z,12Z));PC(18:2(9Z,12Z)/18:2(9Z,12Z));–;–;–;HMDB0008138;–;–;–;–;–;782,5676741;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L30 detection.;34136379;Wan et al., 2021;5147;;
PC(18:0/20:4(8Z,11Z,14Z,17Z));PC(18:0/20:4(8Z,11Z,14Z,17Z));PC(18:0/20:4(8Z,11Z,14Z,17Z));–;–;–;HMDB0008049;–;–;–;–;–;810,599091;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L31 detection.;34136379;Wan et al., 2021;5148;;
L-isoleucine;L-isoleucine;L-isoleucine;–;–;–;HMDB0000172;–;–;–;–;–;132,1018405;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;ROC analysis;–;0,967;0,9333;0,9667;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L32 detection.;34136379;Wan et al., 2021;5149;;
1-linoleoylglycerophosphocholine;1-linoleoylglycerophosphocholine;1-linoleoylglycerophosphocholine;–;–;–;HMDB0010386;–;–;–;–;–;520,3385644;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L33 detection.;34136379;Wan et al., 2021;5150;;
PC(16:0/20:4(5Z,8Z,11Z,14Z));PC(16:0/20:4(5Z,8Z,11Z,14Z));PC(16:0/20:4(5Z,8Z,11Z,14Z));–;–;–;HMDB0007982;–;–;–;–;–;804,5499407;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L34 detection.;34136379;Wan et al., 2021;5151;;
PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));–;–;–;HMDB0007991;–;–;–;–;–;806,5674193;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L35 detection.;34136379;Wan et al., 2021;5152;;
LysoPC(18:0);LysoPC(18:0);LysoPC(18:0);–;–;–;HMDB0010384;–;–;–;–;–;546,3524004;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L36 detection.;34136379;Wan et al., 2021;5153;;
LysoPC(18:3(9Z,12Z,15Z));LysoPC(18:3(9Z,12Z,15Z));LysoPC(18:3(9Z,12Z,15Z));–;–;–;HMDB0010388;–;–;–;–;–;562,3134118;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L37 detection.;34136379;Wan et al., 2021;5154;;
LysoPC(16:1(9Z)/0:0);LysoPC(16:1(9Z)/0:0);LysoPC(16:1(9Z)/0:0);–;–;–;HMDB0010383;–;–;–;–;–;538,3134614;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L38 detection.;34136379;Wan et al., 2021;5155;;
PC(18:1(11Z)/18:3(6Z,9Z,12Z));PC(18:1(11Z)/18:3(6Z,9Z,12Z));PC(18:1(11Z)/18:3(6Z,9Z,12Z));–;–;–;HMDB0008073;–;–;–;–;–;826,5586321;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L39 detection.;34136379;Wan et al., 2021;5156;;
PC(20:2(11Z,14Z)/18:1(11Z));PC(20:2(11Z,14Z)/18:1(11Z));PC(20:2(11Z,14Z)/18:1(11Z));–;–;–;HMDB0008334;–;–;–;–;–;856,6065374;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L40 detection.;34136379;Wan et al., 2021;5157;;
PC(16:0/20:3(5Z,8Z,11Z));PC(16:0/20:3(5Z,8Z,11Z));PC(16:0/20:3(5Z,8Z,11Z));–;–;–;HMDB0007980;–;–;–;–;–;828,5748635;Serum;diagnosis;squamous cell carcinomas+adenocarcinomas;I, II;48;21, 27;59.1 (38-75);smoker, non-smoker;healthy;30;–;–;–;LC;ESI;both;Q-TOF;–;Progenesis QI 2.3;HMDB, Metlin;Progenesis QI 2.3, SPSS;PCA, OPLS-DA, Student’s t test ;–;–;–;<0.05;–;>1;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolites of signiﬁcance and the associated metabolic pathways., Mutation gene information, CTC NGS analysis of cancer-related gene mutations in lung cancer patients., CellCollector captures representative CTC graphs and CTC and CTC PD-L41 detection.;34136379;Wan et al., 2021;5158;;
L-lactic acid;L-lactic acid;L-lactic acid;–;–;–;HMDB0001311;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,909;3,21E-017;1,16E-016;1,269;–;–;–;–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5159;;
2-hydroxybutyric acid;2-hydroxybutyric acid;2-hydroxybutyric acid;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;1,016;3,57E-010;4,02E-010;1,034;ROC analysis;–;0.993 (Combination of cholesterol, oleic acid, 4-hydroxybutyric acid, myo-inositol, and 2-hydroxybutyric acid);–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5160;;
ketoleucine;ketoleucine;ketoleucine;–;–;–;HMDB0000695;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,885;4,73E-013;8,51E-013;1,08;–;–;–;–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5161;;
4-hydroxybutyric acid;4-hydroxybutyric acid;4-hydroxybutyric acid;–;–;–;HMDB0000710;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,885;2,02E-022;1,21E-021;1,23;ROC analysis;–;0.993 (Combination of cholesterol, oleic acid, 4-hydroxybutyric acid, myo-inositol, and 2-hydroxybutyric acid);–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5162;;
pelargonic acid;pelargonic acid;pelargonic acid;–;–;–;HMDB0000847;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,903;1,89E-012;2,62E-012;1,114;–;–;–;–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5163;;
threonic acid;threonic acid;threonic acid;–;–;–;HMDB0000943;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,89;3,61E-018;1,62E-017;1,196;–;–;–;–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5164;;
palmitoleic acid;palmitoleic acid;palmitoleic acid;–;–;–;HMDB0003229;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,913;0,00000197;0,00000197;1,003;–;–;–;–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5165;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,913;8,06E-016;2,42E-015;1,156;–;–;–;–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5166;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,926;3,65E-013;7,31E-013;1,062;ROC analysis;–;0.993 (Combination of cholesterol, oleic acid, 4-hydroxybutyric acid, myo-inositol, and 2-hydroxybutyric acid);–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5167;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,905;1,53E-014;3,95E-014;1,072;ROC analysis;–;0.993 (Combination of cholesterol, oleic acid, 4-hydroxybutyric acid, myo-inositol, and 2-hydroxybutyric acid);–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5168;;
stearic acid;stearic acid;stearic acid;–;–;–;HMDB0000827;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,927;5,61E-013;8,42E-013;1,107;–;–;–;–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5169;;
arachidic acid;arachidic acid;arachidic acid;–;–;–;HMDB0002212;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,914;5,32E-013;8,7E-013;1,028;–;–;–;–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5170;;
MG(0:0/16:0/0:0);MG(0:0/16:0/0:0);MG(0:0/16:0/0:0);–;–;–;HMDB0011533;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,858;3,98E-029;3,58E-028;1,303;–;–;–;–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5171;;
cholesterol;cholesterol;cholesterol;–;–;–;HMDB0000067;–;–;–;–;–;–;Serum;diagnosis;lung cancer;I, II, III, IV;57;38, 19;Median: 62 (52-69);smoker, non-smoker;healthy;59;48, 11;Median: 60 (59-62);smoker, non-smoker;GC;EI;–;quadrupole;–;MassHunter Workstation software, Mass Profiler Professional software ;NIST14, HMDB, Golm Metabolome Database;SPSS, SIMCA-P, GraphPad Prism;Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA;–;–;0,84;9,76E-031;1,76E-029;1,337;ROC analysis;–;0.993 (Combination of cholesterol, oleic acid, 4-hydroxybutyric acid, myo-inositol, and 2-hydroxybutyric acid);–;–;–;–;–;–;–;–;China;–;Signaling Pathway by IPA Network Analysis, Biological pathway of proliferation-associated candidate biomarkers;34056907;Zheng et al. 2021 ;5172;;
GABA;GABA;GABA;–;–;–;HMDB0000112;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8 ;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;0,000127;0,00039;1,043;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5173;;
serine;serine;serine;–;–;–;HMDB0000187;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8 ;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;7,7E-017;1,37E-015;1,853;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5174;;
cytosine;cytosine;cytosine;–;–;–;HMDB0000630;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;1,12E-014;1,64E-013;1,926;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5175;;
uracil;uracil;uracil;–;–;–;HMDB0000300;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;1,53E-009;8,47E-009;1,686;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5176;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;0,0000215;0,0000742;1,183;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5177;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;0,000204;0,000605;1,877;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5178;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;3,87E-013;3,21E-012;1,613;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5179;;
pyroglutamic  acid;pyroglutamic  acid;pyroglutamic  acid;–;–;–;HMDB0000267;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;0,000000281;0,00000132;1,379;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5180;;
ketoleucine;ketoleucine;ketoleucine;–;–;–;HMDB0000695;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;3,9E-011;2,62E-010;1,659;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5181;;
adenine;adenine;adenine;–;–;–;HMDB0000034;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;1,99E-013;1,77E-012;1,72;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5182;;
imidazolepropionic acid;imidazolepropionic acid;imidazolepropionic acid;–;–;–;HMDB0002271;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;4,57E-015;7,11E-014;1,857;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5183;;
allysine;allysine;allysine;–;–;–;–;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;0,000000587;0,00000248;1,425;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5184;;
Phenylglyoxylic acid;Phenylglyoxylic acid;Phenylglyoxylic acid;–;–;–;HMDB0001587;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;1,82E-013;1,68E-012;1,722;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5185;;
guanine;guanine;guanine;–;–;–;HMDB0000132;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;4,77E-011;3,04E-010;1,581;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5186;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;9,95E-030;1,24E-027;2,446;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5187;;
3-hydroxyanthranilic  acid;3-hydroxyanthranilic  acid;3-hydroxyanthranilic  acid;–;–;–;HMDB0001476;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;0,0000385;0,00013;1,135;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5188;;
gentisic acid;gentisic acid;gentisic acid;–;–;–;HMDB0000152;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;1,03E-017;1,97E-016;2,043;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5189;;
NAcetylproline;NAcetylproline;NAcetylproline;–;–;–;–;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;4,03E-012;2,95E-011;1,735;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5190;;
arginine;arginine;arginine;–;–;–;HMDB0000517;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;9,74E-009;5,05E-008;1,409;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5191;;
NAcetyltaurine;NAcetyltaurine;NAcetyltaurine;–;–;–;–;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;7,42E-041;1,85E-038;2,737;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5192;;
N-acetyl-L-glutamic  acid;N-acetyl-L-glutamic  acid;N-acetyl-L-glutamic  acid;–;–;–;–;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;7,82E-027;4,87E-025;2,394;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5193;;
N-acetylhistidine;N-acetylhistidine;N-acetylhistidine;–;–;–;–;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;1,21E-010;7,53E-010;1,61;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5194;;
glycylphenylalanine;glycylphenylalanine;glycylphenylalanine;–;–;–;HMDB0028848;–;–;–;–;–;–;Saliva;diagnosis;lung cancer;I ;45;16, 29;Median: 57.8;smoker, non-smoker;healthy;25;10, 15;Median: 52.9;smoker, non-smoker;–;MALDI;Negative;TOF/TOF;MS/MS;FlexAnalysis, ClinproTools software, R script ;HMDB;SIMCA;Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA;–;–;–;1,92E-022;5,98E-021;2,27;ROC analysis;–;0.986 (Combination);97.2 (Combination);92% (Combination);–;–;–;–;–;–;China;–;Pathway map of the differential metabolites, Heatmap analysis of significant genes, Pathway analysis ;34342461;Jiang et al. 2021 ;5195;;
creatine;creatine;creatine;–;–;–;HMDB0000064;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,34;<0.001;<0.001;–;ROC analysis;–;0.941 (Creatine + myoinositol + LPE 16:0 );0.844 (Creatine + myoinositol + LPE 16:0 );0.944 (Creatine + myoinositol + LPE 16:0 );–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5196;;
6-phosphonoglucono-D-lactone;6-phosphonoglucono-D-lactone;6-phosphonoglucono-D-lactone;–;–;–;HMDB0001127;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;2;0,001;0,028;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5197;;
2-hydroxy-6-aminopurine;2-hydroxy-6-aminopurine;2-hydroxy-6-aminopurine;–;–;–;HMDB0000403;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;2,42;<0.001;<0.001;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5198;;
8-hydroxy-2-deoxyguanosine;8-hydroxy-2-deoxyguanosine;8-hydroxy-2-deoxyguanosine;–;–;–;HMDB0003333;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;2,44;0,001;0,028;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5199;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;2,27;0,001;0,028;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5200;;
myo-inositol;myo-inositol;myo-inositol;–;–;–;HMDB0000211;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;2,03;<0.001;<0.001;–;ROC analysis;–;0.941 (Creatine + myoinositol + LPE 16:0 );0.844 (Creatine + myoinositol + LPE 16:0 );0.944 (Creatine + myoinositol + LPE 16:0 );–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5201;;
Cer(d18:0/16:0)-2;Cer(d18:0/16:0)-2;Cer(d18:0/16:0)-2;–;–;–;HMDB0011760;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,29;<0.001;<0.001;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5202;;
LPC 15:0 sn-1;LPC 15:0 sn-1;LPC 15:0 sn-1;–;–;–;HMDB0010381;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;2,87;<0.001;<0.001;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5203;;
LPC 17:0 sn-1;LPC 17:0 sn-1;LPC 17:0 sn-1;–;–;–;HMDB0012108;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;2,18;0,002;0,042;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5204;;
LPE 16:0 sn-1;LPE 16:0 sn-1;LPE 16:0 sn-1;–;–;–;HMDB0011503;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;3,05;0,002;0,042;–;ROC analysis;–;0.941 (Creatine + myoinositol + LPE 16:0 );0.844 (Creatine + myoinositol + LPE 16:0 );0.944 (Creatine + myoinositol + LPE 16:0 );–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5205;;
LPE 18:1 sn-1;LPE 18:1 sn-1;LPE 18:1 sn-1;–;–;–;HMDB0011506;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;2,73;0,001;0,028;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5206;;
PC 36:0;PC 36:0;PC 36:0;–;–;–;HMDB0008036;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,54;0,002;0,042;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5207;;
PC 38:1;PC 38:1;PC 38:1;–;–;–;HMDB0008300;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,38;<0.001;<0.001;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5208;;
PC O 36:1;PC O 36:1;PC O 36:1;–;–;–;HMDB0013414;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,55;0,002;0,042;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5209;;
SM 35:2;SM 35:2;SM 35:2;–;–;–;–;–;–;–;–;–;–;tissue;diagnosis;AC;I, II, III;45 ;–;–;–;SCC;18 ;–;–;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;1,24;0,001;0,028;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020 ;5210;;
6-phosphogluconic acid;6-phosphogluconic acid;6-phosphogluconic acid;–;–;–;HMDB0001316;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;1,65;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5211;;
citric acid;citric acid;citric acid;–;–;–;HMDB0000094;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;1,66;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5212;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,66;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5213;;
glyceraldehyde-3-phosphate;glyceraldehyde-3-phosphate;glyceraldehyde-3-phosphate;–;–;–;–;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;1,24;0,038;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5214;;
D-glucose 6-phosphate;D-glucose 6-phosphate;D-glucose 6-phosphate;–;–;–;–;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;1,85;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5215;;
D-Sedoheptuiose 7-phosphate;D-Sedoheptuiose 7-phosphate;D-Sedoheptuiose 7-phosphate;–;–;–;–;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;1,84;0,002;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5216;;
D-Erythrose 4-phosphate;D-Erythrose 4-phosphate;D-Erythrose 4-phosphate;–;–;–;HMDB0001321;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;1,78;0,002;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5217;;
5-deoxy-5'-methylthioadenosine;5-deoxy-5'-methylthioadenosine;5-deoxy-5'-methylthioadenosine;–;–;–;HMDB0001173;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,49;0,004;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5218;;
SAH;SAH;SAH;–;–;–;HMDB0000939;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,64;0,027;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5219;;
xanthine;xanthine;xanthine;–;–;–;HMDB0000292;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,47;<0.001;–;–;ROC analysis;–;0.802 (xanthine + PC 35:2);–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5220;;
creatine;creatine;creatine;–;–;–;HMDB0000064;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,6;0,027;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5221;;
glutathione;glutathione;glutathione;–;–;–;HMDB0000125;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,22;0,02;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5222;;
oxidized glutathione;oxidized glutathione;oxidized glutathione;–;–;–;HMDB0003337;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,5;0,044;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5223;;
carnitine C4:0;carnitine C4:0;carnitine C4:0;–;–;–;HMDB0002013;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,75;0,024;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5224;;
carnitine C18:1;carnitine C18:1;carnitine C18:1;–;–;–;HMDB0006464;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,81;0,041;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5225;;
FFA C20:2;FFA C20:2;FFA C20:2;–;–;–;–;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,75;0,049;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5226;;
FFA C20:3;FFA C20:3;FFA C20:3;–;–;–;–;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,71;0,028;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5227;;
Eicosatrienoic acid methyl ester;Eicosatrienoic acid methyl ester;Eicosatrienoic acid methyl ester;–;–;–;–;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,91;0,006;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5228;;
LPC 15:0 sn-1;LPC 15:0 sn-1;LPC 15:0 sn-1;–;–;–;HMDB0010381;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,4;0,006;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5229;;
LPC 15:0 sn-2;LPC 15:0 sn-2;LPC 15:0 sn-2;–;–;–;HMDB0010381;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,64;0,04;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5230;;
LPC 18:1 sn-2;LPC 18:1 sn-2;LPC 18:1 sn-2;–;–;–;–;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,73;0,04;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5231;;
LPC 22:0 sn-2;LPC 22:0 sn-2;LPC 22:0 sn-2;–;–;–;HMDB0010398;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;1,93;0,008;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5232;;
LPC 22:4 sn-2;LPC 22:4 sn-2;LPC 22:4 sn-2;–;–;–;HMDB0010401;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,74;0,032;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5233;;
LPE 16:1 sn-1;LPE 16:1 sn-1;LPE 16:1 sn-1;–;–;–;HMDB0011504;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,55;0,015;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5234;;
LPE 16:1 sn-2;LPE 16:1 sn-2;LPE 16:1 sn-2;–;–;–;HMDB0011504;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,58;0,017;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5235;;
LPE 18:0 sn-1;LPE 18:0 sn-1;LPE 18:0 sn-1;–;–;–;HMDB0011130;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,51;0,037;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5236;;
LPE 18:1 sn-2;LPE 18:1 sn-2;LPE 18:1 sn-2;–;–;–;HMDB0011506;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,72;0,008;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5237;;
LPE 20:1 sn-1;LPE 20:1 sn-1;LPE 20:1 sn-1;–;–;–;HMDB0011512;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,3;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5238;;
LPE 22:4 sn-2;LPE 22:4 sn-2;LPE 22:4 sn-2;–;–;–;HMDB0011523;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,8;0,031;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5239;;
LPE 22:6 sn-2;LPE 22:6 sn-2;LPE 22:6 sn-2;–;–;–;HMDB0011526;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,75;0,006;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5240;;
PC 32:0;PC 32:0;PC 32:0;–;–;–;HMDB0000564;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;1,22;0,013;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5241;;
PC 33:1;PC 33:1;PC 33:1;–;–;–;HMDB0008099;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,63;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5242;;
PC 33:2;PC 33:2;PC 33:2;–;–;–;HMDB0008132;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,7;0,003;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5243;;
PC 35:2;PC 35:2;PC 35:2;–;–;–;HMDB0008330;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,62;<0.001;–;–;ROC analysis;–;0.802 (xanthine + PC 35:2);–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5244;;
PC 35:3;PC 35:3;PC 35:3;–;–;–;HMDB0008396;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,67;<0.001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5245;;
PC O 34:2-2;PC O 34:2-2;PC O 34:2-2;–;–;–;HMDB0011151;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,67;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5246;;
PE O 36:3;PE O 36:3;PE O 36:3;–;–;–;–;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,64;0,01;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5247;;
PE 32:1;PE 32:1;PE 32:1;–;–;–;–;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,56;0,002;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5248;;
PE 38:1;PE 38:1;PE 38:1;–;–;–;HMDB0009255;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,61;0,001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5249;;
PE 38:4;PE 38:4;PE 38:4;–;–;–;HMDB0009291;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,76;0,007;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5250;;
PE 38:6;PE 38:6;PE 38:6;–;–;–;HMDB0009294;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,8;0,048;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5251;;
PE O 34:3;PE O 34:3;PE O 34:3;–;–;–;–;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,44;0,005;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5252;;
SM 36:2;SM 36:2;SM 36:2;–;–;–;–;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;1,23;0,033;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5253;;
sphinganine;sphinganine;sphinganine;–;–;–;HMDB0000269;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;1,65;0,021;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5254;;
sphingosine;sphingosine;sphingosine;–;–;–;HMDB0000252;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;1,4;0,021;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5255;;
kynurenine;kynurenine;kynurenine;–;–;–;HMDB0000684;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,62;0,031;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5256;;
oxypurinol;oxypurinol;oxypurinol;–;–;–;HMDB0000786;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,43;<0.001;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5257;;
pregnenolone;pregnenolone;pregnenolone;–;–;–;HMDB0000253;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,35;0,006;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5258;;
N8-Acetylspermidine;N8-Acetylspermidine;N8-Acetylspermidine;–;–;–;HMDB0002189;–;–;–;–;–;–;Lung carcinoma tissue;diagnosis;NSCLC;I, II, III;85;51, 34;59 ± 12;–;benign lung tissues ;85;51, 34;59 ± 12;–;LC;ESI;both;Q-TOF;MS/MS;MarkerView workstation, MultiQuant 3.0.3;OSI-SMMS;SIMCA-P, SPSS;PCA, PLS-DA, non-parametric test ;–;–;0,3;0,002;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Metabolic pathways for lung cancer, Heat map of diﬀerential metabolites;32693607;You et al. 2020;5259;;
FA(18:1);FA(18:1);FA(18:1);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020 ;5260;;
FA(18:2);FA(18:2);FA(18:2);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020 ;5261;;
FA(18:3);FA(18:3);FA(18:3);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5262;;
FA(20:1);FA(20:1);FA(20:1);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5263;;
FA(20:2);FA(20:2);FA(20:2);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5264;;
FA(20:3);FA(20:3);FA(20:3);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5265;;
FA(20:4);FA(20:4);FA(20:4);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;ROC analysis;–;1.000 (FA(20:4) + FA(22:0) + LPE(20:4));100% (FA(20:4) + FA(22:0) + LPE(20:4));100% (FA(20:4) + FA(22:0) + LPE(20:4));–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5266;;
FA(20:5);FA(20:5);FA(20:5);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5267;;
FA(22:2);FA(22:2);FA(22:2);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5268;;
FA(22:3);FA(22:3);FA(22:3);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5269;;
FA(22:4);FA(22:4);FA(22:4);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5270;;
FA(22:5);FA(22:5);FA(22:5);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5271;;
FA(22:6);FA(22:6);FA(22:6);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5272;;
FA(24:4);FA(24:4);FA(24:4);–;–;–;HMDB0006246;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5273;;
FA(24:5);FA(24:5);FA(24:5);–;–;–;HMDB0006323;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5274;;
FA(24:6);FA(24:6);FA(24:6);–;–;–;HMDB0002007;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5275;;
LdMePE(18:0);LdMePE(18:0);LdMePE(18:0);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5276;;
LPC(18:0);LPC(18:0);LPC(18:0);–;–;–;HMDB0010384;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5277;;
LPE(18:0p);LPE(18:0p);LPE(18:0p);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5278;;
O.AHFA(18:1/18:0);O.AHFA(18:1/18:0);O.AHFA(18:1/18:0);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5279;;
OAHFA(18:1/20:3);OAHFA(18:1/20:3);OAHFA(18:1/20:3);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5280;;
OAHFA(18:2/18:1);OAHFA(18:2/18:1);OAHFA(18:2/18:1);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5281;;
OAHFA(18:2/22:6;OAHFA(18:2/22:6;OAHFA(18:2/22:6;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5282;;
LPC(15:1);LPC(15:1);LPC(15:1);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5283;;
LPC(20:1p);LPC(20:1p);LPC(20:1p);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5284;;
PE(18:0/18:1);PE(18:0/18:1);PE(18:0/18:1);–;–;–;HMDB0008992;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5285;;
FA(15:0);FA(15:0);FA(15:0);–;–;–;HMDB0000826;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5286;;
FA(16:0);FA(16:0);FA(16:0);–;–;–;HMDB0000220;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5287;;
FA(18:0);FA(18:0);FA(18:0);–;–;–;HMDB0000827;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5288;;
FA(20:0);FA(20:0);FA(20:0);–;–;–;HMDB0002212;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5289;;
FA(22:0);FA(22:0);FA(22:0);–;–;–;HMDB0000944;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;ROC analysis;–;1.000 (FA(20:4) + FA(22:0) + LPE(20:4));100% (FA(20:4) + FA(22:0) + LPE(20:4));100% (FA(20:4) + FA(22:0) + LPE(20:4));–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5290;;
LdMePE(18:2);LdMePE(18:2);LdMePE(18:2);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5291;;
LPC(18:2);LPC(18:2);LPC(18:2);–;–;–;HMDB0010386;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5292;;
LPE(18:1);LPE(18:1);LPE(18:1);–;–;–;HMDB0011505;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5293;;
LPE(18:2);LPE(18:2);LPE(18:2);–;–;–;HMDB0011477;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5294;;
LPE(20:3);LPE(20:3);LPE(20:3);–;–;–;HMDB0011484;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5295;;
LPE(20:4);LPE(20:4);LPE(20:4);–;–;–;HMDB0011487;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;ROC analysis;–;1.000 (FA(20:4) + FA(22:0) + LPE(20:4));100% (FA(20:4) + FA(22:0) + LPE(20:4));100% (FA(20:4) + FA(22:0) + LPE(20:4));–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5296;;
LPE(22:6);LPE(22:6);LPE(22:6);–;–;–;HMDB0011496;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5297;;
OAHFA(18:0/20:2);OAHFA(18:0/20:2);OAHFA(18:0/20:2);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;non-small cell lung cancer;I, II, III, IV;39;0, 39;61.64 ± 11.60;–;healthy control ;46;0, 46;55.26 ± 16.24;–;LC;ESI;both;Q-TOF;MS/MS;Peakview workstation, Multiquant software;in-house database;SIMCA-P, Multi Experiment Viewer ;PLS-DA by SIMCA-P, Mann-Whitney test ;–;–;–;<0.05;–;–;–;–;–;–;–;–;–;–;–;–;–;China;–;Related pathway for several fatty acids, Heatmap of the differential lipids ;32145537;Noreldeen et al. 2020;5298;;
12S-HHT;12S-HHT;12S-HHT;–;–;–;HMDB0012535;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 18;–;–;healthy control ;40;18, 22;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;4,3399159715;1,08845524517E-006;–;3,8353594456;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021 ;5299;;
LysoPC 14:0;LysoPC 14:0;LysoPC 14:0;–;–;–;HMDB0010379;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 19;–;–;healthy control ;40;18, 23;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;3,6845639196;1,72609354388519E-007;–;3,5179721011;ROC analysis;–;0,895;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021 ;5300;;
beta-Santalyl acetate;beta-Santalyl acetate;beta-Santalyl acetate;–;–;–;HMDB0038024;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 20;–;–;healthy control ;40;18, 24;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;3,3739561493;1,24263920048145E-006;–;3,4137619912;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5301;;
LysoPC 16:1;LysoPC 16:1;LysoPC 16:1;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 21;–;–;healthy control ;40;18, 25;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;3,1583723096;5,05649620444054E-007;–;3,2905220211;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5302;;
3-cyclohexyl-1,1-dimethylurea;3-cyclohexyl-1,1-dimethylurea;3-cyclohexyl-1,1-dimethylurea;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 22;–;–;healthy control ;40;18, 26;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;3,1233372348;1,49360145331155E-012;–;4,6704161094;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5303;;
acetyl-DL-carnitine;acetyl-DL-carnitine;acetyl-DL-carnitine;–;–;–;HMDB0240773;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 23;–;–;healthy control ;40;18, 27;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,9605581066;1,34209198867761E-005;–;2,8859284305;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5304;;
docosatrienoic acid;docosatrienoic acid;docosatrienoic acid;–;–;–;HMDB0002823;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 24;–;–;healthy control ;40;18, 28;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,8524934753;5,10582668536452E-013;–;4,0592520619;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5305;;
Plasmenyl-PC 16:0; PC(P-14:0/2:0);Plasmenyl-PC 16:0; PC(P-14:0/2:0);Plasmenyl-PC 16:0; PC(P-14:0/2:0);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 25;–;–;healthy control ;40;18, 29;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,8412376285;1,01420402477319E-007;–;3,229527835;–;–;–;–;–;–;–;–;–;–;–;China;–;5306;34527604;Zhao et al. 2021
LysoPE 18:3;LysoPE 18:3;LysoPE 18:3;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 26;–;–;healthy control ;40;18, 30;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,63937214;7,16119918901602E-008;–;3,1362603334;ROC analysis;–;0,908;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5307;;
8Z,14Z-Eicosadienoic acid;8Z,14Z-Eicosadienoic acid;8Z,14Z-Eicosadienoic acid;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 27;–;–;healthy control ;40;18, 31;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,4232529843;0,0040961086;–;1,7851815838;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5308;;
5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid, 1,5-lactone;5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid, 1,5-lactone;5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid, 1,5-lactone;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 28;–;–;healthy control ;40;18, 32;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,4042223624;0,0002121341;–;2,66764125;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5309;;
LysoPE 18:2;LysoPE 18:2;LysoPE 18:2;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 29;–;–;healthy control ;40;18, 33;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,3190837518;1,76157470095402E-007;–;2,9713402425;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5310;;
desmethylofloxacin;desmethylofloxacin;desmethylofloxacin;–;–;–;HMDB0251059;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 30;–;–;healthy control ;40;18, 34;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,3050852182;0,0345506743;–;1,3003193501;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5311;;
PC 9:0; PC(4:0/5:0);PC 9:0; PC(4:0/5:0);PC 9:0; PC(4:0/5:0);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 31;–;–;healthy control ;40;18, 35;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,242259425;9,40074515479541E-010;–;3,2278668656;–;–;–;–;–;–;–;–;–;–;–;China;–;5312;34527604;Zhao et al. 2021
LysoPA 18:2; LysoPA 18:2;LysoPA 18:2; LysoPA 18:2;LysoPA 18:2; LysoPA 18:2;–;–;–;HMDB0007852;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 32;–;–;healthy control ;40;18, 36;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,2421962298;0,0007192577;–;2,2753288318;–;–;–;–;–;–;–;–;–;–;–;China;–;5313;34527604;Zhao et al. 2021
LysoPC 18:3;LysoPC 18:3;LysoPC 18:3;–;–;–;HMDB0010388;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 33;–;–;healthy control ;40;18, 37;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,1983449971;1,06990497903297E-006;–;2,7463495028;ROC analysis;–;0,893;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5314;;
LysoPE 22:6;LysoPE 22:6;LysoPE 22:6;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 34;–;–;healthy control ;40;18, 38;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,1817881011;1,31232559412658E-005;–;2,6652353993;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5315;;
LysoPE 20:3;LysoPE 20:3;LysoPE 20:3;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 35;–;–;healthy control ;40;18, 39;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,169410635;1,59449976076393E-007;–;2,8493737239;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5316;;
linoleoylcarnitine;linoleoylcarnitine;linoleoylcarnitine;–;–;–;HMDB0006469;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 36;–;–;healthy control ;40;18, 40;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,1362906755;1,83110703303293E-009;–;3,077871775;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5317;;
LysoPE 18:1;LysoPE 18:1;LysoPE 18:1;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 37;–;–;healthy control ;40;18, 41;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,1068637966;1,33340820016805E-007;–;2,8487583276;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5318;;
dehydrocarpaine I;dehydrocarpaine I;dehydrocarpaine I;–;–;–;HMDB0030271;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 38;–;–;healthy control ;40;18, 42;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,0965677849;0,0007073416;–;2,092560407;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5319;;
TG 62:17; TG(18:4/22:6/22:7);TG 62:17; TG(18:4/22:6/22:7);TG 62:17; TG(18:4/22:6/22:7);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 39;–;–;healthy control ;40;18, 43;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,0712638444;0,000001672;–;2,6461486382;–;–;–;–;–;–;–;–;–;–;–;China;–;5320;34527604;Zhao et al. 2021
LysoPE 22:5;LysoPE 22:5;LysoPE 22:5;–;–;–;HMDB0240261;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 40;–;–;healthy control ;40;18, 44;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,0612971774;0,0018687735;–;1,9089249981;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5321;;
TG 66:21; TG(22:7/22:7/22:7);TG 66:21; TG(22:7/22:7/22:7);TG 66:21; TG(22:7/22:7/22:7);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 41;–;–;healthy control ;40;18, 45;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,0439273819;2,28601196099626E-005;–;2,5187831917;–;–;–;–;–;–;–;–;–;–;–;China;–;5322;34527604;Zhao et al. 2021
Plasmenyl-PE 18:0; PE(P-15:0/3:0);Plasmenyl-PE 18:0; PE(P-15:0/3:0);Plasmenyl-PE 18:0; PE(P-15:0/3:0);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 42;–;–;healthy control ;40;18, 46;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,030316671;1,46918250732802E-005;–;2,446265197;–;–;–;–;–;–;–;–;–;–;–;China;–;5323;34527604;Zhao et al. 2021
11.alpha.-Hydroxyprogesterone .beta.-D-glucuronide;11.alpha.-Hydroxyprogesterone .beta.-D-glucuronide;11.alpha.-Hydroxyprogesterone .beta.-D-glucuronide;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 43;–;–;healthy control ;40;18, 47;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,0245121348;1,56880839928078E-009;–;3,0078511612;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5324;;
LysoPE 16:0;LysoPE 16:0;LysoPE 16:0;–;–;–;HMDB0011477;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 44;–;–;healthy control ;40;18, 48;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,010689336;2,63606866231616E-008;–;2,8598115205;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5325;;
omega.-3 Arachidonic acid methyl ester;omega.-3 Arachidonic acid methyl ester;omega.-3 Arachidonic acid methyl ester;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 45;–;–;healthy control ;40;18, 49;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;2,0078512696;0,000033687;–;2,480645963;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5326;;
acrolein;acrolein;acrolein;–;–;–;HMDB0041822;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 46;–;–;healthy control ;40;18, 50;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,9817068055;7,53572011070399E-008;–;2,7615234267;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5327;;
Trp-Leu;Trp-Leu;Trp-Leu;–;–;–;HMDB0029087;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 47;–;–;healthy control ;40;18, 51;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,9585366488;1,44695803931964E-013;–;3,3240847972;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5328;;
riboflavin;riboflavin;riboflavin;–;–;–;HMDB0000244;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 48;–;–;healthy control ;40;18, 52;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,9296513219;0,0079759504;–;1,6541742197;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5329;;
5-hexyltetrahydro-2-furanoctanoic acid;5-hexyltetrahydro-2-furanoctanoic acid;5-hexyltetrahydro-2-furanoctanoic acid;–;–;–;HMDB0031127;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 49;–;–;healthy control ;40;18, 53;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,9222424883;3,88397836346182E-007;–;2,7149228528;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5330;;
Neurine;Neurine;Neurine;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 50;–;–;healthy control ;40;18, 54;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,9001269345;6,77801950328638E-009;–;2,9620583245;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5331;;
Trp-Glu;Trp-Glu;Trp-Glu;–;–;–;HMDB0029082;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 51;–;–;healthy control ;40;18, 55;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,8979716049;3,86313911852565E-010;–;2,9509412655;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5332;;
LysoPC 15:0;LysoPC 15:0;LysoPC 15:0;–;–;–;HMDB0010381;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 52;–;–;healthy control ;40;18, 56;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,8863466994;0,000078636;–;2,2037508486;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5333;;
8-HETrE;8-HETrE;8-HETrE;–;–;–;HMDB0060052;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 53;–;–;healthy control ;40;18, 57;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,8805293513;0,0054685518;–;1,938300354;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5334;;
LysoPE 20:4;LysoPE 20:4;LysoPE 20:4;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 54;–;–;healthy control ;40;18, 58;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,87893105;1,48503401488112E-007;–;2,6516000194;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5335;;
PC(16:0/20:3(5Z,8Z,11Z));PC(16:0/20:3(5Z,8Z,11Z));PC(16:0/20:3(5Z,8Z,11Z));–;–;–;HMDB0007980;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 55;–;–;healthy control ;40;18, 59;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,8765567578;0,0044001371;–;1,5147987207;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5336;;
12R-Hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid;12R-Hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid;12R-Hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 56;–;–;healthy control ;40;18, 60;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,8748071576;0,0105178212;–;1,9649619811;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5337;;
ormosanine;ormosanine;ormosanine;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 57;–;–;healthy control ;40;18, 61;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,8695167153;3,7555439582928E-009;–;2,708080552;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5338;;
LysoPC 22:5;LysoPC 22:5;LysoPC 22:5;–;–;–;HMDB0010402;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 58;–;–;healthy control ;40;18, 62;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,8479375958;4,36036412742962E-005;–;2,277358211;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5339;;
L-propionylcarnitine;L-propionylcarnitine;L-propionylcarnitine;–;–;–;HMDB0000824;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 59;–;–;healthy control ;40;18, 63;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,83497421;0,00055132;–;2,1367909359;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5340;;
LysoPC 20:5;LysoPC 20:5;LysoPC 20:5;–;–;–;HMDB0010397;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 60;–;–;healthy control ;40;18, 64;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,8329586685;0,0110067651;–;1,9391333035;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5341;;
oleoyl-L-carnitine;oleoyl-L-carnitine;oleoyl-L-carnitine;–;–;–;HMDB0005065;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 61;–;–;healthy control ;40;18, 65;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,8271407087;5,78776895494849E-006;–;2,422930492;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5342;;
pyruvic acid;pyruvic acid;pyruvic acid;–;–;–;HMDB0000243;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 62;–;–;healthy control ;40;18, 66;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,825032721;3,81066409255031E-006;–;2,3929175654;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5343;;
7-hydroxyquetiapine;7-hydroxyquetiapine;7-hydroxyquetiapine;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 63;–;–;healthy control ;40;18, 67;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,8029543247;0,0001633371;–;2,1506112846;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5344;;
LysoPC 22:6;LysoPC 22:6;LysoPC 22:6;–;–;–;HMDB0010404;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 64;–;–;healthy control ;40;18, 68;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,7822768707;0,0021532873;–;1,8995259006;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5345;;
N-lactoyl-leucine;N-lactoyl-leucine;N-lactoyl-leucine;–;–;–;HMDB0062176;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 65;–;–;healthy control ;40;18, 69;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,7577767525;0,0002208833;–;2,1278128919;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5346;;
PC(18:3(6Z,9Z,12Z)/16:0);PC(18:3(6Z,9Z,12Z)/16:0);PC(18:3(6Z,9Z,12Z)/16:0);–;–;–;HMDB0008166;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 66;–;–;healthy control ;40;18, 70;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,7530910542;0,0123191111;–;1,6443998294;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5347;;
germbudine;germbudine;germbudine;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 67;–;–;healthy control ;40;18, 71;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,7411086089;0,000000064;–;2,499435828;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5348;;
LysoPE 18:0;LysoPE 18:0;LysoPE 18:0;–;–;–;HMDB0011495;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 68;–;–;healthy control ;40;18, 72;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,7234822982;0,0001166492;–;2,1204633789;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5349;;
ent-16b,19-Kauranediol 19-acetate;ent-16b,19-Kauranediol 19-acetate;ent-16b,19-Kauranediol 19-acetate;–;–;–;HMDB0036801;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 69;–;–;healthy control ;40;18, 73;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,7186171141;0,0082150969;–;1,9091397237;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5350;;
LysoPC 20:3;LysoPC 20:3;LysoPC 20:3;–;–;–;HMDB0010394;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 70;–;–;healthy control ;40;18, 74;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,7103281863;9,32210502642203E-007;–;2,330884569;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5351;;
8(9)-epoxy-5Z,11Z,14Z-eicosatrienoic acid;8(9)-epoxy-5Z,11Z,14Z-eicosatrienoic acid;8(9)-epoxy-5Z,11Z,14Z-eicosatrienoic acid;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 71;–;–;healthy control ;40;18, 75;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,7017753559;1,11085852006511E-005;–;2,3216413255;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5352;;
Plasmenyl-PC 18:0; PC(P-14:0/4:0);Plasmenyl-PC 18:0; PC(P-14:0/4:0);Plasmenyl-PC 18:0; PC(P-14:0/4:0);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 72;–;–;healthy control ;40;18, 76;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,690323556;4,9509352823936E-007;–;2,3431230251;–;–;–;–;–;–;–;–;–;–;–;China;–;5353;34527604;Zhao et al. 2021
palmitoylcarnitine;palmitoylcarnitine;palmitoylcarnitine;–;–;–;HMDB0000222;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 73;–;–;healthy control ;40;18, 77;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6846100372;1,07680849199372E-006;–;2,3263982101;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5354;;
(S)-Reticuline;(S)-Reticuline;(S)-Reticuline;–;–;–;HMDB0003601;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 74;–;–;healthy control ;40;18, 78;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6803798085;0,0001618345;–;1,9991310291;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5355;;
linoleic acid;linoleic acid;linoleic acid;–;–;–;HMDB0000673;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 75;–;–;healthy control ;40;18, 79;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6772057983;0,0061718307;–;1,7264484387;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5356;;
1,2-Di-(9Z,12Z,15Z-octadecatrienoyl)-sn-glycero-3-phosphocholine;1,2-Di-(9Z,12Z,15Z-octadecatrienoyl)-sn-glycero-3-phosphocholine;1,2-Di-(9Z,12Z,15Z-octadecatrienoyl)-sn-glycero-3-phosphocholine;–;–;–;HMDB0008206;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 76;–;–;healthy control ;40;18, 80;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6740146421;0,0053372518;–;1,5373492316;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5357;;
adipoyl-L-carnitine;adipoyl-L-carnitine;adipoyl-L-carnitine;–;–;–;HMDB0061677;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 77;–;–;healthy control ;40;18, 81;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6697665558;0,0002012357;–;2,024413859;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5358;;
acylcarnitine 18:3;acylcarnitine 18:3;acylcarnitine 18:3;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 78;–;–;healthy control ;40;18, 82;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6638695195;7,0467171636835E-006;–;2,2406440071;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5359;;
methyl .gamma.-linolenate;methyl .gamma.-linolenate;methyl .gamma.-linolenate;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 79;–;–;healthy control ;40;18, 83;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6610375595;0,0036792081;–;1,5589628128;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5360;;
cocaine;cocaine;cocaine;–;–;–;HMDB0015043;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 80;–;–;healthy control ;40;18, 84;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6540859986;0,0001506723;–;2,3551530432;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5361;;
irbesartan;irbesartan;irbesartan;–;–;–;HMDB0015163;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 81;–;–;healthy control ;40;18, 85;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6473521573;2,69342441687241E-007;–;2,3365931426;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5362;;
11,14,17-eicosatrienoic acid, (Z,Z,Z)-;11,14,17-eicosatrienoic acid, (Z,Z,Z)-;11,14,17-eicosatrienoic acid, (Z,Z,Z)-;–;–;–;HMDB0060039;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 82;–;–;healthy control ;40;18, 86;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6387532307;2,08976789300556E-005;–;2,1299191782;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5363;;
LysoPC 17:1;LysoPC 17:1;LysoPC 17:1;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 83;–;–;healthy control ;40;18, 87;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6301333113;2,08313109684984E-005;–;2,0263732983;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5364;;
1-(3-(Trifluoromethyl)phenyl)piperazine;1-(3-(Trifluoromethyl)phenyl)piperazine;1-(3-(Trifluoromethyl)phenyl)piperazine;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 84;–;–;healthy control ;40;18, 88;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6223770709;0,0004336165;–;1,8053560893;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5365;;
pyroglutamic acid;pyroglutamic acid;pyroglutamic acid;–;–;–;HMDB0000267;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 85;–;–;healthy control ;40;18, 89;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6174245985;1,27811761461224E-005;–;2,1572802181;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5366;;
drofenine;drofenine;drofenine;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 86;–;–;healthy control ;40;18, 90;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6151917119;2,68943477653489E-010;–;2,5294759818;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5367;;
glutamyltryptophan;glutamyltryptophan;glutamyltryptophan;–;–;–;HMDB0028830;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 87;–;–;healthy control ;40;18, 91;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6139751407;3,62893098656161E-005;–;2,3222129874;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5368;;
3-tert-Butyl-4-hydroxyanisole;3-tert-Butyl-4-hydroxyanisole;3-tert-Butyl-4-hydroxyanisole;–;–;–;HMDB0059925;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 88;–;–;healthy control ;40;18, 92;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6122167894;0,0013345811;–;1,8857732798;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5369;;
acylcarnitine 20:3;acylcarnitine 20:3;acylcarnitine 20:3;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 89;–;–;healthy control ;40;18, 93;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,6042150796;0,0001802048;–;2,0396737062;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5370;;
6-(3-Dimethylaminopropionyl)forskolin;6-(3-Dimethylaminopropionyl)forskolin;6-(3-Dimethylaminopropionyl)forskolin;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 90;–;–;healthy control ;40;18, 94;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5892128254;0,00307579;–;1,6605131307;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5371;;
acylcarnitine 16:1;acylcarnitine 16:1;acylcarnitine 16:1;–;–;–;HMDB0006317;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 91;–;–;healthy control ;40;18, 95;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5867249177;0,0018034693;–;1,7481790597;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5372;;
LysoPC 20:4;LysoPC 20:4;LysoPC 20:4;–;–;–;HMDB0010395;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 92;–;–;healthy control ;40;18, 96;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5864992749;0,0005361826;–;1,9535485502;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5373;;
butaprost (free acid);butaprost (free acid);butaprost (free acid);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 93;–;–;healthy control ;40;18, 97;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5864399647;0,0274135218;–;1,4888156408;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5374;;
4-methylumbelliferone;4-methylumbelliferone;4-methylumbelliferone;–;–;–;HMDB0059622;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 94;–;–;healthy control ;40;18, 98;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5810604768;0,0001237431;–;1,9573078003;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5375;;
LysoPC 18:0;LysoPC 18:0;LysoPC 18:0;–;–;–;HMDB0010384;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 95;–;–;healthy control ;40;18, 99;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5698902926;0,0051572795;–;1,5747439394;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5376;;
LysoPS 20:4; LysoPS 20:4;LysoPS 20:4; LysoPS 20:4;LysoPS 20:4; LysoPS 20:4;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 96;–;–;healthy control ;40;18, 100;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,56428466;2,96856980920345E-006;–;2,2524831713;–;–;–;–;–;–;–;–;–;–;–;China;–;5377;34527604;Zhao et al. 2021
stearamide;stearamide;stearamide;–;–;–;HMDB0034146;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 97;–;–;healthy control ;40;18, 101;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5622640895;0,0306879697;–;1,303879978;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5378;;
LysoPC 16:0;LysoPC 16:0;LysoPC 16:0;–;–;–;HMDB0010382;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 98;–;–;healthy control ;40;18, 102;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5582540055;7,60311412924404E-007;–;2,1237600711;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5379;;
acylcarnitine 20:2;acylcarnitine 20:2;acylcarnitine 20:2;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 99;–;–;healthy control ;40;18, 103;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,552291667;7,58136581872892E-006;–;2,0163238825;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5380;;
chloridazone-methyl-desphenyl;chloridazone-methyl-desphenyl;chloridazone-methyl-desphenyl;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 100;–;–;healthy control ;40;18, 104;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5428429208;0,000021935;–;2,0257699529;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5381;;
PC(18:2(9Z,12Z)/18:2(9Z,12Z));PC(18:2(9Z,12Z)/18:2(9Z,12Z));PC(18:2(9Z,12Z)/18:2(9Z,12Z));–;–;–;HMDB0008138;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 101;–;–;healthy control ;40;18, 105;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5413518552;0,0448764257;–;1,3682251074;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5382;;
2S-Amino-4E-octadecene-1,3S-diol;2S-Amino-4E-octadecene-1,3S-diol;2S-Amino-4E-octadecene-1,3S-diol;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 102;–;–;healthy control ;40;18, 106;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5367581912;3,24984334092767E-006;–;2,0031457106;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5383;;
9-oxoprosta-10,12Z,14E-trienoic acid;9-oxoprosta-10,12Z,14E-trienoic acid;9-oxoprosta-10,12Z,14E-trienoic acid;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 103;–;–;healthy control ;40;18, 107;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5310739869;0,0055495764;–;1,5657906091;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5384;;
2,2,6,7-Tetramethylbicyclo[4.3.0]nona-1(9),4-diene-7,8-diol;2,2,6,7-Tetramethylbicyclo[4.3.0]nona-1(9),4-diene-7,8-diol;2,2,6,7-Tetramethylbicyclo[4.3.0]nona-1(9),4-diene-7,8-diol;–;–;–;HMDB0036686;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 104;–;–;healthy control ;40;18, 108;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5237652621;0,002913564;–;1,5726494999;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5385;;
methyl dihydrojasmonate;methyl dihydrojasmonate;methyl dihydrojasmonate;–;–;–;HMDB0031740;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 105;–;–;healthy control ;40;18, 109;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5232882271;0,0091741212;–;1,332327479;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5386;;
perfluoroundecanoic acid;perfluoroundecanoic acid;perfluoroundecanoic acid;–;–;–;HMDB0061743;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 106;–;–;healthy control ;40;18, 110;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5220195335;0,0352163281;–;1,4484512659;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5387;;
drostanolone;drostanolone;drostanolone;–;–;–;HMDB0014996;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 107;–;–;healthy control ;40;18, 111;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5194357051;0,0023879732;–;1,6201952132;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5388;;
acylcarnitine 20:1;acylcarnitine 20:1;acylcarnitine 20:1;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 108;–;–;healthy control ;40;18, 112;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,503723652;0,0048040844;–;1,6505715707;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5389;;
3-decen-2-one;3-decen-2-one;3-decen-2-one;–;–;–;HMDB0031410;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 109;–;–;healthy control ;40;18, 113;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5024160415;0,0077166614;–;1,8375007392;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5390;;
Plasmenyl-PC 44:5; PC(P-22:0/22:5);Plasmenyl-PC 44:5; PC(P-22:0/22:5);Plasmenyl-PC 44:5; PC(P-22:0/22:5);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 110;–;–;healthy control ;40;18, 114;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;1,5000886494;0,0002366072;–;1,7601894278;–;–;–;–;–;–;–;–;–;–;–;China;–;5391;34527604;Zhao et al. 2021
8-isoprostaglandin E2;8-isoprostaglandin E2;8-isoprostaglandin E2;–;–;–;HMDB0005844;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 111;–;–;healthy control ;40;18, 115;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,6619399233;0,0012640372;–;2,0195170304;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5392;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 112;–;–;healthy control ;40;18, 116;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,661145963;0,0011851754;–;3,0880471447;ROC analysis;–;0,769;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5393;;
2-butyl-4-methylphenol;2-butyl-4-methylphenol;2-butyl-4-methylphenol;–;–;–;HMDB0032060;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 113;–;–;healthy control ;40;18, 117;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,6605287472;0,0007779907;–;2,2708181429;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5394;;
AcylGlcADG 66:18; AcylGlcADG(22:6/22:6/22:6);AcylGlcADG 66:18; AcylGlcADG(22:6/22:6/22:6);AcylGlcADG 66:18; AcylGlcADG(22:6/22:6/22:6);–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 114;–;–;healthy control ;40;18, 118;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,6559936658;0,000000006;–;2,3610655701;ROC analysis;–;0,906;–;–;–;–;–;–;–;–;China;–;5395;34527604;Zhao et al. 2021
isopropyl tiglate;isopropyl tiglate;isopropyl tiglate;–;–;–;HMDB0037624;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 115;–;–;healthy control ;40;18, 119;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,6443960655;0,0020962054;–;2,0867498106;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5396;;
indoxyl sulfate;indoxyl sulfate;indoxyl sulfate;–;–;–;HMDB0000682;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 116;–;–;healthy control ;40;18, 120;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,6274355474;0,0079730417;–;2,043770311;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5397;;
paraxanthine;paraxanthine;paraxanthine;–;–;–;HMDB0001860;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 117;–;–;healthy control ;40;18, 121;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,6264262771;0,0274073178;–;2,2560381661;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5398;;
decanoyl-L-Carnitine;decanoyl-L-Carnitine;decanoyl-L-Carnitine;–;–;–;HMDB0000651;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 118;–;–;healthy control ;40;18, 122;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,6256336309;0,0007679755;–;2,3486578762;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5399;;
octanoylcarnitine;octanoylcarnitine;octanoylcarnitine;–;–;–;HMDB0000791;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 119;–;–;healthy control ;40;18, 123;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,6240334972;0,0008038868;–;2,1721066525;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5400;;
theobromine;theobromine;theobromine;–;–;–;HMDB0002825;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 120;–;–;healthy control ;40;18, 124;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,603359046;0,0086049119;–;3,0271835972;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5401;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 121;–;–;healthy control ;40;18, 125;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,5973411786;0,0015208978;–;3,2482398326;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5402;;
5.alpha.-Androstan-3.beta.-ol-17-one sulfate;5.alpha.-Androstan-3.beta.-ol-17-one sulfate;5.alpha.-Androstan-3.beta.-ol-17-one sulfate;–;–;–;HMDB0062657;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 122;–;–;healthy control ;40;18, 126;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,5911212661;0,0037980568;–;2,5834236586;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5403;;
acylcarnitine 13:1;acylcarnitine 13:1;acylcarnitine 13:1;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 123;–;–;healthy control ;40;18, 127;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,5879808456;0,0006362814;–;1,9751092926;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5404;;
cyclamate;cyclamate;cyclamate;–;–;–;HMDB0031340;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 124;–;–;healthy control ;40;18, 128;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,5750690118;0,03055443;–;2,0720702542;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5405;;
1,2,3-Trihydroxybenzene;1,2,3-Trihydroxybenzene;1,2,3-Trihydroxybenzene;–;–;–;HMDB0013674;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 125;–;–;healthy control ;40;18, 129;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,570497402;0,0439270707;–;2,0073170512;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5406;;
trandolaprilat;trandolaprilat;trandolaprilat;–;–;–;HMDB0060583;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 126;–;–;healthy control ;40;18, 130;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,5663294702;0,0253946794;–;1,6558343184;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5407;;
perfluorooctanoic acid;perfluorooctanoic acid;perfluorooctanoic acid;–;–;–;HMDB0256329;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 127;–;–;healthy control ;40;18, 131;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,5644227848;0,0013117682;–;2,64814399;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5408;;
acylcarnitine 11:0;acylcarnitine 11:0;acylcarnitine 11:0;–;–;–;HMDB0006202;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 128;–;–;healthy control ;40;18, 132;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,56299802;2,74635490981068E-006;–;2,5720296571;ROC analysis;–;0,854;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5409;;
acylcarnitine 13:0;acylcarnitine 13:0;acylcarnitine 13:0;–;–;–;–;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 129;–;–;healthy control ;40;18, 133;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,5574551273;0,0033634484;–;1,9916942761;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5410;;
O2'-4a-cyclic-tetrahydrobiopterin;O2'-4a-cyclic-tetrahydrobiopterin;O2'-4a-cyclic-tetrahydrobiopterin;–;–;–;HMDB0013031;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 130;–;–;healthy control ;40;18, 134;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,5541189057;2,89631291596081E-005;–;2,6307324004;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5411;;
3,4,5-trimethoxycinnamic acid;3,4,5-trimethoxycinnamic acid;3,4,5-trimethoxycinnamic acid;–;–;–;HMDB0002511;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 131;–;–;healthy control ;40;18, 135;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,5461977694;0,0051630495;–;2,2213757398;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5412;;
catechol;catechol;catechol;–;–;–;HMDB0000957;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 132;–;–;healthy control ;40;18, 136;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,5398496285;0,0021208142;–;2,573508505;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5413;;
pyrocatechol sulfate;pyrocatechol sulfate;pyrocatechol sulfate;–;–;–;HMDB0059724;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 133;–;–;healthy control ;40;18, 137;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,5194499745;0,0019237021;–;2,8025739439;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5414;;
2-Amino-3,4-dimethylimidazo[4,5-f]quinoline;2-Amino-3,4-dimethylimidazo[4,5-f]quinoline;2-Amino-3,4-dimethylimidazo[4,5-f]quinoline;–;–;–;HMDB0029707;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 134;–;–;healthy control ;40;18, 138;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,4956369499;0,0013645906;–;2,7029037636;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5415;;
His-Thr;His-Thr;His-Thr;–;–;–;HMDB0028895;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 135;–;–;healthy control ;40;18, 139;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,4884832197;0,0015738927;–;2,7797114675;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5416;;
D8'-Merulinic acid A;D8'-Merulinic acid A;D8'-Merulinic acid A;–;–;–;HMDB0041454;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 136;–;–;healthy control ;40;18, 140;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,4811260009;0,0086798823;–;1,988479728;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5417;;
2,4-dihydroxyacetophenone 5-sulfate;2,4-dihydroxyacetophenone 5-sulfate;2,4-dihydroxyacetophenone 5-sulfate;–;–;–;HMDB0041646;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 137;–;–;healthy control ;40;18, 141;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,4001224763;0,0055633768;–;2,1708524963;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5418;;
perfluorohexane sulfonic acid;perfluorohexane sulfonic acid;perfluorohexane sulfonic acid;–;–;–;HMDB0094700;–;–;–;–;–;–;Serum;diagnosis;LCC, ADC, SCC, SCLC;I, II, III, IV;39;21, 138;–;–;healthy control ;40;18, 142;–;–;LC;ESI;both;Q-TOF;MS/MS;XCMS, CAMERA, metaX;KEGG, HMDB;SPSS, R;Student’s t-test, PLS-DA, ;–;–;0,394188304;0,000293826;–;2,8709175212;–;–;–;–;–;–;–;–;–;–;–;China;–;Heatmap of the differential metabolites, HCA, Mapping of association networks, Pathway enrichment analysis;34527604;Zhao et al. 2021;5419;;
arginine;arginine;arginine;–;–;–;HMDB0000517;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0244335195;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021 ;5420;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0069498359;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021 ;5421;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0349107443;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5422;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0058454301;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5423;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0403583542;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5424;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;3,34948245580247E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5425;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0014824409;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5426;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0007844713;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5427;;
leucine/isoleucine;leucine/isoleucine;leucine/isoleucine;–;–;–;HMDB0000687;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0018755674;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5428;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;2,07510954729076E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5429;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0001244551;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5430;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0001933989;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5431;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0002160052;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5432;;
tryphophan;tryphophan;tryphophan;–;–;–;HMDB0000929;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;2,25059209455949E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5433;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0494101429;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5434;;
methylhistidine;methylhistidine;methylhistidine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0037107613;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5435;;
acetylaspartic acid;acetylaspartic acid;acetylaspartic acid;–;–;–;HMDB0000812;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0015430288;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5436;;
pyroglutamic acid;pyroglutamic acid;pyroglutamic acid;–;–;–;HMDB0000267;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0012708626;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5437;;
pyroglutamic acid;pyroglutamic acid;pyroglutamic acid;–;–;–;HMDB0000267;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0305555012;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5438;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0008182223;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5439;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0015756662;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5440;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,003830214;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5441;;
glutathione;glutathione;glutathione;–;–;–;HMDB0000125;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0226701284;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5442;;
glutathione;glutathione;glutathione;–;–;–;HMDB0000125;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0094708966;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5443;;
glutathione;glutathione;glutathione;–;–;–;HMDB0000125;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0005145887;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5444;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0330107535;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5445;;
guanosine monophosphate;guanosine monophosphate;guanosine monophosphate;–;–;–;HMDB0001397;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;3,26585471700252E-008;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5446;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0059610274;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5447;;
uracil;uracil;uracil;–;–;–;HMDB0000300;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0006612301;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5448;;
uridine monophosphate (UMP);uridine monophosphate (UMP);uridine monophosphate (UMP);–;–;–;HMDB0000288;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,000000069;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5449;;
uridine diphosphate glucose;uridine diphosphate glucose;uridine diphosphate glucose;–;–;–;HMDB0000286;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;1,7305634063824E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5450;;
adenosine monophosphate;adenosine monophosphate;adenosine monophosphate;–;–;–;HMDB0000045;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;6,76273467697838E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5451;;
methylthioadenosine;methylthioadenosine;methylthioadenosine;–;–;–;HMDB0001173;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0002120352;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5452;;
methylthioadenosine;methylthioadenosine;methylthioadenosine;–;–;–;HMDB0001173;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0002704219;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5453;;
oxidized glutathione;oxidized glutathione;oxidized glutathione;–;–;–;HMDB0003337;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,00003686;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5454;;
xantine;xantine;xantine;–;–;–;HMDB0000292;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0109762106;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5455;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0010213106;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5456;;
L-threonic acid/hypoxanthine;L-threonic acid/hypoxanthine;L-threonic acid/hypoxanthine;–;–;–;HMDB0000943;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0032085628;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5457;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0199518343;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5458;;
aminobutyric acid;aminobutyric acid;aminobutyric acid;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0033661477;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5459;;
acetylneuraminic acid;acetylneuraminic acid;acetylneuraminic acid;–;–;–;HMDB0000230;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0242964445;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5460;;
Dipicolinic acid (DPA);Dipicolinic acid (DPA);Dipicolinic acid (DPA);–;–;–;HMDB0033161;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;2,12327872846216E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5461;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;5,62153260757281E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5462;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;3,4640827567551E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5463;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0050260462;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5464;;
AMDA;AMDA;AMDA;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0038688149;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5465;;
bilirubin;bilirubin;bilirubin;–;–;–;HMDB0000054;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;5,82175689672696E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5466;;
bilirubin;bilirubin;bilirubin;–;–;–;HMDB0000054;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;4,11603380163219E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5467;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0023174915;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5468;;
creatine;creatine;creatine;–;–;–;HMDB0000064;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0001616953;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5469;;
creatine;creatine;creatine;–;–;–;HMDB0000064;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0035270804;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5470;;
dihydrothymine;dihydrothymine;dihydrothymine;–;–;–;HMDB0000079;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,037645583;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5471;;
dimethylglycine;dimethylglycine;dimethylglycine;–;–;–;HMDB0000092;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0042282186;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5472;;
ethanolamine phosphate;ethanolamine phosphate;ethanolamine phosphate;–;–;–;HMDB0000224;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,000031954;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5473;;
ethanolamine phosphate;ethanolamine phosphate;ethanolamine phosphate;–;–;–;HMDB0000224;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;4,19433486653191E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5474;;
phosphoethanolamine;phosphoethanolamine;phosphoethanolamine;–;–;–;HMDB0000224;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0002379126;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5475;;
niacinamide;niacinamide;niacinamide;–;–;–;HMDB0001406;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;4,26764353398309E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5476;;
nicotinamide;nicotinamide;nicotinamide;–;–;–;HMDB0001406;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0003309446;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5477;;
stearamide;stearamide;stearamide;–;–;–;HMDB0034146;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0294327587;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5478;;
trimethylamine;trimethylamine;trimethylamine;–;–;–;HMDB0000906;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0351862577;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5479;;
glucose-6-phosphate;glucose-6-phosphate;glucose-6-phosphate;–;–;–;HMDB0001401;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0328804936;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5480;;
diacetylspermine;diacetylspermine;diacetylspermine;–;–;–;HMDB0002172;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,00275091;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5481;;
acetylspermidine;acetylspermidine;acetylspermidine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;1,62102852722968E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5482;;
phytosphingosine;phytosphingosine;phytosphingosine;–;–;–;HMDB0004610;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0223532188;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5483;;
sphingosine;sphingosine;sphingosine;–;–;–;HMDB0000252;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0091983682;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5484;;
sphingosine;sphingosine;sphingosine;–;–;–;HMDB0000252;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0021710954;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5485;;
Glycerophospho-N-hexadecenyl Ethanolamine;Glycerophospho-N-hexadecenyl Ethanolamine;Glycerophospho-N-hexadecenyl Ethanolamine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0165265309;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5486;;
adrenic acid;adrenic acid;adrenic acid;–;–;–;HMDB0002226;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0069047415;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5487;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0404623208;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5488;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0184722318;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5489;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0485065683;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5490;;
docosahexaenoic acid;docosahexaenoic acid;docosahexaenoic acid;–;–;–;HMDB0002183;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0012080378;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5491;;
eicosadienoic acid;eicosadienoic acid;eicosadienoic acid;–;–;–;HMDB0005060;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;4,89120780572856E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5492;;
Eicosatrienoic acid (ETrE);Eicosatrienoic acid (ETrE);Eicosatrienoic acid (ETrE);–;–;–;HMDB0060039;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;1,58626720734082E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5493;;
oleic acid;oleic acid;oleic acid;–;–;–;HMDB0000207;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0118960011;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5494;;
palmitic acid;palmitic acid;palmitic acid;–;–;–;HMDB0000220;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0216092388;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5495;;
arachidoyl carnitine;arachidoyl carnitine;arachidoyl carnitine;–;–;–;HMDB0006460;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0110860615;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5496;;
arachidonoylcarnitine;arachidonoylcarnitine;arachidonoylcarnitine;–;–;–;HMDB0006455;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0206912401;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5497;;
butyrylcarnitine;butyrylcarnitine;butyrylcarnitine;–;–;–;HMDB0002013;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0003753216;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5498;;
butyrylcarnitine;butyrylcarnitine;butyrylcarnitine;–;–;–;HMDB0002013;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,013041629;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5499;;
eicosadienoylcarnitine;eicosadienoylcarnitine;eicosadienoylcarnitine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0089091411;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5500;;
docosadienoylcarnitine;docosadienoylcarnitine;docosadienoylcarnitine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0036879402;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5501;;
eicoseneoylcarnitine;eicoseneoylcarnitine;eicoseneoylcarnitine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0052947401;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5502;;
heptadecanoyl carnitine;heptadecanoyl carnitine;heptadecanoyl carnitine;–;–;–;HMDB0006210;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0208176432;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5503;;
hexadecanoylcarnitine;hexadecanoylcarnitine;hexadecanoylcarnitine;–;–;–;HMDB0000222;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0043162442;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5504;;
Hexadecenoylcarnitine;Hexadecenoylcarnitine;Hexadecenoylcarnitine;–;–;–;HMDB0253127;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0013055171;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5505;;
hydroxyhexanoylcarnitine;hydroxyhexanoylcarnitine;hydroxyhexanoylcarnitine;–;–;–;HMDB0013131;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0449704426;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5506;;
hydroxyoctadecenoylcarnitine;hydroxyoctadecenoylcarnitine;hydroxyoctadecenoylcarnitine;–;–;–;HMDB0253282;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0214923425;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5507;;
hydroxyvalerylcarnitine;hydroxyvalerylcarnitine;hydroxyvalerylcarnitine;–;–;–;HMDB0013132;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0014857015;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5508;;
octadecadienylcarnitine;octadecadienylcarnitine;octadecadienylcarnitine;–;–;–;HMDB0255895;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0122331827;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5509;;
Octadecenoylcarnitine;Octadecenoylcarnitine;Octadecenoylcarnitine;–;–;–;HMDB0094687;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0113694232;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5510;;
octanoylcarnitine;octanoylcarnitine;octanoylcarnitine;–;–;–;HMDB0000791;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0389452751;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5511;;
Pentadecanoylcarnitine;Pentadecanoylcarnitine;Pentadecanoylcarnitine;–;–;–;HMDB0062517;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,006685;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5512;;
stearoylcarnitine;stearoylcarnitine;stearoylcarnitine;–;–;–;HMDB0000848;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0062062211;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5513;;
tetradecanoylcarnitine;tetradecanoylcarnitine;tetradecanoylcarnitine;–;–;–;HMDB0005066;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0203601689;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5514;;
Tetradecenoylcarnitine;Tetradecenoylcarnitine;Tetradecenoylcarnitine;–;–;–;HMDB0258884;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0099943436;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5515;;
valerylcarnitine;valerylcarnitine;valerylcarnitine;–;–;–;HMDB0013128;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0170305887;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5516;;
Galactosylceramide (d18:1/16:0)/Glucosylceramide (d18:1/16:0);Galactosylceramide (d18:1/16:0)/Glucosylceramide (d18:1/16:0);Galactosylceramide (d18:1/16:0)/Glucosylceramide (d18:1/16:0);–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0016251151;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5517;;
LysoPA 18:1;LysoPA 18:1;LysoPA 18:1;–;–;–;HMDB0007855;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0008733125;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5518;;
LysoPC 14:0;LysoPC 14:0;LysoPC 14:0;–;–;–;HMDB0010379;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0329235228;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5519;;
LysoPC 14:0;LysoPC 14:0;LysoPC 14:0;–;–;–;HMDB0010379;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0381514585;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5520;;
LysoPC 15:0;LysoPC 15:0;LysoPC 15:0;–;–;–;HMDB0010381;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0018112767;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5521;;
LysoPC 15:0;LysoPC 15:0;LysoPC 15:0;–;–;–;HMDB0010381;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0033026513;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5522;;
LysoPC 16:0;LysoPC 16:0;LysoPC 16:0;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0097463793;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5523;;
LysoPC 16:0 sn1;LysoPC 16:0 sn1;LysoPC 16:0 sn1;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,009157545;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5524;;
LysoPC 16:0 sn1;LysoPC 16:0 sn1;LysoPC 16:0 sn1;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0125331409;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5525;;
LysoPC 16:0 sn1;LysoPC 16:0 sn1;LysoPC 16:0 sn1;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0106300454;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5526;;
LysoPC 16:0 sn2;LysoPC 16:0 sn2;LysoPC 16:0 sn2;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0326978971;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5527;;
LysoPC 16:0 sn2;LysoPC 16:0 sn2;LysoPC 16:0 sn2;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,025174873;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5528;;
LysoPC 16:0 sn2;LysoPC 16:0 sn2;LysoPC 16:0 sn2;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0172728642;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5529;;
LysoPC 16:1 sn1;LysoPC 16:1 sn1;LysoPC 16:1 sn1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0003921799;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5530;;
LysoPC 16:1 sn2;LysoPC 16:1 sn2;LysoPC 16:1 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0052244045;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5531;;
LysoPC 16:1 sn2;LysoPC 16:1 sn2;LysoPC 16:1 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0147506844;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5532;;
LysoPC 17:0;LysoPC 17:0;LysoPC 17:0;–;–;–;HMDB0012108;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0237654702;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5533;;
LysoPC 17:0;LysoPC 17:0;LysoPC 17:0;–;–;–;HMDB0012108;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0392453925;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5534;;
LysoPC 18:1 sn1;LysoPC 18:1 sn1;LysoPC 18:1 sn1;–;–;–;HMDB0002815;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,029495834;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5535;;
LysoPC 18:1 sn1;LysoPC 18:1 sn1;LysoPC 18:1 sn1;–;–;–;HMDB0002815;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0231106909;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5536;;
LysoPC 18:1 sn2;LysoPC 18:1 sn2;LysoPC 18:1 sn2;–;–;–;HMDB0002815;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0044441276;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5537;;
LysoPC 18:2;LysoPC 18:2;LysoPC 18:2;–;–;–;HMDB0010386;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0081486838;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5538;;
LysoPC 18:2 sn1;LysoPC 18:2 sn1;LysoPC 18:2 sn1;–;–;–;HMDB0010386;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0116829423;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5539;;
LysoPC 18:2 sn1;LysoPC 18:2 sn1;LysoPC 18:2 sn1;–;–;–;HMDB0010386;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0072832304;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5540;;
LysoPC 18:2 sn2;LysoPC 18:2 sn2;LysoPC 18:2 sn2;–;–;–;HMDB0010386;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0007860177;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5541;;
LysoPC 18:2 sn2;LysoPC 18:2 sn2;LysoPC 18:2 sn2;–;–;–;HMDB0010386;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0010613727;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5542;;
LysoPC 20:2;LysoPC 20:2;LysoPC 20:2;–;–;–;HMDB0010392;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0065593291;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5543;;
LysoPC 20:2;LysoPC 20:2;LysoPC 20:2;–;–;–;HMDB0010392;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0080601209;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5544;;
LysoPC 20:3;LysoPC 20:3;LysoPC 20:3;–;–;–;HMDB0010394;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0097899232;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5545;;
LysoPC 20:3 sn1;LysoPC 20:3 sn1;LysoPC 20:3 sn1;–;–;–;HMDB0010394;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0090543955;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5546;;
LysoPC 20:3 sn2;LysoPC 20:3 sn2;LysoPC 20:3 sn2;–;–;–;HMDB0010394;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0001410842;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5547;;
LysoPC 20:4;LysoPC 20:4;LysoPC 20:4;–;–;–;HMDB0010395;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0245408064;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5548;;
LysoPC 20:4;LysoPC 20:4;LysoPC 20:4;–;–;–;HMDB0010395;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0080756613;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5549;;
LysoPC 22:6 sn1;LysoPC 22:6 sn1;LysoPC 22:6 sn1;–;–;–;HMDB0010404;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0028148669;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5550;;
LysoPC 22:6 sn1;LysoPC 22:6 sn1;LysoPC 22:6 sn1;–;–;–;HMDB0010404;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0005543663;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5551;;
LysoPC 22:6 sn2;LysoPC 22:6 sn2;LysoPC 22:6 sn2;–;–;–;HMDB0010404;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;5,33357473746012E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5552;;
LysoPC 22:6 sn2;LysoPC 22:6 sn2;LysoPC 22:6 sn2;–;–;–;HMDB0010404;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0004009004;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5553;;
LysoPE 18:2 sn2;LysoPE 18:2 sn2;LysoPE 18:2 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,000884952;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5554;;
LysoPE 22:5;LysoPE 22:5;LysoPE 22:5;–;–;–;HMDB0240261;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0104817277;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5555;;
LysoPE P-16:0;LysoPE P-16:0;LysoPE P-16:0;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0213326156;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5556;;
LysoPE P-17:0;LysoPE P-17:0;LysoPE P-17:0;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0309852549;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5557;;
LysoPG 18:0;LysoPG 18:0;LysoPG 18:0;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0475112309;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5558;;
LysoPG 18:1 sn1;LysoPG 18:1 sn1;LysoPG 18:1 sn1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0246318608;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5559;;
LysoPG 18:1 sn2;LysoPG 18:1 sn2;LysoPG 18:1 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;1,27572803523771E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5560;;
LysoPG 18:2;LysoPG 18:2;LysoPG 18:2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0437164573;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5561;;
LysoPG 20:4;LysoPG 20:4;LysoPG 20:4;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0341371851;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5562;;
LysoPG 22:6;LysoPG 22:6;LysoPG 22:6;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0379803506;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5563;;
LysoPI 16:0;LysoPI 16:0;LysoPI 16:0;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0076028416;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5564;;
LysoPI 18:0;LysoPI 18:0;LysoPI 18:0;–;–;–;HMDB0240261;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0441028683;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5565;;
LysoPI 18:1 sn1;LysoPI 18:1 sn1;LysoPI 18:1 sn1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0081244326;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5566;;
LysoPI 18:2;LysoPI 18:2;LysoPI 18:2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0069530235;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5567;;
LysoPI 20:3;LysoPI 20:3;LysoPI 20:3;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0278359598;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5568;;
LysoPI 20:3 sn2;LysoPI 20:3 sn2;LysoPI 20:3 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0087931195;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5569;;
LysoPI 20:4 sn2;LysoPI 20:4 sn2;LysoPI 20:4 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0002909344;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5570;;
PC 14:0/18:2; PC 16:1/16:1;PC 14:0/18:2; PC 16:1/16:1;PC 14:0/18:2; PC 16:1/16:1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,008894934;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;5571;34282765;Kowalczyk et al. 2021
PC 14:0/22:6;PC 14:0/22:6;PC 14:0/22:6;–;–;–;HMDB0007892;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0011962315;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5572;;
PC 15:0/20:4;PC 15:0/20:4;PC 15:0/20:4;–;–;–;HMDB0007949;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,017939189;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5573;;
PC 16:0/18:2;PC 16:0/18:2;PC 16:0/18:2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0124410655;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5574;;
PC 16:1/20:4;PC 16:1/20:4;PC 16:1/20:4;–;–;–;HMDB0008015;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0094606285;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5575;;
PC 16:1/22:6;PC 16:1/22:6;PC 16:1/22:6;–;–;–;HMDB0008023;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0003439573;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5576;;
PC 17:0/20:4;PC 17:0/20:4;PC 17:0/20:4;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0261197506;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5577;;
PC 18:0/22:6;PC 18:0/22:6;PC 18:0/22:6;–;–;–;HMDB0008057;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0087434597;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5578;;
PC 18:1/22:6;PC 18:1/22:6;PC 18:1/22:6;–;–;–;HMDB0008123;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0031654555;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5579;;
PC 18:1/22:6;PC 18:1/22:6;PC 18:1/22:6;–;–;–;HMDB0008123;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0033224363;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5580;;
PC 18:2/22:6;PC 18:2/22:6;PC 18:2/22:6;–;–;–;HMDB0008156;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0183172868;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5581;;
PC 18:2/22:6;PC 18:2/22:6;PC 18:2/22:6;–;–;–;HMDB0008156;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0416154374;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5582;;
PC 20:4/14:0;PC 20:4/14:0;PC 20:4/14:0;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0308502037;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5583;;
PC 20:4/22:4;PC 20:4/22:4;PC 20:4/22:4;–;–;–;HMDB0008449;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0004770301;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5584;;
PC 29:0;PC 29:0;PC 29:0;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0185283819;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5585;;
PC 34:1 Plasm;PC 34:1 Plasm;PC 34:1 Plasm;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0033075174;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5586;;
PC 35:1;PC 35:1;PC 35:1;–;–;–;HMDB0008297;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0090129748;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5587;;
PC 35:5;PC 35:5;PC 35:5;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0016982731;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5588;;
PC 36:6;PC 36:6;PC 36:6;–;–;–;HMDB0008172;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0005450048;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5589;;
PC 38:3;PC 38:3;PC 38:3;–;–;–;HMDB0008334;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,004770061;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5590;;
PC 38:3;PC 38:3;PC 38:3;–;–;–;HMDB0008334;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0134304802;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5591;;
PC 38:5;PC 38:5;PC 38:5;–;–;–;HMDB0008337;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0050745279;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5592;;
PC 38:5;PC 38:5;PC 38:5;–;–;–;HMDB0008337;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0137717845;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5593;;
PC 40:6;PC 40:6;PC 40:6;–;–;–;HMDB0008345;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0245039874;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5594;;
PC 40:6 Plasm;PC 40:6 Plasm;PC 40:6 Plasm;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0379042582;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5595;;
PC 40:8;PC 40:8;PC 40:8;–;–;–;HMDB0008443;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0032160163;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5596;;
PC 40:9;PC 40:9;PC 40:9;–;–;–;HMDB0008731;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0021042222;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5597;;
PC 42:8;PC 42:8;PC 42:8;–;–;–;HMDB0008354;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,011254462;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5598;;
PC P-18:0/22:6;PC P-18:0/22:6;PC P-18:0/22:6;–;–;–;HMDB0011262;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0291989978;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5599;;
PC P-18:1/20:4;PC P-18:1/20:4;PC P-18:1/20:4;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0169947545;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5600;;
PE 16:0/22:6;PE 16:0/22:6;PE 16:0/22:6;–;–;–;HMDB0008946;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0284936291;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5601;;
PE 17:0/20:4;PE 17:0/20:4;PE 17:0/20:4;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0011576956;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5602;;
PE 32:2;PE 32:2;PE 32:2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0306449843;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5603;;
PE 36:5;PE 36:5;PE 36:5;–;–;–;HMDB0009451;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0005829278;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5604;;
SM 32:1;SM 32:1;SM 32:1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0040339326;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5605;;
SM 35:1;SM 35:1;SM 35:1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0174718278;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5606;;
SM 35:1;SM 35:1;SM 35:1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0031389718;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5607;;
SM (d18:1/18:0);SM (d18:1/18:0);SM (d18:1/18:0);–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,004120449;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5608;;
SM(d18:0/16:0);SM(d18:0/16:0);SM(d18:0/16:0);–;–;–;HMDB0010168;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0063600152;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5609;;
SM(d18:1/12:0);SM(d18:1/12:0);SM(d18:1/12:0);–;–;–;HMDB0012096;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0003333945;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5610;;
SM(d18:1/12:0);SM(d18:1/12:0);SM(d18:1/12:0);–;–;–;HMDB0012096;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0001584917;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5611;;
SM(d18:2/14:0);SM(d18:2/14:0);SM(d18:2/14:0);–;–;–;HMDB0240637;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0083156623;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5612;;
SM(d18:2/14:0);SM(d18:2/14:0);SM(d18:2/14:0);–;–;–;HMDB0240637;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0163495987;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5613;;
SM(d18:2/15:0);SM(d18:2/15:0);SM(d18:2/15:0);–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;adenocarcinoma (ADC);I, II, III;33;23, 10;64.77 ± 8.44;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0109240418;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5614;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0001280279;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5615;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,00195201;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5616;;
glutamic acid;glutamic acid;glutamic acid;–;–;–;HMDB0000148;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0199134122;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5617;;
glutamine;glutamine;glutamine;–;–;–;HMDB0000641;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0193316656;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5618;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0108847298;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5619;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0040386525;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5620;;
histidine;histidine;histidine;–;–;–;HMDB0000177;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0181781403;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5621;;
leucine;leucine;leucine;–;–;–;HMDB0000687;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0015714688;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5622;;
leucine/isoleucine;leucine/isoleucine;leucine/isoleucine;–;–;–;HMDB0000687;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0074226116;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5623;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0002007342;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5624;;
phenylalanine;phenylalanine;phenylalanine;–;–;–;HMDB0000159;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0028154198;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5625;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0020132187;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5626;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0009960787;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5627;;
proline;proline;proline;–;–;–;HMDB0000162;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;9,58513153509115E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5628;;
tryphophan;tryphophan;tryphophan;–;–;–;HMDB0000929;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;2,92254454289424E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5629;;
tyrosine;tyrosine;tyrosine;–;–;–;HMDB0000158;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0314222923;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5630;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,001389852;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5631;;
methylhistidine;methylhistidine;methylhistidine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0040785474;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5632;;
acetylaspartic acid;acetylaspartic acid;acetylaspartic acid;–;–;–;HMDB0000812;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0273010653;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5633;;
pyroglutamic acid;pyroglutamic acid;pyroglutamic acid;–;–;–;HMDB0000267;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0056050122;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5634;;
hydroxyglutaric acid;hydroxyglutaric acid;hydroxyglutaric acid;–;–;–;HMDB0059655;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0008601178;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5635;;
betaina;betaina;betaina;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0029414479;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5636;;
betaine;betaine;betaine;–;–;–;HMDB0000043;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0323850625;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5637;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0162489155;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5638;;
glutathione;glutathione;glutathione;–;–;–;HMDB0000125;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0023173399;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5639;;
glutathione;glutathione;glutathione;–;–;–;HMDB0000125;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0010588182;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5640;;
glutathione;glutathione;glutathione;–;–;–;HMDB0000125;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0007972428;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5641;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0003261814;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5642;;
guanosine monophosphate;guanosine monophosphate;guanosine monophosphate;–;–;–;HMDB0001397;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;1,72651716301472E-007;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5643;;
uracil;uracil;uracil;–;–;–;HMDB0000300;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0152029445;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5644;;
uridine monophosphate (UMP);uridine monophosphate (UMP);uridine monophosphate (UMP);–;–;–;HMDB0000288;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;2,26026031280223E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5645;;
uridine diphosphate glucose;uridine diphosphate glucose;uridine diphosphate glucose;–;–;–;HMDB0000286;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0005648021;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5646;;
adenosine monophosphate;adenosine monophosphate;adenosine monophosphate;–;–;–;HMDB0000045;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;1,21828129248386E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5647;;
methylthioadenosine;methylthioadenosine;methylthioadenosine;–;–;–;HMDB0001173;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0014888914;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5648;;
methylthioadenosine;methylthioadenosine;methylthioadenosine;–;–;–;HMDB0001173;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0002572345;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5649;;
oxidized glutathione;oxidized glutathione;oxidized glutathione;–;–;–;HMDB0003337;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0005649254;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5650;;
xantine;xantine;xantine;–;–;–;HMDB0000292;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0004960552;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5651;;
hypoxanthine;hypoxanthine;hypoxanthine;–;–;–;HMDB0000157;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0012606139;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5652;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0139333785;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5653;;
aminobutyric acid;aminobutyric acid;aminobutyric acid;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0007762448;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5654;;
lactic acid;lactic acid;lactic acid;–;–;–;HMDB0000190;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;7,25316275777142E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5655;;
malic acid;malic acid;malic acid;–;–;–;HMDB0000156;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0006180583;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5656;;
AMDA;AMDA;AMDA;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0008382922;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5657;;
bilirubin;bilirubin;bilirubin;–;–;–;HMDB0000054;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;3,86319047466703E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5658;;
bilirubin;bilirubin;bilirubin;–;–;–;HMDB0000054;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;4,8530159446779E-008;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5659;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;2,88108141782888E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5660;;
creatine;creatine;creatine;–;–;–;HMDB0000064;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0004683257;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5661;;
creatine;creatine;creatine;–;–;–;HMDB0000064;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,000005072;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5662;;
dihydrothymine;dihydrothymine;dihydrothymine;–;–;–;HMDB0000079;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0124104998;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5663;;
dimethylglycine;dimethylglycine;dimethylglycine;–;–;–;HMDB0000092;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0235731078;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5664;;
ethanolamine phosphate;ethanolamine phosphate;ethanolamine phosphate;–;–;–;HMDB0000224;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;1,67233331255004E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5665;;
ethanolamine phosphate;ethanolamine phosphate;ethanolamine phosphate;–;–;–;HMDB0000224;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0001050248;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5666;;
phosphoethanolamine;phosphoethanolamine;phosphoethanolamine;–;–;–;HMDB0000224;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0011009546;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5667;;
niacinamide;niacinamide;niacinamide;–;–;–;HMDB0001406;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;4,76989421175948E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5668;;
nicotinamide;nicotinamide;nicotinamide;–;–;–;HMDB0001406;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0005435202;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5669;;
acetylspermidine;acetylspermidine;acetylspermidine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0009693132;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5670;;
phytosphingosine;phytosphingosine;phytosphingosine;–;–;–;HMDB0004610;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0032721235;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5671;;
sphingosine;sphingosine;sphingosine;–;–;–;HMDB0000252;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0411815456;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5672;;
sphingosine;sphingosine;sphingosine;–;–;–;HMDB0000252;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0001648724;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5673;;
piperidine;piperidine;piperidine;–;–;–;HMDB0034301;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0036431971;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5674;;
adrenic acid;adrenic acid;adrenic acid;–;–;–;HMDB0002226;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;1,69461277910064E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5675;;
adrenic acid;adrenic acid;adrenic acid;–;–;–;HMDB0002226;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0005843502;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5676;;
docosahexaenoic acid;docosahexaenoic acid;docosahexaenoic acid;–;–;–;HMDB0002183;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0051814551;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5677;;
eicosadienoic acid;eicosadienoic acid;eicosadienoic acid;–;–;–;HMDB0005060;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;4,8106457118967E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5678;;
eicosapentaenoic acid;eicosapentaenoic acid;eicosapentaenoic acid;–;–;–;HMDB0001999;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0463721449;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5679;;
Eicosatrienoic acid (ETrE);Eicosatrienoic acid (ETrE);Eicosatrienoic acid (ETrE);–;–;–;HMDB0060039;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0018347519;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5680;;
acetylcarnitine;acetylcarnitine;acetylcarnitine;–;–;–;HMDB0000201;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0453339345;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5681;;
arachidonoylcarnitine;arachidonoylcarnitine;arachidonoylcarnitine;–;–;–;HMDB0006455;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0233124622;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5682;;
butyrylcarnitine;butyrylcarnitine;butyrylcarnitine;–;–;–;HMDB0002013;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0016657023;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5683;;
butyrylcarnitine;butyrylcarnitine;butyrylcarnitine;–;–;–;HMDB0002013;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0018377356;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5684;;
carnitine;carnitine;carnitine;–;–;–;HMDB0000062;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0178883403;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5685;;
eicosadienoylcarnitine;eicosadienoylcarnitine;eicosadienoylcarnitine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;9,21935308145801E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5686;;
docosadienoylcarnitine;docosadienoylcarnitine;docosadienoylcarnitine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;2,98191405318696E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5687;;
eicoseneoylcarnitine;eicoseneoylcarnitine;eicoseneoylcarnitine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0002606828;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5688;;
heptadecanoyl carnitine;heptadecanoyl carnitine;heptadecanoyl carnitine;–;–;–;HMDB0006210;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0012333489;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5689;;
hexadecanoylcarnitine;hexadecanoylcarnitine;hexadecanoylcarnitine;–;–;–;HMDB0000222;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0002896179;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5690;;
Hexadecenoylcarnitine;Hexadecenoylcarnitine;Hexadecenoylcarnitine;–;–;–;HMDB0253127;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0003059141;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5691;;
Hexadecenoylcarnitine;Hexadecenoylcarnitine;Hexadecenoylcarnitine;–;–;–;HMDB0253127;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0050170696;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5692;;
hydroxybutyrylcarnitine;hydroxybutyrylcarnitine;hydroxybutyrylcarnitine;–;–;–;HMDB0013127;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0026309239;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5693;;
hydroxyhexadecanoylcarnitine;hydroxyhexadecanoylcarnitine;hydroxyhexadecanoylcarnitine;–;–;–;HMDB0061642;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0176005747;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5694;;
hydroxymyristoylcarnitine;hydroxymyristoylcarnitine;hydroxymyristoylcarnitine;–;–;–;HMDB0013166;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0070172188;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5695;;
hydroxyoctadecenoylcarnitine;hydroxyoctadecenoylcarnitine;hydroxyoctadecenoylcarnitine;–;–;–;HMDB0253282;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,000197445;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5696;;
hydroxyoctanoyl carnitine;hydroxyoctanoyl carnitine;hydroxyoctanoyl carnitine;–;–;–;HMDB0061634;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0183088698;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5697;;
hydroxytetradecenoylcarnitine;hydroxytetradecenoylcarnitine;hydroxytetradecenoylcarnitine;–;–;–;HMDB0253296;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0010529881;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5698;;
hydroxyvalerylcarnitine;hydroxyvalerylcarnitine;hydroxyvalerylcarnitine;–;–;–;HMDB0013132;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,000002363;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5699;;
octadecadienylcarnitine;octadecadienylcarnitine;octadecadienylcarnitine;–;–;–;HMDB0255895;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0381498906;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5700;;
octadecadienylcarnitine;octadecadienylcarnitine;octadecadienylcarnitine;–;–;–;HMDB0255895;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0001055274;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5701;;
Octadecenoylcarnitine;Octadecenoylcarnitine;Octadecenoylcarnitine;–;–;–;HMDB0094687;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,000122046;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5702;;
Octadecenoylcarnitine;Octadecenoylcarnitine;Octadecenoylcarnitine;–;–;–;HMDB0094687;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0003777501;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5703;;
octanoylcarnitine;octanoylcarnitine;octanoylcarnitine;–;–;–;HMDB0000791;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0416763826;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5704;;
Pentadecanoylcarnitine;Pentadecanoylcarnitine;Pentadecanoylcarnitine;–;–;–;HMDB0062517;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;1,9130069266784E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5705;;
propionylcarnitine;propionylcarnitine;propionylcarnitine;–;–;–;HMDB0000824;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0213391661;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5706;;
tetradecanoylcarnitine;tetradecanoylcarnitine;tetradecanoylcarnitine;–;–;–;HMDB0005066;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0009079264;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5707;;
Tetradecenoylcarnitine;Tetradecenoylcarnitine;Tetradecenoylcarnitine;–;–;–;HMDB0258884;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0089825484;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5708;;
Galactosylceramide (d18:1/16:0)/Glucosylceramide (d18:1/16:0);Galactosylceramide (d18:1/16:0)/Glucosylceramide (d18:1/16:0);Galactosylceramide (d18:1/16:0)/Glucosylceramide (d18:1/16:0);–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0004381809;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5709;;
LysoPC 15:0;LysoPC 15:0;LysoPC 15:0;–;–;–;HMDB0010381;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0367799113;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5710;;
LysoPC 15:0;LysoPC 15:0;LysoPC 15:0;–;–;–;HMDB0010381;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0183717025;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5711;;
LysoPC 16:1 Plasm;LysoPC 16:1 Plasm;LysoPC 16:1 Plasm;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0366151061;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5712;;
LysoPC 16:1 sn1;LysoPC 16:1 sn1;LysoPC 16:1 sn1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0003665779;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5713;;
LysoPC 16:1 sn1;LysoPC 16:1 sn1;LysoPC 16:1 sn1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0158837043;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5714;;
LysoPC 16:1 sn2;LysoPC 16:1 sn2;LysoPC 16:1 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0025487094;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5715;;
LysoPC 16:1 sn2;LysoPC 16:1 sn2;LysoPC 16:1 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0019282584;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5716;;
LysoPC 18:1 sn2;LysoPC 18:1 sn2;LysoPC 18:1 sn2;–;–;–;HMDB0002815;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0022222619;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5717;;
LysoPC 18:1 sn2;LysoPC 18:1 sn2;LysoPC 18:1 sn2;–;–;–;HMDB0002815;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0001838267;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5718;;
LysoPC 18:2 sn2;LysoPC 18:2 sn2;LysoPC 18:2 sn2;–;–;–;HMDB0010386;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;4,48536008623092E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5719;;
LysoPC 18:2 sn2;LysoPC 18:2 sn2;LysoPC 18:2 sn2;–;–;–;HMDB0010386;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;8,7168100254321E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5720;;
LysoPC 20:1;LysoPC 20:1;LysoPC 20:1;–;–;–;HMDB0010391;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,003895235;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5721;;
LysoPC 20:2;LysoPC 20:2;LysoPC 20:2;–;–;–;HMDB0010392;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;4,28349386372746E-007;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5722;;
LysoPC 20:2;LysoPC 20:2;LysoPC 20:2;–;–;–;HMDB0010392;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0001411558;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5723;;
LysoPC 20:3;LysoPC 20:3;LysoPC 20:3;–;–;–;HMDB0010394;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0063022572;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5724;;
LysoPC 20:3 sn1;LysoPC 20:3 sn1;LysoPC 20:3 sn1;–;–;–;HMDB0010394;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0092898991;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5725;;
LysoPC 20:3 sn2;LysoPC 20:3 sn2;LysoPC 20:3 sn2;–;–;–;HMDB0010394;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;1,3761291682242E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5726;;
LysoPC 20:4;LysoPC 20:4;LysoPC 20:4;–;–;–;HMDB0010395;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0171103009;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5727;;
LysoPC 22:6 sn2;LysoPC 22:6 sn2;LysoPC 22:6 sn2;–;–;–;HMDB0010404;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;2,77839555925639E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5728;;
LysoPC 22:6 sn2;LysoPC 22:6 sn2;LysoPC 22:6 sn2;–;–;–;HMDB0010404;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;2,4616268471117E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5729;;
LysoPC O-16:1 / LysoPC P-16:0;LysoPC O-16:1 / LysoPC P-16:0;LysoPC O-16:1 / LysoPC P-16:0;–;–;–;HMDB0010407;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0425769393;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5730;;
LysoPE 16:0 sn1;LysoPE 16:0 sn1;LysoPE 16:0 sn1;–;–;–;HMDB0011508;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0302239371;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5731;;
LysoPE 16:0 sn1;LysoPE 16:0 sn1;LysoPE 16:0 sn1;–;–;–;HMDB0011508;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0251204856;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5732;;
LysoPE 16:0 sn2;LysoPE 16:0 sn2;LysoPE 16:0 sn2;–;–;–;HMDB0011516;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0026482445;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5733;;
LysoPE 16:0 sn2;LysoPE 16:0 sn2;LysoPE 16:0 sn2;–;–;–;HMDB0011516;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0361517746;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5734;;
LysoPE 16:1;LysoPE 16:1;LysoPE 16:1;–;–;–;HMDB0011517;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0079089512;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5735;;
LysoPE 18:0 sn2;LysoPE 18:0 sn2;LysoPE 18:0 sn2;–;–;–;HMDB0011152;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0395155312;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5736;;
LysoPE 18:2 sn2;LysoPE 18:2 sn2;LysoPE 18:2 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0175784116;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5737;;
LysoPE 20:4;LysoPE 20:4;LysoPE 20:4;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0338377967;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5738;;
LysoPE 22:6;LysoPE 22:6;LysoPE 22:6;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0082620192;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5739;;
LysoPE P-17:0;LysoPE P-17:0;LysoPE P-17:0;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0157891539;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5740;;
LysoPG 18:0;LysoPG 18:0;LysoPG 18:0;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0090583712;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5741;;
LysoPG 18:1 sn1;LysoPG 18:1 sn1;LysoPG 18:1 sn1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0029327011;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5742;;
LysoPG 18:1 sn2;LysoPG 18:1 sn2;LysoPG 18:1 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,004837585;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5743;;
LysoPI 18:1 sn2;LysoPI 18:1 sn2;LysoPI 18:1 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0390324177;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5744;;
LysoPI 18:2;LysoPI 18:2;LysoPI 18:2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0210052792;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5745;;
LysoPI 20:3 sn1;LysoPI 20:3 sn1;LysoPI 20:3 sn1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0004030498;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5746;;
LysoPI 20:3 sn2;LysoPI 20:3 sn2;LysoPI 20:3 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;9,96246717919795E-006;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5747;;
LysoPI 20:4 sn2;LysoPI 20:4 sn2;LysoPI 20:4 sn2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;6,37907200030628E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5748;;
PC 14:0/22:6;PC 14:0/22:6;PC 14:0/22:6;–;–;–;HMDB0007892;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0352817744;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5749;;
PC 15:0/20:4;PC 15:0/20:4;PC 15:0/20:4;–;–;–;HMDB0007949;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0007385244;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5750;;
PC 16:1/22:6;PC 16:1/22:6;PC 16:1/22:6;–;–;–;HMDB0008023;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0152794633;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5751;;
PC 17:0/20:4;PC 17:0/20:4;PC 17:0/20:4;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0132478445;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5752;;
PC 18:0/22:6;PC 18:0/22:6;PC 18:0/22:6;–;–;–;HMDB0008057;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;5,79588658015628E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5753;;
PC 18:1/22:6;PC 18:1/22:6;PC 18:1/22:6;–;–;–;HMDB0008123;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0018737604;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5754;;
PC 18:2/22:6;PC 18:2/22:6;PC 18:2/22:6;–;–;–;HMDB0008156;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0010088249;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5755;;
PC 18:2/22:6;PC 18:2/22:6;PC 18:2/22:6;–;–;–;HMDB0008156;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0088066381;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5756;;
PC 20:4/22:4;PC 20:4/22:4;PC 20:4/22:4;–;–;–;HMDB0008449;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;3,70592170462362E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5757;;
PC 20:4/22:6;PC 20:4/22:6;PC 20:4/22:6;–;–;–;HMDB0008739;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0214705283;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5758;;
PC 35:1;PC 35:1;PC 35:1;–;–;–;HMDB0008297;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0484247418;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5759;;
PC 35:5;PC 35:5;PC 35:5;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;7,94564832804132E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5760;;
PC 36:4 Plasm;PC 36:4 Plasm;PC 36:4 Plasm;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0499045785;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5761;;
PC 36:6;PC 36:6;PC 36:6;–;–;–;HMDB0008172;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0063508755;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5762;;
PC 38:3;PC 38:3;PC 38:3;–;–;–;HMDB0008334;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0274325375;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5763;;
PC 38:3;PC 38:3;PC 38:3;–;–;–;HMDB0008334;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0288229919;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5764;;
PC 38:5;PC 38:5;PC 38:5;–;–;–;HMDB0008337;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;3,69844375155908E-005;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5765;;
PC 38:5;PC 38:5;PC 38:5;–;–;–;HMDB0008337;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0231793067;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5766;;
PC 38:5;PC 38:5;PC 38:5;–;–;–;HMDB0008337;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0267004113;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5767;;
PC 40:6;PC 40:6;PC 40:6;–;–;–;HMDB0008345;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0326044848;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5768;;
PC 40:6;PC 40:6;PC 40:6;–;–;–;HMDB0008345;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0343974872;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5769;;
PC 42:8;PC 42:8;PC 42:8;–;–;–;HMDB0008354;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0002890419;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5770;;
PC P-16:0/18:2;PC P-16:0/18:2;PC P-16:0/18:2;–;–;–;HMDB0011211;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0074956501;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5771;;
PC P-18:0/22:6;PC P-18:0/22:6;PC P-18:0/22:6;–;–;–;HMDB0011262;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0048602208;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5772;;
PE 32:2;PE 32:2;PE 32:2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0349810488;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5773;;
SM 36:2;SM 36:2;SM 36:2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0029365356;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5774;;
SM (d18:1/18:0);SM (d18:1/18:0);SM (d18:1/18:0);–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0153498512;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5775;;
SM(d18:0/16:0);SM(d18:0/16:0);SM(d18:0/16:0);–;–;–;HMDB0010168;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0154858279;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5776;;
SM(d18:1/12:0);SM(d18:1/12:0);SM(d18:1/12:0);–;–;–;HMDB0012096;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0242401222;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5777;;
SM(d18:1/12:0);SM(d18:1/12:0);SM(d18:1/12:0);–;–;–;HMDB0012096;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0320137663;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5778;;
valine;valine;valine;–;–;–;HMDB0000883;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0115154522;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5779;;
acetylaspartic acid;acetylaspartic acid;acetylaspartic acid;–;–;–;HMDB0000812;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0284726148;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5780;;
hydroxyglutaric acid;hydroxyglutaric acid;hydroxyglutaric acid;–;–;–;HMDB0059655;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0284726148;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5781;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0466883646;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5782;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0202853819;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5783;;
taurine;taurine;taurine;–;–;–;HMDB0000251;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0400397738;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5784;;
guanosine;guanosine;guanosine;–;–;–;HMDB0000133;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0018513174;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5785;;
inosine;inosine;inosine;–;–;–;HMDB0000195;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0247752084;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5786;;
xantine;xantine;xantine;–;–;–;HMDB0000292;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0434103409;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5787;;
L-threonic acid/hypoxanthine;L-threonic acid/hypoxanthine;L-threonic acid/hypoxanthine;–;–;–;HMDB0000943;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0284726148;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5788;;
uric acid;uric acid;uric acid;–;–;–;HMDB0000289;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0325372011;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5789;;
creatinine;creatinine;creatinine;–;–;–;HMDB0000562;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0202853819;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5790;;
creatine;creatine;creatine;–;–;–;HMDB0000064;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0098306127;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5791;;
creatine;creatine;creatine;–;–;–;HMDB0000064;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0040714143;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5792;;
dihydrothymine;dihydrothymine;dihydrothymine;–;–;–;HMDB0000079;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0270902923;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5793;;
ethanolamine phosphate;ethanolamine phosphate;ethanolamine phosphate;–;–;–;HMDB0000224;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0475093879;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5794;;
ethanolamine phosphate;ethanolamine phosphate;ethanolamine phosphate;–;–;–;HMDB0000224;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,023677432;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5795;;
trimethylamine;trimethylamine;trimethylamine;–;–;–;HMDB0000906;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0439896964;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5796;;
Glycerophospho-(N-acyl)-ethanolamine;Glycerophospho-(N-acyl)-ethanolamine;Glycerophospho-(N-acyl)-ethanolamine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0216627395;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5797;;
glycerophospho-N-heptacenyl ethanolamine;glycerophospho-N-heptacenyl ethanolamine;glycerophospho-N-heptacenyl ethanolamine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0106060798;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5798;;
Glycerophospho-N-heptadecanoyl Ethanolamine;Glycerophospho-N-heptadecanoyl Ethanolamine;Glycerophospho-N-heptadecanoyl Ethanolamine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0078761939;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5799;;
Glycerophospho-N-hexadecenyl Ethanolamine;Glycerophospho-N-hexadecenyl Ethanolamine;Glycerophospho-N-hexadecenyl Ethanolamine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0183748448;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5800;;
glycerophospho-N-octadecanoyl ethanolamine;glycerophospho-N-octadecanoyl ethanolamine;glycerophospho-N-octadecanoyl ethanolamine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0146704776;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5801;;
Glycerophospho-N-octadecenyl Ethanolamine;Glycerophospho-N-octadecenyl Ethanolamine;Glycerophospho-N-octadecenyl Ethanolamine;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0466883646;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5802;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0310129062;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5803;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0184049551;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5804;;
arachidonic acid;arachidonic acid;arachidonic acid;–;–;–;HMDB0001043;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0284726148;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5805;;
docosahexaenoic acid;docosahexaenoic acid;docosahexaenoic acid;–;–;–;HMDB0002183;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0284726148;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5806;;
eicosapentaenoic acid;eicosapentaenoic acid;eicosapentaenoic acid;–;–;–;HMDB0001999;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0184049551;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5807;;
Eicosatrienoic acid (ETrE);Eicosatrienoic acid (ETrE);Eicosatrienoic acid (ETrE);–;–;–;HMDB0060039;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0322616767;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5808;;
carnitine;carnitine;carnitine;–;–;–;HMDB0000062;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,021100455;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5809;;
hydroxyoctanoyl carnitine;hydroxyoctanoyl carnitine;hydroxyoctanoyl carnitine;–;–;–;HMDB0061634;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0270902923;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5810;;
octadecadienylcarnitine;octadecadienylcarnitine;octadecadienylcarnitine;–;–;–;HMDB0255895;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0114178691;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5811;;
LysoPA 18:1;LysoPA 18:1;LysoPA 18:1;–;–;–;HMDB0007855;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0255945376;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5812;;
LysoPC 15:0;LysoPC 15:0;LysoPC 15:0;–;–;–;HMDB0010381;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0133970509;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5813;;
LysoPC 15:0;LysoPC 15:0;LysoPC 15:0;–;–;–;HMDB0010381;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0197111147;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5814;;
LysoPC 16:0;LysoPC 16:0;LysoPC 16:0;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0151467744;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5815;;
LysoPC 16:0 sn1;LysoPC 16:0 sn1;LysoPC 16:0 sn1;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0158567993;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5816;;
LysoPC 16:0 sn1;LysoPC 16:0 sn1;LysoPC 16:0 sn1;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0151467744;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5817;;
LysoPC 16:0 sn1;LysoPC 16:0 sn1;LysoPC 16:0 sn1;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0151467744;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5818;;
LysoPC 16:0 sn2;LysoPC 16:0 sn2;LysoPC 16:0 sn2;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0199448799;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5819;;
LysoPC 16:0 sn2;LysoPC 16:0 sn2;LysoPC 16:0 sn2;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0251482884;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5820;;
LysoPC 16:0 sn2;LysoPC 16:0 sn2;LysoPC 16:0 sn2;–;–;–;HMDB0010382;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0178092625;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5821;;
LysoPC 16:1 Plasm;LysoPC 16:1 Plasm;LysoPC 16:1 Plasm;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,022739629;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5822;;
LysoPC 17:0;LysoPC 17:0;LysoPC 17:0;–;–;–;HMDB0012108;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0135248036;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5823;;
LysoPC 17:0;LysoPC 17:0;LysoPC 17:0;–;–;–;HMDB0012108;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0151467744;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5824;;
LysoPC 18:0;LysoPC 18:0;LysoPC 18:0;–;–;–;HMDB0010384;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0164369844;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5825;;
LysoPC 18:0 sn1;LysoPC 18:0 sn1;LysoPC 18:0 sn1;–;–;–;HMDB0010384;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0176269127;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5826;;
LysoPC 18:0 sn1;LysoPC 18:0 sn1;LysoPC 18:0 sn1;–;–;–;HMDB0010384;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,016668206;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5827;;
LysoPC 18:0 sn2;LysoPC 18:0 sn2;LysoPC 18:0 sn2;–;–;–;HMDB0010384;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0151467744;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5828;;
LysoPC 18:0 sn2;LysoPC 18:0 sn2;LysoPC 18:0 sn2;–;–;–;HMDB0010384;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0397436709;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5829;;
LysoPC 18:1 sn1;LysoPC 18:1 sn1;LysoPC 18:1 sn1;–;–;–;HMDB0002815;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0310129062;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5830;;
LysoPC 18:1 sn1;LysoPC 18:1 sn1;LysoPC 18:1 sn1;–;–;–;HMDB0002815;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0406075365;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5831;;
LysoPC 18:2;LysoPC 18:2;LysoPC 18:2;–;–;–;HMDB0010386;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0155487517;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5832;;
LysoPC 18:2 sn1;LysoPC 18:2 sn1;LysoPC 18:2 sn1;–;–;–;HMDB0010386;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0415052613;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5833;;
LysoPC 18:2 sn1;LysoPC 18:2 sn1;LysoPC 18:2 sn1;–;–;–;HMDB0010386;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0452235707;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5834;;
LysoPC 18:2 sn2;LysoPC 18:2 sn2;LysoPC 18:2 sn2;–;–;–;HMDB0010386;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0478632064;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5835;;
LysoPE 16:0 sn1;LysoPE 16:0 sn1;LysoPE 16:0 sn1;–;–;–;HMDB0011508;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,031195314;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5836;;
LysoPE 16:0 sn1;LysoPE 16:0 sn1;LysoPE 16:0 sn1;–;–;–;HMDB0011508;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0228388233;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5837;;
LysoPE 16:0 sn2;LysoPE 16:0 sn2;LysoPE 16:0 sn2;–;–;–;HMDB0011516;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0158422631;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5838;;
LysoPE 17:0;LysoPE 17:0;LysoPE 17:0;–;–;–;HMDB0011523;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,016668206;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5839;;
LysoPE 18:0 sn1;LysoPE 18:0 sn1;LysoPE 18:0 sn1;–;–;–;HMDB0011526;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0184049551;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5840;;
LysoPE 18:0 sn2;LysoPE 18:0 sn2;LysoPE 18:0 sn2;–;–;–;HMDB0011152;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0413371617;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5841;;
LysoPE 18:1;LysoPE 18:1;LysoPE 18:1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0230073971;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5842;;
LysoPE 18:2 sn1;LysoPE 18:2 sn1;LysoPE 18:2 sn1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0263226724;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5843;;
LysoPE 22:4;LysoPE 22:4;LysoPE 22:4;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0361874555;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5844;;
LysoPE 22:5;LysoPE 22:5;LysoPE 22:5;–;–;–;HMDB0240261;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0196512934;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5845;;
LysoPE P-16:0;LysoPE P-16:0;LysoPE P-16:0;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0192246371;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5846;;
LysoPI 16:0;LysoPI 16:0;LysoPI 16:0;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0151467744;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5847;;
LysoPI 18:0;LysoPI 18:0;LysoPI 18:0;–;–;–;HMDB0240261;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0397436709;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5848;;
LysoPI 18:1 sn1;LysoPI 18:1 sn1;LysoPI 18:1 sn1;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0397436709;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5849;;
LysoPI 18:2;LysoPI 18:2;LysoPI 18:2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0495033103;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5850;;
LysoPI 20:3;LysoPI 20:3;LysoPI 20:3;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0352887824;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5851;;
PC 16:1/20:4;PC 16:1/20:4;PC 16:1/20:4;–;–;–;HMDB0008015;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0219895044;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5852;;
PE 17:0/20:4;PE 17:0/20:4;PE 17:0/20:4;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0361874555;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5853;;
SM 36:2;SM 36:2;SM 36:2;–;–;–;–;–;–;–;–;–;–;Tissue;diagnosis;squemous cell carcinoma (SCC);I, II, III;54;39, 15;64.45 ± 8.02;–;adenocarcinoma (ADC);33;23, 10;64.77 ± 8.44;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0466883646;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5854;;
PC 40:7;PC 40:7;PC 40:7;–;–;–;HMDB0008347;–;–;–;–;–;–;Plasma;diagnosis;adenocarcinoma (ADC);I, II, III;32;20, 12;64.16 ± 6.91;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,023170888;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5855;;
PE P-16:0/18:2;PE P-16:0/18:2;PE P-16:0/18:2;–;–;–;HMDB0008928;–;–;–;–;–;–;Plasma;diagnosis;adenocarcinoma (ADC);I, II, III;32;20, 12;64.16 ± 6.91;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,017628072;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5856;;
PC 36:0 Plasm;PC 36:0 Plasm;PC 36:0 Plasm;–;–;–;–;–;–;–;–;–;–;Plasma;diagnosis;squemous cell carcinoma (SCC);I, II, III;33;21, 12;64.45 ± 8.77;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0285458;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5857;;
LysoPC 18:3;LysoPC 18:3;LysoPC 18:3;–;–;–;HMDB0010388;–;–;–;–;–;–;Plasma;diagnosis;squemous cell carcinoma (SCC);I, II, III;33;21, 12;64.45 ± 8.77;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,027123968;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5858;;
PE P-16:0/18:2;PE P-16:0/18:2;PE P-16:0/18:2;–;–;–;HMDB0008928;–;–;–;–;–;–;Plasma;diagnosis;squemous cell carcinoma (SCC);I, II, III;33;21, 12;64.45 ± 8.77;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0009552;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5859;;
SM(d18:2/15:0);SM(d18:2/15:0);SM(d18:2/15:0);–;–;–;–;–;–;–;–;–;–;Plasma;diagnosis;squemous cell carcinoma (SCC);I, II, III;33;21, 12;64.45 ± 8.77;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,023797312;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5860;;
PE P-18:1/20:4; PE P-16:0/22:5;PE P-18:1/20:4; PE P-16:0/22:5;PE P-18:1/20:4; PE P-16:0/22:5;–;–;–;–;–;–;–;–;–;–;Plasma;diagnosis;squemous cell carcinoma (SCC);I, II, III;33;21, 12;64.45 ± 8.77;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0281280869;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;5861;34282765;Kowalczyk et al. 2021
PE 20:4/P-18:0;PE 20:4/P-18:0;PE 20:4/P-18:0;–;–;–;–;–;–;–;–;–;–;Plasma;diagnosis;squemous cell carcinoma (SCC);I, II, III;33;21, 12;64.45 ± 8.77;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0025613973;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5862;;
PC O-16:1/18:2;PC O-16:1/18:2;PC O-16:1/18:2;–;–;–;HMDB0013413;–;–;–;–;–;–;Plasma;diagnosis;squemous cell carcinoma (SCC);I, II, III;33;21, 12;64.45 ± 8.77;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0009552;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5863;;
PC 20:5/P-16:0;PC 20:5/P-16:0;PC 20:5/P-16:0;–;–;–;–;–;–;–;–;–;–;Plasma;diagnosis;squemous cell carcinoma (SCC);I, II, III;33;21, 12;64.45 ± 8.77;–;healthy control ;20;13, 7;61.5 ± 12.06;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,0214175004;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5864;;
PC 15:0/22:6;PC 15:0/22:6;PC 15:0/22:6;–;–;–;HMDB0008724;–;–;–;–;–;–;Plasma;diagnosis;squemous cell carcinoma (SCC);I, II, III;33;21, 12;64.45 ± 8.77;–;adenocarcinoma (ADC);32;20, 12;64.16 ± 6.91;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,022288728;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5865;;
PC 18:1/22:6;PC 18:1/22:6;PC 18:1/22:6;–;–;–;HMDB0008123;–;–;–;–;–;–;Plasma;diagnosis;squemous cell carcinoma (SCC);I, II, III;33;21, 12;64.45 ± 8.77;–;adenocarcinoma (ADC);32;20, 12;64.16 ± 6.91;–;LC;ESI;both;Q-TOF;–;Mass Hunter Qualitative Analysis Software, Mass Profiler Professional ;METLIN, KEGG, LIPIDMAPS, and HMDB;Matlab;Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) ;–;–;–;0,02265989;–;–;–;–;–;–;–;–;–;–;–;–;–;Poland;–;Summary of metabolic pathways;34282765;Kowalczyk et al. 2021;5866;;
cyclopropane, 1,1,2,2-tetramethyl-;cyclopropane, 1,1,2,2-tetramethyl-;cyclopropane, 1,1,2,2-tetramethyl-;–;–;–;–;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;0,5;0;–;2;–;–;–;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021 ;5867;;
oxirane, ethenyl-;oxirane, ethenyl-;oxirane, ethenyl-;–;–;–;–;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;1,6;0;–;1,9;ROC analysis;–;0,79;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021 ;5868;;
3-butene-1,2-diol, 1-(2-furanyl)-;3-butene-1,2-diol, 1-(2-furanyl)-;3-butene-1,2-diol, 1-(2-furanyl)-;–;–;–;–;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;0,7;0;–;1,8;–;–;–;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5869;;
methacrylic anhydride;methacrylic anhydride;methacrylic anhydride;–;–;–;–;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;0,6;0;–;1,8;–;–;–;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5870;;
2-pentanone, 4-amino-4-methyl-;2-pentanone, 4-amino-4-methyl-;2-pentanone, 4-amino-4-methyl-;–;–;–;–;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;1,4;0;–;1,8;ROC analysis;–;0,761;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5871;;
cyclohexane, 1-methyl-2-propyl-;cyclohexane, 1-methyl-2-propyl-;cyclohexane, 1-methyl-2-propyl-;–;–;–;–;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;1,4;0;–;1,6;ROC analysis;–;0,78;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5872;;
2-ethylthiolane, S,S-dioxide;2-ethylthiolane, S,S-dioxide;2-ethylthiolane, S,S-dioxide;–;–;–;–;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;1,4;0;–;1,5;ROC analysis;–;0,754;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5873;;
hexanenitrile, 5-methyl-;hexanenitrile, 5-methyl-;hexanenitrile, 5-methyl-;–;–;–;–;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;1,3;0,01;–;1,3;–;–;–;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5874;;
acetic acid ethenyl ester;acetic acid ethenyl ester;acetic acid ethenyl ester;–;–;–;HMDB0031209;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;1,3;0,01;–;1,3;ROC analysis;–;0,794;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5875;;
1-butene, 2,3-dimethyl-;1-butene, 2,3-dimethyl-;1-butene, 2,3-dimethyl-;–;–;–;–;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;0,7;0,02;–;1,3;–;–;–;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5876;;
2,3-butanedione;2,3-butanedione;2,3-butanedione;–;–;–;HMDB0003407;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;0,7;0,02;–;1,4;–;–;–;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5877;;
2-chloroaniline-5-sulfonic acid;2-chloroaniline-5-sulfonic acid;2-chloroaniline-5-sulfonic acid;–;–;–;–;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;1,3;0,02;–;1,3;–;–;–;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5878;;
3-butene-1,2-diol;3-butene-1,2-diol;3-butene-1,2-diol;–;–;–;HMDB0245828;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;0,7;0,02;–;1,2;–;–;–;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5879;;
methyl vinyl ketone;methyl vinyl ketone;methyl vinyl ketone;–;–;–;HMDB0061873;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;1,4;0,03;–;1,2;–;–;–;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5880;;
Silane, tetramethyl-;Silane, tetramethyl-;Silane, tetramethyl-;–;–;–;HMDB0094690;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;1,4;0,04;–;1,2;ROC analysis;–;0,854;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5881;;
cyclotetrasiloxane, octamethyl-;cyclotetrasiloxane, octamethyl-;cyclotetrasiloxane, octamethyl-;–;–;–;–;–;–;–;–;–;–;Pleural effusion;diagnosis;squamous cell carcinoma, adenocarcinoma, small cell lung cancer;–;38;24, 14;65.7 ± 12.4;current, former, never smoker, enviromental tobacco ;non-malignant control  ;30;17, 13;77.5 ± 13.1;current, former, never smoker, enviromental tobacco ;GC;EI;–;quadrupole;–;Mzmine;KEGG;SIMCA, SPSS;Student’s t-test, PCA, PLS-DA;–;–;1,3;0,04;–;1,1;–;–;–;–;–;–;–;–;–;–;–;Taiwan;–;Pathway analysis ;34193905;Chen et al. 2021;5882;;
